

# Revised American Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Differentiated Thyroid Cancer

The American Thyroid Association (ATA) Guidelines Taskforce  
on Thyroid Nodules and Differentiated Thyroid Cancer

David S. Cooper, M.D.<sup>1</sup> (Chair)\*, Gerard M. Doherty, M.D.,<sup>2</sup> Bryan R. Haugen, M.D.,<sup>3</sup>  
Richard T. Kloos, M.D.,<sup>4</sup> Stephanie L. Lee, M.D., Ph.D.,<sup>5</sup> Susan J. Mandel, M.D., M.P.H.,<sup>6</sup>  
Ernest L. Mazzaferri, M.D.,<sup>7</sup> Bryan McIver, M.D., Ph.D.,<sup>8</sup> Furio Pacini, M.D.,<sup>9</sup> Martin Schlumberger, M.D.,<sup>10</sup>  
Steven I. Sherman, M.D.,<sup>11</sup> David L. Steward, M.D.,<sup>12</sup> and R. Michael Tuttle, M.D.<sup>13</sup>

**Background:** Thyroid nodules are a common clinical problem, and differentiated thyroid cancer is becoming increasingly prevalent. Since the publication of the American Thyroid Association's guidelines for the management of these disorders was published in 2006, a large amount of new information has become available, prompting a revision of the guidelines.

**Methods:** Relevant articles through December 2008 were reviewed by the task force and categorized by topic and level of evidence according to a modified schema used by the United States Preventative Services Task Force.

**Results:** The revised guidelines for the management of thyroid nodules include recommendations regarding initial evaluation, clinical and ultrasound criteria for fine-needle aspiration biopsy, interpretation of fine-needle aspiration biopsy results, and management of benign thyroid nodules. Recommendations regarding the initial management of thyroid cancer include those relating to optimal surgical management, radioiodine remnant ablation, and suppression therapy using levothyroxine. Recommendations related to long-term management of differentiated thyroid cancer include those related to surveillance for recurrent disease using ultrasound and serum thyroglobulin as well as those related to management of recurrent and metastatic disease.

**Conclusions:** We created evidence-based recommendations in response to our appointment as an independent task force by the American Thyroid Association to assist in the clinical management of patients with thyroid nodules and differentiated thyroid cancer. They represent, in our opinion, contemporary optimal care for patients with these disorders.

**T**HYROID NODULES ARE a common clinical problem. Epidemiologic studies have shown the prevalence of palpable thyroid nodules to be approximately 5% in women and 1% in men living in iodine-sufficient parts of the world (1,2). In contrast, high-resolution ultrasound (US) can detect thyroid

nodules in 19–67% of randomly selected individuals with higher frequencies in women and the elderly (3). The clinical importance of thyroid nodules rests with the need to exclude thyroid cancer which occurs in 5–15% depending on age, sex, radiation exposure history, family history, and other factors

\*Authors are listed in alphabetical order and were appointed by ATA to independently formulate the content of this manuscript. None of the scientific or medical content of the manuscript was dictated by the ATA.

<sup>1</sup>The Johns Hopkins University School of Medicine, Baltimore, Maryland.

<sup>2</sup>University of Michigan Medical Center, Ann Arbor, Michigan.

<sup>3</sup>University of Colorado Health Sciences Center, Denver, Colorado.

<sup>4</sup>The Ohio State University, Columbus, Ohio.

<sup>5</sup>Boston University Medical Center, Boston, Massachusetts.

<sup>6</sup>University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.

<sup>7</sup>University of Florida College of Medicine, Gainesville, Florida.

<sup>8</sup>The Mayo Clinic, Rochester, Minnesota.

<sup>9</sup>The University of Siena, Siena, Italy.

<sup>10</sup>Institute Gustave Roussy, Paris, France.

<sup>11</sup>University of Texas M.D. Anderson Cancer Center, Houston, Texas.

<sup>12</sup>University of Cincinnati Medical Center, Cincinnati, Ohio.

<sup>13</sup>Memorial Sloan-Kettering Cancer Center, New York, New York.

(4,5). Differentiated thyroid cancer (DTC), which includes papillary and follicular cancer, comprises the vast majority (90%) of all thyroid cancers (6). In the United States, approximately 37,200 new cases of thyroid cancer will be diagnosed in 2009 (7). The yearly incidence has increased from 3.6 per 100,000 in 1973 to 8.7 per 100,000 in 2002, a 2.4-fold increase ( $p < 0.001$  for trend) and this trend appears to be continuing (8). Almost the entire change has been attributed to an increase in the incidence of papillary thyroid cancer (PTC), which increased 2.9-fold between 1988 and 2002. Moreover, 49% of the rising incidence consisted of cancers measuring 1 cm or smaller and 87% consisted of cancers measuring 2 cm or smaller (8). This tumor shift may be due to the increasing use of neck ultrasonography and early diagnosis and treatment (9), trends that are changing the initial treatment and follow-up for many patients with thyroid cancer.

In 1996, the American Thyroid Association (ATA) published treatment guidelines for patients with thyroid nodules and DTC (10). Over the last decade, there have been many advances in the diagnosis and therapy of both thyroid nodules and DTC. Controversy exists in many areas, including the most cost-effective approach in the diagnostic evaluation of a thyroid nodule, the extent of surgery for small thyroid cancers, the use of radioactive iodine to ablate remnant tissue following thyroidectomy, the appropriate use of thyroxine suppression therapy, and the role of human recombinant thyrotropin (rhTSH). In recognition of the changes that have taken place in the overall management of these clinically important problems, the ATA appointed a task force to re-examine the current strategies that are used to diagnose and treat thyroid nodules and DTC, and to develop clinical guidelines using principles of evidence-based medicine. Members of the taskforce included experts in thyroid nodule and thyroid cancer management with representation from the fields of endocrinology, surgery, and nuclear medicine. The medical opinions expressed here are those of the authors; none were dictated by the ATA. The final document was approved by the ATA Board of Directors and endorsed (in alphabetical order) by the American Association of Clinical Endocrinologists (AACE), American College of Endocrinology, British Association of Head and Neck Oncologists (BAHNO), The Endocrine Society, European Association for Cranio-Maxillo-Facial Surgery (EACMFS), European Association of Nuclear Medicine (EANM), European Society of Endocrine Surgeons (ESES), European Society for Paediatric Endocrinology (ESPE), International Association of Endocrine Surgeons (IAES), and Latin American Thyroid Society (LATS).

Other groups have previously developed guidelines, including the American Association of Clinical Endocrinologists and the American Association of Endocrine Surgeons (11), the British Thyroid Association and The Royal College of Physicians (12), and the National Comprehensive Cancer Network (13) that have provided somewhat conflicting recommendations due to the lack of high quality evidence from randomized controlled trials. The European Thyroid Association has published consensus guidelines for the management of DTC (14). The European Association of Nuclear Medicine has also recently published consensus guidelines for radioiodine (RAI) therapy of DTC (15).

The ATA guidelines taskforce used a strategy similar to that employed by the National Institutes of Health for its Consensus Development Conferences (<http://consensus.nih.gov/>

[aboutcdp.htm](#)), and developed a series of clinically relevant questions pertaining to thyroid nodule and thyroid cancer diagnosis and treatment. These questions were as follows:

—**Questions regarding thyroid nodules**

- What is the appropriate evaluation of clinically or incidentally discovered thyroid nodule(s)?
  - What laboratory tests and imaging modalities are indicated?
  - What is the role of fine-needle aspiration (FNA)?
- What is the best method of long-term follow up of patients with thyroid nodules?
- What is the role of medical therapy of patients with benign thyroid nodules?
- How should thyroid nodules in children and pregnant women be managed?

—**Questions regarding the initial management of DTC**

- What is the role of preoperative staging with diagnostic imaging and laboratory tests?
- What is the appropriate operation for indeterminate thyroid nodules and DTC?
- What is the role of postoperative staging systems and which should be used?
- What is the role of postoperative RAI remnant ablation?
- What is the role of thyrotropin (TSH) suppression therapy?
- Is there a role for adjunctive external beam irradiation or chemotherapy?

—**Questions regarding the long term management of DTC**

- What are the appropriate features of long-term management?
- What is the role of serum thyroglobulin (Tg) assays?
- What is the role of US and other imaging techniques during follow-up?
- What is the role of TSH suppression in long-term follow-up?
- What is the most appropriate management of patients with metastatic disease?
- How should Tg-positive, scan-negative patients be managed?
- What is the role of external radiation therapy?
- What is the role of chemotherapy?

—**What are directions for future research?**

The initial ATA guidelines were published in 2006 (16). Because of the rapid growth of the literature on this topic, plans for revising the guidelines within 24–36 months of publication were made at the inception of the project. Relevant articles on thyroid cancer were identified using the same search criteria employed for the original guidelines (16). Individual task force members submitted suggestions for clarification of prior recommendations, as well as new information derived from studies published since 2004. Relevant literature continued to be reviewed through December 2008. To begin the revision process, a half-day meeting was held on June 2, 2007. The Task Force was broadened to include European experts and a head and neck surgeon. Three subsequent half-day meetings were held on October 5, 2007; July 13, 2008; and October 5, 2008, to review these suggestions and for additional comments to be considered. The meeting in July 2008 also included a meeting with six additional surgeons in

TABLE 1. ORGANIZATION OF MANAGEMENT GUIDELINE RECOMMENDATIONS, TABLES, AND FIGURES FOR PATIENTS WITH THYROID NODULES AND DIFFERENTIATED THYROID CANCER

Page	Location key <sup>a</sup>	Sections and subsections	Item <sup>b</sup>
1171	[A1]	<b>THYROID NODULE GUIDELINES</b>	T1
1171	[A2]	Evaluation of Newly Discovered Thyroid Nodules	F1
1171	[A3]	Laboratory tests	
1171	[A4]	Serum TSH	R1–R2
1171	[A5]	Serum thyroglobulin (Tg)	R3
1171	[A6]	Serum calcitonin	R4
1173	[A7]	Role of fine-needle aspiration (FNA)	
1173	[A8]	Ultrasound (US) with FNA	R5, T3
1174	[A9]	Cytopathological interpretation of FNA samples	
1174	[A10]	Nondiagnostic cytology	R6
1174	[A11]	Cytology suggesting papillary thyroid cancer (PTC)	R7
1174	[A12]	Indeterminate cytology	R8–R10
1175	[A13]	Benign cytology	R11
1175	[A14]	Multinodular goiter (MNG)/multiple thyroid nodules	R12–R13
1175	[A15]	Long-Term Follow-Up of Thyroid Nodules	R14–R15
1176	[A16]	Medical therapy for benign thyroid nodules	R16–R17
1176	[A17]	Thyroid nodules in children	R18
1176	[A18]	Thyroid nodules in pregnant women	R19–R20
1176	[B1]	<b>DIFFERENTIATED THYROID CANCER (DTC): INITIAL MANAGEMENT GUIDELINES</b>	
1176	[B2]	Goals of Initial Therapy of DTC	
1177	[B3]	Preoperative staging of DTC	
1177	[B4]	Neck imaging	R21–R22
1177	[B5]	Serum Tg	R23
1177	[B6]	Thyroid surgery	
1178	[B7]	Surgery for nondiagnostic biopsy	R24–R25
1178	[B8]	Surgery for biopsy diagnostic of malignancy	R26
1179	[B9]	Lymph node dissection	R27–R28, F2
1180	[B10]	Completion thyroidectomy	R29–R30
1180	[B11]	Postoperative staging systems	
1180	[B12]	Role of postoperative staging	
1180	[B13]	AJCC/UICC TNM staging	R31, T4
1181	[B14]	Role of postoperative remnant ablation	R32, T5
1183	[B15]	Preparation for radioiodine (RAI) remnant ablation	R33, F3
1183	[B16]	rhTSH preparation	R34
1183	[B17]	RAI scanning before RAI ablation	R35
1185	[B18]	Radiation doses for RAI ablation	R36–R37
1185	[B19]	Low-iodine diet for RAI ablation	R38
1185	[B20]	Post RAI ablation whole-body RAI scan	R39
1185	[B21]	Post Initial Therapy of DTC	
1185	[B22]	Role of TSH suppression therapy	
1185	[B23]	Degree of initial TSH suppression required	R40
1186	[B24]	Adjunctive measures	
1186	[B25]	External beam irradiation	R41
1186	[B26]	Chemotherapy	R42
1186	[C1]	<b>DTC: LONG-TERM MANAGEMENT</b>	
1186	[C2]	Appropriate Features of Long-Term Management	
1186	[C3]	Appropriate method of follow-up after surgery	F4
1186	[C4]	Criteria for absence of persistent tumor	
1186	[C5]	Role of serum Tg assays	R43–R45
1189	[C6]	Whole body RAI scans, US, and other imaging	

<sup>a</sup>If viewing these guidelines on the Web, or in a File, copy the Location Key to the Find or Search Function to navigate rapidly to the desired section.  
<sup>b</sup>R, recommendation; T, table; F, figure.

(continued)

TABLE 1. (CONTINUED)

Page	Location key <sup>a</sup>	Sections and subsections	Item <sup>b</sup>
1189	[C7]	Diagnostic whole-body RAI scans	R46–R47
1189	[C8]	Cervical ultrasound	R48a–c
1189	[C9]	FDG-PET Scanning	R48d
1189	[C10]	Role of thyroxine suppression of TSH	R49
1190	[C11]	Management of Metastatic Disease	
1190	[C12]	Surgery for locoregional metastases	R50
1190	[C13]	Surgery for aerodigestive invasion	R51
1191	[C14]	RAI for local or distant metastatic disease	
1191	[C15]	Methods for administering RAI	R52–R54
1191	[C16]	The use of lithium in RAI therapy	R55
1191	[C17]	Metastasis to various organs	
1192	[C18]	Pulmonary metastasis	R56–R58
1192	[C19]	Non-RAI-avid pulmonary disease	R59
1193	[C20]	Bone metastases	R60–R64
1193	[C21]	Brain metastases	R65–R67
1194	[C22]	Management of Complications of RAI Therapy	R68–R70
1194	[C23]	Secondary malignancies and leukemia from RAI	R71
1194	[C24]	Other risks to bone marrow from RAI	R72
1194	[C25]	Effects of RAI on gonads and in nursing women	R73–R74
1195	[C26]	Management of Tg Positive, RAI Scan–Negative Patients	R75–R77, F5
1197	[C27]	Patients with a negative post-treatment whole-body scan	R78–R79
1197	[C28]	External beam radiation for metastatic disease	R80
1197	[D1]	<b>DIRECTIONS FOR FUTURE RESEARCH</b>	
1197	[D2]	Novel Therapies and Clinical Trials	
1197	[D3]	Inhibitors of oncogenic signaling pathways	
1197	[D4]	Modulators of growth or apoptosis	
1197	[D5]	Angiogenesis inhibitors	
1197	[D6]	Immunomodulators	
1197	[D7]	Gene therapy	
1198	[D8]	Better Understanding of the Long-Term Risks of RAI	
1198	[D9]	Clinical Significance of Persistent Low-Level Tg	
1198	[D10]	The Problem of Tg Antibodies	
1198	[D11]	Small Cervical Lymph Node Metastases	
1198	[D12]	Improved Risk Stratification	

TABLE 2. STRENGTH OF PANELISTS' RECOMMENDATIONS BASED ON AVAILABLE EVIDENCE

Rating	Definition
<b>A</b>	<b>Strongly recommends.</b> The recommendation is based on good evidence that the service or intervention can improve important health outcomes. Evidence includes consistent results from well-designed, well-conducted studies in representative populations that directly assess effects on health outcomes.
<b>B</b>	<b>Recommends.</b> The recommendation is based on fair evidence that the service or intervention can improve important health outcomes. The evidence is sufficient to determine effects on health outcomes, but the strength of the evidence is limited by the number, quality, or consistency of the individual studies; generalizability to routine practice; or indirect nature of the evidence on health outcomes.
<b>C</b>	<b>Recommends.</b> The recommendation is based on expert opinion.
<b>D</b>	<b>Recommends against.</b> The recommendation is based on expert opinion.
<b>E</b>	<b>Recommends against.</b> The recommendation is based on fair evidence that the service or intervention does not improve important health outcomes or that harms outweigh benefits.
<b>F</b>	<b>Strongly recommends against.</b> The recommendation is based on good evidence that the service or intervention does not improve important health outcomes or that harms outweigh benefits.
<b>I</b>	<b>Recommends neither for nor against.</b> The panel concludes that the evidence is insufficient to recommend for or against providing the service or intervention because evidence is lacking that the service or intervention improves important health outcomes, the evidence is of poor quality, or the evidence is conflicting. As a result, the balance of benefits and harms cannot be determined.

Adapted from the U.S. Preventive Services Task Force, Agency for Healthcare Research and Quality (17).

an effort to produce guidelines related to central neck dissection that would be as authoritative as possible. The organization of management guideline recommendations is shown in Table 1. It was agreed to continue to categorize the published data and strength of recommendations using a modified schema proposed by the U.S. Preventive Services Task Force (17) (Table 2).

### [A1] THYROID NODULE GUIDELINES

A thyroid nodule is a discrete lesion within the thyroid gland that is radiologically distinct from the surrounding thyroid parenchyma. Some palpable lesions may not correspond to distinct radiologic abnormalities (18). Such abnormalities do not meet the strict definition for thyroid nodules. Nonpalpable nodules detected on US or other anatomic imaging studies are termed incidentally discovered nodules or "incidentalomas." Nonpalpable nodules have the same risk of malignancy as palpable nodules with the same size (19). Generally, only nodules >1 cm should be evaluated, since they have a greater potential to be clinically significant cancers. Occasionally, there may be nodules <1 cm that require evaluation because of suspicious US findings, associated lymphadenopathy, a history of head and neck irradiation, or a history of thyroid cancer in one or more first-degree relatives. However, some nodules <1 cm lack these warning signs yet eventually cause morbidity and mortality. These are rare and, given unfavorable cost/benefit considerations, attempts to diagnose and treat all small thyroid cancers in an effort to prevent these rare outcomes would likely cause more harm than good. Approximately 1–2% of people undergoing 2-deoxy-2-[<sup>18</sup>F]fluoro-D-glucose positron emission tomography (<sup>18</sup>FDG-PET) imaging for other reasons have thyroid nodules discovered incidentally. Since the risk of malignancy in these <sup>18</sup>FDG-positive nodules is about 33% and the cancers may be more aggressive (20), such lesions require prompt evaluation (21–23). When seen, diffuse <sup>18</sup>FDG uptake is likely related to underlying autoimmune thyroiditis.

### [A2] What is the appropriate evaluation of clinically or incidentally discovered thyroid nodule(s)? (See Fig. 1 for algorithm)

With the discovery of a thyroid nodule, a complete history and physical examination focusing on the thyroid gland and adjacent cervical lymph nodes should be performed. Pertinent historical factors predicting malignancy include a history of childhood head and neck irradiation, total body irradiation for bone marrow transplantation (24), family history of thyroid carcinoma, or thyroid cancer syndrome (e.g., Cowden's syndrome, familial polyposis, Carney complex, multiple endocrine neoplasia [MEN] 2, Werner syndrome) in a first-degree relative, exposure to ionizing radiation from fallout in childhood or adolescence (25), and rapid growth and hoarseness. Pertinent physical findings suggesting possible malignancy include vocal cord paralysis, lateral cervical lymphadenopathy, and fixation of the nodule to surrounding tissues.

[A3] What laboratory tests and imaging modalities are indicated?

[A4] Serum TSH with US and with or without scan. With the discovery of a thyroid nodule >1 cm in any diameter or

diffuse or focal thyroidal uptake on <sup>18</sup>FDG-PET scan, a serum TSH level should be obtained. If the serum TSH is subnormal, a radionuclide thyroid scan should be obtained to document whether the nodule is hyperfunctioning (i.e., tracer uptake is greater than the surrounding normal thyroid), isofunctioning or "warm" (i.e., tracer uptake is equal to the surrounding thyroid), or nonfunctioning (i.e., has uptake less than the surrounding thyroid tissue). Since hyperfunctioning nodules rarely harbor malignancy, if one is found that corresponds to the nodule in question, no cytologic evaluation is necessary. If overt or subclinical hyperthyroidism is present, additional evaluation is required. Higher serum TSH, even within the upper part of the reference range, is associated with increased risk of malignancy in a thyroid nodule (26).

### ■ RECOMMENDATION 1

Measure serum TSH in the initial evaluation of a patient with a thyroid nodule. If the serum TSH is subnormal, a radionuclide thyroid scan should be performed using either technetium <sup>99m</sup>Tc pertechnetate or <sup>123</sup>I. Recommendation rating: A

Diagnostic thyroid US should be performed in all patients with a suspected thyroid nodule, nodular goiter, or radiographic abnormality; e.g., a nodule found incidentally on computed tomography (CT) or magnetic resonance imaging (MRI) or thyroidal uptake on <sup>18</sup>FDG-PET scan. Thyroid US can answer the following questions: Is there truly a nodule that corresponds to the palpable abnormality? How large is the nodule? Does the nodule have benign or suspicious features? Is suspicious cervical lymphadenopathy present? Is the nodule greater than 50% cystic? Is the nodule located posteriorly in the thyroid gland? These last two features might decrease the accuracy of FNA biopsy performed with palpation (27,28). Also, there may be other thyroid nodules present that require biopsy based on their size and appearance (18,29,30). As already noted, FNA is recommended especially when the serum TSH is elevated because, compared with normal thyroid glands, the rate of malignancy in nodules in thyroid glands involved with Hashimoto's thyroiditis is as least as high or possibly higher (31,32).

### ■ RECOMMENDATION 2

Thyroid sonography should be performed in all patients with known or suspected thyroid nodules. Recommendation rating: A

[A5] Serum Tg measurement. Serum Tg levels can be elevated in most thyroid diseases and are an insensitive and nonspecific test for thyroid cancer (33).

### ■ RECOMMENDATION 3

Routine measurement of serum Tg for initial evaluation of thyroid nodules is not recommended. Recommendation rating: F

[A6] Serum calcitonin measurement. The utility of serum calcitonin has been evaluated in a series of prospective, nonrandomized studies (34–37). The data suggest that the




FIG. 1. Algorithm for the evaluation of patients with one or more thyroid nodules.

<sup>a</sup>If the scan does not show uniform distribution of tracer activity, ultrasound may be considered to assess for the presence of a cystic component.

use of routine serum calcitonin for screening may detect C-cell hyperplasia and medullary thyroid cancer at an earlier stage and overall survival may be improved. However, most studies rely on pentagastrin stimulation testing to increase specificity. This drug is no longer available in the United States, and there remain unresolved issues

of sensitivity, specificity, assay performance and cost-effectiveness. A recent cost-effectiveness analysis suggested that calcitonin screening would be cost effective in the United States (38). However, the prevalence estimates of medullary thyroid cancer in this analysis included patients with C-cell hyperplasia and micromedullary carcinoma,

TABLE 3. SONOGRAPHIC AND CLINICAL FEATURES OF THYROID NODULES AND RECOMMENDATIONS FOR FNA

<i>Nodule sonographic or clinical features</i>	<i>Recommended nodule threshold size for FNA</i>	
High-risk history <sup>a</sup>		
Nodule WITH suspicious sonographic features <sup>b</sup>	>5 mm	Recommendation A
Nodule WITHOUT suspicious sonographic features <sup>b</sup>	>5 mm	Recommendation I
Abnormal cervical lymph nodes	All <sup>c</sup>	Recommendation A
Microcalcifications present in nodule	≥1 cm	Recommendation B
Solid nodule		
AND hypoechoic	>1 cm	Recommendation B
AND iso- or hyperechoic	≥1–1.5 cm	Recommendation C
Mixed cystic–solid nodule		
WITH any suspicious ultrasound features <sup>b</sup>	≥1.5–2.0 cm	Recommendation B
WITHOUT suspicious ultrasound features	≥2.0 cm	Recommendation C
Spongiform nodule	≥2.0 cm <sup>d</sup>	Recommendation C
Purely cystic nodule	FNA not indicated <sup>e</sup>	Recommendation E

<sup>a</sup>High-risk history: History of thyroid cancer in one or more first degree relatives; history of external beam radiation as a child; exposure to ionizing radiation in childhood or adolescence; prior hemithyroidectomy with discovery of thyroid cancer, <sup>18</sup>FDG avidity on PET scanning; MEN2/FMTC-associated RET protooncogene mutation, calcitonin >100 pg/mL. MEN, multiple endocrine neoplasia; FMTC, familial medullary thyroid cancer.

<sup>b</sup>Suspicious features: microcalcifications; hypoechoic; increased nodular vascularity; infiltrative margins; taller than wide on transverse view.

<sup>c</sup>FNA cytology may be obtained from the abnormal lymph node in lieu of the thyroid nodule.

<sup>d</sup>Sonographic monitoring without biopsy may be an acceptable alternative (see text) (48).

<sup>e</sup>Unless indicated as therapeutic modality (see text).

which have an uncertain clinical significance. If the unstimulated serum calcitonin determination has been obtained and the level is greater than 100 pg/mL, medullary cancer is likely present (39).

■ **RECOMMENDATION 4**

The panel cannot recommend either for or against the routine measurement of serum calcitonin. Recommendation rating: I

[A7] What is the role of FNA biopsy? FNA is the most accurate and cost-effective method for evaluating thyroid nodules. Retrospective studies have reported lower rates of both nondiagnostic and false-negative cytology specimens from FNA procedures performed via US guidance compared to palpation (40,41). Therefore, for nodules with a higher likelihood of either a nondiagnostic cytology (>25–50% cystic component) (28) or sampling error (difficult to palpate or posteriorly located nodules), US-guided FNA is preferred (see Table 3). If the diagnostic US confirms the presence of a predominantly solid nodule corresponding to what is palpated, the FNA may be performed via palpation or US guidance. Traditionally FNA biopsy results are divided into four categories: nondiagnostic, malignant (risk of malignancy at surgery >95%), indeterminate or suspicious for neoplasm, and benign. The recent National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference proposed a more expanded classification for FNA cytology that adds two additional categories: suspicious for malignancy (risk of malignancy 50–75%) and follicular lesion of undetermined significance (risk of malignancy 5–10%). The conference further recommended that “neoplasm, either follicular or Hürthle cell

neoplasm” be substituted for “indeterminate” (risk of malignancy 15–25%) (42).

[A8] US for FNA decision making (see Table 3). Various sonographic characteristics of a thyroid nodule have been associated with a higher likelihood of malignancy (43–48). These include nodule hypoechogenicity compared to the normal thyroid parenchyma, increased intranodular vascularity, irregular infiltrative margins, the presence of microcalcifications, an absent halo, and a shape taller than the width measured in the transverse dimension. With the exception of suspicious cervical lymphadenopathy, which is a specific but insensitive finding, no single sonographic feature or combinations of features is adequately sensitive or specific to identify all malignant nodules. However, certain features and combination of features have high predictive value for malignancy. Furthermore, the most common sonographic appearances of papillary and follicular thyroid cancer differ. A PTC is generally solid or predominantly solid and hypoechoic, often with infiltrative irregular margins and increased nodular vascularity. Microcalcifications, if present, are highly specific for PTC, but may be difficult to distinguish from colloid. Conversely, follicular cancer is more often iso- to hyperechoic and has a thick and irregular halo, but does not have microcalcifications (49). Follicular cancers that are <2 cm in diameter have not been shown to be associated with metastatic disease (50).

Certain sonographic appearances may also be highly predictive of a benign nodule. A pure cystic nodule, although rare (<2% of all nodules), is highly unlikely to be malignant (47). In addition, a spongiform appearance, defined as an aggregation of multiple microcystic components in more than 50% of the nodule volume, is 99.7% specific for identification of a benign

thyroid nodule (48,51,52). In a recent study, only 1 of 360 malignant nodules demonstrated this appearance (48) and in another report, a spongiform appearance had a negative predictive value for malignancy of 98.5% (52). Elastography is an emerging and promising sonographic technique that requires additional validation with prospective studies (53).

Routine FNA is not recommended for subcentimeter nodules. However, the presence of a solid hypoechoic nodule with microcalcifications is highly suggestive of PTC. Although most micropapillary carcinomas may be incidental findings, a subset may be more clinically relevant, especially those >5 mm in diameter (54). These include nodules that have abnormal lymph nodes detected clinically or with imaging at presentation (55,56). Therefore, after imaging a subcentimeter nodule with a suspicious appearance, sonographic assessment of lateral neck and central neck lymph nodes (more limited due to the presence of the thyroid) must be performed. Detection of abnormal lymph nodes should lead to FNA of the lymph node. Other groups of patients for whom consideration of FNA of a subcentimeter nodule may be warranted include those with a higher likelihood of malignancy (high risk history): 1) family history of PTC (57); 2) history of external beam radiation exposure as a child (58); 3) exposure to ionizing radiation in childhood or adolescence (59); 4) history of prior hemithyroidectomy with discovery of thyroid cancer; and 5) <sup>18</sup>F-DG-PET-positive thyroid nodules.

Mixed cystic-solid nodules and predominantly cystic with >50% cystic component are generally evaluated by FNA with directed biopsy of the solid component (especially the vascular component.) Cyst drainage may also be performed, especially in symptomatic patients.

#### ■ RECOMMENDATION 5 (see Table 3)

- (a) FNA is the procedure of choice in the evaluation of thyroid nodules. Recommendation rating: A
- (b) US guidance for FNA is recommended for those nodules that are nonpalpable, predominantly cystic, or located posteriorly in the thyroid lobe. Recommendation rating: B

[A9] What are the principles of the cytopathological interpretation of FNA samples?

[A10] *Nondiagnostic cytology.* Nondiagnostic biopsies are those that fail to meet specified criteria for cytologic adequacy that have been previously established (the presence of at least six follicular cell groups, each containing 10–15 cells derived from at least two aspirates of a nodule) (5). After an initial nondiagnostic cytology result, repeat FNA with US guidance will yield a diagnostic cytology specimen in 75% of solid nodules and 50% of cystic nodules (28). Therefore, such biopsies need to be repeated using US guidance (60) and, if available, on-site cytologic evaluation, which may substantially increase cytology specimen adequacy (61,62). However, up to 7% of nodules continue to yield nondiagnostic cytology results despite repeated biopsies and may be malignant at the time of surgery (63,64).

#### ■ RECOMMENDATION 6

- (a) US guidance should be used when repeating the FNA procedure for a nodule with an initial nondiagnostic cytology result. Recommendation rating: A

- (b) Partially cystic nodules that repeatedly yield nondiagnostic aspirates need close observation or surgical excision. Surgery should be more strongly considered if the cytologically nondiagnostic nodule is solid. Recommendation rating: B

[A11] *Cytology suggesting PTC.*

#### ■ RECOMMENDATION 7

If a cytology result is diagnostic of or suspicious for PTC, surgery is recommended (65). Recommendation rating: A

[A12] *Indeterminate cytology (follicular or Hürthle cell neoplasm follicular lesion of undetermined significance, atypia).* Indeterminate cytology, reported as “follicular neoplasm” or “Hürthle cell neoplasm” can be found in 15–30% of FNA specimens (4) and carries a 20–30% risk of malignancy (42), while lesions reported as atypia or follicular lesion of undetermined significance are variably reported and have 5–10% risk of malignancy (42). While certain clinical features such as male sex and nodule size (>4 cm) (66), older patient age (67), or cytologic features such as presence of atypia (68) can improve the diagnostic accuracy for malignancy in patients with indeterminate cytology, overall predictive values are still low. Many molecular markers (e.g., galectin-3 (69), cytokeratin, BRAF) have been evaluated to improve diagnostic accuracy for indeterminate nodules (70–72). Recent large prospective studies have confirmed the ability of genetic markers (BRAF, Ras, RET/PTC) and protein markers (galectin-3) to improve preoperative diagnostic accuracy for patients with indeterminate thyroid nodules (69,73,74). Many of these markers are available for commercial use in reference laboratories but have not yet been widely applied in clinical practice. It is likely that some combination of molecular markers will be used in the future to optimize management of patients with indeterminate cytology on FNA specimens.

Recently, <sup>18</sup>F-DG-PET scanning has been utilized in an effort to distinguish those indeterminate nodules that are benign from those that are malignant (75–78). <sup>18</sup>F-DG-PET scans appear to have relatively high sensitivity for malignancy but low specificity, but results vary among studies (79).

#### ■ RECOMMENDATION 8

- (a) The use of molecular markers (e.g., BRAF, RAS, RET/PTC, Pax8-PPAR $\gamma$ , or galectin-3) may be considered for patients with indeterminate cytology on FNA to help guide management. Recommendation rating: C
- (b) The panel cannot recommend for or against routine clinical use of <sup>18</sup>F-DG-PET scan to improve diagnostic accuracy of indeterminate thyroid nodules. Recommendation rating: I

#### ■ RECOMMENDATION 9

If the cytology reading reports a follicular neoplasm, a <sup>123</sup>I thyroid scan may be considered, if not already done, especially if the serum TSH is in the low-normal range. If a concordant autonomously functioning nodule is not seen, lobectomy or total thyroidectomy should be considered. Recommendation rating: C

#### ■ RECOMMENDATION 10

If the reading is “suspicious for papillary carcinoma” or “Hürthle cell neoplasm,” a radionuclide scan is not needed,



and either lobectomy or total thyroidectomy is recommended, depending on the lesion's size and other risk factors. Recommendation rating: A

[A13] *Benign cytology.*

#### ■ RECOMMENDATION 11

If the nodule is benign on cytology, further immediate diagnostic studies or treatment are not routinely required. Recommendation rating: A

[A14] How should multinodular thyroid glands or multinodular goiters be evaluated for malignancy? Patients with multiple thyroid nodules have the same risk of malignancy as those with solitary nodules (18,44). However, one large study found that a solitary nodule had a higher likelihood of malignancy than did a nonsolitary nodule ( $p < 0.01$ ), although the risk of malignancy per patient was the same and independent of the number of nodules (47). A diagnostic US should be performed to delineate the nodules, but if only the "dominant" or largest nodule is aspirated, the thyroid cancer may be missed (44). Radionuclide scanning should also be considered in patients with multiple thyroid nodules, if the serum TSH is in the low or low-normal range, with FNA being reserved for those nodules that are shown to be hypofunctioning.

#### ■ RECOMMENDATION 12

- (a) In the presence of two or more thyroid nodules  $>1$  cm, those with a suspicious sonographic appearance (see text and Table 3) should be aspirated preferentially. Recommendation rating: B
- (b) If none of the nodules has a suspicious sonographic appearance and multiple sonographically similar coalescent nodules with no intervening normal parenchyma are present, the likelihood of malignancy is low and it is reasonable to aspirate the largest nodules only and observe the others with serial US examinations. Recommendation rating: C

#### ■ RECOMMENDATION 13

A low or low-normal serum TSH concentration may suggest the presence of autonomous nodule(s). A technetium  $^{99m}\text{Tc}$  pertechnetate or  $^{123}\text{I}$  scan should be performed and directly compared to the US images to determine functionality of each nodule  $>1$ – $1.5$  cm. FNA should then be considered only for those isofunctioning or nonfunctioning nodules, among which those with suspicious sonographic features should be aspirated preferentially. Recommendation rating: B

#### [A15] *What are the best methods for long-term follow-up of patients with thyroid nodules?*

Thyroid nodules diagnosed as benign require follow-up because of a low, but not negligible, false-negative rate of up to 5% with FNA (41,80), which may be even higher with nodules  $>4$  cm (81). While benign nodules may decrease in size, they often increase in size, albeit slowly (82). One study of cytologically benign thyroid nodules  $<2$  cm followed by ultrasonography for about 38 months found that the rate of thyroid nodule growth did not distinguish between benign and malignant nodules (83).

Nodule growth is not in and of itself pathognomonic of malignancy, but growth is an indication for repeat biopsy. For mixed cystic–solid nodules, the indication for repeat biopsy should be based upon growth of the solid component. For nodules with benign cytologic results, recent series report a higher false-negative rate with palpation FNA (1–3%) (40,84,85) than with US FNA (0.6%) (40). Since the accuracy of physical examination for nodule size is likely inferior to that of US (30), it is recommended that serial US be used in follow-up of thyroid nodules to detect clinically significant changes in size. There is no consensus on the definition of nodule growth, however, or the threshold that would require rebiopsy. Some groups suggest a 15% increase in nodule volume, while others recommend measuring a change in the mean nodule diameter (82,86). One reasonable definition of growth is a 20% increase in nodule diameter with a minimum increase in two or more dimensions of at least 2 mm. This approximates the 50% increase in nodule volume that was found by Brauer *et al.* (87) to be the minimally significant reproducibly recorded change in nodule size. These authors suggested that only volume changes of at least 49% or more can be interpreted as nodule shrinkage or growth and consequently suggest that future investigations should not describe changes in nodule volume  $<50\%$  as significant. A 50% cutoff for nodule volume reduction or growth, which is used in many studies, appears to be appropriate and safe, since the false-negative rate for malignant thyroid nodules on repeat FNA is low (88,89).

#### ■ RECOMMENDATION 14

- (a) It is recommended that all benign thyroid nodules be followed with serial US examinations 6–18 months after the initial FNA. If nodule size is stable (i.e., no more than a 50% change in volume or  $<20\%$  increase in at least two nodule dimensions in solid nodules or in the solid portion of mixed cystic–solid nodules), the interval before the next follow-up clinical examination or US may be longer, e.g., every 3–5 years. Recommendation rating: C
- (b) If there is evidence for nodule growth either by palpation or sonographically (more than a 50% change in volume or a 20% increase in at least two nodule dimensions with a minimal increase of 2 mm in solid nodules or in the solid portion of mixed cystic–solid nodules), the FNA should be repeated, preferably with US guidance. Recommendation rating: B

Cystic nodules that are cytologically benign can be monitored for recurrence (fluid reaccumulation) which can be seen in 60–90% of patients (90,91). For those patients with subsequent recurrent symptomatic cystic fluid accumulation, surgical removal, generally by hemithyroidectomy, or percutaneous ethanol injection (PEI) are both reasonable strategies. Four controlled studies demonstrated a 75–85% success rate after PEI compared with a 7–38% success rate in controls treated by simple cyst evacuation or saline injection. Success was achieved after an average of two PEI treatments. Complications included mild to moderate local pain, flushing, dizziness, and dysphonia (90–93).

#### ■ RECOMMENDATION 15

Recurrent cystic thyroid nodules with benign cytology should be considered for surgical removal or PEI based on

compressive symptoms and cosmetic concerns. Recommendation rating: B

[A16] What is the role of medical therapy for benign thyroid nodules? Evidence from multiple randomized control trials and three meta-analyses suggest that thyroid hormone in doses that suppress the serum TSH to subnormal levels may result in a decrease in nodule size and may prevent the appearance of new nodules in regions of the world with borderline low iodine intake. Data in iodine-sufficient populations are less compelling (94–96), with large studies suggesting that only about 17–25% of thyroid nodules shrink more than 50% with levothyroxine (LT<sub>4</sub>) suppression of serum TSH (94–96).

#### ■ RECOMMENDATION 16

Routine suppression therapy of benign thyroid nodules in iodine sufficient populations is not recommended. Recommendation rating: F

#### ■ RECOMMENDATION 17

Patients with growing nodules that are benign after repeat biopsy should be considered for continued monitoring or intervention with surgery based on symptoms and clinical concern. There are no data on the use of LT<sub>4</sub> in this subpopulation of patients. Recommendation rating: I

[A17] How should thyroid nodules in children be managed? Thyroid nodules occur less frequently in children than in adults. In one study in which approximately 5000 children aged 11–18 years were assessed annually in the southwestern United States, palpable thyroid nodules occurred in approximately 20 per 1000 children, with an annual incidence of 7 new cases per 1000 children (97). Some studies have shown the frequency of malignancy to be higher in children than adults, in the range of 15–20% (98–100), whereas other data have suggested that the frequency of thyroid cancer in childhood thyroid nodules is similar to that of adults (101,102). FNA biopsy is sensitive and specific in the diagnosis of childhood thyroid nodules (99–101).

#### ■ RECOMMENDATION 18

The diagnostic and therapeutic approach to one or more thyroid nodules in a child should be the same as it would be in an adult (clinical evaluation, serum TSH, US, FNA). Recommendation rating: A

[A18] How should thyroid nodules in pregnant women be managed? It is uncertain if thyroid nodules discovered in pregnant women are more likely to be malignant than those found in nonpregnant women (103), since there are no population-based studies on this question. The evaluation is the same as for a nonpregnant patient, with the exception that a radionuclide scan is contraindicated. In addition, for patients with nodules diagnosed as DTC by FNA during pregnancy, delaying surgery until after delivery does not affect outcome (104).

#### ■ RECOMMENDATION 19

For euthyroid and hypothyroid pregnant women with thyroid nodules, FNA should be performed. For women with suppressed serum TSH levels that persist after the first trimester, FNA may be deferred until after pregnancy and cessation of lactation, when a radionuclide scan can be

performed to evaluate nodule function. Recommendation rating: A

If the FNA cytology is consistent with PTC, surgery is recommended. However, there is no consensus about whether surgery should be performed during pregnancy or after delivery. To minimize the risk of miscarriage, surgery during pregnancy should be done in the second trimester before 24 weeks gestation (105). However, PTC discovered during pregnancy does not behave more aggressively than that diagnosed in a similar-aged group of nonpregnant women (104,106). A retrospective study of pregnant women with DTC found there to be no difference in either recurrence, or survival rates, between women operated on during or after their pregnancy (104). Further, retrospective data suggest that treatment delays of less than 1 year from the time of thyroid cancer discovery do not adversely affect patient outcome (107). Finally, a recent study reported a higher rate of complications in pregnant women undergoing thyroid surgery compared with nonpregnant women (108). Some experts recommend thyroid hormone suppression therapy for pregnant women with FNA suspicious for or diagnostic of PTC, if surgery is deferred until the postpartum period (109).

#### ■ RECOMMENDATION 20

(a) A nodule with cytology indicating PTC discovered early in pregnancy should be monitored sonographically and if it grows substantially (as defined above) by 24 weeks gestation, surgery should be performed at that point. However, if it remains stable by midgestation or if it is diagnosed in the second half of pregnancy, surgery may be performed after delivery. In patients with more advanced disease, surgery in the second trimester is reasonable. Recommendation rating: C

(b) In pregnant women with FNA that is suspicious for or diagnostic of PTC, consideration could be given to administration of LT<sub>4</sub> therapy to keep the TSH in the range of 0.1–1 mU/L. Recommendation rating: C

### [B1] DIFFERENTIATED THYROID CANCER: INITIAL MANAGEMENT GUIDELINES

Differentiated thyroid cancer, arising from thyroid follicular epithelial cells, accounts for the vast majority of thyroid cancers. Of the differentiated cancers, papillary cancer comprises about 85% of cases compared to about 10% that have follicular histology, and 3% that are Hürthle cell or oxyphil tumors (110). In general, stage for stage, the prognoses of PTC and follicular cancer are similar (107,110). Certain histologic subtypes of PTC have a worse prognosis (tall cell variant, columnar cell variant, diffuse sclerosing variant), as do more highly invasive variants of follicular cancer. These are characterized by extensive vascular invasion and invasion into extrathyroidal tissues or extensive tumor necrosis and/or mitoses. Other poorly differentiated aggressive tumor histologies include trabecular, insular, and solid subtypes (111). In contrast, minimally invasive follicular thyroid cancer, is characterized histologically by microscopic penetration of the tumor capsule without vascular invasion, and carries no excess mortality (112–115).

#### [B2] Goals of initial therapy of DTC

The goals of initial therapy of DTC are follows:

1. To remove the primary tumor, disease that has extended beyond the thyroid capsule, and involved cervical lymph nodes. Completeness of surgical resection is an important determinant of outcome, while residual metastatic lymph nodes represent the most common site of disease persistence/recurrence (116–118).
2. To minimize treatment-related morbidity. The extent of surgery and the experience of the surgeon both play important roles in determining the risk of surgical complications (119,120).
3. To permit accurate staging of the disease. Because disease staging can assist with initial prognostication, disease management, and follow-up strategies, accurate postoperative staging is a crucial element in the management of patients with DTC (121,122).
4. To facilitate postoperative treatment with radioactive iodine, where appropriate. For patients undergoing RAI remnant ablation, or RAI treatment of residual or metastatic disease, removal of all normal thyroid tissue is an important element of initial surgery (123). Near total or total thyroidectomy also may reduce the risk for recurrence within the contralateral lobe (124).
5. To permit accurate long-term surveillance for disease recurrence. Both RAI whole-body scanning (WBS) and measurement of serum Tg are affected by residual normal thyroid tissue. Where these approaches are utilized for long-term monitoring, near-total or total-thyroidectomy is required (125).
6. To minimize the risk of disease recurrence and metastatic spread. Adequate surgery is the most important treatment variable influencing prognosis, while radioactive iodine treatment, TSH suppression, and external beam irradiation each play adjunctive roles in at least some patients (125–128).

[B3] What is the role of preoperative staging with diagnostic imaging and laboratory tests?

[B4] *Neck imaging.* Differentiated thyroid carcinoma (particularly papillary carcinoma) involves cervical lymph nodes in 20–50% of patients in most series using standard pathologic techniques (45,129–132), and may be present even when the primary tumor is small and intrathyroidal (133). The frequency of micrometastases may approach 90%, depending on the sensitivity of the detection method (134,135). However, the clinical implications of micrometastases are likely less significant compared to macrometastases. Preoperative US identifies suspicious cervical adenopathy in 20–31% of cases, potentially altering the surgical approach (136,137) in as many as 20% of patients (138,139). However, preoperative US identifies only half of the lymph nodes found at surgery, due to the presence of the overlying thyroid gland (140).

Sonographic features suggestive of abnormal metastatic lymph nodes include loss of the fatty hilus, a rounded rather than oval shape, hypoechogenicity, cystic change, calcifications, and peripheral vascularity. No single sonographic feature is adequately sensitive for detection of lymph nodes with metastatic thyroid cancer. A recent study correlated the sonographic features acquired 4 days preoperatively directly with the histology of 56 cervical lymph nodes. Some of the most specific criteria were short axis >5 mm (96%), presence of cystic areas (100%), presence of hyperechogenic punctuations re-

presenting either colloid or microcalcifications (100%), and peripheral vascularity (82%). Of these, the only one with sufficient sensitivity was peripheral vascularity (86%). All of the others had sensitivities <60% and would not be adequate to use as single criterion for identification of malignant involvement (140). As shown by earlier studies (141,142), the feature with the highest sensitivity was absence of a hilus (100%), but this had a low specificity of only 29%. The location of the lymph nodes may also be useful for decision-making. Malignant lymph nodes are much more likely to occur in levels III, IV, and VI than in level II (140,142). Figure 2 illustrates the delineation of cervical lymph node Levels I through VI.

Confirmation of malignancy in lymph nodes with a suspicious sonographic appearance is achieved by US-guided FNA aspiration for cytology and/or measurement of Tg in the needle washout. This FNA measurement of Tg is valid even in patients with circulating Tg autoantibodies (143,144).

Accurate staging is important in determining the prognosis and tailoring treatment for patients with DTC. However, unlike many tumor types, the presence of metastatic disease does not obviate the need for surgical excision of the primary tumor in DTC (145). Because metastatic disease may respond to RAI therapy, removal of the thyroid as well as the primary tumor and accessible locoregional disease remains an important component of initial treatment even in metastatic disease.

As US evaluation is uniquely operator dependent, alternative imaging procedures may be preferable in some clinical settings, though the sensitivities of CT, MRI, and PET for the detection of cervical lymph node metastases are all relatively low (30–40%) (146). These alternative imaging modalities, as well as laryngoscopy and endoscopy, may also be useful in the assessment of large, rapidly growing, or retrosternal or invasive tumors to assess the involvement of extrathyroidal tissues (147,148).

#### ■ RECOMMENDATION 21

Preoperative neck US for the contralateral lobe and cervical (central and especially lateral neck compartments) lymph nodes is recommended for all patients undergoing thyroidectomy for malignant cytologic findings on biopsy. US-guided FNA of sonographically suspicious lymph nodes should be performed to confirm malignancy if this would change management. Recommendation rating: B

#### ■ RECOMMENDATION 22


Routine preoperative use of other imaging studies (CT, MRI, PET) is not recommended. Recommendation rating: E

[B5] *Measurement of serum Tg.* There is limited evidence that high preoperative concentrations of serum Tg may predict a higher sensitivity for postoperative surveillance with serum Tg (149). Evidence that this impacts patient management or outcomes is not yet available.

#### ■ RECOMMENDATION 23

Routine preoperative measurement of serum Tg is not recommended. Recommendation rating: E

[B6] What is the appropriate operation for indeterminate thyroid nodules and DTC? The goals of thyroid surgery can include provision of a diagnosis after a nondiagnostic or



**FIG. 2.** Lymph node compartments separated into levels and sublevels. Level VI contains the thyroid gland, and the adjacent nodes bordered superiorly by the hyoid bone, inferiorly by the innominate (brachiocephalic) artery, and laterally on each side by the carotid sheaths. The level II, III, and IV nodes are arrayed along the jugular veins on each side, bordered anteromedially by level VI and laterally by the posterior border of the sternocleidomastoid muscle. The level III nodes are bounded superiorly by the level of the hyoid bone, and inferiorly by the cricoid cartilage; levels II and IV are above and below level III, respectively. The level I node compartment includes the submental and submandibular nodes, above the hyoid bone, and anterior to the posterior edge of the submandibular gland. Finally, the level V nodes are in the posterior triangle, lateral to the lateral edge of the sternocleidomastoid muscle. Levels I, II, and V can be further subdivided as noted in the figure. The inferior extent of level VI is defined as the suprasternal notch. Many authors also include the pretracheal and paratracheal superior mediastinal lymph nodes above the level of the innominate artery (sometimes referred to as level VII) in central neck dissection (166).

indeterminate biopsy, removal of the thyroid cancer, staging, and preparation for radioactive ablation and serum Tg monitoring. Surgical options to address the primary tumor should be limited to hemithyroidectomy with or without isthmusectomy, near-total thyroidectomy (removal of all grossly visible thyroid tissue, leaving only a small amount [ $<1$  g] of tissue adjacent to the recurrent laryngeal nerve near the ligament of Berry), and total thyroidectomy (removal of all grossly visible thyroid tissue). Subtotal thyroidectomy, leaving  $>1$  g of tissue with the posterior capsule on the uninvolved side, is an inappropriate operation for thyroid cancer (150).

[B7] *Surgery for a nondiagnostic biopsy, a biopsy suspicious for papillary cancer or suggestive of "follicular neoplasm" (including special consideration for patients with other risk factors).* Amongst solitary thyroid nodules with an indeterminate ("follicular neoplasm" or Hürthle cell neoplasm) biopsy, the risk of malignancy is approximately 20% (151–153). The risk is higher with large tumors ( $>4$  cm), when atypical features (e.g., cellular pleomorphism) are seen on biopsy, when the biopsy reading is "suspicious for papillary carcinoma," in patients with a family history of thyroid carcinoma, and in patients with a history of radiation exposure (66,154,155). For solitary nodules that are repeatedly nondiagnostic on biopsy, the risk of malignancy is unknown but is probably closer to 5–10% (63).

#### ■ RECOMMENDATION 24

For patients with an isolated indeterminate solitary nodule who prefer a more limited surgical procedure, thyroid lobectomy is the recommended initial surgical approach. Recommendation rating: C

#### ■ RECOMMENDATION 25

- Because of an increased risk for malignancy, total thyroidectomy is indicated in patients with indeterminate nodules who have large tumors ( $>4$  cm), when marked atypia is seen on biopsy, when the biopsy reading is "suspicious for papillary carcinoma," in patients with a family history of thyroid carcinoma, and in patients with a history of radiation exposure. Recommendation rating: A
- Patients with indeterminate nodules who have bilateral nodular disease, or those who prefer to undergo bilateral thyroidectomy to avoid the possibility of requiring a future surgery on the contralateral lobe, should also undergo total or near-total thyroidectomy. Recommendation rating: C

[B8] *Surgery for a biopsy diagnostic for malignancy.* Near-total or total thyroidectomy is recommended if the primary thyroid carcinoma is  $>1$  cm (156), there are contralateral

thyroid nodules present or regional or distant metastases are present, the patient has a personal history of radiation therapy to the head and neck, or the patient has first-degree family history of DTC. Older age (>45 years) may also be a criterion for recommending near-total or total thyroidectomy even with tumors <1–1.5 cm, because of higher recurrence rates in this age group (112,116,122,123,157). Increased extent of primary surgery may improve survival for high-risk patients (158–160) and low-risk patients (156). A study of over 50,000 patients with PTC found on multivariate analysis that total thyroidectomy significantly improved recurrence and survival rates for tumors >1.0 cm (156). When examined separately, even patients with 1.0–2.0 cm tumors who underwent lobectomy, had a 24% higher risk of recurrence and a 49% higher risk of thyroid cancer mortality ( $p=0.04$  and  $p<0.04$ , respectively). Other studies have also shown that rates of recurrence are reduced by total or near total thyroidectomy among low-risk patients (122,161,162).

#### ■ RECOMMENDATION 26

For patients with thyroid cancer >1 cm, the initial surgical procedure should be a near-total or total thyroidectomy unless there are contraindications to this surgery. Thyroid lobectomy alone may be sufficient treatment for small (<1 cm), low-risk, unifocal, intrathyroidal papillary carcinomas in the absence of prior head and neck irradiation or radiologically or clinically involved cervical nodal metastases. Recommendation rating: A

[B9] *Lymph node dissection.* Regional lymph node metastases are present at the time of diagnosis in 20–90% of patients with papillary carcinoma and a lesser proportion of patients with other histotypes (129,139). Although PTC lymph node metastases are reported by some to have no clinically important effect on outcome in low risk patients, a study of the Surveillance, Epidemiology, and End Results (SEER) database found, among 9904 patients with PTC, that lymph node metastases, age >45 years, distant metastasis, and large tumor size significantly predicted poor outcome on multivariate analysis (163). All-cause survival at 14 years was 82% for PTC without lymph node and 79% with lymph node metastases ( $p<0.05$ ). Another recent SEER registry study concluded that cervical lymph node metastases conferred an independent risk of decreased survival, but only in patients with follicular cancer and patients with papillary cancer over age 45 years (164). Also, the risk of regional recurrence is higher in patients with lymph node metastases, especially in those patients with multiple metastases and/or extracapsular nodal extension (165).

In many patients, lymph node metastases in the central compartment (166) do not appear abnormal preoperatively with imaging (138) or by inspection at the time of surgery. Central compartment dissection (therapeutic or prophylactic) can be achieved with low morbidity in experienced hands (167–171), and may convert some patients from clinical N0 to pathologic N1a, upstaging patients over age 45 from American Joint Committee on Cancer (AJCC) stage I to III (172). A

recent consensus conference statement discusses the relevant anatomy of the central neck compartment, delineates the nodal subgroups within the central compartment commonly involved with thyroid cancer, and defines the terminology relevant to central compartment neck dissection (173).

Comprehensive bilateral central compartment node dissection may improve survival compared to historic controls and reduce risk for nodal recurrence (174). In addition, selective unilateral paratracheal central compartment node dissection increases the proportion of patients who appear disease free with unmeasurable Tg levels 6 months after surgery (175). Other studies of central compartment dissection have demonstrated higher morbidity, primarily recurrent laryngeal nerve injury and transient hypoparathyroidism, with no reduction in recurrence (176,177). In another study, comprehensive (bilateral) central compartment dissection demonstrated higher rates of transient hypoparathyroidism compared to selective (unilateral) dissection with no reduction in rates of undetectable or low Tg levels (178). Although some lymph node metastases may be treated with radioactive iodine, several treatments may be necessary, depending upon the histology, size, and number of metastases (179).

#### ■ RECOMMENDATION 27\*

- (a) Therapeutic central-compartment (level VI) neck dissection for patients with clinically involved central or lateral neck lymph nodes should accompany total thyroidectomy to provide clearance of disease from the central neck. Recommendation rating: B
- (b) Prophylactic central-compartment neck dissection (ipsilateral or bilateral) may be performed in patients with papillary thyroid carcinoma with clinically uninvolved central neck lymph nodes, especially for advanced primary tumors (T3 or T4). Recommendation rating: C
- (c) Near-total or total thyroidectomy without prophylactic central neck dissection may be appropriate for small (T1 or T2), noninvasive, clinically node-negative PTCs and most follicular cancer. Recommendation rating: C

These recommendations (R27a–c) should be interpreted in light of available surgical expertise. For patients with small, noninvasive, apparently node-negative tumors, the balance of risk and benefit may favor simple near-total thyroidectomy with close intraoperative inspection of the central compartment with compartmental dissection only in the presence of obviously involved lymph nodes. This approach may increase the chance of future locoregional recurrence, but overall this approach may be safer in less experienced surgical hands.

Lymph nodes in the lateral neck (compartments II–V), level VII (anterior mediastinum), and rarely in Level I may also be involved by thyroid cancer (129,180). For those patients in whom nodal disease is evident clinically, on preoperative US and nodal FNA or Tg measurement, or at the time of surgery, surgical resection may reduce the risk of recurrence and possibly mortality (56,139,181). Functional compartmental

\*R27a, 27b, 27c, and 28 were developed in collaboration with an *ad hoc* committee of endocrinologists (David S. Cooper, M.D., Richard T. Kloos, M.D., Susan J. Mandel, M.D., M.P.H., and R. Michael Tuttle, M.D.), otolaryngology-head and neck surgeons (Gregory Randolph, M.D., David Steward, M.D., David Terris, M.D. and Ralph Tufano, M.D.), and endocrine surgeons (Sally Carty, M.D., Gerard M. Doherty, M.D., Quan-Yang Duh, M.D., and Robert Udelsman, M.D., M.B.A.)

en-bloc neck dissection is favored over isolated lymphadenectomy (“berry picking”) with limited data suggesting improved mortality (118,182–184).

#### ■ RECOMMENDATION 28\*

Therapeutic lateral neck compartmental lymph node dissection should be performed for patients with biopsy-proven metastatic lateral cervical lymphadenopathy. Recommendation rating: B

[B10] *Completion thyroidectomy.* Completion thyroidectomy may be necessary when the diagnosis of malignancy is made following lobectomy for an indeterminate or non-diagnostic biopsy. Some patients with malignancy may require completion thyroidectomy to provide complete resection of multicentric disease (185), and to allow RAI therapy. Most (186,187) but not all (185) studies of papillary cancer have observed a higher rate of cancer in the opposite lobe when multifocal (two or more foci), as opposed to unifocal, disease is present in the ipsilateral lobe. The surgical risks of two-stage thyroidectomy (lobectomy followed by completion thyroidectomy) are similar to those of a near-total or total thyroidectomy (188).

#### ■ RECOMMENDATION 29

Completion thyroidectomy should be offered to those patients for whom a near-total or total thyroidectomy would have been recommended had the diagnosis been available before the initial surgery. This includes all patients with thyroid cancer except those with small (<1 cm), unifocal, intrathyroidal, node-negative, low-risk tumors. Therapeutic central neck lymph node dissection should be included if the lymph nodes are clinically involved. Recommendation rating: B

#### ■ RECOMMENDATION 30

Ablation of the remaining lobe with radioactive iodine has been used as an alternative to completion thyroidectomy (189). It is unknown whether this approach results in similar long-term outcomes. Consequently, routine radioactive iodine ablation in lieu of completion thyroidectomy is not recommended. Recommendation rating: D

[B11] What is the role of postoperative staging systems and which should be used?

[B12] *The role of postoperative staging.* Postoperative staging for thyroid cancer, as for other cancer types, is used: 1) to permit prognostication for an individual patient with DTC; 2) to tailor decisions regarding postoperative adjunctive therapy, including RAI therapy and TSH suppression, to assess the patient’s risk for disease recurrence and mortality; 3) to make decisions regarding the frequency and intensity of follow-up, directing more intensive follow-up towards patients at highest risk; and 4) to enable accurate communication regarding a patient among health care professionals. Staging systems also allow evaluation of differing therapeutic strategies applied to comparable groups of patients in clinical studies.

[B13] *AJCC/UICC TNM staging.* Application of the AJCC/International Union against Cancer (AJCC/UICC) classification system based on pTNM parameters and age is recommended for tumors of all types, including thyroid cancer (121,190), because it provides a useful shorthand method to describe the extent of the tumor (191) (Table 4). This classification is also used for hospital cancer registries and epidemiologic studies. In thyroid cancer, the AJCC/UICC stage does not take account of several additional independent prognostic variables and may risk misclassification of some patients. Numerous other schemes have been developed in an effort to achieve more accurate risk factor stratification, including CAEORTC, AGES, AMES, U of C, MACIS, OSU, MSKCC, and NTCTCS systems. (107,116,122,159,192–195). These schemes take into account a number of factors identified as prognostic for outcome in multivariate analysis of retrospective studies, with the most predictive factors generally being regarded as the presence of distant metastases, the age of the patient, and the extent of the tumor. These and other risk factors are weighted differently among these systems according to their importance in predicting outcome, but no scheme has demonstrated clear superiority (195). Each of the schemes allows accurate identification of the majority (70–85%) of patients at low-risk of mortality (T1–3, M0 patients), allowing the follow-up and management of these patients to be less intensive than the higher-risk minority (T4 and M1 patients), who may benefit from a more aggressive management strategy (195). Nonetheless, none of the examined staging classifications is able to account for more than a small proportion of the uncertainty in either short-term, disease-specific mortality or the likelihood of remaining disease free (121,195,196). AJCC/IUCC staging was developed to predict risk for death, not recurrence. For assessment of risk of recurrence, a three-level stratification can be used:

- Low-risk patients have the following characteristics: 1) no local or distant metastases; 2) all macroscopic tumor has been resected; 3) there is no tumor invasion of locoregional tissues or structures; 4) the tumor does not have aggressive histology (e.g., tall cell, insular, columnar cell carcinoma) or vascular invasion; 5) and, if <sup>131</sup>I is given, there is no <sup>131</sup>I uptake outside the thyroid bed on the first posttreatment whole-body RAI scan (RxWBS) (197–199).
- Intermediate-risk patients have any of the following: 1) microscopic invasion of tumor into the perithyroidal soft tissues at initial surgery; 2) cervical lymph node metastases or <sup>131</sup>I uptake outside the thyroid bed on the RxWBS done after thyroid remnant ablation (200,201); or 3) tumor with aggressive histology or vascular invasion (202–204).
- High-risk patients have 1) macroscopic tumor invasion, 2) incomplete tumor resection, 3) distant metastases, and possibly 4) thyroglobulinemia out of proportion to what is seen on the posttreatment scan (205).

Since initial staging is based on clinico-pathologic factors that are available shortly after diagnosis and initial therapy, the AJCC stage of the patient does not change over time.

\*See footnote, page 1179.

TABLE 4. TNM CLASSIFICATION SYSTEM FOR DIFFERENTIATED THYROID CARCINOMA

	Definition	
T1	Tumor diameter 2 cm or smaller	
T2	Primary tumor diameter >2 to 4 cm	
T3	Primary tumor diameter >4 cm limited to the thyroid or with minimal extrathyroidal extension	
T4 <sub>a</sub>	Tumor of any size extending beyond the thyroid capsule to invade subcutaneous soft tissues, larynx, trachea, esophagus, or recurrent laryngeal nerve	
T4 <sub>b</sub>	Tumor invades prevertebral fascia or encases carotid artery or mediastinal vessels	
TX	Primary tumor size unknown, but without extrathyroidal invasion	
N0	No metastatic nodes	
N1 <sub>a</sub>	Metastases to level VI (pretracheal, paratracheal, and prelaryngeal/Delphian lymph nodes)	
N1 <sub>b</sub>	Metastasis to unilateral, bilateral, contralateral cervical or superior mediastinal nodes	
NX	Nodes not assessed at surgery	
M0	No distant metastases	
M1	Distant metastases	
MX	Distant metastases not assessed	
Stages		
	<i>Patient age &lt;45 years</i>	<i>Patient age 45 years or older</i>
Stage I	Any T, any N, M0	T1, N0, M0
Stage II	Any T, any N, M1	T2, N0, M0
Stage III		T3, N0, M0
		T1, N1 <sub>a</sub> , M0
		T2, N1 <sub>a</sub> , M0
Stage IVA		T3, N1 <sub>a</sub> , M0
		T4 <sub>a</sub> , N0, M0
		T4 <sub>a</sub> , N1 <sub>a</sub> , M0
		T1, N1 <sub>b</sub> , M0
Stage IVB		T2, N1 <sub>b</sub> , M0
		T3, N1 <sub>b</sub> , N0
		T4 <sub>a</sub> , N1 <sub>b</sub> , M0
Stage IVC		T4 <sub>b</sub> , Any N, M0
		Any T, Any N, M1

Used with the permission of the American Joint Committee on Cancer (AJCC), Chicago, Illinois. The original source for this material is the AJCC Cancer Staging Manual, Sixth Edition (435).

However, depending on the clinical course of the disease and response to therapy, the risk of recurrence and the risk of death may change over time. Appropriate management requires an ongoing reassessment of the risk of recurrence and the risk of disease-specific mortality as new data are obtained during follow-up (206).

■ **RECOMMENDATION 31**

Because of its utility in predicting disease mortality, and its requirement for cancer registries, AJCC/UICC staging is recommended for all patients with DTC. The use of postoperative clinico-pathologic staging systems is also recommended to improve prognostication and to plan follow-up for patients with DTC. Recommendation rating: B

[B14] What is the role of postoperative RAI remnant ablation? Postoperative RAI remnant ablation is increasingly being used to eliminate the postsurgical thyroid remnant (122). Ablation of the small amount of residual normal thyroid remaining after total thyroidectomy may facilitate the early detection of recurrence based on serum Tg measurement and/or RAI WBS. Additionally, the posttherapy scan ob-

tained at the time of remnant ablation may facilitate initial staging by identifying previously undiagnosed disease, especially in the lateral neck. Furthermore, from a theoretical point of view, this first dose of RAI may also be considered *adjuvant therapy* because of the potential tumoricidal effect on persistent thyroid cancer cells remaining after appropriate surgery in patients at risk for recurrence or disease specific mortality. Depending on the risk stratification of the individual patient, the primary goal of the first dose of RAI after total thyroidectomy may be 1) *remnant ablation* (to facilitate detection of recurrent disease and initial staging), 2) *adjuvant therapy* (to decrease risk of recurrence and disease specific mortality by destroying suspected, but unproven metastatic disease), or 3) *RAI therapy* (to treat known persistent disease). While these three goals are closely interrelated, a clearer understanding of the specific indications for treatment will improve our ability to select patients most likely to benefit from RAI after total thyroidectomy, and will also influence our recommendations regarding choice of administered activity for individual patients. Supporting the use of RAI as adjuvant therapy, a number of large, retrospective studies show a significant reduction in the rates of disease recurrence

(107,159,160,207) and cause-specific mortality (159,160,207–209). However, other similar studies show no such benefit, at least among the majority of patients with PTC, who are at the lowest risk for mortality (110,122,162,209–212). In those studies that show benefit, the advantage appears to be restricted to patients with tumors >1.5 cm, or with residual disease following surgery, while lower-risk patients do not show evidence for benefit (122,159,213). The National Thyroid Cancer Treatment Cooperative Study Group (NTCTCSG) report (214) of 2936 patients found after a median follow-up of 3 years, that near-total thyroidectomy followed by RAI therapy and aggressive thyroid hormone suppression therapy predicted improved overall survival of patients with NTCTCSG stage III and IV disease, and was also beneficial for patients with NTCTCSG stage II disease. No impact of therapy was observed in patients with stage I disease. It should be noted that the NTCTCSG staging criteria are similar but not identical to the AJCC criteria. Thus, older patients with microscopic extrathyroidal extension are stage II in the NTCTCSG system, but are stage III in the AJCC system. There are recent data suggesting a benefit of RAI in patients with more aggressive histologies (215). There are no prospective randomized trials that have addressed this question (209). Unfortunately, many clinical circumstances have not been examined with regard to the efficacy of RAI ablative therapy. Table 5 presents a framework for deciding whether RAI is worthwhile, solely based on the AJCC classification, and provides the rationale for therapy and the strength of existing evidence for or against treatment.

In addition to the major factors listed in Table 5, several other histological features may place the patient at higher risk of local recurrence or metastases than would have been predicted by the AJCC staging system. These include worrisome histologic subtypes (such as tall cell, columnar, insular, and solid variants, as well as poorly differentiated thyroid cancer),

the presence of intrathyroidal vascular invasion, or the finding of gross or microscopic multifocal disease. While many of these features have been associated with increased risk, there are inadequate data to determine whether RAI ablation has a benefit based on specific histologic findings, independent of tumor size, lymph node status, and the age of the patient. Therefore, while RAI ablation is not recommended for all patients with these higher risk histologic features, the presence of these features in combination with size of the tumor, lymph node status, and patient age may increase the risk of recurrence or metastatic spread to a degree that is high enough to warrant RAI ablation in selected patients. However, in the absence of data for most of these factors, clinical judgment must prevail in the decision-making process. For microscopic multifocal papillary cancer, when all foci are <1 cm, recent data suggest that RAI is of no benefit in preventing recurrence (216,217).

Nonpapillary histologies (such as follicular thyroid cancer and Hürthle cell cancer) are generally regarded as higher risk tumors. Expert opinion supports the use of RAI in almost all of these cases. However, because of the excellent prognosis associated with surgical resection alone in small follicular thyroid cancers manifesting only capsular invasion (without vascular invasion (so-called “minimally invasive follicular cancer”), RAI ablation may not be required for all patients with this histological diagnosis (112).

#### ■ RECOMMENDATION 32

- (a) RAI ablation is recommended for all patients with known distant metastases, gross extrathyroidal extension of the tumor regardless of tumor size, or primary tumor size >4 cm even in the absence of other higher risk features (see Table 5 for strength of evidence).
- (b) RAI ablation is recommended for selected patients with 1–4 cm thyroid cancers confined to the thyroid,

TABLE 5. MAJOR FACTORS IMPACTING DECISION MAKING IN RADIOIODINE REMNANT ABLATION

Factors	Description	Expected benefit			RAI ablation usually recommended	Strength of evidence
		Decreased risk of death	Decreased risk of recurrence	May facilitate initial staging and follow-up		
T1	1 cm or less, intrathyroidal or microscopic multifocal	No	No	Yes	No	E
	1–2 cm, intrathyroidal	No	Conflicting data <sup>a</sup>	Yes	Selective use <sup>a</sup>	I
T2	>2–4 cm, intrathyroidal	No	Conflicting data <sup>a</sup>	Yes	Selective use <sup>a</sup>	C
T3	>4 cm					
	<45 years old	No	Conflicting data <sup>a</sup>	Yes	Yes	B
	≥45 years old	Yes	Yes	Yes	Yes	B
	Any size, any age, minimal extrathyroidal extension	No	Inadequate data <sup>a</sup>	Yes	Selective use <sup>a</sup>	I
T4	Any size with gross extrathyroidal extension	Yes	Yes	Yes	Yes	B
Nx,N0	No metastatic nodes documented	No	No	Yes	No	I
N1	<45 years old	No	Conflicting data <sup>a</sup>	Yes	Selective use <sup>a</sup>	C
	>45 years old	Conflicting data	Conflicting data <sup>a</sup>	Yes	Selective use <sup>a</sup>	C
M1	Distant metastasis present	Yes	Yes	Yes	Yes	A

<sup>a</sup>Because of either conflicting or inadequate data, we cannot recommend either for or against RAI ablation for this entire subgroup. However, selected patients within this subgroup with higher risk features may benefit from RAI ablation (see modifying factors in the text).



who have documented lymph node metastases, or other higher risk features (see preceding paragraphs) when the combination of age, tumor size, lymph node status, and individual histology predicts an intermediate to high risk of recurrence or death from thyroid cancer (see Table 5 for strength of evidence for individual features). Recommendation rating: C (for selective use in higher risk patients)

- (c) RAI ablation is not recommended for patients with unifocal cancer <1 cm without other higher risk features (see preceding paragraphs). Recommendation rating: E
- (d) RAI ablation is not recommended for patients with multifocal cancer when all foci are <1 cm in the absence other higher risk features (see preceding paragraphs). Recommendation rating: E

[B15] How should patients be prepared for RAI ablation? (see Fig. 3) Remnant ablation requires TSH stimulation. No controlled studies have been performed to assess adequate levels of endogenous TSH for optimal ablation therapy or follow-up testing. Noncontrolled studies suggest that a TSH of >30 mU/L is associated with increased RAI uptake in tumors (218), while studies using single dose exogenous TSH suggest maximal thyrocyte stimulation at TSH levels between 51 and 82 mU/L (219, 220). However, the total area under the TSH curve, and not simply the peak serum TSH concentration, is also potentially important for optimal RAI uptake by thyroid follicular cells. Endogenous TSH elevation can be achieved by two basic approaches to thyroid hormone withdrawal, stopping LT<sub>4</sub> and switching to LT<sub>3</sub> for 2–4 weeks followed by withdrawal of LT<sub>3</sub> for 2 weeks, or discontinuation of LT<sub>4</sub> for 3 weeks without use of LT<sub>3</sub>. Both methods of preparation can achieve serum TSH levels >30 mU/L in >90% of patients (220–229). These two approaches have not been directly compared for efficiency of patient preparation (efficacy of ablation, iodine uptake, Tg levels, disease detection), although a recent prospective study showed no difference in hypothyroid symptoms between these two approaches (230). Other preparative methods have been proposed, but have not been validated by other investigators (231,232). Children with thyroid cancer achieve adequate TSH elevation within 14 days of LT<sub>4</sub> withdrawal (233). A low serum Tg level at the time of ablation has excellent negative predictive value for absence of residual disease, and the risk of persistent disease increases with higher stimulated Tg levels (198,205,234).

#### ■ RECOMMENDATION 33

Patients undergoing RAI therapy or diagnostic testing can be prepared by LT<sub>4</sub> withdrawal for at least 2–3 weeks or LT<sub>3</sub> treatment for 2–4 weeks and LT<sub>3</sub> withdrawal for 2 weeks with measurement of serum TSH to determine timing of testing or therapy (TSH >30 mU/L). Thyroxine therapy (with or without LT<sub>3</sub> for 7–10 days) may be resumed on the second or third day after RAI administration. Recommendation rating: B

[B16] Can rhTSH (Thyrogen™) be used in lieu of thyroxine withdrawal for remnant ablation? For most patients, including those unable to tolerate hypothyroidism or unable to generate an elevated TSH, remnant ablation can be achieved with

rhTSH (235,236). A prospective randomized study found that thyroid hormone withdrawal and rhTSH stimulation were equally effective in preparing patients for <sup>131</sup>I remnant ablation with 100 mCi with significantly improved quality of life (237). Another randomized study using rhTSH showed that ablation rates were comparable with 50 mCi compared to 100 mCi with a significant decrease (33%) in whole-body irradiation (238). Finally, a recent study has shown that ablation rates were similar with either withdrawal or preparation with rhTSH using 50 mCi of <sup>131</sup>I (239). In addition, short-term recurrence rates have been found to be similar in patients prepared with thyroid hormone withdrawal or rhTSH (240). Recombinant human TSH is approved for remnant ablation in the United States, Europe, and many other countries around the world.

#### ■ RECOMMENDATION 34


Remnant ablation can be performed following thyroxine withdrawal or rhTSH stimulation. Recommendation rating: A

[B17] Should RAI scanning be performed before RAI ablation? RAI WBS provides information on the presence of iodine-avid thyroid tissue, which may represent the normal thyroid remnant or the presence of residual disease in the postoperative setting. In the presence of a large thyroid remnant, the scan is dominated by uptake within the remnant, potentially masking the presence of extrathyroidal disease within locoregional lymph nodes, the upper mediastinum, or even at distant sites, reducing the sensitivity of disease detection (241). Furthermore, there is an increasing trend to avoid pretherapy RAI scans altogether because of its low impact on the decision to ablate, and because of concerns over <sup>131</sup>I-induced stunning of normal thyroid remnants (242) and distant metastases from thyroid cancer (243). Stunning is defined as a reduction in uptake of the <sup>131</sup>I therapy dose induced by a pretreatment diagnostic activity. Stunning occurs most prominently with higher activities (5–10 mCi) of <sup>131</sup>I (244), with increasing time between the diagnostic dose and therapy (245), and does not occur if the treatment dose is given within 72 hours of the scanning dose (246). However, the accuracy of low-activity <sup>131</sup>I scans has been questioned, and some research has reported quantitatively the presence of stunning below the threshold of visual detection (247). Although comparison studies show excellent concordance between <sup>123</sup>I and <sup>131</sup>I for tumor detection, optimal <sup>123</sup>I activity and time to scan after <sup>123</sup>I administration are not known (248). Furthermore, <sup>123</sup>I is expensive, is not universally available, its short half life (t<sub>1/2</sub> = 13 hours) makes handling this isotope logistically more difficult (249), and stunning may also occur though to a lesser degree than with <sup>131</sup>I (245). Furthermore, a recent study showed no difference in ablation rates between patients that had pretherapy scans with <sup>123</sup>I (81%) compared to those who had received diagnostic scans using 2 mCi of <sup>131</sup>I (74%, *p* > 0.05) (250). Alternatively, determination of the thyroid bed uptake, without scanning, can be achieved using 10–100 μCi <sup>131</sup>I.

#### ■ RECOMMENDATION 35

Pretherapy scans and/or measurement of thyroid bed uptake may be useful when the extent of the thyroid remnant cannot be accurately ascertained from the surgical report or neck ultrasonography, or when the results would alter

**ALGORITHM FOR REMNANT ABLATION:  
Initial Follow-Up in Patients with Differentiated Thyroid  
Carcinoma in Whom Remnant Ablation is Indicated  
One to Three Months after Surgery**



**FIG. 3.** Algorithm for initial follow-up of patients with differentiated thyroid carcinoma.

<sup>a</sup>EBRT, external beam radiotherapy. The usual indication for EBRT is macroscopic unresectable tumor in a patient older than 45 years; it is not usually recommended for children and adults less than age 45.

<sup>b</sup>Neck ultrasonography of operated cervical compartments is often compromised for several months after surgery.

<sup>c</sup>Tg, thyroglobulin with anti-thyroglobulin antibody measurement; serum Tg is usually measured by immunometric assay and may be falsely elevated for several weeks by injury from surgery or by heterophile antibodies, although a very high serum Tg level after surgery usually indicates residual disease.

<sup>d</sup>Some clinicians suspect residual disease when malignant lymph nodes, or tumors with aggressive histologies (as defined in the text) have been resected, or when there is a microscopically positive margin of resection.

<sup>e</sup>rhTSH is recombinant human TSH and is administered as follows: 0.9 mg rhTSH i.m. on two consecutive days, followed by <sup>131</sup>I therapy on the third day.

<sup>f</sup>THW is levothyroxine and/or triiodothyronine withdrawal.

<sup>g</sup>See text for exceptions regarding remnant ablation. The smallest amount of <sup>131</sup>I necessary to ablate normal thyroid remnant tissue should be used. DxWBS (diagnostic whole-body scintigraphy) is not usually necessary at this point, but may be performed if the outcome will change the decision to treat with radioiodine and/or the amount of administered activity.

<sup>h</sup>RxWBS is posttreatment whole-body scan done 5 to 8 days after therapeutic <sup>131</sup>I administration.

<sup>i</sup>Uptake in the thyroid bed may indicate normal remnant tissue or residual central neck nodal metastases.

either the decision to treat or the activity of RAI that is administered. If performed, pretherapy scans should utilize  $^{123}\text{I}$  (1.5–3 mCi) or low-activity  $^{131}\text{I}$  (1–3 mCi), with the therapeutic activity optimally administered within 72 hours of the diagnostic activity. Recommendation rating: C

[B18] *What activity of  $^{131}\text{I}$  should be used for remnant ablation?* Successful remnant ablation is usually defined as an absence of visible RAI uptake on a subsequent diagnostic RAI scan or an undetectable stimulated serum Tg. Activities between 30 and 100 mCi of  $^{131}\text{I}$  generally show similar rates of successful remnant ablation (251–254) and recurrence rates (213). Although there is a trend toward higher ablation rates with higher activities (255,256), a recent prospective randomized study found no significant difference in the remnant ablation rate using 30 or 100 mCi of  $^{131}\text{I}$  (257). Furthermore, there are data showing that 30 mCi is effective in ablating the remnant with rhTSH preparation (258). In pediatric patients, it is preferable to adjust the ablation activity according to the patient's body weight (259) or surface area (260).

#### ■ RECOMMENDATION 36

The minimum activity (30–100 mCi) necessary to achieve successful remnant ablation should be utilized, particularly for low-risk patients. Recommendation rating: B

#### ■ RECOMMENDATION 37

If residual microscopic disease is suspected or documented, or if there is a more aggressive tumor histology (e.g., tall cell, insular, columnar cell carcinoma), then higher activities (100–200 mCi) may be appropriate. Recommendation rating: C

[B19] *Is a low-iodine diet necessary before remnant ablation?* The efficacy of radioactive iodine depends on the radiation dose delivered to the thyroid tissue (261). Low-iodine diets (<50  $\mu\text{g}/\text{d}$  of dietary iodine) and simple recommendations to avoid iodine contamination have been recommended prior to RAI therapy (261–263) to increase the effective radiation dose. A history of possible iodine exposure (e.g., intravenous contrast, amiodarone use) should be sought. Measurement of iodine excretion with a spot urinary iodine determination may be a useful way to identify patients whose iodine intake could interfere with RAI remnant ablation (263). Information about low-iodine diets can be obtained at the Thyroid Cancer Survivors Association website ([www.thyca.org](http://www.thyca.org)).

#### ■ RECOMMENDATION 38

A low-iodine diet for 1–2 weeks is recommended for patients undergoing RAI remnant ablation, particularly for those patients with high iodine intake. Recommendation rating: B

[B20] *Should a posttherapy scan be performed following remnant ablation?* Posttherapy whole-body iodine scanning is typically conducted approximately 1 week after RAI therapy to visualize metastases. Additional metastatic foci have been reported in 10–26% of patients scanned following high-dose RAI treatment compared with the diagnostic scan (264,265). The new abnormal uptake was found most often in

the neck, lungs, and mediastinum, and the newly discovered disease altered the disease stage in approximately 10% of the patients, affecting clinical management in 9–15% (264–266). Iodine 131 single photon emission computed tomography (SPECT)/CT fusion imaging may provide superior lesion localization after remnant ablation, but it is still a relatively new imaging modality (267).

#### ■ RECOMMENDATION 39

A posttherapy scan is recommended following RAI remnant ablation. This is typically done 2–10 days after the therapeutic dose is administered, although published data supporting this time interval are lacking. Recommendation rating: B

#### [B21] *Postsurgery and RAI therapy early management of DTC*

[B22] *What is the role of TSH suppression therapy?* DTC expresses the TSH receptor on the cell membrane and responds to TSH stimulation by increasing the expression of several thyroid specific proteins (Tg, sodium-iodide symporter) and by increasing the rates of cell growth (268). Suppression of TSH, using supra-physiologic doses of  $\text{LT}_4$ , is used commonly to treat patients with thyroid cancer in an effort to decrease the risk of recurrence (127,214,269). A meta-analysis supported the efficacy of TSH suppression therapy in preventing major adverse clinical events (RR = 0.73; CI = 0.60–0.88;  $p < 0.05$ ) (269).

[B23] *What is the appropriate degree of initial TSH suppression?* Retrospective and prospective studies have demonstrated that TSH suppression to below 0.1 mU/L may improve outcomes in high-risk thyroid cancer patients (127,270), though no such evidence of benefit has been documented in low-risk patients. A prospective cohort study (214) of 2936 patients found that overall survival improved significantly when the TSH was suppressed to undetectable levels in patients with NTCTCSG stage III or IV disease and suppressed to the subnormal to undetectable range in patients with NTCTCSG stage II disease; however, in the latter group there was no incremental benefit from suppressing TSH to undetectable levels. Suppression of TSH was not beneficial in patients with stage I disease. In another study, there was a positive association between serum TSH levels and the risk for recurrent disease and cancer-related mortality (271). Adverse effects of TSH suppression may include the known consequences of subclinical thyrotoxicosis, including exacerbation of angina in patients with ischemic heart disease, increased risk for atrial fibrillation in older patients (272), and increased risk of osteoporosis in postmenopausal women (273).

#### ■ RECOMMENDATION 40

Initial TSH suppression to below 0.1 mU/L is recommended for high-risk and intermediate-risk thyroid cancer patients, while maintenance of the TSH at or slightly below the lower limit of normal (0.1–0.5 mU/L) is appropriate for low-risk patients. Similar recommendations apply to low-risk patients who have not undergone remnant ablation, i.e., serum TSH 0.1–0.5 mU/L. Recommendation rating: B

[B24] Is there a role for adjunctive external beam irradiation or chemotherapy?

[B25] *External beam irradiation.* External beam irradiation is used infrequently in the management of thyroid cancer except as a palliative treatment for locally advanced, otherwise unresectable disease (274). There are reports of responses among patients with locally advanced disease (275,276) and improved relapse-free and cause-specific survival in patients over age 60 with extrathyroidal extension but no gross residual disease (277). It remains unknown whether external beam radiation might reduce the risk for recurrence in the neck following adequate primary surgery and/or RAI treatment in patients with aggressive histologic subtypes (278).

#### ■ RECOMMENDATION 41

The use of external beam irradiation to treat the primary tumor should be considered in patients over age 45 with grossly visible extrathyroidal extension at the time of surgery and a high likelihood of microscopic residual disease, and for those patients with gross residual tumor in whom further surgery or RAI would likely be ineffective. The sequence of external beam irradiation and RAI therapy depends on the volume of gross residual disease and the likelihood of the tumor being RAI responsive. Recommendation rating: B

[B26] *Chemotherapy.* There are no data to support the use of adjunctive chemotherapy in the management of DTC. Doxorubicin may act as a radiation sensitizer in some tumors of thyroid origin (279), and could be considered for patients with locally advanced disease undergoing external beam radiation.

#### ■ RECOMMENDATION 42

There is no role for the routine adjunctive use of chemotherapy in patients with DTC. Recommendation rating: F

### [C1] DTC: LONG-TERM MANAGEMENT GUIDELINES

#### [C2] *What are the appropriate features of long-term management?*

Accurate surveillance for possible recurrence in patients thought to be free of disease is a major goal of long-term follow-up. Tests with high negative predictive value allow identification of patients unlikely to experience disease recurrence, so that less aggressive management strategies can be used that may be more cost effective and safe. Similarly, patients with a higher risk of recurrence are monitored more aggressively because it is believed that early detection of recurrent disease offers the best opportunity for effective treatment. A large study (280), found that the residual life span in disease-free patients treated with total or near-total thyroidectomy and <sup>131</sup>I for remnant ablation and, in some cases, high dose <sup>131</sup>I for residual disease, was similar to that in the general Dutch population. In contrast, the life expectancy for patients with persistent disease was reduced to 60% of that in the general population but varied widely depending upon tumor features. Age was not a factor in disease-specific mortality when patients were compared with aged matched individuals in the Dutch population. Treatment thus appears safe and does not shorten life expectancy. Although an in-

creased incidence of second tumors in thyroid cancer patients has been recognized (157,281) this elevated risk was not found to be associated with the use of <sup>131</sup>I in another study (282), and RAI therapy in low-risk patients did not affect median overall survival in another (210). Patients with persistent or recurrent disease are offered treatment to cure or to delay future morbidity or mortality. In the absence of such options, therapies to palliate by substantially reducing tumor burden or preventing tumor growth are utilized, with special attention paid to tumors threatening critical structures.

A second goal of long-term follow-up is to monitor thyroxine suppression or replacement therapy, to avoid under-replacement or overly aggressive therapy (283).

#### [C3] *What is the appropriate method for following patients after surgery with or without remnant ablation?*

See Fig. 4 for an algorithm for the first 6–12 months of management.

[C4] What are the criteria for absence of persistent tumor? In patients who have undergone total or near-total thyroidectomy and thyroid remnant ablation, disease-free status comprises all of the following:

- 1) no clinical evidence of tumor,
- 2) no imaging evidence of tumor (no uptake outside the thyroid bed on the initial posttreatment WBS, or, if uptake outside the thyroid bed had been present, no imaging evidence of tumor on a recent diagnostic scan and neck US), and
- 3) undetectable serum Tg levels during TSH suppression and stimulation in the absence of interfering antibodies.

[C5] What is the role of serum Tg assays in the follow up of DTC? Measurement of serum Tg levels is an important modality to monitor patients for residual or recurrent disease. Most laboratories currently use immunometric assays to measure serum Tg, and it is important that these assays are calibrated against the CRM-457 international standard. Despite improvements in standardization of thyroglobulin assays, there is still a twofold difference between some assays (149), leading to the recommendation that measurements in individual patients over time be performed in the same assay. Immunometric assays are prone to interference from Tg autoantibodies, which commonly cause falsely low serum Tg measurements. Radioimmunoassays may be less prone to antibody interference, but are not as widely available, and their role in the clinical care of patients is uncertain. In the absence of antibody interference, serum Tg has a high degree of sensitivity and specificity to detect thyroid cancer, especially after total thyroidectomy and remnant ablation, with the highest degrees of sensitivity noted following thyroid hormone withdrawal or stimulation using rhTSH (284). Serum Tg measurements obtained during thyroid hormone suppression of TSH, and, less commonly during TSH stimulation, may fail to identify patients with relatively small amounts of residual tumor (197,285,286). Conversely, even TSH-stimulated Tg measurement may fail to identify patients with clinically significant tumor, due to anti-Tg antibodies or less commonly to defective or absent production and secretion of




FIG. 4. Longer term follow-up of patients with differentiated thyroid carcinoma.

<sup>a</sup>TgAb is anti-thyroglobulin antibody usually measured by immunometric assay.

<sup>b</sup>Heterophile antibodies may be a cause of falsely elevated serum Tg levels (436,437). The use of heterophile blocking tubes or heterophile blocking reagents have reduced, but not completely eliminated this problem. Tg that rises with TSH stimulation and falls with TSH suppression is unlikely to result from heterophile antibodies.

<sup>c</sup>See text concerning further information regarding levels of Tg at which therapy should be considered.

<sup>d</sup>Tg radioimmunoassay (RIA) may be falsely elevated or suppressed by TgAb. Tg results following TSH stimulation with rhTSH or thyroid hormone withdrawal are invalidated by TgAb in the serum even when Tg is measured by most RIA tests. TgAb levels often decline to undetectable levels over years following surgery (306). A rising level of TgAb may be an early indication of recurrent disease (305).

<sup>e</sup>See text for decision regarding surgery versus medical therapy, and surgical approaches to locoregional metastases. FNA confirmation of malignancy is generally advised. Preoperative chest CT is recommended as distant metastases may change management.

immunoreactive Tg by tumor cells (286). Tg levels should be interpreted in light of the pretest probability of clinically significant residual tumor. An aggressive or poorly differentiated tumor may be present despite low basal or stimulated Tg; in contrast, a minimally elevated stimulated Tg may occur in patients at low risk for clinically significant morbidity (287). Nevertheless, a single rhTSH-stimulated serum Tg <0.5 ng/mL in the absence of anti-Tg antibody has an approximately 98–99.5% likelihood of identifying patients completely free of tumor on follow-up (288,289).

Follow-up of low-risk patients who have undergone total or near-total thyroidectomy alone without <sup>131</sup>I remnant ablation or hemithyroidectomy alone may represent a challenge. A cohort of 80 consecutive patients with very low-risk papillary thyroid microcarcinoma who had undergone near-total thyroidectomy without postoperative RAI treatment was studied over 5 years (290). The rhTSH-stimulated serum Tg levels were ≤1 ng/mL in 45 patients (56%) and >1 ng/mL in 35 (44%) patients in whom rhTSH-stimulated Tg levels were as high as 25 ng/mL. The diagnostic WBS (DxWBS) revealed uptake in the thyroid bed but showed no pathological uptake in any patient, and thyroid bed uptake correlated with the rhTSH-stimulated serum Tg levels ( $p < 0.0001$ ). Neck ultrasonography identified lymph node metastases in both Tg-positive and Tg-negative patients. The authors concluded that for follow-up of this group of patients: 1) WBS was ineffective in detecting metastases; 2) neck ultrasonography as the main surveillance tool was highly sensitive in detecting node metastases; and 3) detectable rhTSH-stimulated serum Tg levels mainly depended upon the size of thyroid remnants.

Initial follow-up for low-risk patients (about 85% of postoperative patients) who have undergone total or near-total thyroidectomy and <sup>131</sup>I remnant ablation should be based mainly on TSH-suppressed Tg and cervical US, followed by TSH-stimulated serum Tg measurements if the TSH-suppressed Tg testing is undetectable (197,285). However, a Tg assay with a functional sensitivity of 0.1 ng/mL may reduce the need to perform TSH-stimulated Tg measurements during the initial follow-up of some patients. In one study of this assay, a T<sub>4</sub>-suppressed serum Tg <0.1 ng/mL was only rarely (2.5%) associated with an rhTSH-stimulated Tg >2 ng/mL; however, 61.5% of the patients had baseline Tg elevation >0.1 ng/mL, but only one patient was found to have residual tumor (291). In another study of the same assay (292), a TSH-suppressed serum Tg level was >0.1 ng/mL in 14% of patients, but the false-positive rate was 35% using an rhTSH-stimulated Tg cutoff of >2 ng/mL, raising the possibility of unnecessary testing and treatment. The only prospective study also documented increased sensitivity of detection of disease at the expense of reduced specificity (293).

Approximately 20% of patients who are clinically free of disease with serum Tg levels <1 ng/mL during thyroid hormone suppression of TSH (285) will have a serum Tg level >2 ng/mL after rhTSH or thyroid hormone withdrawal at 12 months after initial therapy with surgery and RAI. In this patient population, one third will have identification of persistent or recurrent disease and of increasing Tg levels, and the other two thirds will remain free of clinical disease and will have stable or decreasing stimulated serum Tg levels over time (294). There is good evidence that a Tg cutoff level above 2 ng/mL following rhTSH stimulation is highly sensitive in identifying

patients with persistent tumor (285,295–300). However, the results of serum Tg measurements made on the same serum specimen differ among assay methods (149). Therefore, the Tg cutoff may differ significantly among medical centers and laboratories. Further, the clinical significance of minimally detectable Tg levels is unclear, especially if only detected following TSH stimulation. In these patients, the trend in serum Tg over time will typically identify patients with clinically significant residual disease. A rising unstimulated or stimulated serum Tg indicates disease that is likely to become clinically apparent (294,301).

The presence of anti-Tg antibodies, which occur in approximately 25% of thyroid cancer patients (302) and 10% of the general population (303), will falsely lower serum Tg determinations in immunometric assays (304). The use of recovery assays in this setting to detect significant interference is controversial (201,304). Serial serum anti-Tg antibody quantification using the same methodology may serve as an imprecise surrogate marker of residual normal thyroid tissue or tumor (305, 306).

#### ■ RECOMMENDATION 43

Serum Tg should be measured every 6–12 months by an immunometric assay that is calibrated against the CRM-457 standard. Ideally, serum Tg should be assessed in the same laboratory and using the same assay, during follow-up of patients with DTC who have undergone total or near total thyroidectomy with or without thyroid remnant ablation. Thyroglobulin antibodies should be quantitatively assessed with every measurement of serum Tg. Recommendation rating: A

#### ■ RECOMMENDATION 44

Periodic serum Tg measurements and neck ultrasonography should be considered during follow-up of patients with DTC who have undergone less than total thyroidectomy, and in patients who have had a total thyroidectomy but not RAI ablation. While specific cutoff levels during TSH suppression or stimulation that optimally distinguish normal residual thyroid tissue from persistent thyroid cancer are unknown, rising Tg values over time are suspicious for growing thyroid tissue or cancer. Recommendation rating: B

#### ■ RECOMMENDATION 45

(a) In low-risk patients who have had remnant ablation and negative cervical US and undetectable TSH-suppressed Tg within the first year after treatment, serum Tg should be measured after thyroxine withdrawal or rhTSH stimulation approximately 12 months after the ablation to verify absence of disease. Recommendation rating: A

The timing or necessity of subsequent stimulated testing is uncertain for those found to be free of disease, because there is infrequent benefit in this patient cohort from repeated TSH-stimulated Tg testing (289).

(b) Low-risk patients who have had remnant ablation, negative cervical US, and undetectable TSH-stimulated Tg can be followed primarily with yearly clinical examination and Tg measurements on thyroid hormone replacement. Recommendation rating: B

[C6] What are the roles of diagnostic whole-body RAI scans, US, and other imaging techniques during follow-up of DTC?

[C7] *Diagnostic whole-body RAI scans.* There are two main issues that affect the use of DxWBS during follow-up: stunning (described above) and accuracy. A DxWBS is most useful during follow-up when there is little or no remaining normal thyroid tissue. Disease not visualized on the DxWBS, regardless of the activity of  $^{131}\text{I}$  employed, may occasionally be visualized on the RxWBS images done after larger, therapeutic amounts of  $^{131}\text{I}$  (285,307–310). Following RAI ablation, when the posttherapy scan does not reveal uptake outside the thyroid bed, subsequent DxWBS have low sensitivity and are usually not necessary in low-risk patients who are clinically free of residual tumor and have an undetectable serum Tg level on thyroid hormone and negative cervical US (197,285,309,311).

#### ■ RECOMMENDATION 46

After the first RxWBS performed following RAI remnant ablation, low-risk patients with an undetectable Tg on thyroid hormone with negative antithyroglobulin antibodies and a negative US do not require routine DxWBS during follow-up. Recommendation rating: F

#### ■ RECOMMENDATION 47

DxWBS, either following thyroid hormone withdrawal or rhTSH, 6–12 months after remnant ablation may be of value in the follow-up of patients with high or intermediate risk of persistent disease (see risk stratification system under AJCC/UICC TNM staging), but should be done with  $^{123}\text{I}$  or low activity  $^{131}\text{I}$ . Recommendation rating: C

[C8] *Cervical ultrasonography.* Cervical ultrasonography is highly sensitive in the detection of cervical metastases in patients with DTC (139,290,312). Recent data suggest that measurement of Tg in the needle washout fluid enhances the sensitivity of FNA of cervical nodes that are suspicious on US (313,314). Cervical metastases occasionally may be detected by neck ultrasonography even when TSH-stimulated serum Tg levels remain undetectable (201,296).

#### ■ RECOMMENDATION 48

- Following surgery, cervical US to evaluate the thyroid bed and central and lateral cervical nodal compartments should be performed at 6–12 months and then periodically, depending on the patient's risk for recurrent disease and Tg status. Recommendation rating: B
- If a positive result would change management, ultrasonographically suspicious lymph nodes greater than 5–8 mm in the smallest diameter should be biopsied for cytology with Tg measurement in the needle washout fluid. Recommendation rating: A
- Suspicious lymph nodes less than 5–8 mm in largest diameter may be followed without biopsy with consideration for intervention if there is growth or if the node threatens vital structures. Recommendation rating: C

[C9]  *$^{18}\text{F}$ FDG-PET scanning.* For many years, the primary clinical application of  $^{18}\text{F}$ FDG-PET scanning in thyroid cancer was to localize disease in Tg-positive ( $>10$  ng/mL), RAI scan-negative patients (315). When used for this indication, insur-

ance providers have usually required documentation that the patient had a follicular derived thyroid cancer with suppressed or stimulated Tg  $>10$  ng/mL in the setting of a negative DxWBS. Still, the impact of  $^{18}\text{F}$ FDG-PET imaging on biochemical cure, survival, or progression-free survival in this setting are not well defined.

More recently, publications provide data that support the use of  $^{18}\text{F}$ FDG-PET scanning for indications beyond simple disease localization in Tg-positive, RAI scan-negative patients (315,316).

Current additional clinical uses of  $^{18}\text{F}$ FDG-PET scanning may include:

- Initial staging and follow-up of high-risk patients with poorly differentiated thyroid cancers unlikely to concentrate RAI in order to identify sites of disease that may be missed with RAI scanning and conventional imaging.
- Initial staging and follow-up of invasive or metastatic Hürthle cell carcinoma.
- As a powerful prognostic tool for identifying which patients with known distant metastases are at highest risk for disease-specific mortality.
- As a selection tool to identify those patients unlikely to respond to additional RAI therapy.
- As a measurement of posttreatment response following external beam irradiation, surgical resection, embolization, or systemic therapy.

As can be seen from the list of indications above, low-risk patients are very unlikely to require  $^{18}\text{F}$ FDG-PET scanning as part of initial staging or follow-up. Additionally, inflammatory lymph nodes, suture granulomas, and increased muscle activity are common causes of false-positive  $^{18}\text{F}$ FDG-PET findings. Therefore, cytologic or histologic confirmation is required before one can be certain that an  $^{18}\text{F}$ FDG-positive lesion represents metastatic disease.

The sensitivity of  $^{18}\text{F}$ FDG-PET scanning may be marginally improved with TSH stimulation (especially in patients with low Tg values), but the clinical benefit of identifying these additional small foci is yet to be proven (316).

- In addition to its proven role in the localization of disease in Tg-positive, RAI scan-negative patients,  $^{18}\text{F}$ FDG-PET scanning may be employed 1) as part of initial staging in poorly differentiated thyroid cancers and invasive Hürthle cell carcinomas, especially those with other evidence of disease on imaging or because of elevated serum Tg levels, and 2) as a prognostic tool in patients with metastatic disease to identify those patients at highest risk for rapid disease progression and disease-specific mortality, 3) and as an evaluation of posttreatment response following systemic or local therapy of metastatic or locally invasive disease. Recommendation rating: C

[C10] What is the role of thyroxine TSH suppression during thyroid hormone therapy in the long-term follow-up of DTC? A meta-analysis has suggested an association (269) between thyroid hormone suppression therapy and reduction of major adverse clinical events. The appropriate degree of TSH suppression by  $\text{LT}_4$  is still unknown, especially in high-risk patients rendered free of disease. One study found that a constantly suppressed TSH ( $\leq 0.05$  mU/L) was associated with

a longer relapse-free survival than when serum TSH levels were always 1 mU/L or greater, and that the degree of TSH suppression was an independent predictor of recurrence in multivariate analysis (270). Conversely, another large study found that disease stage, patient age, and <sup>131</sup>I therapy independently predicted disease progression, but that the degree of TSH suppression did not (127). A third study showed that during LT<sub>4</sub> therapy the mean Tg levels were significantly higher when TSH levels were normal than when TSH levels were suppressed (<0.5 mU/L) but only in patients with local or distant relapse (317). A fourth study of 2936 patients found that overall survival improved significantly when the TSH was suppressed to <0.1 mU/L in patients with NTCTCSG stage III or IV disease and to 0.1 to about 0.5 range in patients with NTCTCSG stage II disease; however, there was no incremental benefit from suppressing TSH to undetectable levels in stage II patients and suppression of TSH was of no benefit in patients with stage I disease (214). Another recent study found that a serum TSH threshold of 2 mU/L differentiated best between patients free of disease and those with relapse or cancer-related mortality (271). No prospective studies have been performed examining the risk of recurrence and death from thyroid cancer associated with varying serum TSH levels, based on the criteria for the absence of tumor at 6–12 months postsurgery and RAI ablation outlined above in [C3].

#### ■ RECOMMENDATION 49

- (a) In patients with persistent disease, the serum TSH should be maintained below 0.1 mU/L indefinitely in the absence of specific contraindications. Recommendation rating: B
- (b) In patients who are clinically and biochemically free of disease but who presented with high risk disease, consideration should be given to maintaining TSH-suppressive therapy to achieve serum TSH levels of 0.1–0.5 mU/L for 5–10 years. Recommendation rating: C
- (c) In patients free of disease, especially those at low risk for recurrence, the serum TSH may be kept within the low normal range (0.3–2 mU/L). Recommendation rating: B
- (d) In patients who have not undergone remnant ablation who are clinically free of disease and have undetectable suppressed serum Tg and normal neck US, the serum TSH may be allowed to rise to the low normal range (0.3–2 mU/L). Recommendation rating: C

#### [C11] What is the most appropriate management of DTC patients with metastatic disease?

Metastases discovered during follow-up are likely manifestations of persistent disease that has survived initial treatment. Some patients will have a reduction in tumor burden with additional treatments that may offer a survival or palliative benefit (318–322). The preferred hierarchy of treatment for metastatic disease (in order) is surgical excision of locoregional disease in potentially curable patients, <sup>131</sup>I therapy for RAI-avid disease, external beam radiation, watchful waiting with patients with stable or slowly progressive asymptomatic disease, and experimental trials, especially for patients with significantly progressive macroscopic refractory disease. Experimental trials may be tried before external beam radiation in special circumstances, in part because of the morbidity of external beam radiation and its relative lack of efficacy. A

small fraction of patients may benefit from radiofrequency ablation (323), ethanol ablation (324), or chemo-embolization (325). Additionally, surgical therapy in selected incurable patients is important to prevent complications in targeted areas, such as the central nervous system (CNS) and central neck compartment. Conversely, watchful waiting may be appropriate for selected patients with stable asymptomatic local metastatic disease, and most patients with stable asymptomatic non-CNS distant metastatic disease.

[C12] What is the surgical management of locoregional metastases? Surgery is favored for locoregional (i.e., cervical lymph nodes and/or soft tissue tumor in the neck) recurrences, when distant metastases are not present. Approximately one third to one half of patients may become free of disease in short-term follow-up (288). It is not clear that treatment of locoregional disease is beneficial in the setting of untreatable distant metastases, except for possible palliation of symptoms or prevention of airway or aerodigestive obstruction. Impalpable metastatic lymph nodes, visualized on US or other anatomic imaging modality, that have survived initial <sup>131</sup>I therapy should be considered for resection. Conversely, the benefit to removing asymptomatic small (<5–8 mm) metastatic lymph nodes towards improving gross clinical disease recurrences or disease-specific survival is unproven. When surgery is elected, most surgeons endorse comprehensive or selective ipsilateral compartmental dissection of previously unexplored compartments with clinically significant persistent or recurrent disease (i.e., lymph nodes >0.8 cm in diameter,) while sparing vital structures (e.g., ipsilateral central neck dissection [level VI], selective neck dissection levels II–IV, or modified neck dissection [levels II–V sparing the spinal accessory nerve, the internal jugular vein, and sternocleidomastoid muscle] (326) as opposed to “berry picking,” limited lymph node resection procedures, or ethanol ablation (324), because microscopic lymph node metastases are commonly more extensive than would appear from imaging studies alone (183,327,328). Conversely, compartmental surgical dissections may not be feasible in the setting of compartments that have been previously explored due to extensive scarring, and only a more limited or targeted lymph node resection may be possible.

#### ■ RECOMMENDATION 50

- (a) Therapeutic comprehensive compartmental lateral and/or central neck dissection, sparing uninvolved vital structures, should be performed for patients with persistent or recurrent disease confined to the neck. Recommendation rating: B
- (b) Limited compartmental lateral and/or central compartmental neck dissection may be a reasonable alternative to more extensive comprehensive dissection for patients with recurrent disease within compartments having undergone prior comprehensive dissection and/or external beam radiotherapy. Recommendation rating: C

[C13] What is the surgical management of aerodigestive invasion? For tumors that invade the upper aerodigestive tract, surgery combined with additional therapy such as <sup>131</sup>I and/or external beam radiation is generally advised (329,330). Patient outcome is related to complete resection of all gross



disease with the preservation of function, with techniques ranging from shaving tumor off the trachea or esophagus for superficial invasion, to more aggressive techniques when the trachea is more deeply invaded (e.g., direct intraluminal invasion) including tracheal resection and anastomosis (331–333) or laryngopharyngoesophagectomy. Patients who are not curable may undergo less aggressive local treatment in cases of asphyxia or significant hemoptysis, and as a preliminary step prior to subsequent radical or palliative treatments (330).

#### ■ RECOMMENDATION 51

When technically feasible, surgery for aerodigestive invasive disease is recommended in combination with RAI and/or external beam radiotherapy. Recommendation rating: B

[C14] What is the nature of RAI therapy for locoregional or distant metastatic disease? For regional nodal metastases discovered on DxWBS, RAI may be employed, although surgery is typically used in the presence of bulky disease or disease amenable to surgery found on anatomic imaging such as US, CT scanning, or MRI. Radioiodine is also used adjunctively following surgery for regional nodal disease or aerodigestive invasion if residual RAI avid disease is present or suspected.

[C15] *Dose and methods of administering <sup>131</sup>I for locoregional or metastatic disease.* Despite the apparent effectiveness of <sup>131</sup>I therapy in many patients, the optimal therapeutic activity remains uncertain and controversial (334). There are three approaches to <sup>131</sup>I therapy: empiric fixed amounts, therapy determined by the upper bound limit of blood and body dosimetry, and quantitative tumor dosimetry (335). Dosimetric methods are often reserved for patients with distant metastases or unusual situations such as renal insufficiency (336,337) or when therapy with rhTSH stimulation is deemed necessary. Comparison of outcome among these methods from published series is difficult (334). No prospective randomized trial to address the optimal therapeutic approach has been published. Arguments in favor of higher activities cite a positive relationship between the total <sup>131</sup>I uptake per tumor mass and outcome (225), while others have not confirmed this relationship (338). In the future, the use of <sup>123</sup>I or <sup>131</sup>I with modern SPECT/CT or <sup>124</sup>I PET-based dosimetry may facilitate whole-body and lesional dosimetry (339,340).

The maximum tolerated radiation absorbed dose (MTRD), commonly defined as 200 rads (cGy) to the blood, is potentially exceeded in a significant number of patients undergoing empiric treatment with various amounts of <sup>131</sup>I. In one study (341) 1–22% of patients treated with <sup>131</sup>I according to dosimetry calculations would have theoretically exceeded the MTRD had they been empirically treated with 100–300 mCi of <sup>131</sup>I. Another study (342) found that an empirically administered <sup>131</sup>I activity of 200 mCi would exceed the MTRD in 8–15% of patients younger than age 70 and 22–38% of patients aged 70 years and older. Administering 250 mCi empirically would have exceeded the MTRD in 22% of patients younger than 70 and 50% of patients 70 and older.

#### ■ RECOMMENDATION 52

(a) In the treatment of locoregional or metastatic disease, no recommendation can be made about the superiority

of one method of RAI administration over another (empiric high dose vs. blood and/or body dosimetry vs. lesional dosimetry.) Recommendation rating: I

(b) Empirically administered amounts of <sup>131</sup>I exceeding 200 mCi that often potentially exceed the maximum tolerable tissue dose should be avoided in patients over age 70 years. Recommendation rating: A

No randomized trial comparing thyroid hormone withdrawal therapy to rhTSH-mediated therapy for treatment of metastatic disease has been reported but there is, despite a growing body of nonrandomized studies regarding this use (343–352), one small comparative study that showed the radiation dose to metastatic foci is lower with rhTSH than that following withdrawal (353). Many of these case reports and series report disease stabilization or improvement in some patients following rhTSH-mediated <sup>131</sup>I therapy. The use of rhTSH does not eliminate and may even increase the possibility of rapid swelling of metastatic lesions (348,354–356).

#### ■ RECOMMENDATION 53

There are currently insufficient outcome data to recommend rhTSH-mediated therapy for all patients with metastatic disease being treated with <sup>131</sup>I. Recommendation rating: D

#### ■ RECOMMENDATION 54

Recombinant human TSH-mediated therapy may be indicated in selected patients with underlying comorbidities making iatrogenic hypothyroidism potentially risky, in patients with pituitary disease who are unable to raise their serum TSH, or in patients in whom a delay in therapy might be deleterious. Such patients should be given the same or higher activity that would have been given had they been prepared with hypothyroidism or a dosimetrically determined activity. Recommendation rating: C

[C16] Use of lithium in <sup>131</sup>I therapy. Lithium inhibits iodine release from the thyroid without impairing iodine uptake, thus enhancing <sup>131</sup>I retention in normal thyroid and tumor cells (357). One study (358) found that lithium increased the estimated <sup>131</sup>I radiation dose in metastatic tumors an average of more than twofold, but primarily in those tumors that rapidly cleared iodine. On the other hand, another more recent study was unable to document any clinical advantage of lithium therapy on outcome in patients with metastatic disease, despite an increase in RAI uptake in tumor deposits (359).

#### ■ RECOMMENDATION 55

Since there are no outcome data that demonstrate a better outcome of patients treated with lithium as an adjunct to <sup>131</sup>I therapy, the data are insufficient to recommend lithium therapy. Recommendation rating: I

[C17] How should distant metastatic disease to various organs be treated? The overall approach to treatment of distant metastatic thyroid cancer is based upon the following observations and oncologic principles:

1. Morbidity and mortality are increased in patients with distant metastases, but individual prognosis depends

upon factors including histology of the primary tumor, distribution and number of sites of metastasis (e.g., brain, bone, lung), tumor burden, age at diagnosis of metastases, and  $^{18}\text{F}$ FDG and RAI avidity (320,351, 360–366).

2. Improved survival is associated with responsiveness to surgery and/or RAI (320,351,360–366).
3. In the absence of demonstrated survival benefit, certain interventions can provide significant palliation or reduce morbidity (325,367–369).
4. In the absence of improved survival, palliative benefit, or reduced potential morbidity, the value of empiric therapeutic intervention is significantly limited by the potential for toxicity.
5. Treatment of a specific metastatic area must be considered in light of the patient's performance status and other sites of disease; e.g., 5–20% of patients with distant metastases die from progressive cervical disease (366,370).
6. Longitudinal re-evaluation of patient status and continuing re-assessment of potential benefit and risk of intervention is required.
7. The overall poor outcome of patients with radiographically evident or symptomatic metastases that do not respond to RAI, the complexity of multidisciplinary treatment considerations and the availability of prospective clinical trials should encourage the clinician to refer such patients to tertiary centers with particular expertise.

[C18] *Treatment of pulmonary metastases.* In the management of the patient with pulmonary metastases, key criteria for therapeutic decisions include 1) size of metastatic lesions (macronodular typically detected by chest radiography; micronodular typically detected by CT; lesions beneath the resolution of CT); 2) avidity for RAI and, if applicable, response to prior RAI therapy; and 3) stability (or lack thereof) of metastatic lesions. Pulmonary pneumonitis and fibrosis are rare complications of high-dose radioactive iodine treatment. Dosimetry studies with a limit of 80 mCi whole-body retention at 48 hours and 200 cGy to the red bone marrow should be considered in patients with diffuse  $^{131}\text{I}$  pulmonary uptake (371). If pulmonary fibrosis is suspected, then appropriate periodic pulmonary function testing and consultation should be obtained. The presence of pulmonary fibrosis may limit the ability to further treat metastatic disease with RAI.

#### ■ RECOMMENDATION 56

Pulmonary micrometastases should be treated with RAI therapy, and repeated every 6–12 months as long as disease continues to concentrate RAI and respond clinically, because the highest rates of complete remission are reported in these subgroups (360,365,372,373). Recommendation rating: A

#### ■ RECOMMENDATION 57

The selection of RAI activity to administer for pulmonary micrometastases can be empiric (100–200 mCi) or estimated by dosimetry to limit whole-body retention to 80 mCi at 48 hours and 200 cGy to the red bone marrow. Recommendation rating: B

Macronodular pulmonary metastases may also be treated with RAI if demonstrated to be iodine avid. How many doses of RAI to give and how often to give it is a decision that must be individualized based on the disease response to treatment, the rate of disease progression in between treatments, age of the patient, the presence or absence of other metastatic lesions, and the availability of other treatment options including clinical trials (360,365).

#### ■ RECOMMENDATION 58

Radioiodine-avid macronodular metastases should be treated with RAI and treatment should be repeated when objective benefit is demonstrated (decrease in the size of the lesions, decreasing Tg), but complete remission is not common and survival remains poor. The selection of RAI activity to administer can be made empirically (100–200 mCi) or estimated by lesional dosimetry or dosimetry to limit whole-body retention to 80 mCi at 48 hours and 200 cGy to the red bone marrow. Recommendation rating: B

[C19] *Non-RAI-avid pulmonary disease.* Radioiodine is of no benefit in patients with non-RAI-avid disease. In the setting of a negative diagnostic RAI scan, micronodular pulmonary metastases may demonstrate a positive post-treatment scan and measurable benefit to RAI therapy, whereas this is unlikely in the setting of macronodular metastases. In one study, administration of 200–300 mCi of RAI to 10 patients with pulmonary macrometastases who had negative 3 mCi diagnostic scans was associated with a five-fold increase in the median TSH-suppressed Tg, and death was reported in several patients within 4 years of treatment (374). Although not specifically limited to pulmonary lesions, patients with increasing volumes of  $^{18}\text{F}$ FDG-avid disease seen on PET scans were less likely to respond to RAI and more likely to die during a 3-year follow-up compared with  $^{18}\text{F}$ FDG-negative patients (375). Another study found that RAI therapy of metastatic lesions that were positive on  $^{18}\text{F}$ FDG-PET scanning was of no benefit (376). In other studies of  $^{18}\text{F}$ FDG-PET imaging, however, insufficient details exist in patients known to have pulmonary metastases to assess the utility of this modality to predict treatment response or prognosis (377). A study (378) that retrospectively examined the clinical course of 400 thyroid cancer patients with distant metastases who had undergone  $^{18}\text{F}$ FDG-PET scanning found that although age, initial tumor stage, histology, Tg level, RAI uptake, and PET outcomes all correlated with survival by univariate analysis, only age and PET results were strong predictors of survival. There were significant inverse relationships between survival and both the glycolytic rate of the most active lesion and the number of  $^{18}\text{F}$ FDG-avid lesions. The study found tumors that did not concentrate  $^{18}\text{F}$ FDG had a significantly better prognosis after a median follow-up of about 8 years than did tumors that avidly concentrated  $^{18}\text{F}$ FDG.

Most studies evaluating systemic therapy for metastatic disease have focused on patients with pulmonary metastases. Traditional cytotoxic chemotherapeutic agents, such as doxorubicin and cisplatin, are generally associated with no more than 25% partial response rates, complete remission has been rare, and toxicities from these treatments are considerable (379). Doxorubicin monotherapy, which remains the only treatment for metastatic thyroid carcinoma approved by the

U.S. Food and Drug Administration, is occasionally effective when dosed appropriately (60–75 mg/m<sup>2</sup> every 3 weeks) (380–383), but durable responses are uncommon. Most studies of combination chemotherapy show no increased response over single agent doxorubicin and increased toxicity (384). Some specialists recommend consideration of single agent doxorubicin or paclitaxel, or a combination of these agents, based on limited data in anaplastic thyroid carcinoma (385). One recent study evaluated the effect of combination chemotherapy (carboplatinum and epirubicin) under TSH stimulation (endogenous or rhTSH) (386), demonstrating an overall rate of complete and partial response of 37%. These data need to be confirmed prior to consideration for general use. Recently published phase II trials suggest that anti-angiogenic therapies may produce partial response rates of up to 31% and stabilize another 40–50% of patients with progressive metastatic disease (387–391). Clinical benefit lasting at least 24 weeks was observed in about half of patients. The orally available anti-angiogenic tyrosine kinase inhibitors (axitinib, motesanib, and sorafenib) have numerous common side effects, including hypertension, diarrhea, fatigue, skin rashes and erythema, and weight loss, and various drug-specific toxicities have been reported as well. These side effects, although often mild and responsive to supportive care measures, justify suggesting that treatment with these agents should be limited to specialists experienced in their use. Similar results are also being reported with use of sunitinib, but phase II studies are still ongoing. Serum TSH levels may increase with the use of these agents. Serum TSH should be monitored, and the thyroxine dose increased as needed. Multiple other agents are in clinical trials, targeting pathways involved in angiogenesis, cell cycle regulation, and tumor differentiation.

If the patient qualifies for a clinical trial, they should consider bypassing traditional chemotherapy and moving directly to clinical trials. However, often patients cannot participate in clinical trials because of the time and expense required, or failure to meet strict eligibility criteria. Most available trials can be found listed at [www.clinicaltrials.gov](http://www.clinicaltrials.gov), [www.nci.nih.gov](http://www.nci.nih.gov), [www.centerwatch.com](http://www.centerwatch.com), or [www.thyroid.org](http://www.thyroid.org).

#### ■ RECOMMENDATION 59

- (a) Evidence of benefit of routine treatment of non-RAI-avid pulmonary metastases is insufficient to recommend any specific systemic therapy. For many patients, metastatic disease is slowly progressive and patients can often be followed conservatively on TSH-suppressive therapy with minimal evidence of radiographic or symptomatic progression. For selected patients, however, other treatment options need to be considered, such as metastasectomy, endobronchial laser ablation, or external beam radiation for palliation of symptomatic intrathoracic lesions (e.g., obstructing or bleeding endobronchial masses), and pleural or pericardial drainage for symptomatic effusions. Referral for participation in clinical trials should be considered. Recommendation rating: C
- (b) Referral for participation in clinical trials should be considered for patients with progressive or symptomatic metastatic disease. For those patients who do not participate in clinical trials, treatment with tyrosine

kinase inhibitors should be considered. Recommendation rating: B

[C20] *Treatment of bone metastases.* In the management of the patient with bone metastases, key criteria for therapeutic decisions include 1) the presence of or the risk for pathologic fracture, particularly in a weight-bearing structure; 2) risk for neurologic compromise from vertebral lesions; 3) presence of pain; 4) avidity of RAI uptake; and 5) potential significant marrow exposure from radiation arising from RAI-avid pelvic metastases.

#### ■ RECOMMENDATION 60

Complete surgical resection of isolated symptomatic metastases has been associated with improved survival and should be considered, especially in patients <45 years old with slowly progressive disease (320,363). Recommendation rating: B

#### ■ RECOMMENDATION 61

RAI therapy of iodine-avid bone metastases has been associated with improved survival and should be employed (320,365), although RAI is rarely curative. The RAI activity administered can be given empirically (100–200 mCi) or determined by dosimetry (225). Recommendation rating: B

#### ■ RECOMMENDATION 62

When skeletal metastatic lesions arise in locations where acute swelling may produce severe pain, fracture, or neurologic complications, external radiation and the concomitant use of glucocorticoids to minimize potential TSH-induced and/or radiation-related tumor expansion should be strongly considered (392). Recommendation rating: C

#### ■ RECOMMENDATION 63

Painful lesions that cannot be resected can also be treated by several options individually or in combination, including RAI, external beam radiotherapy, intra-arterial embolization (325,393), radiofrequency ablation (394), periodic pamidronate or zoledronate infusions (with monitoring for development of possible mandibular osteonecrosis) (369), or vertebroplasty or kyphoplasty (395). While many of these modalities have been shown to relieve bone pain in cancer, they have not necessarily been reported to have been used in thyroid cancer patients. Recommendation rating: C

#### ■ RECOMMENDATION 64

Evidence is insufficient to recommend treatment of asymptomatic, non-RAI-responsive, stable lesions that do not threaten nearby critical structures. Recommendation rating: I

[C21] *Treatment of brain metastases.* Brain metastases typically occur in older patients with more advanced disease and are associated with a poor prognosis (351). Surgical resection and external beam radiotherapy traditionally have been the mainstays of therapy (351,396). There are few data showing efficacy of RAI.

#### ■ RECOMMENDATION 65

Complete surgical resection of CNS metastases should be considered regardless of RAI avidity, because it is

associated with significantly longer survival. Recommendation rating: B

#### ■ RECOMMENDATION 66

CNS lesions that are not amenable to surgery should be considered for external beam irradiation. Optimally, very targeted approaches (such as radiosurgery) are employed to limit the radiation exposure of the surrounding brain tissue. Whole brain and spine irradiation could be considered if multiple metastases are present. Recommendation rating: C

#### ■ RECOMMENDATION 67

If CNS metastases do concentrate RAI, then RAI could be considered. If RAI is being considered, prior external beam radiotherapy and concomitant glucocorticoid therapy are strongly recommended to minimize the effects of a potential TSH-induced increase in tumor size and the subsequent inflammatory effects of the RAI (392). Recommendation rating: C

#### [C22] What is the management of complications of RAI therapy?

While RAI appears to be a reasonably safe therapy, it is associated with a cumulative dose-related low risk of early- and late-onset complications such as salivary gland damage, dental caries (397), nasolacrimal duct obstruction (398), and secondary malignancies (157,281,399,400). Therefore, it is important to ensure that the benefits of RAI therapy, especially repeated courses, outweigh the potential risks. There is probably no dose of RAI that is completely safe nor is there any maximum cumulative dose that could not be used in selected situations. However, with higher individual and cumulative doses there are increased risks of side effects as discussed previously.

For acute transient loss of taste or change in taste and sialadenitis, recommended measures to prevent damage to the salivary glands have included amifostine, hydration, sour candies, and cholinergic agents (401), but evidence is insufficient to recommend for or against these modalities. One recent study suggested sour candy may actually increase salivary gland damage when given within 1 hour of RAI therapy, as compared to its use until 24 hours posttherapy (402). For chronic salivary gland complications, such as dry mouth and dental caries, cholinergic agents may increase salivary flow (401).

#### ■ RECOMMENDATION 68

The evidence is insufficient to recommend for or against the routine use of preventive measures to prevent salivary gland damage after RAI therapy. Recommendation rating: I

#### ■ RECOMMENDATION 69

Patients with xerostomia are at increased risk of dental caries and should discuss preventive strategies with their dentists. Recommendation rating: C

#### ■ RECOMMENDATION 70

Surgical correction should be considered for nasolacrimal outflow obstruction, which often presents as excessive

tearing (epiphora) but also predisposes to infection. Recommendation rating: B

[C23] What is the risk of second malignancies and leukemia from RAI therapy? Most long-term follow-up studies variably report a very low risk of secondary malignancies (bone and soft tissue malignancies, including breast, colorectal, kidney, and salivary cancers, and myeloma and leukemia) in long-term survivors (157,281). A meta-analysis of two large multicenter studies showed that the risk of second malignancies was significantly increased at 1.19 (95% CI: 1.04–1.36;  $p < 0.010$ ), relative to thyroid cancer survivors not treated with RAI (403). The risk of leukemia was also significantly increased in thyroid cancer survivors treated with RAI, with a relative risk of 2.5 (95% CI: 1.13–5.53;  $p < 0.024$ ) (403). The risk of secondary malignancies is dose related (157), with an excess absolute risk of 14.4 solid cancers and of 0.8 leukemias per gigabecquerel of  $^{131}\text{I}$  at 10,000 person-years of follow-up. Cumulative  $^{131}\text{I}$  activities above 500–600 mCi are associated with a significant increase in risk. There appears to be an increased risk of breast cancer in women with thyroid cancer (281,399,404). It is unclear whether this is due to screening bias, RAI therapy, or other factors. An elevated risk of breast cancer with  $^{131}\text{I}$  was not observed in another study (282). The use of laxatives may decrease radiation exposure of the bowel, and vigorous oral hydration will reduce exposure of the bladder and gonads (15).

#### ■ RECOMMENDATION 71

Because there is no evidence demonstrating a benefit of more intensive screening, all thyroid cancer patients should be encouraged to seek age-appropriate screenings for cancer according to routine health maintenance recommendations. Patients who receive a cumulative  $^{131}\text{I}$  activity in excess of 500–600 mCi should be advised that they may have a small excess risk of developing leukemia and solid tumors in the future. Recommendation rating: C

[C24] What are other risks to the bone marrow from RAI therapy? Published data indicate that when administered activities are selected to remain below 200 cGy to the bone marrow, minimal transient effects are noted in white blood cell and platelet counts (371). However, persistent mild decrements in white blood cell count and/or platelets are not uncommon in patients who have received multiple RAI therapies. Further, radiation to the bone marrow is impacted by several factors, including renal function.

#### ■ RECOMMENDATION 72

Patients receiving therapeutic doses of RAI should have baseline CBC and assessment of renal function. Recommendation rating: C

[C25] What are the effects of RAI on gonadal function and in nursing women? Women about to receive radioactive iodine therapy should first undergo pregnancy testing. Gonadal tissue is exposed to radiation from RAI in the blood, urine, and feces. Temporary amenorrhea/oligomenorrhea lasting 4–10 months occurs in 20–27% of menstruating women after  $^{131}\text{I}$  therapy for thyroid cancer. Although the numbers of patients studied are small, long-term rates of in-

fertility, miscarriage, and fetal malformation do not appear to be elevated in women after RAI therapy (405–407). One large retrospective study suggested that pregnancy should be postponed for 1 year after therapy because of an increase in miscarriage rate (408), although this was not confirmed in another similarly designed study (409). Ovarian damage from RAI therapy may result in menopause occurring approximately 1 year earlier than the general population, but this result was not associated with cumulative dose administered or the age at which the therapy was given (410). In men, RAI therapy may be associated with a temporary reduction in sperm counts and elevated serum follicle-stimulating hormone (FSH) levels (411,412). Higher cumulative activities (500–800 mCi) in men are associated with an increased risk of persistent elevation of serum FSH levels, but fertility and risks of miscarriage or congenital abnormalities in subsequent pregnancies are not changed with moderate RAI activities (~200 mCi) (413,414). Permanent male infertility is unlikely with a single ablative activity of RAI, but theoretically there could be cumulative damage with multiple treatments. It has been suggested that sperm banking be considered in men who may receive cumulative RAI activities  $\geq 400$  mCi (412). Gonadal radiation exposure is reduced with good hydration, frequent micturition to empty the bladder, and avoidance of constipation (415).

#### ■ RECOMMENDATION 73

Women receiving RAI therapy should avoid pregnancy for 6–12 months. Recommendation rating: C

#### ■ RECOMMENDATION 74

- (a) Radioactive iodine should not be given to nursing women. Depending on the clinical situation, RAI therapy could be deferred until a time when lactating women have stopped breast-feeding for at least 6–8 weeks. Recommendation rating: B
- (b) Dopaminergic agents might be useful in decreasing breast exposure in recently lactating women, although caution should be exercised given the risk of serious side effects associated with their routine use to suppress postpartum lactation. Recommendation rating: C

#### **[C26] What is the management of Tg-positive, RAI scan–negative patients?**

If the unstimulated Tg is or becomes detectable, or increases over time, or if stimulated Tg levels rise to greater than 2 ng/mL, imaging of the neck and chest should be performed to search for metastatic disease, typically with neck US and with thin cut (5–7 mm) helical chest CT. Iodinated contrast should be avoided if RAI therapy is planned within the subsequent few months, although intravenous contrast may aid in identification of cervical and mediastinal disease. In addition, for patients with a prior history of metastatic cervical lymph nodes in the anterior compartments, cross-sectional imaging with either neck CT or MRI should be considered to evaluate the retropharyngeal lymph nodes that cannot be imaged by sonography. If imaging is negative for disease that is potentially curable by surgery, or the serum Tg appears out of proportion to the identified surgically resectable disease, then whole-body  $^{18}\text{F}$ FDG-PET imaging may be obtained if the stimulated serum Tg is

$>10$  ng/mL. If the  $^{18}\text{F}$ FDG PET scan is negative, then empiric therapy with RAI (100–200 mCi) should be considered to aid localization or for therapy of surgically incurable disease (Fig. 5). This approach may identify the location of persistent disease in approximately 50% of patients (307,416) with a wide range of reported success. Some investigators have reported a fall in serum Tg after empiric RAI therapy in patients with negative DxWBS (417,418), but there is no evidence for improved survival with empiric therapy in this setting (374,418). On the other hand, Tg levels may decline without specific therapy during the first years of follow-up (418).

When the RxWBS after empiric  $^{131}\text{I}$  therapy is negative,  $^{18}\text{F}$ FDG-PET scanning is indicated if not already obtained. Integrated  $^{18}\text{F}$ FDG-PET/CT is able to improve diagnostic accuracy of  $^{18}\text{F}$ FDG-PET in patients with iodine-negative tumors. In a study of 40 such patients, in whom PET and CT images were scored blindly, the diagnostic accuracy was 93% for integrated  $^{18}\text{F}$ FDG-PET/CT and 78% for PET alone ( $p < 0.5$ ) (419). In 74% of the patients with suspicious  $^{18}\text{F}$ FDG foci, integrated  $^{18}\text{F}$ FDG-PET/CT added relevant information to the side-by-side interpretation of PET and CT images by precisely localizing the lesions.  $^{18}\text{F}$ FDG-PET/CT fusion studies led to a change of therapy in 48% of the patients. In another study,  $^{18}\text{F}$ FDG-PET/CT changed the clinical management of 44% of 61 patients, including surgery, radiation therapy, or chemotherapy (420). The rate of PET scan positivity is low (11–13%) in patients with stimulated Tg levels  $<10$  ng/mL (421,422). Some have argued that  $^{18}\text{F}$ FDG-PET scanning should be performed prior to empiric RAI therapy (423), since tumors that are  $^{18}\text{F}$ FDG-PET positive do not generally concentrate RAI (376), and RAI therapy is unlikely to alter the poorer outcome in such patients (378).

A cutoff value of Tg above which a patient should be treated with an empiric dose of RAI is difficult to determine, due in part to the wide variation in available Tg assays (including those used in reports suggesting benefit of such therapy) and the differences in Tg levels based on method and degree of TSH stimulation or suppression. Recent studies have reported primarily on patients with Tg levels after T<sub>4</sub> withdrawal of 10 ng/mL or higher, and it has been suggested that a corresponding level after rhTSH stimulation would be 5 ng/mL (308,374,416,418,424). A Tg level that is rising may warrant greater concern for the need for empiric therapy, although data regarding the appropriate rate of change are minimal (301). However a detectable but low Tg level at 9–12 months following remnant ablation may not warrant further therapy.

#### ■ RECOMMENDATION 75

Empiric radioactive iodine therapy (100–200 mCi) might be considered in patients with elevated (Tg levels after T<sub>4</sub> withdrawal of 10 ng/mL or higher, or a level of 5 ng/mL or higher after rhTSH stimulation) or rising serum Tg levels in whom imaging has failed to reveal a potential tumor source. If the posttherapy scan is negative, no further RAI therapy should be administered. Recommendation rating: C

#### ■ RECOMMENDATION 76

If persistent nonresectable disease is localized after an empiric dose of RAI, and there is objective evidence of




FIG. 5. Considerations for empiric treatment with radioiodine.

<sup>a</sup>Empiric <sup>131</sup>I therapy should be done with meticulous patient preparation, including low-iodine diet and, if iodine contamination is a possibility, urinary iodine measurements. If the RxWBS is negative or subsequent follow-up studies show no therapeutic benefit, further empiric <sup>131</sup>I should not be administered.

<sup>b</sup>Tg that rises with TSH stimulation and falls with TSH suppression is unlikely to result from heterophile antibodies.

<sup>c</sup>National Cancer Institute Common Terminology Criteria for Adverse Events, Version 3.0, (<http://ctep.cancer.gov>).

<sup>d</sup>Dosimetry could be considered to allow administration of maximum radioiodine activity if the tumor is life-threatening.

<sup>e</sup>A dose of 200 mCi could exceed the maximum tolerable dose in older individuals (see Recommendation 52b).

significant tumor reduction, then RAI therapy should be repeated until the tumor has been eradicated or the tumor no longer responds to treatment. The risk of repeated therapeutic doses of RAI must be balanced against uncertain long-term benefits. Recommendation rating: C

#### ■ RECOMMENDATION 77

In the absence of structurally evident disease, stimulated serum Tg <10 ng/mL with thyroid hormone withdrawal or <5 ng/mL with rhTSH can be followed with continued LT<sub>4</sub> therapy alone, reserving additional therapies for those patients with rising serum Tg levels over time or other evidence of structural disease progression. Recommendation rating: C

[C27] What is the management of patients with a negative RxWBS?

#### ■ RECOMMENDATION 78

(a) If an empiric dose (100–200 mCi) of RAI fails to localize the persistent disease, <sup>18</sup>FDG-PET/CT scanning should be considered, especially in patients with unstimulated serum Tg levels >10–20 ng/mL or in those with aggressive histologies, in order to localize metastatic lesions that may require treatment or continued close observation (425,426). Recommendation rating: B

Stimulation with endogenous TSH following thyroxine withdrawal or rhTSH (316) and CT fusion (427) may minimally enhance the sensitivity and specificity of <sup>18</sup>FDG-PET scanning.

(b) Tg-positive, RxWBS-negative patients with disease that is incurable with surgery and is structurally evident or visualized on <sup>18</sup>FDG-PET/CT scan can be managed with thyroid hormone suppression therapy, external beam radiotherapy, chemotherapy, radiofrequency ablation, chemo-embolization, or monitoring without additional therapy if stable. Clinical trials should also be considered. Recommendation rating: C

#### ■ RECOMMENDATION 79

Tg-positive, RxWBS-negative patients with no structural evidence of disease can be followed with serial structural imaging studies and serial Tg measurements, with both performed more frequently if the Tg level is rising. When and how often to repeat <sup>18</sup>FDG-PET/CT imaging in this setting is less certain. Recommendation rating: C

[C28] What is the role of external beam radiotherapy in treatment of metastatic disease?

#### ■ RECOMMENDATION 80

External beam radiation should be used in the management of unresectable gross residual or recurrent cervical disease, painful bone metastases, or metastatic lesions in critical locations likely to result in fracture, neurological, or compressive symptoms that are not amenable to surgery (e.g., vertebral metastases, CNS metastases, selected mediastinal or subcarinal lymph nodes, pelvic metastases) (277). Recommendation rating: B

[D1] WHAT ARE DIRECTIONS FOR FUTURE RESEARCH?

#### [D2] Novel therapies and clinical trials

While surgery and the judicious use of RAI, as described in these guidelines, is sufficient treatment for the majority of patients with DTC, a minority of these patients experience progressive, life-threatening growth and metastatic spread of the disease. The recent explosion of knowledge regarding the molecular and cellular pathogenesis of cancer has led to the development of a range of targeted therapies, now undergoing clinical evaluation. Efficacy has already been demonstrated for several agents in phase II studies, including axitinib, motesanib, sorafenib, pazopanib, and thalidomide, whereas many others are in ongoing trials. Randomized phase III trials to demonstrate improved survival, improved progression free survival, or superiority of one therapy over another have not been performed, however, and none of these drugs have been specifically approved for treatment of metastatic thyroid carcinoma. These therapies can be grouped into a number of categories.

[D3] Inhibitors of oncogenic signaling pathways. Tyrosine kinase inhibitors of interest in thyroid carcinoma usually target transmembrane tyrosine kinase receptors that initiate signaling through the MAP kinase pathway. This signaling pathway is activated in the majority of PTCs. Inhibitors of RET, RAS, RAF, and MEK kinases target various members of the same signaling pathway. Several of these agents are in development with several clinical trials completed or underway. Specific oncogene targeting for follicular thyroid cancer and Hürthle cell cancer awaits better understanding of the pathways involved in initiation of these tumor types, although responses in patients with these subtypes have been reported in clinical trials.

[D4] Modulators of growth or apoptosis. Key components of growth and apoptotic pathways are targeted by PPAR<sub>γ</sub> activators, including COX2 inhibitors; rexinoids, which activate RXR; bortezomib, which inactivates the cancer proteasome; and derivatives of geldanamycin, which target the hsp-90 protein. Clinical trials in thyroid cancer of each of these agents are available.

[D5] Angiogenesis inhibitors. Targeting of vascular endothelial growth factor (VEGF) receptors and other members of the signaling cascades responsible for neoangiogenesis may limit the growth of cancers by restricting their blood supply. Many of the kinase inhibitors that have been studied to date are very potent inhibitors of the tyrosine kinase of the VEGF receptors. Trials of several of these agents are currently underway in all subtypes of thyroid cancer.

[D6] Immunomodulators. Stimulation of the immune response to cancer may be achieved by augmenting the activity of antigen-presenting dendritic cells. This approach has shown possible benefits in phase I clinical trials, but has not yet been studied in thyroid cancer. The apparent immunogenicity of thyroid cells makes this an attractive approach for future clinical trials.

[D7] Gene therapy. Preclinical studies have demonstrated some efficacy in thyroid cancer cell lines. Approaches include introducing toxic genes under the control of thyroid-specific promoters, or restoration of the p53 tumor suppressor

gene in anaplastic thyroid cancer cell lines. Problems with gene delivery limit the clinical utility of these approaches, which have not yet reached clinical trials in thyroid cancer.

Each of these targeted approaches holds promise for our future ability to treat patients with life-threatening disease unresponsive to traditional therapy. In the meantime, for appropriate patients, entry into one of the available clinical trials may be an attractive option.

#### **[D8] Better understanding of the long-term risks of RAI**

With the more widespread use of RAI in the management of thyroid cancer, and the normal life expectancy of most patients with the disease, it is imperative that we have a better understanding of the long-term risks associated with its use. Research that focuses on how to minimize the impact of RAI on the salivary glands in order to prevent sialadenitis and xerostomia would provide a significant benefit to patients. A better understanding of the long-term effects of RAI on reproductive issues in men and women is also an important topic. Finally, while the risk of second malignancies appears small following the usual activities of RAI used for remnant ablation, we need better understanding of the long-term risks for salivary gland tumors, bladder tumors, and colon cancers when repeated doses of RAI are needed in young patients who are potentially long-term survivors of thyroid cancer.

#### **[D9] Clinical significance of persistent low levels of serum Tg**

After initial surgery and RAI therapy some patients will have persistently detectable stimulated serum Tg when evaluated 9–12 months later. Most of these patients have stimulated Tg levels in the range of 1–10 ng/mL, levels typically associated with a small volume of tissue. Some of these patients demonstrate a subsequent spontaneous fall in Tg over time, others remain stable, while still others demonstrate rising Tg levels. The optimal management of these patients is unknown. How often should they undergo neck US or stimulated serum Tg testing? Will sensitive Tg assays combined with neck US replace stimulation testing? Which (if any) of these patients should undergo chest CT, PET, or empiric RAI therapy? Can we improve our abilities to predict and monitor which patients are likely to be harmed by their disease as opposed to those who will live unaffected by theirs? Does metastatic disease in small local lymph nodes have the potential to metastasize to distant sites during observation while on TSH suppression therapy? The current impetus to test and treat all of these patients is based on the argument that early diagnosis may lead to early treatment of residual disease when treatment is more likely to be effective, as opposed to less effective treatment when the tumor is more bulky, more extensive, or has spread to inoperable locations. However, there is no current proof that aggressive treatment of minimal residual disease improves patient outcome. This is brought into focus by the fact that only about 5% of all PTC patients die of their disease, yet 15–20% of low-risk PTC patients are likely to have persistent disease based on persistent measurable Tg with stimulation testing.

#### **[D10] The problem of Tg antibodies**

Anti-Tg antibodies are a common clinical problem in patients with DTC (305). The presence of these antibodies

usually interferes with serum Tg measurement and recovery assays do not appear to accurately predict this interference (305,428). Decreasing antibody levels are correlated with “disease-free” status while increasing levels suggest persistent disease (306,429). However, there are clear exceptions to this “rule.” These patients are therefore a challenge to manage or study because one often can not be certain of their disease status. This problem limits definitive investigation which, in turn, hampers development of evidence-based guidelines such as these to assist clinicians. Measurement of Tg mRNA in the blood may be a sensitive marker for persistent thyroid cells even in the presence of anti-Tg antibodies (430–432), but RNA extraction is not well standardized and some studies question the specificity of this marker (433,434). Future studies optimizing the measurement of Tg mRNA and perhaps other thyroid-related substances in blood from DTC patients with anti-Tg antibodies are needed to better monitor this challenging subgroup of DTC patients. This goal would also be enhanced by development of Tg assays that have limited interference by anti-Tg antibodies and by methods to clear anti-Tg antibodies prior to Tg measurement.

#### **[D11] Small cervical lymph node metastases**

The rates of cervical lymph node metastases generally range from about 20% to 50% in most large series of DTC, with higher rates in children or when micrometastases are considered. The location and number of lymph node metastases is often difficult to identify before, during, or after surgery, especially micrometastases. Although postoperative <sup>131</sup>I given to ablate the thyroid remnant undoubtedly destroys some micrometastases, the most common site of recurrence is in cervical lymph nodes, which comprise the majority of all recurrences. Future research must consider the dilemma of minimizing iatrogenic patient harm versus preventing cancer morbidity and (perhaps) mortality. Perhaps techniques will be developed to safely remove or destroy small cervical nodal metastases, which in some cases would otherwise progress to overt, clinically significant metastases. Conversely, the clinical significance of very small (<0.5 cm) nodal metastases needs to be clarified by long-term follow-up studies. Development of a cost-effective method to determine which metastases can be safely followed without intervention would be of great benefit.

#### **[D12] Improved risk stratification**

Current risk stratification schemes rely almost exclusively on clinical, pathological, and radiological data obtained during the initial evaluation and therapy of the patient. However, none of the commonly used risk stratification schemes adequately incorporate the prognostic implications of the very detailed pathological descriptions that are provided (e.g., various histological subtypes of thyroid cancer, frequent mitoses, areas of tumor necrosis, minor degrees of extrathyroidal extension, or capsular invasion) or the molecular characteristics of the primary tumor. Furthermore, current staging systems are static representations of the patient at the time of presentation and are not easily modifiable over time as new data become available during follow-up. Therefore, a risk stratification system that incorporates all the important information available at presentation and also evolves over time as new data become available would be useful in providing



ongoing risk assessments that would optimize management throughout the life of the patient.

### Acknowledgments

The taskforce wishes to thank Ms. Bobbi Smith, Executive Director, American Thyroid Association, and Ms. Sheri Slaughter, Assistant to the Taskforce, for their constant help and support. We also wish to thank Sally Carty, M.D., Quan-Yang Duh, M.D., Gregory Randolph, M.D., David Steward, M.D., David Terris, M.D., Ralph Tufano, M.D., and Robert Udelsman, M.D., for their help in developing recommendations related to central neck dissection.

### Disclaimer

It is our goal in formulating these guidelines, and the ATA's goal in providing support for the development of these guidelines, that they assist in the clinical care of patients, and share what we believe is current, rational, and optimal medical practice. In some circumstances, it may be apparent that the level of care recommended may be best provided in limited centers with specific expertise. Finally, it is not the intent of these guidelines to replace individual decision making, the wishes of the patient or family, or clinical judgment.

### Disclosure Statement

These guidelines were funded by the American Thyroid Association without support from any commercial sources.

GMD is a consultant for MedTronic ENT. BRH has received honoraria from Genzyme and grant/research support from Veracyte. RTK has received grant/research support from Genzyme, Bayer-Onyx, Eisai, and Veracyte; is a consultant for Genzyme, Bayer-Onyx, Abbott, and Veracyte; and is on the Speakers Bureau for Genzyme and Abbott. He has received no honoraria for commercial speaking since November 2006 and all commercial consulting since that time has been approved by the ATA Board of Directors, the ATA Ethics Committee, and has been without financial compensation. SLL has received grant/research support from Bayer and is a consultant for Abbott, Onyx, and Bayer. SJM has received grant/research support from Veracyte and has been a CME speaker for Genzyme. ELM is on the Speakers Bureau for Genzyme. FP has received grant/research support from Amgen, Exelixis, and AstraZeneca and is a consultant and on the Speakers Bureau for Genzyme. MS has received grant/research support from Genzyme, Amgen, AstraZeneca, Bayer, Exelixis, and Eisai; is a consultant for Genzyme, AstraZeneca, Bayer, and Exelixis; and is on the Speakers Bureau for Genzyme, AstraZeneca, and Exelixis. SIS has received grant/research support from Genzyme, Amgen, AstraZeneca, and Eisai; is a consultant for AstraZeneca, Eisai, Exelixis, Plexxikon, Oxigene, Semalora, Celgene, and Eli Lilly; is on the Speakers Bureau for Genzyme; and has received honoraria from Abbott. DLS has received grant/research support from Veracyte, Wyeth, Astra-Zeneca, and Gyrus. RMT is a consultant for Genzyme, Abbott, and Eli Lilly, and has received honoraria from Genzyme and Abbott. DSC and BM report that no competing financial interests exist.

### References

1. Tunbridge WMG, Evered DC, Hall R, Appleton D, Brewis M, Clark F, Evans JG, Young E, Bird T, Smith PA 1977 The spectrum of thyroid disease in a community: the Whickham Survey. *Clin Endocrinol (Oxf)* 7:481-493.
2. Vander JB, Gaston EA, Dawber TR 1968 The significance of nontoxic thyroid nodules. *Ann Intern Med* 69:537-540.
3. Tan GH, Gharib H 1997 Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. *Ann Intern Med* 126:226-231.
4. Hegedus L 2004 Clinical practice. The thyroid nodule. *N Engl J Med* 351:1764-1771.
5. Mandel SJ 2004 A 64-year-old woman with a thyroid nodule. *JAMA* 292:2632-2642.
6. Sherman SI 2003 Thyroid carcinoma. *Lancet* 361:501-511.
7. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ 2009 Cancer statistics, 2009. *CA Cancer J Clin*. Published online before print May 27, 2009.
8. Davies L, Welch HG 2006 Increasing incidence of thyroid cancer in the United States, 1973-2002. *JAMA* 295:2164-2167.
9. Leenhardt L, Bernier MO, Boin-Pineau MH, Conte DB, Marechaud R, Niccoli-Sire P, Nocaudie M, Orgiazzi J, Schlumberger M, Wémeau JL, Chérie-Challine L, De Vathaire F 2004 Advances in diagnostic practices affect thyroid cancer incidence in France. *Eur J Endocrinol* 150:133-139.
10. Singer PA, Cooper DS, Daniels GH, Ladenson PW, Greenspan FS, Levy EG, Braverman LE, Clark OH, McDougall IR, Ain KV, Dorfman SG 1996 Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. American Thyroid Association. *Arch Intern Med* 156:2165-2172.
11. American Association of Clinical Endocrinologists 2001 AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. *Endocr Pract* 7:202-220.
12. British Thyroid Association and Royal College of Physicians. 2007 Guidelines for the management of thyroid cancer, 2<sup>nd</sup> Edition. [www.british-thyroid-association.org](http://www.british-thyroid-association.org).
13. National Comprehensive Cancer Network. 2009 Thyroid carcinoma. [www.nccn.org/professionals/physician\\_gls/PDF/thyroid.pdf](http://www.nccn.org/professionals/physician_gls/PDF/thyroid.pdf). Accessed January 28, 2009.
14. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W 2006 European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. *Eur J Endocrinol* 154:787-803.
15. Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, Tennvall J, Bombardieri E 2008 Guidelines for radioiodine therapy of differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* 35:1941-1959.
16. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM 2006 The American Thyroid Association Guidelines Taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. *Thyroid* 16:109-142.
17. U.S. Preventive Services Task Force Ratings: Strength of Recommendations and Quality of Evidence. Guide to Clinical Preventive Services, Third Edition: Periodic Updates, 2000-2003. Agency for Healthcare Research and Quality, Rockville, MD.
18. Marqusee E, Benson CB, Frates MC, Doubilet PM, Larsen PR, Cibas ES, Mandel SJ 2000 Usefulness of ultrasonography in the management of nodular thyroid disease. *Ann Intern Med* 133:696-700.
19. Hagag P, Strauss S, Weiss M 1998 Role of ultrasound-guided fine-needle aspiration biopsy in evaluation of nonpalpable thyroid nodules. *Thyroid* 8:989-995.

20. Are C, Hsu JF, Ghossein RA, Schoder H, Shah JP, Saha AR 2007 Histological aggressiveness of fluorodeoxyglucose positron-emission tomogram (FDG-PET)-detected incidental thyroid carcinomas. *Ann Surg Oncol* **14**:3210–3215.
21. Bogsrud TV, Karantanis D, Nathan MA, Mullan BP, Wiseman GA, Collins DA, Kasperbauer JL, Strome SE, Reading CC, Hay ID, Lowe VJ 2007 The value of quantifying 18F-FDG uptake in thyroid nodules found incidentally on whole-body PET-CT. *Nucl Med Commun* **28**:373–381.
22. Kang KW, Kim SK, Kang HS, Lee ES, Sim JS, Lee IG, Jeong SY, Kim SW 2003 Prevalence and risk of cancer of focal thyroid incidentaloma identified by 18F-fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects. *J Clin Endocrinol Metab* **88**:4100–4104.
23. Choi JY, Lee KS, Kim HJ, Shim YM, Kwon OJ, Park K, Baek CH, Chung JH, Lee KH, Kim BT 2006 Focal thyroid lesions incidentally identified by integrated 18F-FDG PET/CT: clinical significance and improved characterization. *J Nucl Med* **47**:609–615.
24. Curtis RE, Rowlings PA, Deeg HJ, Shriner DA, Socié G, Travis LB, Horowitz MM, Witherspoon RP, Hoover RN, Sobocinski KA, Fraumeni JF, Boice JD, Schoch HG, Sale GE, Storb R, Travis WD, Kolb HJ, Gale RP, Passweg JR 1997 Solid cancers after bone marrow transplantation. *N Engl J Med* **336**:897–904.
25. Pacini F, Vorontsova T, Demidchik E, Molinaro E, Agate, L, Romei C, Shavrova E, Cherstvoy ED, Ivashkevitch Y, Kuchinskaya E, Schlumberger M, Ronga G, Filesi M, Pinchera A 1997 Post-Chernobyl thyroid carcinoma in Belarus children and adolescents: comparison with naturally occurring thyroid carcinoma in Italy and France. *J Clin Endocrinol Metab* **81**:3563–3569.
26. Boelaert K, Horacek J, Holder RL, Watkinson JC, Sheppard MC, Franklyn JA 2006 Serum thyrotropin concentration as a novel predictor of malignancy in thyroid nodules investigated by fine-needle aspiration. *J Clin Endo Metab* **91**:4295–4301.
27. Hall TL, Layfield LJ, Philippe A, Rosenthal D 1989 Sources of diagnostic error in fine needle aspiration of the thyroid. *Cancer* **63**:718–725.
28. Alexander EK, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Marqusee E 2002 Assessment of non-diagnostic ultrasound-guided fine needle aspiration of thyroid nodules. *J Clin Endocrinol Metab* **87**:4924–4927.
29. Brander A, Viikinkoski P, Tuuhea J, Voutilainen L, Kivisaari L 1992 Clinical versus ultrasound examination of the thyroid gland in common clinical practice. *J Clin Ultrasound* **20**:37–42.
30. Tan GH, Gharib H, Reading CC 1995 Solitary thyroid nodule. *Arch Intern Med* **155**:2418–2423.
31. Singh B, Saha AR, Trivedi H, Carew JF, Poluri A, Shah JP 1999 Coexistent Hashimoto's thyroiditis with papillary thyroid carcinoma: impact on presentation, management, and outcome. *Surgery* **126**:1070–1077.
32. Repplinger D, Bargren A, Zhang YW, Adler JT, Haymart M, Chen H 2008 Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer? *J Surg Res* **150**:49–52.
33. Pacini F, Pinchera A, Giani C, Grasso L, Doveri F, Baschieri L 1980. Serum thyroglobulin in thyroid carcinoma and other thyroid disorders. *J Endocrinol Invest* **3**:283–292.
34. Elisei R, Bottici V, Luchetti F, Di Coscio G, Romei C, Grasso L, Miccoli P, Iacconi P, Basolo F, Pinchera A, Pacini F 2004 Impact of routine measurement of serum calcitonin on the diagnosis and outcome of medullary thyroid cancer: experience in 10,864 patients with nodular thyroid disorders. *J Clin Endocrinol Metab* **89**:163–168.
35. Hahn JR, Lee MS, Min YK, Lee MK, Kim KW, Nam SJ, Yang JH, Chung JH 2001 Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. *Thyroid* **11**:73–80.
36. Niccoli P, Wion-Barbot N, Caron P, Henry JF, de Micco C, Saint Andre JP, Bigorgne JC, Modigliani E, Conte-Devolx B 1997 Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. *J Clin Endocrinol Metab* **82**:338–341.
37. Costante G, Meringolo D, Durante C, Bianchi D, Nocera M, Tumino S, Crocetti U, Attard M, Maranghi M, Torlontano M, Filetti S 2007 Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. *J Clin Endocrinol Metab* **92**:450–455.
38. Cheung K, Roman SA, Wang TS, Walker HD, Sosa JA 2008 Calcitonin measurement in the evaluation of thyroid nodules in the United States: a cost-effectiveness and decision analysis. *J Clin Endocrinol Metab* **93**:2173–2180.
39. Gagel RF, Hoff AO, Cote GJ 2005 Medullary thyroid carcinoma. In Werner and Ingbar's *The Thyroid*. Lippincott Williams and Wilkins, Philadelphia, pp 967–988.
40. Danese D, Sciacchitano S, Farsetti A, Andreoli M, Pontecorvi A 1998 Diagnostic accuracy of conventional versus sonography-guided fine-needle aspiration biopsy of thyroid nodules. *Thyroid* **8**:15–21.
41. Carmeci C, Jeffrey RB, McDougall IR, Nowels KW, Weigel RJ 1998 Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. *Thyroid* **8**:283–289.
42. Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK, Frable WJ 2008 Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: a synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. *Diagn Cytopathol* **36**:425–437.
43. Leenhardt L, Hejblum G, Franc B, Fediaevsky LD, Delbot T, Le Guillouzic D, Ménégau F, Guillausseau C, Hoang C, Turpin G, Aurengo A 1999 Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. *J Clin Endocrinol Metab* **84**:24–28.
44. Papini E, Guglielmi R, Bianchini A, Crescenzi A, Taccogna S, Nardi F, Panunzi C, Rinaldi R, Toscano V, Pacella CM 2002 Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. *J Clin Endocrinol Metab* **87**:1941–1946.
45. Nam-Goong IS, Kim HY, Gong G, Lee HK, Hong SJ, Kim WB, Shong YK 2004 Ultrasonography-guided fine-needle aspiration of thyroid incidentaloma: correlation with pathological findings. *Clin Endocrinol (Oxf)* **60**:21–28.
46. Cappelli C, Castellano M, Pirola I, Cumetti D, Agosti B, Gandossi E, Agabiti Rosei E 2007 The predictive value of ultrasound findings in the management of thyroid nodules. *QJM* **100**:29–35.
47. Frates MC, Benson CB, Doubilet PM, Kunreuther E, Conterras M, Cibas ES, Orcutt J, Moore FD Jr, Larsen PR, Marqusee E, Alexander EK 2006 Prevalence and distribution of carcinoma in patients with solitary and multiple thyroid nodules on sonography. *J Clin Endocrinol Metab* **91**:3411–3417.

48. Moon WJ, Jung SL, Lee JH, Na DG, Baek JH, Lee YH, Kim J, Kim HS, Byun JS, Lee DH; Thyroid Study Group, Korean Society of Neuro- and Head and Neck Radiology 2008 Benign and malignant thyroid nodules: US differentiation—multicenter retrospective study. *Radiology* **247**:762–770.
49. Jeh SK, Jung SL, Kim BS, Lee YS 2007 Evaluating the degree of conformity of papillary carcinoma and follicular carcinoma to the reported ultrasonographic findings of malignant thyroid tumor. *Korean J Radiol* **8**:192–197.
50. Machens A, Holzhausen HJ, Dralle H 2005 The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. *Cancer* **103**:2269–2273.
51. Moon WJ, Kwag HJ, Na DG 2009 Are there any specific ultrasound findings of nodular hyperplasia (“leave me alone” lesion) to differentiate it from follicular adenoma? *Acta Radiologica* **50**:383–388.
52. Bonavita JA, Mayo J, Babb J, Bennett G, Oweity T, Macari M, Yee J 2009 Pattern recognition of benign nodules at ultrasound of the thyroid: which nodules can be left alone? *AJR Am J Roentgenol* **193**:207–213.
53. Rago T, Santini F, Scutari M, Pinchera A, Vitti P 2007 Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. *J Clin Endocrinol Metab* **92**:2917–2922.
54. Noguchi S, Yamashita H, Uchino S, Watanabe S 2008 Papillary microcarcinoma. *World J Surg* **32**:747–753.
55. Wada N, Duh QY, Sugino K, Iwasaki H, Kameyama K, Mimura T, Ito K, Takami H, Takanashi Y 2003 Lymph node metastasis from 259 papillary thyroid microcarcinomas: frequency, pattern of occurrence and recurrence, and optimal strategy for neck dissection. *Ann Surg* **237**:399–407.
56. Ito Y, Tomoda C, Uruno T, Takamura Y, Miya A, Kobayashi K, Matsuzuka F, Kuma K, Miyauchi A 2004 Preoperative ultrasonographic examination for lymph node metastasis: usefulness when designing lymph node dissection for papillary microcarcinoma of the thyroid. *World J Surg* **28**:498–501.
57. Hemminki K, Eng C, Chen B 2005 Familial risks for non-medullary thyroid cancer. *J Clin Endocrinol Metab* **90**:5747–5753.
58. Schneider AB, Ron E, Lubin J, Stovall M, Gierlowski TC 1993 Dose-response relationships for radiation-induced thyroid cancer and thyroid nodules: evidence for the prolonged effects of radiation on the thyroid. *J Clin Endocrinol Metab* **77**:362–369.
59. Shibata Y, Yamashita S, Masyakin VB, Panasyuk GD, Nagataki S 2001 15 years after Chernobyl: new evidence of thyroid cancer. *Lancet* **358**:1965–1966.
60. Braga M, Cavalcanti TC, Collaco LM, Graf H 2001 Efficacy of ultrasound-guided fine-needle aspiration biopsy in the diagnosis of complex thyroid nodules. *J Clin Endocrinol Metab* **86**:4089–4091.
61. Redman R, Zalaznick H, Mazzaferri EL, Massoll NA 2006 The impact of assessing specimen adequacy and number of needle passes for fine-needle aspiration biopsy of thyroid nodules. *Thyroid* **16**:55–60.
62. Baloch ZW, Tam D, Langer J, Mandel S, LiVolsi VA, Gupta PK 2000 Ultrasound-guided fine-needle aspiration biopsy of the thyroid: role of on-site assessment and multiple cytologic preparations. *Diagn Cytopathol* **23**:425–429.
63. de los Santos ET, Keyhani-Rofagha S, Cunningham JJ, Mazzaferri EL 1990 Cystic thyroid nodules. The dilemma of malignant lesions. *Arch Intern Med* **150**:1422–1427.
64. Yeh MW, Demircan O, Ituarte P, Clark OH 2004 False-negative fine-needle aspiration cytology results delay treatment and adversely affect outcome in patients with thyroid carcinoma. *Thyroid* **14**:207–215.
65. Gharib H, Goellner JR, Johnson DA 1993 Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. *Clin Lab Med* **13**:699–709.
66. Tuttle RM, Lemar H, Burch HB 1998 Clinical features associated with an increased risk of thyroid malignancy in patients with follicular neoplasia by fine-needle aspiration. *Thyroid* **8**:377–383.
67. Tyler DS, Winchester DJ, Caraway NP, Hickey RC, Evans DB 1994 Indeterminate fine-needle aspiration biopsy of the thyroid: identification of subgroups at high risk for invasive carcinoma. *Surgery* **116**:1054–1060.
68. Kelman AS, Rathan A, Leibowitz J, Burstein DE, Haber RS 2001 Thyroid cytology and the risk of malignancy in thyroid nodules: importance of nuclear atypia in indeterminate specimens. *Thyroid* **11**:271–277.
69. Bartolazzi A, Orlandi F, Saggiorato E, Volante M, Arecco F, Rossetto R, Palestini N, Ghigo E, Papotti M, Bussolati G, Martegani MP, Pantellini F, Carpi A, Giovagnoli MR, Monti S, Toscano V, Sciacchitano S, Pennelli GM, Mian C, Pelizzo MR, Rugge M, Troncone G, Palombini L, Chiappetta G, Botti G, Vecchione A, Bellocchio R; Italian Thyroid Cancer Study Group (ITCSG) 2008 Galectin-3-expression analysis in the surgical selection of follicular thyroid nodules with indeterminate fine-needle aspiration cytology: a prospective multicentre study. *Lancet Oncol* **9**:543–549.
70. Segev DL, Clark DP, Zeiger MA, Umbricht C 2003 Beyond the suspicious thyroid fine needle aspirate. A review. *Acta Cytol* **47**:709–722.
71. Haugen BR, Woodmansee WW, McDermott MT 2002 Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. *Clin Endo* **56**:281–290.
72. Sapio MR, Posca D, Raggioli A, Guerra A, Marotta V, Deandrea M, Motta M, Limone PP, Troncone G, Caleo A, Rossi G, Fenzi G, Vitale M 2007 Detection of RET/PTC, TRK and BRAF mutations in preoperative diagnosis of thyroid nodules with indeterminate cytological findings. *Clin Endocrinol (Oxf)* **66**:678–683.
73. Nikiforov YE, Nikiforov YE, Steward DL, Robinson-Smith TM, Haugen BR, Klopper JP, Zhu Z, Fagin JA, Falciglia M, Weber K, Nikiforova MN 2009 Molecular testing for mutations in improving the fine-needle aspiration diagnosis of thyroid nodules. *J Clin Endocrinol Metab* **94**:2092–2098.
74. Franco C, Martínez V, Allamand JP, Medina F, Glasinovic A, Osorio M, Schachter D 2009 Molecular markers in thyroid fine-needle aspiration biopsy: a prospective study. *Appl Immunohistochem Mol Morphol* **17**:211–215.
75. Mitchell JC, Grant F, Evenson AR, Parker JA, Hasselgren PO, Parangi S 2005. Preoperative evaluation of thyroid nodules with 18FDG-PET/CT. *Surgery* **138**:1166–1174; discussion 1174–1175.
76. de Geus-Oei LF, Pieters GF, Bonenkamp JJ, Mudde AH, Bleeker-Rovers CP, Corstens FH, Oyen WJ 2006 18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. *J Nucl Med* **47**:770–775.
77. Kim JM, Ryu JS, Kim TY, Kim WB, Kwon GY, Gong G, Moon DH, Kim SC, Hong SJ, Shong YK 2007 18F-fluorodeoxyglucose positron emission tomography does not predict malignancy in thyroid nodules cytologically

- diagnosed as follicular neoplasm. *J Clin Endocrinol Metab* **92**:1630–1634.
78. Sebastianes FM, Cerci JJ, Zanon PH, Soares J Jr, Chibana LK, Tomimori EK, de Camargo RY, Izaki M, Giorgi MC, Eluf-Neto J, Meneghetti JC, Pereira MA 2007 Role of 18F-fluorodeoxyglucose positron emission tomography in preoperative assessment of cytologically indeterminate thyroid nodules. *J Clin Endocrinol Metab* **92**:4485–4488.
  79. Hales NW, Kreml GA, Medina JE 2008 Is there a role for fluorodeoxyglucose positron emission tomography/computed tomography in cytologically indeterminate thyroid nodules? *Am J Otolaryngol* **29**:113–118.
  80. Ylagan LR, Farkas T, Dehner LP 2004 Fine needle aspiration of the thyroid: a cytohistologic correlation and study of discrepant cases. *Thyroid* **14**:35–41.
  81. McCoy KL, Jabbour N, Ogilvie JB, Ohori NP, Carty SE, Yim JH 2007 The incidence of cancer and rate of false-negative cytology in thyroid nodules greater than or equal to 4 cm in size. *Surgery* **142**:837–844.
  82. Alexander EK, Hurwitz S, Heering JP, Benson CB, Frates MC, Doubilet PM, Cibas ES, Larsen PR, Marqusee E 2003 Natural history of benign solid and cystic thyroid nodules. *Ann Int Med* **138**:315–318.
  83. Asanuma K, Kobayashi S, Shingu K, Hama Y, Yokoyama S, Fujimori M, Amano J 2001 The rate of tumour growth does not distinguish between malignant and benign thyroid nodules. *Eur J Surg* **167**:102–105.
  84. Erdogan MF, Kamel N, Aras D, Akdogan A, Baskal N, Erdogan G 1998 Value of re-aspirations in benign nodular thyroid disease. *Thyroid* **8**:1087–1090.
  85. Orlandi A, Puscar A, Capriata E, Fideleff H 2005 Repeated fine-needle aspiration of the thyroid in benign nodular thyroid disease: critical evaluation of long-term follow-up. *Thyroid* **15**:274–278.
  86. Papini E, Petrucci L, Guglielmi R, Panunzi C, Rinaldi R, Bacci V, Crescenzi A, Nardi F, Fabbri R, Pacella CM 1998 Long-term changes in nodular goiter: a 5-year prospective randomized trial of levothyroxine suppressive therapy for benign cold thyroid nodules. *J Clin Endocrinol Metab* **83**:780–783.
  87. Brauer VF, Eder P, Miehle K, Wiesner TD, Hasenclever H, Paschke R 2005 Interobserver variation for ultrasound determination of thyroid nodule volumes. *Thyroid* **15**:1169–1175.
  88. Brander AE, Viikinkoski VP, Nickels JI, Kivisaari LM 2000 Importance of thyroid abnormalities detected at US screening: a 5-year follow-up. *Radiology* **215**:801–806.
  89. Oertel YC, Miyahara-Felipe L, Mendoza MG, Yu K 2007 Value of repeated fine needle aspirations of the thyroid: an analysis of over ten thousand FNAs. *Thyroid* **17**:1061–1066.
  90. Bennedbaek FN, Hegedüs L 2003 Treatment of recurrent thyroid cysts with ethanol: a randomized double-blind controlled trial. *J Clin Endocrinol Metab* **88**:5773–5777.
  91. Valcavi R, Frasoldati A 2004 Ultrasound-guided percutaneous ethanol injection therapy in thyroid cystic nodules. *Endocr Pract* **10**:269–275.
  92. Antonelli A, Campatelli A, Di Vito A, Alberti B, Baldi V, Salvioni G, Fallahi P, Baschieri L 1994 Comparison between ethanol sclerotherapy and emptying with injection of saline in treatment of thyroid cysts. *Clin Investig* **72**:971–974.
  93. Verde G, Papini E, Pacella CM, Gallotti C, Delpiano S, Strada S, Fabbri R, Bizzarri G, Rinaldi R, Panunzi C, Geili D 1994 Ultrasound guided percutaneous ethanol injection in the treatment of cystic thyroid nodules. *Clin Endocrinol (Oxf)* **41**:719–724.
  94. Zelmanovitz F, Genro S, Gross JL 1998 Suppressive therapy with levothyroxine for solitary thyroid nodules: a double-blind controlled clinical study and cumulative meta-analyses. *J Clin Endocrinol Metab* **83**:3881–3885.
  95. Wemeau JL, Caron P, Schwartz C, Schlienger JL, Orgiazzi J, Cousty C, Vlaeminck-Guillem V 2002 Effects of thyroid-stimulating hormone suppression with levothyroxine in reducing the volume of solitary thyroid nodules and improving extranodular nonpalpable changes: a randomized, double-blind, placebo-controlled trial by the French Thyroid Research Group. *J Clin Endocrinol Metab* **87**:4928–4934.
  96. Castro MR, Caraballo PJ, Morris JC 2002 Effectiveness of thyroid hormone suppressive therapy in benign solitary thyroid nodules: a meta-analysis. *J Clin Endocrinol Metab* **87**:4154–4159.
  97. Rallison ML, Dobyns BM, Keating FR Jr, Rall JE, Tyler FH 1975 Thyroid nodularity in children. *JAMA* **233**:1069–1072.
  98. Raab SS, Silverman JF, Elsheikh TM, Thomas PA, Wakely PE 1995 Pediatric thyroid nodules: disease demographics and clinical management as determined by fine needle aspiration biopsy. *Pediatrics* **95**:46–49.
  99. Corrias A, Einaudi S, Chiorboli E, Weber G, Crino A, Andreo M, Cesaretti G, de Sanctis L, Messina MF, Segni M, Cicchetti M, Vigone M, Pasquino AM, Spera S, de Luca F, Mussa GC, Bona G 2001 Accuracy of fine needle aspiration biopsy of thyroid nodules in detecting malignancy in childhood: comparison with conventional clinical, laboratory, and imaging approaches. *J Clin Endocrinol Metab* **86**:4644–4648.
  100. Hung W 1999 Solitary thyroid nodules in 93 children and adolescents, a 35-years experience. *Horm Res* **52**:15–18.
  101. Gharib H, Zimmerman D, Goellner JR, Bridley SM, LeBlanc SM 1995 Fine-needle aspiration biopsy: Use in diagnosis and management of pediatric thyroid diseases. *Endo Pract* **1**:9–13.
  102. Arda IS, Yildirim S, Demirhan B, Firat S 2001 Fine needle aspiration biopsy of thyroid nodules. *Arch Dis Child* **85**:313–317.
  103. Tan GH, Gharib H, Goellner JR, van Heerden JA, Bahn RS 1996 Management of thyroid nodules in pregnancy. *Arch Intern Med* **156**:2317–2320.
  104. Moosa M, Mazzaferri EL 1997 Outcome of differentiated thyroid cancer diagnosed in pregnant women. *J Clin Endocrinol Metab* **82**:2862–2866.
  105. Mestman JH, Goodwin TM, Montoro MM 1995 Thyroid disorders of pregnancy. *Endocrinol Metab Clin North Am* **24**:41–71.
  106. Herzon FS, Morris DM, Segal MN, Rauch G, Parnell T 1994 Coexistent thyroid cancer and pregnancy. *Arch Otolaryngol Head Neck Surg* **120**:1191–1193.
  107. Mazzaferri EL, Jhiang SM 1994 Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. *Am J Med* **97**:418–428.
  108. Kuy S, Roman SA, Desai R, Sosa JA 2009 Outcomes following thyroid and parathyroid surgery in pregnant women. *Arch Surg* **144**:399–406.
  109. Rosen IB, Korman M, Walfish PG 1997 Thyroid nodular disease in pregnancy: current diagnosis and management. *Clin Obstet Gynecol* **40**:81–89.
  110. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995. *Cancer* **83**:2638–2648.

111. Volante M, Landolfi S, Chiusa L, Palestini N, Motta M, Codegone A, Torchio B, Papotti MG 2004 Poorly differentiated carcinomas of the thyroid with trabecular, insular, and solid patterns: a clinicopathologic study of 183 patients. *Cancer* **100**:950–957.
112. van Heerden JA, Hay ID, Goellner JR, Salomao D, Ebersold JR, Bergstralh EJ, Grant CS 1992 Follicular thyroid carcinoma with capsular invasion alone: a nonthreatening malignancy. *Surgery*. **112**:1130–6.
113. Sanders LE, Silverman M 1998 Follicular and Hürthle cell carcinoma: predicting outcome and directing therapy. *Surgery* **124**:967–974.
114. Lo CY, Chan WF, Lam KY, Wan KY 2005 Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. *Ann Surg* **242**:708–715.
115. D'Avanzo A, Treseler P, Ituarte PH, Wong M, Streja L, Greenspan FS, Siperstein AE, Duh QY, Clark OH 2004. Follicular thyroid carcinoma: histology and prognosis. *Cancer* **100**:1123–1129.
116. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS 1993 Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. *Surgery* **114**:1050–1057; discussion 1057–1058.
117. Shah MD, Hall FT, Eski SJ, Witterick IJ, Walfish PG, Freeman JL 2003 Clinical course of thyroid carcinoma after neck dissection. *Laryngoscope* **113**:2102–2107.
118. Wang TS, Dubner S, Szytler LA, Heller KS 2004 Incidence of metastatic well-differentiated thyroid cancer in cervical lymph nodes. *Arch Otolaryngol Head Neck Surg* **130**:110–113.
119. Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R 1998 The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. *Ann Surg* **228**:320–330.
120. Friedman M, Pacella BL, Jr 1990 Total versus subtotal thyroidectomy. Arguments, approaches, and recommendations. *Otolaryngol Clin North Am* **23**:413–427.
121. Brierley JD, Panzarella T, Tsang RW, Gospodarowicz MK, O'Sullivan B 1997 A comparison of different staging systems predictability of patient outcome. Thyroid carcinoma as an example. *Cancer* **79**:2414–2423.
122. Hay ID, Thompson GB, Grant CS, Bergstralh EJ, Dvorak CE, Gorman CA, Maurer MS, McIver B, Mullan BP, Oberg AL, Powell CC, van Heerden JA, Goellner JR 2002 Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940–1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients. *World J Surg* **26**:879–885.
123. Lin JD, Chao TC, Huang MJ, Weng HF, Tzen KY 1998 Use of radioactive iodine for thyroid remnant ablation in well-differentiated thyroid carcinoma to replace thyroid reoperation. *Am J Clin Oncol* **21**:77–81.
124. Esnaola NF, Cantor SB, Sherman SI, Lee JE, Evans DB 2001 Optimal treatment strategy in patients with papillary thyroid cancer: a decision analysis. *Surgery* **130**:921–930.
125. Mazzaferri EL 1999 An overview of the management of papillary and follicular thyroid carcinoma. *Thyroid* **9**:421–427.
126. Mazzaferri EL 2000 Long-term outcome of patients with differentiated thyroid carcinoma: effect of therapy. *Endocr Pract* **6**:469–476.
127. Cooper DS, Specker B, Ho M, Sperling M, Ladenson PW, Ross DS, Ain KB, Bigos ST, Brierley JD, Haugen BR, Klein I, Robbins J, Sherman SI, Taylor T, Maxon HR 3rd 1998 Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: results from the National Thyroid Cancer Treatment Cooperative Registry. *Thyroid* **8**:737–744.
128. Kim TH, Yang DS, Jung KY, Kim CY, Choi MS 2003 Value of external irradiation for locally advanced papillary thyroid cancer. *Int J Radiat Oncol Biol Phys* **55**:1006–1012.
129. Grebe SK, Hay ID 1996 Thyroid cancer nodal metastases: biologic significance and therapeutic considerations. *Surg Oncol Clin N Am* **5**:43–63.
130. Scheumann GF, Gimm O, Wegener G, Hundeshagen H, Dralle H 1994 Prognostic significance and surgical management of locoregional lymph node metastases in papillary thyroid cancer. *World J Surg* **18**:559–568.
131. Ito Y, Uruno T, Nakano K, Takamura Y, Miya A, Kobayashi K, Yokozawa T, Matsuzuka F, Uchimi T, Kuwano M, Miyoshi E, Matsuura N, Kuma K, Miyauchi A 2003 An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid. *Thyroid* **13**:381–387.
132. Chow SM, Law SC, Chan JK, Au SK, Yau S, Lau WH 2003 Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality. *Cancer* **98**:31–40.
133. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ 1992 Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. *Surgery* **112**:1139–1146; discussion 1146–1147.
134. Qubain SW, Nakano S, Baba M, Takao S, Aikou T 2002 Distribution of lymph node micrometastasis in pN0 well-differentiated thyroid carcinoma. *Surgery* **131**:249–256.
135. Arturi F, Russo D, Giuffrida D, Ippolito A, Perrotti N, Vigneri R, Filetti S 1997 Early diagnosis by genetic analysis of differentiated thyroid cancer metastases in small lymph nodes. *J Clin Endocrinol Metab* **82**:1638–1641.
136. Solorzano CC, Carneiro DM, Ramirez M, Lee TM, Irvin GL 3rd 2004 Surgeon-performed ultrasound in the management of thyroid malignancy. *Am Surg* **70**:576–580; discussion 580–582.
137. Shimamoto K, Satake H, Sawaki A, Ishigaki T, Funahashi H, Imai T 1998 Preoperative staging of thyroid papillary carcinoma with ultrasonography. *Eur J Radiol* **29**:4–10.
138. Stulak JM, Grant CS, Farley DR, Thompson GB, van Heerden JA, Hay ID, Reading CC, Charboneau JW 2006 Value of preoperative ultrasonography in the surgical management of initial and reoperative papillary thyroid cancer. *Arch Surg* **141**:489–494.
139. Kouvaraki MA, Shapiro SE, Fornage BD, Edeiken-Monro BS, Sherman SI, Vassilopoulou-Sellin R, Lee JE, Evans DB 2003 Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer. *Surgery* **134**:946–954; discussion 954–955.
140. Leboulleux S, Girard E, Rose M, Travagli JP, Sabbah N, Caillou B, Hartl DM, Lassau N, Baudin E, Schlumberger M 2007 Ultrasound criteria of malignancy for cervical lymph nodes in patients followed up for differentiated thyroid cancer. *J Clin Endocrinol Metab* **92**:3590–3594.
141. Frasoldati A, Valcavi R 2004 Challenges in neck ultrasonography: lymphadenopathy and parathyroid glands. *Endocr Pract* **10**:261–268.
142. Kuna SK, Bracic I, Tesic V, Kuna K, Herceg GH, Dodig D 2006 Ultrasonographic differentiation of benign from malignant neck lymphadenopathy in thyroid cancer. *J Ultrasound Med* **25**:1531–1537.

143. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R 2003 Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. *Cancer* **97**:90–96.
144. Boi F, Baghino G, Atzeni F, Lai ML, Faa G, Mariotti S 2006 The diagnostic value for differentiated thyroid carcinoma metastases of thyroglobulin (Tg) measurement in washout fluid from fine-needle aspiration biopsy of neck lymph nodes is maintained in the presence of circulating anti-Tg antibodies. *J Clin Endocrinol Metab* **91**:1364–1369.
145. Stephenson BM, Wheeler MH, Clark OH 1994 The role of total thyroidectomy in the management of differentiated thyroid cancer. *Curr Opin Gen Surg* **5**:3–59.
146. Jeong HS, Baek CH, Son YI, Choi JY, Kim HJ, Ko YH, Chung JH, Baek HJ 2006 Integrated 18F-FDG PET/CT for the initial evaluation of cervical node level of patients with papillary thyroid carcinoma: comparison with ultrasound and contrast-enhanced CT. *Clin Endocrinol (Oxf)* **65**:402–407.
147. Kresnik E, Gallowitsch HJ, Mikosch P, Stettner H, Igerc I, Gomez I, Kumnig G, Lind P 2003 Fluorine-18-fluorodeoxyglucose positron emission tomography in the preoperative assessment of thyroid nodules in an endemic goiter area. *Surgery* **133**:294–299.
148. Zbaren P, Becker M, Lang H 1997 Pretherapeutic staging of hypopharyngeal carcinoma. Clinical findings, computed tomography, and magnetic resonance imaging compared with histopathologic evaluation. *Arch Otolaryngol Head Neck Surg* **123**:908–913.
149. Spencer CA, Bergoglio LM, Kazarosyan M, Fatemi S, Lopresti JS 2005 Clinical impact of thyroglobulin (Tg) and Tg autoantibody method differences on the management of patients with differentiated thyroid carcinomas. *J Clin Endocrinol Metab* **90**:5566–5575.
150. Duren M, Yavuz N, Bukey Y, Ozyegin MA, Gundogdu S, Açbay O, Hatemi H, Uslu I, Onsel C, Aksoy F, Oz F, Unal G, Duren E 2000 Impact of initial surgical treatment on survival of patients with differentiated thyroid cancer: experience of an endocrine surgery center in an iodine-deficient region. *World J Surg* **24**:1290–1294.
151. Gharib H, Goellner JR, Zinsmeister AR, Grant CS, Van Heerden JA 1984. Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings. *Ann Intern Med* **101**:25–28.
152. Baloch ZW, Fleisher S, LiVolsi VA, Gupta PK 2002 Diagnosis of “follicular neoplasm”: a gray zone in thyroid fine-needle aspiration cytology. *Diagn Cytopathol* **26**:41–44.
153. Sclabas GM, Staerckel GA, Shapiro SE, Fornage BD, Sherman SL, Vassilopoulos-Sellin R, Lee JE, Evans DB 2003 Fine-needle aspiration of the thyroid and correlation with histopathology in a contemporary series of 240 patients. *Am J Surg* **186**:702–709; discussion 709–710.
154. Goldstein RE, Netterville JL, Burkey B, Johnson JE 2002 Implications of follicular neoplasms, atypia, and lesions suspicious for malignancy diagnosed by fine-needle aspiration of thyroid nodules. *Ann Surg* **235**:656–662.
155. Schlinkert RT, van Heerden JA, Goellner JR, Gharib H, Smith SL, Rosales RF, Weaver AL 1997 Factors that predict malignant thyroid lesions when fine-needle aspiration is “suspicious for follicular neoplasm”. *Mayo Clin Proc* **72**:913–916.
156. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, Sturgeon C 2007 Extent of surgery affects survival for papillary thyroid cancer. *Ann Surg* **246**:375–381.
157. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schwartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M 2003 Second primary malignancies in thyroid cancer patients. *Br J Cancer* **89**:1638–1644.
158. Mazzaferri EL, Young RL 1981 Papillary thyroid carcinoma: a 10 year follow-up report of the impact of therapy in 576 patients. *Am J Med* **70**:511–518.
159. DeGroot LJ, Kaplan EL, McCormick M, Straus FH 1990 Natural history, treatment, and course of papillary thyroid carcinoma. *J Clin Endocrinol Metab* **71**:414–424.
160. Samaan NA, Schultz PN, Hickey RC, Goepfert H, Haynie TP, Johnston DA, Ordonez NG 1992 The results of various modalities of treatment of well differentiated thyroid carcinomas: a retrospective review of 1599 patients. *J Clin Endocrinol Metab* **75**:714–720.
161. Saha AR, Shah JP, Loree TR 1997 Differentiated thyroid cancer presenting initially with distant metastasis. *Am J Surg* **174**:474–476.
162. Sanders LE, Cady B 1998 Differentiated thyroid cancer: reexamination of risk groups and outcome of treatment. *Arch Surg* **133**:419–425.
163. Podnos YD, Smith D, Wagman LD, Ellenhorn JD 2005 The implication of lymph node metastasis on survival in patients with well-differentiated thyroid cancer. *Am Surg* **71**:731–734.
164. Zaydfudim V, Feurer ID, Griffin MR, Phay JE 2008 The impact of lymph node involvement on survival in patients with papillary and follicular thyroid carcinoma. *Surgery* **144**:1070–1077; discussion 1077–1078.
165. Leboulleux S, Rubino C, Baudin E, Caillou B, Hartl DM, Bidart JM, Travagli JP, Schlumberger M 2005 Prognostic factors for persistent or recurrent disease of papillary thyroid carcinoma with neck lymph node metastases and/or tumor extension beyond the thyroid capsule at initial diagnosis. *J Clin Endocrinol Metab* **90**:5723–5729.
166. Robbins KT, Saha AR, Medina JE, Califano JA, Wolf GT, Ferlito A, Som PM, Day TA; Committee for Neck Dissection Classification, American Head and Neck Society 2008 Consensus statement on the classification and terminology of neck dissection. *Arch Otolaryngol Head Neck Surg* **134**:536–538.
167. Olson JA, Jr., DeBenedetti MK, Baumann DS, Wells SA, Jr 1996 Parathyroid autotransplantation during thyroidectomy. Results of long-term follow-up. *Ann Surg* **223**:472–478; discussion 478–480.
168. Gimm O, Rath FW, Dralle H 1998 Pattern of lymph node metastases in papillary thyroid carcinoma. *Br J Surg* **85**:252–254.
169. Henry JF, Gramatica L, Denizot A, Kvachenyuk A, Puccini M, Defechereux T 1998 Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma. *Langenbecks Arch Surg* **383**:167–169.
170. Cheah WK, Arici C, Ituarte PH, Siperstein AE, Duh QY, Clark OH 2002 Complications of neck dissection for thyroid cancer. *World J Surg* **26**:1013–1016.
171. White ML, Gauger PG, Doherty GM 2007 Central lymph node dissection in differentiated thyroid cancer. *World J Surg* **31**:895–904.
172. Bonnet S, Hartl D, Leboulleux S, Baudin E, Lombroso JD, Al Ghuzlan A, Chami L, Schlumberger M, Travagli JP 2009 Prophylactic lymph node dissection for papillary thyroid cancer less than 2 cm: implications for radioiodine treatment. *J Clin Endocrinol Metab* **94**:1162–1167.

173. The ATA Surgery Working Group 2009 Consensus Statement on the Terminology and Classification of Central Neck Dissection for Thyroid Cancer. *Thyroid* **19**:1153–1158.
174. Tisell LE, Nilsson B, Molne J, Hansson G, Fjälling M, Jansson S, Wingren U 1996 Improved survival of patients with papillary thyroid cancer after surgical microdissection. *World J Surg* **20**:854–859.
175. Sywak M, Cornford L, Roach P, Stalberg P, Sidhu S, Delbridge L 2006 Routine ipsilateral level VI lymphadenectomy reduces postoperative thyroglobulin levels in papillary thyroid cancer. *Surgery* **140**:1000–1007.
176. Roh JL, Park JY, Park CI 2007 Total thyroidectomy plus neck dissection in differentiated papillary thyroid carcinoma patients: pattern of nodal metastasis, morbidity, recurrence, and postoperative levels of serum parathyroid hormone. *Ann Surg* **245**:604–610.
177. Cavicchi O, Piccin O, Caliceti U, De Cataldis A, Pasquali R, Ceroni AR 2007 Transient hypoparathyroidism following thyroidectomy: a prospective study and multivariate analysis of 604 consecutive patients. *Otolaryngol Head Neck Surg* **137**:654–658.
178. Lee YS, Kim SW, Kim SW, Kim SK, Kang HS, Lee ES, Chung KW 2007 Extent of routine central lymph node dissection with small papillary thyroid carcinoma. *World J Surg* **31**:1954–1959.
179. Kozak OV, Muzichenko LV, Trembach AM, Voit NU, Turicina VV 2006 First treatment activity and outcome of radioiodine therapy in thyroid cancer patients with metastases in lymph nodes: mathematical correlation and clinical implications. *Exp Oncol* **28**:75–79.
180. Machens A, Hinze R, Thomusch O, Dralle H 2002 Pattern of nodal metastasis for primary and reoperative thyroid cancer. *World J Surg* **26**:22–28.
181. Gemenjager E, Perren A, Seifert B, Schuler G, Schweizer I, Heitz PU 2003 Lymph node surgery in papillary thyroid carcinoma. *J Am Coll Surg* **197**:182–190.
182. Kupferman ME, Patterson M, Mandel SJ, LiVolsi V, Weber RS 2004 Patterns of lateral neck metastasis in papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* **130**:857–860.
183. Kupferman ME, Patterson DM, Mandel SJ, LiVolsi V, Weber RS 2004 Safety of modified radical neck dissection for differentiated thyroid carcinoma. *Laryngoscope* **114**:403–406.
184. Goropoulos A, Karamoshos K, Christodoulou A, Ntitsias T, Paulou K, Samaras A, Xirou P, Efstratiou I 2004 Value of the cervical compartments in the surgical treatment of papillary thyroid carcinoma. *World J Surg* **28**:1275–1281.
185. Pacini F, Elisei R, Capezzone M, Miccoli P, Molinaro E, Basolo F, Agate L, Bottici V, Raffaelli M, Pinchera A 2001 Contralateral papillary thyroid cancer is frequent at completion thyroidectomy with no difference in low- and high-risk patients. *Thyroid* **11**:877–881.
186. Pasiaka JL, Thompson NW, McLeod MK, Burney RE, Macha M 1992 The incidence of bilateral well-differentiated thyroid cancer found at completion thyroidectomy. *World J Surg* **16**:711–716; discussion 716–717.
187. Kim ES, Kim TY, Koh JM, Kim YI, Hong SJ, Kim WB, Shong YK 2004 Completion thyroidectomy in patients with thyroid cancer who initially underwent unilateral operation. *Clin Endocrinol (Oxf)* **61**:145–148.
188. Erdem E, Gulcelik MA, Kuru B, Alagol H 2003 Comparison of completion thyroidectomy and primary surgery for differentiated thyroid carcinoma. *Eur J Surg Oncol* **29**:747–749.
189. Randolph GW, Daniels GH 2002 Radioactive iodine lobe ablation as an alternative to completion thyroidectomy for follicular carcinoma of the thyroid. *Thyroid* **12**:989–996.
190. Loh KC, Greenspan FS, Gee L, Miller TR, Yeo PP 1997 Pathological tumor-node-metastasis (pTNM) staging for papillary and follicular thyroid carcinomas: a retrospective analysis of 700 patients. *J Clin Endocrinol Metab* **82**:3553–3562.
191. Wittekind C, Compton CC, Greene FL, Sobin LH 2002 TNM residual tumor classification revisited. *Cancer* **94**:2511–2516.
192. Byar DP, Green SB, Dor P, Williams ED, Colon J, van Gilse HA, Mayer M, Sylvester RJ, van Glabbeke M 1979 A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. *Eur J Cancer* **15**:1033–1041.
193. Cady B, Rossi R 1988 An expanded view of risk-group definition in differentiated thyroid carcinoma. *Surgery* **104**:947–953.
194. Shaha AR, Loree TR, Shah JP 1995 Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. *Surgery* **118**:1131–1136; discussion 1136–1138.
195. Sherman SI, Brierley JD, Sperling M, Ain KB, Bigos ST, Cooper DS, Haugen BR, Ho M, Klein I, Ladenson PW, Robbins J, Ross DS, Specker B, Taylor T, Maxon HR 3<sup>rd</sup> 1998 Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. National Thyroid Cancer Treatment Cooperative Study Registry Group. *Cancer* **83**:1012–1021.
196. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, Pereira AM, Romijn JA, Smit JW 2006 Survival and death causes in differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **91**:313–319.
197. Schlumberger M, Berg G, Cohen O, Duntas L, Jamar F, Jarzab B, Limbert E, Lind P, Pacini F, Reiners C, Sánchez Franco F, Toft A, Wiersinga WM 2004 Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective. *Eur J Endocrinol* **150**:105–112.
198. Toubeau M, Touzery C, Arveux P, Chaplain G, Vaillant G, Berriolo A, Riedinger JM, Boichot C, Cochet A, Brunotte F 2004 Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer. *J Nucl Med* **45**:988–994.
199. Rouxel A, Hejblum G, Bernier MO, Boelle PY, Menegaux F, Mansour G, Hoang C, Aurengo A, Leenhardt L 2004 Prognostic factors associated with the survival of patients developing loco-regional recurrences of differentiated thyroid carcinomas. *J Clin Endocrinol Metab* **89**:5362–5368.
200. Cailleux AF, Baudin E, Travagli JP, Ricard M, Schlumberger M 2000 Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer? *J Clin Endocrinol Metab* **85**:175–178.
201. Bachelot A, Cailleux AF, Klain M, Baudin E, Ricard M, Bellon N, Caillou B, Travagli JP, Schlumberger M 2002 Relationship between tumor burden and serum thyroglobulin level in patients with papillary and follicular thyroid carcinoma. *Thyroid* **12**:707–711.
202. Wenig BM, Thompson LD, Adair CF, Shmookler B, Heffess CS 1998 Thyroid papillary carcinoma of columnar cell type: a clinicopathologic study of 16 cases. *Cancer* **82**:740–753.
203. Prendiville S, Burman KD, Ringel MD, Shmookler BM, Deeb ZE, Wolfe K, Azumi N, Wartofsky L, Sessions RB

- 2000 Tall cell variant: an aggressive form of papillary thyroid carcinoma. *Otolaryngol Head Neck Surg* **122**:352–357.
204. Akslen LA, Livolsi VA 2000 Prognostic significance of histologic grading compared with subclassification of papillary thyroid carcinoma. *Cancer* **88**:1902–1908.
205. Kim TY, Kim WB, Kim ES, Ryu JS, Yeo JS, Kim SC, Hong SJ, Shong YK 2005 Serum thyroglobulin levels at the time of 131I remnant ablation just after thyroidectomy are useful for early prediction of clinical recurrence in low-risk patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **90**:1440–1445.
206. Tuttle RM, Leboeuf R 2008 Follow up approaches in thyroid cancer: a risk adapted paradigm. *Endocrinol Metab Clin North Am* **37**:419–435.
207. Mazzaferri EL, Jhiang SM 1994 Differentiated thyroid cancer long-term impact of initial therapy. *Trans Am Clin Climatol Assoc* **106**:151–168; discussion 168–170.
208. Taylor T, Specker B, Robbins J, Sperling M, Ho M, Ain K, Bigos ST, Brierley J, Cooper D, Haugen B, Hay I, Hertzberg V, Klein I, Klein H, Ladenson P, Nishiyama R, Ross D, Sherman S, Maxon HR 1998 Outcome after treatment of high-risk papillary and non-Hürthle-cell follicular thyroid carcinoma. *Ann Intern Med* **129**:622–627.
209. Sawka AM, Brierley JD, Tsang RW, Thabane L, Rotstein L, Gafni A, Straus S, Goldstein DP 2008 An updated systematic review and commentary examining the effectiveness of radioactive iodine remnant ablation in well-differentiated thyroid cancer. *Endocrinol Metab Clin North Am*. **37**:457–480.
210. Kim S, Wei JP, Braverman JM, Brams DM 2004 Predicting outcome and directing therapy for papillary thyroid carcinoma. *Arch Surg* **139**:390–394; discussion 393–394.
211. Sugitani I, Fujimoto Y 1999 Symptomatic versus asymptomatic papillary thyroid microcarcinoma: a retrospective analysis of surgical outcome and prognostic factors. *Endocr J*. **46**:209–216.
212. Lundgren CI, Hall P, Dickman PW, Zedenius J 2007 Influence of surgical and postoperative treatment on survival in differentiated thyroid cancer. *Br J Surg* **94**:571–577.
213. Mazzaferri EL 1997 Thyroid remnant 131I ablation for papillary and follicular thyroid carcinoma. *Thyroid* **7**:265–271.
214. Jonklaas J, Sarlis NJ, Litofsky D, Ain KB, Bigos ST, Brierley JD, Cooper DS, Haugen BR, Ladenson PW, Magner J, Robbins J, Ross DS, Skarulis M, Maxon HR, Sherman SI 2006 Outcomes of patients with differentiated thyroid carcinoma following initial therapy. *Thyroid* **16**:1229–1242.
215. Jung TS, Kim TY, Kim KW, Oh YL, Park do J, Cho BY, Shong YK, Kim WB, Park YJ, Jung JH, Chung JH 2007 Clinical features and prognostic factors for survival in patients with poorly differentiated thyroid carcinoma and comparison to the patients with the aggressive variants of papillary thyroid carcinoma. *Endocr J*. **54**:265–274.
216. Hay ID, Hutchinson ME, Gonzalez-Losada T, McIver B, Reinalda ME, Grant CS, Thompson GB, Sebo TJ, Goellner JR 2009 Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period. *Surgery* **144**:980–987.
217. Ross DS, Litofsky D, Ain KB, Brierley JD, Cooper DS, Haugen BR, Jonklaas J, Ladenson PW, Magner J, Robbins J, Skarulis MC, Steward DL, Maxon HR, Sherman SI 2009 Recurrence after treatment of micropapillary thyroid cancer. *Thyroid* **19**:1043–1048.
218. Edmonds CJ, Hayes S, Kermod JC., Thompson BD 1977 Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radioiodine. *Br J Radiol* **50**:799–807.
219. Torres MS, Ramirez L, Simkin PH, Braverman LE, Emerson CH 2001 Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. *J Clin Endocrinol Metab* **86**:1660–1664.
220. Hershman JM, Edwards CL 1972 Serum thyrotropin (TSH) levels after thyroid ablation compared with TSH levels after exogenous bovine TSH: implications for 131-I treatment of thyroid carcinoma. *J Clin Endocrinol Metab* **34**:814–818.
221. Martin ND 1978 Endogenous serum TSH levels and metastatic survey scans in thyroid cancer patients using triiodothyronine withdrawal. *Clin Nucl Med* **3**:401–403.
222. Hilts SV, Hellman D, Anderson J, Woolfenden J, Van Antwerp J, Patton D 1979 Serial TSH determination after T3 withdrawal or thyroidectomy in the therapy of thyroid carcinoma. *J Nucl Med* **20**:928–932.
223. Goldman JM, Line BR, Aamodt RL, Robbins J 1980 Influence of triiodothyronine withdrawal time on 131I uptake postthyroidectomy for thyroid cancer. *J Clin Endocrinol Metab* **50**:734–739.
224. Schneider AB, Line B, Goldman JM, Robbins J 1981 Sequential serum thyroglobulin determinations, 131I scans, and 131I uptakes after triiodothyronine withdrawal in patients with thyroid cancer. *J Clin Endocrinol Metab* **53**:1199–1206.
225. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. *N Engl J Med* **309**:937–941.
226. Liel Y 2002 Preparation for radioactive iodine administration in differentiated thyroid cancer patients. *Clin Endocrinol(Oxf)* **57**:523–527.
227. Sanchez R, Espinosa-de-los-Monteros AL, Mendoza V, Brea E, Hernandez I, Sosa E, Mercado M 2002 Adequate thyroid-stimulating hormone levels after levothyroxine discontinuation in the follow-up of patients with well-differentiated thyroid carcinoma. *Arch Med Res* **33**:478–481.
228. Grigsby PW, Siegel BA, Bekker S, Clutter WE, Moley JF 2004 Preparation of patients with thyroid cancer for 131I scintigraphy or therapy by 1–3 weeks of thyroxine discontinuation. *J Nucl Med* **45**:567–570.
229. Serhal DI, Nasrallah MP, Arafah BM 2004 Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. *J Clin Endocrinol Metab* **89**:3285–3289.
230. Leboeuf R, Perron P, Carpentier AC, Verreault J, Langlois MF 2007 L-T3 preparation for whole-body scintigraphy: a randomized-controlled trial. *Clin Endocrinol (Oxf)* **67**:839–844.
231. Guimaraes V, DeGroot LJ 1996 Moderate hypothyroidism in preparation for whole body 131I scintiscans and thyroglobulin testing. *Thyroid* **6**:69–73.
232. Maxon HR 1999 Detection of residual and recurrent thyroid cancer by radionuclide imaging. *Thyroid* **9**:443–446.
233. Kuijt WJ, Huang SA 2005 Children with differentiated thyroid cancer achieve adequate hyperthyrotropinemia within 14 days of levothyroxine withdrawal. *J Clin Endocrinol Metab* **90**:6123–6125.
234. Heemstra KA, Liu YY, Stokkel M, Kievit J, Corssmit E, Pereira AM, Romijn JA, Smit JW 2007 Serum thyroglobulin



- concentrations predict disease-free remission and death in differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* **66**:58–64.
235. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM 2002 A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. *J Nucl Med* **43**:1482–1488.
  236. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A 2002 Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. *J Clin Endocrinol Metab* **87**:4063–4068.
  237. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. *J Clin Endocrinol Metab* **91**:926–932.
  238. Pilli T, Brianzoni E, Capocetti F, Castagna MG, Fattori S, Pogggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. *J Clin Endocrinol Metab* **92**:3542–3546.
  239. Chianelli M, Todino V, Graziano F, Panunzi C, Pace D, Guglielmi R, Signore A, Papini E 2009 Low dose (2.0 GBq; 54 mCi) radioiodine postsurgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low risk patients. *Eur J Endocrinol* **160**:431–436.
  240. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. *J Nucl Med* **49**:764–770.
  241. Carril JM, Quirce R, Serrano J, Banzo I, Jiménez-Bonilla JF, Tabuenca O, Barquín RG 1997 Total-body scintigraphy with thallium-201 and iodine-131 in the follow-up of differentiated thyroid cancer. *J Nucl Med* **38**:686–692.
  242. Muratet JP, Giraud P, Daver A, Minier JF, Gamelin E, Larra F 1997 Predicting the efficacy of first iodine-131 treatment in differentiated thyroid carcinoma. *J Nucl Med* **38**:1362–1368.
  243. Leger AF, Pellan M, Dagousset F, Chevalier A, Keller I, Clerc J 2005 A case of stunning of lung and bone metastases of papillary thyroid cancer after a therapeutic dose (3.7 GBq) of 131I and review of the literature: implications for sequential treatments. *Br J Radiol* **78**:428–432.
  244. Park HM, Park YH, Zhou XH 1997 Detection of thyroid remnant/metastasis without stunning: an ongoing dilemma. *Thyroid* **7**:277–280.
  245. Hilditch TE, Dempsey MF, Bolster AA, McMenemin RM, Reed NS 2002 Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I. *Eur J Nucl Med Mol Imaging* **29**:783–788.
  246. Morris LF, Waxman AD, Braunstein GD 2001 The nonimpact of thyroid stunning: remnant ablation rates in 131I-scanned and non-scanned individuals. *J Clin Endocrinol Metab* **86**:3507–3511.
  247. Lassmann M, Luster M, Hanscheid H, Reiners C 2004 Impact of (131)I diagnostic activities on the biokinetics of thyroid remnants. *J Nucl Med* **45**:619–625.
  248. Anderson GS, Fish S, Nakhoda K, Zhuang H, Alava A, Mandel SJ 2003 Comparison of I-123 and I-131 for whole-body imaging after stimulation by recombinant human thyrotropin: a preliminary report. *Clin Nucl Med* **28**:93–96.
  249. Gerard SK, Cavalieri RR 2002 I-123 diagnostic thyroid tumor whole-body scanning with imaging at 6, 24, and 48 hours. *Clin Nucl Med* **27**:1–8.
  250. Silberstein EB 2007 Comparison of outcomes after (123)I versus (131)I pre-ablation imaging before radioiodine ablation in differentiated thyroid carcinoma. *J Nucl Med* **48**:1043–1046.
  251. Rosario PW, Reis JS, Barroso AL, Rezende LL, Padrao EL, Fagundes TA 2004 Efficacy of low and high 131I doses for thyroid remnant ablation in patients with differentiated thyroid carcinoma based on post-operative cervical uptake. *Nucl Med Commun* **25**:1077–1081.
  252. Bal C, Padhy AK, Jana S, Pant GS, Basu AK 1996 Prospective randomized clinical trial to evaluate the optimal dose of 131 I for remnant ablation in patients with differentiated thyroid carcinoma. *Cancer* **77**:2574–2580.
  253. Creutzig H 1987 High or low dose radioiodine ablation of thyroid remnants? *Eur J Nucl Med* **12**:500–502.
  254. Johansen K, Woodhouse NJ, Odugbesan O 1991 Comparison of 1073 MBq and 3700 MBq iodine-131 in postoperative ablation of residual thyroid tissue in patients with differentiated thyroid cancer. *J Nucl Med* **32**:252–254.
  255. Doi SA, Woodhouse NJ 2000 Ablation of the thyroid remnant and 131I dose in differentiated thyroid cancer. *Clin Endocrinol (Oxf)* **52**:765–773.
  256. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA 2007 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. *J Clin Endocrinol Metab* **92**:28–38.
  257. Maenpaa HO, Heikkonen J, Vaalavirta L, Tenhunen M, Joensuu H 2008 Low vs. high radioiodine activity to ablate the thyroid after thyroidectomy for cancer: a randomized study. *PLoS ONE* **3**:e1885.
  258. Barbaro D, Boni G, Meucci G, Simi U, Lapi P, Orsini P, Pasquini C, Piazza F, Caciagli M, Mariani G 2003 Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. *J Clin Endocrinol Metab* **88**:4110–4115.
  259. Franzius C, Dietlein M, Biermann M, Frühwald M, Linden T, Bucskey P, Reiners C, Schober O 2007 Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer. *Nuklearmedizin* **46**:224–231.
  260. Jarzab B, Handkiewicz-Junak D, Wloch J 2005 Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative review. *Endocr Relat Cancer* **12**:773–803.
  261. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, Chen IW 1983 Low iodine diet in I-131 ablation of thyroid remnants. *Clin Nucl Med* **8**:123–126.
  262. Goslings BM 1975 Proceedings: Effect of a low iodine diet on 131-I therapy in follicular thyroid carcinomata. *J Endocrinol* **64**:30P.

263. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW 2003 Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* **58**:428–435.
264. Fatourechhi V, Hay ID, Mullan BP, Wiseman GA, Eghbali-Fatourechhi GZ, Thorson LM, Gorman CA 2000 Are post-therapy radioiodine scans informative and do they influence subsequent therapy of patients with differentiated thyroid cancer? *Thyroid* **10**:573–577.
265. Sherman SI, Tielens ET, Sostre S, Wharam MD Jr, Ladenson PW 1994 Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. *J Clin Endocrinol Metab* **78**:629–634.
266. Souza Rosario PW, Barroso AL, Rezende LL, Padrao EL, Fagundes TA, Penna GC, Purisch S 2004 Post I-131 therapy scanning in patients with thyroid carcinoma metastases: an unnecessary cost or a relevant contribution? *Clin Nucl Med* **29**:795–798.
267. Wong KK, Zarzhevsky N, Cahill JM, Frey KA, Avram AM 2008 Incremental value of diagnostic 131I SPECT/CT fusion imaging in the evaluation of differentiated thyroid carcinoma. *AJR Am J Roentgenol* **191**:1785–1794.
268. Brabant G 2008 Thyrotropin suppressive therapy in thyroid carcinoma: what are the targets? *J Clin Endocrinol Metab* **93**:1167–1169.
269. McGriff NJ, Csako G, Gourgiotis L, Lori CG, Pucino F, Sarlis NJ 2002 Effects of thyroid hormone suppression therapy on adverse clinical outcomes in thyroid cancer. *Ann Med* **34**:554–564.
270. Pujol P, Daures JP, Nsakala N, Baldet L, Bringer J, Jaffiol C 1996 Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. *J Clin Endocrinol Metab* **81**:4318–4323.
271. Hovens GC, Stokkel MP, Kievit J, Corssmit EP, Pereira AM, Romijn JA, Smit JW 2007 Associations of serum thyrotropin concentrations with recurrence and death in differentiated thyroid cancer. *J Clin Endocrinol Metab* **92**:2610–2615.
272. Sawin CT, Geller A, Wolf PA, Belanger AJ, Baker E, Bacharach P, Wilson PW, Benjamin EJ, D'Agostino RB 1994 Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. *N Engl J Med* **33**:1249–1252.
273. Toft AD 2001 Clinical practice. Subclinical hyperthyroidism. *N Engl J Med* **345**:512–516.
274. Wilson PC, Millar BM, Brierley JD 2004 The management of advanced thyroid cancer. *Clin Oncol (R Coll Radiol)* **16**:561–568.
275. Ford D, Giridharan S, McConkey C, Hartley A, Brammer C, Watkinson JC, Glaholm J 2003 External beam radiotherapy in the management of differentiated thyroid cancer. *Clin Oncol (R Coll Radiol)* **15**:337–341.
276. Terezakis SA, Lee KS, Ghossein RA, Rivera M, Tuttle RM, Wolden SL, Zelefsky MJ, Wong RJ, Patel SG, Pfister DG, Shaha AR, Lee NY 2008 Role of external beam radiotherapy in patients with advanced or recurrent non-anaplastic thyroid cancer: Memorial Sloan-Kettering Cancer Center experience. *Int J Radiat Oncol Biol Phys* **73**:795–801.
277. Brierley J, Tsang R, Panzarella T, Bana N 2005 Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. *Clin Endocrinol (Oxf)* **63**:418–427.
278. Sanders EM Jr, LiVolsi VA, Brierley J, Shin J, Randolph GW 2007 An evidence-based review of poorly differentiated thyroid cancer. *World J Surg* **31**:934–945.
279. Kim JH, Leeper RD 1987 Treatment of locally advanced thyroid carcinoma with combination doxorubicin and radiation therapy. *Cancer* **60**:2372–2375.
280. Links TP, van Tol KM, Jager PL, Plukker JT, Piers DA, Boezen HM, Dullaart RP, de Vries EG, Sluiter WJ 2005 Life expectancy in differentiated thyroid cancer: a novel approach to survival analysis. *Endocr Relat Cancer* **12**:273–280.
281. Brown AP, Chen J, Hitchcock YJ, Szabo A, Schriever DC, Tward JD 2008 The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer. *J Clin Endocrinol Metab* **93**:504–515.
282. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Sallé F, Mahoudeau J, Bardet S 2004 Risk of second primary cancer following differentiated thyroid cancer. *Eur J Nucl Med Mol Imaging* **31**:685–691.
283. Biondi B, Filetti S, Schlumberger M 2005 Thyroid-hormone therapy and thyroid cancer: a reassessment. *Nat Clin Pract Endocrinol Metab* **1**:32–40.
284. Eustatia-Rutten CF, Smit JW, Romijn JA, van der Kleij-Corssmit EP, Pereira AM, Stokkel MP, Kievit J 2004 Diagnostic value of serum thyroglobulin measurements in the follow-up of differentiated thyroid carcinoma, a structured meta-analysis. *Clin Endocrinol (Oxf)* **61**:61–74.
285. Mazzaferri EL, Robbins RJ, Braverman LE, Pacini F, Haugen B, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 Authors' response: a consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. *J Clin Endocrinol Metab* **88**:4508–4509.
286. Bachelot A, Leboulleux S, Baudin E, Hartl DM, Caillou B, Travagli JP, Schlumberger M 2005 Neck recurrence from thyroid carcinoma: serum thyroglobulin and high-dose total body scan are not reliable criteria for cure after radioiodine treatment. *Clin Endocrinol (Oxf)* **62**:376–379.
287. Robbins RJ, Srivastava S, Shaha A, Ghossein R, Larson SM, Fleisher M, Tuttle RM 2004 Factors influencing the Basal and recombinant human thyrotropin-stimulated serum thyroglobulin in patients with metastatic thyroid carcinoma. *J Clin Endocrinol Metab* **89**:6010–6016.
288. Kloos RT, Mazzaferri EL 2005 A single recombinant human thyrotrophin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. *J Clin Endocrinol Metab* **90**:5047–5057.
289. Castagna MG, Brilli L, Pilli T, Montanaro A, Cipri C, Fioravanti C, Sestini F, Capezzone M, Pacini F 2008 Limited value of repeat recombinant thyrotropin (rhTSH)-stimulated thyroglobulin testing in differentiated thyroid carcinoma patients with previous negative rhTSH-stimulated thyroglobulin and undetectable basal serum thyroglobulin levels. *J Clin Endocrinol Metab* **93**:76–81.
290. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciantè V, Di Giorgio A, Bruno R, Filetti S, Trischitta V 2006 Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with

- papillary thyroid microcarcinoma who have not undergone radioiodine therapy. *J Clin Endocrinol Metab* **91**:60–63.
291. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, Fatourehchi V 2007 Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human TSH-stimulated thyroglobulin in follow-up of thyroid cancer patients. *J Clin Endocrinol Metab* **92**:82–87.
  292. Iervasi A, Iervasi G, Ferdeghini M, Solimeo C, Bottoni A, Rossi L, Colato C, Zucchelli GC 2007 Clinical relevance of highly sensitive Tg assay in monitoring patients treated for differentiated thyroid cancer. *Clin Endocrinol (Oxf)* **67**:434–441.
  293. Schlumberger M, Hitzel A, Toubert ME, Corone C, Troalen F, Schlageter MH, Claustrat F, Koscielny S, Taieb D, Toubreau M, Bonichon F, Borson-Chazot F, Leenhardt L, Schvartz C, Dejax C, Brenot-Rossi I, Torlontano M, Tenenbaum F, Bardet S, Bussière F, Girard JJ, Morel O, Schneegans O, Schlienger JL, Prost A, So D, Archambeaud F, Ricard M, Benhamou E 2007 Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients. *J Clin Endocrinol Metab* **92**:2487–2495.
  294. Baudin E, Do Cao C, Cailleux AF, Leboulleux S, Travagli JP, Schlumberger M 2003 Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients. *J Clin Endocrinol Metab* **88**:1107–1111.
  295. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. *J Clin Endocrinol Metab* **84**:3877–3885.
  296. David A, Blotta A, Bondanelli M, Rossi R, Roti E, Braverman LE, Busutti L, degli Uberti EC 2001 Serum thyroglobulin concentrations and (131)I whole-body scan results in patients with differentiated thyroid carcinoma after administration of recombinant human thyroid-stimulating hormone. *J Nucl Med* **42**:1470–1475.
  297. Mazzaferri EL, Kloos RT 2002 Is diagnostic iodine-131 scanning with recombinant human TSH (rhTSH) useful in the follow-up of differentiated thyroid cancer after thyroid ablation? *J Clin Endocrinol Metab* **87**:1490–1498.
  298. Haugen BR, Ridgway EC, McLaughlin BA, McDermott MT 2002 Clinical comparison of whole-body radioiodine scan and serum thyroglobulin after stimulation with recombinant human thyrotropin. *Thyroid* **12**:37–43.
  299. Lima N, Cavaliere H, Tomimori E, Knobel M, Medeiros-Neto G 2002 Prognostic value of serial serum thyroglobulin determinations after total thyroidectomy for differentiated thyroid cancer. *J Endocrinol Invest* **25**:110–115.
  300. Wartofsky L 2002 Management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin. *Thyroid* **12**:583–590.
  301. Schaap J, Eustatia-Rutten CF, Stokkel M, Links TP, Diamant M, van der Velde EA, Romijn JA, Smit JW 2002 Does radioiodine therapy have disadvantageous effects in non-iodine accumulating differentiated thyroid carcinoma? *Clin Endocrinol (Oxf)* **57**:117–124.
  302. Spencer CA, LoPresti JS, Fatemi S, Nicoloff JT 1999 Detection of residual and recurrent differentiated thyroid carcinoma by serum thyroglobulin measurement. *Thyroid* **9**:435–441. Review.
  303. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, Braverman LE 2002 Serum TSH, T(4), and thyroid antibodies in the United States population (1988 to 1994): National Health and Nutrition Examination Survey (NHANES III). *J Clin Endocrinol Metab* **87**:489–499.
  304. Spencer CA 2004 Challenges of serum thyroglobulin (thyroglobulin) measurement in the presence of thyroglobulin autoantibodies. *J Clin Endocrinol Metab* **89**:3702–3704.
  305. Spencer CA, Takeuchi M, Kazarosyan M, Wang CC, Guttler RB, Singer PA, Fatemi S, LoPresti JS, Nicoloff JT 1998 Serum thyroglobulin autoantibodies: prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **83**:1121–1127.
  306. Chiovato L, Latrofa F, Braverman LE, Pacini F, Capezzone M, Masserini L, Grasso L, Pinchera A 2003 Disappearance of humoral thyroid autoimmunity after complete removal of thyroid antigens. *Ann Intern Med* **139**:346–351.
  307. Schlumberger M, Mancusi F, Baudin E, Pacini F 1997 131-I Therapy for elevated thyroglobulin levels. *Thyroid* **7**:273–276.
  308. Mazzaferri EL, Kloos RT 2001 Current approaches to primary therapy for papillary and follicular thyroid cancer. *J Clin Endocrinol Metab* **86**:1447–1463.
  309. Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A 2002 Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum thyroglobulin levels after initial treatment. *J Clin Endocrinol Metab* **87**:1499–1501.
  310. Koh JM, Kim ES, Ryu JS, Hong SJ, Kim WB, Shong YK 2003 Effects of therapeutic doses of 131I in thyroid papillary carcinoma patients with elevated thyroglobulin level and negative 131I whole-body scan: comparative study. *Clin Endocrinol (Oxf)* **58**:421–427.
  311. Torlontano M, Crocetti U, D'Aloiso L, Bonfitto N, Di Giorgio A, Modoni S, Valle G, Frusciante V, Bisceglia M, Filetti S, Schlumberger M, Trischitta V 2003 Serum thyroglobulin and 131I whole body scan after recombinant human TSH stimulation in the follow-up of low-risk patients with differentiated thyroid cancer. *Eur J Endocrinol* **148**:19–24.
  312. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyroglobulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **88**:3668–3673.
  313. Snozek CL, Chambers EP, Reading CC, Sebo TJ, Sistrunk JW, Singh RJ, Grebe SK 2007 Serum thyroglobulin, high-resolution ultrasound, and lymph node thyroglobulin in diagnosis of differentiated thyroid carcinoma nodal metastases. *J Clin Endocrinol Metab* **92**:4278–4281.
  314. Cunha N, Rodrigues F, Curado F, Ilhéu O, Cruz C, Naidenov P, Rascão MJ, Ganho J, Gomes I, Pereira H, Real O, Figueiredo P, Campos B, Valido F 2007 Thyroglobulin detection in fine-needle aspirates of cervical lymph nodes: a technique for the diagnosis of metastatic differentiated thyroid cancer. *Eur J Endocrinol* **157**:101–107.
  315. Larson SM, Robbins R 2002 Positron emission tomography in thyroid cancer management. *Semin Roentgenol* **37**:169–174.
  316. Leboulleux S, Schroeder PR, Busaidy NL, Auperin A, Corone C, Jacene HA, Ewertz ME, Bournaud C, Wahl RL,

- Sherman SI, Ladenson PW, Schlumberger M 2009 Assessment of the incremental value of recombinant TSH stimulation before FDG PET/CT imaging to localize residual differentiated thyroid cancer. *J Clin Endocrinol Metab* **94**:1310–1316.
317. Wang PW, Wang ST, Liu RT, Chien WY, Tung SC, Lu YC, Chen HY, Lee CH 1999 Levothyroxine suppression of thyroglobulin in patients with differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **84**:4549–4553.
318. Leeper RD 1973 The effect of <sup>131</sup>I therapy on survival of patients with metastatic papillary or follicular thyroid carcinoma. *J Clin Endocrinol Metab* **36**:1143–1152.
319. Beierwaltes WH, Nishiyama RH, Thompson NW, Copp JE, Kubo A 1982 Survival time and “cure” in papillary and follicular thyroid carcinoma with distant metastases: statistics following University of Michigan therapy. *J Nucl Med* **23**:561–568.
320. Bernier MO, Leenhardt L, Hoang C, Aurengo A, Mary JY, Menegaux F, Enkaoua E, Turpin G, Chiras J, Saillant G, Hejblum G 2001 Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. *J Clin Endocrinol Metab* **86**:1568–1573.
321. Sampson E, Brierly JD, Le LW, Rotstein L, Tsang RW 2007 Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. *Cancer* **110**:1451–1456.
322. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lombroso JD, De Vathaire F, Schlumberger M 2006 Long term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. *J Clin Endocrinol Metab* **92**:450–455.
323. Dupuy DE, Monchik JM, Decrea C, Pisharodi L 2001 Radiofrequency ablation of regional recurrence from well-differentiated thyroid malignancy. *Surgery* **130**:971–977.
324. Lewis BD, Hay ID, Charboneau JW, McIver B, Reading CC, Goellner JR 2002 Percutaneous ethanol injection for treatment of cervical lymph node metastases in patients with papillary thyroid carcinoma. *Am J Roentgenol* **178**:699–704.
325. Eustatia-Rutten CF, Romijn JA, Guijt MJ, Vielvoye GJ, van den Berg R, Corssmit EP, Pereira AM, Smit JW 2003 Outcome of palliative embolization of bone metastases in differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **88**:3184–3189.
326. Uchino S, Noguchi S, Yamashita H, Watanabe S 2004 Modified radical neck dissection for differentiated thyroid cancer: operative technique. *World J Surg* **28**:1199–1203.
327. Noguchi S, Yamashita H, Murakami N, Nakayama I, Toda M, Kawamoto H 1996 Small carcinomas of the thyroid. A long-term follow-up of 867 patients. *Arch Surg* **131**:187–191.
328. Marchesi M, Biffoni M, Biancari F, Berni A, Campana FP 2003 Predictors of outcome for patients with differentiated and aggressive thyroid carcinoma. *Eur J Surg Suppl* **588**:46–50.
329. Ge JH, Zhao RL, Hu JL, Zhou WA 2004 Surgical treatment of advanced thyroid carcinoma with aero-digestive invasion. *Zhonghua Er Bi Yan Hou Ke Za Zhi* **39**:237–240.
330. Avenia N, Ragusa M, Monacelli M, Calzolari F, Daddi N, Di Carlo L, Semeraro A, Puma F 2004 Locally advanced thyroid cancer: therapeutic options. *Chir Ital* **56**:501–508.
331. McCaffrey JC 2000 Evaluation and treatment of aero-digestive tract invasion by well-differentiated thyroid carcinoma. *Cancer Control* **7**:246–252.
332. Musholt TJ, Musholt PB, Behrend M, Raab R, Scheumann GF, Klempnauer J 1999 Invasive differentiated thyroid carcinoma: tracheal resection and reconstruction procedures in the hands of the endocrine surgeon. *Surgery* **126**:1078–1087; discussion 1087–1088.
333. Czaja JM, McCaffrey TV 1997 The surgical management of laryngotracheal invasion by well-differentiated papillary thyroid carcinoma. *Arch Otolaryngol Head Neck Surg* **123**:484–490.
334. Van Nostrand D, Atkins F, Yeganeh F, Acio E, Bursaw R, Wartofsky L 2002 Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. *Thyroid* **12**:121–134.
335. Robbins RJ, Schlumberger MJ 2005 The evolving role of (<sup>131</sup>)I for the treatment of differentiated thyroid carcinoma. *J Nucl Med* **46**:28S–37S.
336. Holst JP, Burman KD, Atkins F, Umans JG, Jonklaas J 2005 Radioiodine therapy for thyroid cancer and hyperthyroidism in patients with end-stage renal disease on hemodialysis. *Thyroid* **15**:1321–1331.
337. Driedger AA, Quirk S, McDonald TJ, Ledger S, Gray D, Wall W, Yoo J 2006 A pragmatic protocol for I-131 rhTSH-stimulated ablation therapy in patients with renal failure. *Clin Nucl Med* **31**:454–457.
338. Samuel AM, Rajashekharrao B, Shah DH 1998 Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. *J Nucl Med* **39**:1531–1536.
339. Sgouros G, Kolbert KS, Sheikh A, Pentlow KS, Mun EF, Barth A, Robbins RJ, Larson SM 2004 Patient-specific dosimetry for <sup>131</sup>I thyroid cancer therapy using <sup>124</sup>I PET and 3-dimensional-internal dosimetry (3D-ID) software. *J Nucl Med* **45**:1366–1372.
340. Jentzen W, Freudenberg L, Eising EG, Sonnenschein W, Knust J, Bockisch A 2008 Optimized <sup>124</sup>I PET dosimetry protocol for radioiodine therapy of differentiated thyroid cancer. *J Nucl Med* **49**:1017–1023.
341. Kulkarni K, Nostrand DV, Atkins F, Aiken M, Burman K, Wartofsky L 2006 The relative frequency in which empiric dosages of radioiodine would potentially overtreat or undertreat patients who have metastatic well-differentiated thyroid cancer. *Thyroid* **16**:1019–1023.
342. Tuttle RM, Leboeuf R, Robbins RJ, Qualey R, Pentlow K, Larson SM, Chan CY 2006 Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. *J Nucl Med* **47**:1587–1591.
343. Rudavsky AZ, Freeman LM 1997 Treatment of scan-negative, thyroglobulin-positive metastatic thyroid cancer using radioiodine <sup>131</sup>I and recombinant human thyroid stimulating hormone. *J Clin Endocrinol Metab* **82**:11–14.
344. Ringel MD, Ladenson PW 1996 Diagnostic accuracy of <sup>131</sup>I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. *J Clin Endocrinol Metab* **81**:1724–1725.
345. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thyrotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **85**:3640–3645.
346. Mariani G, Ferdeghini M, Augeri C, Villa G, Taddei GZ, Scopinaro G, Boni G, Bodei L, Rabitti C, Molinari E, Bianchi R 2000 Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with

- differentiated thyroid cancer. *Cancer Biother Radiopharm* **15**:211–217.
347. Perros P 1999 Recombinant human thyroid-stimulating hormone (rhTSH) in the radioablation of well-differentiated thyroid cancer: preliminary therapeutic experience. *J Endocrinol Invest* **22**:30–34.
  348. Lippi F, Capezzone M, Angelini F, Taddei D, Molinaro E, Pinchera A, Pacini F 2001 Radioiodine treatment of metastatic differentiated thyroid cancer in patients on L-thyroxine, using recombinant human TSH. *Eur J Endocrinol* **144**:5–11.
  349. Pellegriti G, Scollo C, Giuffrida D, Vigneri R, Squatrito S, Pezzino V 2001 Usefulness of recombinant human thyrotropin in the radiometabolic treatment of selected patients with thyroid cancer. *Thyroid* **11**:1025–1030.
  350. Adler ML, Macapinlac HA, Robbins RJ 1998 Radioiodine treatment of thyroid cancer with the aid of recombinant human thyrotropin. *Endocr Pract* **4**:282–286.
  351. Chiu AC, Delpassand ES, Sherman SI 1997 Prognosis and treatment of brain metastases in thyroid carcinoma. *J Clin Endocrinol Metab* **82**:3637–3642.
  352. Lau WF, Zacharin MR, Waters K, Wheeler G, Johnston V, Hicks RJ 2006 Management of paediatric thyroid carcinoma: recent experience with recombinant human thyroid stimulating hormone in preparation for radioiodine therapy. *Intern Med J* **36**:564–570.
  353. Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, Dudczak R 2006 Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. *Clin Endocrinol (Oxf)* **65**:519–523.
  354. Vargas GE, Uy H, Bazan C, Guise TA, Bruder JM 1999 Hemiplegia after thyrotropin alfa in a hypothyroid patient with thyroid carcinoma metastatic to the brain. *J Clin Endocrinol Metab* **84**:3867–3871.
  355. Robbins RJ, Voelker E, Wang W, Macapinlac HA, Larson SM 2000 Compassionate use of recombinant human thyrotropin to facilitate radioiodine therapy: case report and review of literature. *Endocr Pract* **6**:460–464.
  356. Braga M, Ringel MD, Cooper DS 2001 Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. *J Clin Endocrinol Metab* **86**:5148–5151.
  357. Pons F, Carrio I, Estorch M, Ginjaume M, Pons J, Milián R 1987 Lithium as an adjuvant of iodine-131 uptake when treating patients with well-differentiated thyroid carcinoma. *Clin Nucl Med* **12**:644–647.
  358. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins J 1999 Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. *J Clin Endocrinol Metab* **84**:912–916.
  359. Liu YY, van der Pluijm G, Karperien M, Stokkel MP, Pereira AM, Morreau J, Kievit J, Romijn JA, Smit JW 2006 Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. *Clin Endocrinol (Oxf)* **64**:617–624.
  360. Ronga G, Filesi M, Montesano T, Di Nicola AD, Pace C, Travascio L, Ventroni G, Antonaci A, Vestri AR 2004 Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. *Q J Nucl Med Mol Imaging* **48**:12–19.
  361. Lin JD, Chao TC, Chou SC, Hsueh C 2004 Papillary thyroid carcinomas with lung metastases. *Thyroid* **14**:1091–1096.
  362. Shoup M, Stojadinovic A, Nissan A, Ghossein RA, Freedman S, Brennan MF, Shah JP, Shaha AR 2003 Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. *J Am Coll Surg* **197**:191–197.
  363. Zettinig G, Fueger BJ, Passler C, Kaserer K, Pirich C, Dudczak R, Niederle B 2002 Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma—surgery or conventional therapy? *Clin Endocrinol (Oxf)* **56**:377–382.
  364. Pittas AG, Adler M, Fazzari M, Tickoo S, Rosai J, Larson SM, Robbins RJ 2000 Bone metastases from thyroid carcinoma: clinical characteristics and prognostic variables in one hundred forty-six patients. *Thyroid* **10**:261–268.
  365. Schlumberger M, Challeton C, De Vathaire F, Travagli J-P, Gardet P, Lumbroso J-D, Francesc C, Fontaine F, Ricard M, Parmentier C 1996 Radioactive iodine treatment and external radiotherapy for lung and bone metastases from thyroid carcinoma. *J Nucl Med* **37**:598–605.
  366. Dinneen SF, Valimaki MJ, Bergstrahl EJ, Goellner JR, Gorman CA, Hay ID 1995 Distant metastases in papillary thyroid carcinoma: 100 cases observed at one institution during 5 decades. *J Clin Endocrinol Metab* **80**:2041–2045.
  367. Foote RL, Brown PD, Garces YI, McIver B, Kasperbauer JL 2003 Is there a role for radiation therapy in the management of Hürthle cell carcinoma? *Int J Radiat Oncol Biol Phys* **56**:1067–1072.
  368. Pak H, Gourgiotis L, Chang WI, Guthrie LC, Skarulis MC, Reynolds JC, Merino MJ, Schrupp DS, Libutti SK, Alexander HR, Jr, Sarlis NJ 2003 Role of metastasectomy in the management of thyroid carcinoma: the NIH experience. *J Surg Oncol* **82**:10–18.
  369. Vitale G, Fonderico F, Martignetti A, Caraglia M, Ciccarelli A, Nuzzo V, Abbruzzese A, Lupoli G 2001 Pamidronate improves the quality of life and induces clinical remission of bone metastases in patients with thyroid cancer. *Br J Cancer* **84**:1586–1590.
  370. Kitamura Y, Shimizu K, Nagahama M, Sugino K, Ozaki O, Mimura T, Ito K, Tanaka S 1999 Immediate causes of death in thyroid carcinoma: clinicopathological analysis of 161 fatal cases. *J Clin Endocrinol Metab* **84**:4043–4049.
  371. Benua RS, Cicale NR, Sonenberg M, Rawson RW 1962 The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. *AJR* **87**:171.
  372. Ilgan S, Karacalioglu AO, Pabuscuy Y, Atac GK, Arslan N, Ozturk E, Gunalp B, Ozguven MA 2004 Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. *Eur J Nucl Med Mol Imaging* **3**:825–830.
  373. Hod N, Hagag P, Baumer M, Sandbank J, Horne T 2005 Differentiated thyroid carcinoma in children and young adults: evaluation of response to treatment. *Clin Nucl Med* **30**:387–390.
  374. Fatourehchi V, Hay ID, Javedan H, Wiseman GA, Mullan BP, Gorman CA 2002 Lack of impact of radioiodine therapy in thyroglobulin-positive, diagnostic whole-body scan-negative patients with follicular cell-derived thyroid cancer. *J Clin Endocrinol Metab* **87**:1521–1526.
  375. Wang W, Larson SM, Fazzari M, Tickoo SK, Kolbert K, Sgouros G, Yeung H, Macapinlac H, Rosai J, Robbins RJ 2000 Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. *J Clin Endocrinol Metab* **85**:1107–1113.
  376. Wang W, Larson SM, Tuttle RM, Kalaigian H, Kolbert K, Sonenberg M, Robbins RJ 2001 Resistance of [18F]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions

- to treatment with high-dose radioactive iodine. *Thyroid* **11**:1169–1175.
377. Hooft L, Hoekstra OS, Deville W, Lips P, Teule GJ, Boers M, van Tulder MW 2001 Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography in the follow-up of papillary or follicular thyroid cancer. *J Clin Endocrinol Metab* **86**:3779–3786.
  378. Robbins RJ, Wan Q, Grewal RK, Reibke R, Gonen M, Strauss HW, Tuttle RM, Drucker W, Larson SM 2006 Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning. *J Clin Endocrinol Metab* **91**:498–505.
  379. Sarlis NJ 2001 Metastatic thyroid cancer unresponsive to conventional therapies: novel management approaches through translational clinical research. *Curr Drug Targets Immune Endocr Metabol Disord* **1**:103–115.
  380. Gottlieb JA, Hill CS, Jr., Ibanez ML, Clark RL 1972 Chemotherapy of thyroid cancer. An evaluation of experience with 37 patients. *Cancer* **30**:848–853.
  381. Gottlieb JA, Hill CS, Jr 1974 Chemotherapy of thyroid cancer with adriamycin. Experience with 30 patients. *N Engl J Med* **290**:93–197.
  382. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B 1977 Dose response evaluation of adriamycin in human neoplasia. *Cancer* **39**:1940–1948.
  383. Pacini F, Vitti P, Martino E, Giani C, Bambini G, Pinchera A, Bascheri L 1984 Treatment of refractory thyroid cancer with adriamycin. *Drugs Experimental Clinical Research* **10**:911–916.
  384. Haugen BR 1999 Management of the patient with progressive radioiodine non-responsive disease. *Semin Surg Oncol* **16**:34–41.
  385. Ain KB, Egorin MJ, DeSimone PA 2000 Treatment of anaplastic thyroid carcinoma with paclitaxel: phase 2 trial using ninety-six-hour infusion. Collaborative Anaplastic Thyroid Cancer Health Intervention Trials (CATCHIT) Group. *Thyroid* **10**:587–594.
  386. Santini F, Bottici V, Elisei R, Montanelli L, Mazzeo S, Basolo F, Pinchera A, Pacini F 2002 Cytotoxic effects of carboplatinum and epirubicin in the setting of an elevated serum thyrotropin for advanced poorly differentiated thyroid cancer. *J Clin Endocrinol Metab* **87**:4160–4165.
  387. Ain KB, Lee C, Williams KD 2007 Phase II trial of thalidomide for therapy of radioiodine-unresponsive and rapidly progressive thyroid carcinomas. *Thyroid* **17**:663–670.
  388. Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tورتoric M, Shalinsky DR, Liau KF, Cohen RB 2008 Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. *J Clin Oncol* **26**:4708–4713.
  389. Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ, Brose MS 2008 Phase II trial of sorafenib in advanced thyroid cancer. *J Clin Oncol* **26**:4714–4719.
  390. Sherman SI, Wirth LJ, Droz JP, Hofmann M, Bastholt L, Martins RG, Licitra L, Eschenberg MJ, Sun YN, Juan T, Stepan DE, Schlumberger MJ 2008 Motesanib diphosphate in progressive differentiated thyroid cancer. *N Engl J Med* **359**:31–42.
  391. Kloos RT, Ringel MD, Knopp MV, Hall NC, King M, Stevens R, Liang J, Wakely PE Jr, Vasko VV, Saji M, Rittenberry J, Wei L, Arbogast D, Collamore M, Wright JJ, Grever M, Shah MH 2009 Phase II trial of sorafenib in metastatic thyroid cancer. *J Clin Oncol* **27**:1675–1684.
  392. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F 2005 rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. *Endocr Relat Cancer* **12**:49–64.
  393. Van Tol KM, Hew JM, Jager PL, Vermey A, Dullaart RP, Links TP 2000 Embolization in combination with radioiodine therapy for bone metastases from differentiated thyroid carcinoma. *Clin Endocrinol (Oxf)* **52**:653–659.
  394. Posteraro AF, Dupuy DE, Mayo-Smith WW 2004 Radiofrequency ablation of bony metastatic disease. *Clin Radiol* **59**:803–811.
  395. Masala S, Fiori R, Massari F, Simonetti G 2003 Vertebroplasty and kyphoplasty: new equipment for malignant vertebral fractures treatment. *J Exp Clin Cancer Res* **22**:75–79.
  396. McWilliams RR, Giannini C, Hay ID, Atkinson JL, Stafford SL, Buckner JC 2003 Management of brain metastases from thyroid carcinoma: a study of 16 pathologically confirmed cases over 25 years. *Cancer* **98**:356–362.
  397. Walter MA, Turtschi CP, Schindler C, Minnig P, Müller-Brand J, Müller B 2007 The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study. *J Nucl Med* **48**:1620–1625.
  398. Kloos RT, Duvuuri V, Jhiang SM, Cahill KV, Foster JA, Burns JA 2002 Nasolacrimal drainage system obstruction from radioactive iodine therapy for thyroid carcinoma. *J Clin Endocrinol Metab* **87**:5817–5820.
  399. Sandeep TC, Strachan MW, Reynolds RM, Brewster DH, Scélo G, Pukkala E, Hemminki K, Anderson A, Tracey E, Friis S, McBride ML, Kee-Seng C, Pompe-Kirn V, Kliever EV, Tonita JM, Jonasson JG, Martos C, Boffetta P, Brennan P 2006 Second primary cancers in thyroid cancer patients: a multinational record linkage study. *J Clin Endocrinol Metab* **91**:1819–1825.
  400. Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I, Straus S, Brierley JD, Tsang RW, Gafni A, Rotstein L, Sawka AM 2007 Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. *Thyroid* **17**:1277–1288.
  401. Mandel SJ, Mandel L 2003 Radioactive iodine and the salivary glands. *Thyroid* **13**:265–271.
  402. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S 2005 Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? *J Nucl Med* **46**:261–266.
  403. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, Straus S, Ezzat S, Goldstein DP 2009 Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. *Thyroid* **19**:451–457.
  404. Chen AY, Levy L, Goepfert H, Brown BW, Spitz MR, Vassilopoulou-Sellin R 2001 The development of breast carcinoma in women with thyroid carcinoma. *Cancer* **92**:225–231.
  405. Vini L, Hyer S, Al-Saadi A, Pratt B, Harmer C 2002 Prognosis for fertility and ovarian function after treatment with radioiodine for thyroid cancer. *Postgrad Med J* **78**:92.
  406. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L 1995 Assessment of female fertility and carci-

- nogenesis after iodine-131 therapy for differentiated thyroid carcinoma. *J Nucl Med* **36**:21–27.
407. Sawka AM, Lakra DC, Lea J, Alshehri B, Tsang RW, Brierley JD, Straus S, Thabane L, Gafni A, Ezzat S, George SR, Goldstein DP 2008 A systematic review examining the effects of therapeutic radioactive iodine on ovarian function and future pregnancy in female thyroid cancer survivors. *Clin Endocrinol (Oxf)* **69**:479–490.
  408. Schlumberger M, De Vathaire F, Ceccarelli C, Delisle MJ, Francese C, Couette JE, Pinchera A, Parmentier C 1996 Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. *J Nucl Med* **37**:606–612.
  409. Garsi JP, Schlumberger M, Rubino C, Ricard M, Labbé M, Paoletti C, Ceccarelli C, Schvartz C, Henri-Amar M, Couette JE, de Vathaire F 2008 Therapeutic administration of 131I for differentiated thyroid cancer, radiation dose to ovaries and outcome of pregnancies. *J Nucl Med* **49**:845–852.
  410. Ceccarelli C, Benicivelli W, Morciano D, Pinchera A, Pacini F 2001 I-131 therapy for differentiated thyroid cancer leads to an earlier onset of menopause: Results of a retrospective study. *J Clin Endocrinol Metab* **86**:3512.
  411. Wichers M, Benz E, Palmedo H, Biersack HJ, Grunwald F, Klingmuller D 2000 Testicular function after radioiodine therapy for thyroid carcinoma. *Eur J Nucl Med* **27**:503–507.
  412. Hyer S, Vini L, O'Connell M, Pratt B, Harmer C 2002 Testicular dose and fertility in men following I(131) therapy for thyroid cancer. *Clin Endocrinol (Oxf)* **56**:755–758.
  413. Lushbaugh CC, Casarett GW 1976 The effects of gonadal irradiation in clinical radiation therapy: a review. *Cancer* **37**:1111–1125.
  414. Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ 1976 Subsequent fertility and birth histories of children and adolescents treated with I-131 for thyroid cancer. *J Nucl Med* **17**:460–464.
  415. Mazzaferri E 2002 Gonadal damage from 131I therapy for thyroid cancer. *Clin Endocrinol* **57**:313–314.
  416. van Tol KM, Jager PL, de Vries EG, Piers DA, Boezen HM, Sluiter WJ, Dullaart RP, Links TP 2003 Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. *Eur J Endocrinol* **148**:589–596.
  417. Pineda JD, Lee T, Ain K, Reynolds JC, Robbins J 1995 Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. *J Clin Endocrinol Metab* **80**:1488–1492.
  418. Pacini F, Agate L, Elisei R, Capezzone M, Ceccarelli C, Lippi F, Molinaro E, Pinchera A 2001 Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. *J Clin Endocrinol Metab* **86**:4092–4097.
  419. Palmedo H, Bucerius J, Joe A, Strunk H, Hortling N, Meyka S, Roedel R, Wolff M, Wardelmann E, Biersack HJ, Jaeger U 2006 Integrated PET/CT in differentiated thyroid cancer: diagnostic accuracy and impact on patient management. *J Nucl Med* **47**:616–624.
  420. Shamma A, Degirmenci B, Mountz JM, McCook BM, Branstetter B, Bencherif B, Joyce JM, Carty SE, Kuffner HA, Avril N 2007 18F-FDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. *J Nucl Med* **48**:221–226.
  421. Dietlein M, Scheidhauer K, Voth E, Theissen P, Schicha H 1997 Fluorine-18 fluorodeoxyglucose positron emission tomography and iodine-131 whole-body scintigraphy in the follow-up of differentiated thyroid cancer. *Eur J Nucl Med* **24**:1342–1348.
  422. Schlüter B, Bohuslavizki KH, Beyer W, Plotkin M, Buchert R, Clausen M 2001 Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. *J Nucl Med* **42**:71–76.
  423. Kloos RT 2008 Approach to the patient with a positive serum thyroglobulin and a negative radioiodine scan after initial therapy for differentiated thyroid cancer. *J Clin Endocrinol Metab* **93**:1519–1525.
  424. Kabasakal L, Selcuk NA, Shafipour H, Ozmen O, Onsel C, Uslu I 2004 Treatment of iodine-negative thyroglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. *Eur J Nucl Med Mol Imaging* **31**:1500–1504.
  425. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ 1999 [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels. *J Clin Endocrinol Metab* **84**:2291–2302.
  426. Helal BO, Merlet P, Toubert ME, Franc B, Schvartz C, Gauthier-Koelesnikov H, Prigent A, Syrota A 2001 Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy. *J Nucl Med* **42**:1464–1469.
  427. Nahas Z, Goldenberg D, Fakhry C, Ewertz M, Zeiger M, Ladenson PW, Wahl R, Tufano RP 2005 The role of positron emission tomography/computed tomography in the management of recurrent papillary thyroid carcinoma. *Laryngoscope* **115**:237–243.
  428. Rosario PW, Maia FF, Fagundes TA, Vasconcelos FP, Cardoso LD, Purisch S 2004 Antithyroglobulin antibodies in patients with differentiated thyroid carcinoma: methods of detection, interference with serum thyroglobulin measurement and clinical significance. *Arq Bras Endocrinol Metabol* **48**:487–492.
  429. Chung JK, Park YJ, Kim TY, So Y, Kim SK, Park DJ, Lee DS, Lee MC, Cho BY 2002 Clinical significance of elevated level of serum antithyroglobulin antibody in patients with differentiated thyroid cancer after thyroid ablation. *Clin Endocrinol (Oxf)* **57**:215–221.
  430. Chinnappa P, Taguba L, Arciaga R, Faiman C, Siperstein A, Mehta AE, Reddy SK, Nasr C, Gupta MK 2004 Detection of thyrotropin-receptor messenger ribonucleic acid (mRNA) and thyroglobulin mRNA transcripts in peripheral blood of patients with thyroid disease: sensitive and specific markers for thyroid cancer. *J Clin Endocrinol Metab* **89**:3705–3709.
  431. Li D, Butt A, Clarke S, Swaminathana R 2004 Real-time quantitative PCR measurement of thyroglobulin mRNA in peripheral blood of thyroid cancer patients and healthy subjects. *Ann N Y Acad Sci* **1022**:147–151.
  432. Grammatopoulos D, Elliott Y, Smith SC, Brown I, Grieve RJ, Hillhouse EW, Levine MA, Ringel MD 2003 Measurement of thyroglobulin mRNA in peripheral blood as an adjunctive test for monitoring thyroid cancer. *Mol Pathol* **56**:162–166.
  433. Elisei R, Vivaldi A, Agate L, Molinaro E, Nencetti C, Grasso L, Pinchera A, Pacini F 2004 Low specificity of blood thyroglobulin messenger ribonucleic acid assay prevents its

- use in the follow-up of differentiated thyroid cancer patients. *J Clin Endocrinol Metab* **89**:33–39.
434. Bellantone R, Lombardi CP, Bossola M, Ferrante A, Princi P, Boscherini M, Maussier L, Salvatori M, Rufini V, Reale F, Romano L, Tallini G, Zelano G, Pontecorvi A 2001 Validity of thyroglobulin mRNA assay in peripheral blood of postoperative thyroid carcinoma patients in predicting tumor recurrences varies according to the histologic type: results of a prospective study. *Cancer* **92**:2273–2279.
435. Greene FL (ed) 2002 *AJCC Cancer Staging Manual*, 6th ed. Springer-Verlag, New York.
436. Preissner CM, Dodge LA, O’Kane DJ, Singh RJ, Grebe SK 2005 Prevalence of heterophilic antibody interference in eight automated tumor marker immunoassays. *Clin Chem* **51**:208–210.
437. Preissner CM, O’Kane DJ, Singh RJ, Morris JC, Grebe SK 2003 Phantoms in the assay tube: heterophile antibody interferences in serum thyroglobulin assays. *J Clin Endocrinol Metab* **88**:3069–3074.

Address correspondence to:

*David S. Cooper, M.D.*

*Division of Endocrinology*

*The Johns Hopkins University School of Medicine*

*1830 East Monument Street Suite 333*

*Baltimore, MD 21287*

*E-mail: dscooper@jhmi.edu*



**This article has been cited by:**

1. Matthew T. Olson, Martha A. Zeiger Thyroid Fine-Needle Aspiration and Cytological Diagnosis 1417-1422.e2. [[CrossRef](#)]
2. Juan P. Brito, Ian D. Hay, Robert L. Foote Thyroid Cancer 715-730.e3. [[CrossRef](#)]
3. Edwin L. Kaplan, Peter Angelos, Benjamin C. James, Sapna Nagar, Raymon H. Grogan Surgery of the Thyroid 1666-1692.e4. [[CrossRef](#)]
4. Furio Pacini, Francesco Chiofalo, Leslie J. De Groot Thyroid Neoplasia 1601-1628.e10. [[CrossRef](#)]
5. Valentina Cirello, Carla Colombo, Michela Perrino, Simone De Leo, Marina Muzza, Maria Antonia Maffini, Laura Fugazzola. 2015. Fetal cell microchimerism in papillary thyroid cancer: A role in the outcome of the disease. *International Journal of Cancer* **137**:10.1002/ijc.v137.12, 2989-2993. [[CrossRef](#)]
6. Nicole L Lebo, Francois Raymond, Michael J Odell. 2015. Selectively false-positive radionuclide scan in a patient with sarcoidosis and papillary thyroid cancer: a case report and review of the literature. *Journal of Otolaryngology - Head & Neck Surgery* **44**. . [[CrossRef](#)]
7. Badr Ibrahim, Véronique-Isabelle Forest, Michael Hier, Alex M. Mlynarek, Derin Caglar, Richard J. Payne. 2015. Completion thyroidectomy: predicting bilateral disease. *Journal of Otolaryngology - Head & Neck Surgery* **44**. . [[CrossRef](#)]
8. Francis Worden, Martin Fassnacht, Yuankai Shi, Tatiana Hadjieva, Françoise Bonichon, Ming Gao, Laura Fugazzola, Yuichi Ando, Yasuhisa Hasegawa, Do Joon Park, Young Kee Shong, Johannes W A Smit, John Chung, Christian Kappeler, Gerold Meinhardt, Martin Schlumberger, Marcia S Brose. 2015. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. *Endocrine-Related Cancer* **22**, 877-887. [[CrossRef](#)]
9. Jian Zhu, Xinli Wang, Xiaoxuan Zhang, Peifeng Li, Haifeng Hou. 2015. Clinicopathological features of recurrent papillary thyroid cancer. *Diagnostic Pathology* **10**. . [[CrossRef](#)]
10. Fernanda Vaisman, Denise P Carvalho, Mario Vaisman. 2015. A new appraisal of iodine refractory thyroid cancer. *Endocrine-Related Cancer* **22**, R301-R310. [[CrossRef](#)]
11. Shilpa S. Murthy, Nir Eyal, Ole Frithjof Norheim, Daniel T. Ruan, Georges Ntakiyiruta, Riviello Robert. 2015. Standard of care versus second-best: Ethical dilemmas in surgery for high risk papillary thyroid cancer in low and middle-income countries. *Journal of Cancer Policy* **6**, 8-10. [[CrossRef](#)]
12. Anna M. Sawka, Sharon Straus, Gary Rodin, Kevin E. Thorpe, Shereen Ezzat, Amiram Gafni, David P. Goldstein. 2015. Decision aid on radioactive iodine treatment for early stage papillary thyroid cancer: update to study protocol with follow-up extension. *Trials* **16**. . [[CrossRef](#)]
13. Marco Medici, Norra Kwong, Trevor E. Angell, Ellen Marqusee, Matthew I. Kim, Mary C. Frates, Carol B. Benson, Edmund S. Cibas, Justine A. Barletta, Jeffrey F. Krane, Daniel T. Ruan, Nancy L. Cho, Atul A. Gawande, Francis D. Moore, Erik K. Alexander. 2015. The variable phenotype and low-risk nature of RAS-positive thyroid nodules. *BMC Medicine* **13**. . [[CrossRef](#)]
14. Manish M George, Jay Goswamy, Susannah E Penney. 2015. Embolic suppurative thyroiditis with concurrent carcinoma in pregnancy: lessons in management through a case report. *Thyroid Research* **8**. . [[CrossRef](#)]
15. Shrikant Tamhane, Hossein Gharib. 2015. Thyroid nodules update in diagnosis and management. *Clinical Diabetes and Endocrinology* **1**. . [[CrossRef](#)]
16. 2015. *Thyroid Research* **8**. . [[CrossRef](#)]
17. Kaoru Kobayashi, Mitsuyoshi Hirokawa, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroo Masuoka, Takuya Higashiyama, Minoru Kihara, Yasuhiro Ito, Akihiro Miya, Nobuyuki Amino, Akira Miyauchi. 2015. Metastatic carcinoma to the thyroid gland from renal cell carcinoma: role of ultrasonography in preoperative diagnosis. *Thyroid Research* **8**. . [[CrossRef](#)]
18. Juan Martínez-Aguilar, Roderick Clifton-Bligh, Mark P Molloy. 2015. A multiplexed, targeted mass spectrometry assay of the S100 protein family uncovers the isoform-specific expression in thyroid tumours. *BMC Cancer* **15**. . [[CrossRef](#)]
19. Sarah W. Lai, Derek J. Roberts, Doreen M. Rabi, Karin Y. Winston. 2015. Diagnostic accuracy of fine needle aspiration biopsy for detection of malignancy in pediatric thyroid nodules: protocol for a systematic review and meta-analysis. *Systematic Reviews* **4**. . [[CrossRef](#)]
20. Andre R Le, Gregory W Thompson, Benjamin John A Hoyt. 2015. Thyroid Fine-needle aspiration biopsy: an evaluation of its utility in a community setting. *Journal of Otolaryngology - Head & Neck Surgery* **44**. . [[CrossRef](#)]
21. Savvas Frangos, Ioannis P. Iakovou, Robert J. Marlowe, Nicolaos Eftychiou, Loukia Patsali, Anna Vanezi, Androulla Savva, Vassilis Mpalaris, Evanthia I. Giannoula. 2015. Difficulties in deciding whether to ablate patients with putatively “low-intermediate-risk” differentiated thyroid carcinoma: do guidelines mainly apply in the centres that produce them? Results of a retrospective, two-centre quality assurance study. *European Journal of Nuclear Medicine and Molecular Imaging* **42**, 2045-2055. [[CrossRef](#)]

22. Yi Li, Yan Wang, Qiong Wu, Bing Hu. 2015. Transforming Growth Factor  $\beta$ 1 Could Influence Thyroid Nodule Elasticity and Also Improve Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma. *Ultrasound in Medicine & Biology* **41**, 2866-2872. [[CrossRef](#)]
23. Ghobad Azizi, James M. Keller, Michelle L. Mayo, Kelé Piper, David Puett, Karly M. Earp, Carl D. Malchoff. 2015. Thyroid Nodules and Shear Wave Elastography: A New Tool in Thyroid Cancer Detection. *Ultrasound in Medicine & Biology* **41**, 2855-2865. [[CrossRef](#)]
24. Anthony E. Samir, Manish Dhyani, Arash Anvari, Jason Prescott, Elkan F. Halpern, William C. Faquin, Antonia Stephen. 2015. Shear-Wave Elastography for the Preoperative Risk Stratification of Follicular-patterned Lesions of the Thyroid: Diagnostic Accuracy and Optimal Measurement Plane. *Radiology* **277**, 565-573. [[CrossRef](#)]
25. Sagit Stern, Ohad Hilly, Einav Horowitz, Moshe Leshno, Raphael Feinmesser. 2015. Is There Justification for Total Thyroidectomy in Low-Risk Papillary Thyroid Carcinoma? A Decision-Analysis Model. *World Journal of Surgery* **39**, 2707-2717. [[CrossRef](#)]
26. Ki Nam Park, Kyung Yoon Kang, Hyun Sook Hong, Han-Shin Jeong, Seung Won Lee. 2015. Predictive Value of Estimated Tumor Volume Measured by Ultrasonography for Occult Central Lymph Node Metastasis in Papillary Thyroid Carcinoma. *Ultrasound in Medicine & Biology* **41**, 2849-2854. [[CrossRef](#)]
27. Soo-Yeon Kim, Jin Young Kwak, Eun-Kyung Kim, Jung Hyun Yoon, Hee Jung Moon. 2015. Association of Preoperative US Features and Recurrence in Patients with Classic Papillary Thyroid Carcinoma. *Radiology* **277**, 574-583. [[CrossRef](#)]
28. Chiaw-Ling Chng, Tom R. Kurzawinski, Tim Beale. 2015. Value of sonographic features in predicting malignancy in thyroid nodules diagnosed as follicular neoplasm on cytology. *Clinical Endocrinology* **83**:10.1111/cen.2015.83.issue-5, 711-716. [[CrossRef](#)]
29. Alfredo Campenni, Luca Giovanella, Salvatore A. Pignata, Maria A. Violi, Massimiliano Siracusa, Angela Alibrandi, Mariacarla Moleti, Ernesto Amato, Rosaria M. Ruggeri, Francesco Vermiglio, Sergio Baldari. 2015. Thyroid remnant ablation in differentiated thyroid cancer. *Nuclear Medicine Communications* **36**, 1100-1106. [[CrossRef](#)]
30. Pierpaolo Trimboli, Giorgio Treglia, Ramin Sadeghi, Francesco Romanelli, Luca Giovanella. 2015. Reliability of real-time elastography to diagnose thyroid nodules previously read at FNAC as indeterminate: a meta-analysis. *Endocrine* **50**, 335-343. [[CrossRef](#)]
31. Marialuisa Sponziello, Antonella Verrienti, Francesca Rosignolo, Roberta Francesca De Rose, Valeria Pecce, Valentina Maggisano, Cosimo Durante, Stefania Bulotta, Giuseppe Damante, Laura Giacomelli, Cira Rosaria Tiziana Di Gioia, Sebastiano Filetti, Diego Russo, Marilena Celano. 2015. PDE5 expression in human thyroid tumors and effects of PDE5 inhibitors on growth and migration of cancer cells. *Endocrine* **50**, 434-441. [[CrossRef](#)]
32. Sze Ling Wong, Simon Grodski, Meei J. Yeung, Jonathan W. Serpell. 2015. Anti-thyroid antibodies as a predictor of thyroid cancer. *ANZ Journal of Surgery* **85**:10.1111/ans.2015.85.issue-11, 849-853. [[CrossRef](#)]
33. Chase D. Hendrickson, Richard J. Comi. 2015. ON THE EDGE OF DISEASE. *Endocrine Practice* **21**, 1303-1305. [[CrossRef](#)]
34. Samantha Peiling Yang, Lee Suat Ying, Stephanie Saw, R. Michael Tuttle, Kavita Venkataraman, Chia Su-Ynn. 2015. PRACTICAL BARRIERS TO IMPLEMENTATION OF THYROID CANCER GUIDELINES IN THE ASIA-PACIFIC REGION. *Endocrine Practice* **21**, 1255-1268. [[CrossRef](#)]
35. Won-Jin Moon, Jung Hwan Baek, Jin Woo Choi, Young Joong Kim, Eun Ju Ha, Hyun Kyung Lim, Dong Eun Song, Jeong Hyun Lee, Young Kee Shong. 2015. THE VALUE OF GROSS VISUAL ASSESSMENT OF SPECIMEN ADEQUACY FOR LIQUID-BASED CYTOLOGY DURING ULTRASOUND-GUIDED, FINE-NEEDLE ASPIRATION OF THYROID NODULES. *Endocrine Practice* **21**, 1219-1226. [[CrossRef](#)]
36. Choi Young Jun, Baek Jung Hwan, Baek Seung Hee, Shim Woo Hyun, Lee Kang Dae, Lee Hyoung Shin, Shong Young Kee, Ha Eun Ju, Lee Jeong Hyun. Web-Based Malignancy Risk Estimation for Thyroid Nodules Using Ultrasonography Characteristics: Development and Validation of a Predictive Model. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
37. Alexis Vrachimis, Burkhard Riemann, Uwe Mäder, Christoph Reiners, Frederik A. Verburg. 2015. Endogenous TSH levels at the time of  $^{131}\text{I}$  ablation do not influence ablation success, recurrence-free survival or differentiated thyroid cancer-related mortality. *European Journal of Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
38. H. Häscheid, M. Lassmann, F. A. Verburg. 2015. Dose optimization in nuclear medicine therapy of benign and malignant thyroid diseases. *Clinical and Translational Imaging* . [[CrossRef](#)]
39. Tracy S. Wang, Paolo Goffredo, Julie Ann Sosa, Sanziana A. Roman. 2015. Papillary Thyroid Microcarcinoma: An Over-Treated Malignancy?: Reply. *World Journal of Surgery* . [[CrossRef](#)]

40. Anna M. Sawka, Sharon Straus, Gary Rodin, Lineke Heus, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Shereen Ezzat, Phillip Segal, Amiram Gafni, Kevin E. Thorpe, David P. Goldstein. 2015. Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow-up from a decision-aid randomized trial. *Cancer* **121**:10.1002/cncr.v121.20, 3717-3726. [[CrossRef](#)]
41. Dr. Bryan R Haugen MD, Dr. Erik K. Alexander, Dr. Keith C. Bible, Dr. Gerard Doherty, Dr. Susan J Mandel, Dr. Yuri E. Nikiforov, Dr. Furio Pacini, Dr. Gregory Randolph, Dr. Anna Sawka, Prof. Martin Schlumberger, Dr. Kathryn G Schuff, Dr. Steven I. Sherman, Dr. Julie Ann Sosa, Dr. D Steward, Dr. R Michael Tuttle MD, Dr. Leonard Wartofsky. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **0**:ja. . [[Abstract](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
42. Aragon Han Patricia, Weng Chien-Hsiang, Khawaja Hunain T., Nagarajan Neeraja, Schneider Eric B., Umbricht Christopher B., Witwer Kenneth W., Zeiger Martha A.. MicroRNA Expression and Association with Clinicopathologic Features in Papillary Thyroid Cancer: A Systematic Review. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
43. A. F. Bendouida, S. Moulessehoul, N. Harir, A. Rih, M. Diaf, L. Belhandouze. 2015. Epidemiology, diagnosis and treatment of thyroid cancer in Western Algeria (Sidi bel Abbes region). *Journal Africain du Cancer / African Journal of Cancer* . [[CrossRef](#)]
44. Hershman Jerome M.. 2015. Cost for Detection of Recurrence of PTC Is Sixfold Higher in Low-Risk Patients. *Clinical Thyroidology* **27**:10, 282-283. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
45. Singh Ospina Naykky, Sebo Thomas J., Morris John C., Castro M. Regina. 2015. The Value of Repeat Thyroid Fine-Needle Aspiration Biopsy in Patients with a Previously Benign Result: How Often Does It Alter Management?. *Thyroid* **25**:10, 1121-1126. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
46. Rosário Pedro Wesley, Calsolari Maria Regina. 2015. What Is the Best Criterion for Repetition of Fine-Needle Aspiration in Thyroid Nodules with Initially Benign Cytology?. *Thyroid* **25**:10, 1115-1120. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
47. Ji Soo Choi, Hye Sun Lee, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2015. The influence of body mass index on the diagnostic performance of pre-operative staging ultrasound in papillary thyroid carcinoma. *Clinical Endocrinology* **83**:10.1111/cen.2015.83.issue-4, 550-555. [[CrossRef](#)]
48. Mohamed Abdelgadir Adam, Paolo Goffredo, Linda Youngwirth, Randall P. Scheri, Sanziana A. Roman, Julie A. Sosa. 2015. Same thyroid cancer, different national practice guidelines: When discordant American Thyroid Association and National Comprehensive Cancer Network surgery recommendations are associated with compromised patient outcome. *Surgery* . [[CrossRef](#)]
49. D. Elaraj, R. Nayar, C. Sturgeon. 2015. Utility of molecular testing in the management of thyroid nodules - a clinical perspective. *Cytopathology* **26**:10.1111/cyt.2015.26.issue-5, 284-287. [[CrossRef](#)]
50. Xi Jin, Liam Masterson, Anant Patel, Liz Hook, James Nicholson, Sarah Jefferies, Mark Gaze, Ramez Nassif, Robert Eller, Tony Hulse, Piyush Jani. 2015. Conservative or radical surgery for pediatric papillary thyroid carcinoma: A systematic review of the literature. *International Journal of Pediatric Otorhinolaryngology* **79**, 1620-1624. [[CrossRef](#)]
51. M. Bongiovanni, F. Molinari, M. Eszlinger, R. Paschke, J. Barizzi, E. Merlo, L. Giovanella, F. Fasolini, F. Cattaneo, F. Ramelli, L. Mazzucchelli, M. Frattini. 2015. Laser capture microdissection is a valuable tool in the preoperative molecular screening of follicular lesions of the thyroid: an institutional experience. *Cytopathology* **26**:10.1111/cyt.2015.26.issue-5, 288-296. [[CrossRef](#)]
52. Françoise Bonichon, Yann Godbert, Afshin Gangi, Xavier Buy, Jean Palussière. 2015. PET/Computed Tomography and Thermoablation (Radiofrequency, Microwave, Cryotherapy, Laser Interstitial Thermal Therapy). *PET Clinics* **10**, 519-540. [[CrossRef](#)]
53. Yong Bae Ji, Han Seok Yoo, Chang Myeon Song, Chul Won Park, Chang Beom Lee, Kyung Tae. 2015. Predictive factors and pattern of central lymph node metastasis in unilateral papillary thyroid carcinoma. *Auris Nasus Larynx* . [[CrossRef](#)]
54. Juan J. Díez, Pedro Iglesias. 2015. Actualización en el diagnóstico de la enfermedad nodular tiroidea. *Medicina Clínica* . [[CrossRef](#)]
55. O. Rubio-Puchol, S. Garzón-Pastor, V. Cortés-Vizcaíno, I. Luna-Boquera, M. Gómez-Balaguer, A. Hernández-Mijares. 2015. Hodgkin's lymphoma of the thyroid in a woman with autoimmune thyroiditis. *Revista Clínica Española* **215**, 405-408. [[CrossRef](#)]
56. Qing-Li Zhu, William C. Faquin, Anthony E. Samir. 2015. Relationship Between Sonographic Characteristics and Afirma Gene Expression Classifier Results in Thyroid Nodules With Indeterminate Fine-Needle Aspiration Cytopathology. *American Journal of Roentgenology* **205**, 861-865. [[CrossRef](#)]
57. David A. Pattison, Michael S. Hofman. 2015. Role of Fluorodeoxyglucose PET/Computed Tomography in Targeted Radionuclide Therapy for Endocrine Malignancies. *PET Clinics* **10**, 461-476. [[CrossRef](#)]
58. Melinda B. Ukrainski, E.A. Pribitkin, J.L. Miller. 2015. Increasing Incidence of Thyroid Nodules and Thyroid Cancer: Does Increased Detection of a Subclinical Reservoir Justify the Associated Anxiety and Treatment?. *Clinical Therapeutics* . [[CrossRef](#)]

59. William C. Faquin, Lawrence Q. Wong, Amir H. Afrogheh, Syed Z. Ali, Justin A. Bishop, Massimo Bongiovanni, Marc P. Pusztaszeri, Christopher J. VandenBussche, Jolanta Gourmaud, Louis J. Vaickus, Zubair W. Baloch. 2015. Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
60. Yong Joon Suh, Hyungju Kwon, Su-jin Kim, June Young Choi, Kyu Eun Lee, Young Joo Park, Do Joon Park, Yeo-Kyu Youn. 2015. Factors Affecting the Locoregional Recurrence of Conventional Papillary Thyroid Carcinoma After Surgery: A Retrospective Analysis of 3381 Patients. *Annals of Surgical Oncology* **22**, 3543-3549. [[CrossRef](#)]
61. Jee Young Kim, So Lyung Jung, Mee Kyung Kim, Tae-Jung Kim, Jae Young Byun. 2015. Differentiation of benign and malignant thyroid nodules based on the proportion of sponge-like areas on ultrasonography: imaging-pathologic correlation. *Ultrasonography* **34**, 304-311. [[CrossRef](#)]
62. Juan José Díez, Juan Carlos Galofré, Amelia Oleaga, Enrique Grande, Mercedes Mitjavila, Pablo Moreno. 2015. Declaración de consenso para la acreditación de unidades multidisciplinarias en cáncer de tiroides. *Endocrinología y Nutrición* . [[CrossRef](#)]
63. Alessandro Mussa, Maurilio De Andrea, Manuela Motta, Alberto Mormile, Nicola Palestini, Andrea Corrias. 2015. Predictors of Malignancy in Children with Thyroid Nodules. *The Journal of Pediatrics* **167**, 886-892.e1. [[CrossRef](#)]
64. Paritosh Suman, Chi-Hsiung Wang, Shabir Husain S. Abadin, Tricia A. Moo-Young, Richard A. Prinz, David J. Winchester. 2015. Risk factors for central lymph node metastasis in papillary thyroid carcinoma: A National Cancer Data Base (NCDB) study. *Surgery* . [[CrossRef](#)]
65. F. Pagni, V. Mainini, M. Garancini, F. Bono, A. Vanzati, V. Giardini, M. Scardilli, P. Goffredo, A. J. Smith, M. Galli, G. De Sio, F. Magni. 2015. Proteomics for the diagnosis of thyroid lesions: preliminary report. *Cytopathology* **26**:10.1111/cyt.2015.26.issue-5, 318-324. [[CrossRef](#)]
66. Altay Aliyev, Jinesh Patel, Jennifer Brainard, Manjula Gupta, Christian Nasr, Betül Hatipoglu, Allan Siperstein, Eren Berber. 2015. Diagnostic accuracy of circulating thyrotropin receptor messenger RNA combined with neck ultrasonography in patients with Bethesda III–V thyroid cytology. *Surgery* . [[CrossRef](#)]
67. Rebecca Zeuren, Agnese Biagini, Ravinder K. Grewal, Gregory W. Randolph, Dipti Kamani, Mona M. Sabra, Ashok R. Shaha, R. Michael Tuttle. 2015. RAI thyroid bed uptake after total thyroidectomy: A novel SPECT-CT anatomic classification system. *The Laryngoscope* **125**:10.1002/lary.v125.10, 2417-2424. [[CrossRef](#)]
68. Naif Fnais, Charlene Soobiah, Khalid AL-Qahtani, Jemila S. Hamid, Laure Perrier, Sharon E. Straus, Andrea C. Tricco. 2015. Diagnostic value of fine needle aspiration BRAFV600E mutation analysis in papillary thyroid cancer: a systematic review and meta-analysis. *Human Pathology* **46**, 1443-1454. [[CrossRef](#)]
69. James X. Wu, Raymond Lam, Mary Levin, Jianyu Rao, Peggy S. Sullivan, Michael W. Yeh. 2015. Effect of malignancy rates on cost-effectiveness of routine gene expression classifier testing for indeterminate thyroid nodules. *Surgery* . [[CrossRef](#)]
70. Xinghua Song, Zhaowei Meng, Qiang Jia, Linlin Zhang, Ke Xu, Jian Tan, Guizhi Zhang, Wei Zheng, Xue Li, Jianping Zhang. 2015. Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer. *Clinical Nuclear Medicine* **40**, 774-779. [[CrossRef](#)]
71. Sofía del Carmen, Sonia Gatiús, Guzmán Franch-Arcas, José Antonio Baena, Oscar Gonzalez, Carlos Zafon, Dolors Cuevas, Joan Valls, Angustias Pérez, Mercedes Martínez, Susana Ros, Carmen García Macías, Carmela Iglesias, Xavier Matías-Guiu, Enrique de Álava. 2015. Concordance study between OSNA and morphologic techniques to detect lymph node metastasis in papillary carcinoma of the thyroid. *Human Pathology* . [[CrossRef](#)]
72. André Uchimura Bastos, Gisele Oler, Bruno Heidi Nakano Nozima, Raquel Ajub Moysés, Janete Maria Cerutti. 2015. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. *European Journal of Endocrinology* **173**, 525-540. [[CrossRef](#)]
73. Kwanhoon Jo, Min-Hee Kim, Yejee Lim, So-Lyung Jung, Ja-Seong Bae, Chan-Kwon Jung, Moo-Il Kang, Bong-Yun Cha, Dong-Jun Lim. 2015. Lowered cutoff of lymph node fine-needle aspiration thyroglobulin in thyroid cancer patients with serum anti-thyroglobulin antibody. *European Journal of Endocrinology* **173**, 489-497. [[CrossRef](#)]
74. Nicola Veronese, Claudio Luchini, Alessia Nottegar, Takuma Kaneko, Giuseppe Sergi, Enzo Manzato, Marco Solmi, Aldo Scarpa. 2015. Prognostic impact of extra-nodal extension in thyroid cancer: A meta-analysis. *Journal of Surgical Oncology* n/a-n/a. [[CrossRef](#)]
75. Ning Qu, Ling Zhang, Qing-hai Ji, Jia-ying Chen, Yong-xue Zhu, Yi-ming Cao, Qiang Shen. 2015. Risk Factors for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma: A Meta-Analysis. *World Journal of Surgery* **39**, 2459-2470. [[CrossRef](#)]
76. David J. Terris, Katrina Chaung, William S. Duke. 2015. Continuous Vagal Nerve Monitoring is Dangerous and Should not Routinely be Done During Thyroid Surgery. *World Journal of Surgery* **39**, 2471-2476. [[CrossRef](#)]

77. Xing-Jian Lai, Bo Zhang, Yu-Xin Jiang, Jian-Chu Li, Rui-Na Zhao, Xiao Yang, Qing Zhang, Xiao-Yan Zhang, Wen-Bo Li, Shen-Ling Zhu. 2015. High Risk of Lateral Nodal Metastasis in Lateral Solitary Solid Papillary Thyroid Cancer. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
78. Collette English, Ruth Casey, Marcia Bell, Diane Bergin, Joseph Murphy. 2015. The Sonographic Features of the Thyroid Gland after Treatment with Radioiodine Therapy in Patients with Graves' Disease. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
79. Scott A. Rivkees. 2015. Evaluating the Rare and Predicting the Worst: Lessons for Thyroid Nodules. *The Journal of Pediatrics* **167**, 790-791. [[CrossRef](#)]
80. Min Ji Jeon, Won Gu Kim, Seonhee Lim, Hyun-Jeung Choi, Soyoung Sim, Tae Yong Kim, Young Kee Shong, Won Bae Kim. 2015. Alpha lipoic acid inhibits proliferation and epithelial mesenchymal transition of thyroid cancer cells. *Molecular and Cellular Endocrinology* . [[CrossRef](#)]
81. I. J. Nixon, L. Y. Wang, I. Ganly, S. G. Patel, L. G. Morris, J. C. Migliacci, R. M. Tuttle, J. P. Shah, A. R. Shaha. 2015. Outcomes for patients with papillary thyroid cancer who do not undergo prophylactic central neck dissection. *British Journal of Surgery* n/a-n/a. [[CrossRef](#)]
82. Yichao Wang, Tao Wei, Junjie Xiong, Peng Chen, Xunli Wang, Lin Zhang, Linbo Gao, Jingqiang Zhu. 2015. Association Between Genetic Polymorphisms in the Promoter Regions of Let-7 and Risk of Papillary Thyroid Carcinoma. *Medicine* **94**, e1879. [[CrossRef](#)]
83. Alexis Vrachimis, Matthias Christian Burg, Christian Wenning, Thomas Allkemper, Matthias Weckesser, Michael Schäfers, Lars Stegger. 2015. [18F]FDG PET/CT outperforms [18F]FDG PET/MRI in differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
84. Hye-Kyung Chung, Ji Sun Nam, Chul Woo Ahn, Yong Sang Lee, Kyung Rae Kim. 2015. Some Elements in Thyroid Tissue are Associated with More Advanced Stage of Thyroid Cancer in Korean Women. *Biological Trace Element Research* . [[CrossRef](#)]
85. Linda M. Youngwirth, Mohamed A. Adam, Randall P. Scheri, Sanziana A. Roman, Julie A. Sosa. 2015. Patients Treated at Low-Volume Centers have Higher Rates of Incomplete Resection and Compromised Outcomes: Analysis of 31,129 Patients with Papillary Thyroid Cancer. *Annals of Surgical Oncology* . [[CrossRef](#)]
86. James D. Brierley, David P. Goldstein, Monika K. Krzyzanowska Thyroid 626-640. [[CrossRef](#)]
87. Tommi T. Hakala, Juhani A. Sand, Arja Jukkola, Heini S. Huhtala, Saara Metso, Pirkko-Liisa Kellokumpu-Lehtinen. 2015. Increased risk of certain second primary malignancies in patients treated for well-differentiated thyroid cancer. *International Journal of Clinical Oncology* . [[CrossRef](#)]
88. Shrestha Rupendra T., Karunamurthy Arivarasan, Amin Khalid, Nikiforov Yuri E., Caramori M. Luiza. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management—A Case Report. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
89. Suk Hyun Lee, Sangwon Han, Hyo Sang Lee, Sun Young Chae, Jong Jin Lee, Dong Eun Song, Jin-Sook Ryu. 2015. Association Between 18F-FDG Avidity and the BRAF Mutation in Papillary Thyroid Carcinoma. *Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
90. Dong Hoon Lee, Tae Mi Yoon, Hee Kyung Kim, Joon Kyoo Lee, Ho Cheol Kang, Sang Chul Lim. 2015. Intraoperative Frozen Biopsy of Central Lymph Node in the Management of Papillary Thyroid Microcarcinoma. *Indian Journal of Otolaryngology and Head & Neck Surgery* . [[CrossRef](#)]
91. M. Regina Castro, John C. Morris, Mabel Ryder, Juan P. Brito, Ian D. Hay. 2015. Most patients with a small papillary thyroid carcinoma enjoy an excellent prognosis and may be managed with minimally invasive therapy or active surveillance. *Cancer* **121**:10.1002/cncr.v121.18, 3364-3365. [[CrossRef](#)]
92. Rosario Pedro Wesley, Furtado Mariana de Souza, Mourão Gabriela Franco, Calsolari Maria Regina. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
93. F. A. Batista, L. S. Ward, M. A. Marcello, M. B. Martins, K. C. Peres, C. Torricelli, N. E. Bufalo, F. A. Soares, M. J. da Silva, L. V. M. Assumpção. 2015. Gene expression of thyroid-specific transcription factors may help diagnose thyroid lesions but are not determinants of tumor progression. *Journal of Endocrinological Investigation* . [[CrossRef](#)]
94. Wing Lok Chan, Sherry CY Ng, Martin WM Law, Victor HF Lee, KY Wan, TW Leung. 2015. Volumetric modulated arc therapy in differentiated thyroid cancer: a treatment planning comparison with intensity-modulated radiotherapy. *Journal of Radiation Oncology* . [[CrossRef](#)]

95. Jung Hyun Yoon, Hye Sun Lee, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2015. Malignancy Risk Stratification of Thyroid Nodules: Comparison between the Thyroid Imaging Reporting and Data System and the 2014 American Thyroid Association Management Guidelines. *Radiology* 150056. [[CrossRef](#)]
96. Vito Cantisani, Piero Maceroni, Vito D'Andrea, Gregorio Patrizi, Mattia Di Segni, Corrado De Vito, Hektor Grazhdani, Andrea M. Isidori, Elisa Giannetta, Adriano Redler, Fabrizio Frattaroli, Laura Giacomelli, Giorgio Di Rocco, Carlo Catalano, Ferdinando D'Ambrosio. 2015. Strain ratio ultrasound elastography increases the accuracy of colour-Doppler ultrasound in the evaluation of Thy-3 nodules. A bi-centre university experience. *European Radiology* . [[CrossRef](#)]
97. Kim Dongwoo, Hwang Sang Hyun, Cha Jongtae, Jo Kwanhyeong, Lee Narae, Yun Mijin. Risk Stratification of Thyroid Incidentalomas Found on PET/CT: The Value of Iodine Content on Noncontrast Computed Tomography. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
98. Stolyarov Yana, Sacks Wendy. 2015. Thyroid Cancer Identified in a Sacral Mass with Increased Iodine Uptake. *Clinical Thyroidology* 27:9, 244-248. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
99. Al Afif Ayham, Williams Blair A., Rigby Mathew H., Bullock Martin J., Taylor S. Mark, Trites Jonathan, Hart Robert D.. 2015. Multifocal Papillary Thyroid Cancer Increases the Risk of Central Lymph Node Metastasis. *Thyroid* 25:9, 1008-1012. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
100. Wang Laura Y., Ghossein Ronald, Palmer Frank L., Nixon Iain J., Tuttle R. Michael, Shaha Ashok R., Shah Jatin P., Patel Snehal G., Ganly Ian. 2015. Microscopic Positive Margins in Differentiated Thyroid Cancer Is Not an Independent Predictor of Local Failure. *Thyroid* 25:9, 993-998. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
101. Wiebel Jaime L., Esfandiari Nazanene H., Papaleontiou Maria, Worden Francis P., Haymart Megan R.. 2015. Evaluating Positron Emission Tomography Use in Differentiated Thyroid Cancer. *Thyroid* 25:9, 1026-1032. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
102. Sung Tae-Yon, Lee Yu-mi, Yoon Jong Ho, Chung Ki-Wook, Hong Suck Joon. 2015. The Best Surgical Tips for Parathyroid Preservation in Thyroid Surgery. *VideoEndocrinology* 2:3. . [[Abstract](#)] [[Full Text HTML](#)]
103. Juan C. Baez, David Zurakowski, Sara O. Vargas, Edward Y. Lee. 2015. Incidental Thyroid Nodules Detected on Thoracic Contrast-Enhanced CT in the Pediatric Population: Prevalence and Outcomes. *American Journal of Roentgenology* 205, W360-W365. [[CrossRef](#)]
104. Hong-Jun Song, Zhong-Ling Qiu, Chen-Tian Shen, Wei-Jun Wei, Quan-Yong Luo. 2015. Pulmonary metastases in differentiated thyroid cancer: efficacy of radioiodine therapy and prognostic factors. *European Journal of Endocrinology* 173, 399-408. [[CrossRef](#)]
105. Kanhaiyalal Agrawal, Abdulredha A.H. Esmail, Gopinath Gnanasegaran, Shaunak Navalkisoor, Bhagwant Rai Mittal, Ignac Fogelman. 2015. Pitfalls and Limitations of Radionuclide Imaging in Endocrinology. *Seminars in Nuclear Medicine* 45, 440-457. [[CrossRef](#)]
106. Jonathan M. Fussey, Rosa Crunkhorn, Miroslav Tedla, Martin O. Weickert, Hisham Mehanna. 2015. External beam radiotherapy in differentiated thyroid carcinoma: A systematic review. *Head & Neck* n/a-n/a. [[CrossRef](#)]
107. Raquel M. Carneiro, Benedito A. Carneiro, Mark Agulnik, Peter A. Kopp, Francis J. Giles. 2015. Targeted therapies in advanced differentiated thyroid cancer. *Cancer Treatment Reviews* 41, 690-698. [[CrossRef](#)]
108. Marc P. Pusztaszeri, Jeffrey F. Krane, William C. Faquin. 2015. BRAF testing and thyroid FNA. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
109. Livia Lamartina, David S. Cooper. 2015. Radioiodine remnant ablation in low-risk differentiated thyroid cancer: the "con" point of view. *Endocrine* 50, 67-71. [[CrossRef](#)]
110. Yoo Jin Lee, Dong Wook Kim, Young Mi Park, Ha Kyoung Park, Soo Jin Jung, Do Hun Kim, Seok Mo Lee, Minkyung Oh. 2015. Comparison of sonographic and cytological diagnoses of solid thyroid nodules: Emphasis on the discordant cases. *Diagnostic Cytopathology* n/a-n/a. [[CrossRef](#)]
111. Ayse Arduc, Bercecm Aycicek Dogan, Mazhar Muslum Tuna, Yasemin Tutuncu, Serhat Isik, Dilek Berker, Serdar Guler. 2015. Higher body mass index and larger waist circumference may be predictors of thyroid carcinoma in patients with Hürthle-cell lesion/neoplasm fine-needle aspiration diagnosis. *Clinical Endocrinology* 83:10.1111/cen.2015.83.issue-3, 405-411. [[CrossRef](#)]
112. Steven Orlov, Farnaz Salari, Lawrence Kashat, Jeremy L. Freeman, Allan Vescan, Ian J. Witterick, Paul G. Walfish. 2015. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer. *Endocrine* 50, 130-137. [[CrossRef](#)]
113. S.C. Clement, R.P. Peeters, C.M. Ronckers, T.P. Links, M.M. van den Heuvel-Eibrink, E.J.M. Nieveen van Dijkum, R.R. van Rijn, H.J.H. van der Pal, S.J. Neggers, L.C.M. Kremer, B.L.F. van Eck-Smit, H.M. van Santen. 2015. Intermediate and long-

- term adverse effects of radioiodine therapy for differentiated thyroid carcinoma – A systematic review. *Cancer Treatment Reviews* . [[CrossRef](#)]
114. Bo-Ji Liu, Dan-Dan Li, Hui-Xiong Xu, Le-Hang Guo, Yi-Feng Zhang, Jun-Mei Xu, Chang Liu, Lin-Na Liu, Xiao-Long Li, Xiao-Hong Xu, Shen Qu, Mingzhao Xing. 2015. Quantitative Shear Wave Velocity Measurement on Acoustic Radiation Force Impulse Elastography for Differential Diagnosis between Benign and Malignant Thyroid Nodules: A Meta-analysis. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
115. Daniel C McFarland, Rajan P Dang, Brett A. Miles, Krzysztof Misiukiewicz. 2015. Four Difficult Thyroid Cancer Cases: Incorporating Medical Therapies. *Seminars in Oncology* . [[CrossRef](#)]
116. Mirela S. Petrulea, Theo S. Plantinga, Jan W. Smit, Carmen E. Georgescu, Romana T. Netea-Maier. 2015. PI3K/Akt/mTOR: A promising therapeutic target for non-medullary thyroid carcinoma. *Cancer Treatment Reviews* **41**, 707-713. [[CrossRef](#)]
117. Ozan Gökdoğan, Ahmet Koybasioglu, Erkin Ismail, Timucin Erol, Gokcen Alagoz, Banu Yagmurlu, Seref Komurcu. 2015. Hoarseness: an unusual presentation of primary thyroid lymphoma with laryngeal infiltration. *Brazilian Journal of Otorhinolaryngology* . [[CrossRef](#)]
118. Sendhil Rajan, Chitresh Kumar. 2015. Letter to the editor regarding association of vascular invasion with mortality in follicular thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
119. E. D. Rossi, T. Bizzarro, G. Fadda, A. Pontecorvi, V. Bernet, A. Nassar. 2015. The cytological diagnosis of a 'benign thyroid lesion': is it a real safe diagnosis for the patient?. *Cytopathology* n/a-n/a. [[CrossRef](#)]
120. Pablo Baquero, Eva Jiménez-Mora, Adrián Santos, Marina Lasa, Antonio Chiloeches. 2015. TGF $\beta$  induces epithelial-mesenchymal transition of thyroid cancer cells by both the BRAF/MEK/ERK and Src/FAK pathways. *Molecular Carcinogenesis* n/a-n/a. [[CrossRef](#)]
121. Ming-Hsun Wu, Wen T. Shen, Jessica Gosnell, Quan-Yang Duh. 2015. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer. *Head & Neck* **37**:10.1002/hed.v37.9, 1336-1343. [[CrossRef](#)]
122. Rui-Na Zhao, Bo Zhang, Xiao Yang, Yu-Xin Jiang, Xing-Jian Lai, Xiao-Yan Zhang. 2015. Logistic Regression Analysis of Contrast-Enhanced Ultrasound and Conventional Ultrasound Characteristics of Sub-centimeter Thyroid Nodules. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
123. D. Hartl. 2015. Tumori del corpo della tiroide. *EMC - Otorinolaringoiatria* **14**, 1-12. [[CrossRef](#)]
124. Wen-Bo Li, Bo Zhang, Qing-Li Zhu, Yu-Xin Jiang, Jian Sun, Meng Yang, Jian-Chu Li. 2015. Comparison between Thin-Slice 3-D Volumetric Ultrasound and Conventional Ultrasound in the Differentiation of Benign and Malignant Thyroid Lesions. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
125. Kenneth B. Ain. 2015. Radioiodine-remnant ablation in low-risk differentiated thyroid cancer: pros. *Endocrine* **50**, 61-66. [[CrossRef](#)]
126. Linwah Yip, Marina N. Nikiforova, Jenny Y. Yoo, Kelly L. McCoy, Michael T. Stang, Michael J. Armstrong, Kristina J. Nicholson, N. Paul Ohori, Christopher Coyne, Steven P. Hodak, Robert L. Ferris, Shane O. LeBeau, Yuri E. Nikiforov, Sally E. Carty. 2015. Tumor Genotype Determines Phenotype and Disease-related Outcomes in Thyroid Cancer. *Annals of Surgery* **262**, 519-525. [[CrossRef](#)]
127. Ryan W. Berg, Tina W. Yen, Douglas B. Evans, Bryan Hunt, Francisco A. Quiroz, Stuart D. Wilson, Tracy S. Wang. 2015. Analysis of an institutional protocol for thyroid lobectomy: Utility of routine intraoperative frozen section and expedited (overnight) pathology. *Surgery* . [[CrossRef](#)]
128. Nayana U. Patel, Kristin McKinney, Sarah M. Kreidler, Teresa M. Bieker, Paul Russ, Katherine Roberts, Deborah H. Glueck, Maria Albuja-Cruz, Joshua Klopper, Bryan R. Haugen. 2015. Ultrasound-based clinical prediction rule model for detecting papillary thyroid cancer in cervical lymph nodes: A pilot study. *Journal of Clinical Ultrasound* n/a-n/a. [[CrossRef](#)]
129. S C Del Duca, M G Santaguida, N Brusca, I Gatto, M Cellini, L Gargano, C Verga Falzacappa, F M Frattaroli, C Virili, M Centanni. 2015. Individually-tailored thyroxine requirement in the same patients before and after thyroidectomy: a longitudinal study. *European Journal of Endocrinology* **173**, 351-357. [[CrossRef](#)]
130. Moeber Mahzari, Amel Arnaout, Mark S. Freedman. 2015. Alemtuzumab Induced Thyroid Disease in Multiple Sclerosis: A Review and Approach to Management. *Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques* **42**, 284-291. [[CrossRef](#)]
131. Jong-Ryool Oh, Byeong-Cheol Ahn, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee. 2015. Radioiodine Scan Index: A Simplified, Quantitative Treatment Response Parameter for Metastatic Thyroid Carcinoma. *Nuclear Medicine and Molecular Imaging* **49**, 174-181. [[CrossRef](#)]

132. Hye Jeong Kim, Jae Hoon Chung. 2015. Reply to Letter to the Editor regarding association of vascular invasion with increased mortality in patients with minimally invasive follicular thyroid carcinoma but not widely invasive follicular thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
133. Le Zhao, Rong Jiang, Man Xu, Ping Zhu, Xiao-Mei Mo, Ni Wang, George G. Chen, Zhi-Min Liu. 2015. Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
134. Min-Hee Kim, Si Luo, Sun Hee Ko, Ja-Seong Bae, Jaechan Lim, Dong-Jun Lim, Yongmin Kim. 2015. Thyroid Nodule Parameters Influencing Performance of Ultrasound Elastography Using Intrinsic Compression. *Ultrasound in Medicine & Biology* 41, 2333-2339. [[CrossRef](#)]
135. Bin Xu, Ronald Ghossein. 2015. Encapsulated Thyroid Carcinoma of Follicular Cell Origin. *Endocrine Pathology* 26, 191-199. [[CrossRef](#)]
136. Ruoyang Shi, Qiuying Yao, Lianming Wu, Qinyi Zhou, Qing Lu, Runlin Gao, Jiani Hu, Leslie Kao, Ashika Bains, Zhaowen Yan, Yongming Dai, Jianrong Xu, Yan Zhou. 2015. T 2 \* mapping at 3.0T MRI for differentiation of papillary thyroid carcinoma from benign thyroid nodules. *Journal of Magnetic Resonance Imaging* n/a-n/a. [[CrossRef](#)]
137. I. Marturano, M. Russo, A. Spadaro, A. Latina, P. Malandrino, C. Regalbuto. 2015. Comparison of conventional l-thyroxine withdrawal and moderate hypothyroidism in preparation for whole-body 131-I scan and thyroglobulin testing. *Journal of Endocrinological Investigation* 38, 1017-1022. [[CrossRef](#)]
138. Edward G. Grant, Franklin N. Tessler, Jenny K. Hoang, Jill E. Langer, Michael D. Beland, Lincoln L. Berland, John J. Cronan, Terry S. Desser, Mary C. Frates, Ulrike M. Hamper, William D. Middleton, Carl C. Reading, Leslie M. Scoutt, A. Thomas Stavros, Sharlene A. Teefey. 2015. Thyroid Ultrasound Reporting Lexicon: White Paper of the ACR Thyroid Imaging, Reporting and Data System (TIRADS) Committee. *Journal of the American College of Radiology* . [[CrossRef](#)]
139. R.L. Cazzato, F. Bonichon, X. Buy, Y. Godbert, B.H. de Figueiredo, V. Pointillart, J. Palussière. 2015. Over ten years of single-institution experience in percutaneous image-guided treatment of bone metastases from differentiated thyroid cancer. *European Journal of Surgical Oncology (EJSO)* 41, 1247-1255. [[CrossRef](#)]
140. Christa L. Jillard, Randall P. Scheri, Julie Ann Sosa. 2015. What Is the Optimal Treatment of Papillary Thyroid Cancer?. *Advances in Surgery* 49, 79-93. [[CrossRef](#)]
141. Sung-Eun Yang, Peggy S. Sullivan, Jianhua Zhang, Rekha Govind, Mary R. Levin, Jian-Yu Rao, Neda A. Moatamed. 2015. Has Afirma gene expression classifier testing refined the indeterminate thyroid category in cytology?. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
142. Soo-Yeon Kim, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Jin Young Kwak. 2015. Application of Texture Analysis in the Differential Diagnosis of Benign and Malignant Thyroid Nodules: Comparison With Gray-Scale Ultrasound and Elastography. *American Journal of Roentgenology* 205, W343-W351. [[CrossRef](#)]
143. Linwah Yip. 2015. Risk-Directed Algorithms for Pediatric PTC Patients: Is It Time?. *World Journal of Surgery* 39, 2266-2268. [[CrossRef](#)]
144. Hyoung Shin Lee, Chanwoo Park, Sung Won Kim, Taejung Park, Bong Kwon Chun, Jong Chul Hong, Kang Dae Lee. 2015. Correlation of minimal extrathyroidal extension with pathologic features of lymph node metastasis in patients with papillary thyroid carcinoma. *Journal of Surgical Oncology* n/a-n/a. [[CrossRef](#)]
145. Bin Xu, Laura Wang, R. Michael Tuttle, Ian Ganly, Ronald Ghossein. 2015. Prognostic impact of extent of vascular invasion in low-grade encapsulated follicular cell-derived thyroid carcinomas: a clinicopathologic study of 278 cases. *Human Pathology* . [[CrossRef](#)]
146. Michal Mekel, Hayim Gilshtein, Abbas Al-Kurd, Bishara Bishara, Michael M. Krausz, Herbert R. Freund, Yoram Kluger, Ahmed Eid, Haggi Mazeh. 2015. Negative Fine-Needle Aspiration in Patients with Goiter: Should We Doubt It?. *World Journal of Surgery* . [[CrossRef](#)]
147. Zeming Liu, Tao Huang. 2015. Papillary Thyroid Microcarcinoma: An Over-Treated Malignancy?. *World Journal of Surgery* . [[CrossRef](#)]
148. Claudia Martinuzzi, Lorenza Pastorino, Virginia Andreotti, Anna Garuti, Michele Minuto, Roberto Fiocca, Giovanna Bianchi-Scarrà, Paola Ghiorzo, Federica Grillo, Luca Mastracci. 2015. A combination of immunohistochemistry and molecular approaches improves highly sensitive detection of BRAF mutations in papillary thyroid cancer. *Endocrine* . [[CrossRef](#)]
149. Christelle de la Fouchardiere, Nadia Oussaid, Olfä Derbel, Myriam Decaussin-Petrucci, Marie-Eve Fondrevelle, Qing Wang, Pierre-Paul Bringuier, Claire Bournaud-Salinas, Jean-Louis Peix, Jean-Christophe Lifante, Anne-Laure Giraudet, Jonathan Lopez, Françoise Borson-Chazot. 2015. Does Molecular Genotype Provide Useful Information in the Management of Radioiodine Refractory Thyroid Cancers? Results of a Retrospective Study. *Targeted Oncology* . [[CrossRef](#)]



150. Woo Jung Choi, Jung Hwan Baek, Young Jun Choi, Jeong Hyun Lee, Eun Ju Ha, Won Chan Lee, Hyun Kyung Lim, Won Bae Kim. 2015. Management of cystic or predominantly cystic thyroid nodules: role of simple aspiration of internal fluid. *Endocrine Research* 1-5. [[CrossRef](#)]
151. F. Tunca, I. C. Sormaz, Y. Iscan, Y. G. Senyurek, T. Terzioglu. 2015. Comparison of histopathological features and prognosis of classical and follicular variant papillary thyroid carcinoma. *Journal of Endocrinological Investigation* . [[CrossRef](#)]
152. Pitoia Fabián, Jerkovich Fernando, Urciuoli Carolina, Schmidt Angélica, Abelleira Erika, Bueno Fernanda, Cross Graciela, Tuttle R. Michael. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
153. Ralhan Ranju, Veyhl Joe, Chaker Seham, Assi Jasmeet, Alyass Akram, Jeganathan Ajitha, Somasundaram Raj Thani, MacMillan Christina, Freeman Jeremy, Vescan Allan D., Witterick Ian J., Walfish Paul G.. Immunohistochemical Subcellular Localization of Protein Biomarkers Distinguishes Benign from Malignant Thyroid Nodules: Potential for Fine-Needle Aspiration Biopsy Clinical Application. *Thyroid*, ahead of print. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
154. Ali Kagan Coskun. 2015. The Significance of BRAF V600e Mutation and Preoperative Ultrasound for Central Compartment Lymph Node Metastasis in Papillary Thyroid Microcarcinoma. *World Journal of Surgery* . [[CrossRef](#)]
155. Orgiazzi Jacques. 2015. Is the Replacement Dose of Levothyroxine Affected By the Presence of the Thyroid Gland?. *Clinical Thyroidology* 27:8, 205-208. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
156. Scheffel Rafael Selbach, Zanella André B., Antunes Denise, Dora José Miguel, Maia Ana Luiza. 2015. Low Recurrence Rates in a Cohort of Differentiated Thyroid Carcinoma Patients: A Referral Center Experience. *Thyroid* 25:8, 883-889. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
157. Seo Gi Hyeon, Cho Yoon Young, Chung Jae Hoon, Kim Sun Wook. 2015. Increased Risk of Leukemia After Radioactive Iodine Therapy in Patients with Thyroid Cancer: A Nationwide, Population-Based Study in Korea. *Thyroid* 25:8, 927-934. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
158. Choi Sang Hyun, Baek Jung Hwan, Lee Jeong Hyun, Choi Young Jun, Song Dong Eun, Chung Ki-Wook, Kim Tae Yong, Shong Young Kee. 2015. Evaluation of the Clinical Usefulness of BRAFV600E Mutation Analysis of Core-Needle Biopsy Specimens in Thyroid Nodules with Previous Atypia of Undetermined Significance or Follicular Lesions of Undetermined Significance Results. *Thyroid* 25:8, 897-903. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
159. Sang Hyun Choi, Jung Hwan Baek, Jeong Hyun Lee, Young Jun Choi, Eun Ju Ha, Dong Eun Song, Jae Kyun Kim, Ki-Wook Chung, Tae Yong Kim, Won Bae Kim, Young Kee Shong. 2015. Initial clinical experience with BRAF V600E mutation analysis of core-needle biopsy specimens from thyroid nodules. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
160. Yafu Yin, Qiufen Mao, Song Chen, Na Li, Xuena Li, Yaming Li. 2015. A Clinical Trial of Optimal Time Interval Between Ablation and Diagnostic Activity When a Pretherapy RAI Scanning Is Performed on Patients With Differentiated Thyroid Carcinoma. *Medicine* 94, e1308. [[CrossRef](#)]
161. Hwan Seo Lee, Jong-Lyel Roh, Gyungyup Gong, Kyung-Ja Cho, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim. 2015. Risk Factors for Re-recurrence After First Reoperative Surgery for Locoregional Recurrent/Persistent Papillary Thyroid Carcinoma. *World Journal of Surgery* 39, 1943-1950. [[CrossRef](#)]
162. Caroline E. Reinke, Elizabeth M. Sonnenberg, Giorgos C. Karakousis, Douglas L. Fraker, Rachel R. Kelz. 2015. Variation in cost of total thyroidectomy across the United States, 2007 to 2008. *The American Journal of Surgery* 210, 302-308. [[CrossRef](#)]
163. A. Gandhi, B. Ranganathan, S.A. Thiryayi, M. Rowland, B.K. Yap. 2015. Variations in single/two stage thyroidectomies for cancer may be due to differences in thyroid fine needle cytology provision. *European Journal of Surgical Oncology (EJSO)* 41, 1033-1038. [[CrossRef](#)]
164. Cristina Ogrin, Bradley A. Ford, Stephanie L. Stauffer, Matthew D. Krasowski, Antoine E. Azar. 2015. POSITIVE TEST FOR ANTITHYROGLOBULIN ANTIBODIES DUE TO ADMINISTRATION OF IMMUNOGLOBULIN REPLACEMENT THERAPY IN A PATIENT WITH THYROID CANCER. *Endocrine Practice* 21, 966-971. [[CrossRef](#)]
165. Hee Jung Moon, Hye Sun Lee, Eun-Kyung Kim, Su Yeon Ko, Jae Young Seo, Woon Ju Park, Hye Young Park, Jin Young Kwak. 2015. Thyroid nodules ≤5 mm on ultrasonography: are they “leave me alone” lesions?. *Endocrine* 49, 735-744. [[CrossRef](#)]
166. Dania Hirsch, Eyal Robenshtok, Gideon Bachar, Diana Braslavsky, Carlos Benbassat. 2015. The Implementation of the Bethesda System for Reporting Thyroid Cytopathology Improves Malignancy Detection Despite Lower Rate of Thyroidectomy in Indeterminate Nodules. *World Journal of Surgery* 39, 1959-1965. [[CrossRef](#)]

167. Jong-In Na, Jo-Heon Kim, Hye-Jeong Kim, Hee-Kyung Kim, Kyung-Sub Moon, Ji-Shin Lee, Jae-Hyuk Lee, Kyung-Hwa Lee, Jong-Tae Park. 2015. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations. *Virchows Archiv* **467**, 155-168. [[CrossRef](#)]
168. Karen Gomez-Hernandez, Shereen Ezzat. 2015. Lessons learned from thyroglobulin concentrations after total thyroidectomy and radioactive iodine ablation for differentiated thyroid cancer. *Clinical Biochemistry* **48**, 747-748. [[CrossRef](#)]
169. Seog Yun Park, Yuh-S Jung, Chang Hwan Ryu, Chang Yoon Lee, You Jin Lee, Eun Kyung Lee, Seok-Ki Kim, Tae Sung Kim, Tae Hyun Kim, Jeyun Jang, Daeyoon Park, Seung Myung Dong, Jae-Goo Kang, Jin Soo Lee, Junsun Ryu. 2015. Identification of occult tumors by whole-specimen mapping in solitary papillary thyroid carcinoma. *Endocrine-Related Cancer* **22**, 679-686. [[CrossRef](#)]
170. Riccardo Giannini, Liborio Torregrossa, Stefano Gottardi, Lorenzo Fregoli, Nicla Borrelli, Mauro Savino, Elisabetta Macerola, Paolo Vitti, Paolo Miccoli, Fulvio Basolo. 2015. Digital gene expression profiling of a series of cytologically indeterminate thyroid nodules. *Cancer Cytopathology* **123**:10.1002/cncy.v123.8, 461-470. [[CrossRef](#)]
171. Juan P. Brito, M. Regina Castro, Diana S. Dean, Vahab Fatourechi, Marius Stan. 2015. Survey of current approaches to non-diagnostic fine-needle aspiration from solid thyroid nodules. *Endocrine* **49**, 745-751. [[CrossRef](#)]
172. Laura Y. Wang, Benjamin R. Roman, Jocelyn C. Migliacci, Frank L. Palmer, R. Michael Tuttle, Ashok R. Shaha, Jatin P. Shah, Snehal G. Patel, Ian Ganly. 2015. Cost-effectiveness analysis of papillary thyroid cancer surveillance. *Cancer* n/a-n/a. [[CrossRef](#)]
173. Frederik A. Verburg, Uwe Mäder, Markus Luster, Heribert Häscheid, Christoph Reiners. 2015. Determinants of successful ablation and complete remission after total thyroidectomy and 131I therapy of paediatric differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* **42**, 1390-1398. [[CrossRef](#)]
174. Erik K. Alexander. 2015. Improving the approach to non-diagnostic aspirates: learning from each other. *Endocrine* **49**, 575-576. [[CrossRef](#)]
175. Robert L. Witt. 2015. Outcome of thyroid gene expression classifier testing in clinical practice. *The Laryngoscope* n/a-n/a. [[CrossRef](#)]
176. Svetlana Paskaš, Jelena Janković, Vladan Živaljević, Svetislav Tatić, Vesna Božić, Aleksandra Nikolić, Dragica Radojković, Svetlana Savin, Dubravka Cvejić. 2015. Malignant risk stratification of thyroid FNA specimens with indeterminate cytology based on molecular testing. *Cancer Cytopathology* **123**:10.1002/cncy.v123.8, 471-479. [[CrossRef](#)]
177. C. L. Chng, T. Beale, Y. Adjei-Gyamfi, Y. Gupta, G. Kocjan. 2015. The role of the cytopathologist's interpretation in achieving diagnostic adequacy of head and neck fine needle aspirates. *Cytopathology* **26**:10.1111/cyt.2015.26.issue-4, 224-230. [[CrossRef](#)]
178. Jin Young Park, Dong Wook Kim, Ha Kyung Park, Tae Kwun Ha, Soo Jin Jung, Do Hun Kim, Sang Kyun Bae. 2015. Comparison of T stage, N stage, multifocality, and bilaterality in papillary thyroid carcinoma patients according to the presence of coexisting lymphocytic thyroiditis. *Endocrine Research* **40**, 151-155. [[CrossRef](#)]
179. Adriana Sondermann, Flavia Maziero Andreghetto, Ana Carolina Bernardini Moulatlet, Elivane da Silva Victor, Marilia Germanos de Castro, Fábio Dumas Nunes, Lenine Garcia Brandão, Patricia Severino. 2015. MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. *Clinical & Experimental Metastasis* **32**, 521-530. [[CrossRef](#)]
180. Heywood Choi, Katayoon Kasaian, Adrienne Melck, Kaye Ong, Steven J.M. Jones, Adam White, Sam M. Wiseman. 2015. Papillary thyroid carcinoma: prognostic significance of cancer presentation. *The American Journal of Surgery* **210**, 298-301. [[CrossRef](#)]
181. Lucas Leite Cunha, Marjory Alana Marcello, Suely Nonogaki, Elaine Cristina Morari, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward. 2015. CD8+ tumour-infiltrating lymphocytes and COX2 expression may predict relapse in differentiated thyroid cancer. *Clinical Endocrinology* **83**:10.1111/cen.2015.83.issue-2, 246-253. [[CrossRef](#)]
182. Karen E. Schoedel, Jenna Wolfe, Steven P. Hodak, Shane O. Lebeau, Linwah Yip, Sally E. Carty, Marina N. Nikiforova, Yuri E. Nikiforov, N. Paul Otori. 2015. Significance of what is not sampled: Characteristics of thyroid nonmicrocarcinomas (>1.0 cm) that were not targeted. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
183. Vinay T. Fernandes, Matthew J. R. Magarey, Dev P. Kamdar, Jeremy L. Freeman. 2015. Surgeon performed ultrasound-guided fine-needle aspirates of the thyroid: 1067 biopsies and learning curve in a teaching center. *Head & Neck* n/a-n/a. [[CrossRef](#)]
184. Emilie Wang, Tezo Karedan, Cesar A. Perez. 2015. New insights in the treatment of radioiodine refractory differentiated thyroid carcinomas. *Anti-Cancer Drugs* **26**, 689-697. [[CrossRef](#)]
185. Lei Zhang, Thomas Krausz, Richard M. DeMay. 2015. A Pilot Study of Galectin-3, HBME-1, and p27 Triple Immunostaining Pattern for Diagnosis of Indeterminate Thyroid Nodules in Cytology With Correlation to Histology. *Applied Immunohistochemistry & Molecular Morphology* **23**, 481-490. [[CrossRef](#)]

186. Parisha Bhatia, Zakaria Y Abd Elmageed, Paul Friedlander, Rizwan Aslam, Emad Kandil. 2015. The utility of molecular markers in pre-operative assessment of thyroid nodules. *Future Oncology* **11**, 2343-2350. [[CrossRef](#)]
187. Seo Ki Kim, Jun Ho Lee, Jung-Woo Woo, Inhye Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim. 2015. BRAF V600E mutation: Differential impact on central lymph node metastasis by tumor size in papillary thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
188. Domenico Damiani, Voichita Suci, Philippe Vielh. 2015. Cytopathology of Follicular Cell Nodules. *Endocrine Pathology* . [[CrossRef](#)]
189. E. M. Triviño Ibáñez, M. A. Muros, E. Torres Vela, J. M. Llamas Elvira. 2015. The role of early 18F-FDG PET/CT in therapeutic management and ongoing risk stratification of high/intermediate-risk thyroid carcinoma. *Endocrine* . [[CrossRef](#)]
190. Charoonsak Somboonporn, Chetta Ngamjarus, Kannika Chatham, Krisana Roysri. Low- versus high-dose of radioiodine for thyroid remnant ablation in differentiated thyroid carcinoma after thyroidectomy . [[CrossRef](#)]
191. Jandee Lee, Cho Rok Lee, Cheol Ryong Ku, Sang-Wook Kang, Jong Ju Jeong, Dong Yeob Shin, Kee-Hyun Nam, Sang Geun Jung, Eun Jig Lee, Woong Youn Chung, Young Suk Jo. 2015. Association Between Obesity and BRAFV600E Mutation Status in Patients with Papillary Thyroid Cancer. *Annals of Surgical Oncology* . [[CrossRef](#)]
192. Heejin Kim, Hahn Jin Jung, Sang Yeon Lee, Tack-Kyun Kwon, Kwang Hyun Kim, Myung-Whun Sung, J. Hun Hah. 2015. Prognostic factors of locally invasive well-differentiated thyroid carcinoma involving the trachea. *European Archives of Oto-Rhino-Laryngology* . [[CrossRef](#)]
193. Silvia Martina Ferrari, Ugo Politti, Roberto Spisni, Gabriele Materazzi, Enke Baldini, Salvatore Ulisse, Paolo Miccoli, Alessandro Antonelli, Poupak Fallahi. 2015. Sorafenib in the treatment of thyroid cancer. *Expert Review of Anticancer Therapy* 1-12. [[CrossRef](#)]
194. Pierpaolo Trimboli, Leo Guidobaldi, Stefano Amendola, Naim Nasrollah, Francesco Romanelli, Daniela Attanasio, Giovanni Ramacciato, Enrico Saggiorato, Stefano Valabrega, Anna Crescenzi. 2015. Galectin-3 and HBME-1 improve the accuracy of core biopsy in indeterminate thyroid nodules. *Endocrine* . [[CrossRef](#)]
195. Makhija Chhaya, Su Yungpo Bernard, Goldner Whitney. 2015. Unusual Case of Papillary Thyroid Carcinoma with Choroidal Metastasis. *Thyroid* **25**:7, 860-864. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
196. Nakamura Hiroto, Hirokawa Mitsuyoshi, Ota Hisashi, Kihara Minoru, Miya Akihiro, Miyauchi Akira. 2015. Is an Increase in Thyroid Nodule Volume a Risk Factor for Malignancy?. *Thyroid* **25**:7, 804-811. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
197. Rosario Pedro Wesley, Mourão Gabriela Franco, Siman Thássio Leonardo, Calsolari Maria Regina. 2015. Serum Thyroglobulin Measured With a Second-Generation Assay in Patients Undergoing Total Thyroidectomy Without Radioiodine Remnant Ablation: A Prospective Study. *Thyroid* **25**:7, 769-775. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
198. Marti Jennifer L., Davies Louise, Haymart Megan R., Roman Benjamin R., Tuttle R. Michael, Morris Luc G.T.. 2015. Inappropriate Use of Radioactive Iodine for Low-Risk Papillary Thyroid Cancer Is Most Common in Regions with Poor Access to Healthcare. *Thyroid* **25**:7, 865-866. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
199. Wu James X., Beni Catherine E., Zanocho Kyle A., Sturgeon Cord, Yeh Michael W.. 2015. Cost-Effectiveness of Long-Term Every Three-Year Versus Annual Postoperative Surveillance for Low-Risk Papillary Thyroid Cancer. *Thyroid* **25**:7, 797-803. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
200. Francis Gary L., Waguespack Steven G., Bauer Andrew J., Angelos Peter, Benvenga Salvatore, Cerutti Janete M., Dinauer Catherine A., Hamilton Jill, Hay Ian D., Luster Markus, Parisi Marguerite T., Rachmiel Marianna, Thompson Geoffrey B., Yamashita Shunichi. 2015. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. *Thyroid* **25**:7, 716-759. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
201. LaFranchi Stephen H.. 2015. Inaugural Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer: Children Are Not Small Adults. *Thyroid* **25**:7, 713-715. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
202. Vivian Y. Park, Eun-Kyung Kim, Hye Sun Lee, Hee Jung Moon, Jung Hyun Yoon, Jin Young Kwak. 2015. Real-Time PCR Cycle Threshold Values for the BRAFV600E Mutation in Papillary Thyroid Microcarcinoma May Be Associated With Central Lymph Node Metastasis. *Medicine* **94**, e1149. [[CrossRef](#)]
203. A.J.M. Ortega, R.G. Vázquez, J.I.C. Cuenca, M.A.M. Brocca, J. Castilla, J.M.M. Martínez, E.N. González. 2015. 131I treatment in Differentiated Thyroid Cancer and End-Stage Renal Disease. *Revista Española de Medicina Nuclear e Imagen Molecular* . [[CrossRef](#)]
204. Nollaig O Donohoe, R. Kintu-Luwaga, Jarleth Bolger, Jane Odubu Fualal. 2015. A Prospective Analysis of Thyroidectomy Outcomes in a Resource-Limited Setting. *World Journal of Surgery* **39**, 1708-1711. [[CrossRef](#)]

205. Chandrasekhar Bal, Sanjana Ballal, Ramya Soundararajan, Saurav Chopra, Aayushi Garg. 2015. Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment. *Cancer Medicine* 4:10.1002/cam4.2015.4.issue-7, 1031-1038. [[CrossRef](#)]
206. Marco Raffaelli, Carmela De Crea, Luca Sessa, Guido Fadda, Chiara Bellantone, Celestino P. Lombardi. 2015. Ipsilateral Central Neck Dissection Plus Frozen Section Examination Versus Prophylactic Bilateral Central Neck Dissection in cN0 Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* 22, 2302-2308. [[CrossRef](#)]
207. Ali S. Alzahrani, Dania Alkhafaji, Mahmoud Tuli, Hindi Al-Hindi, Bakr Bin Sadiq. 2015. Comparison of differentiated thyroid cancer in children and adolescents ( $\leq 20$  years) with young adults. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
208. Altay Aliyev, Manjula Gupta, Christian Nasr, Betul Hatipoglu, Mira Milas, Allan Siperstein, Eren Berber. 2015. CIRCULATING THYROID-STIMULATING HORMONE RECEPTOR MESSENGER RNA AS A MARKER OF TUMOR AGGRESSIVENESS IN PATIENTS WITH PAPILLARY THYROID MICROCARCINOMA. *Endocrine Practice* 21, 777-781. [[CrossRef](#)]
209. Hyungju Kwon, June Young Choi, Jae Hoon Moon, Hyo Jin Park, Won Woo Lee, Kyu Eun Lee. 2015. Effect of Hashimoto thyroiditis on low-dose radioactive-iodine remnant ablation. *Head & Neck* n/a-n/a. [[CrossRef](#)]
210. Altay Aliyev, Saranya Soundararajan, Emre Bucak, Manjula Gupta, Betul Hatipoglu, Christian Nasr, Allan Siperstein, Eren Berber. 2015. The utility of peripheral thyrotropin receptor mRNA in the management of differentiated thyroid cancer. *Surgery* . [[CrossRef](#)]
211. Charlotte Demoor-Goldschmidt, Chiraz Fayeche, Pauline Girard, Dominique Plantaz. 2015. Tumeurs secondaires : incidence, facteurs de risque et recommandations de prévention. *Bulletin du Cancer* 102, 656-664. [[CrossRef](#)]
212. Laura Y. Wang, Frank L. Palmer, Jocelyn C. Migliacci, Iain J. Nixon, Ashok R. Shaha, Jatin P. Shah, Robert Michael Tuttle, Snehal G. Patel, Ian Ganly. 2015. Role of RAI in the management of incidental N1a disease in papillary thyroid cancer. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
213. Josephine H. Li, Zhiheng H. He, Vivek Bansal, James V. Hennessey. 2015. Low iodine diet in differentiated thyroid cancer: a review. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
214. S M Keh, S K El-Shunnar, T Palmer, S F Ahsan. 2015. Incidence of malignancy in solitary thyroid nodules. *The Journal of Laryngology & Otology* 129, 677-681. [[CrossRef](#)]
215. Olov Norlén, Amanda Charlton, Leba M. Sarkis, Tony Henwood, Albert Shun, Anthony J. Gill, Leigh Delbridge. 2015. Risk of malignancy for each Bethesda class in pediatric thyroid nodules. *Journal of Pediatric Surgery* 50, 1147-1149. [[CrossRef](#)]
216. Fabio Pagni, Vincenzo L'Imperio, Francesca Bono, Mattia Garancini, Gaia Roversi, Gabriele De Sio, Manuel Galli, Andrew James Smith, Clizia Chinello, Fulvio Magni. 2015. Proteome analysis in thyroid pathology. *Expert Review of Proteomics* 1-16. [[CrossRef](#)]
217. Saïd C. Azoury, Rachel Aufforth, Mei He, Zhiming Yang, Naris Nilubol, Electron Kebebew. 2015. Quantitative reverse transcription polymerase chain reaction-based detection of thyroid-specific gene expression in fine-needle aspirate for thyroid cancer recurrence evaluation: A case report and review of the literature. *Head & Neck* n/a-n/a. [[CrossRef](#)]
218. Jason A. Glenn, Tina W.F. Yen, Gilbert G. Fareau, Azadeh A. Carr, Douglas B. Evans, Tracy S. Wang. 2015. Institutional experience with lateral neck dissections for thyroid cancer. *Surgery* . [[CrossRef](#)]
219. Myung Chul Lee, Hoon Park, Byeong-Cheol Lee, Guk-Haeng Lee, Ik Joon Choi. 2015. Comparison of quality of life between open and endoscopic thyroidectomy for papillary thyroid cancer. *Head & Neck* n/a-n/a. [[CrossRef](#)]
220. Hui Qu, Guo-rui Sun, Yao Liu, Qing-si He. 2015. Clinical risk factors for central lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis. *Clinical Endocrinology* 83:10.1111/cen.2015.83.issue-1, 124-132. [[CrossRef](#)]
221. Patricia Papendieck, Laura Gruñeiro-Papendieck, Marcela Venara, Oscar Acha, Hugo Cozzani, Fernanda Mateos, Silvana Maglio, Maria Lujan Calcagno, Ignacio Bergada, Ana Chiesa. 2015. Differentiated Thyroid Cancer in Children: Prevalence and Predictors in a Large Cohort with Thyroid Nodules Followed Prospectively. *The Journal of Pediatrics* 167, 199-201. [[CrossRef](#)]
222. Elisabeth Gschwandtner, Tobias Klatte, Natalia Swietek, Claudia Bures, Friedrich Kober, Johannes Ott, Andrea Schultheis, Nikolaus Neuhold, Michael Hermann. 2015. Increase of papillary thyroid microcarcinoma and a plea for restrictive treatment: A retrospective study of 1,391 prospective documented patients. *Surgery* . [[CrossRef](#)]
223. Y. Che, S. Jin, C. Shi, L. Wang, X. Zhang, Y. Li, J. H. Baek. 2015. Treatment of Benign Thyroid Nodules: Comparison of Surgery with Radiofrequency Ablation. *American Journal of Neuroradiology* 36, 1321-1325. [[CrossRef](#)]
224. Young Chan Lee, Young Gyu Eun, Yu-Mee Sohn, Sang Youl Rhee, Il Ki Hong, Suk Chon, Seung Joon Oh, Deog Yoon Kim. 2015. Predictive Factors for Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma by Preoperative Ultrasonographic and Pathological Features. *World Journal of Surgery* 39, 1736-1741. [[CrossRef](#)]

225. Giorgio Treglia, Pierpaolo Trimboli, Frederik A. Verburg, Markus Luster, Luca Giovannella. 2015. Prevalence of normal TSH value among patients with autonomously functioning thyroid nodule. *European Journal of Clinical Investigation* **45**:10.1111/eci.2015.45.issue-7, 739-744. [[CrossRef](#)]
226. Giriraj K. Sharma, Vaninder K. Dhillon, Rizwan Masood, Dennis R. Maceri. 2015. Overexpression of EphB4, EphrinB2, and epidermal growth factor receptor in papillary thyroid carcinoma: A pilot study. *Head & Neck* **37**:10.1002/hed.v37.7, 964-969. [[CrossRef](#)]
227. Ah Reum Khang, Sun Wook Cho, Hoon Sung Choi, Hwa Young Ahn, Won Sang Yoo, Kyung Won Kim, Keon Wook Kang, Ka Hee Yi, Do Joon Park, Dong Soon Lee, June-Key Chung, Bo Youn Cho, Young Joo Park. 2015. The risk of second primary malignancy is increased in differentiated thyroid cancer patients with a cumulative 131 I dose over 37 GBq. *Clinical Endocrinology* **83**:10.1111/cen.2015.83.issue-1, 117-123. [[CrossRef](#)]
228. Sara Abu-Ghanem, Oded Cohen, Anna Lazutkin, Yasmin Abu-Ghanem, Dan M. Fliss, Moshe Yehuda. 2015. Evaluation of clinical presentation and referral indications for ultrasound-guided fine-needle aspiration biopsy of the thyroid as possible predictors of thyroid cancer. *Head & Neck* n/a-n/a. [[CrossRef](#)]
229. Hyobin Seo, Dong Gyu Na, Ji-Hoon Kim, Kyung Won Kim, Ji Won Yoon. 2015. Ultrasound-Based Risk Stratification for Malignancy in Thyroid Nodules: A Four-Tier Categorization System. *European Radiology* **25**, 2153-2162. [[CrossRef](#)]
230. Alejandro Martí, Alfredo Romero-Rojas, Orlando Mojica, Diana Cuéllar. 2015. Metástasis pancreática, sitio inusual de diseminación por cáncer de tiroides. Documentada por PET CT/FDG y estudio histopatológico. *Revista Colombiana de Cancerología* **19**, 184-190. [[CrossRef](#)]
231. Melissa Ng, Sam M Wiseman. 2015. Utility of sentinel lymph node biopsy for thyroid cancer: a comprehensive review. *Expert Review of Endocrinology & Metabolism* **10**, 399-411. [[CrossRef](#)]
232. Reza Vali, Marianna Rachmiel, Jill Hamilton, Mohamad El Zein, Jonathan Wasserman, Danny L. Costantini, Martin Charron, Alan Daneman. 2015. The role of ultrasound in the follow-up of children with differentiated thyroid cancer. *Pediatric Radiology* **45**, 1039-1045. [[CrossRef](#)]
233. Elisabeth Mamelle, Isabelle Borget, Sophie Leboulleux, Haïtham Mirghani, Carlos Suárez, Phillip K. Pellitteri, Ashok R. Shaha, Marc Hamoir, K. Thomas Robbins, Avi Khafif, Juan P. Rodrigo, Carl E. Silver, Alessandra Rinaldo, Alfio Ferlito, Dana M. Hartl. 2015. Impact of prophylactic central neck dissection on oncologic outcomes of papillary thyroid carcinoma: a review. *European Archives of Oto-Rhino-Laryngology* **272**, 1577-1586. [[CrossRef](#)]
234. Sophocles Lanitis, V. Ganis, G. Sgourakis, P. Brotzakis, A. Bryonidou, C. Karaliotas. 2015. Occult cancer after thyroidectomy for benign thyroid disorders. Is total thyroidectomy justified based on these grounds?. *Hellenic Journal of Surgery* **87**, 309-316. [[CrossRef](#)]
235. Feng-Hsuan Liu, Sheng-Fong Kuo, Chuen Hsueh, Tzu-Chieh Chao, Jen-Der Lin. 2015. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis. *Journal of Surgical Oncology* n/a-n/a. [[CrossRef](#)]
236. Robert L. Witt, V. Raman Sukumar, Fady Gerges. 2015. Surgeon-performed ultrasound-guided FNAC with on-site cytopathology improves adequacy and accuracy. *The Laryngoscope* **125**:10.1002/lary.v125.7, 1633-1636. [[CrossRef](#)]
237. Roberto Garberoglio, Camillo Aliberti, Marialuisa Appetecchia, Marco Attard, Giuseppe Bocuzzi, Flavio Boraso, Giorgio Borretta, Giuseppe Caruso, Maurilio Deandrea, Milena Freddi, Gabriella Gallone, Giovanni Gandini, Guido Gasparri, Carlo Gazzera, Ezio Ghigo, Maurizio Grosso, Paolo Limone, Mauro Maccario, Luigi Mansi, Alberto Mormile, Pier Giorgio Nasi, Fabio Orlandi, Donatella Pacchioni, Claudio Maurizio Pacella, Nicola Palestini, Enrico Papini, Maria Rosa Pelizzo, Andrea Piotto, Teresa Rago, Fabrizio Riganti, Lodovico Rosato, Ruth Rossetto, Antonio Scarmozzino, Stefano Spiezia, Ornella Testori, Roberto Valcavi, Andrea Veltri, Paolo Vitti, Matteo Zingrillo. 2015. Radiofrequency ablation for thyroid nodules: which indications? The first Italian opinion statement. *Journal of Ultrasound* . [[CrossRef](#)]
238. Chan Kwon Jung, Hye Sook Min, Hyo Jin Park, Dong Eun Song, Jang Hee Kim, So Yeon Park, Hyunju Yoo, Mi Kyung Shin. 2015. Pathology Reporting of Thyroid Core Needle Biopsy: A Proposal of the Korean Endocrine Pathology Thyroid Core Needle Biopsy Study Group. *Journal of Pathology and Translational Medicine* . [[CrossRef](#)]
239. Paolo Goffredo, Christa Jillard, Samantha Thomas, Randall P. Scheri, Julie Ann Sosa, Sanziana Roman. 2015. Minimally invasive follicular carcinoma: predictors of vascular invasion and impact on patterns of care. *Endocrine* . [[CrossRef](#)]
240. E. S. Mendoza, A. A. Lopez, V. A. U. Valdez, E. C. Cunanan, B. J. Matawaran, S. A. Kho, M. H. Sero-Gomez. 2015. Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital. *Journal of Endocrinological Investigation* . [[CrossRef](#)]
241. Lu Yonggang, Moreira Andre L., Hatzoglou Vaios, Stambuk Hilda E., Gonen Mithat, Mazaheri Yousef, Deasy Joseph O., Shaha Ashok R., Tuttle R. Michael, Shukla-Dave Amita. 2015. Using Diffusion-Weighted MRI to Predict Aggressive Histological

- Features in Papillary Thyroid Carcinoma: A Novel Tool for Pre-Operative Risk Stratification in Thyroid Cancer. *Thyroid* 25:6, 672-680. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
242. Sacks Wendy. 2015. What Are Treatment Considerations for Pregnant Women with Thyroid Cancer?. *Clinical Thyroidology* 27:6, 158-161. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
243. Hershman Jerome M.. 2015. Ablative RAI Therapy Improves Overall Survival of Patients with Intermediate-Risk Papillary Thyroid Cancer. *Clinical Thyroidology* 27:6, 147-149. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
244. Marti Jennifer L., Jain Kunal S., Morris Luc G.T.. 2015. Increased Risk of Second Primary Malignancy in Pediatric and Young Adult Patients Treated with Radioactive Iodine for Differentiated Thyroid Cancer. *Thyroid* 25:6, 681-687. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
245. Yi Kyung Sik, Kim Ji-hoon, Na Dong Gyu, Seo Hyobin, Min Hye Sook, Won Jae-Kyung, Yun Tae Jin, Ryoo Inseon, Kim Su Chin, Choi Seung Hong, Sohn Chul-Ho. 2015. Usefulness of Core Needle Biopsy for Thyroid Nodules with Macrocalcifications: Comparison with Fine-Needle Aspiration. *Thyroid* 25:6, 657-664. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
246. Yang Jingge, Wang Cunchuan, Li Jinyi, Yang Wah, Cao Guo, Wong Hong-meng, Zhai Hening, Liu Weijun. 2015. Complete Endoscopic Thyroidectomy via Oral Vestibular Approach Versus Areola Approach for Treatment of Thyroid Diseases. *Journal of Laparoendoscopic & Advanced Surgical Techniques* 25:6, 470-476. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
247. Soizic Masson-Deshayes, Claire Schwartz, Cécile Dalban, Sofiane Guendouzen, Jean-Marie Pochart, Audrey Dalac, Sandrine Fieffe, Claire Bruna-Muraille, Tienhan Sandrine Dabakuyo-Yonli, Dimitri Papathanassiou. 2015. Prognostic Value of 18F-FDG PET/CT Metabolic Parameters in Metastatic Differentiated Thyroid Cancers. *Clinical Nuclear Medicine* 40, 469-475. [CrossRef]
248. Valeria M. Moncayo, Kimberly E. Applegate, Richard Duszak, Bruce J. Barron, Jim Fitz, Raghuvver K. Halkar, Daniel J. Lee, David M. Schuster. 2015. The Nuclear Medicine Therapy Care Coordination Service. *Academic Radiology* 22, 771-778. [CrossRef]
249. T. Wei, R. Chen, X. Zou, F. Liu, Z. Li, J. Zhu. 2015. Predictive factors of contralateral paratracheal lymph node metastasis in unilateral papillary thyroid carcinoma. *European Journal of Surgical Oncology (EJSO)* 41, 746-750. [CrossRef]
250. Lindsey Enewold, Linda C. Harlan, Jennifer L. Stevens, Elad Sharon. 2015. Thyroid Cancer Presentation and Treatment in the United States. *Annals of Surgical Oncology* 22, 1789-1797. [CrossRef]
251. Chang Myeon Song, Dong Won Lee, Yong Bae Ji, Jin Hyeok Jeong, Jung Hwan Park, Kyung Tae. 2015. Frequency and pattern of central lymph node metastasis in papillary carcinoma of the thyroid isthmus. *Head & Neck* n/a-n/a. [CrossRef]
252. B.H.-H. Lang, C. KH Wong, C. TY Chan. 2015. Initial attributable cost and economic burden of clinically-relevant differentiated thyroid cancer: A health care service provider perspective. *European Journal of Surgical Oncology (EJSO)* 41, 758-765. [CrossRef]
253. Paola Catanuto, Jun Tashiro, Ferenc G. Rick, Patricia Sanchez, Carmen C. Solorzano, Marilyn K. Glassberg, Norman L. Block, John I. Lew, Sharon J. Elliot, Andrew V. Schally. 2015. Expression of Receptors for Pituitary-Type Growth Hormone-Releasing Hormone (pGHRH-R) in Human Papillary Thyroid Cancer Cells: Effects of GHRH Antagonists on Matrix Metalloproteinase-2. *Hormones and Cancer* 6, 100-106. [CrossRef]
254. John. C. Hardman, J. A. Smith, P. Nankivell, N. Sharma, J. C. Watkinson. 2015. Re-operative thyroid surgery: a 20-year prospective cohort study at a tertiary referral centre. *European Archives of Oto-Rhino-Laryngology* 272, 1503-1508. [CrossRef]
255. Francisco Igor B. Macedo, Vijay K. Mittal. 2015. Total thyroidectomy versus lobectomy as initial operation for small unilateral papillary thyroid carcinoma: A meta-analysis. *Surgical Oncology* 24, 117-122. [CrossRef]
256. Cihad Hamidi, Cemil Göya, Salih Hattapoğlu, Ömer Uslukaya, Memik Teke, Mehmet Sedat Durmaz, Mehmet Siddik Yavuz, Arif Hamidi, Güven Tekbaş. 2015. Acoustic Radiation Force Impulse (ARFI) imaging for the distinction between benign and malignant thyroid nodules. *La radiologia medica* 120, 579-583. [CrossRef]
257. James C. Lee, Jing-Ting Zhao, Justin Gundara, Jonathan Serpell, Leon A. Bach, Stan Sidhu. 2015. Papillary thyroid cancer-derived exosomes contain miRNA-146b and miRNA-222. *Journal of Surgical Research* 196, 39-48. [CrossRef]
258. Yingjie Zhang, Jun Liang, Xue Yang, Ke Yang, Yansong Lin. 2015. Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin. *Nuclear Medicine Communications* 36, 553-559. [CrossRef]
259. M. Lee, Y.K. Lee, T.J. Jeon, H.S. Chang, B.-W. Kim, Y.S. Lee, C.S. Park, Y.H. Ryu. 2015. Frequent visualization of thyroglossal duct remnant on post-ablation 131I-SPECT/CT and its clinical implications. *Clinical Radiology* 70, 638-643. [CrossRef]

260. Ziauddin Zia Saad, John R. Buscombe. 2015. Sentinel lymph node: established and new areas of use. *Clinical and Translational Imaging* **3**, 225-236. [[CrossRef](#)]
261. Ioannis Iakovou, Dimitrios G. Goulis, Zinovia Tsinaslanidou, Evanthia Giannoula, Grammatiki Katsikaki, Iordanis Konstantinidis. 2015. Effect of recombinant human thyroid-stimulating hormone or levothyroxine withdrawal on salivary gland dysfunction after radioactive iodine administration for thyroid remnant ablation. *Head & Neck* n/a-n/a. [[CrossRef](#)]
262. Lauren E. Henke, John D. Pfeifer, Changqing Ma, Stephanie M. Perkins, Todd DeWees, Samir El-Mofty, Jeffrey F. Moley, Brian Nussenbaum, Bruce H. Haughey, Thomas J. Baranski, Julie K. Schwarz, Perry W. Grigsby. 2015. BRAF mutation is not predictive of long-term outcome in papillary thyroid carcinoma. *Cancer Medicine* **4**:10.1002/cam4.2015.4.issue-6, 791-799. [[CrossRef](#)]
263. Charles Marcus, Alexander Antoniou, Arman Rahmim, Paul Ladenson, Rathan M Subramaniam. 2015. Fluorodeoxyglucose positron emission tomography/computerized tomography in differentiated thyroid cancer management: Importance of clinical justification and value in predicting survival. *Journal of Medical Imaging and Radiation Oncology* **59**:10.1111/jmro.2015.59.issue-3, 281-288. [[CrossRef](#)]
264. Zhaowei Meng, Jian Tan, Guizhi Zhang, Weijun Tian, Qiang Fu, Weidong Li, Xianghui He, Shuanghu Wu, Zhiqiang Yang, Xiaoyu Liang, Liyan Dong, Qing Zhang, Li Liu, Yujie Zhang, Ke Xu, Boning Liu, Ning Li, Xue Li, Qiang Jia, Yajing He, Sheng Wang, Renfei Wang, Wei Zheng, Xinghua Song, Jianping Zhang, Tianpeng Hu, Na Liu, Arun Upadhyaya. 2015. Evaluation of serum midkine as a biomarker in differentiated thyroid cancer. *Life Sciences* **130**, 18-24. [[CrossRef](#)]
265. Su-jin Kim, Jun Pyo Myong, Hyeon-Gun Jee, Young Jun Chai, June Young Choi, Hye Sook Min, Kyu Eun Lee, Yeo-Kyu Youn. 2015. Combined effect of Hashimoto's thyroiditis and BRAF V600E mutation status on aggressiveness in papillary thyroid cancer. *Head & Neck* n/a-n/a. [[CrossRef](#)]
266. Theodore Karatzas, Georgios Charitoudis, Dimitrios Vasileiadis, Stylianos Kapetanakis, Ioannis Vasileiadis. 2015. Surgical treatment for dominant malignant nodules of the isthmus of the thyroid gland: A case control study. *International Journal of Surgery* **18**, 64-68. [[CrossRef](#)]
267. Carles Zafon, Manel Puig-Domingo, Josefina Biarnés, Irene Halperin, Maria Rosa Bella, Ignasi Castells, Cintia González, Ana Megía, Lola Santos, Luís García-Pascual, Jordi Lluís Reverter, Eduarda Pizarro, Dídac Mauricio. 2015. Estudio descriptivo de las características del cáncer diferenciado de tiroides en Cataluña en el periodo 1998-2012. Registro CECaT. *Endocrinología y Nutrición* **62**, 264-269. [[CrossRef](#)]
268. Juan José Díez, Amelia Oleaga, Cristina Álvarez-Escolá, Tomás Martín, Juan Carlos Galofré. 2015. Guía clínica para el manejo de pacientes con carcinoma diferenciado de tiroides de bajo riesgo. *Endocrinología y Nutrición* **62**, e57-e72. [[CrossRef](#)]
269. Louise Davies, Luc G.T. Morris, Megan Haymart, Amy Y. Chen, David Goldenberg, John Morris, Jennifer B. Ogilvie, David J. Terris, James Netterville, Richard J. Wong, Gregory Randolph. 2015. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY DISEASE STATE CLINICAL REVIEW: THE INCREASING INCIDENCE OF THYROID CANCER. *Endocrine Practice* **21**, 686-696. [[CrossRef](#)]
270. Rifki Ucler, Cafer Kaya, Neslihan Çuhacı, Abbas Ali Tam, Celil Alper Usluogulları, Fevzi Balkan, Reyhan Ersoy, Bekir Cakır. 2015. THYROID NODULES WITH 2 PRIOR INADEQUATE FINE-NEEDLE ASPIRATION RESULTS: EFFECT OF INCREASING THE DIAMETER OF THE NEEDLE. *Endocrine Practice* **21**, 595-603. [[CrossRef](#)]
271. Min Jung Bae, Sang Soo Kim, Won Jin Kim, Yang Seon Yi, Yun Kyung Jeon, Bo Hyun Kim, Byung Joo Lee, Jin Choon Lee, In Joo Kim, Soo Geun Wang, Yong Ki Kim. 2015. High prevalence of papillary thyroid cancer in Korean women with insulin resistance. *Head & Neck* n/a-n/a. [[CrossRef](#)]
272. Seo Ki Kim, Jung-Woo Woo, Jun Ho Lee, Inhye Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim. 2015. Role of BRAF V600E mutation as an indicator of the extent of thyroidectomy and lymph node dissection in conventional papillary thyroid carcinoma. *Surgery* . [[CrossRef](#)]
273. G. Vannucchi, S. De Leo, M. Perrino, S. Rossi, D. Tosi, V. Cirello, C. Colombo, G. Bulfamante, L. Vicentini, L. Fugazzola. 2015. Impact of estrogen and progesterone receptor expression on the clinical and molecular features of papillary thyroid cancer. *European Journal of Endocrinology* **173**, 29-36. [[CrossRef](#)]
274. Giacomo Sturniolo, Maria Antonia Violi, Bruno Galletti, Sergio Baldari, Alfredo Campenni, Francesco Vermiglio, Mariacarla Moleti. 2015. Differentiated thyroid carcinoma in lingual thyroid. *Endocrine* . [[CrossRef](#)]
275. Heejin Kim, Kyung Jin Na, Jae Hyuk Choi, Byeong-Cheol Ahn, Dongbin Ahn, Jin Ho Sohn. 2015. Feasibility of FDG-PET/CT for the initial diagnosis of papillary thyroid cancer. *European Archives of Oto-Rhino-Laryngology* . [[CrossRef](#)]
276. M Tarabichi, M Saiselet, C Trésallet, C Hoang, D Larsimont, G Andry, C Maenhaut, V Detours. 2015. Revisiting the transcriptional analysis of primary tumours and associated nodal metastases with enhanced biological and statistical controls: application to thyroid cancer. *British Journal of Cancer* **112**, 1665-1674. [[CrossRef](#)]

277. Miguel Paja, Jose L. del Cura, Rosa Zabala, Igone Corta, Aitzol Lizarraga, Amelia Oleaga, Amaia Expósito, M. Teresa Gutiérrez, Aitziber Ugalde, José I. López. 2015. Ultrasound-guided core-needle biopsy in thyroid nodules. A study of 676 consecutive cases with surgical correlation. *European Radiology* . [CrossRef]
278. Seong-Jang Kim, Samuel Chang. 2015. Predictive value of intratumoral heterogeneity of F-18 FDG uptake for characterization of thyroid nodules according to Bethesda categories of fine needle aspiration biopsy results. *Endocrine* . [CrossRef]
279. Remonti Luciana Reck, Kramer Caroline Kaercher, Leitão Cristiane Bauermann, Pinto Lana Catani F., Gross Jorge Luiz. 2015. Thyroid Ultrasound Features and Risk of Carcinoma: A Systematic Review and Meta-Analysis of Observational Studies. *Thyroid* 25:5, 538-550. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links] [Supplemental Material]
280. Semrad Thomas J., Semrad Alison M., Farwell D. Gregory, Chen Yingjia, Cress Rosemary. 2015. Initial Treatment Patterns in Younger Adult Patients with Differentiated Thyroid Cancer in California. *Thyroid* 25:5, 509-513. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
281. Hershman Jerome M.. 2015. Benign Thyroid Nodules Remain Benign During Follow-up. *Clinical Thyroidology* 27:5, 109-111. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
282. Wreesmann Volkert B., Nixon Iain J., Rivera Michael, Katabi Nora, Palmer Frank, Ganly Ian, Shaha Ashok R., Tuttle R. Michael, Shah Jatin P., Patel Snehal G., Ghossein Ronald A.. 2015. Prognostic Value of Vascular Invasion in Well-Differentiated Papillary Thyroid Carcinoma. *Thyroid* 25:5, 503-508. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
283. S. Ting, S. Synoracki, K.W. Schmid. 2015. Die C-Zellen der Schilddrüse und ihre Pathologie. *Der Pathologe* 36, 246-253. [CrossRef]
284. Jaime L. Wiebel, Mousumi Banerjee, Daniel G. Muenz, Francis P. Worden, Megan R. Haymart. 2015. Trends in imaging after diagnosis of thyroid cancer. *Cancer* 121:10.1002/cncr.v121.9, 1387-1394. [CrossRef]
285. M. N. Basaran, M. M. Tuna, E. Karakılıç, B. A. Doğan, N. N. İmga, D. Berker, S. Güler. 2015. Characterization of V804M-mutated RET proto-oncogene associated with familial medullary thyroid cancer, report of the largest Turkish family. *Journal of Endocrinological Investigation* 38, 541-546. [CrossRef]
286. Francesco Cicone, Annalisa Papa, Chiara Lauri, Anna Tofani, Camilla Virili, Marco Centanni, Francesco Scopinaro, Bruno Annibale. 2015. Thyro-gastric autoimmunity in patients with differentiated thyroid cancer: a prospective study. *Endocrine* 49, 163-169. [CrossRef]
287. Kastley Marvin, Kourosh Parham. 2015. Differentiated Thyroid Cancer in People Aged 85 and Older. *Journal of the American Geriatrics Society* 63:10.1111/jgs.2015.63.issue-5, 932-937. [CrossRef]
288. Romana T. Netea-Maier. 2015. Schilddrüsenkarzinom. *Bijblijeven* 31, 238-249. [CrossRef]
289. Ian Ganly, Laura Wang, R. Michael Tuttle, Nora Katabi, Gustavo A. Ceballos, H. Ruben Harach, Ronald Ghossein. 2015. Invasion rather than nuclear features correlates with outcome in encapsulated follicular tumors: further evidence for the reclassification of the encapsulated papillary thyroid carcinoma follicular variant. *Human Pathology* 46, 657-664. [CrossRef]
290. S. Manso García, M.J. Velasco Marcos. 2015. Valor actual de la ecografía en la caracterización de los nódulos tiroideos. Revisión de las últimas guías clínicas de actuación. *Radiología* 57, 248-258. [CrossRef]
291. S. Synoracki, S.T. Schmid, S. Ting, K.W. Schmid. 2015. Die C-Zellen der Schilddrüse und ihre Pathologie. *Der Pathologe* 36, 254-260. [CrossRef]
292. Sanjana Ballal, Ramya Soundararajan, Aayushi Garg, Saurav Chopra, Chandrasekhar Bal. 2015. Intermediate-risk differentiated thyroid carcinoma patients who were surgically ablated do not need adjuvant radioiodine therapy: long-term outcome study. *Clinical Endocrinology* n/a-n/a. [CrossRef]
293. Jesús María Villar del Moral, Víctor Soria Aledo, Alberto Colina Alonso, Benito Flores Pastor, María Teresa Gutiérrez Rodríguez, Joaquín Ortega Serrano, Pedro Parra Hidalgo, Susana Ros López. 2015. Clinical Pathway for Thyroidectomy. *Cirugía Española (English Edition)* 93, 283-299. [CrossRef]
294. Ohad Hilly, Lea Rath-Wolfson, Rumelia Koren, Aviram Mizrachi, Yaniv Hamzany, Gideon Bachar, Thomas Shpitzer. 2015. CD1a-positive dendritic cell density predicts disease-free survival in papillary thyroid carcinoma. *Pathology - Research and Practice* . [CrossRef]
295. Rosângela Caetano, Cláudia Regina Garcia Bastos, Ione Ayala Gualandi de Oliveira, Rondineli Mendes da Silva, Clarisse Pereira Dias Drumond Fortes, Vera Lucia Edais Pepe, Lenice Gnocchi Reis, José Ueleres Braga. 2015. Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative 131 I whole-body scan results: A meta-analysis. *Head & Neck* n/a-n/a. [CrossRef]
296. Roberto Rocchi, Maria Antonietta Altea, Michele Marinò, Francesca Menconi, Marenza Leo, Eleonora Sisti, Maria Antonietta Profilo, Paola Lepri, Marco Nardi, Paolo Vitti, Claudio Marcocci, Francesco Latrofa. 2015. Optic Neuropathy in 2



- Thyroidectomized Patients with Moderate to Severe Graves Ophthalmopathy Following L-Thyroxine Withdrawal Prior to Radioiodine Treatment for Thyroid Carcinoma. *AACE Clinical Case Reports* 1, e119-e122. [[CrossRef](#)]
297. Marcelo A. Queiroz, Martin W. Huellner. 2015. PET/MR in Cancers of the Head and Neck. *Seminars in Nuclear Medicine* 45, 248-265. [[CrossRef](#)]
298. Ahmed Deniwar, Catherine Hambleton, Tina Thethi, Krzysztof Moroz, Emad Kandil. 2015. Examining the Bethesda criteria risk stratification of thyroid nodules. *Pathology - Research and Practice* 211, 345-348. [[CrossRef](#)]
299. S. Shinohara, M. Kikuchi, A. Suehiro, I. Kishimoto, H. Harada, M. Hino, T. Ishihara. 2015. Characteristics and prognosis of patients with thyroglobulin-positive and radioactive iodine whole-body scan-negative differentiated thyroid carcinoma. *Japanese Journal of Clinical Oncology* 45, 427-432. [[CrossRef](#)]
300. Wendy Sacks, Glenn D Braunstein. 2015. Clinically meaningful end points in the evolving treatment paradigm for radioactive iodine-refractory differentiated thyroid cancer. *Expert Review of Endocrinology & Metabolism* 10, 337-344. [[CrossRef](#)]
301. Kyoungjune Pak, Sunghwan Suh, Hyunsook Hong, Gi Jeong Cheon, Seo Kyung Hahn, Keon Wook Kang, E. Edmund Kim, Dong Soo Lee, June-Key Chung. 2015. Diagnostic values of thyroglobulin measurement in fine-needle aspiration of lymph nodes in patients with thyroid cancer. *Endocrine* 49, 70-77. [[CrossRef](#)]
302. Tamas Kelly. 2015. An examination of myth: A favorable cardiovascular risk-benefit analysis of high-dose thyroid for affective disorders. *Journal of Affective Disorders* 177, 49-58. [[CrossRef](#)]
303. Eunyoung Kim, June Young Choi, Do Hoon Koo, Kyu Eun Lee, Yeo-Kyu Youn. 2015. Differences in the characteristics of papillary thyroid microcarcinoma  $\leq 5$  mm and  $> 5$  mm in diameter. *Head & Neck* 37:10.1002/hed.v37.5, 694-697. [[CrossRef](#)]
304. Pierpaolo Trimboli, Giorgio Treglia, Emma Condorelli, Francesco Romanelli, Anna Crescenzi, Massimo Bongiovanni, Luca Giovanella. 2015. BRAF-mutated carcinomas among thyroid nodules with prior indeterminate FNA report: a systematic review and meta-analysis. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
305. Jesús María Villar del Moral, Víctor Soria Aledo, Alberto Colina Alonso, Benito Flores Pastor, María Teresa Gutiérrez Rodríguez, Joaquín Ortega Serrano, Pedro Parra Hidalgo, Susana Ros López. 2015. Vía clínica de tiroidectomía. *Cirugía Española* 93, 283-299. [[CrossRef](#)]
306. Inn-Chul Nam, Hoon Choi, Eun-Sook Kim, Eun-Young Mo, Young-Hak Park, Dong-Il Sun. 2015. Characteristics of thyroid nodules causing globus symptoms. *European Archives of Oto-Rhino-Laryngology* 272, 1181-1188. [[CrossRef](#)]
307. S. Tabur, H. Korkmaz, M. Özkaya, U. Elboğa, M. Tarakçioğlu, N. Aksoy, E. Akarsu. 2015. Serum calprotectin: a new potential biomarker for thyroid papillary carcinoma. *Tumor Biology* . [[CrossRef](#)]
308. X. Wang, W. Cheng, J. Li, A. Su, T. Wei, F. Liu, J. Zhu. 2015. ENDOCRINE TUMOURS: Familial nonmedullary thyroid carcinoma is a more aggressive disease: a systematic review and meta-analysis. *European Journal of Endocrinology* 172, R253-R262. [[CrossRef](#)]
309. Tihana Ibrahimasic, Ronald Ghossein, Diane L. Carlson, Iain J. Nixon, Frank L. Palmer, Snehal G. Patel, Robert M. Tuttle, Ashok Shaha, Jatin P. Shah, Ian Ganly. 2015. Undetectable Thyroglobulin Levels in Poorly Differentiated Thyroid Carcinoma Patients Free of Macroscopic Disease After Initial Treatment: Are They Useful?. *Annals of Surgical Oncology* . [[CrossRef](#)]
310. Jonathan Lerner, Melanie Goldfarb. 2015. Pediatric Thyroid Microcarcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]
311. Victoria Lai, Tina W. F. Yen, Brian T. Rose, Gilbert G. Fareau, Sarah M. Misustin, Douglas B. Evans, Tracy S. Wang. 2015. The Effect of Thyroiditis on the Yield of Central Compartment Lymph Nodes in Patients with Papillary Thyroid Cancer. *Annals of Surgical Oncology* . [[CrossRef](#)]
312. Buryk Melissa A., Simons Jeffrey P., Picarsic Jennifer, Monaco Sara E., Ozolek John A., Joyce Judith, Gurtunca Nursen, Nikiforov Yuri E., Witchel Selma Feldman. 2015. Can Malignant Thyroid Nodules Be Distinguished from Benign Thyroid Nodules in Children and Adolescents by Clinical Characteristics? A Review of 89 Pediatric Patients with Thyroid Nodules. *Thyroid* 25:4, 392-400. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
313. Jeon Min Ji, Kim Won Gu, Jang Eun Kyung, Choi Yun Mi, Lee Yu-Mi, Sung Tae-Yon, Yoon Jong Ho, Chung Ki-Wook, Hong Suck Joon, Baek Jung Hwan, Lee Jeong Hyun, Kim Tae Yong, Shong Young Kee, Kim Won Bae. 2015. Thyroglobulin Level in Fine-Needle Aspirates for Preoperative Diagnosis of Cervical Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma: Two Different Cutoff Values According to Serum Thyroglobulin Level. *Thyroid* 25:4, 410-416. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
314. Nascimento Camila, Borget Isabelle, Al Ghuzlan Abir, Deandreis Désirée, Hartl Dana, Lumbroso Jean, Berdelou Amandine, Lepoutre-Lussey Charlotte, Mirghani Haïtham, Baudin Eric, Schlumberger Martin, Leboulleux Sophie. 2015. Postoperative Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography: An Important Imaging Modality in Patients with Aggressive Histology of Differentiated Thyroid Cancer. *Thyroid* 25:4, 437-444. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

315. Sacks Wendy, Wong Ronnie Meiyi, Bresee Catherine, Braunstein Glenn D.. 2015. Use of Evidence-Based Guidelines Reduces Radioactive Iodine Treatment in Patients with Low-Risk Differentiated Thyroid Cancer. *Thyroid* **25**:4, 377-385. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
316. Eszlinger Markus, Piana Simonetta, Moll Anja, Bösenberg Eileen, Bisagni Alessandra, Ciarrocchi Alessia, Ragazzi Moira, Paschke Ralf. 2015. Molecular Testing of Thyroid Fine-Needle Aspirations Improves Presurgical Diagnosis and Supports the Histologic Identification of Minimally Invasive Follicular Thyroid Carcinomas. *Thyroid* **25**:4, 401-409. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
317. E. D. Rossi, L. Revelli, E. Giustozzi, P. Straccia, E. Stigliano, C. P. Lombardi, A. Pontecorvi, G. Fadda. 2015. Large non-functioning parathyroid cysts: our institutional experience of a rare entity and a possible pitfall in thyroid cytology. *Cytopathology* **26**:10.1111/cyt.2015.26.issue-2, 114-121. [CrossRef]
318. Fabián Pitoia, Erika Abelleira, Fernanda Bueno, Carolina Urciuoli, Angélica Schmidt, Hugo Niepomniszcze. 2015. Insulin resistance is another factor that increases the risk of recurrence in patients with thyroid cancer. *Endocrine* **48**, 894-901. [CrossRef]
319. Anthony Ciarallo, Charles Marcus, Mehdi Taghipour, Rathan M. Subramaniam. 2015. Value of Fluorodeoxyglucose PET/Computed Tomography Patient Management and Outcomes in Thyroid Cancer. *PET Clinics* **10**, 265-278. [CrossRef]
320. Francesco Perri, Luciano Pezzullo, Maria Grazia Chiofalo, Secondo Lastoria, Francesca Di Gennaro, Giuseppina Della Vittoria Scarpato, Francesco Caponigro. 2015. Targeted therapy: A new hope for thyroid carcinomas. *Critical Reviews in Oncology/Hematology* **94**, 55-63. [CrossRef]
321. Peter T White, Mark S Cohen. 2015. The discovery and development of sorafenib for the treatment of thyroid cancer. *Expert Opinion on Drug Discovery* **10**, 427-439. [CrossRef]
322. Young Woo Chang, Hwan Soo Kim, Hoon Yub Kim, Jae Bok Lee, Jeoung Won Bae, Gil Soo Son. 2015. Should central lymph node dissection be considered for all papillary thyroid microcarcinoma?. *Asian Journal of Surgery* . [CrossRef]
323. Omar Abdel-Rahman. 2015. Targeting vascular endothelial growth factor (VEGF) pathway in iodine-refractory differentiated thyroid carcinoma (DTC): From bench to bedside. *Critical Reviews in Oncology/Hematology* **94**, 45-54. [CrossRef]
324. Tomoaki Sasaki, Basim Nabaa, Koji Takahashi, Atsutaka Okizaki, Shunta Ishitoya. 2015. Non-contrast-enhanced computed tomography attenuation in the parotid glands before radioiodine therapy for thyroid carcinoma could be a predictor of radiovulnerability. *Nuclear Medicine Communications* **36**, 350-355. [CrossRef]
325. Naris Nilubol, Electron Kebebew. 2015. Should small papillary thyroid cancer be observed? A population-based study. *Cancer* **121**:10.1002/cncr.v121.7, 1017-1024. [CrossRef]
326. Ji Soo Choi, Chung Mo Nam, Eun-Kyung Kim, Hee Jung Moon, Kyung Hwa Han, Jin Young Kwak. 2015. Evaluation of serum thyroid-stimulating hormone as indicator for fine-needle aspiration in patients with thyroid nodules. *Head & Neck* **37**:10.1002/hed.v37.4, 498-504. [CrossRef]
327. Alaa Al Nofal, Michael R. Gionfriddo, Asma Javed, Qusay Haydour, Juan P. Brito, Larry J. Prokop, Siobhan T. Pittock, Mohammad Hassan Murad. 2015. Accuracy of thyroid nodule sonography for the detection of thyroid cancer in children: systematic review and meta-analysis. *Clinical Endocrinology* n/a-n/a. [CrossRef]
328. Bing Zheng, Jun Liu, Jianlei Gu, Yao Lu, Wei Zhang, Min Li, Hui Lu. 2015. A three-gene panel that distinguishes benign from malignant thyroid nodules. *International Journal of Cancer* **136**:10.1002/ijc.v136.7, 1646-1654. [CrossRef]
329. Mark L. Urken, Mira Milas, Gregory W. Randolph, Ralph Tufano, Donald Bergman, Victor Bernet, Elise M. Brett, James D. Brierley, Rhoda Cobin, Gerard Doherty, Joshua Klopper, Stephanie Lee, Josef Machac, Jeffrey I. Mechanick, Lisa A. Orloff, Douglas Ross, Robert C. Smallridge, David J Terris, Jason B Clain, Michael Tuttle. 2015. Management of recurrent and persistent metastatic lymph nodes in well-differentiated thyroid cancer: A multifactorial decision-making guide for the thyroid cancer care collaborative. *Head & Neck* **37**:10.1002/hed.v37.4, 605-614. [CrossRef]
330. Colleen M. Kiernan, Alexander A. Parikh, Lee L. Parks, Carmen C. Solórzano. 2015. Use of Radioiodine after Thyroid Lobectomy in Patients with Differentiated Thyroid Cancer: Does It Change Outcomes?. *Journal of the American College of Surgeons* **220**, 617-625. [CrossRef]
331. Víctor Manuel Andía Melero, María Martín de Santa-Olalla Llanes, Marcel Sambo Salas, Juan Carlos Percovich Hualpa, Marta Motilla de la Cámara, Luis Collado Yurrita. 2015. Comparación de sistemas de estadificación del carcinoma diferenciado de tiroides en una población española. *Endocrinología y Nutrición* **62**, 152-160. [CrossRef]
332. Celeste C. L. Quianzon, Pamela R. Schroeder. 2015. Initial evaluation of thyroid nodules by primary care physicians and internal medicine residents. *Journal of Community Hospital Internal Medicine Perspectives* **5** . [CrossRef]
333. Zhen Gooi, Bryan K. Ward, David J. Mener, Ozan B. Ozgursoy, Sara I. Pai. 2015. A staged thyroidectomy approach for gastric bypass patients. *The Laryngoscope* **125**:10.1002/lary.v125.4, 1028-1030. [CrossRef]

334. Bianca Gibelli, Rosa Dionisio, Mohssen Ansarin. 2015. Role of hemithyroidectomy in differentiated thyroid cancer. *Current Opinion in Otolaryngology & Head and Neck Surgery* **23**, 99-106. [[CrossRef](#)]
335. Xuewen Liu, Dian Ouyang, Hui Li, Rong Zhang, Yanchun Lv, Ankui Yang, Chuanmiao Xie. 2015. Papillary Thyroid Cancer: Dual-Energy Spectral CT Quantitative Parameters for Preoperative Diagnosis of Metastasis to the Cervical Lymph Nodes. *Radiology* **275**, 167-176. [[CrossRef](#)]
336. Solveig Grenfell, Daniel Roos, James Rijken, Braden Higgs, Ian Kirkwood. 2015. Comparison of effective I-131 half-life between thyroid hormone withdrawal and recombinant human thyroid-stimulating hormone for thyroid cancer: A retrospective study. *Journal of Medical Imaging and Radiation Oncology* **59**:10.1111/jmro.2015.59.issue-2, 248-254. [[CrossRef](#)]
337. Rafał Czepczyński, Magdalena Matysiak-Grześ, Maria Gryczyńska, Maciej Bączyk, Anna Wyszomirska, Marek Stajgis, Marek Ruchała. 2015. Peptide Receptor Radionuclide Therapy of Differentiated Thyroid Cancer: Efficacy and Toxicity. *Archivum Immunologiae et Therapiae Experimentalis* **63**, 147-154. [[CrossRef](#)]
338. Donald S. A. McLeod, Kelly Carruthers, Dev A. S. Kevat. 2015. Optimal Differentiated Thyroid Cancer Management in the Elderly. *Drugs & Aging* **32**, 283-294. [[CrossRef](#)]
339. Michael J. Campbell, Leah Candell, Carolyn D. Seib, Jessica E. Gosnell, Quan-Yang Duh, Orlo H. Clark, Wen T. Shen. 2015. Unanticipated Thyroid Cancer in Patients with Substernal Goiters: Are We Underestimating the Risk?. *Annals of Surgical Oncology* **22**, 1214-1218. [[CrossRef](#)]
340. Pierpaolo Trimboli, Anna Crescenzi. 2015. Thyroid core needle biopsy: taking stock of the situation. *Endocrine* **48**, 779-785. [[CrossRef](#)]
341. D. A. Pagsisihan, A. H. I. Aguilar, M. P. D. D. Maningat. 2015. Orbital metastasis as initial manifestation of a widespread papillary thyroid microcarcinoma. *Case Reports* **2015**, bcr2014208870-bcr2014208870. [[CrossRef](#)]
342. Ingrida Albužytė, Gražina Lingė, Gražina Mickunaitienė, Gražina Kleinotienė, Jelena Rascon. 2015. VAIKU SKYDLIAUKĖS VEŽYS PO PERSIRGTOS ONKOLOGINĖS LIGOS. *Medicinos teorija ir praktika* **21**, 110-116. [[CrossRef](#)]
343. Qing Xia, Shuai Dong, Ping-Da Bian, Jue Wang, Cheng-Jiang Li. 2015. Effects of endocrine therapy on the prognosis of elderly patients after surgery for papillary thyroid carcinoma. *European Archives of Oto-Rhino-Laryngology*. [[CrossRef](#)]
344. Ji-hoon Kim, Won Sang Yoo, Young Joo Park, Do Joon Park, Tae Jin Yun, Seung Hong Choi, Chul-Ho Sohn, Kyu Eun Lee, Myung-Whun Sung, Yeo-Kyu Youn, Kwang Hyun Kim, Bo Youn Cho. 2015. Efficacy and Safety of Radiofrequency Ablation for Treatment of Locally Recurrent Thyroid Cancers Smaller than 2 cm. *Radiology* 140079. [[CrossRef](#)]
345. Sangeet Ghai, Stefanie Y. Lee, Patrice M. Bret, Ravi J. Menezes, Scott L. Boerner, Yongheng Jia, Kulsoom A. Maan, Rudolf Boci, Wasim Javed, Mostafa Atri. 2015. Thyroid Biopsy Specialists: A Quality Initiative to Reduce Wait Times and Improve Adequacy Rates. *Radiology* 140620. [[CrossRef](#)]
346. Feng Xiaoxi, Milas Mira, O'Malley Margaret, LaGuardia Lisa, Berber Eren, Jin Judy, Metzger Rosemarie, Mitchell Jamie, Shin Joyce, Burke Carol A., Kalady Matthew, Church James, Siperstein Allan. 2015. Characteristics of Benign and Malignant Thyroid Disease in Familial Adenomatous Polyposis Patients and Recommendations for Disease Surveillance. *Thyroid* **25**:3, 325-332. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
347. Chen Jian, Zheng Hongmei, He Jialin. 2015. 3D Laparoscopic Revision Thyroidectomy Through an Anterior Chest Approach: A Case Report. *Journal of Laparoendoscopic & Advanced Surgical Techniques* **25**:3, 238-242. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
348. Wang Laura Y., Smith Andrew W., Palmer Frank L., Tuttle R. Michael, Mahrous Azhar, Nixon Iain J., Patel Snehal G., Ganly Ian, Fagin James A., Boucai Laura. 2015. Thyrotropin Suppression Increases the Risk of Osteoporosis Without Decreasing Recurrence in ATA Low- and Intermediate-Risk Patients with Differentiated Thyroid Carcinoma. *Thyroid* **25**:3, 300-307. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
349. Melanie Goldfarb. 2015. Thyroid microcarcinoma in pediatric patients: how aggressive do we need to be?. *International Journal of Endocrine Oncology* **2**, 1-3. [[CrossRef](#)]
350. Brajendra Baser, Vishal R. Munjal, Manya Thakur Roy. 2015. Papillary Carcinoma of Thyroid with an Unusual Presentation. *Indian Journal of Otolaryngology and Head & Neck Surgery* **67**, 145-148. [[CrossRef](#)]
351. Hannah A. Blair, Greg L. Plosker. 2015. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma. *Targeted Oncology* **10**, 171-178. [[CrossRef](#)]
352. Julia Klebe, Christian Happel, Frank Grünwald, Hüdayi Korkusuz. 2015. Visualization of tissue alterations in thyroid nodules after microwave ablation. *Nuclear Medicine Communications* **36**, 260-267. [[CrossRef](#)]
353. Mengzi He, Yinlong Zhao, Heqing Yi, Hui Sun, Xiaodong Liu, Shumei Ma. 2015. The combination of TP53INP1, TP53INP2 and AXIN2: potential biomarkers in papillary thyroid carcinoma. *Endocrine* **48**, 712-717. [[CrossRef](#)]

354. Se Kyung Lee, Jun Ho Lee, Soo Youn Bae, Jiyoung Kim, Minkuk Kim, Hyun-Chul Lee, Yoon Yang Jung, Won Ho Kil, Seok Won Kim, Jeong Eon Lee, Seok Jin Nam, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim. 2015. Lateral neck sentinel lymph node biopsy in papillary thyroid carcinoma, is it really necessary? A randomized, controlled study. *Surgery* **157**, 518-525. [[CrossRef](#)]
355. Dapeng Xiang, Liangqi Xie, Yuanliang Xu, Zhiyu Li, Yurong Hong, Ping Wang. 2015. Papillary thyroid microcarcinomas located at the middle part of the middle third of the thyroid gland correlates with the presence of neck metastasis. *Surgery* **157**, 526-533. [[CrossRef](#)]
356. Kevin C. Choong, Christopher R. McHenry. 2015. Thyroid cancer in patients with toxic nodular goiter—is the incidence increasing?. *The American Journal of Surgery* . [[CrossRef](#)]
357. Frederico F. R. Maia, Patricia S. Matos, Elizabeth J. Pavin, Denise E. Zantut-Wittmann. 2015. Thyroid imaging reporting and data system score combined with Bethesda system for malignancy risk stratification in thyroid nodules with indeterminate results on cytology. *Clinical Endocrinology* **82**:10.1111/cen.2015.82.issue-3, 439-444. [[CrossRef](#)]
358. Qiang Chen, Tao Wei, Xun-li Wang, Zhi-hui Li, Zhen-hong Du, Jing-qiang Zhu. 2015. The total number of prelaryngeal and pretracheal lymph node metastases: is it a reliable predictor of contralateral central lymph node metastasis in papillary thyroid carcinoma?. *Journal of Surgical Research* . [[CrossRef](#)]
359. Jue Jiang, Xu Shang, Hua Wang, Yong-Bo Xu, Ya Gao, Qi Zhou. 2015. Diagnostic value of contrast-enhanced ultrasound in thyroid nodules with calcification. *The Kaohsiung Journal of Medical Sciences* **31**, 138-144. [[CrossRef](#)]
360. Yoshifumi Noda, Masayuki Kanematsu, Satoshi Goshima, Hiroshi Kondo, Haruo Watanabe, Hiroshi Kawada, Kyongtae T. Bae. 2015. MRI of the Thyroid for Differential Diagnosis of Benign Thyroid Nodules and Papillary Carcinomas. *American Journal of Roentgenology* **204**, W332-W335. [[CrossRef](#)]
361. Tien-Chun Chang. 2015. The Roles of Ultrasonography and Ultrasonography-guided Fine-needle Aspiration Cytology in the Planning of Management of Thyroid Cancers. *Journal of Medical Ultrasound* **23**, 17-24. [[CrossRef](#)]
362. Junwei Zhang, Zhaojin Chen, Gopinathan Anil. 2015. Ultrasound-guided thyroid nodule biopsy: outcomes and correlation with imaging features. *Clinical Imaging* **39**, 200-206. [[CrossRef](#)]
363. C. Bellecine, E. Vigliar, U. Malapelle, P. Pisapia, G. Conzo, B. Biondi, A. Vetrani, G. Troncone. 2015. Cytopathologists can reliably perform ultrasound-guided thyroid fine needle aspiration: a 1-year audit on 3715 consecutive cases. *Cytopathology* n/a-n/a. [[CrossRef](#)]
364. Kanungnij Thamnirat, Chirawat Utamakul, Wichana Chamroonrat, Arpakorn Kositwattanarerk, Yoch Anongpornjossakul, Chanika Sritara. 2015. Factors Affecting Disease-Free Status of Differentiated Thyroid Carcinoma Patients. *Asian Pacific Journal of Cancer Prevention* **16**, 737-740. [[CrossRef](#)]
365. Flavia Magri, Spyridon Chytiris, Francesca Zerbini, Valentina Capelli, Margherita Gaiti, Andrea Carbone, Rodolfo Fonte, Alberto Malovini, Mario Rotondi, Riccardo Bellazzi, Luca Chiovato. 2015. The Maximal Stiffness Evaluation by Real Time Ultrasound Elastography, An Improved Tool for the Differential Diagnosis of Thyroid Nodules. *Endocrine Practice* 1-22. [[CrossRef](#)]
366. J. Lee, M.-Y. Seol, S. Jeong, H. J. Kwon, C. R. Lee, C. R. Ku, S.-W. Kang, J. J. Jeong, D. Y. Shin, K.-H. Nam, E. J. Lee, W. Y. Chung, Y. S. Jo. 2015. KSR1 is coordinately regulated with Notch signaling and oxidative phosphorylation in thyroid cancer. *Journal of Molecular Endocrinology* **54**, 115-124. [[CrossRef](#)]
367. Romana T. Netea-Maier, Viola KlÄ¼ck, Theo S. Plantinga, Johannes W. A. Smit. 2015. Autophagy in Thyroid Cancer: Present Knowledge and Future Perspectives. *Frontiers in Endocrinology* **6** . [[CrossRef](#)]
368. F. Li, G. Chen, C. Sheng, A. M. Gusdon, Y. Huang, Z. Lv, H. Xu, M. Xing, S. Qu. 2015. BRAFV600E mutation in papillary thyroid microcarcinoma: a meta-analysis. *Endocrine Related Cancer* **22**, 159-168. [[CrossRef](#)]
369. To Joshua, Goldberg Alyse S., Jones Jennifer, Zhang Junhui, Lowe Julia, Ezzat Shereen, Gilbert Jeremy, Zahedi Afshan, Segal Phillip, Sawka Anna M.. 2015. A Systematic Review of Randomized Controlled Trials for Management of Persistent Post-Treatment Fatigue in Thyroid Cancer Survivors. *Thyroid* **25**:2, 198-210. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
370. Alpert Erin H., Wenig Bruce M., Dewey Eliza H., Su Henry K., Dos Reis Laura, Urken Mark L.. 2015. Size Distribution of Metastatic Lymph Nodes with Extranodal Extension in Patients with Papillary Thyroid Cancer: A Pilot Study. *Thyroid* **25**:2, 238-241. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
371. Rossi Martina, Buratto Mattia, Tagliati Federico, Rossi Roberta, Lupo Sabrina, Trasforini Giorgio, Lanza Giovanni, Franceschetti Paola, Bruni Stefania, degli Uberti Ettore, Zatelli Maria Chiara. 2015. Relevance of BRAFV600E Mutation Testing Versus RAS Point Mutations and RET/PTC Rearrangements Evaluation in the Diagnosis of Thyroid Cancer. *Thyroid* **25**:2, 221-228. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
372. Cord Sturgeon. 2015. All Cervical Sonography Is Not Created Equal. *Annals of Surgical Oncology* **22**, 355-357. [[CrossRef](#)]

373. Ha Kyoung Park, Dong Wook Kim, Tae Kwun Ha, Hye Jung Choo, Young Mi Park, Soo Jin Jung, Do Hun Kim, Sang Kyun Bae. 2015. Factors associated with postoperative hypothyroidism after lobectomy in papillary thyroid microcarcinoma patients. *Endocrine Research* **40**, 49-53. [[CrossRef](#)]
374. Rachel T. McGrath, Veronica A. Preda, Philip Clifton-Bligh, Bruce Robinson, Mark Sywak, Leigh Delbridge, Peter Ward, Roderick J. Clifton-Bligh, Diana L. Learoyd. 2015. Is there a role for an ultrasensitive thyroglobulin assay in patients with serum antithyroglobulin antibodies? A large (Australian) cohort study in differentiated thyroid cancer. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
375. Kris R. Jatana, Donald Zimmerman. 2015. Pediatric Thyroid Nodules and Malignancy. *Otolaryngologic Clinics of North America* **48**, 47-58. [[CrossRef](#)]
376. Woo Jung Choi, Jeong Seon Park, Hye Ryoung Koo, Soo-Yeon Kim, Min Sung Chung, Kyung Tae. 2015. Ultrasound Elastography Using Carotid Artery Pulsation in the Differential Diagnosis of Sonographically Indeterminate Thyroid Nodules. *American Journal of Roentgenology* **204**, 396-401. [[CrossRef](#)]
377. Tao-Yeuan Wang, Chien-Liang Liu, Ming-Jen Chen, Jie-Jen Lee, Pou Chu Pun, Shih-Ping Cheng. 2015. Expression of haem oxygenase-1 correlates with tumour aggressiveness and BRAF V 600E expression in thyroid cancer. *Histopathology* **66**:10.1111/his.2015.66.issue-3, 447-456. [[CrossRef](#)]
378. Sherif M. El-Refaei, Shereen W. Yassin, Khaled Salman, Tarek Al Munshy, Manal Al-Ezzi, Yasser M. Al-Sayed, Maha Abd Elkareem Husseni. 2015. Comparison between low and high radioactive iodine (131I) reablation dose in patients with papillary thyroid cancer. *Nuclear Medicine Communications* **36**, 114-119. [[CrossRef](#)]
379. Tao Li, Pei Zhou, Xuming Zhang, Mingyue Ding, Ming Yuchi, Yiyong Li. 2015. Diagnosis of Thyroid Nodules Using Virtual Touch Tissue Quantification Value and Anteroposterior/Transverse Diameter Ratio. *Ultrasound in Medicine & Biology* **41**, 384-392. [[CrossRef](#)]
380. Bihong Chen, Akshay Jain, Andrew Dagus, Peiguo Chu, Lalit Vora, Ellie Maghami, Behrouz Salehian. 2015. Comparison of the Efficacy and Safety of Ultrasound-Guided Core Needle Biopsy Versus Fine-Needle Aspiration for Evaluating Thyroid Nodules. *Endocrine Practice* **21**, 128-135. [[CrossRef](#)]
381. Cigdem Soydal, Mine Araz, Elgin Ozkan, Emrah Arslantaş, Ozlem N. Kucuk, Gulseren Aras. 2015. Assessment of recurrence rates in papillary thyroid microcarcinoma patients with and without histopathological risk factors after radioiodine ablation treatment. *Nuclear Medicine Communications* **36**, 109-113. [[CrossRef](#)]
382. A. Gazdag, E. V. Nagy, A. Erdei, M. Bodor, E. Berta, Z. Szabó, Z. Jenei. 2015. Aortic stiffness and left ventricular function in patients with differentiated thyroid cancer. *Journal of Endocrinological Investigation* **38**, 133-142. [[CrossRef](#)]
383. Amr Amin, Gehan Younis, Khalid Sayed, Zenat Saeed. 2015. Cervical lymph node metastasis in differentiated thyroid carcinoma. *Nuclear Medicine Communications* **36**, 120-124. [[CrossRef](#)]
384. Katy Gallop, Cicely Kerr, Stacey Simmons, Bryan McIver, Ezra E. W. Cohen. 2015. A qualitative evaluation of the validity of published health utilities and generic health utility measures for capturing health-related quality of life (HRQL) impact of differentiated thyroid cancer (DTC) at different treatment phases. *Quality of Life Research* **24**, 325-338. [[CrossRef](#)]
385. Laura Y. Wang, Frank L. Palmer, Dorothy Thomas, Iain J. Nixon, R. Michael Tuttle, Jatin P. Shah, Snehal G. Patel, Ashok R. Shaha, Ian Ganly. 2015. Level 7 Disease Does Not Confer Worse Outcome than Level 6 Disease in Differentiated Thyroid Cancer. *Annals of Surgical Oncology* **22**, 441-445. [[CrossRef](#)]
386. Sarah C. Oltmann, David F. Schneider, Herbert Chen, Rebecca S. Sippel. 2015. All Thyroid Ultrasound Evaluations are Not Equal: Sonographers Specialized in Thyroid Cancer Correctly Label Clinical N0 Disease in Well Differentiated Thyroid Cancer. *Annals of Surgical Oncology* **22**, 422-428. [[CrossRef](#)]
387. Marc H. Willis. 2015. Carpe Diem: Population Health. *Journal of the American College of Radiology* **12**, 127-128. [[CrossRef](#)]
388. Monica Beck. 2015. Radiation Safety in the Management of Patients Undergoing Radioactive Iodine Ablation Therapy. *Clinical Journal of Oncology Nursing* **19**, 44-46. [[CrossRef](#)]
389. G. H. Daniels, L. Hegedüs, S. P. Marso, M. A. Nauck, B. Zinman, R. M. Bergenstal, J. F. E. Mann, J. Derving Karsbøl, A. C. Moses, J. B. Buse, R. M. Tuttle. 2015. LEADER 2: baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: preliminary observations. *Diabetes, Obesity and Metabolism* n/a-n/a. [[CrossRef](#)]
390. Paul J. Davis, Aleck Herbergs, Mary K. Luidens, Hung-Yun Lin. 2015. Recurrence of Differentiated Thyroid Carcinoma During Full TSH Suppression: Is the Tumor Now Thyroid Hormone Dependent?. *Hormones and Cancer* **6**, 7-12. [[CrossRef](#)]
391. Jandee Lee, Seonhyang Jeong, Jae Hyun Park, Cho Rok Lee, Cheol Ryong Ku, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Dong Yeob Shin, Eun Jig Lee, Woong Youn Chung, Young Suk Jo. 2015. Aberrant Expression of COT Is Related to Recurrence of Papillary Thyroid Cancer. *Medicine* **94**, e548. [[CrossRef](#)]

392. Soo-Yeon Kim, Eun-Kyung Kim, Jin Young Kwak, Hee Jung Moon, Jung Hyun Yoon. 2015. What to do with thyroid nodules showing benign cytology and BRAFV600E mutation? A study based on clinical and radiologic features using a highly sensitive analytic method. *Surgery* **157**, 354-361. [[CrossRef](#)]
393. Pierpaolo Trimboli, Giorgio Treglia, Leo Guidobaldi, Francesco Romanelli, Giuseppe Nigri, Stefano Valabrega, Ramin Sadeghi, Anna Crescenzi, William C. Faquin, Massimo Bongiovanni, Luca Giovanella. 2015. Detection rate of FNA cytology in medullary thyroid carcinoma: a meta-analysis. *Clinical Endocrinology* **82**:10.1111/cen.2015.82.issue-2, 280-285. [[CrossRef](#)]
394. Leonardo Pace, Michele Klain, Barbara Salvatore, Emanuele Nicolai, Emilia Zampella, Roberta Assante, Teresa Pellegrino, Giovanni Storto, Rosa Fonti, Marco Salvatore. 2015. Prognostic Role of 18F-FDG PET/CT in the Postoperative Evaluation of Differentiated Thyroid Cancer Patients. *Clinical Nuclear Medicine* **40**, 111-115. [[CrossRef](#)]
395. Kalliopi Pazaitou-Panayiotou, Paschalia K. Iliadou, Stylianos Mandanas, Theofanis Vasileiadis, Periklis Mitsakis, Konstantinos Tziomalos, Maria Alevizaki, Frideriki Patakiouta. 2015. Papillary Thyroid Carcinomas in Patients under 21 Years of Age: Clinical and Histologic Characteristics of Tumors  $\leq 10$  mm. *The Journal of Pediatrics* **166**, 451-456.e2. [[CrossRef](#)]
396. Symeon Tournis, Julia D. Antoniou, Chrysoula G. Liakou, John Christodoulou, Evangelia Papakitsou, Antonios Galanos, Konstantinos Makris, Helen Marketos, Stamatina Nikopoulou, Ioanna Tzavara, Ioannis K. Triantafyllopoulos, Ismene Dontas, Nikolaos Papaioannou, Georgios P. Lyritys, Maria Alevizaki. 2015. Volumetric bone mineral density and bone geometry assessed by peripheral quantitative computed tomography in women with differentiated thyroid cancer under TSH suppression. *Clinical Endocrinology* **82**:10.1111/cen.2015.82.issue-2, 197-204. [[CrossRef](#)]
397. Joel A. Smith, Neil Sharma, Paul Nankivell, John C. Watkinson. 2015. The presentation, natural history and outcome of T1 a/b thyroid cancer with regard to new grading systems. *European Archives of Oto-Rhino-Laryngology* **272**, 439-444. [[CrossRef](#)]
398. Jenny K. Hoang, Jill E. Langer, William D. Middleton, Carol C. Wu, Lynwood W. Hammers, John J. Cronan, Franklin N. Tessler, Edward G. Grant, Lincoln L. Berland. 2015. Managing Incidental Thyroid Nodules Detected on Imaging: White Paper of the ACR Incidental Thyroid Findings Committee. *Journal of the American College of Radiology* **12**, 143-150. [[CrossRef](#)]
399. Sohyun Park, Ji-In Bang, Ho-Young Lee, Sang-Eun Kim. 2015. Does 131I Radioactivity Interfere with Thyroglobulin Measurement in Patients Undergoing Radioactive Iodine Therapy with Recombinant Human TSH?. *Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
400. Hai-Shan Zhang, Ren-Jie Wang, Qing-Feng Fu, Shi Gao, Bu-Tong Sun, Hui Sun, Qing-Jie Ma. 2015. Diagnostic value of Thyroglobulin Measurement with Fine-needle Aspiration Biopsy for Lymph Node Metastases in Patients with a History of Differentiated Thyroid Cancer. *Asian Pacific Journal of Cancer Prevention* **15**, 10905-10909. [[CrossRef](#)]
401. Yu-Rong Hong, Cao-Xin Yan, Guo-Qiang Mo, Zhi-Yan Luo, Ying Zhang, Yong Wang, Pin-Tong Huang. 2015. Conventional US, elastography, and contrast enhanced US features of papillary thyroid microcarcinoma predict central compartment lymph node metastases. *Scientific Reports* **5**, 7748. [[CrossRef](#)]
402. Mafalda Marcelino, Ana Lopes, Deolinda Madureira, Teresa Ferreira, Edward Limbert, Valeriano Leite. 2015. Ability of the rhTSH stimulation test to predict relapse in patients with differentiated thyroid carcinoma, after long-term follow-up. *Oncology Letters* . [[CrossRef](#)]
403. K. E. Lee, Y. J. Park, B. Cho, Y. Hwang, J. Y. Choi, S.-j. Kim, H. Choi, H.-C. Choi, A. R. An, D. J. Park, S. K. Park, Y.-K. Youn. 2015. Protocol of a Thyroid Cancer Longitudinal Study (T-CALOS): a prospective, clinical and epidemiological study in Korea. *BMJ Open* **5**, e007234-e007234. [[CrossRef](#)]
404. Wu James X., Young Stephanie, Ro Kevin, Li Ning, Leung Angela M., Chiu Harvey K., Harari Avital, Yeh Michael W.. 2015. Reproductive Outcomes and Nononcologic Complications After Radioactive Iodine Ablation for Well-Differentiated Thyroid Cancer. *Thyroid* **25**:1, 133-138. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
405. Tufano Ralph P., Clayman Gary, Heller Keith S., Inabnet William B., Kebebew Electron, Shaha Ashok, Steward David L., Tuttle R. Michael, for the American Thyroid Association Surgical Affairs Committee Writing Task Force. 2015. Management of Recurrent/Persistent Nodal Disease in Patients with Differentiated Thyroid Cancer: A Critical Review of the Risks and Benefits of Surgical Intervention Versus Active Surveillance. *Thyroid* **25**:1, 15-27. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
406. Yeh Michael W., Bauer Andrew J., Bernet Victor A., Ferris Robert L., Loevner Laurie A., Mandel Susan J., Orloff Lisa A., Randolph Gregory W., Steward David L., for the American Thyroid Association Surgical Affairs Committee Writing Task Force. 2015. American Thyroid Association Statement on Preoperative Imaging for Thyroid Cancer Surgery. *Thyroid* **25**:1, 3-14. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
407. Londero Stefano Christian, Krogdahl Annelise, Bastholt Lars, Overgaard Jens, Pedersen Henrik Baymler, Hahn Christoffer Holst, Bentzen Jens, Schytte Sten, Christiansen Peer, Gerke Oke, Godballe Christian, A study from The Danish Thyroid Cancer

- Group—DATHYRCA. 2015. Papillary Thyroid Carcinoma in Denmark, 1996–2008: Outcome and Evaluation of Established Prognostic Scoring Systems in a Prospective National Cohort. *Thyroid* **25**:1, 78–84. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
408. Sena Hwang, Dong Yeob Shin, Eun Kyung Kim, Woo Ick Yang, Jung Woo Byun, Su Jin Lee, Gyuri Kim, Soo Jung Im, Eun Jig Lee. 2015. Focal Lymphocytic Thyroiditis Nodules Share the Features of Papillary Thyroid Cancer on Ultrasound. *Yonsei Medical Journal* **56**, 1338. [[CrossRef](#)]
409. Tomoko Fujimoto, Mitsuyoshi Hirokawa, Hisashi Ota, Tomonori Yabuta, Mitsuhiro Fukushima, Kaoru Kobayashi, Nobuyuki Amino, Akira Miyauchi. 2015. Characteristic sonographic features of cribriform papillary thyroid carcinoma for differentiation from other thyroid nodules. *Journal of Medical Ultrasonics* **42**, 83–87. [[CrossRef](#)]
410. Luca Giovannella, Ulla Feldt-Rasmussen, Frederik A. Verburg, Stephan K. Grebe, Mario Plebani, Penelope M. Clark. 2015. Thyroglobulin measurement by highly sensitive assays: focus on laboratory challenges. *Clinical Chemistry and Laboratory Medicine (CCLM)* **53**. . [[CrossRef](#)]
411. Brian R. Englum, John Pura, Shelby D. Reed, Sanziana A. Roman, Julie A. Sosa, Randall P. Scheri. 2015. A Bedside Risk Calculator to Preoperatively Distinguish Follicular Thyroid Carcinoma from Follicular Variant of Papillary Thyroid Carcinoma. *World Journal of Surgery* . [[CrossRef](#)]
412. M Zou, E Y Baitei, R A Al-Rijjal, R S Parhar, F A Al-Mohanna, S Kimura, C Pritchard, H A Binessa, A S Alzahrani, H H Al-Khalaf, A Hawwari, M Akhtar, A M Assiri, B F Meyer, Y Shi. 2015. TSH overcomes BrafV600E-induced senescence to promote tumor progression via downregulation of p53 expression in papillary thyroid cancer. *Oncogene* . [[CrossRef](#)]
413. Vito Cantisani, Hektor Grazhdani, Elena Drakonaki, Vito D'Andrea, Mattia Di Segni, Erton Kaleshi, Fabrizio Calliada, Carlo Catalano, Adriano Redler, Luca Brunese, Francesco Maria Drudi, Angela Fumarola, Giovanni Carbotta, Fabrizio Frattaroli, Nicola Di Leo, Mauro Ciccariello, Marcello Caratozzolo, Ferdinando D'Ambrosio. 2015. Strain US Elastography for the Characterization of Thyroid Nodules: Advantages and Limitation. *International Journal of Endocrinology* **2015**, 1–8. [[CrossRef](#)]
414. Jung Hyun Yoon, Eun-Kyung Kim, Jin Young Kwak, Hee Jung Moon. 2015. Effectiveness and Limitations of Core Needle Biopsy in the Diagnosis of Thyroid Nodules: Review of Current Literature. *Journal of Pathology and Translational Medicine* **49**:3, 230. [[CrossRef](#)]
415. Carlo Cappelli, Ilenia Pirola, Elena Gandossi, Annamaria Formenti, Barbara Agosti, Maurizio Castellano. 2015. Elastography Evaluation of Benign Thyroid Nodules in Patients Affected by Hashimoto's Thyroiditis. *International Journal of Endocrinology* **2015**, 1. [[CrossRef](#)]
416. Kuk-Jin Kim, Seok-Mo Kim, Yong Sang Lee, Woong Youn Chung, Hang-Seok Chang, Cheong Soo Park. 2015. Prognostic Significance of Tumor Multifocality in Papillary Thyroid Carcinoma and its Relationship with Primary Tumor Size: A Retrospective Study of 2,309 Consecutive Patients. *Annals of Surgical Oncology* **22**, 125–131. [[CrossRef](#)]
417. Jenny K. Hoang, Allen T. Grady, Xuan V. Nguyen. 2015. What to do with incidental thyroid nodules identified on imaging studies? Review of current evidence and recommendations. *Current Opinion in Oncology* **27**, 8–14. [[CrossRef](#)]
418. I. Koutelidakis, S. Kalaitzis, G. Chatzimavroudis, J. Makris. 2015. Lateral neck dissection in the management of papillary thyroid cancer. *Hellenic Journal of Surgery* **87**, 49–52. [[CrossRef](#)]
419. Su Jung Choi, Kyung Pyo Jung, Sun Seong Lee, Yun Soo Park, Seok Mo Lee, Sang Kyun Bae. 2015. Clinical Usefulness of F-18 FDG PET/CT in Papillary Thyroid Cancer with Negative Radioiodine Scan and Elevated Thyroglobulin Level or Positive Anti-thyroglobulin Antibody. *Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
420. Séverine M. Niederer-Wüst, Wolfram Jochum, Diana Förbs, Michael Brändle, Stefan Bilz, Thomas Clerici, René Oettli, Joachim Müller, Sarah R. Haile, Silvia Ess, Sandro J. Stoeckli, Martina A. Broglie. 2015. Impact of clinical risk scores and BRAF V600E mutation status on outcome in papillary thyroid cancer. *Surgery* **157**, 119–125. [[CrossRef](#)]
421. Yoon Se Lee, Yun Sung Lim, Jin-Choon Lee, Soo-Geun Wang, Hee-Young Park, Shine Young Kim, Byung-Joo Lee. 2015. Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer. *Oral Oncology* **51**, 77–83. [[CrossRef](#)]
422. Jin Young Kwak. 2015. Postoperative Surveillance of Thyroid Cancer: In View of a Radiologist. *Journal of Korean Thyroid Association* **8**, 8. [[CrossRef](#)]
423. Jeppe Kiilerich Lauridsen, Max Rohde, Anders Thomassen. 2015. 18F-Fluorodeoxyglucose–Positron Emission Tomography/Computed Tomography in Malignancies of the Thyroid and in Head and Neck Squamous Cell Carcinoma. *PET Clinics* **10**, 75–88. [[CrossRef](#)]
424. H. Fürst. 2015. Chirurgische Behandlung des differenzierten und medullären Schilddrüsenkarzinoms entsprechend internationaler Leitlinien. *Der Onkologe* **21**:7, 577. [[CrossRef](#)]

425. Chiara Dobrinja, Stella Bernardi, Bruno Fabris, Rita Eramo, Petra Makovac, Gabriele Bazzocchi, Lanfranco Piscopello, Enrica Barro, Nicolò de Manzini, Deborah Bonazza, Maurizio Pinamonti, Fabrizio Zanconati, Fulvio Stacul. 2015. Surgical and Pathological Changes after Radiofrequency Ablation of Thyroid Nodules. *International Journal of Endocrinology* 2015, 1. [[CrossRef](#)]
426. Snezana Zivancevic Simonovic, Olgica Mihaljevic, Ivana Majstorovic, Predrag Djurdjevic, Irena Kostic, Olivera Milosevic Djurdjevic, Ljiljana Mijatovic Teodorovic. 2015. Cytokine production in peripheral blood cells of patients with differentiated thyroid cancer: elevated Th2/Th9 cytokine production before and reduced Th2 cytokine production after radioactive iodine therapy. *Cancer Immunology, Immunotherapy* 64:1, 75. [[CrossRef](#)]
427. Mark Henry Joven, George S. Hutfless, Robert J. Anderson. 2015. Follicular Thyroid Cancer with Pulmonary Metastasis Presenting as Toxic Autonomously Functioning Thyroid Nodule. *AACE Clinical Case Reports* 1, e49-e52. [[CrossRef](#)]
428. Juan J. Díez, Enrique Grande, Pedro Iglesias. 2015. Postoperative radioiodine ablation in patients with low risk differentiated thyroid carcinoma. *Medicina Clínica (English Edition)* 144, 35-41. [[CrossRef](#)]
429. Tomasz Stokowy, Bartosz Wojtaś, Jolanta Krajewska, Ewa Stobiecka, Henning Dralle, Thomas Musholt, Steffen Hauptmann, Dariusz Lange, László Hegedüs, Barbara Jarzab, Knut Krohn, Ralf Paschke, Markus Eszlinger. 2015. A two miRNA classifier differentiates follicular thyroid carcinomas from follicular thyroid adenomas. *Molecular and Cellular Endocrinology* 399, 43-49. [[CrossRef](#)]
430. M. Winter, J. Winter, A. Heinzl, F. F. Behrendt, T. Krohn, F. M. Mottaghy, F. A. Verburg. 2015. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. *Nuklearmedizin* 54. . [[CrossRef](#)]
431. Elizabeth A. McAninch, Violet S. Lagari. 2015. Acute-on-Chronic Kidney Injury in Thyroid Hormone Withdrawal: A Case with Possible Implications for Radioactive Iodine Planning. *Case Reports in Endocrinology* 2015, 1-3. [[CrossRef](#)]
432. Christopher Lee, Brenna Chalmers, Daniel Treister, Sumita Adhya, Benjamin Godwin, Lingyun Ji, Susan Groshen, Edward Grant. 2015. Thyroid Lesions Visualized on CT. *Academic Radiology* 22:2, 203. [[CrossRef](#)]
433. Funda Aydin, Murat Sipahi, Evrim Surer Budak, Ali Ozan Oner, Serkan Demirelli, Metin Erkilic, Firat Gungor. 2015. Role of Tc-99m pertechnetate for remnant scintigraphy, post-thyroidectomy, and serum thyroglobulin and antithyroglobulin antibody levels in the patients with differentiated thyroid cancer. *Annals of Nuclear Medicine* . [[CrossRef](#)]
434. Byung Seup Kim, Kyung Ho Kang, Sung Jun Park. 2015. Robotic modified radical neck dissection by bilateral axillary breast approach for papillary thyroid carcinoma with lateral neck metastasis. *Head & Neck* 37:10.1002/hed.v37.1, 37-45. [[CrossRef](#)]
435. Jenny K. Hoang, Julie A. Sosa, Xuan V. Nguyen, P. Leo Galvin, Jorge D. Oldan. 2015. Imaging Thyroid Disease. *Radiologic Clinics of North America* 53, 145-161. [[CrossRef](#)]
436. Víctor Manuel Andía Melero, María Martín de Santa-Olalla Llanes, Marcel Sambo Salas, Juan Carlos Percovich Hualpa, Marta Motilla de la Cámara, Luis Collado Yurrita. 2015. Comparison of differentiated thyroid carcinoma staging systems in a Spanish population. *Endocrinología y Nutrición (English Edition)* 62:4, 152. [[CrossRef](#)]
437. Jolanta Krajewska, Aleksandra Kukulska, Barbara Jarzab. 2015. Drug safety evaluation of lenvatinib for thyroid cancer. *Expert Opinion on Drug Safety* 1. [[CrossRef](#)]
438. Rickul Varshney, Veronique-Isabelle Forest, Marco A Mascarella, Faisal Zawawi, Louise Rochon, Michael P Hier, Alex Mlynarek, Michael Tamilia, Richard J Payne. 2015. The McGill thyroid nodule score – does it help with indeterminate thyroid nodules?. *Journal of Otolaryngology - Head & Neck Surgery* 44, 2. [[CrossRef](#)]
439. Young Gyung Shin, Hee Kang, Young Doc Joh, Kyung Soon Jeong, Beom Su Kim. 2015. Ultrasonographic Features of Metastatic Lymph Nodes in Papillary Thyroid Microcarcinomas and Macrocarcinomas. *Journal of the Korean Society of Radiology* 72, 92. [[CrossRef](#)]
440. Seo Ki Kim, Jun Ho Lee, Jung-Woo Woo, Inhye Park, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim. 2015. Prediction Table and Nomogram as Tools for Diagnosis of Papillary Thyroid Carcinoma. *Medicine* 94:21, e760. [[CrossRef](#)]
441. R. Paschke Struma mit Euthyreose – Internistische Therapie 1-8. [[CrossRef](#)]
442. Aarti Mathur, Martha A. Zeiger. 2015. Genomic medicine for cancer prognosis. *Journal of Surgical Oncology* 111:1, 31. [[CrossRef](#)]
443. Jolanta Krajewska, Daria Handkiewicz-Junak, Barbara Jarzab. 2015. Sorafenib for the treatment of thyroid cancer: an updated review. *Expert Opinion on Pharmacotherapy* 16:4, 573. [[CrossRef](#)]
444. Karla Judith González-Colunga, Abelardo Loya-Solis, Luis Ángel Ceceñas-Falcón, Oralia Barboza-Quintana, René Rodríguez-Gutiérrez. 2015. Warthin-Like Papillary Thyroid Carcinoma Associated with Lymphadenopathy and Hashimoto's Thyroiditis. *Case Reports in Endocrinology* 2015, 1-5. [[CrossRef](#)]



445. Ahmet Dirikoc, Sefika Burcak Polat, Zuhale Kandemir, Cevdet Aydin, Didem Ozdemir, Fatma Dilek Dellal, Reyhan Ersoy, Bekir Cakir. 2015. Comparison of ultrasonography features and malignancy rate of toxic and nontoxic autonomous nodules: a preliminary study. *Annals of Nuclear Medicine* . [CrossRef]
446. Jo Sung Jung, Sang Mi Lee, Sang Jin Kim, Jiyoung Choi, Sun Wook Han. 2015. Prediction of the success of thyroid remnant ablation using preablative <sup>99m</sup>Tc pertechnetate scintigraphy and postablative dual <sup>131</sup>I scintigraphy. *Nuclear Medicine Communications* **36**, 38-44. [CrossRef]
447. Ruijun Han, Fenghua Li, Yan Wang, Zhiqiang Ying, Yun Zhang. 2015. Virtual touch tissue quantification (VTQ) in the diagnosis of thyroid nodules with coexistent chronic autoimmune Hashimoto's thyroiditis: A preliminary study. *European Journal of Radiology* **84**:2, 327. [CrossRef]
448. Yan-Rong Li, Szu-Tah Chen, Chuen Hseuh, Tzu-Chieh Chao, Tsung-Ying Ho, Jen-Der Lin. 2015. Risk factors of distant metastasis in the follicular variant of papillary thyroid carcinoma. *Journal of the Formosan Medical Association* . [CrossRef]
449. Dana M. Hartl, Sophie Leboulleux, Fritz-Line Velayoudom-Céphise, Haïtham Mirghani, Désirée Déandréis, Martin Schlumberger. 2015. Management of Retropharyngeal Node Metastases from Thyroid Carcinoma. *World Journal of Surgery* **39**:5, 1274. [CrossRef]
450. Nils Rudqvist, Johan Spetz, Emil Schüler, Britta Langen, Toshima Z. Parris, Khalil Helou, Eva Forssell-Aronsson. 2015. Gene expression signature in mouse thyroid tissue after <sup>131</sup>I and <sup>211</sup>At exposure. *EJNMMI Research* **5**:1. . [CrossRef]
451. Johannes Gossner. 2015. Thyroliipomas – Prevalence in Computed Tomography and Suggestions for Pragmatic Management. *Polish Journal of Radiology* **80**, 305-308. [CrossRef]
452. Jun Woo Jung, June Young Choi, Kyu Eun Lee, Kwi Won Park. 2015. Immunohistochemical and Molecular Markers Associated with Differentiated Thyroid Carcinoma. *Journal of Korean Thyroid Association* **8**, 50. [CrossRef]
453. Taejung Park, Hyeongsin Lee, Seongwon Kim, Bugyeong Kim, Hyosang Park, Hyeongu Lee, Daeseok Shin, Nakyeong Kim, Kangdae Lee. 2015. The Development of an Automatic Thyroid Cancer Staging, Prognosis Predicting and Follow-Up Strategy Suggesting Calculator with Concurrent Data Input Process. *Korean Journal of Otorhinolaryngology-Head and Neck Surgery* **58**:6, 407. [CrossRef]
454. A. Pfestroff, M. Dietlein, M. Luster. 2015. Nuklearmedizinische Diagnostik, Therapie und Nachsorge des Schilddrüsenkarzinoms. *Der Onkologe* **21**:7, 597. [CrossRef]
455. Osman Ilkay Ozdamar, Gul Ozbilen Acar, Cigdem Kafkasli, M. Tayyar Kalcioğlu, Tulay Zenginkinet, H. Gonca Tamer. 2015. Papillary Thyroid Microcarcinoma with a Large Cystic Dilated Lymph Node Metastasis to the Neck Mimicking a Branchial Cleft Cyst: A Potential Pitfall. *Case Reports in Otolaryngology* **2015**, 1-4. [CrossRef]
456. Doh Young Lee, Kyoung Ho Oh, Jae-Gu Cho, Soon-Young Kwon, Jeong-Soo Woo, Seung-Kuk Baek, Kwang-Yoon Jung. 2015. The Benefits and Risks of Prophylactic Central Neck Dissection for Papillary Thyroid Carcinoma: Prospective Cohort Study. *International Journal of Endocrinology* **2015**, 1. [CrossRef]
457. Li Gao. 2015. Association between Decreased Serum Parathyroid Hormone after Total Thyroidectomy and Persistent Hypoparathyroidism. *Medical Science Monitor* **21**, 1223-1231. [CrossRef]
458. Marie Le Mercier, Nicky D'Haene, Nancy De Nève, Oriane Blanchard, Caroline Degand, Sandrine Rorive, Isabelle Salmon. 2015. Next-generation sequencing improves the diagnosis of thyroid FNA specimens with indeterminate cytology. *Histopathology* **66**:10.1111/his.2015.66.issue-2, 215-224. [CrossRef]
459. W. Jentzen, A.-S. Moldovan, M. Ruhlmann, R. Gorges, A. Bockisch, S. Rosenbaum-Krumme. 2015. Lowest effective <sup>131</sup>I activity for thyroid remnant ablation of differentiated thyroid cancer patients. *Nuklearmedizin* **54**:3, 137. [CrossRef]
460. Yong-il Kim, Hyung-Jun Im, Jin Chul Paeng, Gi Jeong Cheon, Keon Wook Kang, Dong Soo Lee, Do Joon Park, Young Joo Park, June-Key Chung. 2015. Serum thyroglobulin level after radioiodine therapy (Day 3) to predict successful ablation of thyroid remnant in postoperative thyroid cancer. *Annals of Nuclear Medicine* **29**:2, 184. [CrossRef]
461. Chei Won Kim, Seokbo Hong, Se Hwan Oh, Jung Jin Lee, Joo Young Han, Seongbin Hong, So Hun Kim, Moonsuk Nam, Yong Seong Kim. 2015. Change of Bone Mineral Density and Biochemical Markers of Bone Turnover in Patients on Suppressive Levothyroxine Therapy for Differentiated Thyroid Carcinoma. *Journal of Bone Metabolism* **22**, 135. [CrossRef]
462. Marc Pusztaszeri, He Wang, Edmund S. Cibas, Celeste N. Powers, Massimo Bongiovanni, Syed Ali, Kamal K. Khurana, Paul J. Michaels, William C. Faquin. 2015. Fine-needle aspiration biopsy of secondary neoplasms of the thyroid gland: A multi-institutional study of 62 cases. *Cancer Cytopathology* **123**, 19-29. [CrossRef]
463. Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang, Dong-Hoon Kim, Dong Hyun Kim. 2015. Characteristics of Neck Level VI Lymph Nodes in Papillary Thyroid Carcinoma: Correlation Between Nodal Characteristics and Primary Tumor. *Endocrine Pathology* **26**:1, 15. [CrossRef]

464. Carles Zafon, Manel Puig-Domingo, Josefina Biarnés, Irene Halperin, Maria Rosa Bella, Ignasi Castells, Cintia González, Ana Megia, Lola Santos, Luís García-Pascual, Jordi Lluís Reverter, Eduarda Pizarro, Didac Mauricio. 2015. A descriptive study of the characteristics of differentiated thyroid cancer in Catalonia during the period 1998–2012. The CECaT registry. *Endocrinología y Nutrición (English Edition)* **62**:6, 264. [[CrossRef](#)]
465. F. Rosignolo, V. Maggisano, M. Sponziello, M. Celano, C. R. T. Di Gioia, M. D'Agostino, L. Giacomelli, A. Verrienti, M. Dima, V. Pecce, C. Durante. 2015. Reduced expression of  $THR\beta$  in papillary thyroid carcinomas: relationship with BRAF mutation, aggressiveness and miR expression. *Journal of Endocrinological Investigation* . [[CrossRef](#)]
466. D. Hartl. 2015. Tumores de la glándula tiroidea. *EMC - Otorrinolaringología* **44**:3, 1. [[CrossRef](#)]
467. Kyung-Hee Kim, Min-Hee Kim, Ye-Jee Lim, Ihn Suk Lee, Ja-Seong Bae, Dong-Jun Lim, Ki Hyun Baek, Jong Min Lee, Moo-Il Kang, Bong-Yun Cha. 2015. Identification of Intermediate- to High-Risk Papillary Thyroid Carcinoma Patients Who May Be Safely Managed without the Performance of Delayed Stimulated Thyroglobulin Measurements following Total Thyroidectomy and Radioactive Iodine Therapy. *International Journal of Endocrinology* **2015**, 1-7. [[CrossRef](#)]
468. Jenny K. Hoang, Xuan V. Nguyen, Louise Davies. 2015. Overdiagnosis of Thyroid Cancer. *Academic Radiology* **22**:8, 1024. [[CrossRef](#)]
469. Soo Youn Cho, Tae Hyun Lee, Yun Hyi Ku, Hong Il Kim, Guk Haeng Lee, Min Joo Kim. 2015. Central lymph node metastasis in papillary thyroid microcarcinoma can be stratified according to the number, the size of metastatic foci, and the presence of desmoplasia. *Surgery* **157**, 111-118. [[CrossRef](#)]
470. Young Hen Lee, Jung Hwan Baek, So Lyung Jung, Jin Young Kwak, Ji-hoon Kim, Jung Hee Shin. 2015. Ultrasound-Guided Fine Needle Aspiration of Thyroid Nodules: A Consensus Statement by the Korean Society of Thyroid Radiology. *Korean Journal of Radiology* **16**, 391. [[CrossRef](#)]
471. Tracy S. Wang, Adwoa Opoku-Boateng, Sanziana A. Roman, Julie Ann Sosa. 2015. Prophylactic thyroidectomy: Who needs it, when, and why. *Journal of Surgical Oncology* **111**:1, 61. [[CrossRef](#)]
472. Hak Hoon Jun, Seok Mo Kim, Bup Woo Kim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park. 2015. Overcoming the Limitations of Fine Needle Aspiration Biopsy: Detection of Lateral Neck Node Metastasis in Papillary Thyroid Carcinoma. *Yonsei Medical Journal* **56**, 182. [[CrossRef](#)]
473. Mohiedean Ghofrani, Idris Tolgay Ocal. 2015. Medullary Thyroid Carcinoma. *Pathology Case Reviews* **20**, 204-209. [[CrossRef](#)]
474. Hyukjin Yoon, Sung Hoon Kim, Joo Hyun O, Ye Young Seo, Yeongjoo Lee, Hyoungwoo Kim, Jiyoung Ryu. 2015. Correlation of Consecutive Serum Thyroglobulin Levels During Hormone Withdrawal and Failure of Initial Radioiodine Ablation in Thyroid Cancer Patients. *Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
475. S. Palimeri, P. Gousis, B. Vlassopoulou. 2015. Indications of radioactive iodine ablation in papillary thyroid cancer. *Hellenic Journal of Surgery* **87**, 53-57. [[CrossRef](#)]
476. Amy Chow, Xinjiang Cai, Sophia Hu, Xiangbing Wang. 2015. Iodine Deficiency-Induced Goiter in Central New Jersey: A Case Series. *AACE Clinical Case Reports* **1**, e40-e44. [[CrossRef](#)]
477. Pedro Wesley Rosario, Gabriela Franco Mourão, Maria Regina Calsolari. 2015. Is Stimulated Thyroglobulin Necessary after Ablation in All Patients with Papillary Thyroid Carcinoma and Basal Thyroglobulin Detectable by a Second-Generation Assay?. *International Journal of Endocrinology* **2015**, 1. [[CrossRef](#)]
478. Andrew G. Gianoukakis. 2015. Thyroglobulin antibody status and differentiated thyroid cancer. *Current Opinion in Oncology* **27**, 26-32. [[CrossRef](#)]
479. Kyoung Sook Won. 2015. Low Dose versus High Dose Radioiodine Therapy. *Journal of Korean Thyroid Association* **8**, 14. [[CrossRef](#)]
480. Jung-Soo Pyo, Jin Hee Sohn, Guhyun Kang, Dong-Hoon Kim, Jisup Yun. 2015. Total Surface Area Is Useful for Differentiating between Aggressive and Favorable Multifocal Papillary Thyroid Carcinomas. *Yonsei Medical Journal* **56**, 355. [[CrossRef](#)]
481. Shouhao Feng, Shengli Lin, Jidong Zou, Yulong Wang, Qinghai Ji, Zhenghua Lv. 2015. Association between rs12045440 Polymorphism in the CAPZB Intron and Serum TSH Concentrations in Chinese Thyroid Tumor Patients. *International Journal of Endocrinology* **2015**, 1. [[CrossRef](#)]
482. Nicoleta C. Arva, Sarah G. Deitch. 2015. Reclassification of cytologically atypical thyroid nodules based on radiologic features in pediatric patients. *Journal of Pediatric Endocrinology and Metabolism* **28**. . [[CrossRef](#)]
483. Haijun Zhou, Dina R. Mody, Debora Smith, Maura B. Lloyd, Jon Kempainen, Jeffrey Houghton, Dennis Wylie, Anna E. Szafranska-Schwarzbach, Hidehiro Takei. 2015. FNA needle rinses preserved in Cytolyt are acceptable specimen type for mutation testing of thyroid nodules. *Journal of the American Society of Cytopathology* . [[CrossRef](#)]

484. Anjali Mishra, Prasanta Kumar Pradhan, Sanjay Gambhir, Myilvaganan Sabaretanam, Archana Gupta, Satish Babu. 2015. Preoperative contrast-enhanced computerized tomography should not delay radioiodine ablation in differentiated thyroid carcinoma patients. *Journal of Surgical Research* **193**:2, 731. [[CrossRef](#)]
485. K. Agrawal, J. Weaver, R. Ngu, H. Krishnamurthy Mohan. 2015. Clinical significance of patterns of incidental thyroid uptake at 18F-FDG PET/CT. *Clinical Radiology* **70**:5, 536. [[CrossRef](#)]
486. Young Jun Choi, Jung Hwan Baek, Min Ji Hong, Jeong Hyun Lee. 2015. Inter-Observer Variation in Ultrasound Measurement of the Volume and Diameter of Thyroid Nodules. *Korean Journal of Radiology* **16**, 560. [[CrossRef](#)]
487. Pierpaolo Trimboli, Leo Guidobaldi, Massimo Bongiovanni, Anna Crescenzi, Maria Alevizaki, Luca Giovanella, Liron Pantanowitz. 2015. Use of fine-needle aspirate calcitonin to detect medullary thyroid carcinoma: A systematic review. *Diagnostic Cytopathology* n/a. [[CrossRef](#)]
488. M. Lassmann, H. Hänscheid. 2015. Individuelle Dosimetrie bei der Radiojodtherapie. *Der Onkologe* **21**:7, 611. [[CrossRef](#)]
489. I. Koutelidakis, A. Doundis, G. Chatzimavroudis, J. Makris. 2015. The role of prophylactic central compartment neck dissection in papillary thyroid cancer. *Hellenic Journal of Surgery* **87**, 41-48. [[CrossRef](#)]
490. Ming-Kai Chen, David W. Cheng. 2015. What is the role of dosimetry in patients with advanced thyroid cancer?. *Current Opinion in Oncology* **27**, 33-37. [[CrossRef](#)]
491. K.W. Schmid, D. Führer. 2015. Rolle der Molekularpathologie beim Schilddrüsenkarzinom. *Der Onkologe* **21**:7, 584. [[CrossRef](#)]
492. Jeong Won Lee, Sang Mi Lee, Jiyoun Choi. 2015. Clinical significance of diffuse hepatic uptake on post-therapeutic early and delayed 131I scan in differentiated thyroid cancer: a preliminary report. *Annals of Nuclear Medicine* **29**:2, 190. [[CrossRef](#)]
493. Fábio Muradás Girardi, Marinez Bizarro Barra, Cláudio Galleano Zettler. 2015. Predictive Factors for Lymph Node Metastasis in Solitary Papillary Thyroid Carcinomas: A Retrospective Study. *Pathology & Oncology Research* **21**, 59-64. [[CrossRef](#)]
494. Seunggyun Ha, So Won Oh, Yu Kyeong Kim, Do Hoon Koo, Young Ho Jung, Ka Hee Yi, June-Key Chung. 2015. Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer. *Journal of Korean Medical Science* **30**, 876. [[CrossRef](#)]
495. Marina Muzza, Carla Colombo, Stefania Rossi, Delfina Tosi, Valentina Cirello, Michela Perrino, Simone De Leo, Elisa Magnani, Elisa Pignatti, Beatrice Vigo, Manuela Simoni, Gaetano Bulfamante, Leonardo Vicentini, Laura Fugazzola. 2015. Telomerase in differentiated thyroid cancer: Promoter mutations, expression and localization. *Molecular and Cellular Endocrinology* **399**, 288-295. [[CrossRef](#)]
496. Yoon Kyoung So, Myung Woo Kim, Young-Ik Son. 2015. Multifocality and Bilaterality of Papillary Thyroid Microcarcinoma. *Clinical and Experimental Otorhinolaryngology* **8**, 174. [[CrossRef](#)]
497. I. Koutelidakis, A. Ananiadis, V. Papaziogas, J. Makris. 2015. Surgical management of differentiated papillary and follicular thyroid cancer. *Hellenic Journal of Surgery* **87**, 38-40. [[CrossRef](#)]
498. Jung Hyun Yoon, Hye Sun Lee, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2015. Thyroid Nodules: Nondiagnostic Cytologic Results according to Thyroid Imaging Reporting and Data System before and after Application of the Bethesda System. *Radiology* **276**:2, 579. [[CrossRef](#)]
499. Surasawadee Ausavarat, Jiraporn Sripraporn, Busara Satayaban, Wanna Thongnoppakhun, Aunchalee Laipiriyakun, Boontham Amornkitticharoen, Rujaporn Chanachai, Chaveevan Pattanachak. 2015. Circulating thyrotropin receptor messenger ribonucleic acid is not an effective marker in the follow-up of differentiated thyroid carcinoma. *Thyroid Research* **8**:1. . [[CrossRef](#)]
500. Chen-Tian Shen, Wei-Jun Wei, Zhong-Ling Qiu, Hong-Jun Song, Quan-Yong Luo. 2015. Value of post-therapeutic 131I scintigraphy in stimulated serum thyroglobulin-negative patients with metastatic differentiated thyroid carcinoma. *Endocrine* . [[CrossRef](#)]
501. Ji Soo Choi, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2015. Higher body mass index may be a predictor of extrathyroidal extension in patients with papillary thyroid microcarcinoma. *Endocrine* **48**:1, 264. [[CrossRef](#)]
502. Marjory Alana Marcello, Antonio Ramos Calixto, Jacqueline Fatima Martins de Almeida, Mariana Bonjiorno Martins, Lucas Leite Cunha, Camila Ayume Amano Cavallari, Elba C. S. Etchebehere, Ligia Vera Montalli da Assumpção, Bruno Geloneze, Andre Lopes Carvalho, Laura Sterian Ward. 2015. Polymorphism in LEP and LEPR May Modify Leptin Levels and Represent Risk Factors for Thyroid Cancer. *International Journal of Endocrinology* **2015**, 1-8. [[CrossRef](#)]
503. Nikola Besic, Marta Dremelj, Andreja Schwartzbartl-Pavec, Barbara Gazic. 2015. Neoadjuvant chemotherapy in 13 patients with locally advanced poorly differentiated thyroid carcinoma based on Turin proposal - a single institution experience. *Radiology and Oncology* **49**. . [[CrossRef](#)]
504. I. Kostoglou-Athanassiou. 2015. Indications for surgical treatment in benign thyroid disease. *Hellenic Journal of Surgery* **87**, 18-23. [[CrossRef](#)]

505. Sohail Bakkar, Gabriele Materazzi, Marco Biricotti, Luigi De Napoli, Massimo Conte, David Galleri, Aleksandr Aghababayan, Paolo Miccoli. 2015. Minimally invasive video-assisted thyroidectomy (MIVAT) from A to Z. *Surgery Today* . [[CrossRef](#)]
506. Chang Wook Lee, Gyungyup Gong, Jong-Lyel Roh. 2015. Intraoperative Diagnosis of Central Compartment Lymph Node Metastasis Predicts Recurrence of Patients with Papillary Thyroid Carcinoma and Clinically Node-Negative Lateral Neck and May Guide Extent of Initial Surgery. *World Journal of Surgery* **39**, 194-202. [[CrossRef](#)]
507. Niveen A. Abo-Touk, Dalia H. Zayed. 2015. The Efficacy of Thyrotropin Suppression Therapy in Treatment of Differentiated Thyroid Cancer after Total Thyroidectomy. *Forum of Clinical Oncology* **6** . [[CrossRef](#)]
508. D. Georgiadou, A. Diamantopoulos, G.N. Zografos. 2015. Nomenclature of thyroid surgical procedures. *Hellenic Journal of Surgery* **87**, 9-10. [[CrossRef](#)]
509. Cunchuan Wang, Zhiqi Feng, Jinyi Li, Wah Yang, Hening Zhai, Nim Choi, Jingge Yang, Youzhu Hu, Yunlong Pan, Guo Cao. 2015. Endoscopic thyroidectomy via areola approach: summary of 1,250 cases in a single institution. *Surgical Endoscopy* **29**, 192-201. [[CrossRef](#)]
510. Linwah Yip. 2015. Molecular markers for thyroid cancer diagnosis, prognosis, and targeted therapy. *Journal of Surgical Oncology* **111**:1, 43. [[CrossRef](#)]
511. Doh Young Lee, Jungirl Seok, Woo-Jin Jeong, Soon-Hyun Ahn. 2015. Prediction of thyroid hormone supplementation after thyroid lobectomy. *Journal of Surgical Research* **193**, 273-278. [[CrossRef](#)]
512. Jandee Lee, Mi-Youn Seol, Seonhyang Jeong, Cho Rok Lee, Cheol Ryong Ku, Sang-Wook Kang, Jong Ju Jeong, Dong Yeob Shin, Kee-Hyun Nam, Eun Jig Lee, Woong Youn Chung, Young Suk Jo. 2015. A Metabolic Phenotype Based on Mitochondrial Ribosomal Protein Expression as a Predictor of Lymph Node Metastasis in Papillary Thyroid Carcinoma. *Medicine* **94**, e380. [[CrossRef](#)]
513. Carlos Aitor Macias, Dena Arumugam, Renee L. Arlow, Oliver S. Eng, Shou-En Lu, Parisa Javidian, Tomer Davidov, Stanley Z. Trooskin. 2015. A Risk Model to Determine Surgical Treatment in Patients with Thyroid Nodules with Indeterminate Cytology. *Annals of Surgical Oncology* **22**:5, 1527. [[CrossRef](#)]
514. Benjamin R. Roman, Mahmoud I. Awad, Snehal G. Patel. 2015. Defining Value-Driven Care in Head and Neck Oncology. *Current Oncology Reports* **17** . [[CrossRef](#)]
515. Sue Chang, Jeffrey F. Krane. 2015. Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance. *Pathology Case Reviews* **20**, 110-114. [[CrossRef](#)]
516. V. Tiedje, K.W. Schmid, F. Weber, A. Bockisch, D. Führer. 2015. Differenzierte Schilddrüsenkarzinome. *Der Internist* **56**:2, 153. [[CrossRef](#)]
517. Giorgio Grani, Mimma D'Alessandri, Giovanni Carbotta, Angela Nesca, Marianna Del Sordo, Stefania Alessandrini, Carmela Coccaro, Roberta Rendina, Marta Bianchini, Natalie Prinzi, Angela Fumarola. 2015. Grey-Scale Analysis Improves the Ultrasonographic Evaluation of Thyroid Nodules. *Medicine* **94**:27, e1129. [[CrossRef](#)]
518. S. Lanitis, G. Sourtse, A. Kouloura, V. Ganis. 2015. Thyroid surgery: Does frozen section have a role? If yes, in which cases?. *Hellenic Journal of Surgery* **87**, 31-33. [[CrossRef](#)]
519. Hyeong Ju Kwon, Eun-Kyung Kim, Jin Young Kwak. 2015. Value of Additional von Kossa Staining in Thyroid Nodules with "Suspicious for Malignancy" on Cytology. *Journal of Korean Thyroid Association* **8**, 81. [[CrossRef](#)]
520. Myung Ho Rho, Dong Wook Kim. 2015. Long-Term Ultrasonography Follow-Up of Thyroid Colloid Cysts at the Health Center: A Single-Center Study. *International Journal of Endocrinology* **2015**, 1. [[CrossRef](#)]
521. Jing Qin, Zhenqian Yu, Haixia Guan, Liangfeng Shi, Yongping Liu, Na Zhao, Zhongyan Shan, Cheng Han, Yushu Li, Weiping Teng. 2015. High Thyroglobulin Antibody Levels Increase the Risk of Differentiated Thyroid Carcinoma. *Disease Markers* **2015**, 1-7. [[CrossRef](#)]
522. Seun Choi, Chang Ju Na, Jeonghun Kim, Yeon-Hee Han, Hee-Kwon Kim, Hwan-Jeong Jeong, Myung-Hee Sohn, Seok Tae Lim. 2014. Comparison of Therapeutic Efficacy and Clinical Parameters Between Recombinant Human Thyroid Stimulating Hormone and Thyroid Hormone Withdrawal in High-Dose Radioiodine Treatment with Differentiated Thyroid Cancer. *Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
523. Jonklaas Jacqueline, Bianco Antonio C., Bauer Andrew J., Burman Kenneth D., Cappola Anne R., Celi Francesco S., Cooper David S., Kim Brian W., Peeters Robin P., Rosenthal M. Sara, Sawka Anna M.. 2014. Guidelines for the Treatment of Hypothyroidism: Prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. *Thyroid* **24**:12, 1670-1751. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

524. Li Zhe, Franklin Jason, Zelcer Shayna, Sexton Tracy, Husein Murad. 2014. Ultrasound Surveillance for Thyroid Malignancies in Survivors of Childhood Cancer Following Radiotherapy: A Single Institutional Experience. *Thyroid* 24:12, 1796-1805. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links] [Supplemental Material]
525. Bahl Manisha, Sosa Julie A., Eastwood James D., Hobbs Hasan A., Nelson Rendon C., Hoang Jenny K.. 2014. Using the 3-Tiered System for Categorizing Workup of Incidental Thyroid Nodules Detected on CT, MRI, or PET/CT: How Many Cancers Would Be Missed?. *Thyroid* 24:12, 1772-1778. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
526. Nguyen Chau, Wang Marilene. 2014. Practice Patterns in the Surgical Treatment of Papillary Thyroid Microcarcinoma. *Thyroid* 24:12, 1816-1817. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
527. Laura Y. Wang, Iain J. Nixon, Frank L. Palmer, Dorothy Thomas, R. Michael Tuttle, Ashok R. Shaha, Snehal G. Patel, Jatin P. Shah, Ian Ganly. 2014. Comparable outcomes for patients with pT1a and pT1b differentiated thyroid cancer: Is there a need for change in the AJCC classification system?. *Surgery* 156, 1484-1490. [CrossRef]
528. Hee Jeong Park, Geum-Cheol Jeong, Seong Young Kwon, Jung-Joon Min, Hee-Seung Bom, Ki Seong Park, Sang-Geon Cho, Sae-Ryung Kang, Jahae Kim, Ho-Chun Song, Ari Chong, Su Woong Yoo. 2014. Stimulated Serum Thyroglobulin Level at the Time of First Dose of Radioactive Iodine Therapy Is the Most Predictive Factor for Therapeutic Failure in Patients With Papillary Thyroid Carcinoma. *Nuclear Medicine and Molecular Imaging* 48, 255-261. [CrossRef]
529. Tao Wei, Zhihui Li, Judy Jin, Rui Chen, Yanping Gong, Zhenhong Du, Rixiang Gong, Jingqiang Zhu. 2014. Autotransplantation of Inferior Parathyroid glands during central neck dissection for papillary thyroid carcinoma: A retrospective cohort study. *International Journal of Surgery* 12, 1286-1290. [CrossRef]
530. Aya Ebina, Iwao Sugitani, Yoshihide Fujimoto, Keiko Yamada. 2014. Risk-adapted management of papillary thyroid carcinoma according to our own risk group classification system: Is thyroid lobectomy the treatment of choice for low-risk patients?. *Surgery* 156, 1579-1589. [CrossRef]
531. Saad Ajmal, Sarah Rapoport, Haiyan Ramirez Battle, Peter J. Mazzaglia. 2014. The Natural History of the Benign Thyroid Nodule: What Is the Appropriate Follow-Up Strategy?. *Journal of the American College of Surgeons* . [CrossRef]
532. Xiao-Jun Zhang, Yao-Rong Su, Dan Liu, De-Bin Xu, Mu-Sheng Zeng, Wen-Kuan Chen. 2014. Thymosin beta 10 correlates with lymph node metastases of papillary thyroid carcinoma. *Journal of Surgical Research* 192, 487-493. [CrossRef]
533. Vicki J. Schnadig. 2014. Ultrasonography, FNA, mutations, hormones and thyroid nodule obsession in the twenty-first century: a cytopathologist's plea for reason in the age of thyroid storm. *Endocrine* 47, 664-667. [CrossRef]
534. David J. Phillips, David I. Kutler, William I. Kuhel. 2014. Incidental thyroid nodules in patients with primary hyperparathyroidism. *Head & Neck* 36:10.1002/hed.v36.12, 1763-1765. [CrossRef]
535. Wayne S. Lee, Barnard J.A. Palmer, Arturo Garcia, Vincent E. Chong, Terrence H. Liu. 2014. BRAF mutation in papillary thyroid cancer: A cost-utility analysis of preoperative testing. *Surgery* 156, 1569-1578. [CrossRef]
536. Dong Yeob Shin, Young Ki Lee, Kwang Joon Kim, Kyeong Hye Park, Sena Hwang, Se Hee Park, Eun-Kyung Kim, Hyeong Ju Kwon, Eun Jig Lee. 2014. Thyroid Cancers with Benign-Looking Sonographic Features Have Different Lymph Node Metastatic Risk and Histologic Subtypes According to Nodule Size. *Endocrine Pathology* 25, 378-384. [CrossRef]
537. Mazin Merdad, Antoine Eskander, John De Almeida, Jeremy Freeman, Lorne Rotstein, Shereen Ezzat, Anna M Sawka, David P Goldstein. 2014. Current management of papillary thyroid microcarcinoma in Canada. *Journal of Otolaryngology - Head & Neck Surgery* 43. . [CrossRef]
538. Elena-Daphne Thies, Karina Tanase, Uwe Maeder, Markus Luster, Andreas K. Buck, Heribert Hänscheid, Christoph Reiners, Frederik A. Verburg. 2014. The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging* 41, 2281-2290. [CrossRef]
539. M.-L. Matthey-Gie, S. M. Walsh, A. C. O'Neill, A. Lowery, D. Evoy, D. Gibbons, R. S. Prichard, S. Skehan, E. W. McDermott. 2014. Ultrasound predictors of malignancy in indeterminate thyroid nodules. *Irish Journal of Medical Science (1971 -)* 183, 633-637. [CrossRef]
540. Bernardo Dias Pereira, René Gerhard, Fernando Schmitt. 2014. Putting an eye on cytological specimens: An audit of the clinical impact of thyroid fine-needle aspiration in different health care settings. *Diagnostic Cytopathology* 42:10.1002/dc.v42.12, 1009-1012. [CrossRef]
541. Chowdhury F. Miah, Jessica A. Zaman, Mitchell Simon, Tomer Davidov, Stanley Z. Trooskin. 2014. The utility of lymph node mapping sonogram and thyroglobulin surveillance in post thyroidectomy papillary thyroid cancer patients. *Surgery* 156, 1491-1497. [CrossRef]
542. Ka Kit Wong, Daniel J. Wale, Lorraine M. Fig, Milton D. Gross. 2014. SPET-CT in thyroid cancer: a systematic review. *Clinical and Translational Imaging* 2, 459-475. [CrossRef]

543. Cameron D. Adkisson, Gina M. Howell, Kelly L. McCoy, Michaele J. Armstrong, Meghan L. Kelley, Michael T. Stang, Judith M. Joyce, Steven P. Hodak, Sally E. Carty, Linwah Yip. 2014. Surgeon volume and adequacy of thyroidectomy for differentiated thyroid cancer. *Surgery* **156**, 1453-1460. [[CrossRef](#)]
544. Guido Fadda, Esther Diana Rossi. 2014. Immunohistochemical Diagnosis of Thyroid Tumors. *Surgical Pathology Clinics* **7**, 491-500. [[CrossRef](#)]
545. Aparna Lakshmanan, Daniel Scarberry, Daniel H. Shen, Sissy M. Jhiang. 2014. Modulation of Sodium Iodide Symporter in Thyroid Cancer. *Hormones and Cancer* **5**, 363-373. [[CrossRef](#)]
546. Sertac Asa, Sabire Yilmaz Aksoy, Betül Vatankulu, Anar Aliyev, Lebriz Uslu, Meftune Ozhan, Sait Sager, Metin Halac, Kerim Sonmezoglu. 2014. The role of FDG-PET/CT in differentiated thyroid cancer patients with negative iodine-131 whole-body scan and elevated anti-Tg level. *Annals of Nuclear Medicine* **28**, 970-979. [[CrossRef](#)]
547. Jonathan Khalifa, Laure Vieilleveigne, Sabrina Boyrie, Monia Ouali, Thomas Filleron, Michel Rives, Anne Laprie. 2014. Dosimetric comparison between helical tomotherapy and volumetric modulated arc-therapy for non-anaplastic thyroid cancer treatment. *Radiation Oncology* **9**. . [[CrossRef](#)]
548. Jolanta Krajewska, Barbara Jarzab. 2014. Novel therapies for thyroid cancer. *Expert Opinion on Pharmacotherapy* **15**, 2641-2652. [[CrossRef](#)]
549. Hengqiang Zhao, Yuan Tian, Zeming Liu, Xiaoyu Li, Mengyu Feng, Tao Huang. 2014. Correlation Between Iodine Intake and Thyroid Disorders: A Cross-Sectional Study from the South of China. *Biological Trace Element Research* **162**, 87-94. [[CrossRef](#)]
550. Sandip Basu. 2014. Employing Bayesian approach to the intermediate risk categories of the Bethesda thyroid cytopathology reporting system: can FDG PET/CT find a strong enough evidence-base to be practised clinically as an adjunct?. *European Journal of Nuclear Medicine and Molecular Imaging* **41**, 2354-2355. [[CrossRef](#)]
551. Sally E. Carty. 2014. 2014 American Association of Endocrine Surgeons Presidential Address: Evolution. *Surgery* **156**, 1289-1296. [[CrossRef](#)]
552. James F. Tsang, Daniel P. Levin, William D. Leslie. 2014. Thyroglobulin Flare Response After Radioiodine Ablation in 2 Patients With Differentiated Thyroid Cancer. *Clinical Nuclear Medicine* **1**. [[CrossRef](#)]
553. Moran Amit, Yaron Rudnicki, Yoav Binenbaum, Leonor Trejo-Leider, Jacob T. Cohen, Ziv Gil. 2014. Defining the outcome of patients with delayed diagnosis of differentiated thyroid cancer. *The Laryngoscope* **124**:10.1002/lary.v124.12, 2837-2840. [[CrossRef](#)]
554. Peggy S. Sullivan, Sharon L. Hirschowitz, Po Chu Fung, Sophia K. Apple. 2014. The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda System. *Cancer Cytopathology* **122**:10.1002/cncy.v122.12, 866-872. [[CrossRef](#)]
555. Young Jun Chai, Young A. Kim, Hyeon-Gun Jee, Jin Wook Yi, Bo Gun Jang, Kyu Eun Lee, Young Joo Park, Yeo-Kyu Youn. 2014. Expression of the embryonic morphogen Nodal in differentiated thyroid carcinomas: Immunohistochemistry assay in tissue microarray and The Cancer Genome Atlas data analysis. *Surgery* **156**, 1559-1568. [[CrossRef](#)]
556. Youn Hee Jee, Francesco S. Celi, Maureen Sampson, David B. Sacks, Alan T. Remaley, Electron Kebebew, Jeffrey Baron. 2014. Midkine concentrations in fine-needle aspiration of benign and malignant thyroid nodules. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
557. Michael W. Deutschmann, Laura Chin-Lenn, Jennifer Au, Alan Brilz, Steve Nakoneshny, Joseph C. Dort, Janice L. Pasioka, Shamir P. Chandarana. 2014. Extent of Central Neck Dissection among Thyroid Cancer Surgeons: A Cross-sectional Analysis. *Head & Neck* n/a-n/a. [[CrossRef](#)]
558. Andre Isaac, Caroline C Jeffery, Hadi Seikaly, Hani Al-Marzouki, Jeffrey R Harris, Daniel A O'Connell. 2014. Predictors of non-diagnostic cytology in surgeon-performed ultrasound guided fine needle aspiration of thyroid nodules. *Journal of Otolaryngology - Head & Neck Surgery* **43**. . [[CrossRef](#)]
559. Jun Yang, Lin-Fa Li, Xiu-Ming Zhang, Qin Xu, Jun-½ Zhang, Wan-Wen Weng, Meng-Jie Dong. 2014. Unusual synchronous skeletal muscle and lung metastasis in papillary thyroid cancer: A case report and review of the literature. *Oncology Letters* . [[CrossRef](#)]
560. Nunzia Brusca, Susanna Carlotta Del Duca, Rita Salvatori, Antonio D'Agostini, Pina Cannas, Maria Giulia Santaguida, Camilla Virili, Loredana Bianchi, Lucilla Gargano, Marco Centanni. 2014. A Case Report of Thyroid Carcinoma Confined To Ovary And Concurrently Occult in The Thyroid: Is Conservative Treatment Always Advised?. *International Journal of Endocrinology and Metabolism* **13**. . [[CrossRef](#)]
561. Betul Unal, Cem Sezer. 2014. Diagnostic Value of Ultrasound-Guided Fine Needle Aspiration Biopsy in Malignant Thyroid Nodules: Utility for Micronodules. *Asian Pacific Journal of Cancer Prevention* **15**, 8613-8616. [[CrossRef](#)]

562. Ling-Na Mao, Ping Wang, Zhi-Yu Li, Yong Wang, Zheng-Ya Song. 2014. Risk factor analysis for central nodal metastasis in papillary thyroid carcinoma. *Oncology Letters* . [[CrossRef](#)]
563. Campenni Alfredo, Giovanella Luca, Siracusa Massimiliano, Stipo Maria Elena, Alibrandi Angela, Cucinotta Mariapaola, Ruggeri Rosaria M., Baldari Sergio. 2014. Is Malignant Nodule Topography an Additional Risk Factor for Metastatic Disease in Low-Risk Differentiated Thyroid Cancer?. *Thyroid* **24**:11, 1607-1611. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
564. Siegel Jeffrey A., Silberstein Edward B.. 2014. The AEC/NRC 30mCi Rule: Regulatory Origins and Clinical Consequences for <sup>131</sup>I Remnant Ablative Doses. *Thyroid* **24**:11, 1625-1635. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
565. Julie Ann Sosa. 2014. What's Old is New Again. *Annals of Surgical Oncology* **21**, 3719-3720. [[CrossRef](#)]
566. Adebowale J Adeniran, Pei Hui. 2014. Best practice of BRAF V600E mutation testing for the diagnosis and management of thyroid cancers. *Expert Review of Endocrinology & Metabolism* **9**, 571-577. [[CrossRef](#)]
567. Marcos Alejandro Cohen Sabban, Cintia Palmero, Beatriz Bertrand, Ana Aiello, Amalia Ghiglioni, Maria Celina Mac Donell, Cecilia Croci, Patricia Cabaeiro, Guillermo Juan Juvenal. 2014. Incidencia de cáncer de tiroides en la provincia de Neuquén, período 2001-2012. *Endocrinología y Nutrición* **61**, 455-459. [[CrossRef](#)]
568. Sang Hyun Choi, Jung Hwan Baek, Jeong Hyun Lee, Young Jun Choi, Min Ji Hong, Dong Eun Song, Jae Kyun Kim, Jong Ho Yoon, Won Bae Kim. 2014. Thyroid nodules with initially non-diagnostic, fine-needle aspiration results: comparison of core-needle biopsy and repeated fine-needle aspiration. *European Radiology* **24**, 2819-2826. [[CrossRef](#)]
569. Richard G. Barr. 2014. Elastography in Clinical Practice. *Radiologic Clinics of North America* **52**, 1145-1162. [[CrossRef](#)]
570. Stephanie F. Coquia, Linda C. Chu, Ulrike M. Hamper. 2014. The Role of Sonography in Thyroid Cancer. *Radiologic Clinics of North America* **52**, 1283-1294. [[CrossRef](#)]
571. Yujie Zhang, Zhaowei Meng, Mingfang Zhang, Jian Tan, Weijun Tian, Xianghui He, Qiang Fu, Ke Xu, Qing He, Mei Zhu, Xue Li, Guizhi Zhang, Yajing He, Qiang Jia, Jianping Zhang, Sheng Wang, Xinghua Song. 2014. Immunohistochemical evaluation of midkine and nuclear factor-kappa B as diagnostic biomarkers for papillary thyroid cancer and synchronous metastasis. *Life Sciences* **118**, 39-45. [[CrossRef](#)]
572. Chae Moon Hong, Seung Hyun Son, Choon-Young Kim, Do-Hoon Kim, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn. 2014. Emptying effect of massage on parotid gland radioiodine content. *Nuclear Medicine Communications* **35**, 1127-1131. [[CrossRef](#)]
573. Giovanni Conzo, Nicola Avenia, Giuseppe Bellastella, Giancarlo Candela, Annamaria de Bellis, Katherine Esposito, Daniela Pasquali, Andrea Polistena, Luigi Santini, Antonio Agostino Sinisi. 2014. The role of surgery in the current management of differentiated thyroid cancer. *Endocrine* **47**, 380-388. [[CrossRef](#)]
574. Jane Gibson, Stephen Young, Bing Leng, Riyam Zreik, Arundhati Rao. 2014. Molecular diagnostic testing of cytology specimens: current applications and future considerations. *Journal of the American Society of Cytopathology* **3**, 280-294. [[CrossRef](#)]
575. Tianrun Liu, Xuan Su, Weichao Chen, Lie Zheng, Li Li, AnKui Yang. 2014. A mathematical model using computed tomography for the diagnosis of metastatic central compartment lymph nodes in papillary thyroid carcinoma. *European Radiology* **24**, 2827-2834. [[CrossRef](#)]
576. Arturo Garcia, Barnard J.A. Palmer, Nancy A. Parks, Terrence H. Liu. 2014. Routine prophylactic central neck dissection for low-risk papillary thyroid cancer is not cost-effective. *Clinical Endocrinology* **81**:10.1111/cen.2014.81.issue-5, 754-761. [[CrossRef](#)]
577. M. Bahl, J. A. Sosa, R. C. Nelson, J. K. Hoang. 2014. Imaging-Detected Incidental Thyroid Nodules that Undergo Surgery: A Single-Center Experience Over 1 Year. *American Journal of Neuroradiology* **35**, 2176-2180. [[CrossRef](#)]
578. Michael D. Beland, Thomas J.T. Anderson, Michael K. Atalay, David J. Grand, John J. Cronan. 2014. Resident Experience Increases Diagnostic Rate of Thyroid Fine-Needle Aspiration Biopsies. *Academic Radiology* **21**, 1490-1494. [[CrossRef](#)]
579. Mohammed Aldawish, Naresh Jha, Alexander J. B. McEwan, Diane Severin, Sunita Ghosh, Donald W. Morrish. 2014. Low but measurable stimulated serum thyroglobulin levels <2 µg/L frequently predict incomplete response in differentiated thyroid cancer patients. *Endocrine Research* **39**, 157-163. [[CrossRef](#)]
580. Chandler Park, Jessica Perini, Roger W Farmer, Tanya Fancy, Manish Monga, Scot C Remick. 2014. Sorafenib and thyroid cancer. *Expert Review of Endocrinology & Metabolism* **9**, 561-570. [[CrossRef](#)]
581. Chae Moon Hong, Won Kee Lee, Shin Young Jeong, Sang-Woo Lee, Byeong-Cheol Ahn, Jaetae Lee. 2014. Superiority of delayed risk stratification in differentiated thyroid cancer after total thyroidectomy and radioactive iodine ablation. *Nuclear Medicine Communications* **35**, 1119-1126. [[CrossRef](#)]

582. Marcos Alejandro Cohen Sabban, Cintia Palmero, Beatriz Bertrand, Ana Aiello, Amalia Ghiglioni, Maria Celina Mac Donell, Cecilia Croci, Patricia Cabaeiro, Guillermo Juan Juvenal. 2014. Incidence rate of thyroid cancer in Neuquén (2001–2012). *Endocrinología y Nutrición (English Edition)* **61**, 455–459. [[CrossRef](#)]
583. Valeria M. Moncayo, John N. Aarsvold, Naomi P. Alazraki. 2014. Nuclear Medicine Imaging and Therapy: Gender Biases in Disease. *Seminars in Nuclear Medicine* **44**, 413–422. [[CrossRef](#)]
584. Emily Steinhagen, Vanessa W. Hui, Rachel A. Levy, Arnold J. Markowitz, Stephanie Fish, Richard J. Wong, Rupa Sood, Stephanie M. Ochman, José G. Guillem. 2014. Results of a prospective thyroid ultrasound screening program in adenomatous polyposis patients. *The American Journal of Surgery* **208**, 764–769. [[CrossRef](#)]
585. R. Blumhardt, E. A. Wolin, W. T. Phillips, U. A. Salman, R. C. Walker, B. C. Stack, D. Metter. 2014. Current controversies in the initial post-surgical radioactive iodine therapy for thyroid cancer: a narrative review. *Endocrine Related Cancer* **21**, R473–R484. [[CrossRef](#)]
586. Szymon Hryhorowicz, Katarzyna Ziemnicka, Marta Kaczmarek-Ryś, Justyna Hoppe-Gołębiewska, Andrzej Pławski, Marzena Skrzypczak-Zielińska, Małgorzata Szkudlarek, Monika Gołąb, Bartłomiej Budny, Marek Ruchała, Ryszard Słowski. 2014. CCND1 gene polymorphic variants in patients with differentiated thyroid carcinoma. *Oncology Letters* . [[CrossRef](#)]
587. H. Choi, J. A. Lim, H. Y. Ahn, S. W. Cho, K. E. Lee, K. W. Kim, K. H. Yi, M.-W. Sung, Y.-K. Youn, J.-K. Chung, Y. J. Park, D. J. Park, B. Y. Cho. 2014. Secular trends in the prognostic factors for papillary thyroid cancer. *European Journal of Endocrinology* **171**, 667–675. [[CrossRef](#)]
588. Kushchayeva Yevgeniya S., Kushchayev Sergiy V., Wexler Jason A., Carroll Nancy M., Preul Mark C., Teytelboym Oleg M., Sonntag Volker K.H., Van Nostrand Douglas, Burman Kenneth D., Boyle Lisa M.. 2014. Current Treatment Modalities for Spinal Metastases Secondary to Thyroid Carcinoma. *Thyroid* **24**:10, 1443–1455. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
589. Smallridge Robert C., Diehl Nancy, Bernet Victor. 2014. Practice Trends in Patients with Persistent Detectable Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scans: A Survey of American Thyroid Association Members. *Thyroid* **24**:10, 1501–1507. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
590. Beaudenon-Huibregtse Sylvie, Alexander Erik K., Guttler Richard B., Hershman Jerome M., Babu Varsha, Blevins Thomas C., Moore Paul, Andrus Bernard, Labourier Emmanuel. 2014. Centralized Molecular Testing for Oncogenic Gene Mutations Complements the Local Cytopathologic Diagnosis of Thyroid Nodules. *Thyroid* **24**:10, 1479–1487. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
591. Roman Benjamin R., Feingold Jordyn H., Patel Snehal G., Shaha Ashok R., Shah Jatin P., Tuttle R. Michael, Epstein Andrew J.. 2014. The 2009 American Thyroid Association Guidelines Modestly Reduced Radioactive Iodine Use for Thyroid Cancers Less Than 1 cm. *Thyroid* **24**:10, 1549–1550. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
592. Felipe Fierro. 2014. Terapia empírica con I-131: ¿sigue vigente?. *Revista Colombiana de Cancerología* **18**, 155–156. [[CrossRef](#)]
593. Lynda Louhibi, Amparo Marco, Pedro J. Pinés, José C. Padillo, Inés Gómez, Miguel A. Valero, Mubarak Alramadán, Sandra Herranz, Miguel Aguirre, Antonio Hernández. 2014. Demographic, clinical, and genetic characteristics of patients with medullary thyroid cancer in the past 16 years in Castilla-La Mancha. *Endocrinología y Nutrición (English Edition)* **61**, 398–403. [[CrossRef](#)]
594. Gabriele Galatà, Klaus-Martin Schulte. 2014. Management of the thyroid nodule. *Surgery (Oxford)* **32**, 531–536. [[CrossRef](#)]
595. A. Sitges-Serra. 2014. Clinical guidelines at stake. *Journal of Epidemiology & Community Health* **68**, 906–908. [[CrossRef](#)]
596. Christine Spitzweg, Keith C Bible, Lorenz C Hofbauer, John C Morris. 2014. Advanced radioiodine-refractory differentiated thyroid cancer: the sodium iodide symporter and other emerging therapeutic targets. *The Lancet Diabetes & Endocrinology* **2**, 830–842. [[CrossRef](#)]
597. Ricardo R. Lastra, Michelle R. Pramick, Cody J. Crammer, Virginia A. LiVolsi, Zubair W. Baloch. 2014. Implications of a suspicious afirma test result in thyroid fine-needle aspiration cytology: An institutional experience. *Cancer Cytopathology* **122**:10.1002/cncy.v122.10, 737–744. [[CrossRef](#)]
598. Shigenobu Nagataki, Noboru Takamura. 2014. A review of the Fukushima nuclear reactor accident. *Current Opinion in Endocrinology & Diabetes and Obesity* **21**, 384–393. [[CrossRef](#)]
599. H. Dralle, P. Nguyen Thanh. 2014. Totale Thyreoidektomie mit Lymphknoten-dissektion des zentralen Kompartments beim nodal-positiven, organ-kapselinvasiven papillären Schilddrüsenkarzinom. *Der Chirurg* **85**, 895–903. [[CrossRef](#)]
600. Colleen M. Kiernan, J. T. Broome, C. C. Solórzano. 2014. The Bethesda System for Reporting Thyroid Cytopathology: A Single-Center Experience over 5 Years. *Annals of Surgical Oncology* **21**, 3522–3527. [[CrossRef](#)]



601. Charlotte Lepoutre-Lussey, Désirée Deandreis, Sophie Leboulleux, Martin Schlumberger. 2014. Postoperative radioactive iodine administration for differentiated thyroid cancer patients. *Current Opinion in Endocrinology & Diabetes and Obesity* **21**, 363-371. [[CrossRef](#)]
602. Sun Moon, Dong Kim, Seong Kim, Tae Ha, Ha Park, Soo Jung. 2014. Ultrasound Assessment of Degrees of Extrathyroidal Extension in Papillary Thyroid Microcarcinoma. *Endocrine Practice* **20**, 1037-1043. [[CrossRef](#)]
603. Juan P. Brito, Louise Davies. 2014. Is there really an increased incidence of thyroid cancer?. *Current Opinion in Endocrinology & Diabetes and Obesity* **21**, 405-408. [[CrossRef](#)]
604. Stan G. Eilers, Paula LaPolice, Perkins Mukunyadzi, Umesh Kapur, Amy Wendel Spiczka, Ajay Shah, Husain Saleh, Adebawale Adeniran, Amberly Nunez, Indra Balachandran, Jennifer J. Clark, Larry Lemon. 2014. Thyroid fine-needle aspiration cytology: Performance data of neoplastic and malignant cases as identified from 1558 responses in the ASCP Non-GYN Assessment program thyroid fine-needle performance data. *Cancer Cytopathology* **122**:10.1002/cncy.v122.10, 745-750. [[CrossRef](#)]
605. P. Agretti, F. Niccolai, T. Rago, G. De Marco, A. Molinaro, M. Scutari, C. Di Cosmo, G. Di Coscio, M. Vitale, M. Maccheroni, P. Vitti, M. Tonacchera. 2014. BRAF mutation analysis in thyroid nodules with indeterminate cytology: our experience on surgical management of patients with thyroid nodules from an area of borderline iodine deficiency. *Journal of Endocrinological Investigation* **37**, 1009-1014. [[CrossRef](#)]
606. Dapeng Xiang, Yurong Hong, Bo Zhang, Pintong Huang, Guogang Li, Ping Wang, Zhiyu Li. 2014. Contrast-enhanced ultrasound (CEUS) facilitated US in detecting lateral neck lymph node metastasis of thyroid cancer patients: diagnosis value and enhancement patterns of malignant lymph nodes. *European Radiology* **24**, 2513-2519. [[CrossRef](#)]
607. Agnese Proietti, Nicla Borrelli, Riccardo Giannini, Rossana Romani, Giancarlo Di Coscio, Francesca Quilici, Teresa Rago, Paolo Miccoli, Paolo Vitti, Fulvio Basolo. 2014. Molecular characterization of 54 cases of false-negative fine-needle aspiration among 1347 papillary thyroid carcinomas. *Cancer Cytopathology* **122**:10.1002/cncy.v122.10, 751-759. [[CrossRef](#)]
608. Dilek Arpacı, Didem Ozdemir, Neslihan Cuhaci, Gulden Kiyak, Abdussamet Yalcin, Soner Akbaba, Aylin Kilicyazgan, Reyhan Ersoy, Bekir Cakir. 2014. Do repeatedly nondiagnostic fine needle aspirations of thyroid nodules predict malignancy risk?. *Annals of Diagnostic Pathology* **18**, 297-300. [[CrossRef](#)]
609. Carole Spencer, Jonathan LoPresti, Shireen Fatemi. 2014. How sensitive (second-generation) thyroglobulin measurement is changing paradigms for monitoring patients with differentiated thyroid cancer, in the absence or presence of thyroglobulin autoantibodies. *Current Opinion in Endocrinology & Diabetes and Obesity* **21**, 394-404. [[CrossRef](#)]
610. Lynda Louhibi, Amparo Marco, Pedro J. Pinés, José C. Padillo, Inés Gómez, Miguel A. Valero, Mubarak Alramadán, Sandra Herranz, Miguel Aguirre, Antonio Hernández. 2014. Demografía, características clínicas y genéticas de pacientes con carcinoma medular de tiroides en los últimos 16 años en Castilla-La Mancha. *Endocrinología y Nutrición* **61**, 398-403. [[CrossRef](#)]
611. Olov Norlén, Aleksandra Popadich, Schelto Kruijff, Anthony J. Gill, Leba M. Sarkis, Leigh Delbridge, Mark Sywak, Stan Sidhu. 2014. Bethesda III Thyroid Nodules: The Role of Ultrasound in Clinical Decision Making. *Annals of Surgical Oncology* **21**, 3528-3533. [[CrossRef](#)]
612. Sarah M. Khoncarly, Stephen W. Tamarkin, Christopher R. McHenry. 2014. Can ultrasound be used to predict malignancy in patients with a thyroid nodule and an indeterminate fine-needle aspiration biopsy?. *Surgery* **156**, 967-971. [[CrossRef](#)]
613. Diane Donegan, Bryan McIver, Alicia Algeciras-Schimmich. 2014. Clinical Consequences of a Change in Anti-Thyroglobulin Antibody Assays During the Follow-Up of Patients with Differentiated Thyroid Cancer. *Endocrine Practice* **20**, 1032-1036. [[CrossRef](#)]
614. J. Abeillon-du Payrat, P. Caron, F. Borson-Chazot. 2014. Actualités dans la prise en charge des cancers thyroïdiens de souche vésiculaire. *Annales d'Endocrinologie* **75**, S2-S12. [[CrossRef](#)]
615. 2014. Integrated Genomic Characterization of Papillary Thyroid Carcinoma. *Cell* **159**, 676-690. [[CrossRef](#)]
616. Brian Hung-Hin Lang, Carlos K. H. Wong, Raymond K. Y. Tsang, Kai Pun Wong, Birgitta Y. H. Wong. 2014. Evaluating the Cost-Effectiveness of Laryngeal Examination after Elective Total Thyroidectomy. *Annals of Surgical Oncology* **21**, 3548-3556. [[CrossRef](#)]
617. Min Ji Jeon, Tae Yong Kim, Won Gu Kim, Ji Min Han, Eun Kyung Jang, Yun Mi Choi, Dong Eun Song, Jong Ho Yoon, Ki-Wook Chung, Suck Joon Hong, Young Kee Shong, Won Bae Kim. 2014. Differentiating the location of cervical lymph node metastasis is very useful for estimating the risk of distant metastases in papillary thyroid carcinoma. *Clinical Endocrinology* **81**:10.1111/cen.2014.81.issue-4, 593-599. [[CrossRef](#)]
618. Min-Hee Kim, Si Luo, Sun Hee Ko, So-Lyung Jung, Dong-Jun Lim, Yongmin Kim. 2014. Elastography Can Effectively Decrease the Number of Fine-Needle Aspiration Biopsies in Patients with Calcified Thyroid Nodules. *Ultrasound in Medicine & Biology* **40**, 2329-2335. [[CrossRef](#)]

619. Augusto Llamas-Olier, María Cristina Martínez, Amelia De los Reyes, Enrique Cadena, Leonardo Rojas, Humberto Varela, Alejandro Marti, Álvaro Calderón, Emperatriz Angarita. 2014. Terapia empírica del cáncer de tiroides con I-131 como estrategia diagnóstica para identificar lesiones ocultas en pacientes con tiroglobulina elevada sin enfermedad estructural identificable. *Revista Colombiana de Cancerología* **18**, 157-165. [[CrossRef](#)]
620. Bin Liu, Weiai Peng, Rui Huang, Rong Tian, Yu Zeng, Anren Kuang. 2014. Thyroid Cancer: Radiation Safety Precautions in 131 I Therapy Based on Actual Biokinetic Measurements. *Radiology* **273**, 211-219. [[CrossRef](#)]
621. Carol Evans, Sarah Tennant, Petros Perros. 2014. Thyroglobulin in differentiated thyroid cancer. *Clinica Chimica Acta* . [[CrossRef](#)]
622. Mohamed Abdelgadir Adam, John Pura, Lin Gu, Michaela A. Dinan, Douglas S. Tyler, Shelby D. Reed, Randall Scheri, Sanziana A. Roman, Julie A. Sosa. 2014. Extent of Surgery for Papillary Thyroid Cancer Is Not Associated With Survival. *Annals of Surgery* **260**, 601-607. [[CrossRef](#)]
623. Margret Ehlers, Matthias Schott. 2014. Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?. *Trends in Endocrinology & Metabolism* . [[CrossRef](#)]
624. Tomohiro Sakashita, Akihiro Homma, Hiromitsu Hatakeyama, Takatsugu Mizumachi, Satoshi Kano, Jun Furusawa, Satoshi Iizuka, Kimiko Hoshino, Kanako C. Hatanaka, Koji Oba, Satoshi Fukuda. 2014. The Potential Diagnostic Role of the Number of Ultrasonographic Characteristics for Patients with Thyroid Nodules Evaluated as Bethesda Iâ€“V. *Frontiers in Oncology* **4** . [[CrossRef](#)]
625. Jolanta Krajewska, Barbara Jarzab. 2014. Lenvatinib for the treatment of radioiodine-refractory follicular and papillary thyroid cancer. *Expert Opinion on Orphan Drugs* 1-10. [[CrossRef](#)]
626. R. Liu, M. Xing. 2014. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. *Endocrine Related Cancer* **21**, 825-830. [[CrossRef](#)]
627. Lei Li, Bao-Ding Chen, Hai-Feng Zhu, Shu Wu, Da Wei, Jian-Quan Zhang, Li Yu. 2014. Comparison of Pre-Operation Diagnosis of Thyroid Cancer with Fine Needle Aspiration and Core-needle Biopsy: a Meta-analysis. *Asian Pacific Journal of Cancer Prevention* **15**, 7187-7193. [[CrossRef](#)]
628. G. Azizi, J. Keller, M. Lewis, K. Piper, D. Puett, K. M. Rivenbark, C. Malchoff. 2014. Association of Hashimoto's Thyroiditis with Thyroid Cancer. *Endocrine Related Cancer* . [[CrossRef](#)]
629. Armstrong Michael J., Yang Huaitao, Yip Linwah, Ohori N. Paul, McCoy Kelly L., Stang Michael T., Hodak Steven P., Nikiforova Marina N., Carty Sally E., Nikiforov Yuri E.. 2014. PAX8/PPAR $\gamma$  Rearrangement in Thyroid Nodules Predicts Follicular-Pattern Carcinomas, in Particular the Encapsulated Follicular Variant of Papillary Carcinoma. *Thyroid* **24**:9, 1369-1374. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
630. Su Henry K., Dos Reis Laura L., Lupo Mark A., Milas Mira, Orloff Lisa A., Langer Jill E., Brett Elise M., Kazam Elias, Lee Stephanie L., Minkowitz Gerald, Alpert Erin H., Dewey Eliza H., Urken Mark L.. 2014. Striving Toward Standardization of Reporting of Ultrasound Features of Thyroid Nodules and Lymph Nodes: A Multidisciplinary Consensus Statement. *Thyroid* **24**:9, 1341-1349. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
631. Grant Edward G.. 2014. Repeat FNA Is Unnecessary for Many Nodules with Initially Nondiagnostic Results. *Clinical Thyroidology* **26**:9, 243-246. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
632. Angell Trevor E., Lechner Melissa G., Jang Julie K., Correa Adrian J., LoPresti Jonathan S., Epstein Alan L.. 2014. BRAFV600E in Papillary Thyroid Carcinoma Is Associated with Increased Programmed Death Ligand 1 Expression and Suppressive Immune Cell Infiltration. *Thyroid* **24**:9, 1385-1393. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
633. Renaud Florence, Gnemmi Viviane, Devos Patrick, Aubert Sébastien, Crépin Michel, Coppin Lucie, Ramdane Nassima, Bouchindhomme Brigitte, d'Herbomez Michelle, Van Seuningen Isabelle, Do Cao Christine, Pattou François, Carnaille Bruno, Pigny Pascal, Wémeau Jean-Louis, Leteurtre Emmanuelle. 2014. MUC1 Expression in Papillary Thyroid Carcinoma Is Associated with BRAF Mutation and Lymph Node Metastasis; the Latter is the Most Important Risk Factor of Relapse. *Thyroid* **24**:9, 1375-1384. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
634. Yvette Carter, Nicholas Yeutter, Haggi Mazeh. 2014. Thyroglossal duct remnant carcinoma: Beyond the Sistrunk procedure. *Surgical Oncology* **23**, 161-166. [[CrossRef](#)]
635. Tracy S. Wang, Paolo Goffredo, Julie Ann Sosa, Sanziana A. Roman. 2014. Papillary Thyroid Microcarcinoma: An Over-Treated Malignancy?. *World Journal of Surgery* **38**, 2297-2303. [[CrossRef](#)]
636. Stephanie Flukes, Nat Lenzo, Girolamo Moschilla, Chady Sader. 2014. Positron emission tomography-positive thyroid nodules: rate of malignancy and histological features. *ANZ Journal of Surgery* n/a-n/a. [[CrossRef](#)]

637. Soo Yeon Hahn, Boo-Kyung Han, Eun Young Ko, Jung Hee Shin, Eun Sook Ko. 2014. Ultrasound Findings of Papillary Thyroid Carcinoma Originating in the Isthmus: Comparison With Lobe-Originating Papillary Thyroid Carcinoma. *American Journal of Roentgenology* **203**, 637-642. [[CrossRef](#)]
638. Kevin E. Fisher, Stewart G. Neill, Laleh Ehsani, Shelley A. Caltharp, Momin T. Siddiqui, Cynthia Cohen. 2014. Immunohistochemical Investigation of BRAF p.V600E Mutations in Thyroid Carcinoma Using 2 Separate BRAF Antibodies. *Applied Immunohistochemistry & Molecular Morphology* **22**, 562-567. [[CrossRef](#)]
639. Marc P. Pusztaszeri, Jeffrey F. Krane, Edmund S. Cibas, Gilbert Daniels, William C. Faquin. 2014. FNAB of benign thyroid nodules with papillary hyperplasia: A cytological and histological evaluation. *Cancer Cytopathology* **122**, 666-677. [[CrossRef](#)]
640. M.B. Roldán Martín, L. Soriano Guillén, M.T. Muñoz Calvo. 2014. Alteraciones endocrinológicas más frecuentes en la adolescencia. *Medicine - Programa de Formación Médica Continuada Acreditado* **11**, 3588-3604. [[CrossRef](#)]
641. V. Marotta, C. Sciammarella, M. Vitale, A. Colao, A. Faggiano. 2014. The evolving field of kinase inhibitors in thyroid cancer. *Critical Reviews in Oncology/Hematology* . [[CrossRef](#)]
642. Fabián Pitoia, Fernanda Bueno, Graciela Cross. 2014. Long-Term Survival and Low Effective Cumulative Radioiodine Doses to Achieve Remission in Patients With <sup>131</sup>Iodine-Avid Lung Metastasis From Differentiated Thyroid Cancer. *Clinical Nuclear Medicine* **39**, 784-790. [[CrossRef](#)]
643. Cheng-Ping Wang. 2014. ENT-Head and Neck Ultrasound in Taiwan. *Journal of Medical Ultrasound* **22**, 127-128. [[CrossRef](#)]
644. Thomas J. T. Anderson, Michael K. Atalay, David J. Grand, Grayson L. Baird, John J. Cronan, Michael D. Beland. 2014. Management of Nodules with Initially Nondiagnostic Results of Thyroid Fine-Needle Aspiration: Can We Avoid Repeat Biopsy?. *Radiology* **272**, 777-784. [[CrossRef](#)]
645. Paul B. Romesser, Eric J. Sherman, Ashok R. Shaha, Ming Lian, Richard J. Wong, Mona Sabra, Shyam S. Rao, James A. Fagin, R. Michael Tuttle, Nancy Y. Lee. 2014. External beam radiotherapy with or without concurrent chemotherapy in advanced or recurrent non-anaplastic non-medullary thyroid cancer. *Journal of Surgical Oncology* **110**:10.1002/jso.v110.4, 375-382. [[CrossRef](#)]
646. Kiminori Sugino, Kaori Kameyama, Mitsuji Nagahama, Wataru Kitagawa, Hiroshi Shibuya, Keiko Ohkuwa, Takashi Uruno, Junko Akaishi, Akifumi Suzuki, Chie Masaki, Ken-ichi Matsuzo, Michikazu Kawano, Koichi Ito. 2014. Does Completion Thyroidectomy Improve the Outcome of Patients with Minimally Invasive Follicular Carcinoma of the Thyroid?. *Annals of Surgical Oncology* **21**, 2981-2986. [[CrossRef](#)]
647. Jae Hyun Park, Jandee Lee, Nor Azham Hakim, Ha Yan Kim, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Keum-Seok Bae, Seong Joon Kang, Woong Youn Chung. 2014. Robotic thyroidectomy learning curve for beginning surgeons with little or no experience of endoscopic surgery. *Head & Neck* n/a-n/a. [[CrossRef](#)]
648. Flemming Forsberg, Priscilla Machado, Sharon Segal, Yoko Okamura, Gilles Guenette, Cynthia Rapp, Andrej Lyschik. Microvascular blood flow in the thyroid: Preliminary results with a novel imaging technique 2237-2240. [[CrossRef](#)]
649. Dong Wook Kim. 2014. Computed Tomography Features of Papillary Thyroid Carcinomas. *Journal of Computer Assisted Tomography* **1**. [[CrossRef](#)]
650. Christelle Roger, Karim Chikh, Véronique Raverot, Francine Claustrat, Françoise Borson-Chazot, Claire Bournaud-Salinas, Anne Charrié. 2014. New-generation thyroglobulin assay: Performance and implications for follow-up of differentiated thyroid carcinoma. *Annales d'Endocrinologie* **75**, 227-231. [[CrossRef](#)]
651. Ashley E. Wenaas, Celeste Z. Nagy, Yin Yiu, Li Xu, Kelsey Horter, Jose P. Zevallos. 2014. Demographic and socioeconomic factors predictive of compliance with American Thyroid Association guidelines for the treatment for advanced papillary thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
652. Agnaldo José Graciano, Carlos Takahiro Chone, Carlos Augusto Fischer, Giuliano Stefanello Bublitz, Ana Jacinta de Aquino Peixoto. 2014. Repeated fine-needle aspiration cytology for the diagnosis and follow-up of thyroid nodules. *Brazilian Journal of Otorhinolaryngology* **80**, 422-427. [[CrossRef](#)]
653. Melih Cayonu, Aydin Acar, Adil Eryilmaz, Oguzhan Oguz. 2014. Surgical Approach and Outcomes for Revision Surgery of the Central Neck Compartment. *The Journal of Craniofacial Surgery* **25**, 1797-1800. [[CrossRef](#)]
654. D. Champa, M. A. Russo, X.-H. Liao, S. Refetoff, R. A. Ghossein, A. Di Cristofano. 2014. Obatoclox overcomes resistance to cell death in aggressive thyroid carcinomas by countering Bcl2a1 and Mcl1 overexpression. *Endocrine Related Cancer* **21**, 755-767. [[CrossRef](#)]
655. Kyung Sook Jo, Young-Sil An, Su Jin Lee, Euy-Young Soh, Jeonghun Lee, Yoon-Sok Chung, Dae Jung Kim, Seok-Ho Yoon, Dong Hyun Lee, Joon-Kee Yoon. 2014. Significance of Salivary Gland Radioiodine Retention on Post-ablation <sup>131</sup>I Scintigraphy as a Predictor of Salivary Gland Dysfunction in Patients with Differentiated Thyroid Carcinoma. *Nuclear Medicine and Molecular Imaging* **48**, 203-211. [[CrossRef](#)]

656. Sai Vignesh T, Siva Subramaniyan V, Kumar T Rajamani, Siva Sankara Sai S. An interactive GUI tool for thyroid Uptake studies using Gamma Camera 305-309. [[CrossRef](#)]
657. Hetal H. Patel, Neerav Goyal, David Goldenberg. 2014. Imaging, genetic testing, and biomarker assessment of follicular cell-derived thyroid cancer. *Annals of Medicine* **46**, 409-416. [[CrossRef](#)]
658. Dae kwon Na, Yoon Jung Choi, Seon Hyeong Choi, Shin Ho Kook, Hee Jin Park. 2014. Evaluation of cervical lymph node metastasis in thyroid cancer patients using real-time CT-navigated ultrasonography: preliminary study. *Ultrasonography* . [[CrossRef](#)]
659. Nosheen Fatima, Maseeh uz Zaman, Mubashir Ikram, Jaweed Akhtar, Najmul Islam, Qamar Masood, Unaiza Zaman, Areeba Zaman. 2014. Baseline Stimulated Thyroglobulin Level as a Good Predictor of Successful Ablation after Adjuvant Radioiodine Treatment for Differentiated Thyroid Cancers. *Asian Pacific Journal of Cancer Prevention* **15**, 6443-6447. [[CrossRef](#)]
660. Lee Minkyung, Lee Yu Kyung, Jeon Tae Joo, Chang Hang Seok, Kim Bup-Woo, Lee Yong Sang, Park Cheong Soo, Ryu Young Hoon. 2014. Low Iodine Diet for One Week Is Sufficient for Adequate Preparation of High Dose Radioactive Iodine Ablation Therapy of Differentiated Thyroid Cancer Patients in Iodine-Rich Areas. *Thyroid* **24**:8, 1289-1296. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
661. Russo Marco, Malandrino Pasqualino, Nicolosi Maria Luisa, Manusia Mario, Marturano Ilenia, Trovato Maria Antonietta, Pellegriti Gabriella, Frasca Francesco, Vigneri Riccardo. 2014. The BRAFV600E Mutation Influences the Short- and Medium-Term Outcomes of Classic Papillary Thyroid Cancer, But Is Not an Independent Predictor of Unfavorable Outcome. *Thyroid* **24**:8, 1267-1274. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
662. Scherl Sophie, Mehra Saral, Clain Jason, Dos Reis Laura L., Persky Mark, Turk Andrew, Wenig Bruce, Husaini Hasan, Urken Mark L.. 2014. The Effect of Surgeon Experience on the Detection of Metastatic Lymph Nodes in the Central Compartment and the Pathologic Features of Clinically Unapparent Metastatic Lymph Nodes: What Are We Missing When We Don't Perform a Prophylactic Dissection of Central Compartment Lymph Nodes in Papillary Thyroid Cancer?. *Thyroid* **24**:8, 1282-1288. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
663. Nilufer Yildirim-Poyraz, Aylin Yazgan, Elif Ozdemir, Aysegul Gozalan, Mutlay Keskin, Reyhan Ersoy, Seyda Turkolmez, Bekir Cakir. 2014. Predictive role of nontumoral sodium iodide symporter activity and preoperative thyroid characteristics in remission process of thyroid cancer patients. *Annals of Nuclear Medicine* **28**, 623-631. [[CrossRef](#)]
664. David W. Schoppy, F. Christopher Holsinger. 2014. Management of the Neck in Thyroid Cancer. *Otolaryngologic Clinics of North America* **47**, 545-556. [[CrossRef](#)]
665. Pitoia Fabián, Abelleira Erika, Tala Hernán, Bueno Fernanda, Urciuoli Carolina, Cross Graciela. 2014. Biochemical persistence in thyroid cancer: is there anything to worry about?. *Endocrine* **46**, 532-537. [[CrossRef](#)]
666. Anthony R Glover, James C Lee, Stan B Sidhu. 2014. Is there an accurate biomarker test for thyroid cancer recurrence on the horizon?. *International Journal of Endocrine Oncology* **1**, 3-5. [[CrossRef](#)]
667. Maythinee Chantadisai, Kanaungnit Kingpetch. 2014. Usefulness of <sup>99m</sup>Tc-pertechnetate whole body scan with neck and chest SPECT/CT for detection of post-surgical thyroid remnant and metastasis in differentiated thyroid cancer patients. *Annals of Nuclear Medicine* **28**, 674-682. [[CrossRef](#)]
668. Zubair W. Baloch, Virginia A. LiVolsi. 2014. Current role and value of fine-needle aspiration in nodular goitre. *Best Practice & Research Clinical Endocrinology & Metabolism* **28**, 531-544. [[CrossRef](#)]
669. Jennifer E. Rosen, Hyunsuk Suh, Nicholas J. Giordano, Ousama M. Aamar, Eladio Rodriguez-Diaz, Irving I. Bigio, Stephanie L. Lee. 2014. Preoperative Discrimination of Benign from Malignant Disease in Thyroid Nodules With Indeterminate Cytology Using Elastic Light-Scattering Spectroscopy. *IEEE Transactions on Biomedical Engineering* **61**, 2336-2340. [[CrossRef](#)]
670. Victoria Lai, Douglas B Evans, Tracy S Wang. 2014. Central compartment lymph node dissection for differentiated thyroid cancer: review of the literature. *International Journal of Endocrine Oncology* **1**, 41-48. [[CrossRef](#)]
671. Laura Reis, Saral Mehra, Sophie Scherl, Jason Clain, Josef Machac, Mark Urken. 2014. The Differential Diagnosis of Central Compartment Radioactive Iodine Uptake After Thyroidectomy: Anatomic and Surgical Considerations. *Endocrine Practice* **20**, 832-838. [[CrossRef](#)]
672. Celestino Pio Lombardi, Marco Raffaelli, Carmela De Crea, Luca Sessa, Rocco Bellantone. 2014. Morbidity of central neck dissection: primary surgery vs reoperation. Results of a case-control study. *Langenbeck's Archives of Surgery* **399**, 747-753. [[CrossRef](#)]
673. Hiroshi Takami, Yasuhiro Ito, Takahiro Okamoto, Naoyoshi Onoda, Hitoshi Noguchi, Akira Yoshida. 2014. Revisiting the Guidelines Issued by the Japanese Society of Thyroid Surgeons and Japan Association of Endocrine Surgeons: A Gradual Move Towards Consensus Between Japanese and Western Practice in the Management of Thyroid Carcinoma. *World Journal of Surgery* **38**, 2002-2010. [[CrossRef](#)]

674. Ke Yang, Hao Wang, Zhiyong Liang, Jun Liang, Fang Li, Yansong Lin. 2014. BRAFV600E Mutation Associated With Non-Radioiodine-Avid Status in Distant Metastatic Papillary Thyroid Carcinoma. *Clinical Nuclear Medicine* **39**, 675-679. [[CrossRef](#)]
675. Mustafa Şahin, Erman Çakal, Mustafa Özbek, Aşkın Güngünes, Müyesser Sayki Arslan, Esra Tural Akkaymak, Bekir Uçan, İlknur Öztürk Ünsal, Nujen Çolak Bozkurt, Tuncay Delibaşı. 2014. Elastography in the differential diagnosis of thyroid nodules in Hashimoto thyroiditis. *Medical Oncology* **31**. . [[CrossRef](#)]
676. Stephanie Smooke-Praw, Kevin Ro, Olga Levin, Philip H. G. Ituarte, Avital Harari, Michael W. Yeh. 2014. Thyroglobulin antibody levels do not predict disease status in papillary thyroid cancer. *Clinical Endocrinology* **81**:10.1111/cen.2014.81.issue-2, 271-275. [[CrossRef](#)]
677. Maisie L. Shindo, Salvatore M. Caruana, Emad Kandil, Judith C. McCaffrey, Lisa A. Orloff, John R. Porterfield, Ashok Shaha, Jennifer Shin, David Terris, Gregory Randolph. 2014. Management of invasive well-differentiated thyroid cancer: An American head and neck society consensus statement: AHNS consensus statement. *Head & Neck* n/a-n/a. [[CrossRef](#)]
678. Zhan-Qiang Jin, Mei-Ying Lin, Wen-Hua Hu, Wei-Yong Li, Shao-Jun Bai. 2014. Gray-Scale Ultrasonography Combined with Elastography Imaging for the Evaluation of Papillary Thyroid Microcarcinoma: As a Prognostic Clinicopathology Factor. *Ultrasound in Medicine & Biology* **40**, 1769-1777. [[CrossRef](#)]
679. Iain J. Nixon, Ashok R. Shaha, Snehal G. Patel. 2014. Surgical Diagnosis. *Otolaryngologic Clinics of North America* **47**, 519-528. [[CrossRef](#)]
680. Tomer Davidov, Michael Nagar, Malca Kierson, Marina Chekmareva, Chunxia Chen, Shou-en Lu, Yong Lin, Victoriya Chernyavsky, Lindsay Potdevin, Dena Arumugam, Nicola Barnard, Stanley Trooskin. 2014. Carbonic anhydrase 4 and crystallin alpha-B immunoreactivity may distinguish benign from malignant thyroid nodules in patients with indeterminate thyroid cytology. *Journal of Surgical Research* **190**, 565-574. [[CrossRef](#)]
681. David L. Steward, Richard T. Kloos. 2014. Clinical Diagnostic Gene Expression Thyroid Testing. *Otolaryngologic Clinics of North America* **47**, 573-593. [[CrossRef](#)]
682. Enrico Papini, Claudio M. Pacella, Irene Misischi, Rinaldo Guglielmi, Giancarlo Bizzarri, Helle Døssing, Laszlo Hegedus. 2014. The advent of ultrasound-guided ablation techniques in nodular thyroid disease: Towards a patient-tailored approach. *Best Practice & Research Clinical Endocrinology & Metabolism* **28**, 601-618. [[CrossRef](#)]
683. Thomas W. Barber, Martin H. Cherk, Duncan J. Topliss, Jonathan W. Serpell, Kenneth S. K. Yap, Michael Bailey, Victor Kalf. 2014. The prevalence of thyroglossal tract thyroid tissue on SPECT/CT following 131 I ablation therapy after total thyroidectomy for thyroid cancer. *Clinical Endocrinology* **81**:10.1111/cen.2014.81.issue-2, 266-270. [[CrossRef](#)]
684. Markus Eszlinger, László Hegedüs, Ralf Paschke. 2014. Ruling in or ruling out thyroid malignancy by molecular diagnostics of thyroid nodules. *Best Practice & Research Clinical Endocrinology & Metabolism* **28**, 545-557. [[CrossRef](#)]
685. Alberto S. Tresoldi, Laura F. Sburlati, Marcello Rodari, Mink Schinkelshoek, Michela Perrino, Simone De Leo, Laura Montefusco, Paolo Colombo, Maura Arosio, Andrea Gerardo Antonio Lania, Laura Fugazzola, Arturo Chiti. 2014. Radioiodine ablation with 1,850 MBq in association with rhTSH in patients with differentiated thyroid cancer. *Journal of Endocrinological Investigation* **37**, 709-714. [[CrossRef](#)]
686. Carolyn D. Seib, Avital Harari, Felix A. Conte, Quan-Yang Duh, Orlo H. Clark, Jessica E. Gosnell. 2014. Utility of serum thyroglobulin measurements after prophylactic thyroidectomy in patients with hereditary medullary thyroid cancer. *Surgery* **156**, 394-398. [[CrossRef](#)]
687. Louise Davies, Gregory Randolph. 2014. Evidence-Based Evaluation of the Thyroid Nodule. *Otolaryngologic Clinics of North America* **47**, 461-474. [[CrossRef](#)]
688. D. N. Poller, S. Glaysher, A. Agrawal, S. Caldera, D. Kim, C. Yiangou. 2014. BRAF V600 co-testing in thyroid FNA cytology: short-term experience in a large cancer centre in the UK. *Journal of Clinical Pathology* **67**, 684-689. [[CrossRef](#)]
689. Linwah Yip, Robert L. Ferris. 2014. Clinical Application of Molecular Testing of Fine-needle Aspiration Specimens in Thyroid Nodules. *Otolaryngologic Clinics of North America* **47**, 557-571. [[CrossRef](#)]
690. Giovanni Conzo, Claudio Mauriello, Giovanni Docimo, Claudio Gambardella, Guglielmo Thomas, Fabio Cavallo, Ernesto Tartaglia, Salvatore Napolitano, Roerto Varriale, Gianluca Rossetti, Landino Fei, Luigi Santini. 2014. Clinicopathological pattern of lymph node recurrence of papillary thyroid cancer. Implications for surgery. *International Journal of Surgery* **12**, S194-S197. [[CrossRef](#)]
691. Shiny Sherlie Varghese, Ashish Varghese, Chris Ayshford. 2014. Differentiated Thyroid Cancer and Pregnancy. *Indian Journal of Surgery* **76**, 293-296. [[CrossRef](#)]
692. Silvia Morbelli, Marcello Bagnasco. 2014. Differentiated thyroid cancer incidentally detected by 18F-FDG PET/CT: patient's future in a hot-spot?. *European Journal of Nuclear Medicine and Molecular Imaging* **41**, 1479-1481. [[CrossRef](#)]

693. Luca Giovanella, Luca Ceriani, Giorgio Treglia. 2014. Role of isotope scan, including positron emission tomography/computed tomography, in nodular goitre. *Best Practice & Research Clinical Endocrinology & Metabolism* **28**, 507-518. [[CrossRef](#)]
694. Arnaldo Piccardo, Matteo Puntoni, Francesco Bertagna, Giorgio Treglia, Luca Foppiani, Federico Arecco, Raffaele Giubbini, Mehrdad Naseri, Angelina Cistaro, Manlio Cabria, Francesca Bardesono, Luca Ceriani, Fabio Orlandi, Luca Giovanella. 2014. 18F-FDG uptake as a prognostic variable in primary differentiated thyroid cancer incidentally detected by PET/CT: a multicentre study. *European Journal of Nuclear Medicine and Molecular Imaging* **41**, 1482-1491. [[CrossRef](#)]
695. Graham R. Williams. 2014. Is prophylactic anti-resorptive therapy required in thyroid cancer patients receiving TSH-suppressive treatment with thyroxine?. *Journal of Endocrinological Investigation* **37**, 775-779. [[CrossRef](#)]
696. Xiao-Yun Liu, Li-Jun Zhu, Dai Cui, Zhi-Xiao Wang, Huan-Huan Chen, Yu Duan, Mei-Ping Shen, Zhi-Hong Zhang, Xiao-Dong Wang, Jia-Wei Chen, Erik Karl Alexander, Tao Yang. 2014. Annual Financial Impact of Thyroidectomies for Nodular Thyroid Disease in China. *Asian Pacific Journal of Cancer Prevention* **15**, 5921-5926. [[CrossRef](#)]
697. A P Carneiro, C F Reis, E C Morari, Y C P Maia, R Nascimento, J M C Bonatto, M A de Souza, L R Goulart, L S Ward. 2014. A putative OTU domain-containing protein 1 deubiquitinating enzyme is differentially expressed in thyroid cancer and identifies less-aggressive tumours. *British Journal of Cancer* **111**, 551-558. [[CrossRef](#)]
698. Rosario Pedro Wesley. 2014. Thyroid Nodules with Atypia or Follicular Lesions of Undetermined Significance (Bethesda Category III): Importance of Ultrasonography and Cytological Subcategory. *Thyroid* **24**:7, 1115-1120. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
699. Angell Trevor E., Spencer Carole A., Rubino Barbara D., Nicoloff John T., LoPresti Jonathan S.. 2014. In Search of an Unstimulated Thyroglobulin Baseline Value in Low-Risk Papillary Thyroid Carcinoma Patients Not Receiving Radioactive Iodine Ablation. *Thyroid* **24**:7, 1127-1133. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
700. Markovina Stephanie, Grigsby Perry W., Schwarz Julie K, DeWees Todd, Moley Jeffrey F., Siegel Barry A., Perkins Stephanie M.. 2014. Treatment Approach, Surveillance, and Outcome of Well-Differentiated Thyroid Cancer in Childhood and Adolescence. *Thyroid* **24**:7, 1121-1126. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
701. Sabra Mona M., Grewal Ravinder K., Ghossein Ronald A., Tuttle R. Michael. 2014. Higher Administered Activities of Radioactive Iodine Are Associated with Less Structural Persistent Response in Older, but Not Younger, Papillary Thyroid Cancer Patients with Lateral Neck Lymph Node Metastases. *Thyroid* **24**:7, 1088-1095. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
702. Durante Cosimo, Tognini Sara, Montesano Teresa, Orlandi Fabio, Torlontano Massimo, Puxeddu Efsio, Attard Marco, Costante Giuseppe, Tumino Salvatore, Meringolo Domenico, Bruno Rocco, Trulli Fabiana, Toteda Maria, Redler Adriano, Ronga Giuseppe, Filetti Sebastiano, Monzani Fabio, on behalf of the PTC Study Group. 2014. Clinical Aggressiveness and Long-Term Outcome in Patients with Papillary Thyroid Cancer and Circulating Anti-Thyroglobulin Autoantibodies. *Thyroid* **24**:7, 1139-1145. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
703. Paolo Carcoforo, Mattia Portinari, Luciano Feggi, Stefano Panareo, Alessandro De Troia, Maria Chiara Zatelli, Giorgio Trasforini, Ettore degli Uberti, Elena Forini, Carlo V. Feo. 2014. Radio-guided selective compartment neck dissection improves staging in papillary thyroid carcinoma: A prospective study on 345 patients with a 3-year follow-up. *Surgery* **156**, 147-157. [[CrossRef](#)]
704. Markus Luster, Theresia Weber, Frederik A. Verburg. 2014. Differentiated thyroid cancer—personalized therapies to prevent overtreatment. *Nature Reviews Endocrinology* **10**, 563-574. [[CrossRef](#)]
705. J. Fernández Sánchez. 2014. Clasificación TI-RADS de los nódulos tiroideos en base a una escala de puntuación modificada con respecto a los criterios ecográficos de malignidad. *Revista Argentina de Radiología* **78**, 138-148. [[CrossRef](#)]
706. Mingbo Zhang, Yan Zhang, Shuai Fu, Faqin Lv, Jie Tang. 2014. Thyroid nodules with suspicious ultrasound findings: the role of ultrasound-guided core needle biopsy. *Clinical Imaging* **38**, 434-438. [[CrossRef](#)]
707. Clive S. Grant. 2014. Papillary Thyroid Cancer: Strategies for Optimal Individualized Surgical Management. *Clinical Therapeutics* **36**, 1117-1126. [[CrossRef](#)]
708. Lukasz Czerwonka, Jeremy Freeman, Bryan McIver, Gregory W. Randolph, Jatin P. Shah, Ashok R. Shaha, Steven I. Sherman, R. Michael Tuttle, Ian J. Witterick. 2014. Summary of proceedings of the second World Congress on Thyroid Cancer. *Head & Neck* **36**:10.1002/hed.v36.7, 917-920. [[CrossRef](#)]
709. N. P. Sharova, I. R. Sumedi, T. M. Astakhova, A. S. Plekhanova, Y. V. Lyupina, E. E. Shashova, I. V. Kondakova, G. V. Rodoman. 2014. Diagnostics of thyroid cancer: Limitations of the existing methods and perspectives for future developments. *Biology Bulletin* **41**, 318-323. [[CrossRef](#)]
710. N. Nasrollah, P. Trimboli, D. Bianchi, S. Taccogna. 2014. Neck schwannoma diagnosed by core needle biopsy: a case report. *Journal of Ultrasound* . [[CrossRef](#)]

711. X.F. Yu, W.B. Wang, X.D. Teng, H.Y. Wang, X. Chen, H.H. Wang, Z.M. Ma, T.J. Fahey, L.S. Teng. 2014. Clinicopathological and prognostic analysis of follicular thyroid carcinoma in a single institute over a 15-year period. *European Journal of Surgical Oncology (EJSO)* **40**, 869-874. [[CrossRef](#)]
712. Linwah Yip, Laura I. Wharry, Michael J. Armstrong, Ari Silbermann, Kelly L. McCoy, Michael T. Stang, Nobuyuki P. Ohori, Shane O. LeBeau, Christopher Coyne, Marina N. Nikiforova, Julie E. Bauman, Jonas T. Johnson, Mitch E. Tublin, Steven P. Hodak, Yuri E. Nikiforov, Sally E. Carty. 2014. A Clinical Algorithm for Fine-Needle Aspiration Molecular Testing Effectively Guides the Appropriate Extent of Initial Thyroidectomy. *Annals of Surgery* **260**, 163-168. [[CrossRef](#)]
713. Seok-Mo Kim, Hyeung Kyoo Kim, Kuk-Jin Kim, Ho Jin Chang, Bup-Woo Kim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park. 2014. Thyroidectomy without lateral neck dissection for papillary thyroid carcinoma with lateral neck lymph node metastases and negative intraoperative frozen section. *Head & Neck* n/a-n/a. [[CrossRef](#)]
714. Iain J. Nixon, Laura Y. Wang, Frank L. Palmer, R. Michael Tuttle, Ashok R. Shaha, Jatin P. Shah, Snehal G. Patel, Ian Ganly. 2014. The impact of nodal status on outcome in older patients with papillary thyroid cancer. *Surgery* **156**, 137-146. [[CrossRef](#)]
715. Petros Perros, Kristien Boelaert, Steve Colley, Carol Evans, Rhodri M Evans, Georgina Gerrard BA, Jackie Gilbert, Barney Harrison, Sarah J Johnson, Thomas E Giles, Laura Moss, Val Lewington, Kate Newbold, Judith Taylor, Rajesh V Thakker, John Watkinson, Graham R. Williams. 2014. Guidelines for the management of thyroid cancer. *Clinical Endocrinology* **81**, 1-122. [[CrossRef](#)]
716. Giovanni Turtulici, Davide Orlandi, Angelo Corazza, Riccardo Sartoris, Lorenzo Egildo Derchi, Enzo Silvestri, Jung Hwan Baek. 2014. Percutaneous Radiofrequency Ablation of Benign Thyroid Nodules Assisted by a Virtual Needle Tracking System. *Ultrasound in Medicine & Biology* **40**, 1447-1452. [[CrossRef](#)]
717. Adam D. Toll, Esther Diana Rossi, Syed Z. Ali. 2014. Role of ancillary testing in thyroid fine needle aspiration: Review and update. *Journal of the American Society of Cytopathology* **3**, 218-224. [[CrossRef](#)]
718. Dana M. Hartl, Sophie Zago, Sophie Leboulleux, Haïtham Mirghani, Desirée Déandreis, Eric Baudin, Martin Schlumberger. 2014. Resection margins and prognosis in locally invasive thyroid cancer. *Head & Neck* **36**:10.1002/hed.v36.7, 1034-1038. [[CrossRef](#)]
719. Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong, Steven I Sherman, Johannes W A Smit, John Chung, Christian Kappeler, Carol Peña, István Molnár, Martin J Schlumberger. 2014. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *The Lancet* **384**, 319-328. [[CrossRef](#)]
720. Chin-Li Chen, Shih-Hua Lin, Jyh-Cherng Yu, Ming-Lang Shih. 2014. Persistent renal hyperparathyroidism caused by intrathyroidal parathyroid glands. *Journal of the Chinese Medical Association* . [[CrossRef](#)]
721. L. Giovanella, P. M. Clark, L. Chiovato, L. Duntas, R. Elisei, U. Feldt-Rasmussen, L. Leenhardt, M. Luster, C. Schalin-Jantti, M. Schott, E. Seregini, H. Rimmele, J. Smit, F. A. Verburg. 2014. DIAGNOSIS OF ENDOCRINE DISEASE: Thyroglobulin measurement using highly sensitive assays in patients with differentiated thyroid cancer: a clinical position paper. *European Journal of Endocrinology* **171**, R33-R46. [[CrossRef](#)]
722. Elizabeth Bandeira-Echtler, Karla Bergerhoff, Bernd Richter. Levothyroxine or minimally invasive therapies for benign thyroid nodules . [[CrossRef](#)]
723. Lubitz Carrie C., Economopoulos Konstantinos P., Pawlak Amanda C., Lynch Kerry, Dias-Santagata Dora, Faquin William C., Sadow Peter M.. 2014. Hobnail Variant of Papillary Thyroid Carcinoma: An Institutional Case Series and Molecular Profile. *Thyroid* **24**:6, 958-965. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
724. Clain Jason B., Scherl Sophie, Dos Reis Laura, Turk Andrew, Wenig Bruce M., Mehra Saral, Karle William E., Urken Mark L.. 2014. Extrathyroidal Extension Predicts Extranodal Extension in Patients with Positive Lymph Nodes: An Important Association That May Affect Clinical Management. *Thyroid* **24**:6, 951-957. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
725. Cham Stephanie, Zanicco Kyle, Sturgeon Cord, Yeh Michael W., Harari Avital. 2014. Risk-Based Ultrasound Screening for Thyroid Cancer in Obese Patients is Cost-Effective. *Thyroid* **24**:6, 975-986. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
726. Sann Yu Mon, Steven P. Hodak. 2014. Molecular Diagnostics for Thyroid Nodules. *Endocrinology and Metabolism Clinics of North America* **43**, 345-365. [[CrossRef](#)]
727. Sue S. Yom, Ezra Cohen. 2014. The ACR appropriateness criteria® for thyroid carcinoma: Searching for consensus in a rapidly evolving area. *Oral Oncology* **50**, 575-576. [[CrossRef](#)]
728. Linwah Yip. 2014. Thyroid Nodules ≥4 cm: Can Ultrasound and Cytology Reliably Exclude Cancer? Reply. *World Journal of Surgery* **38**, 1556-1557. [[CrossRef](#)]

729. Alexis Vrachimis, Joachim Gerss, Maren Stoyke, Christian Wittekind, Tobias Maier, Christian Wenning, Kambiz Rahbar, Otmar Schober, Burkhard Riemann. 2014. No significant difference in the prognostic value of the 5th and 7th editions of AJCC staging for differentiated thyroid cancer. *Clinical Endocrinology* **80**:10.1111/cen.2014.80.issue-6, 911-917. [[CrossRef](#)]
730. Uma Rajhbeharrysingh, Matthew Taylor, Mira Milas. 2014. Medical Therapy for Advanced Forms of Thyroid Cancer. *Surgical Clinics of North America* **94**, 541-571. [[CrossRef](#)]
731. Glenda G. Callender, Tobias Carling, Emily Christison-Lagay, Robert Udelsman. 2014. Surgery for Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America* **43**, 443-458. [[CrossRef](#)]
732. Eun Ju Ha, Jung Hwan Baek, Jeong Hyun Lee, Jin Kyoung Kim, Jae Kyun Kim, Hyun Kyung Lim, Dong Eun Song, Tae Yon Sung, Tae Yong Kim, Won Bae Kim, Young Kee Shong. 2014. Core needle biopsy can minimise the non-diagnostic results and need for diagnostic surgery in patients with calcified thyroid nodules. *European Radiology* **24**, 1403-1409. [[CrossRef](#)]
733. Aarti Mathur, Matthew T. Olson, Martha A. Zeiger. 2014. Follicular Lesions of the Thyroid. *Surgical Clinics of North America* **94**, 499-513. [[CrossRef](#)]
734. Ning Qu, Ling Zhang, Zhong-wu Lu, Wen-jun Wei, Yan Zhang, Qing-hai Ji. 2014. Risk of malignancy in focal thyroid lesions identified by 18F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography: evidence from a large series of studies. *Tumor Biology* **35**, 6139-6147. [[CrossRef](#)]
735. Patricia Aragon Han, Matthew T. Olson, Roghayeh Fazeli, Jason D. Prescott, Sara I. Pai, Eric B. Schneider, Ralph P. Tufano, Martha A. Zeiger. 2014. The Impact of Molecular Testing on the Surgical Management of Patients with Thyroid Nodules. *Annals of Surgical Oncology* **21**, 1862-1869. [[CrossRef](#)]
736. Giuseppe Esposito. 2014. Initial Radioiodine Administration. *Endocrinology and Metabolism Clinics of North America* **43**, 385-400. [[CrossRef](#)]
737. Sung Hak Lee, Min Hee Kim, Ja Seong Bae, Dong Jun Lim, So Lyung Jung, Chan Kwon Jung. 2014. Clinical Outcomes in Patients with Non-Diagnostic Thyroid Fine Needle Aspiration Cytology: Usefulness of the Thyroid Core Needle Biopsy. *Annals of Surgical Oncology* **21**, 1870-1877. [[CrossRef](#)]
738. Donald S.A. McLeod. 2014. Thyrotropin in the Development and Management of Differentiated Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America* **43**, 367-383. [[CrossRef](#)]
739. M. Sara Rosenthal. 2014. Ethical Issues in the Management of Thyroid Disease. *Endocrinology and Metabolism Clinics of North America* **43**, 545-564. [[CrossRef](#)]
740. Hee Jung Moon, Eun-Kyung Kim, Jin Young Kwak. 2014. Malignancy Risk Stratification in Thyroid Nodules with Benign Results on Cytology: Combination of Thyroid Imaging Reporting and Data System and Bethesda System. *Annals of Surgical Oncology* **21**, 1898-1903. [[CrossRef](#)]
741. José Carlos Fernández-García, Isabel Mancha-Doblas, María Victoria Ortega-Jiménez, José Francisco Ruiz-Escalante, Ignasi Castells-Fusté, Santiago Tofé-Povedano, Iñaki Argüelles-Jiménez, Francisco José Tinahones. 2014. Diagnostic and functional structure of a high-resolution thyroid nodule clinic. *Endocrinología y Nutrición (English Edition)* **61**, 329-334. [[CrossRef](#)]
742. Dongbin Ahn, Jin Ho Sohn, Heejin Kim, Chang Ki Yeo. 2014. Large esophageal schwannoma mimicking thyroid tumor with egg-shell calcification on preoperative ultrasonography. *Asian Journal of Surgery* . [[CrossRef](#)]
743. Giovanni Conzo, Pietro Giorgio Calò, Antonio A. Sinisi, Annamaria De Bellis, Daniela Pasquali, Sergio Iorio, Ernesto Tartaglia, Claudio Mauriello, Claudio Gambardella, Fabio Cavallo, Fabio Medas, Andrea Polistena, Luigi Santini, Nicola Avenia. 2014. Impact of prophylactic central compartment neck dissection on locoregional recurrence of differentiated thyroid cancer in clinically node-negative patients: A retrospective study of a large clinical series. *Surgery* **155**, 998-1005. [[CrossRef](#)]
744. José Carlos Fernández-García, Isabel Mancha-Doblas, María Victoria Ortega-Jiménez, José Francisco Ruiz-Escalante, Ignasi Castells-Fusté, Santiago Tofé-Povedano, Iñaki Argüelles-Jiménez, Francisco José Tinahones. 2014. Estructura diagnóstica y funcional de una consulta de alta resolución de nódulo tiroideo. *Endocrinología y Nutrición* **61**, 329-334. [[CrossRef](#)]
745. Becky T. Muldoon, Vinh Q. Mai, Henry B. Burch. 2014. Management of Graves' Disease. *Endocrinology and Metabolism Clinics of North America* **43**, 495-516. [[CrossRef](#)]
746. Jung Hyun Yoon, Hye Sun Lee, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2014. A nomogram for predicting malignancy in thyroid nodules diagnosed as atypia of undetermined significance/follicular lesions of undetermined significance on fine needle aspiration. *Surgery* **155**, 1006-1013. [[CrossRef](#)]
747. Bhargavi Jois, Ramesh Asopa, Sandip Basu. 2014. Somatostatin Receptor Imaging in Non-131I-Avid Metastatic Differentiated Thyroid Carcinoma for Determining the Feasibility of Peptide Receptor Radionuclide Therapy With 177Lu-DOTATATE. *Clinical Nuclear Medicine* **36**, 505-510. [[CrossRef](#)]



748. Joseph K. Salama, Daniel W. Golden, Sue S. Yom, Madhur Kumar Garg, Joshua Lawson, Mark W. McDonald, Harry Quon, John A. Ridge, Nabil Saba, Richard V. Smith, Francis Worden, Anamaria Reyna Yeung, Jonathan J. Beitler. 2014. ACR Appropriateness Criteria® thyroid carcinoma. *Oral Oncology* **50**, 577-586. [[CrossRef](#)]
749. Scott Wilhelm. 2014. Evaluation of Thyroid Incidentaloma. *Surgical Clinics of North America* **94**, 485-497. [[CrossRef](#)]
750. S. Önder, P. Firat, D. Ates. 2014. The Bethesda system for reporting thyroid cytopathology: an institutional experience of the outcome of indeterminate categories. *Cytopathology* **25**:10.1111/cyt.2014.25.issue-3, 177-184. [[CrossRef](#)]
751. Kenya Kobayashi, Shigeo Takenouchi, Hiroki Mitani, Tuyoshi Yoshida. 2014. Recurrence pattern after conservative surgery for papillary thyroid carcinoma. *Auris Nasus Larynx* . [[CrossRef](#)]
752. Denise P. Momesso, R. Michael Tuttle. 2014. Update on Differentiated Thyroid Cancer Staging. *Endocrinology and Metabolism Clinics of North America* **43**, 401-421. [[CrossRef](#)]
753. Ozgur Omur, Yusuf Baran. 2014. An update on molecular biology of thyroid cancers. *Critical Reviews in Oncology/Hematology* **90**, 233-252. [[CrossRef](#)]
754. Rossella Elisei, Laura Agate, David Viola, Antonio Matrone, Agnese Biagini, Eleonora Molinaro. 2014. How to Manage Patients with Differentiated Thyroid Cancer and a Rising Serum Thyroglobulin Level. *Endocrinology and Metabolism Clinics of North America* **43**, 331-344. [[CrossRef](#)]
755. Maged Abdel Galil Hamed, Ahmed Fathy Abdel Ghany, Noha Mohamed Osman. 2014. The diagnostic usefulness of FDG-PET/CT in detecting tumor recurrence not evident in whole body I131 scan in differentiated thyroid carcinoma. *The Egyptian Journal of Radiology and Nuclear Medicine* **45**, 361-365. [[CrossRef](#)]
756. Manisha Bahl, Julie A. Sosa, Rendon C. Nelson, Ramon M. Esclamado, Kingshuk Roy Choudhury, Jenny K. Hoang. 2014. Trends in Incidentally Identified Thyroid Cancers Over a Decade: A Retrospective Analysis of 2,090 Surgical Patients. *World Journal of Surgery* **38**, 1312-1317. [[CrossRef](#)]
757. J. K. Hoang. 2014. Population-based study provides a step towards evidence-based management of thyroid nodules detected on ultrasound. *Evidence-Based Medicine* **19**, 109-109. [[CrossRef](#)]
758. Sareh Parangi, Hyunsuk Suh. 2014. The Role of Genetic Markers in the Evaluation and Management of Thyroid Nodules. *Surgical Clinics of North America* **94**, 515-528. [[CrossRef](#)]
759. Nisha Nathan, Shannon D. Sullivan. 2014. Thyroid Disorders During Pregnancy. *Endocrinology and Metabolism Clinics of North America* **43**, 573-597. [[CrossRef](#)]
760. Henry T. Hoffman, Umar S. Chaudhry, Yusuf Menda, Robert A. Robinson. 2014. Current Management of Radioiodine Sialadenitis. *Current Otorhinolaryngology Reports* **2**, 70-84. [[CrossRef](#)]
761. Y. C. Kuan, F. H. S. Tan. 2014. Thyroid papillary carcinoma in a 'hot' thyroid nodule. *QJM* **107**, 475-476. [[CrossRef](#)]
762. Rachna M. Goyal, Jacqueline Jonklaas, Kenneth D. Burman. 2014. Management of Recurrent Cervical Papillary Thyroid Cancer. *Endocrinology and Metabolism Clinics of North America* **43**, 565-572. [[CrossRef](#)]
763. Pedro Wesley Rosário. 2014. Thyroid Nodules with Benign Cytology: Is Size  $\geq 4$  cm an Indication for Surgery?. *World Journal of Surgery* **38**, 1554-1555. [[CrossRef](#)]
764. Manisha Bahl, Julie A. Sosa, Rendon C. Nelson, Hasan A. Hobbs, Nathan M. Wnuk, Jenny K. Hoang. 2014. Thyroid Cancers Incidentally Detected at Imaging in a 10-year Period: How Many Cancers Would Be Missed with Use of the Recommendations from the Society of Radiologists in Ultrasound?. *Radiology* **271**, 888-894. [[CrossRef](#)]
765. Charles Marcus, Pat W. Whitworth, Devaki S. Surasi, Sara I. Pai, Rathan M. Subramaniam. 2014. PET/CT in the Management of Thyroid Cancers. *American Journal of Roentgenology* **202**, 1316-1329. [[CrossRef](#)]
766. Ana B Santoro, Daniela D. Vargens, Mateus de Camargo Barros Filho, Daniel A. Bulzico, Luiz Paulo Kowalski, Ricardo M. R. Meirelles, Daniela P. Paula, Ronaldo R.S. Neves, Cencita N. Pessoa, Claudio J Struchine, Guilherme Suarez-Kurtz. 2014. Effect of UGT1A1, UGT1A3, DIO1 and DIO2 polymorphisms on L-thyroxine doses required for TSH suppression in patients with differentiated thyroid cancer. *British Journal of Clinical Pharmacology* n/a-n/a. [[CrossRef](#)]
767. Young Jun Chai, Su-jin Kim, June Young Choi, Do Hoon Koo, Kyu Eun Lee, Yeo-Kyu Youn. 2014. Papillary Thyroid Carcinoma Located in the Isthmus or Upper Third is Associated with Delphian Lymph Node Metastasis. *World Journal of Surgery* **38**, 1306-1311. [[CrossRef](#)]
768. Min Liu, Maomei Ruan, Libo Chen. 2014. Update on the molecular diagnosis and targeted therapy of thyroid cancer. *Medical Oncology* **31** . [[CrossRef](#)]
769. Don C. Yoo, Richard B. Noto, Peter J. Mazzaglia. 2014. Controversy Over Radioiodine Ablation In Thyroid Cancer. *Surgical Clinics of North America* **94**, 573-586. [[CrossRef](#)]

770. Francesco Nardi, Fulvio Basolo, Anna Crescenzi, Guido Fadda, Andrea Frasoldati, Fabio Orlandi, Lucio Palombini, Enrico Papini, Michele Zini, Alfredo Pontecorvi, Paolo Vitti. 2014. Italian consensus for the classification and reporting of thyroid cytology. *Journal of Endocrinological Investigation* **37**, 593-599. [[CrossRef](#)]
771. Su-jin Kim, Seog Yun Park, You Jin Lee, Eun Kyung Lee, Seok-ki Kim, Tae Hyun Kim, Yu-Seog Jung, Junsun Ryu, Jun Pyo Myong, Ki-Wook Chung. 2014. Risk Factors for Recurrence After Therapeutic Lateral Neck Dissection for Primary Papillary Thyroid Cancer. *Annals of Surgical Oncology* **21**, 1884-1890. [[CrossRef](#)]
772. Eleonore Fröhlich, Richard Wahl. 2014. The current role of targeted therapies to induce radioiodine uptake in thyroid cancer. *Cancer Treatment Reviews* **40**, 665-674. [[CrossRef](#)]
773. H Hänscheid, M Lassmann, A K Buck, C Reiners, F A Verburg. 2014. The limit of detection in scintigraphic imaging with I-131 in patients with differentiated thyroid carcinoma. *Physics in Medicine and Biology* **59**, 2353-2368. [[CrossRef](#)]
774. C. Lepoutre-Lussey, D. Maddah, J.-L. Golmard, G. Russ, F. Tissier, C. Tresallet, F. Menegaux, A. Aurengo, L. Leenhardt. 2014. Post-operative neck ultrasound and risk stratification in differentiated thyroid cancer patients with initial lymph node involvement. *European Journal of Endocrinology* **170**, 837-846. [[CrossRef](#)]
775. I. A. Ozemir, B. Gurbuz, B. Bayraktar, S. Aslan, A. Başkent, H. Yalman, R. Yigitbasi, O. Alimoglu. 2014. The Effect of Thyroid-Stimulating Hormone on Tumor Size in Differentiated Thyroid Carcinoma. *Indian Journal of Surgery* . [[CrossRef](#)]
776. Rosário Pedro Wesley, Calsolari Maria Regina. 2014. Thyroid Ablation with 1.1 GBq (30 mCi) Iodine-131 in Patients with Papillary Thyroid Carcinoma at Intermediate Risk for Recurrence. *Thyroid* **24**:5, 826-831. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
777. Bernet Victor, Stancampiano Fernando. 2014. Introduction to Ultrasound-Guided Fine-Needle Aspiration of the Thyroid. *VideoEndocrinology* **1**:1. . [[Abstract](#)] [[Full Text HTML](#)]
778. Wu Dafang, Fink-Bennett Darlene, Campbell Janice. 2014. Thyroid Remnant Ablation Following Administration of a Diagnostic Dose of Iodine-131 Under Thyrogen Stimulation. *Thyroid* **24**:5, 924-925. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
779. Ho Allen S., Sarti Evan E., Jain Kunal S., Wang Hangjun, Nixon Iain J., Shaha Ashok R., Shah Jatin P., Kraus Dennis H., Ghossein Ronald, Fish Stephanie A., Wong Richard J., Lin Oscar, Morris Luc G.T.. 2014. Malignancy Rate in Thyroid Nodules Classified as Bethesda Category III (AUS/FLUS). *Thyroid* **24**:5, 832-839. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
780. Shindo Hisakazu, Amino Nobuyuki, Ito Yasuhiro, Kihara Minoru, Kobayashi Kaoru, Miya Akihiro, Hirokawa Mitsuyoshi, Miyachi Akira. 2014. Papillary Thyroid Microcarcinoma Might Progress During Pregnancy. *Thyroid* **24**:5, 840-844. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
781. Sohn Seo Young, Choi Ji Hun, Kim Na Kyung, Joung Ji Young, Cho Yoon Young, Park Sun Mi, Kim Tae Hun, Jin Sang Man, Bae Ji Cheol, Lee Soo Youn, Chung Jae Hoon, Kim Sun Wook. 2014. The Impact of Iodinated Contrast Agent Administered During Preoperative Computed Tomography Scan on Body Iodine Pool in Patients with Differentiated Thyroid Cancer Preparing for Radioactive Iodine Treatment. *Thyroid* **24**:5, 872-877. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
782. Han Ji Min, Kim Won Gu, Kim Tae Yong, Jeon Min Ji, Ryu Jin-Sook, Song Dong Eun, Hong Suck Joon, Shong Young Kee, Kim Won Bae. 2014. Effects of Low-Dose and High-Dose Postoperative Radioiodine Therapy on the Clinical Outcome in Patients with Small Differentiated Thyroid Cancer Having Microscopic Extrathyroidal Extension. *Thyroid* **24**:5, 820-825. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
783. Byeong-Cheol Ahn. 2014. Requisites for successful theranostics with radionuclide-based reporter gene imaging. *Journal of Drug Targeting* **22**, 295-303. [[CrossRef](#)]
784. Young Hoon Yoon, Ki Ryun Kwon, Seo Young Kwak, Kyeung A. Ryu, Bobae Choi, Jin-Man Kim, Bon Seok Koo. 2014. Tumor size measured by preoperative ultrasonography and postoperative pathologic examination in papillary thyroid carcinoma: relative differences according to size, calcification and coexisting thyroiditis. *European Archives of Oto-Rhino-Laryngology* **271**, 1235-1239. [[CrossRef](#)]
785. Joe Saliba, Richard Payne, Rickul Varshney, Eyal Sela, Anastasios Maniakas, Elham Rahme, Alexander Mlynarek, Derin Caglar, Michael Hier, Michael Tamilia. 2014. Sentinel Lymph Node Biopsy Status Correlates with Postoperative Stimulated Thyroglobulin Levels in Low-risk Papillary Thyroid Cancer Patients. *Endocrine Practice* **20**, 399-404. [[CrossRef](#)]
786. Toshiyuki Ikeoka, Takao Ando, Misa Imaizumi, Ikuko Ueki, Toshiro Usa, Atsushi Kawakami. 2014. Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron. *Endocrine* **46**, 131-137. [[CrossRef](#)]

787. Giovanni Conzo, Andrea Polistena, Pietro Giorgio Calò, Paolo Bononi, Claudio Gambardella, Claudio Mauriello, Ernesto Tartaglia, Stefano Avenia, Alessandro Sanguinetti, Fabio Medas, Giorgio de Toma, Nicola Avenia. 2014. Efficacy of combined treatment for anaplastic thyroid carcinoma: Results of a multinstitutional retrospective analysis. *International Journal of Surgery* . [CrossRef]
788. M.R. Pelizzo, C. Dobrinja, E. Casal Ide, M. Zane, O. Lora, A. Toniato, C. Mian, S. Barollo, M. Izuzquiza, J. Guerrini, N. De Manzini, I. Merante Boschin, D. Rubello. 2014. The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. *Biomedicine & Pharmacotherapy* **68**, 413-417. [CrossRef]
789. Won Sang Yoo, Hoon Sung Choi, Sun Wook Cho, Jae Hoon Moon, Kyung Won Kim, Hyo Jin Park, So Yeon Park, Sang Il Choi, Sung Hee Choi, Soo Lim, Ka Hee Yi, Do Joon Park, Hak Chul Jang, Young Joo Park. 2014. The role of ultrasound findings in the management of thyroid nodules with atypia or follicular lesions of undetermined significance. *Clinical Endocrinology* **80**:10.1111/cen.2014.80.issue-5, 735-742. [CrossRef]
790. Aviram Mizrachi, Raphael Feinmesser, Gideon Bachar, Ohad Hilly, Maya Cohen. 2014. Value of ultrasound in detecting central compartment lymph node metastases in differentiated thyroid carcinoma. *European Archives of Oto-Rhino-Laryngology* **271**, 1215-1218. [CrossRef]
791. Tamas Kelly. 2014. A favorable risk-benefit analysis of High dose thyroid for treatment of bipolar Disorders with regard to osteoporosis. *Journal of Affective Disorders* . [CrossRef]
792. E. Hoseinian-Azghadi, L. Rafat-Motavalli, H. Miri-Hakimabad. 2014. Internal dosimetry estimates using voxelized reference phantoms for thyroid agents. *Journal of Radiation Research* **55**, 407-422. [CrossRef]
793. Carrie C. Lubitz, Chung Y. Kong, Pamela M. McMahon, Gilbert H. Daniels, Yufei Chen, Konstantinos P. Economopoulos, G. Scott Gazelle, Milton C. Weinstein. 2014. Annual financial impact of well-differentiated thyroid cancer care in the United States. *Cancer* **120**:10.1002/cncr.v120.9, 1345-1352. [CrossRef]
794. Hyun Sin In, Dong Wook Kim, Hye Jung Choo, Soo Jin Jung, Taewoo Kang, Ji Hwa Ryu. 2014. Ethanol ablation of benign thyroid cysts and predominantly cystic thyroid nodules: factors that predict outcome. *Endocrine* **46**, 107-113. [CrossRef]
795. Jiyeon Hyeon, Soomin Ahn, Jung Hee Shin, Young Lyun Oh. 2014. The prediction of malignant risk in the category “atypia of undetermined significance/follicular lesion of undetermined significance” of the Bethesda System for Reporting Thyroid Cytopathology using subcategorization and BRAF mutation results. *Cancer Cytopathology* **122**:10.1002/cncy.v122.5, 368-376. [CrossRef]
796. Myung-Chul Lee, Hoon Park, Ik Joon Choi, Byeong-Cheol Lee, Guk-Haeng Lee. 2014. Comparative study of a gasless transaxillary approach versus a bilateral axillo-breast approach for endoscopic thyroidectomy in a single institute. *Head & Neck* **36**:10.1002/hed.v36.5, 702-708. [CrossRef]
797. Salvatore Arena, Adele Latina, Michele Stornello, Giovanna Saraceno, Salvatore Benvenega. 2014. Intranuclear cytoplasmic inclusions in cytologically suspicious or malignant thyroid nodules: identification and correlation with echogenicity and size of the nodules. *Endocrine* **46**, 114-122. [CrossRef]
798. Hideki Murakami, Satoshi Kato, Yasuhiro Ueda, Yoshiyasu Fujimaki, Hiroyuki Tsuchiya. 2014. Reconstruction using a frozen tumor-bearing vertebra in total en bloc spondylectomy can enhance antitumor immunity. *European Spine Journal* **23**, 222-227. [CrossRef]
799. Massimo De Falco, Giuseppe Santangelo, Santolo Del Giudice, Federica Gallucci, Umberto Parmeggiani. 2014. Double probe intraoperative neuromonitoring with a standardized method in thyroid surgery. *International Journal of Surgery* . [CrossRef]
800. Andrea L. Baynes, Andres Del Rio, Catriona McLean, Simon Grodski, Meei J. Yeung, William R. Johnson, Jonathan W. Serpell. 2014. Fine-Needle Aspiration of the Thyroid: Correlating Suspicious Cytology Results with Histological Outcomes. *Annals of Surgical Oncology* **21**, 1653-1658. [CrossRef]
801. Pierpaolo Trimboli, Giorgio Treglia, Leo Guidobaldi, Enrico Saggiorato, Giuseppe Nigri, Anna Crescenzi, Francesco Romanelli, Fabio Orlandi, Stefano Valabrega, Ramin Sadeghi, Luca Giovanella. 2014. Clinical characteristics as predictors of malignancy in patients with indeterminate thyroid cytology: a meta-analysis. *Endocrine* **46**, 52-59. [CrossRef]
802. Jennifer E. Rosen, Paula Gardiner, Robert B. Saper, Elizabeth N. Pearce, Kallista Hammer, Rebecca L. Gupta-Lawrence, Stephanie L. Lee. 2014. Kelp use in patients with thyroid cancer. *Endocrine* **46**, 123-130. [CrossRef]
803. Nathalie Chéreau, Camille Buffet, Christophe Trésallet, Frederique Tissier, Jean-Louis Golmard, Laurence Leenhardt, Fabrice Menegaux. 2014. Does Extracapsular Extension Impact the Prognosis of Papillary Thyroid Microcarcinoma?. *Annals of Surgical Oncology* **21**, 1659-1664. [CrossRef]
804. Sun Jin Herh, Eun-Kyung Kim, Ji Min Sung, Jung Hyun Yoon, Hee Jung Moon, Jin Young Kwak. 2014. Heterogeneous Echogenicity of the Thyroid Parenchyma Does Not Influence the Detection of Multi-focality in Papillary Thyroid Carcinoma on Preoperative Ultrasound Staging. *Ultrasound in Medicine & Biology* **40**, 884-889. [CrossRef]

805. Yaolin Zhou, Anna Kundel, Siobhan T Pittock, Geoffrey B Thompson. 2014. Advanced presentation of paediatric papillary thyroid cancer: A plea for heightened awareness. *Journal of Paediatrics and Child Health* **50**:10.1111/jpc.2014.50.issue-5, 347-351. [[CrossRef](#)]
806. Esther Diana Rossi, Patrizia Straccia, Maurizio Martini, Luca Revelli, Celestino Pio Lombardi, Alfredo Pontecorvi, Guido Fadda. 2014. The role of thyroid fine-needle aspiration cytology in the pediatric population: An institutional experience. *Cancer Cytopathology* **122**:10.1002/cncy.v122.5, 359-367. [[CrossRef](#)]
807. David S. Cohen, Zachary P. VandeGriend, George H. Yoo, Adam J. Folbe, Ho-Sheng Lin. 2014. Risk stratification based on thyroid cytology: Can we rely on national data?. *American Journal of Otolaryngology* **35**, 362-365. [[CrossRef](#)]
808. P. Campanella, F. Ianni, C. A. Rota, S. M. Corsello, A. Pontecorvi. 2014. DIAGNOSIS IN ENDOCRINOLOGY: Quantification of cancer risk of each clinical and ultrasonographic suspicious feature of thyroid nodules: a systematic review and meta-analysis. *European Journal of Endocrinology* **170**, R203-R211. [[CrossRef](#)]
809. Masato Kobayashi, Hiroshi Wakabayashi, Daiki Kayano, Takahiro Konishi, Hironori Kojima, Hiroto Yoneyama, Koichi Okuda, Hiroyuki Tsushima, Masahisa Onoguchi, Keiichi Kawai, Seigo Kinuya. 2014. Application of a medium-energy collimator for I-131 imaging after ablation treatment of differentiated thyroid cancer. *Annals of Nuclear Medicine* . [[CrossRef](#)]
810. D. G. McFadden, A. Vernon, P. M. Santiago, R. Martinez-McFaline, A. Bhutkar, D. M. Crowley, M. McMahon, P. M. Sadow, T. Jacks. 2014. p53 constrains progression to anaplastic thyroid carcinoma in a Braf-mutant mouse model of papillary thyroid cancer. *Proceedings of the National Academy of Sciences* . [[CrossRef](#)]
811. Jun-Mei Xu, Xiao-Hong Xu, Hui-Xiong Xu, Yi-Feng Zhang, Jing Zhang, Le-Hang Guo, Lin-Na Liu, Chang Liu, Shu-Guang Zheng. 2014. Conventional US, US Elasticity Imaging, and Acoustic Radiation Force Impulse Imaging for Prediction of Malignancy in Thyroid Nodules. *Radiology* 132438. [[CrossRef](#)]
812. Zevallos Jose P, Xu Li, Yiu Yin. 2014. The Impact of Socioeconomic Status on the Use of Adjuvant Radioactive Iodine for Papillary Thyroid Cancer. *Thyroid* **24**:4, 758-763. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
813. Versari Annibale, Sollini Martina, Frasoldati Andrea, Fraternali Alessandro, Filice Angelina, Froio Armando, Asti Mattia, Fioroni Federica, Cremonini Nadia, Putzer Daniel, Erba Paola Anna. 2014. Differentiated Thyroid Cancer: A New Perspective with Radiolabeled Somatostatin Analogues for Imaging and Treatment of Patients. *Thyroid* **24**:4, 715-726. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
814. Mehra Saral, Tuttle R. Michael, Bergman Donald, Bernet Victor, Brett Elise, Cobin Rhoda, Doherty Gerard, Klopper Joshua, Lee Stephanie, Machac Josef, Milas Mira, Mechanick Jeffrey I., Orloff Lisa, Randolph Gregory, Ross Douglas S., Smallridge Robert, Terris David, Tufano Ralph, Alon Eran, Clain Jason, Dos Reis Laura, Scherl Sophie, Urken Mark L.. 2014. Improving the Quality of Thyroid Cancer Care: How Does the Thyroid Cancer Care Collaborative Cross the Institute of Medicine's Quality Chasm?. *Thyroid* **24**:4, 615-624. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
815. Rhee Sun Jung, Hahn Soo Yeon, Ko Eun Sook, Ryu Jae Wook, Ko Eun Young, Shin Jung Hee. 2014. Follicular Variant of Papillary Thyroid Carcinoma: Distinct Biologic Behavior Based on Ultrasonographic Features. *Thyroid* **24**:4, 683-688. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
816. A.-L. Giraudet. 2014. TEMP/TDM et TEP/TDM pour les cancers thyroïdiens de souche folliculaire. *Médecine Nucléaire* . [[CrossRef](#)]
817. Jin Young Kwak, Eun-Kyung Kim. 2014. Ultrasound elastography for thyroid nodules: recent advances. *Ultrasonography* **33**, 75-82. [[CrossRef](#)]
818. Jian-Qiao Zhou, Jing-Wen Zhang, Wei-Wei Zhan, Wei Zhou, Ting-Jun Ye, Ying Zhu, Jie-Jie Yao, Jun Liu, Yun-Yun Hu, Edward G. Grant. 2014. Comparison of fine-needle aspiration and fine-needle capillary sampling of thyroid nodules: A prospective study with emphasis on the influence of nodule size. *Cancer Cytopathology* **122**:10.1002/cncy.v122.4, 266-273. [[CrossRef](#)]
819. Heejin Kim, Young Ju Jin, Wonjae Cha, Woo-Jin Jeong, Soon-Hyun Ahn. 2014. Feasibility of super-selective neck dissection for indeterminate lateral neck nodes in papillary thyroid carcinoma. *Head & Neck* **36**:10.1002/hed.v36.4, 487-491. [[CrossRef](#)]
820. Bryan McIver. 2014. Evaluating Thyroid Nodules in the Information Age: New Technologies, New Opportunities, New Challenges. *Endocrine Practice* **20**, 370-373. [[CrossRef](#)]
821. Dang Vu-Phan, Ronald J. Koenig. 2014. Genetics and epigenetics of sporadic thyroid cancer. *Molecular and Cellular Endocrinology* **386**, 55-66. [[CrossRef](#)]
822. Christine J. O'Neill, Nicholas Coorough, James C. Lee, Joshua Clements, Leigh W. Delbridge, Rebecca Sippel, Mark S. Sywak, Herb Chen, Stan B. Sidhu. 2014. Disease outcomes and nodal recurrence in patients with papillary thyroid cancer and lateral neck nodal metastases. *ANZ Journal of Surgery* **84**:10.1111/ans.2014.84.issue-4, 240-244. [[CrossRef](#)]

823. J. K. Hoang, K. R. Choudhury, J. D. Eastwood, R. M. Esclamado, G. H. Lyman, T. M. Shattuck, X. V. Nguyen. 2014. An Exponential Growth in Incidence of Thyroid Cancer: Trends and Impact of CT Imaging. *American Journal of Neuroradiology* **35**, 778-783. [[CrossRef](#)]
824. Eun Sook Ko, Jin Yong Sung, Jung Hee Shin. 2014. Intralesional saline injection for effective ultrasound-guided aspiration of benign viscous cystic thyroid nodules. *Ultrasonography* **33**, 122-127. [[CrossRef](#)]
825. Trevor Rose. 2014. The Reply. *The American Journal of Medicine* **127**, e13. [[CrossRef](#)]
826. Kathryn A. Robinson, William D. Middleton. 2014. Thyroid. *Ultrasound Clinics* . [[CrossRef](#)]
827. Sohee Lee, Cho Rok Lee, Seung Chul Lee, Seulkee Park, Ha Yan Kim, Haiyoung Son, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park, Arthur Cho. 2014. Surgical completeness of robotic thyroidectomy: a prospective comparison with conventional open thyroidectomy in papillary thyroid carcinoma patients. *Surgical Endoscopy* **28**, 1068-1075. [[CrossRef](#)]
828. Kyung Tae, Chang M. Song, Yong B. Ji, Kyung R. Kim, Ji Y. Kim, Yun Y. Choi. 2014. Comparison of surgical completeness between robotic total thyroidectomy versus open thyroidectomy. *The Laryngoscope* **124**:10.1002/lary.v124.4, 1042-1047. [[CrossRef](#)]
829. Pedro Rosário, Wilson Tavares, Michelle Borges, Juan Santos, Maria Calsolari. 2014. Ultrasonographic Differentiation of Cervical Lymph Nodes in Patients with Papillary Thyroid Carcinoma After Thyroidectomy and Radioiodine Ablation: A Prospective Study. *Endocrine Practice* **20**, 293-298. [[CrossRef](#)]
830. S Zaheer, EH Tan, ES Ang, SH Loke, YH Kao, A Goh, WY Wong. 2014. Post-thyroidectomy neck ultrasonography in patients with thyroid cancer and a review of the literature. *Singapore Medical Journal* **55** . [[CrossRef](#)]
831. S. Leboulleux, D. Déandreis, J. Lumbroso, E. Baudin, M. Schlumberger. 2014. Cancers de la thyroïde et traitement par iode 131. *Médecine Nucléaire* . [[CrossRef](#)]
832. Byung Chul Kang, Jong-Lyel Roh, Jeong Hyun Lee, Kyung-Ja Cho, Gyungyub Gong, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim. 2014. Candidates for Limited Lateral Neck Dissection among Patients with Metastatic Papillary Thyroid Carcinoma. *World Journal of Surgery* **38**, 863-871. [[CrossRef](#)]
833. Cho Rok Lee, Haiyoung Son, Sohee Lee, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park. 2014. Lobectomy and Prophylactic Central Neck Dissection for Papillary Thyroid Microcarcinoma: Do Involved Lymph Nodes Mandate Completion Thyroidectomy?. *World Journal of Surgery* **38**, 872-877. [[CrossRef](#)]
834. Christopher R. McHenry, Jonah J. Stulberg. 2014. Prophylactic Central Compartment Neck Dissection for Papillary Thyroid Cancer. *Surgical Clinics of North America* . [[CrossRef](#)]
835. Sarah C. Oltmann, David F. Schneider, Glen Levenson, Tamilselvan Sivashanmugam, Herbert Chen, Rebecca S. Sippel. 2014. Radioactive Iodine Remnant Uptake After Completion Thyroidectomy: Not Such a Complete Cancer Operation. *Annals of Surgical Oncology* **21**, 1379-1383. [[CrossRef](#)]
836. David A. Sloan, Daniel L. Davenport, Roberta J. Eldridge, Cortney Y. Lee. 2014. Surgeon-Driven Thyroid Interrogation of Patients Presenting with Primary Hyperparathyroidism. *Journal of the American College of Surgeons* **218**, 674-683. [[CrossRef](#)]
837. Soo-Yeon Kim, Kyung Hwa Han, Hee Jung Moon, Jin Young Kwak, Woong Youn Chung, Eun-Kyung Kim. 2014. Thyroid Nodules with Benign Findings at Cytologic Examination: Results of Long-term Follow-up with US. *Radiology* **271**, 272-281. [[CrossRef](#)]
838. Elif Özdemir, Nilufer Yildirim Poyraz, Sefika Burcak Polat, Seyda Turkolmez, Reyhan Ersoy, Bekir Cakir. 2014. Diagnostic value of 18F-FDG PET/CT in patients with TENIS syndrome: correlation with thyroglobulin levels. *Annals of Nuclear Medicine* **28**, 241-247. [[CrossRef](#)]
839. Dongbin Ahn, Jin Ho Sohn, Heejin Kim. 2014. Surgeon-performed Intraoperative Tumor Localization in Recurrent Papillary Thyroid Carcinoma by Ultrasound-guided Intratumoral Indigo Carmine Injection. *World Journal of Surgery* . [[CrossRef](#)]
840. E. Mato, C. Gonzalez, A. Moral, J. I. Perez, O. Bell, E. Lerma, A. de Leiva. 2014. ABCG2/BCRP gene expression related with EMT inducer genes in papillary thyroid carcinoma. *Journal of Molecular Endocrinology* . [[CrossRef](#)]
841. D. L. S. Danilovic, E. U. Lima, R. B. Domingues, L. G. Brandao, A. O. Hoff, S. Marui. 2014. Pre-operative role of BRAF in the guidance of the surgical approach and prognosis of differentiated thyroid carcinoma. *European Journal of Endocrinology* **170**, 619-625. [[CrossRef](#)]
842. C.- H. Hsu, C.- L. Huang, Y.- H. Hsu, U. Iqbal, P.- A. Nguyen, W.- S. Jian. 2014. Co-occurrence of second primary malignancy in patients with thyroid cancer. *QJM* . [[CrossRef](#)]
843. R. Chami, R. Moreno-Reyes, B. Corvilain. 2014. TSH measurement is not an appropriate screening test for autonomous functioning thyroid nodules: a retrospective study of 368 patients. *European Journal of Endocrinology* **170**, 593-599. [[CrossRef](#)]

844. V Veschi, M Petroni, A Bartolazzi, P Altavista, C Dominici, C Capalbo, R Boldrini, A Castellano, H P McDowell, B Pizer, L Frati, I Screpanti, A Gulino, G Giannini. 2014. Galectin-3 is a marker of favorable prognosis and a biologically relevant molecule in neuroblastic tumors. *Cell Death and Disease* 5, e1100. [[CrossRef](#)]
845. Pannone Giuseppe, Santoro Angela, Pasquali Daniela, Zamparese Rosanna, Mattoni Marilena, Russo Giuseppe, Landriscina Matteo, Piscazzi Annamaria, Toti Paolo, Cignarelli Mauro, Lo Muzio Lorenzo, Bufo Pantaleo. 2014. The Role of Survivin in Thyroid Tumors: Differences of Expression in Well-Differentiated, Non-Well-Differentiated, and Anaplastic Thyroid Cancers. *Thyroid* 24:3, 511-519. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
846. Goffredo Paolo, Roman Sanziana A., Sosa Julie A.. 2014. Have 2006 ATA Practice Guidelines Affected the Treatment of Differentiated Thyroid Cancer in the United States?. *Thyroid* 24:3, 463-471. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
847. Siu Stephanie, McDonald James Ted, Rajaraman Murali, Franklin Jason, Paul Terri, Rachinsky Irina, Morrison Deric, Imran S. Ali, Burrell Steven, Hart Robert, Driedger Al, Badreddine Mahmoud, Yoo John, Corsten Martin, Van Uum Stan. 2014. Is Lower Socioeconomic Status Associated with More Advanced Thyroid Cancer Stage at Presentation? A Study in Two Canadian Centers. *Thyroid* 24:3, 545-551. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
848. de Figueiredo Feitosa Nathalie Lobo, Crispim Janaina Cristina de Oliveira, Zanetti Bruna Riedo, Magalhães Patrícia Kunzle Ribeiro, Soares Christiane Pienna, Soares Edson Garcia, Neder Luciano, Donadi Eduardo Antonio, Maciel Léa Maria Zanini. 2014. HLA-G Is Differentially Expressed in Thyroid Tissues. *Thyroid* 24:3, 585-592. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
849. Estrada Joshua M., Soldin Danielle, Buckley Timothy M., Burman Kenneth D., Soldin Offie P. 2014. Thyrotropin Isoforms: Implications for Thyrotropin Analysis and Clinical Practice. *Thyroid* 24:3, 411-423. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
850. Udelsman Robert, Zhang Yawei. 2014. The Epidemic of Thyroid Cancer in the United States: The Role of Endocrinologists and Ultrasounds. *Thyroid* 24:3, 472-479. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
851. Rosario Pedro Wesley, Mourão Gabriela Franco, dos Santos Juan Bernard Nascimento, Calsolari Maria Regina. 2014. Is Empirical Radioactive Iodine Therapy Still a Valid Approach to Patients with Thyroid Cancer and Elevated Thyroglobulin?. *Thyroid* 24:3, 533-536. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
852. Juan Carlos Galofré, Garcilaso Riesco-Eizaguirre, Cristina Álvarez-Escolá. 2014. Guía clínica para el manejo del nódulo tiroideo y cáncer de tiroides durante el embarazo. *Endocrinología y Nutrición* 61, 130-138. [[CrossRef](#)]
853. Iwao Sugitani, Yoshihide Fujimoto, Keiko Yamada. 2014. Association Between Serum Thyrotropin Concentration and Growth of Asymptomatic Papillary Thyroid Microcarcinoma. *World Journal of Surgery* 38, 673-678. [[CrossRef](#)]
854. Laura I. Wharry, Kelly L. McCoy, Michael T. Stang, Michael J. Armstrong, Shane O. LeBeau, Mitch E. Tublin, Biatta Sholosh, Ari Silbermann, N. Paul Otori, Yuri E. Nikiforov, Steven P. Hodak, Sally E. Carty, Linwah Yip. 2014. Thyroid Nodules ( $\geq 4$  cm): Can Ultrasound and Cytology Reliably Exclude Cancer?. *World Journal of Surgery* 38, 614-621. [[CrossRef](#)]
855. Wendy Sacks, Glenn Braunstein. 2014. Evolving Approaches in Managing Radioactive Iodine-Refractory Differentiated Thyroid Cancer. *Endocrine Practice* 20, 263-275. [[CrossRef](#)]
856. Takashi Uruno, Hiroshi Shibuya, Wataru Kitagawa, Mitsuji Nagahama, Kiminori Sugino, Koichi Ito. 2014. Optimal Timing of Surgery for Differentiated Thyroid Cancer in Pregnant Women. *World Journal of Surgery* 38, 704-708. [[CrossRef](#)]
857. Schelto Kruijff, Japke F. Petersen, Paul Chen, Ahmed M. Aniss, Roderick J. Clifton-Bligh, Stan B. Sidhu, Leigh W. Delbridge, Anthony J. Gill, Diana Learoyd, Mark S. Sywak. 2014. Patterns of Structural Recurrence in Papillary Thyroid Cancer. *World Journal of Surgery* 38, 653-659. [[CrossRef](#)]
858. Rasha Elshafey, Ashraf Elattar, Mohamed Mlees, Noha Esheba. 2014. Role of quantitative diffusion-weighted MRI and 1H MR spectroscopy in distinguishing between benign and malignant thyroid nodules. *The Egyptian Journal of Radiology and Nuclear Medicine* 45, 89-96. [[CrossRef](#)]
859. Edwin O. Onkendi, Travis J. McKenzie, Melanie L. Richards, David R. Farley, Geoffrey B. Thompson, Jan L. Kasperbauer, Ian D. Hay, Clive S. Grant. 2014. Reoperative Experience with Papillary Thyroid Cancer. *World Journal of Surgery* 38, 645-652. [[CrossRef](#)]
860. Brandon S Sheffield, Hamid Masoudi, Blair Walker, Sam M Wiseman. 2014. Preoperative diagnosis of thyroid nodules using the Bethesda System for Reporting Thyroid Cytopathology: a comprehensive review and meta-analysis. *Expert Review of Endocrinology & Metabolism* 9, 97-110. [[CrossRef](#)]
861. Paula Soares, Ricardo Celestino, Miguel Melo, Elsa Fonseca, Manuel Sobrinho-Simões. 2014. Prognostic biomarkers in thyroid cancer. *Virchows Archiv* 464, 333-346. [[CrossRef](#)]

862. Gilberto Vaz Teixeira, Claudio Roberto Cernea. 2014. Molecular Markers: From Diagnosis to Prognosis in 2013. *Current Otorhinolaryngology Reports* **2**, 35-43. [[CrossRef](#)]
863. Carlos K. H. Wong, Brian Hung-Hin Lang. 2014. A Cost-Utility Analysis for Prophylactic Central Neck Dissection in Clinically Nodal-Negative Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* **21**, 767-777. [[CrossRef](#)]
864. Rosalia Padovani, R. Tuttle, Ravinder Grewal, Steve Larson, Laura Boucai. 2014. Complete Blood Counts are Frequently Abnormal 1 Year after Dosimetry-Guided Radioactive Iodine Therapy for Metastatic Thyroid Cancer. *Endocrine Practice* **20**, 213-220. [[CrossRef](#)]
865. Sarah C. Oltmann, Glen Levenson, Suzy Hsiu-I Lin, David F. Schneider, Herbert Chen, Rebecca S. Sippel. 2014. Markedly elevated thyroglobulin levels in the preoperative thyroidectomy patient correlates with metastatic burden. *Journal of Surgical Research* **187**, 1-5. [[CrossRef](#)]
866. Sofia Tsiroma, Varvara Vlassopoulou, Marinella Tzanela, Phoebe Rondogianni, George Ioannidis, Charalambos Vassilopoulos, Efthimia Botoula, Panagiotis Trivizas, Ioannis Datsis, Stylianos Tsagarakis. 2014. Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer. *Clinical Endocrinology* **80**:10.1111/cen.2014.80.issue-3, 459-463. [[CrossRef](#)]
867. Denise Carneiro-Pla, Sonesh Amin. 2014. Comparison Between Preconsultation Ultrasonography and Office Surgeon-Performed Ultrasound in Patients with Thyroid Cancer. *World Journal of Surgery* **38**, 622-627. [[CrossRef](#)]
868. Hasan A. Hobbs, Manisha Bahl, Rendon C. Nelson, James D. Eastwood, Ramon M. Esclamado, Jenny K. Hoang. 2014. Applying the Society of Radiologists in Ultrasound Recommendations for Fine-Needle Aspiration of Thyroid Nodules: Effect on Workup and Malignancy Detection. *American Journal of Roentgenology* **202**, 602-607. [[CrossRef](#)]
869. Juan J. Diez, Enrique Grande, Pedro Iglesias. 2014. Ablación posquirúrgica con radioyodo en pacientes con carcinoma diferenciado de tiroides de bajo riesgo. *Medicina Clínica* . [[CrossRef](#)]
870. Arun C. Nachiappan, Zeyad A. Metwalli, Brian S. Hailey, Rishi A. Patel, Mary L. Ostrowski, David M. Wynne. 2014. The Thyroid: Review of Imaging Features and Biopsy Techniques with Radiologic-Pathologic Correlation. *RadioGraphics* **34**, 276-293. [[CrossRef](#)]
871. Marina Vivero, Andrew A. Renshaw, Jeffrey F. Krane. 2014. Influence of descriptive terminology on management of atypical thyroid fine-needle aspirates. *Cancer Cytopathology* **122**:10.1002/cncy.v122.3, 175-181. [[CrossRef](#)]
872. Young Jun Chai, Su-jin Kim, Soo Chin Kim, Do Hoon Koo, Hye Sook Min, Kyu Eun Lee, Ji-hoon Kim, Yeo-Kyu Youn. 2014. BRAF mutation in follicular variant of papillary thyroid carcinoma is associated with unfavourable clinicopathological characteristics and malignant features on ultrasonography. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
873. Bruce E. Lehnert, Claire K. Sandstrom, Joel A. Gross, Manjiri Dighe, Ken F. Linnau. 2014. Variability in Management Recommendations for Incidental Thyroid Nodules Detected on CT of the Cervical Spine in the Emergency Department. *Journal of the American College of Radiology* . [[CrossRef](#)]
874. Vito Cantisani, Pietro Lodise, Hektor Grazhdani, Ester Mancuso, Elena Maggini, Giorgio Di Rocco, Ferdinando D'Ambrosio, Fabrizio Calliada, Adriano Redler, Paolo Ricci, Carlo Catalano. 2014. Ultrasound elastography in the evaluation of thyroid pathology. Current status. *European Journal of Radiology* **83**, 420-428. [[CrossRef](#)]
875. Bao-Xian Liu, Xiao-Yan Xie, Jin-Yu Liang, Yan-Ling Zheng, Guang-Liang Huang, Lu-Yao Zhou, Zhu Wang, Ming Xu, Ming-De Lu. 2014. Shear wave elastography versus real-time elastography on evaluation thyroid nodules: A preliminary study. *European Journal of Radiology* . [[CrossRef](#)]
876. Anna Guerra, Vincenza Stasi, Pio Zeppa, Antongiulio Faggiano, Vincenzo Marotta, Mario Vitale. 2014. BRAF V600E assessment by pyrosequencing in fine needle aspirates of thyroid nodules with concurrent Hashimoto's thyroiditis is a reliable assay. *Endocrine* **45**, 249-255. [[CrossRef](#)]
877. Amir H. Lebastchi, Glenda G. Callender. 2014. Thyroid cancer. *Current Problems in Cancer* **38**, 48-74. [[CrossRef](#)]
878. Juan Carlos Galofré, Garcilaso Riesco-Eizaguirre, Cristina Álvarez-Escolá. 2014. Clinical guidelines for management of thyroid nodule and cancer during pregnancy. *Endocrinología y Nutrición (English Edition)* **61**, 130-138. [[CrossRef](#)]
879. Anjali Gupta, Samantha Ly, Luciana A. Castroneves, Mary C. Frates, Carol B. Benson, Henry A. Feldman, Ari J. Wassner, Jessica R. Smith, Ellen Marqusee, Erik K. Alexander, Justine Barletta, Funmilayo Muyide, Peter M. Doubilet, Hope E. Peters, Susan Webb, Biren P. Modi, Harriet J. Paltiel, Yolanda Martins, Kelly Burmeister, Harry Kozakewich, Monica Hollowell, Edmund S. Cibas, Francis D. Moore, Robert C. Shamberger, P. Reed Larsen, Stephen A. Huang. 2014. How Are Childhood Thyroid Nodules Discovered: Opportunities for Improving Early Detection. *The Journal of Pediatrics* **164**, 658-660. [[CrossRef](#)]
880. Amy Cummings, Melanie Goldfarb. 2014. Thyroid Carcinoma Metastases to Axillary Lymph Nodes: Report of Two Rare Cases of Papillary and Medullary Thyroid Carcinoma and Literature Review. *Endocrine Practice* **20**, e34-e37. [[CrossRef](#)]

881. Hyun Su Choi, Sung Hoon Kim, Sonya Youngju Park, Hye Lim Park, Ye Young Seo, Woo Hee Choi. 2014. Clinical Significance of Diffuse Intrathoracic Uptake on Post-Therapy I-131 Scans in Thyroid Cancer Patients. *Nuclear Medicine and Molecular Imaging* **48**, 63-71. [[CrossRef](#)]
882. Hongwei Guo, Min Sun, Wei He, Huanhuan Chen, Wen Li, Jinmei Tang, Wei Tang, Jieli Lu, Yufang Bi, Guang Ning, Tao Yang, Yu Duan. 2014. The prevalence of thyroid nodules and its relationship with metabolic parameters in a Chinese community-based population aged over 40 years. *Endocrine* **45**, 230-235. [[CrossRef](#)]
883. Wenwen Yue, Shurong Wang, Shoujun Yu, Bin Wang. 2014. Ultrasound-guided percutaneous microwave ablation of solitary T1N0M0 papillary thyroid microcarcinoma: Initial experience. *International Journal of Hyperthermia* **30**, 150-157. [[CrossRef](#)]
884. Daniel J. Ledbetter. 2014. Thyroid Surgery in Children. *Seminars in Pediatric Surgery* . [[CrossRef](#)]
885. J. T. Broome, F. Cate, C. C. Solorzano. 2014. Utilization and Impact of Repeat Biopsy for Follicular Lesion/Atypia of Undetermined Significance. *World Journal of Surgery* **38**, 628-633. [[CrossRef](#)]
886. Olov Norlen, Anthony R Glover, Justin S Gundara, Julian CY Ip, Stan B Sidhu. 2014. Best practice for the management of pediatric thyroid cancer. *Expert Review of Endocrinology & Metabolism* **9**, 175-182. [[CrossRef](#)]
887. Jung-Soo Pyo, Guhyun Kang, Dong-Hoon Kim, Chanheun Park, Joo Heon Kim, Jin Hee Sohn. 2014. The Prognostic Relevance of Psammoma Bodies and Ultrasonographic Intratumoral Calcifications in Papillary Thyroid Carcinoma: Reply. *World Journal of Surgery* **38**, 749-749. [[CrossRef](#)]
888. B. H.-H. Lang, Y. J. Chai, B. J. Cowling, H. S. Min, K. E. Lee, Y.-K. Youn. 2014. Is BRAFV600E mutation a marker for central nodal metastasis in small papillary thyroid carcinoma?. *Endocrine Related Cancer* **21**, 285-295. [[CrossRef](#)]
889. Neslihan Çuhaci, Dilek Arpacı, Rifki Üçler, Aylin Kilic Yazgan, Gülten Kıyak, Samet Yalçın, Pamir Eren Ersoy, Gülnür Güler, Reyhan Ersoy, Bekir Çakır. 2014. Malignancy Rate of Thyroid Nodules Defined as Follicular Lesion of Undetermined Significance and Atypia of Undetermined Significance in Thyroid Cytopathology and Its Relation with Ultrasonographic Features. *Endocrine Pathology* . [[CrossRef](#)]
890. Michael Bouvet. 2014. Is there a need for yet another staging system for differentiated thyroid cancer?. *Endocrine* . [[CrossRef](#)]
891. Akkas Burcu Esen, Demirel Busra Bedriye, Vural Gulin Ucmak. 2014. Prognostic Factors Affecting Disease-Specific Survival in Patients with Recurrent and/or Metastatic Differentiated Thyroid Carcinoma Detected by Positron Emission Tomography/Computed Tomography. *Thyroid* **24:2**, 287-295. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
892. Boutzios Georgios, Vasileiadis Ioannis, Zapanti Evangelia, Charitoudis Georgios, Karakostas Efthimios, Ieromonachou Panagiotis, Karatzas Theodore. 2014. Higher Incidence of Tall Cell Variant of Papillary Thyroid Carcinoma in Graves' Disease. *Thyroid* **24:2**, 347-354. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
893. Eszlinger Markus, Krogdahl Annelise, Münz Sina, Rehfeld Christian, Precht Jensen Eva Magrethe, Ferraz Carolina, Bösenberg Eileen, Drieschner Norbert, Scholz Markus, Hegedüs Laszlo, Paschke Ralf. 2014. Impact of Molecular Screening for Point Mutations and Rearrangements in Routine Air-Dried Fine-Needle Aspiration Samples of Thyroid Nodules. *Thyroid* **24:2**, 305-313. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
894. Henriques de Figueiredo Bénédicte, Godbert Yann, Soubeyran Isabelle, Carrat Xavier, Lagarde Philippe, Cazeau Anne-Laure, Italiano Antoine, Sargos Paul, Kantor Guy, Loiseau Hugues, Bonichon Françoise. 2014. Brain Metastases from Thyroid Carcinoma: A Retrospective Study of 21 Patients. *Thyroid* **24:2**, 270-276. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
895. Radowsky Jason S., Howard Robin S., Burch Henry B., Stojadinovic Alexander. 2014. Impact of Degree of Extrathyroidal Extension of Disease on Papillary Thyroid Cancer Outcome. *Thyroid* **24:2**, 241-244. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
896. Chen Amy Y., Bernet Victor J., Carty Sally E., Davies Terry F., Ganly Ian, Inabnet William B. III, Shaha Ashok R.. 2014. American Thyroid Association Statement on Optimal Surgical Management of Goiter. *Thyroid* **24:2**, 181-189. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
897. D. Ahn, J. H. Sohn, J. H. Jeon, J. Y. Jeong. 2014. Clinical impact of microscopic extrathyroidal extension in patients with papillary thyroid microcarcinoma treated with hemithyroidectomy. *Journal of Endocrinological Investigation* **37**, 167-173. [[CrossRef](#)]
898. Woo Jung Choi, Jung Hwan Baek. 2014. Role of core needle biopsy for patients with indeterminate, fine-needle aspiration cytology. *Endocrine* **45**, 1-2. [[CrossRef](#)]
899. Michael Brauckhoff. 2014. Classification of aerodigestive tract invasion from thyroid cancer. *Langenbeck's Archives of Surgery* **399**, 209-216. [[CrossRef](#)]
900. Maurizio Iacobone, Svante Jansson, Marcin Barczyński, Peter Goretzki. 2014. Multifocal papillary thyroid carcinoma—a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbeck's Archives of Surgery* **399**, 141-154. [[CrossRef](#)]



901. T. J. Musholt. 2014. Classification of locoregional lymph nodes in medullary and papillary thyroid cancer. *Langenbeck's Archives of Surgery* **399**, 217-223. [[CrossRef](#)]
902. Yasemin Tutuncu, Dilek Berker, Serhat Isik, Gulhan Akbaba, Ufuk Ozuguz, Ferit Kerim Kucukler, Erdal Göcmen, Yavuz Yalcın, Yusuf Aydin, Serdar Guler. 2014. The frequency of malignancy and the relationship between malignancy and ultrasonographic features of thyroid nodules with indeterminate cytology. *Endocrine* **45**, 37-45. [[CrossRef](#)]
903. Brittany J. Holmes, Lori J. Sokoll, Qing Kay Li. 2014. Measurement of fine-needle aspiration thyroglobulin levels increases the detection of metastatic papillary thyroid carcinoma in cystic neck lesions. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
904. B. Cakir, R. Ersoy, F. N. Cuhaci, C. Aydin, B. Polat, M. Kılıc, A. Yazgan. 2014. Elastasonographic strain index in thyroid nodules with atypia of undetermined significance. *Journal of Endocrinological Investigation* **37**, 127-133. [[CrossRef](#)]
905. Joon Pyo Park, Jong-Lyel Roh, Jeong Hyun Lee, Jung Hwan Baek, Gyungyub Gong, Kyung-Ja Cho, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim. 2014. Risk factors for central neck lymph node metastasis of clinically noninvasive, node-negative papillary thyroid microcarcinoma. *The American Journal of Surgery* . [[CrossRef](#)]
906. Aleksander Konturek, Marcin Barczyński, Wojciech Nowak, Wojciech Wierzchowski. 2014. Risk of lymph node metastases in multifocal papillary thyroid cancer associated with Hashimoto's thyroiditis. *Langenbeck's Archives of Surgery* **399**, 229-236. [[CrossRef](#)]
907. Shozo Okamoto, Tohru Shiga, Yuko Uchiyama, Osamu Manabe, Kentaro Kobayashi, Keiichiro Yoshinaga, Nagara Tamaki. 2014. Lung uptake on I-131 therapy and short-term outcome in patients with lung metastasis from differentiated thyroid cancer. *Annals of Nuclear Medicine* **28**, 81-87. [[CrossRef](#)]
908. Marcin Barczyński, Aleksander Konturek, Małgorzata Stopa, Wojciech Nowak. 2014. Nodal recurrence in the lateral neck after total thyroidectomy with prophylactic central neck dissection for papillary thyroid cancer. *Langenbeck's Archives of Surgery* **399**, 237-244. [[CrossRef](#)]
909. Dong Wook Kim. 2014. Ultrasound-guided fine-needle aspiration of benign thyroid cysts or partially cystic thyroid nodules: a preliminary study for factors predicting successful collapse. *Endocrine* **45**, 67-72. [[CrossRef](#)]
910. Serkan Dogan, Aysegul Atmaca, Selcuk Dagdelen, Belkis Erbas, Tomris Erbas. 2014. Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients. *Endocrine* **45**, 114-121. [[CrossRef](#)]
911. Turker Acar, Suha Sureyya Ozbek, Seval Acar. 2014. Incidentally discovered thyroid nodules: frequency in an adult population during Doppler ultrasonographic evaluation of cervical vessels. *Endocrine* **45**, 73-78. [[CrossRef](#)]
912. Gianlorenzo Dionigi, Jean-Louis Kraimps, Kurt Werner Schmid, Michael Hermann, Sien-Yi Sheu-Grabellus, Pierre Wailly, Anthony Beaulieu, Maria Laura Tanda, Fausto Sessa. 2014. Minimally invasive follicular thyroid cancer (MIFTC)—a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbeck's Archives of Surgery* **399**, 165-184. [[CrossRef](#)]
913. Juan J. Sancho, Thomas W. Jay Lennard, Ivan Paunovic, Frédéric Triponez, Antonio Sitges-Serra. 2014. Prophylactic central neck dissection in papillary thyroid cancer: a consensus report of the European Society of Endocrine Surgeons (ESES). *Langenbeck's Archives of Surgery* **399**, 155-163. [[CrossRef](#)]
914. Qiu-Cheng Wang, Wen Cheng, Xin Wen, Jie-Bing Li, Hui Jing, Chun-Lei Nie. 2014. Shorter Distance Between the Nodule and Capsule has Greater Risk of Cervical Lymph Node Metastasis in Papillary Thyroid Carcinoma. *Asian Pacific Journal of Cancer Prevention* **15**, 855-860. [[CrossRef](#)]
915. Umut Mousa, Cuneyd Anil, Serife Isildak, Alptekin Gursoy, Angelo CarpiBiomolecular Markers for Improving Management of Follicular and Medullary Thyroid Cancer 751-780. [[CrossRef](#)]
916. Marisa Cañadas-Garre, Nuria Pérez, Jesús del Moral, José Orihuela, José Llamas-ElviraBiomarkers in Diagnosis of Papillary Thyroid Carcinoma 679-750. [[CrossRef](#)]
917. Priya H. Dedhia, Gustavo A. Rubio, Mark S. Cohen, Barbra S. Miller, Paul G. Gauger, David T. Hughes. 2014. Potential Effects of Molecular Testing of Indeterminate Thyroid Nodule Fine Needle Aspiration Biopsy on Thyroidectomy Volume. *World Journal of Surgery* . [[CrossRef](#)]
918. Torres Maria Roseneide dos Santos, Nóbrega Neto Sebastião Horácio, Rosas Rosalina Jenner, Martins Aline Lemos Barros, Ramos André Luis Correia, da Cruz Thomaz Rodrigues Porto. 2014. Thyroglobulin in the Washout Fluid of Lymph-Node Biopsy: What Is Its Role in the Follow-Up of Differentiated Thyroid Carcinoma?. *Thyroid* **24**:1, 7-18. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
919. Ross Douglas S., Tuttle R. Michael. 2014. Observing Micropapillary Thyroid Cancers. *Thyroid* **24**:1, 3-6. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

920. Iyer Pallavi, Mayer Jennifer L.R., Ewig Jeffrey M.. 2014. Response to Sorafenib in a Pediatric Patient with Papillary Thyroid Carcinoma with Diffuse Nodular Pulmonary Disease Requiring Mechanical Ventilation. *Thyroid* **24**:1, 169-174. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
921. Carlos Velandia-Carrillo, Edwin Wandurraga-Sánchez, Diego Gómez-Abreo. 2014. Hand-foot syndrome associated with use of sorafenib in a patient with papillary thyroid cancer: a case report. *BMC Endocrine Disorders* **14**, 26. [[CrossRef](#)]
922. Ga Ram Kim, Jung Hyun Yoon, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2014. Benign Aspirates on Follow-Up FNA May Be Enough in Patients with Initial Atypia of Undetermined Significance/Follicular Lesion of Undetermined Significance. *International Journal of Endocrinology* **2014**, 1-8. [[CrossRef](#)]
923. Marc P. Pusztaszeri, Peter M. Sadow, William C. Faquin. 2014. CD117: A novel ancillary marker for papillary thyroid carcinoma in fine-needle aspiration biopsies. *Cancer Cytopathology* **122**:8, 596. [[CrossRef](#)]
924. David F. Schneider, Rebecca S. Sippel. 2014. Measuring Quality in Thyroid Cancer Surgery. *Advances in Endocrinology* **2014**, 1-6. [[CrossRef](#)]
925. Jung Guk Kim. 2014. Molecular Pathogenesis and Targeted Therapies in Well-Differentiated Thyroid Carcinoma. *Endocrinology and Metabolism* **29**, 211. [[CrossRef](#)]
926. Giovanni Conzo, Pietro Giorgio Calò, Claudio Gambardella, Ernesto Tartaglia, Claudio Mauriello, Cristina Della Pietra, Fabio Medas, Rosa Santa Cruz, Francesco Podda, Luigi Santini, Giancarlo Troncone. 2014. Controversies in the surgical management of thyroid follicular neoplasms. Retrospective analysis of 721 patients. *International Journal of Surgery* **12**, S29-S34. [[CrossRef](#)]
927. L. Giovanella, G. Treglia, L. Ceriani, F. Verburg. 2014. Detectable thyroglobulin with negative imaging in differentiated thyroid cancer patients. *Nuklearmedizin* **53**, 1-10. [[CrossRef](#)]
928. Raja Sfar, Tarek Kamoun, Manel Nouira, Hamza Regaieg, Nouha Ammar, Hela Charfi, Achraf Bahloul, Maha Ben Fredj, Kaouther Chatti, Mohsen Guezguez, Habib Essabbah. 2014. Differentiated Thyroid Cancer with Thyroglobulin Elevation and Negative Iodine Scintigraphy (TENIS Syndrome). *International Journal of Otolaryngology and Head & Neck Surgery* **03**, 149-153. [[CrossRef](#)]
929. J.Q. Zhou, C. Zhou, W.W. Zhan, W. Zhou, Y.J. Dong. 2014. Maximal, minimal, and mean pulsed Doppler parameters: Which should be utilized in the diagnosis of thyroid nodules?. *Clinical Radiology* **69**:12, e477. [[CrossRef](#)]
930. Giampaolo Papi, Stefania Corrado, Guido Fadda, Antonino Maiorana, Livia Maccio, Salvatore Maria Corsello, Alfredo Pontecorvi. 2014. Parathyroid Gland Involvement by Thyroid Cancer: Results from a Large Series of Thyroidectomies Performed in Two Italian University Hospitals and Review of the Literature. *Journal of Thyroid Research* **2014**, 1-7. [[CrossRef](#)]
931. Ameer Gomberawalla, Dina M. Elaraj. 2014. How to use molecular testing results to guide surgery. *Current Opinion in Oncology* **26**, 14-21. [[CrossRef](#)]
932. Eon Ju Jeon, Eui Dal Jung. 2014. Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation. *Endocrinology and Metabolism* **29**, 33. [[CrossRef](#)]
933. S. Rinaldi, M. Plummer, C. Biessy, K. K. Tsilidis, J. N. Ostergaard, K. Overvad, A. Tjonneland, J. Halkjaer, M.-C. Boutron-Ruault, F. Clavel-Chapelon, L. Dossus, R. Kaaks, A. Lukanova, H. Boeing, A. Trichopoulou, P. Lagiou, D. Trichopoulos, D. Palli, C. Agnoli, R. Tumino, P. Vineis, S. Panico, H. B. Bueno-de-Mesquita, P. H. Peeters, E. Weiderpass, E. Lund, J. R. Quiros, A. Agudo, E. Molina, N. Larranaga, C. Navarro, E. Ardanaz, J. Manjer, M. Almquist, M. Sandstrom, J. Hennings, K.-T. Khaw, J. Schmidt, R. C. Travis, G. Byrnes, A. Scalbert, I. Romieu, M. Gunter, E. Riboli, S. Franceschi. 2014. Thyroid-Stimulating Hormone, Thyroglobulin, and Thyroid Hormones and Risk of Differentiated Thyroid Carcinoma: The EPIC Study. *JNCI Journal of the National Cancer Institute* **106**:6, dju097. [[CrossRef](#)]
934. Kyoungjune Pak, Gi Jeong Cheon, Keon Wook Kang, Seong-Jang Kim, In-Joo Kim, E. Edmund Kim, Dong Soo Lee, June-Key Chung. 2014. The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials. *Journal of Korean Medical Science* **29**, 811. [[CrossRef](#)]
935. Dongbin Ahn, Jin Ho Sohn, Heejin Kim, Ji Yun Jeong, Hoon Jung. 2014. Clinical Impact of Occult Multifocal Disease Identified after Hemithyroidectomy in Patients with Papillary Thyroid Microcarcinoma. *Korean Journal of Otorhinolaryngology-Head and Neck Surgery* **57**, 166. [[CrossRef](#)]
936. Brian Hung-Hin Lang, Diane T. Y. Chan, Kai Pun Wong, Kandy K. C. Wong, Koon Yat Wan. 2014. Predictive Factors and Pattern of Locoregional Recurrence After Prophylactic Central Neck Dissection in Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* **21**:13, 4181. [[CrossRef](#)]
937. Rene Gerhard, Scott L. Boerner. 2014. The value of second opinion in thyroid cytology: A review. *Cancer Cytopathology* **122**:8, 611. [[CrossRef](#)]
938. Pathologies endocriniennes 55-88. [[CrossRef](#)]

939. Filippo De Luca, Tommaso Aversa, Luca Alessi, Valeria Cama, Daria Costanzo, Cristina Genovese, Veronica Scuderi, Roberta Vadala, Giuseppe Zoccali. 2014. Thyroid nodules in childhood: indications for biopsy and surgery. *Italian Journal of Pediatrics* **40**, 48. [[CrossRef](#)]
940. Kang Dae Lee, Hyoung Shin Lee. 2014. Central Neck Dissection for Papillary Thyroid Carcinoma. *Journal of Korean Thyroid Association* **7**, 140. [[CrossRef](#)]
941. M. J. Jeon, W. G. Kim, W. R. Park, J. M. Han, T. Y. Kim, D. E. Song, K.-W. Chung, J.-S. Ryu, S. J. Hong, Y. K. Shong, W. B. Kim. 2014. Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma. *European Journal of Endocrinology* **170**, 23-30. [[CrossRef](#)]
942. Jeon Yeob Jang, Young-Soo Chang, Eun Hye Kim, Jeong Hwan Moon, Young-Ik Son. 2014. Early Neck Exercises to Reduce Post-Thyroidectomy Syndrome after Uncomplicated Thyroid Surgery: A Prospective Randomized Study. *Journal of Korean Thyroid Association* **7**, 70. [[CrossRef](#)]
943. Radan Dzodic, Marko Buta, Ivan Markovic, Dusica Gavrilovic, Milovan Matovic, Igor Djuricic, Zorka Milovanovic, Gordana Pupic, Slobodan Tasic, Nikola Besic. 2014. Surgical management of well-differentiated thyroid carcinoma in children and adolescents: 33 years of experience of a single institution in Serbia. *Endocrine Journal* **61**, 1079-1086. [[CrossRef](#)]
944. Won Bae Kim. 2014. Management of Recurrent Differentiated Thyroid Carcinoma. *Journal of Korean Thyroid Association* **7**, 40. [[CrossRef](#)]
945. H.-Y. Nam, J. C. Paeng, J.-K. Chung, K. W. Kang, G. J. Cheon, Y. Kim, D. J. Park, Y. J. Park, H. S. Min, D. S. Lee. 2014. Monitoring differentiated thyroid cancer patients with negative serum thyroglobulin. *Nuklearmedizin* **53**, 32-38. [[CrossRef](#)]
946. Gi Hyeon Seo, Jae Hoon Chung. 2014. Analysis of Therapeutic Modalities of Thyroid Cancer in Korea between 2008 and 2012. *Journal of Korean Thyroid Association* **7**, 167. [[CrossRef](#)]
947. Young Don Lee. 2014. Surgical Strategy for Papillary Thyroid Microcarcinoma. *Journal of Korean Thyroid Association* **7**, 48. [[CrossRef](#)]
948. Albert Cano-Palomares, Ignasi Castells, Ismael Capel, Maria Rosa Bella, Santi Barcons, Angel Serrano, Xavier Guirao, Mercedes Rigla. 2014. Response to Initial Therapy of Differentiated Thyroid Cancer Predicts the Long-Term Outcome Better than Classical Risk Stratification Systems. *International Journal of Endocrinology* **2014**, 1-6. [[CrossRef](#)]
949. Seo Young Youn, Jeong Ho Lee, Yun-Woo Chang, Dong Hwan Lee. 2014. Characteristics of thyroid nodules in infant with congenital hypothyroidism. *Korean Journal of Pediatrics* **57**, 85. [[CrossRef](#)]
950. Navin Rudolph, Claudia Dominguez, Anthony Beaulieu, Pierre De Wailly, Jean-Louis Kraimps. 2014. The Morbidity of Reoperative Surgery for Recurrent Benign Nodular Goitre: Impact of Previous Unilateral Thyroid Lobectomy versus Subtotal Thyroidectomy. *Journal of Thyroid Research* **2014**, 1-6. [[CrossRef](#)]
951. Dong Wook Kim. 2014. Long-Term Ultrasound Follow-Up of Thyroid Colloid Cysts. *International Journal of Endocrinology* **2014**, 1-4. [[CrossRef](#)]
952. Vito Cantisani, Hektor Grazhdani, Paolo Ricci, Koenraad Morteale, Mattia Di Segni, Vito D'Andrea, Adriano Redler, Giorgio Di Rocco, Laura Giacomelli, Elena Maggini, Carlo Chiesa, Sukru Mehmet Erturk, Salvatore Sorrenti, Carlo Catalano, Ferdinando D'Ambrosio. 2014. Q-Elastosonography of Solid Thyroid Nodules: Assessment of Diagnostic Efficacy and Interobserver Variability in a Large Patient Cohort. *European Radiology* **24**, 143-150. [[CrossRef](#)]
953. Kwang Hwi Lee, Jung Hee Shin, Boo-Kyung Han, Eun Young Ko, Eun Sook Ko, Soo Yeon Hahn, Joon Young Choi. 2014. Incidental Thyroid Lesions Detected on 18 F-Fluorodeoxyglucose Positron Emission Tomography/CT in Patients with Non-Thyroidal Cancer: Clinical Implications and the Value of Ultrasound. *Journal of the Korean Society of Radiology* **71**, 111. [[CrossRef](#)]
954. Janice D. Ho, James F. Tsang, Kylie A. Scoggan, William D. Leslie. 2014. Urinary Iodine Clearance following Iodinated Contrast Administration: A Comparison of Euthyroid and Postthyroidectomy Subjects. *Journal of Thyroid Research* **2014**, 1-4. [[CrossRef](#)]
955. Roberto Vita, Poupak Fallahi, Alessandro Antonelli, Salvatore Benvenega. 2014. The administration of l-thyroxine as soft gel capsule or liquid solution. *Expert Opinion on Drug Delivery* **11**:7, 1103. [[CrossRef](#)]
956. Ricardo R. Lastra, Virginia A. LiVolsi, Zubair W. Baloch. 2014. Aggressive variants of follicular cell-derived thyroid carcinomas: A cytopathologist's perspective. *Cancer Cytopathology* **122**:7, 484. [[CrossRef](#)]
957. A. Bartolazzi Thyroid Fine Needle Aspiration Cytology# . [[CrossRef](#)]
958. Woo Jin Oh, Young Sub Lee, Uiju Cho, Ja Seong Bae, Sohee Lee, Min Hee Kim, Dong Jun Lim, Gyeong Sin Park, Youn Soo Lee, Chan Kwon Jung. 2014. Classic Papillary Thyroid Carcinoma with Tall Cell Features and Tall Cell Variant Have Similar Clinicopathologic Features. *Korean Journal of Pathology* **48**, 201. [[CrossRef](#)]
959. Linli Tian, Yufei Jiao, Ming Liu, Minghua Li, Hongchao Yao. 2014. Ectopic thyroid papillary carcinoma of nasopharynx associated with adenoid hypertrophy: an unusual presentation. *Head & Face Medicine* **10**, 40. [[CrossRef](#)]

960. Linwah Yip. 2014. Molecular diagnostic testing and the indeterminate thyroid nodule. *Current Opinion in Oncology* **26**, 8-13. [[CrossRef](#)]
961. Ji Hoon Lee, Dong Ki Lee, Sung Ill Jang, Hong Kyu Choi, Chan Ik Park, Ji Eun Yun, Soon Won Hong. 2014. A Case of Pancreatic Metastasis From a Papillary Thyroid Carcinoma Mimicking Pancreatic Cancer. *Korean Journal of Medicine* **87**, 187. [[CrossRef](#)]
962. Danielle L. Gomez, Dorothy I. Shulman. 2014. Hyperparathyroidism Two Years after Radioactive Iodine Therapy in an Adolescent Male. *Case Reports in Pediatrics* **2014**, 1-3. [[CrossRef](#)]
963. Meredith Giuliani, James Brierley. 2014. Indications for the use of external beam radiation in thyroid cancer. *Current Opinion in Oncology* **26**, 45-50. [[CrossRef](#)]
964. Chutintorn Srihrapadang, Pattana Sornmayura, Niramol Chanplakorn, Objoon Trachoo, Pattarana Sae-Chew, Rangsim Aroonroch. 2014. Fine-Needle Aspiration Cytology of Parathyroid Carcinoma Mimic Hürthle Cell Thyroid Neoplasm. *Case Reports in Endocrinology* **2014**, 1-7. [[CrossRef](#)]
965. Enke Baldini, Salvatore Sorrenti, Chiara Tuccilli, Natalie Prinzi, Carmela Coccaro, Antonio Catania, Angelo Filippini, Marco Bononi, Enrico De Antoni, Massimino D'Armiento, Salvatore Ulisse. 2014. Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. *International Journal of Surgery* **12**, S52-S56. [[CrossRef](#)]
966. Yasemin Şenyürek Giles, İnanç Samil Sarıcı, Fatih Tunca, İsmail Cem Sormaz, Artur Salmaslıoğlu, Işık Adalet, İlker Özgür, Serdar Tezelman, Tarık Terzioğlu. 2014. The rate of operative success achieved with radioguided occult lesion localization and intraoperative ultrasonography in patients with recurrent papillary thyroid cancer. *Surgery* **156**:5, 1116. [[CrossRef](#)]
967. Xiaoyun Liu, Lijun Zhu, Dai Cui, Zhixiao Wang, Huanhuan Chen, Yu Duan, Meiping Shen, Yunsong Wu, Rong Rong, Zhihong Zhang, Xiaodong Wang, Jiawei Chen, Erik K. Alexander, Tao Yang. 2014. Coexistence of Histologically Confirmed Hashimoto's Thyroiditis with Different Stages of Papillary Thyroid Carcinoma in a Consecutive Chinese Cohort. *International Journal of Endocrinology* **2014**, 1-7. [[CrossRef](#)]
968. Min Jung Jung, Su Kyoung Kwon. 2014. Expression of Glucagon-Like Peptide-1 Receptor in Papillary Thyroid Carcinoma and Its Clinicopathologic Significance. *Endocrinology and Metabolism* **29**, 536. [[CrossRef](#)]
969. Pedro Marques, Pedro Ratão, Lucília Salgado, Maria João Bugalho. 2014. Thyroid Carcinoma Detected by <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography Among Individuals Without Prior Evidence of Thyroid Disease: Relevance and Clinicopathological Features. *Endocrine Practice* **1**, 1-19. [[CrossRef](#)]
970. Hak Hoon Jun, Seok Mo Kim, Yong Sang Lee, Soon Won Hong, Hang-Seok Chang, Cheong Soo Park. 2014. Cervical bronchogenic cysts mimic metastatic lymph nodes during thyroid cancer surgery. *Annals of Surgical Treatment and Research* **86**, 227. [[CrossRef](#)]
971. Edwin Jadulco Cañete, Cherrie Mae Sison-Peña, Cecilia Alegado Jimeno. 2014. Clinicopathological, Biochemical, and Sonographic Features of Thyroid Nodule Predictive of Malignancy among Adult Filipino Patients in a Tertiary Hospital in the Philippines. *Endocrinology and Metabolism* **29**, 489. [[CrossRef](#)]
972. Linwah Yip. 2014. Use of Molecular Markers for Cytologically Indeterminate Thyroid Nodules to Optimize Surgical Management. *Current Surgery Reports* **2**. . [[CrossRef](#)]
973. Yulu Gu, Xiaoli Liu, Yaqin Yu, Jieping Shi, Lizhe Ai, Hui Sun, Joseph Sam Kanu, Chong Wang, Yawen Liu. 2014. Association of ATM Gene Polymorphism with PTC Metastasis in Female Patients. *International Journal of Endocrinology* **2014**, 1-7. [[CrossRef](#)]
974. Mariana Bonjorno Martins, Marjory Alana Marcello, Fernando de Assis Batista, Lucas Leite Cunha, Elaine Cristina Morari, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward. 2014. CD8+ TIL Recruitment May Revert the Association of MAGE A3 with Aggressive Features in Thyroid Tumors. *Journal of Immunology Research* **2014**, 1-8. [[CrossRef](#)]
975. Gülhan Akbaba, Muhyettin Omar, Murat Polat, Önder Özcan, Ahmet Korkut Belli, Murat Şahan, Neşat Çullu. 2014. Cutaneous Sinus Formation Is a Rare Complication of Thyroid Fine Needle Aspiration Biopsy. *Case Reports in Endocrinology* **2014**, 1-3. [[CrossRef](#)]
976. Jae Hoon Chung. 2014. A Refutation against Unfounded Reports on Thyroid Cancer. *Journal of Korean Thyroid Association* **7**, 1. [[CrossRef](#)]
977. Matthew D Brace, Jun Wang, Mark Petten, Martin J Bullock, Fawaz Makki, Jonathan Trites, S Taylor, Robert D Hart. 2014. Differential expression of transforming growth factor-beta in benign vs. papillary thyroid cancer nodules; a potential diagnostic tool?. *Journal of Otolaryngology - Head & Neck Surgery* **43**, 22. [[CrossRef](#)]
978. Yongsheng Jia, Yang Yu, Xiaolong Li, Songfeng Wei, Xiangqian Zheng, Xiaoyong Yang, Jing Zhao, Tingting Xia, Ming Gao. 2014. Diagnostic value of B-RAF V600E in difficult-to-diagnose thyroid nodules using fine-needle aspiration: Systematic review and meta-analysis. *Diagnostic Cytopathology* **42**:10.1002/dc.v42.1, 94-101. [[CrossRef](#)]

979. D. P. Momesso, F. Vaisman, L. S. C. Caminha, C. H. C. N. Pessoa, R. Corbo, M. Vaisman. 2014. Surgical approach and radioactive iodine therapy for small well-differentiated thyroid cancer. *Journal of Endocrinological Investigation* **37**, 57-64. [[CrossRef](#)]
980. Lauren E. Henke, Stephanie M. Perkins, John D. Pfeifer, Changqing Ma, Yumei Chen, Todd DeWees, Perry W. Grigsby. 2014. BRAF V600E mutational status in pediatric thyroid cancer. *Pediatric Blood & Cancer* n/a-n/a. [[CrossRef](#)]
981. Lie-Hao Jiang, Chao Chen, Zhuo Tan, Xiao-Xiao Lu, Si-Si Hu, Qing-Liang Wang, Xiu-Xiu Hou, Jun Cao, Ming-Hua Ge. 2014. Clinical Characteristics Related to Central Lymph Node Metastasis in cN0 Papillary Thyroid Carcinoma: A Retrospective Study of 916 Patients. *International Journal of Endocrinology* **2014**, 1-6. [[CrossRef](#)]
982. Junhua Yin, Changchun Wang, Qin Shao, Dihong Qu, Zhenya Song, Pengfei Shan, Tao Zhang, Jun Xu, Qin Liang, Songzhao Zhang, Jian Huang. 2014. Relationship between the Prevalence of Thyroid Nodules and Metabolic Syndrome in the Iodine-Adequate Area of Hangzhou, China: A Cross-Sectional and Cohort Study. *International Journal of Endocrinology* **2014**, 1-7. [[CrossRef](#)]
983. Rok Petric, Barbara Gazic, Nikola Besic. 2014. Prognostic factors for disease-specific survival in 108 patients with Hürthle cell thyroid carcinoma: a single-institution experience. *BMC Cancer* **14**, 777. [[CrossRef](#)]
984. S. Schenke, M. Zimny, T. Rink, U. Stahl, M. Fritzel, R. Klett. 2014. 99mTc-MIBI scintigraphy of hypofunctional thyroid nodules. *Nuklearmedizin* **53**, 105-110. [[CrossRef](#)]
985. Juan P Brito, Louise Davies, Claudia Zeballos-Palacios, John C Morris, Victor M Montori. 2014. Papillary lesions of indolent course: reducing the overdiagnosis of indolent papillary thyroid cancer and unnecessary treatment. *Future Oncology* **10**, 1-4. [[CrossRef](#)]
986. Eun-Kyung Kim. 2014. Natural Course of Cytologically Diagnosed Benign Thyroid Nodules. *Journal of Korean Thyroid Association* **7**, 136. [[CrossRef](#)]
987. Stella Bernardi, Chiara Dobrinja, Bruno Fabris, Gabriele Bazzocchi, Nicoletta Sabato, Veronica Ulcigrai, Massimo Giacca, Enrica Barro, Nicolò De Manzini, Fulvio Stacul. 2014. Radiofrequency Ablation Compared to Surgery for the Treatment of Benign Thyroid Nodules. *International Journal of Endocrinology* **2014**, 1-10. [[CrossRef](#)]
988. Hyung Seo Jung, Min Ji Jeon, Dong Eun Song, Suck Joon Hong, Won Gu Kim, Tae Yong Kim, Young Kee Shong, Won Bae Kim. 2014. Time Trends Analysis of Characteristics of Patients with Thyroid Cancer in a Single Medical Center. *Journal of Korean Thyroid Association* **7**, 159. [[CrossRef](#)]
989. In Sun Ryu, Chan Il Song, Seung-Ho Choi, Jong-Lyel Roh, Soon Yuhl Nam, Sang Yoon Kim. 2014. Lymph Node Ratio of the Central Compartment is a Significant Predictor for Locoregional Recurrence After Prophylactic Central Neck Dissection in Patients with Thyroid Papillary Carcinoma. *Annals of Surgical Oncology* **21**, 277-283. [[CrossRef](#)]
990. F. Tartaglia, S. Blasi, A. Giuliani, M. Sgueglia, L. Tromba, S. Carbotta, G. Carbotta, G. Tortorelli. 2014. Central neck dissection in papillary thyroid carcinoma: Results of a retrospective study. *International Journal of Surgery* **12**, S57-S62. [[CrossRef](#)]
991. A.M.<sup>a</sup> Lucas Martín, M. Puig Domingo, J.L. Reverter Calatayud Enfermedades de la glándula tiroides 183-214. [[CrossRef](#)]
992. Roberto F Casal, Mimi N Phan, Keerthana Keshava, Jose M Garcia, Horiana Grosu, D Lazarus, Juan Iribarren, Daniel G Rosen. 2014. The use of endobronchial ultrasound-guided transbronchial needle aspiration in the diagnosis of thyroid lesions. *BMC Endocrine Disorders* **14**, 88. [[CrossRef](#)]
993. M. Ruhlmann, V. Stebner, R. Görges, J. Farahati, D. Simon, A. Bockisch, S. Rosenbaum-Krumme, J. Nagarajah. 2014. Diagnosis of hyperfunctional thyroid nodules. *Nuklearmedizin* **53**. . [[CrossRef](#)]
994. Endocrine System 66-97. [[CrossRef](#)]
995. Yue Xing, Ding-yuan Luo, Miao-yun Long, Shi-lin Zeng, Hong-Hao Li. 2014. High ALDH1A1 expression correlates with poor survival in papillary thyroid carcinoma. *World Journal of Surgical Oncology* **12**, 29. [[CrossRef](#)]
996. Eon Ju Jeon, Eui Dal Jung. 2014. Response: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (*Endocrinol Metab* 2014;29:33-9, Eon Ju Jeon et al.). *Endocrinology and Metabolism* **29**, 208. [[CrossRef](#)]
997. Hasan A. Hobbs, Manisha Bahl, Rendon C. Nelson, Peter G. Kranz, Ramon M. Esclamado, Nathan M. Wnuk, Jenny K. Hoang. 2014. JOURNAL CLUB: Incidental Thyroid Nodules Detected at Imaging: Can Diagnostic Workup Be Reduced by Use of the Society of Radiologists in Ultrasound Recommendations and the Three-Tiered System?. *American Journal of Roentgenology* **202**, 18-24. [[CrossRef](#)]
998. Dong Yeob Shin, Kwang Joon Kim, Yongin Cho, Kyeong Hye Park, Sena Hwang, Woong Youn Chung, Eun Jig Lee. 2014. Body Mass Index Is Associated with Hypercholesterolemia following Thyroid Hormone Withdrawal in Thyroidectomized Patients. *International Journal of Endocrinology* **2014**, 1-8. [[CrossRef](#)]

999. Rok Petric, Hana Besic, Nikola Besic. 2014. Preoperative serum thyroglobulin concentration as a predictive factor of malignancy in small follicular and Hürthle cell neoplasms of the thyroid gland. *World Journal of Surgical Oncology* **12**, 282. [[CrossRef](#)]
1000. Syed Zubair Hussain, Maseeh uz Zaman, Sarwar Malik, Nanik Ram, Ali Asghar, Unaib Rabbani, Nida Aftab, Najmul Islam. 2014. Preablation Stimulated Thyroglobulin/TSH Ratio as a Predictor of Successful I131Remnant Ablation in Patients with Differentiated Thyroid Cancer following Total Thyroidectomy. *Journal of Thyroid Research* **2014**, 1-7. [[CrossRef](#)]
1001. Jae Hyun Park, Kang San Lee, Keum-Seok Bae, Seong Joon Kang. 2014. Regional Lymph Node Metastasis in Papillary Thyroid Cancer. *Journal of Korean Thyroid Association* **7**, 129. [[CrossRef](#)]
1002. Shin Hye Hwang, Ji Min Sung, Eun-Kyung Kim, Hee Jung Moon, Jin Young Kwak. 2014. Imaging-Cytology Correlation of Thyroid Nodules with Initially Benign Cytology. *International Journal of Endocrinology* **2014**, 1-8. [[CrossRef](#)]
1003. Jin Hwa Kim, Na Kyung Kim, Young Lyun Oh, Hye Jeong Kim, Sang Yong Kim, Jae Hoon Chung, Sun Wook Kim. 2014. The Validity of Ultrasonography-Guided Fine Needle Aspiration Biopsy in Thyroid Nodules 4 cm or Larger Depends on Ultrasonography Characteristics. *Endocrinology and Metabolism* **29**, 545. [[CrossRef](#)]
1004. Chan-Hee Jung. 2014. Letter: Diagnostic Whole-Body Scan May Not Be Necessary for Intermediate-Risk Patients with Differentiated Thyroid Cancer after Low-Dose (30 mCi) Radioactive Iodide Ablation (Endocrinol Metab 2014;29:33-9, Eon Ju Jeon et al.). *Endocrinology and Metabolism* **29**:2, 206. [[CrossRef](#)]
1005. María Inés Vera, Tomás Meroño, María Agustina Urrutia, Carina Parisi, Yanina Morosan, Melanie Rosmarin, Marta Schnitman, Fernando Brites, Silvio Grisendi, María Sol Serrano, Wilfredo Luciani, Leonardo Serrano, Carlos Zuk, Guillermo De Barrio, Claudia Cejas, María Cristina Faingold, Gabriela Brenta. 2014. Differential Profile of Ultrasound Findings Associated with Malignancy in Mixed and Solid Thyroid Nodules in an Elderly Female Population. *Journal of Thyroid Research* **2014**, 1-7. [[CrossRef](#)]
1006. Doina Piciu, Andra Piciu. 2014. F-18 FDG-PET-CT in the Diagnostic of a Late Medullary Thyroid Carcinoma Recurrence in a Patient with Follicular-Papillary Thyroid Cancer. *Case Reports in Endocrinology* **2014**, 1-4. [[CrossRef](#)]
1007. Su Yeon Ko, Hye Sun Lee, Eun-Kyung Kim, Jin Young Kwak. 2014. Application of the Thyroid Imaging Reporting and Data System in thyroid ultrasonography interpretation by less experienced physicians. *Ultrasonography* **33**, 49-57. [[CrossRef](#)]
1008. Hye Ju Yeo, A Ra Jo, Hye Won Lee, Dong Won Yi, Yang Ho Kang, Seok Man Son. 2014. Effect of Short-Term Hypothyroid State on Lipid Profile and Cardiovascular Risk Markers in Subjects Preparing Radioactive Iodine Therapy. *Journal of Korean Thyroid Association* **7**, 172. [[CrossRef](#)]
1009. Tae Yong Kim, Won Gu Kim, Won Bae Kim, Young Kee Shong. 2014. Current Status and Future Perspectives in Differentiated Thyroid Cancer. *Endocrinology and Metabolism* **29**, 217. [[CrossRef](#)]
1010. Hamad Elniel H. Eltyib, Ibrahim A. Awad, Naglaa M. Elsayed, Saddig D. Jastaniah. 2014. Real Time Ultrasound Elastography for the Differentiation of Benign and Malignant Thyroid Nodules. *Open Journal of Medical Imaging* **04**, 38-47. [[CrossRef](#)]
1011. Kyung-Jin Yun, Woohyeon Kim, Eun Hee Kim, Min-Hee Kim, Dong-Jun Lim, Moo-Il Kang, Bong-Yun Cha. 2014. Accelerated Disease Progression after Discontinuation of Sorafenib in a Patient with Metastatic Papillary Thyroid Cancer. *Endocrinology and Metabolism* **29**, 388. [[CrossRef](#)]
1012. Ovie Edefe, Jonathan Wadsley, Barney J Harrison, Sabapathy P Balasubramanian. 2014. Treatment related morbidity in differentiated thyroid cancer—a survey of clinicians. *Thyroid Research* **7**, 3. [[CrossRef](#)]
1013. Roberta Lupoli, Marianna Cacciapuoti, Anna Tortora, Livia Barba, Nunzia Verde, Fiammetta Romano, Maria Vastarella, Francesco Fonderico, Stefania Masone, Marco Milone, Giovanni Lupoli, Gelsy Arianna Lupoli. 2014. Clinical outcome in differentiated thyroid carcinoma and microcarcinoma. *International Journal of Surgery* **12**, S148-S151. [[CrossRef](#)]
1014. Brittany N. Bohinc, Jennifer M. Perkins. 2014. Appropriate dosing of adjuvant radioactive iodine for differentiated thyroid cancer. *Current Opinion in Oncology* **26**, 31-35. [[CrossRef](#)]
1015. Pierpaolo Trimboli, Naim Nasrollah, Leo Guidobaldi, Silvia Taccogna, Davide Ciciarella Modica, Stefano Amendola, Francesco Romanelli, Andrea Lenzi, Giuseppe Nigri, Marco Centanni, Luca Giovanella, Stefano Valabrega, Anna Crescenzi. 2014. The use of core needle biopsy as first-line in diagnosis of thyroid nodules reduces false negative and inconclusive data reported by fine-needle aspiration. *World Journal of Surgical Oncology* **12**, 61. [[CrossRef](#)]
1016. Sung Hak Lee, Chan Kwon Jung, Ja Seong Bae, So Lyung Jung, Yeong Jin Choi, Chang Suk Kang. 2014. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma. *Diagnostic Cytopathology* **42**:10.1002/dc.v42.1, 11-17. [[CrossRef](#)]
1017. Sigurdis Haraldsdottir, Manisha H. Shah. 2014. An update on clinical trials of targeted therapies in thyroid cancer. *Current Opinion in Oncology* **26**, 36-44. [[CrossRef](#)]

1018. Seok-Mo Kim, Ki Won Chun, Ho Jin Chang, Bup-Woo Kim, Yong Sang Lee, Hang-Seok Chang, Cheong Soo Park. 2014. Solitary lateral neck node metastasis in papillary thyroid carcinoma. *World Journal of Surgical Oncology* **12**, 109. [[CrossRef](#)]
1019. Jae Young Seo, Eun-Kyung Kim, Jung Hwan Baek, Jung Hee Shin, Kyung Hwa Han, Jin Young Kwak. 2014. Can Ultrasound Be as a Surrogate Marker for Diagnosing a Papillary Thyroid Cancer? Comparison with BRAF Mutation Analysis. *Yonsei Medical Journal* **55**, 871. [[CrossRef](#)]
1020. Jeonghun Lee, Yeongpeck Song, Euy Young Soh. 2014. Central Lymph Node Metastasis Is an Important Prognostic Factor in Patients with Papillary Thyroid Microcarcinoma. *Journal of Korean Medical Science* **29**, 48. [[CrossRef](#)]
1021. Hailing Wang, Lihui Zhao, Xiaojie Xin, Xi Wei, Sheng Zhang, Yigong Li, Ming Gao. 2014. Diagnostic value of elastosonography for thyroid microcarcinoma. *Ultrasonics* **54**:7, 1945. [[CrossRef](#)]
1022. Ka Hee Yi, Kyung Won Kim, Chang Hoon Yim, Eui Dal Jung, Jin-Hoon Chung, Hyun-Kyung Chung, Soon Cheol Hong, Jae Hoon Chung. 2014. Guidelines for the Diagnosis and Management of Thyroid Disease during Pregnancy and Postpartum. *Journal of Korean Thyroid Association* **7**, 7. [[CrossRef](#)]
1023. Eyal Robenshtok, Azeez Farooki, Ravinder K. Grewal, R. Michael Tuttle. 2013. Natural history of small radioiodine-avid bone metastases that have no structural correlate on imaging studies. *Endocrine* . [[CrossRef](#)]
1024. Hyun Joo Shin, Eun-Kyung Kim, Hee Jung Moon, Jung Hyun Yoon, Kyung Hwa Han, Jin Young Kwak. 2013. Can increased tumoral vascularity be a quantitative predicting factor of lymph node metastasis in papillary thyroid microcarcinoma?. *Endocrine* . [[CrossRef](#)]
1025. Z A Antonello, C Nucera. 2013. Orthotopic mouse models for the preclinical and translational study of targeted therapies against metastatic human thyroid carcinoma with BRAFV600E or wild-type BRAF. *Oncogene* . [[CrossRef](#)]
1026. Stefania Corrado, Salvatore Maria Corsello, Antonio Maiorana, Esther Diana Rossi, Alfredo Pontecorvi, Guido Fadda, Giampaolo Papi. 2013. Papillary Thyroid Carcinoma with Predominant Spindle Cell Component: Report of Two Rare Cases and Discussion on the Differential Diagnosis with Other Spindled Thyroid Neoplasm. *Endocrine Pathology* . [[CrossRef](#)]
1027. Antonio Sitges-Serra. 2013. Low-risk papillary thyroid cancer: times are changing. *Expert Review of Endocrinology & Metabolism* **1**-10. [[CrossRef](#)]
1028. James C. Lee, Jing Ting Zhao, Roderick J. Clifton-Bligh, Anthony Gill, Justin S. Gundara, Julian C. Ip, Anthony Glover, Mark S. Sywak, Leigh W. Delbridge, Bruce G. Robinson, Stanley B. Sidhu. 2013. MicroRNA-222 and MicroRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer. *Cancer* **119**:10.1002/cncr.v119.24, 4358-4365. [[CrossRef](#)]
1029. Dutenthefner Simone E., Marui Suemi, Santos Andre B.O., de Lima Erika Urbano, Inoue Milton, Neto Jose S. Brandão, Shiang Christina, Fukushima Julia T., Cernea Claudio R., Friguglietti Celso U.M.. 2013. BRAF: A Tool in the Decision to Perform Elective Neck Dissection?. *Thyroid* **23**:12, 1541-1546. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1030. Kim Hyun Gi, Moon Hee-Jung, Kwak Jin Young, Kim Eun-Kyung. 2013. Diagnostic Accuracy of the Ultrasonographic Features for Subcentimeter Thyroid Nodules Suggested by the Revised American Thyroid Association Guidelines. *Thyroid* **23**:12, 1583-1589. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1031. Valcavi Roberto, Piana Simonetta, Bortolan Giorgio Steconi, Lai Roberta, Barbieri Verter, Negro Roberto. 2013. Ultrasound-Guided Percutaneous Laser Ablation of Papillary Thyroid Microcarcinoma: A Feasibility Study on Three Cases with Pathological and Immunohistochemical Evaluation. *Thyroid* **23**:12, 1578-1582. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1032. Manish Dhyani, William Faquin, Carrie C. Lubitz, Gilbert H. Daniels, Anthony E. Samir. 2013. How to Interpret Thyroid Fine-Needle Aspiration Biopsy Reports: A Guide for the Busy Radiologist in the Era of the Bethesda Classification System. *American Journal of Roentgenology* **201**, 1335-1339. [[CrossRef](#)]
1033. Sun Hye Jeong, Hyun Sook Hong, Eun Hye Lee, Jang Gyu Cha, Ji Sang Park, Jung Ja Kwak. 2013. Outcome of Thyroid Nodules Characterized as Atypia of Undetermined Significance or Follicular Lesion of Undetermined Significance and Correlation With Ultrasound Features and BRAF V600E Mutation Analysis. *American Journal of Roentgenology* **201**, W854-W860. [[CrossRef](#)]
1034. J. Santini, J.-P. Alfonsi, F. Bonichon, A. Bozec, A. Giovanni, B. Goichot, M.-F. Heymann, O. Laccourreye, G. Latil, J.-F. Papon, J.-L. Sadoul, V. Strunski, F. Tissier-Rible. 2013. Patient information ahead of thyroid surgery. Guidelines of the French Society of Oto-Rhino-Laryngology and Head and Neck Surgery (SFORL). *European Annals of Otorhinolaryngology, Head and Neck Diseases* **130**, 363-368. [[CrossRef](#)]
1035. Amr Amin, Ahmed Badwey, Sherif El-Fatah. 2013. Differentiated Thyroid Carcinoma. *Clinical Nuclear Medicine* **1**. [[CrossRef](#)]
1036. J. Santini, J.-P. Alfonsi, F. Bonichon, A. Bozec, A. Giovanni, B. Goichot, M.-F. Heymann, O. Laccourreye, G. Latil, J.-F. Papon, J.-L. Sadoul, V. Strunski, F. Tissier-Rible. 2013. L'information du patient avant chirurgie de la glande thyroïde. Recommandation

- de la Société française d'oto-rhino-laryngologie et de chirurgie de la face et du cou. *Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale* **130**, 361-368. [[CrossRef](#)]
1037. Salem I. Noureldine, Nicole R. Jackson, Ralph P. Tufano, Emad Kandil. 2013. A comparative North American experience of robotic thyroidectomy in a thyroid cancer population. *Langenbeck's Archives of Surgery* **398**, 1069-1074. [[CrossRef](#)]
1038. Sapna Nagar, Briseis Aschebrook-Kilfoy, Edwin L. Kaplan, Peter Angelos, Raymon H. Grogan. 2013. Hurthle cell carcinoma: An update on survival over the last 35 years. *Surgery* **154**, 1263-1271. [[CrossRef](#)]
1039. Samira M. Sadowski, Mei He, Krisana Gesuwan, Neelam Gulati, Francesco Celi, Maria J. Merino, Naris Nilubol, Electron Kebebew. 2013. Prospective screening in familial nonmedullary thyroid cancer. *Surgery* **154**, 1194-1198. [[CrossRef](#)]
1040. Linwah Yip. 2013. Thyroid nodule evaluation: How much is too much?. *Surgery* **154**, 1417-1419. [[CrossRef](#)]
1041. Seong Hyeon Lee, Jeong Su Baek, Joo Young Lee, Jung Ah Lim, Soo Youn Cho, Tae Hyun Lee, Yun Hyi Ku, Hong Il Kim, Min Joo Kim. 2013. Predictive Factors of Malignancy in Thyroid Nodules with a Cytological Diagnosis of Follicular Neoplasm. *Endocrine Pathology* **24**, 177-183. [[CrossRef](#)]
1042. Stephanie Young, Avital Harari, Stephanie Smooke-Praw, Philip H.G. Ituarte, Michael W. Yeh. 2013. Effect of reoperation on outcomes in papillary thyroid cancer. *Surgery* **154**, 1354-1362. [[CrossRef](#)]
1043. Yoon Yang Jung, Chung Hun Lee, So Yeon Park, Hyo Jin Park, Hye Sook Min, Jae Kyung Won, Byung Seup Kim, Han Suk Ryu. 2013. Characteristic tumor growth patterns as novel histomorphologic predictors for lymph node metastasis in papillary thyroid carcinoma. *Human Pathology* **44**, 2620-2627. [[CrossRef](#)]
1044. Hye Jeong Kim, Ji In Lee, Na Kyung Kim, Yong-Ki Min, Sun Wook Kim, Jae Hoon Chung. 2013. Prognostic Implications of Radioiodine Avidity and Serum Thyroglobulin in Differentiated Thyroid Carcinoma with Distant Metastasis. *World Journal of Surgery* **37**, 2845-2852. [[CrossRef](#)]
1045. N. Batawil, T. Alkordy. 2013. Ultrasonographic features associated with malignancy in cytologically indeterminate thyroid nodules. *European Journal of Surgical Oncology (EJSO)* . [[CrossRef](#)]
1046. Sebastian M. Jara, Kathryn A. Carson, Sara I. Pai, Nishant Agrawal, Jeremy D. Richmon, Jason D. Prescott, Alan Dackiw, Martha A. Zeiger, Justin A. Bishop, Ralph P. Tufano. 2013. The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma. *Surgery* **154**, 1272-1282. [[CrossRef](#)]
1047. Eric J. Kuo, Sanziana A. Roman, Julie A. Sosa. 2013. Patients with follicular and Hurthle cell microcarcinomas have compromised survival: A population level study of 22,738 patients. *Surgery* **154**, 1246-1254. [[CrossRef](#)]
1048. Brian Hung-Hin Lang, George C. C. Lee, Cathy P. C. Ng, Kai Pun Wong, Koon Yat Wan, Chung-Yau Lo. 2013. Evaluating the Morbidity and Efficacy of Reoperative Surgery in the Central Compartment for Persistent/Recurrent Papillary Thyroid Carcinoma. *World Journal of Surgery* **37**, 2853-2859. [[CrossRef](#)]
1049. Melissa M. Boltz, Christopher S. Hollenbeak, Eric Schaefer, David Goldenberg, Brian D. Saunders. 2013. Attributable costs of differentiated thyroid cancer in the elderly Medicare population. *Surgery* **154**, 1363-1370. [[CrossRef](#)]
1050. Iain J. Nixon, Ian Ganly, Snehal G. Patel, Luc G. Morris, Frank L. Palmer, Dorothy Thomas, R. Michael Tuttle, Jatin P. Shah, Ashok R. Shaha. 2013. Observation of clinically negative central compartment lymph nodes in papillary thyroid carcinoma. *Surgery* **154**, 1166-1173. [[CrossRef](#)]
1051. Andrew J. Leiker, Tina W. Yen, Kevin Cheung, Douglas B. Evans, Tracy S. Wang. 2013. Cost analysis of thyroid lobectomy and intraoperative frozen section versus total thyroidectomy in patients with a cytologic diagnosis of "suspicious for papillary thyroid cancer". *Surgery* **154**, 1307-1314. [[CrossRef](#)]
1052. Ian D. Hay, Robert A. Lee, Caroline Davidge-Pitts, Carl C. Reading, J. William Charboneau. 2013. Long-term outcome of ultrasound-guided percutaneous ethanol ablation of selected "recurrent" neck nodal metastases in 25 patients with TNM stages III or IVA papillary thyroid carcinoma previously treated by surgery and 131I therapy. *Surgery* **154**, 1448-1455. [[CrossRef](#)]
1053. Julie Ann Sosa, John W. Hanna, Karen A. Robinson, Richard B. Lanman. 2013. Increases in thyroid nodule fine-needle aspirations, operations, and diagnoses of thyroid cancer in the United States. *Surgery* **154**, 1420-1427. [[CrossRef](#)]
1054. Ye-Won Jeon, Young-Ee Ahn, Won-Sang Chung, Hyun-Joo Choi, Young Jin Suh. 2013. Radioactive iodine treatment for node negative papillary thyroid cancer with capsular invasion only: Results of a large retrospective study. *Asia-Pacific Journal of Clinical Oncology* n/a-n/a. [[CrossRef](#)]
1055. Raymon H. Grogan, Sharone P. Kaplan, Hongyuan Cao, Roy E. Weiss, Leslie J. DeGroot, Cassie A. Simon, Omran M.A. Embia, Peter Angelos, Edwin L. Kaplan, Rebecca B. Schechter. 2013. A study of recurrence and death from papillary thyroid cancer with 27 years of median follow-up. *Surgery* **154**, 1436-1447. [[CrossRef](#)]



1056. Mark L. Urken, Jeffery I. Mechanick, Jonathan Sarlin, Sophie Scherl, Bruce M. Wenig. 2013. Pathologic Reporting of Lymph Node Metastases in Differentiated Thyroid Cancer: a Call to Action for the College of American Pathologists. *Endocrine Pathology* . [[CrossRef](#)]
1057. Li-Ping Song, Wen-Hong Zhang, Yang Xiang, Na Zhao. 2013. Quantitative Analysis of Thyroid Blood Flow and Static Imaging in the Differential Diagnosis of Thyroid Nodules. *Asian Pacific Journal of Cancer Prevention* **14**, 6331-6335. [[CrossRef](#)]
1058. Maseeh Uz Zaman, Nosheen Fatima, Ajit Kumar Padhy, Unaiza Zaman. 2013. Controversies about Radioactive Iodine-131 Remnant Ablation in Low Risk Thyroid Cancers: Are We Near A Consensus?. *Asian Pacific Journal of Cancer Prevention* **14**, 6209-6213. [[CrossRef](#)]
1059. Hua Shao, Xiaohui Yu, Cuifang Wang, Qiang Wang, Haixia Guan. 2013. Midkine expression is associated with clinicopathological features and BRAF mutation in papillary thyroid cancer. *Endocrine* . [[CrossRef](#)]
1060. Eda Demir Onal, Fatma Saglam, Muhammed Sacikara, Reyhan Ersoy, Gulnur Guler, Bekir Cakir. 2013. "The Diagnostic Accuracy of Thyroid Nodule Fine-Needle Aspiration Cytology Following Thyroid Surgery: a Case-Control Study". *Endocrine Pathology* . [[CrossRef](#)]
1061. Timothy Kottke, Nicolas Boisgerault, Rosa Maria Diaz, Oliver Donnelly, Diana Rommelfanger-Konkol, Jose Pulido, Jill Thompson, Debabrata Mukhopadhyay, Roger Kaspar, Matt Coffey, Hardev Pandha, Alan Melcher, Kevin Harrington, Peter Selby, Richard Vile. 2013. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. *Nature Medicine* **19**, 1625-1631. [[CrossRef](#)]
1062. Min-Hee Kim, Sun Hee Ko, Ja-Seong Bae, Sung-Hak Lee, Chan-Kwon Jung, Dong-Jun Lim, Ki-Hyun Baek, Sung-Hoon Kim, Jong-Min Lee, Moo-Il Kang, Bong-Yun Cha. 2013. Non-FDG-Avid Primary Papillary Thyroid Carcinoma May Not Differ from FDG-Avid Papillary Thyroid Carcinoma. *Thyroid* **23**:11, 1452-1460. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1063. Fabián Pitoia, Fernanda Bueno, Carolina Urciuoli, Erika Abelleira, Graciela Cross, R. Michael Tuttle. 2013. Outcomes of Patients with Differentiated Thyroid Cancer Risk-Stratified According to the American Thyroid Association and Latin American Thyroid Society Risk of Recurrence Classification Systems. *Thyroid* **23**:11, 1401-1407. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1064. Jandee Lee, Jae Hyun Park, Cho-Rok Lee, Woong Youn Chung, Cheong Soo Park. 2013. Long-Term Outcomes of Total Thyroidectomy Versus Thyroid Lobectomy for Papillary Thyroid Microcarcinoma: Comparative Analysis After Propensity Score Matching. *Thyroid* **23**:11, 1408-1415. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1065. Cristina Familiar Casado, Teresa Antón Bravo, Inmaculada Moraga Guerrero, Araceli Ramos Carrasco, Carmen García García, Santiago Villanueva Curto. 2013. The value of thyroglobulin in washout of fine needle aspirate from 16 cervical lesions in patients with thyroid cancer. *Endocrinología y Nutrición (English Edition)* **60**, 495-503. [[CrossRef](#)]
1066. Alessandro Mussa, Maria Carolina Salerno, Gianni Bona, Malgorzata Wasniewska, Maria Segni, Alessandra Cassio, Maria Cristina Vigone, Roberto Gastaldi, Lorenzo Iughetti, Arianna Santanera, Donatella Capalbo, Patrizia Matarazzo, Filippo De Luca, Giovanna Weber, Andrea Corrias. 2013. Serum Thyrotropin Concentration in Children with Isolated Thyroid Nodules. *The Journal of Pediatrics* **163**, 1465-1470. [[CrossRef](#)]
1067. Lindsay Bischoff, Joseph Curry, Intekhab Ahmed, Edmund Pribitkin, Jeffrey Miller. 2013. Is Above Age 45 Appropriate for Upstaging Well-Differentiated Papillary Thyroid Cancer?. *Endocrine Practice* **19**, 995-997. [[CrossRef](#)]
1068. P. Boute, J. Merlin, A. Biet, P. Cuvelier, V. Strunski, C. Page. 2013. Morbidity of central compartment dissection for differentiated thyroid carcinoma of the follicular epithelium. *European Annals of Otorhinolaryngology, Head and Neck Diseases* **130**, 245-249. [[CrossRef](#)]
1069. Yu-Mi Lee, Onvox Yi, Tae-Yon Sung, Ki-Wook Chung, Jong Ho Yoon, Suck Joon Hong. 2013. Surgical outcomes of robotic thyroid surgery using a double incision gasless transaxillary approach: Analysis of 400 cases treated by the same surgeon. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1070. Gideon Bachar, Inon Buda, Maya Cohen, Tuvia Hadar, Ohad Hilly, Nofrat Schwartz, Thomas Shpitzer, Karl Segal. 2013. Size discrepancy between sonographic and pathological evaluation of solitary papillary thyroid carcinoma. *European Journal of Radiology* **82**, 1899-1903. [[CrossRef](#)]
1071. David F. Schneider, Herbert Chen. 2013. New developments in the diagnosis and treatment of thyroid cancer. *CA: A Cancer Journal for Clinicians* **63**:10.3322/caac.v63.6, 373-394. [[CrossRef](#)]
1072. Eleftherios Koudounarakis, Alexander Karatzanis, Alkiviadis Chatzidakis, Maria Tzardi, George Velegrakis. 2013. Synchronous multifocal medullary and papillary thyroid microcarcinoma detected by elastography. *International Journal of Surgery Case Reports* . [[CrossRef](#)]

1073. P. Boute, J. Merlin, A. Biet, P. Cuvelier, V. Strunski, C. Page. 2013. Morbidité de l'évidement du compartiment central dans les cancers différenciés de souche folliculaire de la glande thyroïde. *Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale* **130**, 250-254. [[CrossRef](#)]
1074. Punam P. Parikh, Bassan J. Allan, John I. Lew. 2013. Sex variability of fine-needle aspiration reliability in the diagnosis of malignancy in thyroid nodules  $\geq 4$  cm. *The American Journal of Surgery* **206**, 778-782. [[CrossRef](#)]
1075. Steve Lee, Daniel E Abbott Well-differentiated thyroid cancer 86-93. [[CrossRef](#)]
1076. Eun Mee Oh, Yoo Seung Chung, Young Don Lee. 2013. Clinical Significance of Delphian Lymph Node Metastasis in Papillary Thyroid Carcinoma. *World Journal of Surgery* **37**, 2594-2599. [[CrossRef](#)]
1077. Hyoung Shin Lee, Hyo Sang Park, Sung Won Kim, Gwan Choi, Hun-Su Park, Jong-Chul Hong, Sung-Geun Lee, Seon Mi Baek, Kang Dae Lee. 2013. Clinical characteristics of papillary thyroid microcarcinoma less than or equal to 5 mm on ultrasonography. *European Archives of Oto-Rhino-Laryngology* **270**, 2969-2974. [[CrossRef](#)]
1078. Tuija Männistö. 2013. Thyroid disease during pregnancy: options for management. *Expert Review of Endocrinology & Metabolism* **8**, 537-547. [[CrossRef](#)]
1079. Jin Young Kwak, Jong Ju Jeong, Sang-Wook Kang, Seulkee Park, Jong Rak Choi, Seo-Jin Park, Eun Kyung Kim, Woong Youn Chung. 2013. Study of peripheral BRAF V600E mutation as a possible novel marker for papillary thyroid carcinomas. *Head & Neck* **35**:10.1002/hed.v35.11, 1630-1633. [[CrossRef](#)]
1080. Zhang Pinyi, Zhang Bin, Bu Jianlong, Liu Yao, Zhang Weifeng. 2013. Risk factors and clinical indication of metastasis to lymph nodes posterior to right recurrent laryngeal nerve in papillary thyroid carcinoma: A single-center study in China. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1081. Daniel Mankarios, Peter Baade, Pip Youl, Robin H. Mortimer, Adedayo A. Onitilo, Anthony Russell, Suhail A. R. Doi. 2013. Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer. *Endocrine* . [[CrossRef](#)]
1082. C. Nascimento, I. Borget, F. Troalen, A. Al Ghuzlan, D. Deandreis, D. Hartl, J. Lumbroso, C. N. Chougnet, E. Baudin, M. Schlumberger, S. Leboulloux. 2013. Ultrasensitive serum thyroglobulin measurement is useful for the follow-up of patients treated with total thyroidectomy without radioactive iodine ablation. *European Journal of Endocrinology* **169**, 689-693. [[CrossRef](#)]
1083. David F. Schneider, Kristin A. Ojomo, Herbert Chen, Rebecca S. Sippel. 2013. Remnant Uptake as a Postoperative Oncologic Quality Indicator. *Thyroid* **23**:10, 1269-1276. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1084. Eric J. Kuo, Paolo Goffredo, Julie A. Sosa, Sanziana A. Roman. 2013. Aggressive Variants of Papillary Thyroid Microcarcinoma Are Associated with Extrathyroidal Spread and Lymph-Node Metastases: A Population-Level Analysis. *Thyroid* **23**:10, 1305-1311. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1085. Frederik A. Verburg, Markus Luster, Cristina Cupini, Luca Chiovato, Leonidas Duntas, Rossella Elisei, Ulla Feldt-Rasmussen, Harald Rimmel, Ettore Seregni, Johannes W.A. Smit, Christian Theimer, Luca Giovanella. 2013. Implications of Thyroglobulin Antibody Positivity in Patients with Differentiated Thyroid Cancer: A Clinical Position Statement. *Thyroid* **23**:10, 1211-1225. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1086. Y.-L. Wang, S.-H. Feng, S.-C. Guo, W.-J. Wei, D.-S. Li, Y. Wang, X. Wang, Z.-Y. Wang, Y.-Y. Ma, L. Jin, Q.-H. Ji, J.-C. Wang. 2013. Confirmation of papillary thyroid cancer susceptibility loci identified by genome-wide association studies of chromosomes 14q13, 9q22, 2q35 and 8p12 in a Chinese population. *Journal of Medical Genetics* **50**, 689-695. [[CrossRef](#)]
1087. B. Riemann, O. Schober, C. Wittekind. 2013. Molekulare Bildgebung und pathologische Diagnostik. *Der Onkologe* **19**, 809-820. [[CrossRef](#)]
1088. Sapna Nagar, Samreen Ahmed, Claire Peeples, Nichole Urban, Judy Boura, Bryan Thibodeau, Jan Akervall, George Wilson, Graham Long, Peter Czako. 2013. Evaluation of genetic biomarkers for distinguishing benign from malignant thyroid neoplasms. *The American Journal of Surgery* . [[CrossRef](#)]
1089. Yu-Mi Lee, Jong Ho Yoon, Onvox Yi, Tae-Yon Sung, Ki-Wook Chung, Won Bae Kim, Suck Joon Hong. 2013. Familial history of non-medullary thyroid cancer is an independent prognostic factor for tumor recurrence in younger patients with conventional papillary thyroid carcinoma. *Journal of Surgical Oncology* n/a-n/a. [[CrossRef](#)]
1090. Theodore Karatzas, Ioannis Vasileiadis, Stylianos Kapetanakis, Efthimios Karakostas, George Chrousos, Gregory Kouraklis. 2013. Risk factors contributing to the difference in prognosis for papillary versus micropapillary thyroid carcinoma. *The American Journal of Surgery* **206**, 586-593. [[CrossRef](#)]
1091. John W. Kunstman, Reju Korah, James M. Healy, Manju Prasad, Tobias Carling. 2013. Quantitative assessment of RASSF1A methylation as a putative molecular marker in papillary thyroid carcinoma. *Surgery* . [[CrossRef](#)]

1092. Shi Cao, Yili Liu. 2013. Effects of concurrent tasks on diagnostic decision making: An experimental investigation. *IIE Transactions on Healthcare Systems Engineering* **3**, 254-262. [[CrossRef](#)]
1093. Kenichi Matsuzo, Kiminori Sugino, Katsuhiko Masudo, Mitsuji Nagahama, Wataru Kitagawa, Hiroshi Shibuya, Keiko Ohkuwa, Takashi Uruno, Akifumi Suzuki, Syunsuke Magoshi, Junko Akaishi, Chie Masaki, Michikazu Kawano, Nobuyasu Suganuma, Yasushi Rino, Munetaka Masuda, Kaori Kameyama, Hiroshi Takami, Koichi Ito. 2013. Thyroid Lobectomy for Papillary Thyroid Cancer: Long-term Follow-up Study of 1,088 Cases. *World Journal of Surgery* . [[CrossRef](#)]
1094. Shanmuga Sundaram Palaniswamy, Padma Subramanyam. 2013. Diagnostic utility of PETCT in thyroid malignancies: an update. *Annals of Nuclear Medicine* **27**, 681-693. [[CrossRef](#)]
1095. Giovanni Conzo, Daniela Pasquali, Giuseppe Bellastella, Katherine Esposito, Carlo Carella, Annamaria Bellis, Giovanni Docimo, Michele Klain, Sergio Iorio, Salvatore Napolitano, Antonietta Palazzo, Alessandra Pizza, Antonio Agostino Sinisi, Emilia Zampella, Antonio Bellastella, Luigi Santini. 2013. Total thyroidectomy, without prophylactic central lymph node dissection, in the treatment of differentiated thyroid cancer. Clinical retrospective study on 221 cases. *Endocrine* **44**, 419-425. [[CrossRef](#)]
1096. Nilufer Yildirim-Poyraz, Elif Ozdemir, Cagla Amutkan, Nuran Adiyaman, Sule Kilinc, Zuhail Kandemir, Fatma Saglam, Seyda Turkolmez, Bekir Cakir. 2013. False-positive iodine-131 whole body scan due to a benign dermal lesion; intradermal nevus (131I uptake in a benign nevus). *Annals of Nuclear Medicine* **27**, 786-790. [[CrossRef](#)]
1097. Maria Galiana Rodríguez Caballero, Lorena Suárez Gutiérrez, Luis Fernández Fernández, Nuria Valdés Gallego, Edelmiro Menéndez Torre. 2013. Cardiac tamponade as first sign of papillary thyroid carcinoma. *Endocrinología y Nutrición (English Edition)* **60**, e1-e2. [[CrossRef](#)]
1098. Cristina Familiar Casado, Teresa Antón Bravo, Inmaculada Moraga Guerrero, Araceli Ramos Carrasco, Carmen García García, Santiago Villanueva Curto. 2013. Utilidad de la tiroglobulina en lavado de aguja del aspirado de 16 lesiones cervicales en pacientes con cáncer de tiroides. *Endocrinología y Nutrición* . [[CrossRef](#)]
1099. P. Y. Fechner. 2013. Assessment of Thyroid Nodules in Children. *AAP Grand Rounds* **30**, 40-40. [[CrossRef](#)]
1100. Kyle Zanocco, Dina Elaraj, Cord Sturgeon. 2013. Routine prophylactic central neck dissection for low-risk papillary thyroid cancer: A cost-effectiveness analysis. *Surgery* . [[CrossRef](#)]
1101. Schelto Kruijff, Ahmed M. Aniss, Paul Chen, Stan B. Sidhu, Leigh W. Delbridge, Bruce Robinson, Roderick J. Clifton-Bligh, Paul Roach, Anthony J. Gill, Diane Learoyd, Mark S. Sywak. 2013. Decreasing the dose of radioiodine for remnant ablation does not increase structural recurrence rates in papillary thyroid carcinoma. *Surgery* . [[CrossRef](#)]
1102. Jung-Soo Pyo, Guhyun Kang, Dong-Hoon Kim, Chanheun Park, Joo Heon Kim, Jin Hee Sohn. 2013. The Prognostic Relevance of Psammoma Bodies and Ultrasonographic Intratumoral Calcifications in Papillary Thyroid Carcinoma. *World Journal of Surgery* **37**, 2330-2335. [[CrossRef](#)]
1103. Amparo Garcia-Burillo, Isabel Roca Bielsa, Oscar Gonzalez, Carles Zafon, Monica Sabate, Josep Castellvi, Xavier Serres, Carmela Iglesias, Ramon Vilallonga, Enric Caubet, Jose Manuel Fort, Jordi Mesa, Manuel Armengol, Joan Castell-Conesa. 2013. SPECT/CT sentinel lymph node identification in papillary thyroid cancer: lymphatic staging and surgical management improvement. *European Journal of Nuclear Medicine and Molecular Imaging* **40**, 1645-1655. [[CrossRef](#)]
1104. Kyle Zanocco, Michael Heller, Dina Elaraj, Cord Sturgeon. 2013. Cost Effectiveness of Intraoperative Pathology Examination during Diagnostic Hemithyroidectomy for Unilateral Follicular Thyroid Neoplasms. *Journal of the American College of Surgeons* **217**, 702-710. [[CrossRef](#)]
1105. Brian Hung-Hin Lang, Kevin Ka-Wan Chu, Raymond King-Yin Tsang, Kai Pun Wong, Birgitta Yee-Hang Wong. 2013. Evaluating the Incidence, Clinical Significance and Predictors for Vocal Cord Palsy and Incidental Laryngopharyngeal Conditions before Elective Thyroidectomy: Is There a Case for Routine Laryngoscopic Examination?. *World Journal of Surgery* . [[CrossRef](#)]
1106. A. P. Vidal, B. M. Andrade, F. Vaisman, J. Cazarin, L. F. R. Pinto, M. M. D. Breitenbach, R. Corbo, A. Caroli-Bottino, F. Soares, M. Vaisman, D. P. Carvalho. 2013. AMP-activated protein kinase signaling is upregulated in papillary thyroid cancer. *European Journal of Endocrinology* **169**, 521-528. [[CrossRef](#)]
1107. M Kathleen Figaro, Cheryl A Fassler, Shubhada Jagasia, Vipul T Lakhani Thyroid Disease: Monitoring and Management Guidelines 225-232. [[CrossRef](#)]
1108. Sophie Leboulleux, Isabelle Borget, Stéphanie Labro, Sophie Bidault, Philippe Vielh, Dana Hartl, Sarah Dauchy, Cécile N. Chougnet, Elizabeth Girard, Sandy Azoulay, Haitham Mirghani, Amandine Berdelou, Jean Lumbroso, Désirée Deandreis, Eric Baudin, Martin Schlumberger, Sophie Laurent. 2013. Frequency and Intensity of Pain Related to Thyroid Nodule Fine-Needle Aspiration Cytology. *Thyroid* **23:9**, 1113-1118. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1109. Jisun Lee, Seung Young Lee, Sang-Hoon Cha, Bum Sang Cho, Min Ho Kang, Ok-Jun Lee. 2013. Fine-Needle Aspiration of Thyroid Nodules with Macrocalcification. *Thyroid* **23:9**, 1106-1112. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

1110. Brian Hung-Hin Lang, Sze-How Ng, Lincoln L.H. Lau, Benjamin J. Cowling, Kai Pun Wong, Koon Yat Wan. 2013. A Systematic Review and Meta-Analysis of Prophylactic Central Neck Dissection on Short-Term Locoregional Recurrence in Papillary Thyroid Carcinoma After Total Thyroidectomy. *Thyroid* **23**:9, 1087-1098. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1111. Richard O Wein. 2013. Acquired disorders of the thyroid following treatment for head and neck cancer. *Expert Review of Endocrinology & Metabolism* **8**, 461-467. [[CrossRef](#)]
1112. Kathleen O'Connell, Tina W. Yen, Francisco Quiroz, Douglas B. Evans, Tracy S. Wang. 2013. The utility of routine preoperative cervical ultrasonography in patients undergoing thyroidectomy for differentiated thyroid cancer. *Surgery* . [[CrossRef](#)]
1113. Yun-Sung Lim, Sung-Won Choi, Yoon Se Lee, Jin-Choon Lee, Byung-Joo Lee, Soo-Geun Wang, Seok-Man Son, In-Ju Kim, Dong-Hoon Shin. 2013. Frozen biopsy of central compartment in papillary thyroid cancer: Quantitative nodal analysis. *Head & Neck* **35**:10.1002/hed.v35.9, 1319-1322. [[CrossRef](#)]
1114. Brian Hung-Hin Lang, Chung-Yau Lo, Kai Pun Wong, Koon Yat Wan. 2013. Should an Involved but Functioning Recurrent Laryngeal Nerve be Shaved or Resected in a Locally Advanced Papillary Thyroid Carcinoma?. *Annals of Surgical Oncology* **20**, 2951-2957. [[CrossRef](#)]
1115. B. Daniel Mahana. 2013. Incidentaloma tiroideo. *Revista Médica Clínica Las Condes* **24**, 754-759. [[CrossRef](#)]
1116. Junsun Ryu, Youn Mi Ryu, Yuh-S. Jung, Su-jin Kim, You Jin Lee, Eun-Kyung Lee, Seok-Ki Kim, Tae-Sung Kim, Tae Hyun Kim, Chang Yoon Lee, Seog Yun Park, Ki Wook Chung. 2013. Extent of thyroidectomy affects vocal and throat functions: A prospective observational study of lobectomy versus total thyroidectomy. *Surgery* **154**, 611-620. [[CrossRef](#)]
1117. Hidalgo V. Soledad. 2013. Trastornos tiroideos en el embarazo. *Revista Médica Clínica Las Condes* **24**, 761-767. [[CrossRef](#)]
1118. Rajarajan Panneerselvan, David F. Schneider, Rebecca S. Sippel, Herbert Chen. 2013. Radioactive iodine scanning is not beneficial but its use persists for euthyroid patients. *Journal of Surgical Research* **184**, 269-273. [[CrossRef](#)]
1119. Elaine Lam, Nguyen Vy, Chris Bajdik, Scott S Strugnell, Blair Walker, Sam M Wiseman. 2013. Synoptic pathology reporting for thyroid cancer: a review and institutional experience. *Expert Review of Anticancer Therapy* **13**, 1073-1079. [[CrossRef](#)]
1120. Roberto J. Lavarello, William R. Ridgway, Sandhya S. Sarwate, Michael L. Oelze. 2013. Characterization of Thyroid Cancer in Mouse Models Using High-Frequency Quantitative Ultrasound Techniques. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
1121. C. Blanchard, C. Brient, C. Volteau, F. Sebag, M. Roy, D. Drui, A. Hamy, M. Mathonnet, J.-F. Henry, E. Mirallié. 2013. Factors predictive of lymph node metastasis in the follicular variant of papillary thyroid carcinoma. *British Journal of Surgery* **100**:10.1002/bjs.2013.100.issue-10, 1312-1317. [[CrossRef](#)]
1122. Chiara Diazzi, Bruno Madeo, Erica Taliani, Lucia Zirilli, Stefania Romano, Antonio Granata, Maria De Santis, Manuela Simoni, Katia Cioni, Cesare Carani, Vincenzo Rochira. 2013. The Diagnostic Value of Calcitonin Measurement in Wash-Out Fluid from Fine-Needle Aspiration of Thyroid Nodules in the Diagnosis of Medullary Thyroid Cancer. *Endocrine Practice* **19**, 769-779. [[CrossRef](#)]
1123. René Gerhard, Sofia Teixeira, Adriana Gaspar da Rocha, Fernando Schmitt. 2013. Thyroid fine-needle aspiration cytology: Is there a place to virtual cytology?. *Diagnostic Cytopathology* **41**:10.1002/dc.v41.9, 793-798. [[CrossRef](#)]
1124. Jia Bin Bai, Rezvaneh Shakerian, James David Westcott, Meir Lichtenstein, Julie A. Miller. 2013. Factors influencing radioiodine uptake after thyroid cancer surgery. *ANZ Journal of Surgery* n/a-n/a. [[CrossRef](#)]
1125. Courtney J. Balentine, Robert P. Domingo, Rishi Patel, Rodolfo Laucirica, James W. Suliburk. 2013. Thyroid lobectomy for indeterminate FNA: not without consequences. *Journal of Surgical Research* **184**, 189-192. [[CrossRef](#)]
1126. Philip S. Bauer, Sara Murray, Nicholas Clark, David S. Pontes, Rebecca S. Sippel, Herbert Chen. 2013. Unilateral thyroidectomy for the treatment of benign multinodular goiter. *Journal of Surgical Research* **184**, 514-518. [[CrossRef](#)]
1127. Pu Cheng, En-Dong Chen, Hua-Min Zheng, Qiu-Xiang He, Quan Li. 2013. Ultrasound Score to Select Subcentimeter-sized Thyroid Nodules Requiring Ultrasound-guided Fine Needle Aspiration Biopsy in Eastern China. *Asian Pacific Journal of Cancer Prevention* **14**, 4689-4692. [[CrossRef](#)]
1128. Chien-Mu Lin, Pat Doyle, Yu-Tse Tsan, Chang-Hsing Lee, Jung-Der Wang, Pau-Chung Chen. 2013. 131I treatment for thyroid cancer and risk of developing primary hyperparathyroidism: a cohort study. *European Journal of Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
1129. Brian Hung-Hin Lang, Carlos K. H. Wong. 2013. A Cost-Minimization Analysis Comparing Total Thyroidectomy Alone and Total Thyroidectomy with Prophylactic Central Neck Dissection in Clinically Nodal-Negative Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]

1130. Heeyoung Kim, Seong-Jang Kim, In-Joo Kim, Keunyoung Kim, Sojung Kim, Bo Hyun Kim, Sang Soo Kim, Jeon Yoon Kyung. 2013. Limited Clinical Value of Periablative Changes of Serum Markers in the Prediction of Biochemical Remission in Patients with Papillary Thyroid Cancer. *Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
1131. Daniele Barbaro, Roberto Mario Incensati, Gabriele Materazzi, Giuseppe Boni, Mariano Grosso, Erica Panicucci, Paola Lapi, Cristina Pasquini, Paolo Miccoli. 2013. The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis. *Endocrine* . [[CrossRef](#)]
1132. Deborah van Dijk, John T.M. Plukker, Ha T.T. Phan, Anneke C. Muller Kobold, Anouk N.A. van der Horst-Schrivers, Liesbeth Jansen, Wim J. Sluiter, Adrienne H. Brouwers, Thera P. Links. 2013. 18-Fluorodeoxyglucose Positron Emission Tomography in the Early Diagnostic Workup of Differentiated Thyroid Cancer Patients with a Negative Post-Therapeutic Iodine Scan and Detectable Thyroglobulin. *Thyroid* **23**:8, 1003-1009. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1133. Richard T. Kloos, Jennifer A. Sipsos, Manuel Tzagournis, Akira Miyauchi, Mario Vaisman, Carlos Benbassat, Furio Pacini, Martin Schlumberger, Florence Mazzaferri, Sissy M. Jhiang, Hossein Gharib, Martin Surks, Gregory W. Randolph, R. Michael Tuttle. 2013. Ernest L. Mazzaferri, MD, MACP (1936–2013). *Thyroid* **23**:8, 917-923. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1134. Taly Meas, Laetitia Vercellino, Isabelle Faugeron, Marie-Elisabeth Toubert. 2013. The 2009 Revised American Thyroid Association Guidelines for Thyroid Cancer: Multifocality in T1 Tumors in Question, For or Against a More Minimalist Approach?. *Thyroid* **23**:8, 1042-1043. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1135. Laura J. Adhikari, Andrew P. Sciallis, Jordan Reynolds, Sarah Jenkins, Carin Smith, Marius N. Stan, Aziza Nassar. 2013. Clinicopathologic Predictors of Thyroid Bed Recurrence of Differentiated Thyroid Cancer Using Ultrasound-Guided Fine-Needle Aspiration Biopsies. *Thyroid* **23**:8, 982-988. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1136. Antonis Valachis, Andreas Nearchou. 2013. Reply to Drs. Qu and Gao. *Acta Oncologica* **52**, 1240-1240. [[CrossRef](#)]
1137. Megan R. Haymart, Mousumi Banerjee, Di Yang, Andrew K. Stewart, Gerard M. Doherty, Ronald J. Koenig, Jennifer J. Griggs. 2013. The Relationship Between Extent of Thyroid Cancer Surgery and Use of Radioactive Iodine. *Annals of Surgery* **258**, 354-358. [[CrossRef](#)]
1138. P.E. Goretzki. 2013. Chirurgie der Schilddrüsenmalignome. *Der Onkologe* **19**, 673-684. [[CrossRef](#)]
1139. Peter W. Hamer, Sebastian R. Aspinall, Peter L. Malycha. 2013. Clinician-performed ultrasound in assessing potentially malignant thyroid nodules. *ANZ Journal of Surgery* n/a-n/a. [[CrossRef](#)]
1140. Babak Fallahi, Davood Beiki, Seyed M. Abedi, Mohsen Saghari, Armaghan Fard-Esfahani, Fariba Akhzari, Bahareh Mokarami, Mohammad Eftekhari. 2013. Does vitamin E protect salivary glands from I-131 radiation damage in patients with thyroid cancer?. *Nuclear Medicine Communications* **34**, 777-786. [[CrossRef](#)]
1141. Donald Zimmerman. 2013. Thyroid carcinoma in children and adolescents. *Current Opinion in Pediatrics* **25**, 528-531. [[CrossRef](#)]
1142. P. E. Goretzki, K. Schwarz, B. Lammers. 2013. Chirurgie der Schilddrüsenmalignome. *best practice onkologie* **8**, 38-47. [[CrossRef](#)]
1143. Qing Kay Li, Summer L. Nugent, Joely Straseski, David Cooper, Stefan Riedel, Frederic B. Askin, Lori J. Sokoll. 2013. Thyroglobulin measurements in fine-needle aspiration cytology of lymph nodes for the detection of metastatic papillary thyroid carcinoma. *Cancer Cytopathology* **121**:10.1002/cncy.v121.8, 440-448. [[CrossRef](#)]
1144. Isabelle Clinckspoor, Lieve Verlinden, Chantal Mathieu, Roger Bouillon, Annemieke Verstuyf, Brigitte Decallonne. 2013. Vitamin D in thyroid tumorigenesis and development. *Progress in Histochemistry and Cytochemistry* **48**, 65-98. [[CrossRef](#)]
1145. Salem I. Noureldine, Ramsy Abdelghani, Ahmad Saeed, Natalia Cortes, Ali Abbas, Rizwan Aslam, Emad Kandil. 2013. Is robotic hemithyroidectomy comparable to its conventional counterpart?. *Surgery* **154**, 363-368. [[CrossRef](#)]
1146. Anne-Katrin Zimmermann, Ulrike Camenisch, Markus P. Rechsteiner, Beata Bode-Lesniewska, Matthias Rössle. 2013. Value of immunohistochemistry in the detection of BRAF V600E mutations in fine-needle aspiration biopsies of papillary thyroid carcinoma. *Cancer Cytopathology* n/a-n/a. [[CrossRef](#)]
1147. Luiz C. Conti de Freitas, Eimear Phelan, Linbo Liu, Joseph Gardecki, Eman Namati, Willian C. Warger, Guillermo J. Tearney, Gregory W. Randolph. 2013. Optical coherence tomography imaging during thyroid and parathyroid surgery: A novel system of tissue identification and differentiation to obviate tissue resection and frozen section. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1148. Luca Giovanella, Arnaldo Piccardo, Gaetano Paone, Luca Foppiani, Giorgio Treglia, Luca Ceriani. 2013. Thyroid lobe ablation with iodine-131 in patients with differentiated thyroid carcinoma. *Nuclear Medicine Communications* **34**, 767-770. [[CrossRef](#)]
1149. Yun Joo Park, Jeong-Ah Kim, Eun Ju Son, Ji Hyun Youk, Cheong Soo Park. 2013. Quantitative Shear Wave Elastography as a Prognostic Implication of Papillary Thyroid Carcinoma (PTC): Elasticity Index Can Predict Extrathyroidal Extension (ETE). *Annals of Surgical Oncology* **20**, 2765-2771. [[CrossRef](#)]

1150. Mario Vitale. 2013. Mutational testing and its utility in thyroid cancer management: the need for something more. *Biomarkers in Medicine* **7**, 571-574. [[CrossRef](#)]
1151. Y. Chong, J.H. Shin, E.S. Ko, B.-K. Han. 2013. Ultrasonographic elastography of thyroid nodules: Is adding strain ratio to colour mapping better?. *Clinical Radiology* . [[CrossRef](#)]
1152. Antonis Valachis, Andreas Nearchou. 2013. High versus low radioiodine activity in patients with differentiated thyroid cancer: A meta-analysis. *Acta Oncologica* **52**, 1055-1061. [[CrossRef](#)]
1153. Kyle Zanocco, Lisa Pitelka-Zengou, Sharvari Dalal, Dina Elaraj, Ritu Nayar, Cord Sturgeon. 2013. Routine On-Site Evaluation of Specimen Adequacy During Initial Ultrasound-Guided Fine Needle Aspiration of Thyroid Nodules: A Cost-Effectiveness Analysis. *Annals of Surgical Oncology* **20**, 2462-2467. [[CrossRef](#)]
1154. Amr Amin, Mahasen Amin, Ahmed Badwey. 2013. Stunning phenomenon after a radioactive iodine-131 diagnostic whole-body scan. *Nuclear Medicine Communications* **34**, 771-776. [[CrossRef](#)]
1155. Kyu Eun Lee, Eunyoung Kim, Do Hoon Koo, June Young Choi, Kyu Hyung Kim, Yeo-Kyu Youn. 2013. Robotic thyroidectomy by bilateral axillo-breast approach: review of 1026 cases and surgical completeness. *Surgical Endoscopy* **27**, 2955-2962. [[CrossRef](#)]
1156. Luciana Souza Cruz Caminha, Denise Prado Momesso, Fernanda Vaisman, Rossana Corbo, Mario Vaisman. 2013. Long-Term Follow-Up of Patients With Differentiated Thyroid Cancer Who had Negative 131I Whole-Body Scan at First Evaluation After Treatment. *Clinical Nuclear Medicine* **1**. [[CrossRef](#)]
1157. Viral Chikani, Duncan Lambie, Anthony Russell. 2013. Pituitary metastases from papillary carcinoma of thyroid: a case report and literature review. *Endocrinology, Diabetes and Metabolism Case Reports* . [[CrossRef](#)]
1158. Marek Niedziela. 2013. Thyroid nodules. *Best Practice & Research Clinical Endocrinology & Metabolism* . [[CrossRef](#)]
1159. Dana M. Hartl, Elisabeth Mabelle, Isabelle Borget, Sophie Leboulleux, Haïtham Mirghani, Martin Schlumberger. 2013. Influence of Prophylactic Neck Dissection on Rate of Retreatment for Papillary Thyroid Carcinoma. *World Journal of Surgery* **37**, 1951-1958. [[CrossRef](#)]
1160. Andreas Bockisch, Sandra Rosenbaum-Krumme. 2013. Cancer: The effect of radioiodine therapy after total thyroidectomy. *Nature Reviews Endocrinology* **9**, 511-512. [[CrossRef](#)]
1161. J. Y. Jung, J. H. Shin, B.- K. Han, E. Y. Ko. 2013. Optimized Cutoff Value and Indication for Washout Thyroglobulin Level According to Ultrasound Findings in Patients with Well-Differentiated Thyroid Cancer. *American Journal of Neuroradiology* . [[CrossRef](#)]
1162. Jae-Yong Park, Bon Seok Koo. 2013. Individualized optimal surgical extent of the lateral neck in papillary thyroid cancer with lateral cervical metastasis. *European Archives of Oto-Rhino-Laryngology* . [[CrossRef](#)]
1163. Antonella Carbone, Pasquale Bellitti, Rocco Bruno. 2013. Lymph node metastasis from undiagnosed occult papillary thyroid cancer. *Endocrine* . [[CrossRef](#)]
1164. K. Pak, S.-J. Kim, I. J. Kim, B. H. Kim, S. S. Kim, Y. K. Jeon. 2013. The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery. *Endocrine Related Cancer* **20**, R203-R213. [[CrossRef](#)]
1165. Leonard Wartofsky. 2013. Should patients with papillary microcarcinoma undergo radioiodine ablation?. *Endocrine* . [[CrossRef](#)]
1166. Gianlorenzo Dionigi, Francesco Frattini. 2013. Staged Thyroidectomy: Time to Consider Intraoperative Neuromonitoring as Standard of Care. *Thyroid* **23**:7, 906-908. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1167. Jonathan H. Vas Nunes, Jonathan R. Clark, Kan Gao, Elizabeth Chua, Peter Campbell, Navin Niles, Ash Gargya, Michael S. Elliott. 2013. Prognostic Implications of Lymph Node Yield and Lymph Node Ratio in Papillary Thyroid Carcinoma. *Thyroid* **23**:7, 811-816. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1168. Dongbin Ahn, Jin Ho Sohn, Ji Young Park. 2013. Surgical complications and recurrence after central neck dissection in cN0 papillary thyroid carcinoma. *Auris Nasus Larynx* . [[CrossRef](#)]
1169. Dong Wook Kim, Yoo Jin Lee, Jae Wook Eom, Soo Jin Jung, Tae Kwun Ha, Taewoo Kang. 2013. Ultrasound-Based Diagnosis for Solid Thyroid Nodules with the Largest Diameter <5 mm. *Ultrasound in Medicine & Biology* **39**, 1190-1196. [[CrossRef](#)]
1170. Dawn M Elfenbein, Randall P Scheri, Sanziana Roman, Julie A Sosa. 2013. Detection and management of cervical lymph nodes in papillary thyroid cancer. *Expert Review of Endocrinology & Metabolism* **8**, 365-378. [[CrossRef](#)]
1171. Joana Couto, Ana Paula Santos, Isabel Torres. 2013. Doença da tiróide secundária a radioterapia. *Revista Portuguesa de Endocrinologia, Diabetes e Metabolismo* **8**, 77-81. [[CrossRef](#)]
1172. Shoichiro Izawa, Tomohisa Okamura, Kazuhiko Matsuzawa, Tsuyoshi Ohkura, Hiroko Ohkura, Kiyosuke Ishiguro, Jaeduk Yoshimura Noh, Keiichi Kamijo, Akio Yoshida, Chiaki Shigemasa, Masahiko Kato, Kazuhiro Yamamoto, Shin-ichi Taniguchi. 2013. Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasia. *Clinical Endocrinology* **79**:10.1111/cen.2013.79.issue-1, 35-42. [[CrossRef](#)]

1173. Xavier M Keutgen, Filippo Filicori, Thomas J Fahey. 2013. Molecular diagnosis for indeterminate thyroid nodules on fine needle aspiration: advances and limitations. *Expert Review of Molecular Diagnostics* **13**, 613-623. [[CrossRef](#)]
1174. Romain Ducoudray, Christophe Trésallet, Gaelle Godiris-Petit, Frédérique Tissier, Laurence Leenhardt, Fabrice Menegaux. 2013. Prophylactic Lymph Node Dissection in Papillary Thyroid Carcinoma: Is There a Place for Lateral Neck Dissection?. *World Journal of Surgery* **37**, 1584-1591. [[CrossRef](#)]
1175. Bryan McIver. 2013. Postoperative surveillance of thyroid carcinoma. *Oral Oncology* **49**, 684-688. [[CrossRef](#)]
1176. Andrew H. Fischer, Cynthia C. Benedict, Mojgan Amrikachi. 2013. Five Top Stories in Cytopathology. *Archives of Pathology & Laboratory Medicine* **137**, 894-906. [[CrossRef](#)]
1177. I.J. Nixon, I. Ganly, J.P. Shah. 2013. Thyroid cancer: Surgery for the primary tumor. *Oral Oncology* **49**, 654-658. [[CrossRef](#)]
1178. Mark Lupo. 2013. Thyroid Nodule Evaluation: US-FNA and On-Site Cytology Assessment. *Endocrine Practice* **19**, 732-734. [[CrossRef](#)]
1179. Matthew J.R. Magarey, Jeremy L. Freeman. 2013. Recurrent well-differentiated thyroid carcinoma. *Oral Oncology* **49**, 689-694. [[CrossRef](#)]
1180. Bryan McIver. 2013. Evaluation of the thyroid nodule. *Oral Oncology* **49**, 645-653. [[CrossRef](#)]
1181. M S Elliott, K Gao, R Gupta, E L Chua, A Gargya, J Clark. 2013. Management of incidental and non-incidental papillary thyroid microcarcinoma. *The Journal of Laryngology & Otology* **127**, S17-S23. [[CrossRef](#)]
1182. Iain J. Nixon, Ashok R. Shaha. 2013. Management of regional nodes in Thyroid Cancer. *Oral Oncology* **49**, 671-675. [[CrossRef](#)]
1183. Iain J Nixon, Ian Ganly. 2013. Radioactive iodine use in patients with low- and intermediate-risk papillary thyroid cancer. *Future Oncology* **9**, 921-923. [[CrossRef](#)]
1184. Shikha Misra, Soumia Meiyappan, Lineke Heus, Jeremy Freeman, Lorne Rotstein, James D. Brierley, Richard W. Tsang, Gary Rodin, Shereen Ezzat, David P. Goldstein, Anna M. Sawka. 2013. Patients' experiences following local-regional recurrence of thyroid cancer: A qualitative study. *Journal of Surgical Oncology* **108**:10.1002/jso.v108.1, 47-51. [[CrossRef](#)]
1185. S E Lee, J U Lee, M H Lee, M J Ryu, S J Kim, Y K Kim, M J Choi, K S Kim, J M Kim, J W Kim, Y W Koh, D-S Lim, Y S Jo, M Shong. 2013. RAF kinase inhibitor-independent constitutive activation of Yes-associated protein 1 promotes tumor progression in thyroid cancer. *Oncogenesis* **2**, e55. [[CrossRef](#)]
1186. Rumana Makhdoomi, Farhat Mustafa, Rais Malik, Salma Bhat, Khurshid Alam, Humaira Bashir, Nuzhat Samoon, Mohsin Rasool, Khalil Mohammed Baba. 2013. Coexistent Papillary Carcinoma of Thyroid and Hashimoto's Thyroiditis – Diagnosis on Fine Needle Aspiration Cytology. *International Journal of Endocrinology and Metabolism* **11**. . [[CrossRef](#)]
1187. Cintia González, Anna Aulinas, Cristina Colom, Diana Tundidor, Lilian Mendoza, Rosa Corcoy, Eugenia Mato, Valeria Alcántara, Eulalia Urgell Rull, Alberto de Leiva. 2013. Thyroglobulin as early prognostic marker to predict remission at 18-24 months in differentiated thyroid carcinoma. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
1188. R. Michael Tuttle, Mona M. Sabra. 2013. Selective use of RAI for ablation and adjuvant therapy after total thyroidectomy for differentiated thyroid cancer: A practical approach to clinical decision making. *Oral Oncology* **49**, 676-683. [[CrossRef](#)]
1189. Cristina Azcona San Julián. 2013. Nódulos tiroideos en la infancia. *Anales de Pediatría Continuada* **11**, 181-186. [[CrossRef](#)]
1190. Carolina Fernandes Reis, Ana Paula Carneiro, Carlos Ueira Vieira, Patrícia Tiemi Fujimura, Elaine Cristina Morari, Sindeval José da Silva, Luiz Ricardo Goulart, Laura Sterian Ward. 2013. An antibody-like peptide that recognizes malignancy among thyroid nodules. *Cancer Letters* **335**, 306-313. [[CrossRef](#)]
1191. David E. Gyorki, Brian Untch, R. Michael Tuttle, Ashok R. Shaha. 2013. Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: An Assessment of the Evidence. *Annals of Surgical Oncology* **20**, 2285-2289. [[CrossRef](#)]
1192. Laura Y. Wang, Mark A. Versnick, Anthony J. Gill, James C. Lee, Stanley B. Sidhu, Mark S. Sywak, Leigh W. Delbridge. 2013. Level VII is an Important Component of Central Neck Dissection for Papillary Thyroid Cancer. *Annals of Surgical Oncology* **20**, 2261-2265. [[CrossRef](#)]
1193. R. Michael Tuttle, I. Ganly. 2013. Risk stratification in medullary thyroid cancer: Moving beyond static anatomic staging. *Oral Oncology* **49**, 695-701. [[CrossRef](#)]
1194. Myriem Boufraquech, Dhaval Patel, Yin Xiong, Electron Kebebew. 2013. Diagnosis of thyroid cancer: state of art. *Expert Opinion on Medical Diagnostics* **7**, 331-342. [[CrossRef](#)]
1195. Kepal N. Patel. 2013. Genetic mutations, molecular markers and future directions in research. *Oral Oncology* **49**, 711-721. [[CrossRef](#)]

1196. Jin Sun Yeon, Jung Hwan Baek, Hyun Kyung Lim, Eun Ju Ha, Jae Kyun Kim, Dong Eun Song, Tae Yong Kim, Jeong Hyun Lee. 2013. Thyroid Nodules with Initially Nondiagnostic Cytologic Results: The Role of Core-Needle Biopsy. *Radiology* **268**, 274-280. [[CrossRef](#)]
1197. Sukhyung Lee, Thomas S. Skelton, Feibi Zheng, Katherine A. Schwartz, Nancy D. Perrier, Jeffrey E. Lee, Roland L. Bassett, Salmaan Ahmed, Savitri Krishnamurthy, Naifa L. Busaidy, Elizabeth G. Grubbs. 2013. The Biopsy-Proven Benign Thyroid Nodule: Is Long-Term Follow-Up Necessary?. *Journal of the American College of Surgeons* **217**, 81-88. [[CrossRef](#)]
1198. Vincent Patron, Martin Hitier, Cécile Bedfert, Alexandre Métreau, Audrey Dugué, Franck Jegoux. 2013. Predictive factors for lateral occult lymph node metastasis in papillary thyroid carcinoma. *European Archives of Oto-Rhino-Laryngology* **270**, 2095-2100. [[CrossRef](#)]
1199. Marcio Griebeler, Hossein Gharib, Geoffrey Thompson. 2013. Medullary Thyroid Carcinoma. *Endocrine Practice* **19**, 703-711. [[CrossRef](#)]
1200. Paolo Goffredo, Julie A. Sosa, Sanziana A. Roman. 2013. Differentiated Thyroid Cancer Presenting with Distant Metastases: A Population Analysis Over Two Decades. *World Journal of Surgery* **37**, 1599-1605. [[CrossRef](#)]
1201. Jin Chung, Eun Kyung Kim, Hyunsun Lim, Eun Ju Son, Jung Hyun Yoon, Ji Hyun Youk, Jeong-Ah Kim, Hee Jung Moon, Jin Young Kwak. 2013. Optimal indication of thyroglobulin measurement in fine-needle aspiration for detecting lateral metastatic lymph nodes in patients with papillary thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1202. Seung Pil Jung, Minkuk Kim, Jun-Ho Choe, Jee Soo Kim, Seok Jin Nam, Jung-Han Kim. 2013. Clinical Implication of Cancer Adhesion in Papillary Thyroid Carcinoma: Clinicopathologic Characteristics and Prognosis Analyzed with Degree of Extrathyroidal Extension. *World Journal of Surgery* **37**, 1606-1613. [[CrossRef](#)]
1203. David A. Kleiman, Toni Beninato, Ashwin Soni, Yiyang Shou, Rasa Zarnegar, Thomas J. Fahey. 2013. Does Bethesda Category Predict Aggressive Features in Malignant Thyroid Nodules?. *Annals of Surgical Oncology* . [[CrossRef](#)]
1204. P. Caria, T. Dettori, D. V. Frau, A. Borghero, A. Cappai, A. Riola, M. L. Lai, F. Boi, P. Calo, A. Nicolosi, S. Mariotti, R. Vanni. 2013. Assessing RET/PTC in thyroid nodule fine-needle aspirates: the FISH point of view. *Endocrine Related Cancer* **20**, 527-536. [[CrossRef](#)]
1205. C. Durante, G. Costante, S. Filetti. 2013. Differentiated thyroid carcinoma: defining new paradigms for postoperative management. *Endocrine Related Cancer* **20**, R141-R154. [[CrossRef](#)]
1206. Richard C. Cabot, Nancy Lee Harris, Eric S. Rosenberg, Jo-Anne O. Shepard, Alice M. Cort, Sally H. Ebeling, Emily K. McDonald, Erik K. Alexander, Gayun Chan-Smutko, Mansi A. Saksena, Ion Popa. 2013. Case 19-2013. *New England Journal of Medicine* **368**, 2416-2424. [[CrossRef](#)]
1207. Seo Young Sohn, Joon Young Choi, Hye Won Jang, Hye Jeong Kim, Sang Man Jin, Se Won Kim, Sunghwan Suh, Kyu Yeon Hur, Jae Hyeon Kim, Jae Hoon Chung, Sun Wook Kim. 2013. Association Between Excessive Urinary Iodine Excretion and Failure of Radioactive Iodine Thyroid Ablation in Patients with Papillary Thyroid Cancer. *Thyroid* **23**:6, 741-747. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1208. Hubertus Hautzel, Elisabeth Pizar, David Lindner, Matthias Schott, Rüdiger Grandt, Hans-Wilhelm Müller. 2013. Impact of Renal Function and Demographic/Anthropomorphic Variables on Peak Thyrotropin After Recombinant Human Thyrotropin Stimulation: A Stepwise Forward Multiple-Regression Analysis. *Thyroid* **23**:6, 662-670. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1209. Wei-Chin Chang, Jui-Yu Chen, Chen-Hsen Lee, An-Hang Yang. 2013. Expression of Decoy Receptor 3 in Diffuse Sclerosing Variant of Papillary Thyroid Carcinoma: Correlation with M2 Macrophage Differentiation and Lymphatic Invasion. *Thyroid* **23**:6, 720-726. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1210. Iain J. Nixon, Ian Ganly, Snehal G. Patel, Frank L. Palmer, Monica M. Di Lorenzo, Ravinder K. Grewal, Steven M. Larson, R. Michael Tuttle, Ashok Shaha, Jatin P. Shah. 2013. The Results of Selective Use of Radioactive Iodine on Survival and on Recurrence in the Management of Papillary Thyroid Cancer, Based on Memorial Sloan-Kettering Cancer Center Risk Group Stratification. *Thyroid* **23**:6, 683-694. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1211. Markus Luster, Theresia Weber, Frederik A. Verburg. 2013. Changes and open issues in the management of differentiated thyroid carcinoma: an overview. *Clinical and Translational Imaging* **1**, 145-148. [[CrossRef](#)]
1212. M. G. Castagna, G. Cevenini, A. Theodoropoulou, F. Maino, S. Memmo, C. Claudia, V. Belardini, E. Brianzoni, F. Pacini. 2013. Post-surgical thyroid ablation with low or high radioiodine activities results in similar outcomes in intermediate risk differentiated thyroid cancer patients. *European Journal of Endocrinology* **169**, 23-29. [[CrossRef](#)]
1213. N. Muñoz Pérez, J. M. Villar del Moral, M. A. Muros Fuentes, M. López de la Torre, J. I. Arcelus Martínez, P. Becerra Massare, D. Esteva Martínez, M. Cañadas Garre, E. Coll Del Rey, P. Bueno Laraño, J. A. Ferrón Orihuela. 2013. Could 18F-FDG-PET/CT



- avoid unnecessary thyroidectomies in patients with cytological diagnosis of follicular neoplasm?. *Langenbeck's Archives of Surgery* **398**, 709-716. [[CrossRef](#)]
1214. David A. Kleiman, Daniel Buitrago, Michael J. Crowley, Toni Beninato, Alexander J. Veach, Pat B. Zanzonico, Moonsoo Jin, Thomas J. Fahey, Rasa Zarnegar. 2013. Thyroid stimulating hormone increases iodine uptake by thyroid cancer cells during BRAF silencing. *Journal of Surgical Research* **182**, 85-93. [[CrossRef](#)]
1215. Esther Diana Rossi, Maurizio Martini, Sara Capodimonti, Celestino Pio Lombardi, Alfredo Pontecorvi, Valerio Gaetano Vellone, Gian Franco Zannoni, Luigi Maria Larocca, Guido Fadda. 2013. BRAF (V600E) mutation analysis on liquid-based cytology-processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinoma. *Cancer Cytopathology* **121**:10.1002/cncy.v121.6, 291-297. [[CrossRef](#)]
1216. Andrew J Bauer, Gary L Francis, Steven G Waguespack, Catherine A Dinauer Differentiated thyroid cancer in children 106-118. [[CrossRef](#)]
1217. Craig P. Giacomini, R. Brooke Jeffrey, Lewis K. Shin. 2013. Ultrasonographic Evaluation of Malignant and Normal Cervical Lymph Nodes. *Seminars in Ultrasound, CT and MRI* **34**, 236-247. [[CrossRef](#)]
1218. Giorgio Treglia, Francesco Bertagna, Arnoldo Piccardo, Luca Giovanella. 2013. 131I whole-body scan or 18FDG PET/CT for patients with elevated thyroglobulin and negative ultrasound?. *Clinical and Translational Imaging* **1**, 175-183. [[CrossRef](#)]
1219. Vincenzo Marotta, Maria Domenica Franzese, Michela Del Prete, Maria Grazia Chiofalo, Valeria Ramundo, Raffaella Esposito, Francesca Marciello, Luciano Pezzullo, Annachiara Carratù, Mario Vitale, Annamaria Colao, Antongiulio Faggiano. 2013. Targeted therapy with kinase inhibitors in aggressive endocrine tumors. *Expert Opinion on Pharmacotherapy* **14**, 1187-1203. [[CrossRef](#)]
1220. George Giannopoulos, Sang-Wook Kang, Jong J. Jeong, Kee-Hyun Nam, Woong Y. Chung. 2013. Robotic Thyroidectomy for Benign Thyroid Diseases. *Surgical Laparoscopy, Endoscopy & Percutaneous Techniques* **23**, 312-315. [[CrossRef](#)]
1221. Massimo Eugenio Dottorini, Massimo Salvatori. 2013. Is radioiodine treatment for thyroid cancer a risk factor for second primary malignancies?. *Clinical and Translational Imaging* **1**, 205-216. [[CrossRef](#)]
1222. Daniele Barbaro, Nicola Desogus, Giuseppe Boni. 2013. Pituitary metastasis of thyroid cancer. *Endocrine* **43**, 485-493. [[CrossRef](#)]
1223. Frederik A. Verburg, Heribert Hänscheid, Markus Luster. 2013. Thyroid remnant ablation in differentiated thyroid carcinoma: when and how. *Clinical and Translational Imaging* **1**, 195-203. [[CrossRef](#)]
1224. John C. Hornberger. 2013. Comparative Effectiveness in Personalized Medicine—Clearly Defining the Intended Use Population. *Value in Health* **16**, 696. [[CrossRef](#)]
1225. K. Alok Pathak, William D. Leslie, Thomas C. Klonisch, Richard W. Nason. 2013. The changing face of thyroid cancer in a population-based cohort. *Cancer Medicine* n/a-n/a. [[CrossRef](#)]
1226. Ji In Lee, Yun Jae Chung, Bo Youn Cho, SeMin Chong, Ju Won Seok, Sung Jun Park. 2013. Postoperative-stimulated serum thyroglobulin measured at the time of 131I ablation is useful for the prediction of disease status in patients with differentiated thyroid carcinoma. *Surgery* **153**, 828-835. [[CrossRef](#)]
1227. Miguel Melo, Gracinda Costa, Francisco Carrilho, Manuela Carvalheiro, Paula Soares Radiotherapy: radioiodine and external beam irradiation treatment of differentiated thyroid carcinomas 78-92. [[CrossRef](#)]
1228. Judy Jin, Roy Phitayakorn, Scott M. Wilhelm, Christopher R. McHenry. 2013. Advances in management of thyroid cancer. *Current Problems in Surgery* **50**, 241-289. [[CrossRef](#)]
1229. Melisachew M. Yeshe, Rosemary H. Tambouret, Elena F. Brachtel. 2013. Fine-Needle Aspiration Cytology in Ethiopia. *Archives of Pathology & Laboratory Medicine* **137**, 791-797. [[CrossRef](#)]
1230. Mariana Bonjorno Martins, Marjory Alana Marcello, Elaine Cristina Morari, Lucas Leite Cunha, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward. 2013. Clinical Utility of KAP-1 Expression in Thyroid Lesions. *Endocrine Pathology* **24**, 77-82. [[CrossRef](#)]
1231. Priscila S. Signorini, Maria Inez C. França, Cleber P. Camacho, Susan C. Lindsey, Flávia O. F. Valente, Teresa S. Kasamatsu, Alberto L. Machado, Camila P. Salim, Rosana Delcelo, Ana O. Hoff, Janete M. Cerutti, Magnus R. Dias-da-Silva, Rui M. B. Maciel. 2013. A ten-year clinical update of a large RET p.Gly533Cys kindred with medullary thyroid carcinoma emphasizes the need for an individualized assessment of affected relatives. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
1232. Byung Chul Kang, Jong-Lyel Roh, Jeong Hyun Lee, Jae Hoon Jung, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim. 2013. Usefulness of Computed Tomography in the Etiologic Evaluation of Adult Unilateral Vocal Fold Paralysis. *World Journal of Surgery* **37**, 1236-1240. [[CrossRef](#)]
1233. Luca Giovanella, Pierpaolo Trimboli, Frederik A. Verburg, Giorgio Treglia, Arnoldo Piccardo, Luca Foppiani, Luca Ceriani. 2013. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients

- with biochemical recurrence of differentiated thyroid carcinoma. *European Journal of Nuclear Medicine and Molecular Imaging* **40**, 874-880. [[CrossRef](#)]
1234. Zvonimir L Milas, Jennifer Brainard, Mira Milas Thyroid cancer: classification and cytological diagnosis 18-32. [[CrossRef](#)]
1235. Yoon Se Lee, Yun-Sung Lim, Jin-Choon Lee, Soo-Geun Wang, In-Ju Kim, Seok-Man Son, Dong Hoon Shin, Byung-Joo Lee. 2013. Nodal status of central lymph nodes as a negative prognostic factor for papillary thyroid carcinoma. *Journal of Surgical Oncology* **107**:10.1002/jso.v107.7, 777-782. [[CrossRef](#)]
1236. F. Capocchetti, E. Biggi, G. Rossi, C. Manni, E. Brianzoni. 2013. Differentiated thyroid carcinoma: diagnosis and dosimetry using 124I PET/CT. *Clinical and Translational Imaging* **1**, 185-193. [[CrossRef](#)]
1237. Joseph M Shulan, Jennifer A Sipos Diagnosis of thyroid cancer 6-17. [[CrossRef](#)]
1238. Seyed Amirhossein Razavi, Tyson A. Hadduck, Gelareh Sadigh, Ben A. Dwamena. 2013. Comparative Effectiveness of Elastographic and B-Mode Ultrasound Criteria for Diagnostic Discrimination of Thyroid Nodules: A Meta-Analysis. *American Journal of Roentgenology* **200**, 1317-1326. [[CrossRef](#)]
1239. Massimo Bongiovanni, Gaetano Paone, Luca Ceriani, Marc Pusztaszeri. 2013. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. *Clinical and Translational Imaging* **1**, 149-161. [[CrossRef](#)]
1240. X.S. Sun, N. Guevara, N. Fakhry, S.-R. Sun, P.-Y. Marcy, J. Santini, J.-F. Bosset, J. Thariat. 2013. Place de la radiothérapie externe dans les cancers de la thyroïde. *Cancer/Radiothérapie* **17**, 233-243. [[CrossRef](#)]
1241. Mustafa Şahin, Bekir Uçan, Zeynep Giniş, Oya Topaloğlu, Aşkın Güngüneş, Nujen Çolak Bozkurt, Müyesser Sayki Arslan, İlknur Öztürk Ünsal, Esra Tural Akkaymak, Taner Demirci, Melia Karaköse, Mustafa Çalışkan, Erman Çakal, Mustafa Özbek, Tuncay Delibaşı. 2013. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients. *Medical Oncology* **30**. . [[CrossRef](#)]
1242. Ravi Kumar Lingam, Mohammad Haroon Qarib, Neil Samuel Tolley. 2013. Evaluating thyroid nodules: predicting and selecting malignant nodules for fine-needle aspiration (FNA) cytology. *Insights into Imaging* . [[CrossRef](#)]
1243. Tada Kunavisarut. 2013. Diagnostic biomarkers of differentiated thyroid cancer. *Endocrine* . [[CrossRef](#)]
1244. E. D. Rossi, M. Martini, S. Capodimonti, P. Straccia, T. Cenci, C. P. Lombardi, A. Pontecorvi, L. M. Larocca, G. Fadda. 2013. Diagnostic and prognostic value of immunocytochemistry and BRAF mutation analysis on liquid-based biopsies of thyroid neoplasms suspicious for carcinoma. *European Journal of Endocrinology* **168**, 853-859. [[CrossRef](#)]
1245. Ronnie Meiyi Wong, Catherine Bresee, Glenn D. Braunstein. 2013. Comparison with Published Systems of a New Staging System for Papillary and Follicular Thyroid Carcinoma. *Thyroid* **23**:5, 566-574. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1246. Christopher Kim, Xiaofeng Bi, Dongsheng Pan, Yingtai Chen, Tobias Carling, Shuangge Ma, Robert Udelsman, Yawei Zhang. 2013. The Risk of Second Cancers After Diagnosis of Primary Thyroid Cancer Is Elevated in Thyroid Microcarcinomas. *Thyroid* **23**:5, 575-582. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1247. Shin Young Jeong, Hae Won Kim, Sang-Woo Lee, Byeong-Cheol Ahn, Jaetae Lee. 2013. Salivary Gland Function 5 Years After Radioactive Iodine Ablation in Patients with Differentiated Thyroid Cancer: Direct Comparison of Pre- and Postablation Scintigraphies and Their Relation to Xerostomia Symptoms. *Thyroid* **23**:5, 609-616. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1248. Brendan C. Stack Jr., Donald L. Bodenner, Twyla B. Bartel, Jacob Boeckmann. 2013. Focal Thyroid Uptake on 18F-Fluorodeoxyglucose Positron Emission Tomography: Interpreting the Data. *Thyroid* **23**:5, 636-637. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1249. Antoine Eskander, Mazin Merdad, Jeremy L. Freeman, Ian J. Witterick. 2013. Pattern of Spread to the Lateral Neck in Metastatic Well-Differentiated Thyroid Cancer: A Systematic Review and Meta-Analysis. *Thyroid* **23**:5, 583-592. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1250. Laszlo Hegedüs, Kerstin K. Soelberg, Thomas H. Brix, Steen J. Bonnema. 2013. Response to Stack et al.. *Thyroid* **23**:5, 637-638. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1251. Roberto Negro, Simonetta Piana, Marisa Ferrari, Moira Ragazzi, Giorgio Gardini, Sofia Asioli, Donatella Pacchioni, Fabrizio Riganti, Roberto Valcavi. 2013. Assessing the Risk of False-Negative Fine-Needle Aspiration Cytology and of Incidental Cancer in Nodular Goiter. *Endocrine Practice* **19**, 444-450. [[CrossRef](#)]
1252. Christopher J. VandenBussche, Christopher D. Gocke, Qing Kay Li. 2013. Fine-needle aspiration of metastatic papillary thyroid carcinoma found in the liver. *Diagnostic Cytopathology* **41**:10.1002/dc.v41.5, 418-424. [[CrossRef](#)]
1253. Supriya S Patel, Melanie Goldfarb. 2013. Well-differentiated thyroid carcinoma: The role of post-operative radioactive iodine administration. *Journal of Surgical Oncology* **107**:10.1002/jso.v107.6, 665-672. [[CrossRef](#)]

1254. Jeffrey P. Guenette, Jack M. Monchik, Damian E. Dupuy. 2013. Image-guided Ablation of Postsurgical Locoregional Recurrence of Biopsy-proven Well-differentiated Thyroid Carcinoma. *Journal of Vascular and Interventional Radiology* **24**, 672-679. [[CrossRef](#)]
1255. Óscar González, Carles Zafón, Isabel Roca. 2013. Selective sentinel lymph node biopsy in papillary thyroid carcinoma. *Endocrinología y Nutrición (English Edition)* . [[CrossRef](#)]
1256. Pierpaolo Trimboli, Nadia Cremonini, Luca Ceriani, Enrico Saggiorato, Leo Guidobaldi, Francesco Romanelli, Claudio Ventura, Oriana Laurenti, Iliaria Messuti, Erica Solaroli, Raffaele Madaio, Massimo Bongiovanni, Fabio Orlandi, Anna Crescenzi, Stefano Valabrega, Luca Giovanella. 2013. Calcitonin measurement in aspiration needle washout fluids has higher sensitivity than cytology in detecting medullary thyroid cancer: a retrospective multicentre study. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]
1257. S Y Hahn, J H Shin, B-K Han, E Y Ko, E S Ko. 2013. Ultrasonography-guided core needle biopsy for the thyroid nodule: does the procedure hold any benefit for the diagnosis when fine-needle aspiration cytology analysis shows inconclusive results?. *The British Journal of Radiology* **86**, 20130007. [[CrossRef](#)]
1258. E. Mariscal Labrador, A. García Burillo, J. Castell-Conesa, G. Obiols Alfonso, N. Kisiel González, M. Barios Profitós, S. Aguadé-Bruix, J. Mesa Manteca. 2013. Positron emission tomography-computed tomography with 18F-fluorodeoxyglucose in patients with recurrent differentiated thyroid carcinoma and negative radioiodine scan. Diagnostic performance and relation with thyroglobulin levels. *Revista Española de Medicina Nuclear e Imagen Molecular (English Edition)* **32**, 146-151. [[CrossRef](#)]
1259. W. K. Yunker, S. F. Hassan, L. B. Ferrell, M. J. Hicks, C. M. Giannoni, D. E. Wesson, C. I. Cassady, J. A. Hernandez, M. L. Brandt, M. E. Lopez. 2013. Needle core biopsy in the diagnosis of pediatric thyroid neoplasms: a single institution retrospective review. *Pediatric Surgery International* **29**, 437-443. [[CrossRef](#)]
1260. Jasna Mihailovic, Ljubomir Stefanovic, Ranka Stankovic. 2013. Influence of Initial Treatment on the Survival and Recurrence in Patients With Differentiated Thyroid Microcarcinoma. *Clinical Nuclear Medicine* **38**, 332-338. [[CrossRef](#)]
1261. Kyu Eun Lee, Il Yong Chung, Eunyoung Kang, Do Hoon Koo, Kyu Hyung Kim, Sung-Won Kim, Yeo-Kyu Youn, Seung Keun Oh. 2013. Ipsilateral and contralateral central lymph node metastasis in papillary thyroid cancer: Patterns and predictive factors of nodal metastasis. *Head & Neck* **35**:10.1002/hed.v35.5, 672-676. [[CrossRef](#)]
1262. Maria B. Albuja-Cruz, Melanie Goldfarb, Stephen S. Gondek, Bassan J. Allan, John I. Lew. 2013. Reliability of fine-needle aspiration for thyroid nodules greater than or equal to 4 cm. *Journal of Surgical Research* **181**, 6-10. [[CrossRef](#)]
1263. Jin Young Kwak, Eun-Kyung Kim. 2013. Cancer: Indeterminate thyroid nodules—added testing, added value?. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1264. David A. Kleiman, Matthew J. Sporn, Toni Beninato, Michael J. Crowley, Anvy Nguyen, Alessia Uccelli, Theresa Scognamiglio, Rasa Zarnegar, Thomas J. Fahey. 2013. Preoperative BRAF(V600E) mutation screening is unlikely to alter initial surgical treatment of patients with indeterminate thyroid nodules. *Cancer* **119**:10.1002/cncr.v119.8, 1495-1502. [[CrossRef](#)]
1265. X. V. Nguyen, K. Roy Choudhury, J. D. Eastwood, G. H. Lyman, R. M. Esclamado, J. D. Werner, J. K. Hoang. 2013. Incidental Thyroid Nodules on CT: Evaluation of 2 Risk-Categorization Methods for Work-Up of Nodules. *American Journal of Neuroradiology* . [[CrossRef](#)]
1266. Eyal Robenshtok, Ravinder K. Grewal, Stephanie Fish, Mona Sabra, R. Michael Tuttle. 2013. A Low Postoperative Nonstimulated Serum Thyroglobulin Level Does Not Exclude the Presence of Radioactive Iodine Avid Metastatic Foci in Intermediate-Risk Differentiated Thyroid Cancer Patients. *Thyroid* **23**:4, 436-442. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1267. Juan P. Brito, Andres J. Yarur, Larry J. Prokop, Bryan McIver, Mohammad Hassan Murad, Victor M. Montori. 2013. Prevalence of Thyroid Cancer in Multinodular Goiter Versus Single Nodule: A Systematic Review and Meta-Analysis. *Thyroid* **23**:4, 449-455. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1268. Dong Wook Kim, Soo Jin Jung, Jae Wook Eom, Taewoo Kang. 2013. Color Doppler Features of Solid, Round, Isoechoic Thyroid Nodules Without Malignant Sonographic Features: A Prospective Cytopathological Study. *Thyroid* **23**:4, 472-476. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1269. Roger T. Anderson, John E. Linnehan, Vanita Tongbram, Karen Keating, Lori J. Wirth. 2013. Clinical, Safety, and Economic Evidence in Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Systematic Literature Review. *Thyroid* **23**:4, 392-407. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1270. Mario Vitale. 2013. Intratumor BRAFV600E Heterogeneity and Kinase Inhibitors in the Treatment of Thyroid Cancer: A Call for Participation. *Thyroid* **23**:4, 517-519. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1271. Chien-Liang Liu, Jie-Jen Lee, Tsang-Pai Liu, Yuan-Ching Chang, Yi-Chiung Hsu, Shih-Ping Cheng. 2013. Blood neutrophil-to-lymphocyte ratio correlates with tumor size in patients with differentiated thyroid cancer. *Journal of Surgical Oncology* **107**:10.1002/jso.v107.5, 493-497. [[CrossRef](#)]

1272. Shih-Ping Cheng, Jie-Jen Lee, Jiun-Lu Lin, Shih-Ming Chuang, Ming-Nan Chien, Chien-Liang Liu. 2013. Characterization of thyroid nodules using the proposed thyroid imaging reporting and data system (TI-RADS). *Head & Neck* **35**:10.1002/hed.v35.4, 541-547. [[CrossRef](#)]
1273. Laurel J. Bessey, Ngan Betty K. Lai, Nicholas E. Coorough, Herbert Chen, Rebecca S. Sippel. 2013. The incidence of thyroid cancer by fine needle aspiration varies by age and gender. *Journal of Surgical Research* . [[CrossRef](#)]
1274. Paolo Miccoli, Lorenzo Fregoli, Rocco Rago, Valeria Matteucci, Mario Miccoli, Gabriele Materazzi. 2013. Increased costs of perioperative risk assessment for thyroid surgery in elderly people (over 80 years) presenting with benign disease. *Langenbeck's Archives of Surgery* **398**, 525-530. [[CrossRef](#)]
1275. Jennifer E. Rosen, Paula Gardiner, Stephanie L. Lee. 2013. Complementary and Integrative Treatments. *Otolaryngologic Clinics of North America* . [[CrossRef](#)]
1276. Hye Jeong Kim, Na Kyung Kim, Ji Hun Choi, Se Won Kim, Sang-Man Jin, Sunghwan Suh, Ji Cheol Bae, Yong-Ki Min, Jae Hoon Chung, Sun Wook Kim. 2013. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma. *Clinical Endocrinology* **78**:10.1111/cen.2013.78.issue-4, 614-620. [[CrossRef](#)]
1277. Spyridon Karras, Nikolaos Pontikides, Gerasimos E Krassas. 2013. Pharmacokinetic evaluation of cabozantinib for the treatment of thyroid cancer. *Expert Opinion on Drug Metabolism & Toxicology* **9**, 507-515. [[CrossRef](#)]
1278. Caroline Lansoy-Kuhn, Jean M. Picquenot, Agathe Edet-Sanson, F erial Mechken, Sophie Laberge-Le Couteulx, Marie Cornic, Pierre Vera. 2013. Relationship between the immunohistochemistry of the primary tumour and 18F-FDG-PET/CT at recurrence in patients with well-differentiated thyroid carcinoma. *Nuclear Medicine Communications* **34**, 340-346. [[CrossRef](#)]
1279. Zubair W. Baloch, Susan J. Mandel, Virginia A. LiVolsi. 2013. Are we ready to modify the Bethesda thyroid fine-needle aspiration classification scheme?. *Cancer Cytopathology* **121**:10.1002/cncy.v121.4, 171-174. [[CrossRef](#)]
1280. X.S. Sun, S.R. Sun, N. Guevara, P.Y. Marcy, I. Peyrottes, S. Lassalle, A. Lacout, J.L. Sadoul, J. Santini, D. Benisvy, A. Lepinoy, J. Thariat. 2013. Indications of external beam radiation therapy in non-anaplastic thyroid cancer and impact of innovative radiation techniques. *Critical Reviews in Oncology/Hematology* **86**, 52-68. [[CrossRef](#)]
1281. Vincent Vander Poorten, Greet Hens, Pierre Delaere. 2013. Thyroid cancer in children and adolescents. *Current Opinion in Otolaryngology & Head and Neck Surgery* **21**, 135-142. [[CrossRef](#)]
1282. N. Paul Ohori, Rashi Singhal, Marina N. Nikiforova, Linwah Yip, Karen E. Schoedel, Christopher Coyne, Kelly L. McCoy, Shane O. LeBeau, Steven P. Hodak, Sally E. Carty, Yuri E. Nikiforov. 2013. BRAF mutation detection in indeterminate thyroid cytology specimens. *Cancer Cytopathology* **121**:10.1002/cncy.v121.4, 197-205. [[CrossRef](#)]
1283. Brian Hung-Hin Lang, Kai Pun Wong, Chung Yeung Cheung, Koon Yat Wan, Chung-Yau Lo. 2013. Evaluating the Prognostic Factors Associated with Cancer-specific Survival of Differentiated Thyroid Carcinoma Presenting with Distant Metastasis. *Annals of Surgical Oncology* **20**, 1329-1335. [[CrossRef](#)]
1284. Iain J. Nixon, Ricard Simo. 2013. The neoplastic goitre. *Current Opinion in Otolaryngology & Head and Neck Surgery* **21**, 143-149. [[CrossRef](#)]
1285. Jonathan Yip, Steven Orlov, David Orlov, Alon Vaisman, Karen G omez Hern andez, Daniel Etarsky, Ipshita Kak, Nikoo Parvinnejad, Jeremy L. Freeman, Paul G. Walfish. 2013. Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence. *Head & Neck* **35**:10.1002/hed.v35.4, 592-598. [[CrossRef](#)]
1286. Kwan Ju Lee, Yun Jung Cho, Jeong Goo Kim, Dong Ho Lee. 2013. How Many Contralateral Papillary Thyroid Carcinomas Can Be Missed?. *World Journal of Surgery* **37**, 780-785. [[CrossRef](#)]
1287. J. Plz ak, J. Astl, G. Psychogios, J. Zenk, P. Lašt vka, J. Betka. 2013. Aktuelle Behandlungskonzepte des papill ren Schilddr senmikrokarzinoms. *HNO* **61**, 300-305. [[CrossRef](#)]
1288. Haggi Mazeh, Yair Levy, Ido Mizrahi, Liat Appelbaum, Nadia Ilyayev, David Halle, Herbert R. Freund, Aviram Nissan. 2013. Differentiating benign from malignant thyroid nodules using micro ribonucleic acid amplification in residual cells obtained by fine needle aspiration biopsy. *Journal of Surgical Research* **180**, 216-221. [[CrossRef](#)]
1289. Ji In Lee, Hye Won Jang, Sun Wook Kim, Jong-Won Kim, Young Lyun Oh, Jae Hoon Chung. 2013. BRAF V600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas. *Head & Neck* **35**:10.1002/hed.v35.4, 548-553. [[CrossRef](#)]
1290. Naoyoshi Onoda, Hidemi Kawajiri, Shinichiro Kashiwagi, Masanori Nakamura, Tsutomu Takashima, Masahiko Osawa, Kenichi Wakasa, Tetsuro Ishikawa, Kosei Hirakawa. 2013. Complete eradication of de-differentiated skin recurrence of papillary thyroid carcinoma with weekly docetaxel. *International Cancer Conference Journal* **2**, 97-100. [[CrossRef](#)]
1291. P. Mehrotra, A. McQueen, S. Kolla, S. J. Johnson, D. L. Richardson. 2013. Does elastography reduce the need for thyroid FNAs?. *Clinical Endocrinology* n/a-n/a. [[CrossRef](#)]

1292. Kyung Tae, Yong Bae Ji, Jin Hyeok Jeong, Kyung Rae Kim, Woong Hwan Choi, You Hern Ahn. 2013. Comparative study of robotic versus endoscopic thyroidectomy by a gasless unilateral axillo-breast or axillary approach. *Head & Neck* 35:10.1002/hed.v35.4, 477-484. [[CrossRef](#)]
1293. Rosj Gallicchio, Sabrina Giacomobono, Daniela Capacchione, Anna Nardelli, Francesco Barbato, Antonio Nappi, Teresa Pellegrino, Giovanni Storto. 2013. Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation?. *Endocrine* . [[CrossRef](#)]
1294. Tracy S. Wang, Julie A. Sosa. 2013. Thyroid gland: Can a nomogram predict death in patients with thyroid cancer?. *Nature Reviews Endocrinology* 9, 192-193. [[CrossRef](#)]
1295. Young Joo Suh, Eun Ju Son, Hee Jung Moon, Eun-Kyung Kim, Kyung Hwa Han, Jin Young Kwak. 2013. Utility of Thyroglobulin Measurements in Fine-Needle Aspirates of Space Occupying Lesions in the Thyroid Bed After Thyroid Cancer Operations. *Thyroid* 23:3, 280-288. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1296. Cléber P. Camacho, Susan C. Lindsey, Maria Clara C. Melo, Ji H. Yang, Fausto Germano-Neto, Flávia de O.F. Valente, Thiago R.N. Lima, Rosa Paula M. Biscolla, José G.H. Vieira, Janete M. Cerutti, Magnus R. Dias-da-Silva, Rui M.B. Maciel. 2013. Measurement of Calcitonin and Calcitonin Gene-Related Peptide mRNA Refines the Management of Patients with Medullary Thyroid Cancer and May Replace Calcitonin-Stimulation Tests. *Thyroid* 23:3, 308-316. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1297. Óscar González, Carles Zafón, Isabel Roca. 2013. Biopsia selectiva del ganglio centinela en el carcinoma papilar de tiroides. *Endocrinología y Nutrición* 60, 111-114. [[CrossRef](#)]
1298. Maria Galiana Rodríguez Caballero, Lorena Suárez Gutiérrez, Luis Fernández Fernández, Nuria Valdés Gallego, Edelmiro Menéndez Torre. 2013. Taponamiento cardíaco como primera manifestación de carcinoma papilar de tiroides. *Endocrinología y Nutrición* . [[CrossRef](#)]
1299. Géraldine Pina, Séverine Dubois, Arnaud Murat, Nicole Berger, Patricia Niccoli, Jean-Louis Peix, Régis Cohen, Claudine Guillausseau, Anne Charrie, Olivier Chabre, Catherine Cornu, Françoise Borson-Chazot, Vincent Rohmer. 2013. Is basal ultrasensitive measurement of calcitonin capable of substituting for the pentagastrin-stimulation test?. *Clinical Endocrinology* 78:10.1111/cen.2013.78.issue-3, 358-364. [[CrossRef](#)]
1300. Marco Raffaelli, Carmela Crea, Luca Sessa, Piero Giustacchini, Rocco Bellantone, Celestino Pio Lombardi. 2013. Can intraoperative frozen section influence the extension of central neck dissection in cN0 papillary thyroid carcinoma?. *Langenbeck's Archives of Surgery* 398, 383-388. [[CrossRef](#)]
1301. William C. Faquin. 2013. Can a gene-expression classifier with high negative predictive value solve the indeterminate thyroid fine-needle aspiration dilemma?. *Cancer Cytopathology* 121, 116-119. [[CrossRef](#)]
1302. Anar Aliyev, Sabire Ylmaz, Meftune Ozhan, Sertac Asa, Metin Halac. 2013. FDG PET/CT in the Detection of Metastases in a Patient With Tg and 131I WBS Negative Follicular Thyroid Cancer. *Clinical Nuclear Medicine* 38, 226-227. [[CrossRef](#)]
1303. Kathryn M. Schuessler, Mousumi Banerjee, Di Yang, Andrew K. Stewart, Gerard M. Doherty, Megan R. Haymart. 2013. Surgeon Training and Use of Radioactive Iodine in Stage I Thyroid Cancer Patients. *Annals of Surgical Oncology* 20, 733-738. [[CrossRef](#)]
1304. Xiao Qin Chen, Rong Hua Shi, Jian Tao Huang, Yun Fu Zhao. 2013. Follicular Variant of Papillary Carcinoma Arising From Lingual Thyroid With Orthotopic Hypoplasia of Thyroid Lobes. *Journal of Oral and Maxillofacial Surgery* 71, 644-648. [[CrossRef](#)]
1305. Nicholas Coorough, Kevin Hudak, Juan Carlos Jaume, Darya Buehler, Suzanne Selvaggi, James Rivas, Rebecca Sippel, Herbert Chen. 2013. Nondiagnostic fine-needle aspirations of the thyroid: is the risk of malignancy higher?. *Journal of Surgical Research* . [[CrossRef](#)]
1306. Daniel I. Glazer, Richard K. J. Brown, Ka Kit Wong, Hatice Savas, Milton D. Gross, Anca M. Avram. 2013. SPECT/CT Evaluation of Unusual Physiologic Radioiodine Biodistributions: Pearls and Pitfalls in Image Interpretation. *RadioGraphics* 33, 397-418. [[CrossRef](#)]
1307. Rosemary A. Recavarren, Patricia M. Houser, Jack Yang. 2013. Potential pitfalls of needle tract effects on repeat thyroid fine-needle aspiration. *Cancer Cytopathology* 121, 155-161. [[CrossRef](#)]
1308. Heather Ferris, Gethin Williams, J. Parker, Jeffrey Garber. 2013. Therapeutic Implications of Diffuse Hepatic Uptake Following I-131 Therapy for Differentiated Thyroid Cancer. *Endocrine Practice* 19, 263-267. [[CrossRef](#)]
1309. Ga Ram Kim, Myung Hyun Kim, Hee Jung Moon, Woong Youn Chung, Jin Young Kwak, Eun-Kyung Kim. 2013. Sonographic Characteristics Suggesting Papillary Thyroid Carcinoma According to Nodule Size. *Annals of Surgical Oncology* 20, 906-913. [[CrossRef](#)]
1310. Mingzhao Xing, Bryan R Haugen, Martin Schlumberger. 2013. Progress in molecular-based management of differentiated thyroid cancer. *The Lancet* 381, 1058-1069. [[CrossRef](#)]

1311. M. J. Shim, J.-L. Roh, G. Gong, K.-J. Choi, J. H. Lee, S.-H. Cho, S. Y. Nam, S. Y. Kim. 2013. Preoperative detection and predictors of level V lymph node metastasis in patients with papillary thyroid carcinoma. *British Journal of Surgery* **100**:10.1002/bjs.v100.4, 497-503. [[CrossRef](#)]
1312. Han Yong Chun, Jaebum Son, Hyunchul Jung, Min Tae Kim, Tae-yun Kim, Kwang Gi Kim, Ji-hoon Kim. 2013. Load and speed effects on thyroid ultrasonography. *Biomedical Engineering Letters* **3**, 51-57. [[CrossRef](#)]
1313. Donald SA McLeod, Anna M Sawka, David S Cooper. 2013. Controversies in primary treatment of low-risk papillary thyroid cancer. *The Lancet* **381**, 1046-1057. [[CrossRef](#)]
1314. Yun J Chung, Jae S Lee, So Y Park, Hyo J Park, Bo Y Cho, Sung J Park, Sei Y Lee, Kyung-Ho Kang, Han S Ryu. 2013. Histomorphological factors in the risk prediction of lymph node metastasis in papillary thyroid carcinoma. *Histopathology* **62**:10.1111/his.2013.62.issue-4, 578-588. [[CrossRef](#)]
1315. Henning Dralle, Thomas J. Musholt, Jochen Schabram, Thomas Steinmüller, Andreja Frilling, Dietmar Simon, Peter E. Goretzki, Bruno Niederle, Christian Scheuba, Thomas Clerici, Michael Hermann, Jochen Kufmann, Kerstin Lorenz, Christoph Nies, Peter Schabram, Arnold Trupka, Andreas Zielke, Wolfram Karges, Markus Luster, Kurt W. Schmid, Dirk Vordermark, Hans-Joachim Schmoll, Reinhard Mühlenberg, Otmar Schober, Harald Rimmele, Andreas Machens. 2013. German Association of Endocrine Surgeons practice guideline for the surgical management of malignant thyroid tumors. *Langenbeck's Archives of Surgery* **398**, 347-375. [[CrossRef](#)]
1316. Michele N. Minuto, Mario Miccoli, David Viola, Clara Ugolini, Riccardo Giannini, Liborio Torregrossa, Lucia Antonangeli, Fabrizio Aghini-Lombardi, Rossella Elisei, Fulvio Basolo, Paolo Miccoli. 2013. Incidental versus clinically evident thyroid cancer: A 5-year follow-up study. *Head & Neck* **35**:10.1002/hed.v35.3, 408-412. [[CrossRef](#)]
1317. L. L. Cunha, M. A. Marcello, E. C. Morari, S. Nonogaki, F. F. Conte, R. Gerhard, F. A. Soares, J. Vassallo, L. S. Ward. 2013. Differentiated thyroid carcinomas may elude the immune system by B7H1 upregulation. *Endocrine Related Cancer* **20**, 103-110. [[CrossRef](#)]
1318. Richard C. Cabot, Nancy Lee Harris, Eric S. Rosenberg, Jo-Anne O. Shepard, Alice M. Cort, Sally H. Ebeling, Emily K. McDonald, Lori J. Wirth, Douglas S. Ross, Gregory W. Randolph, Mary Elizabeth Cunnane, Peter M. Sadow. 2013. Case 5-2013. *New England Journal of Medicine* **368**, 664-673. [[CrossRef](#)]
1319. Huawei Qiu, Ekaterina Boudanova, Anna Park, Julie J. Bird, Denise M. Honey, Christine Zarazinski, Ben Greene, Jonathan S. Kingsbury, Susan Boucher, Julie Pollock, John M. McPherson, Clark Q. Pan. 2013. Site-Specific PEGylation of Human Thyroid Stimulating Hormone to Prolong Duration of Action. *Bioconjugate Chemistry* 130211145355006. [[CrossRef](#)]
1320. Steven P. Hodak, David S. Rosenthal for the American Thyroid Association Clinical Affairs Committee. 2013. Information for Clinicians: Commercially Available Molecular Diagnosis Testing in the Evaluation of Thyroid Nodule Fine-Needle Aspiration Specimens. *Thyroid* **23**:2, 131-134. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1321. Seham Chaker, Ipshita Kak, Christina MacMillan, Ranju Ralhan, Paul G. Walfish. 2013. Activated Leukocyte Cell Adhesion Molecule Is a Marker for Thyroid Carcinoma Aggressiveness and Disease-Free Survival. *Thyroid* **23**:2, 201-208. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1322. Anna M. Sawka, Heather Rilkoff, Richard W. Tsang, James D. Brierley, Lorne Rotstein, Shereen Ezzat, Sylvia L. Asa, Phillip Segal, Catherine Kelly, Afshan Zahedi, Amiram Gafni, David P. Goldstein. 2013. The Rationale of Patients with Early-Stage Papillary Thyroid Cancer for Accepting or Rejecting Radioactive Iodine Remnant Ablation. *Thyroid* **23**:2, 246-247. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1323. Maria Papaleontiou, Mousumi Banerjee, Di Yang, James C. Sisson, Ronald J. Koenig, Megan R. Haymart. 2013. Factors That Influence Radioactive Iodine Use for Thyroid Cancer. *Thyroid* **23**:2, 219-224. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1324. Laticia A. Valle, Revital L. Gorodeski Baskin, Kyle Porter, Jennifer A. Sipos, Raheela Khawaja, Matthew D. Ringel, Richard T. Kloos. 2013. In Thyroidectomized Patients with Thyroid Cancer, a Serum Thyrotropin of 30  $\mu$ U/mL After Thyroxine Withdrawal Is Not Always Adequate for Detecting an Elevated Stimulated Serum Thyroglobulin. *Thyroid* **23**:2, 185-193. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1325. Nikola Besic, Marija Auersperg, Marta Dremelj, Barbara Vidergar-Kralj, Barbara Gazic. 2013. Neoadjuvant Chemotherapy in 16 Patients with Locally Advanced Papillary Thyroid Carcinoma. *Thyroid* **23**:2, 178-184. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1326. Ogechukwu P. Eze, Guoping Cai, Zubair W. Baloch, Ashraf Khan, Renu Virk, Lynwood W. Hammers, Robert Udelsman, Sanziana A. Roman, Julie A. Sosa, Tobias Carling, David Chhieng, Constantine G.A. Theoharis, Manju L. Prasad. 2013. Vanishing Thyroid Tumors: A Diagnostic Dilemma After Ultrasonography-Guided Fine-Needle Aspiration. *Thyroid* **23**:2, 194-200. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]

1327. Diego Russo, Cosimo Durante, Stefania Bulotta, Cinzia Puppini, Efisio Puxeddu, Sebastiano Filetti, Giuseppe Damante. 2013. Targeting histone deacetylase in thyroid cancer. *Expert Opinion on Therapeutic Targets* **17**, 179-193. [[CrossRef](#)]
1328. Antoine Eskander, Gerald M. Devins, Jeremy Freeman, Alice C. Wei, Lorne Rotstein, Nitin Chauhan, Anna M. Sawka, Dale Brown, Jonathan Irish, Ralph Gilbert, Patrick Gullane, Kevin Higgins, Danny Enepekides, David Goldstein. 2013. Waiting for thyroid surgery: A study of psychological morbidity and determinants of health associated with long wait times for thyroid surgery. *The Laryngoscope* **123**:10.1002/lary.v123.2, 541-547. [[CrossRef](#)]
1329. Chineme Enyioha, Sanziana A. Roman, Julie Ann Sosa. 2013. Central lymph node dissection in patients with papillary thyroid cancer: a population level analysis of 14,257 cases. *The American Journal of Surgery* . [[CrossRef](#)]
1330. Amit M. Saindane. 2013. Pitfalls in the Staging of Cancer of Thyroid. *Neuroimaging Clinics of North America* **23**, 123-145. [[CrossRef](#)]
1331. Roberto Vita, Giovanna Saraceno, Francesco Trimarchi, Salvatore Benvenga. 2013. A novel formulation of l-thyroxine (l-T<sub>4</sub>) reduces the problem of l-T<sub>4</sub> malabsorption by coffee observed with traditional tablet formulations. *Endocrine* **43**, 154-160. [[CrossRef](#)]
1332. Brian Hung-Hin Lang, Kai Pun Wong, Koon Yat Wan. 2013. Postablation Stimulated Thyroglobulin Level is an Important Predictor of Biochemical Complete Remission after Reoperative Cervical Neck Dissection in Persistent/Recurrent Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* **20**, 653-659. [[CrossRef](#)]
1333. Dorin Bibicu, Luminita Moraru, Anjan Biswas. 2013. Thyroid Nodule Recognition Based on Feature Selection and Pixel Classification Methods. *Journal of Digital Imaging* **26**, 119-128. [[CrossRef](#)]
1334. Ignasi Castells, Núria Pardo, Sebastián Videla, Gabriel Giménez, Esteve Llargues, Olga Simó, María Asunción Recasens, Xavier Guirao, Xavier Mira, Àngel Serrano, Anna Sanmartí. 2013. Healthcare impact of introduction of thyroid ultrasound in a thyroid nodule pathology unit. *Endocrinología y Nutrición (English Edition)* **60**, 53-59. [[CrossRef](#)]
1335. D.W. Lee, Y.B. Ji, E.S. Sung, J.S. Park, Y.J. Lee, D.W. Park, K. Tae. 2013. Roles of ultrasonography and computed tomography in the surgical management of cervical lymph node metastases in papillary thyroid carcinoma. *European Journal of Surgical Oncology (EJSO)* **39**, 191-196. [[CrossRef](#)]
1336. Iñaki Argüelles, Santiago Tofé. 2013. Relevancia de la ecografía en un servicio de endocrinología. *Endocrinología y Nutrición* **60**, 51-52. [[CrossRef](#)]
1337. M. Barczyński, A. Konturek, M. Stopa, W. Nowak. 2013. Prophylactic central neck dissection for papillary thyroid cancer. *British Journal of Surgery* **100**:10.1002/bjs.v100.3, 410-418. [[CrossRef](#)]
1338. Ignasi Castells, Núria Pardo, Sebastián Videla, Gabriel Giménez, Esteve Llargues, Olga Simó, María Asunción Recasens, Xavier Guirao, Xavier Mira, Àngel Serrano, Anna Sanmartí. 2013. Impacto asistencial tras la introducción de la ecografía tiroidea en una unidad monográfica de atención al nódulo tiroideo. *Endocrinología y Nutrición* **60**, 53-59. [[CrossRef](#)]
1339. Robert L. Witt, Robert L. Ferris, Edmund A. Pribitkin, Steven I. Sherman, David L. Steward, Yuri E. Nikiforov. 2013. Diagnosis and management of differentiated thyroid cancer using molecular biology. *The Laryngoscope* n/a-n/a. [[CrossRef](#)]
1340. Guldeniz Karadeniz Cakmak, Ali U. Emre, Oge Tascilar, Fatma A. Gultekin, Sukru O. Ozdamar, Mustafa Comert. 2013. Diagnostic adequacy of surgeon-performed ultrasound-guided fine needle aspiration biopsy of thyroid nodules. *Journal of Surgical Oncology* **107**:10.1002/jso.v107.2, 206-210. [[CrossRef](#)]
1341. Paolo Goffredo, Sanziana A. Roman, Julie A. Sosa. 2013. Hurthle cell carcinoma. *Cancer* **119**, 504-511. [[CrossRef](#)]
1342. Shuqi Wu, Hui Wang. 2013. Efficacy analysis of 131I therapy and predictive value of preablation stimulated thyroglobulin for lung metastases from differentiated thyroid cancer. *Annales d'Endocrinologie* **74**, 40-44. [[CrossRef](#)]
1343. Iñaki Argüelles, Santiago Tofé. 2013. Importance of ultrasound in a department of endocrinology. *Endocrinología y Nutrición (English Edition)* **60**, 51-52. [[CrossRef](#)]
1344. Sergio Donnay Candil, Juan José Gorgojo Martínez, Helena Requejo Salinas, Elena López Hernández, Francisca Almodóvar Ruiz, Mercedes Mitjavila Casanovas, Fernando Pinedo Moraleda. 2013. A retrospective cohort study of patients diagnosed of thyroid cancer in the southwest Madrid area. Predictive factors in differentiated thyroid cancer. *Endocrinología y Nutrición (English Edition)* **60**, 60-68. [[CrossRef](#)]
1345. Sergio Donnay Candil, Juan José Gorgojo Martínez, Helena Requejo Salinas, Elena López Hernández, Francisca Almodóvar Ruiz, Mercedes Mitjavila Casanovas, Fernando Pinedo Moraleda. 2013. Estudio de cohorte retrospectivo de pacientes diagnosticados de cáncer de tiroides del área suroeste de Madrid. Factores pronósticos en el cáncer diferenciado de tiroides. *Endocrinología y Nutrición* **60**, 60-68. [[CrossRef](#)]

1346. Kyung-Eun Kim, Eun-Kyung Kim, Jung Hyun Yoon, Kyung Hwa Han, Hee Jung Moon, Jin Young Kwak. 2013. Preoperative Prediction of Central Lymph Node Metastasis in Thyroid Papillary Microcarcinoma Using Clinicopathologic and Sonographic Features. *World Journal of Surgery* **37**, 385-391. [[CrossRef](#)]
1347. Naoyoshi Onoda, Tetsuro Ishikawa, Hidemi Kawajiri, Tsutomu Takashima, Kosei Hirakawa. 2013. Pattern of initial metastasis in the cervical lymph node from papillary thyroid carcinoma. *Surgery Today* **43**, 178-184. [[CrossRef](#)]
1348. Tobias Carling, Robert Udelsman. 2013. Thyroid Cancer. *Annual Review of Medicine* **65**, 131125172419005. [[CrossRef](#)]
1349. Yasuhiro Ito, Yuri E. Nikiforov, Martin Schlumberger, Riccardo Vigneri. 2013. Increasing incidence of thyroid cancer: controversies explored. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1350. A. S. Alzahrani, M. Xing. 2013. Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. *Endocrine Related Cancer* **20**, 13-22. [[CrossRef](#)]
1351. M. J. Jeon, J. H. Yoon, J. M. Han, J. H. Yim, S. J. Hong, D. E. Song, J.-S. Ryu, T. Y. Kim, Y. K. Shong, W. B. Kim. 2013. The prognostic value of the metastatic lymph node ratio and maximal metastatic tumor size in pathological N1a papillary thyroid carcinoma. *European Journal of Endocrinology* **168**, 219-225. [[CrossRef](#)]
1352. Thomas J. Gal, Michele Streeter, Jessica Burris, Mahesh Kudrimoti, Kenneth B. Ain, Joseph Valentino. 2013. Quality of Life Impact of External Beam Radiotherapy for Advanced Thyroid Carcinoma. *Thyroid* **23**:1, 64-69. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1353. Ji Hye Yim, Eui Young Kim, Won Bae Kim, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Gyungyub Gong, Suck Joon Hong, Jong Ho Yoon, Young Kee Shong. 2013. Long-Term Consequence of Elevated Thyroglobulin in Differentiated Thyroid Cancer. *Thyroid* **23**:1, 58-63. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1354. Rhys John, Nic Christofides, Carole A. Spencer, David Wild. *Thyroid* 673-693. [[CrossRef](#)]
1355. Luca Giovanella, Massimo Bongiovanni, Pierpaolo Trimboli. 2013. Diagnostic value of thyroglobulin assay in cervical lymph node fine-needle aspirations for metastatic differentiated thyroid cancer. *Current Opinion in Oncology* **25**, 6-13. [[CrossRef](#)]
1356. S. Dießl, F. Verburg, J. Biko, B. Schryen, C. Reiners, A. Buck, H. Hänscheid. 2013. Improved follow-up of patients with differentiated thyroid carcinoma. *Nuklearmedizin* **52**. . [[CrossRef](#)]
1357. Seulkee Park, Jun Soo Jeong, Haeng Rang Ryu, Cho-Rok Lee, Jae Hyun Park, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park. 2013. Differentiated Thyroid Carcinoma of Children and Adolescents: 27-Year Experience in the Yonsei University Health System. *Journal of Korean Medical Science* **28**, 693. [[CrossRef](#)]
1358. M. Meixner, M. Hellmich, M. Dietlein, C. Kobe, H. Schicha, M. Schmidt. 2013. Disease-free survival in papillary and follicular thyroid carcinoma. *Nuklearmedizin* **52**. . [[CrossRef](#)]
1359. Jin Young Kwak, Inkyung Jung, Jung Hwan Baek, Seon Mi Baek, Nami Choi, Yoon Jung Choi, So Lyung Jung, Eun-Kyung Kim, Jeong-Ah Kim, Ji-hoon Kim, Kyu Sun Kim, Jeong Hyun Lee, Joon Hyung Lee, Hee Jung Moon, Won-Jin Moon, Jeong Seon Park, Ji Hwa Ryu, Jung Hee Shin, Eun Ju Son, Jin Yong Sung, Dong Gyu Na. 2013. Image Reporting and Characterization System for Ultrasound Features of Thyroid Nodules: Multicentric Korean Retrospective Study. *Korean Journal of Radiology* **14**, 110. [[CrossRef](#)]
1360. John S. Abele. 2013. Thyroid Ultrasound-Guided Fine-Needle Aspiration. *Pathology Case Reviews* **18**, 25-27. [[CrossRef](#)]
1361. Byeong-Cheol Ahn, Won Kee Lee, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee. 2013. Estimation of True Serum Thyroglobulin Concentration Using Simultaneous Measurement of Serum Antithyroglobulin Antibody. *International Journal of Endocrinology* **2013**, 1-7. [[CrossRef](#)]
1362. Tracy S. Wang, Kevin Cheung, Forough Farrokhyar, Sanziana A. Roman, Julie Ann Sosa. 2013. A Meta-analysis of the Effect of Prophylactic Central Compartment Neck Dissection on Locoregional Recurrence Rates in Patients with Papillary Thyroid Cancer. *Annals of Surgical Oncology* **20**:11, 3477. [[CrossRef](#)]
1363. Hee Jung Suh, Hee Jung Moon, Jin Young Kwak, Ji Soo Choi, Eun-Kyung Kim. 2013. Anaplastic Thyroid Cancer: Ultrasonographic Findings and the Role of Ultrasonography-Guided Fine Needle Aspiration Biopsy. *Yonsei Medical Journal* **54**, 1400. [[CrossRef](#)]
1364. Mona Sabra, R. Tuttle. 2013. Recombinant Human Thyroid-Stimulating Hormone to Stimulate 131-I Uptake for Remnant Ablation and Adjuvant Therapy. *Endocrine Practice* **19**, 149-156. [[CrossRef](#)]
1365. P.E. Goretzki, K. Schwarz, B. Lammers. 2013. Chirurgie der Schilddrüsenmalignome. *HNO* **61**, 71-83. [[CrossRef](#)]
1366. Tsai-Wei Huang, Jun-Hung Lai, Mei-Yi Wu, Shiah-Lian Chen, Chih-Hsiung Wu, Ka-Wai Tam. 2013. Systematic review of clinical practice guidelines in the diagnosis and management of thyroid nodules and cancer. *BMC Medicine* **11**, 191. [[CrossRef](#)]



1367. Ningjian Wang, Hualing Zhai, Yingli Lu. 2013. Is fluorine-18 fluorodeoxyglucose positron emission tomography useful for the thyroid nodules with indeterminate fine needle aspiration biopsy? a meta-analysis of the literature. *Journal of Otolaryngology - Head & Neck Surgery* **42**, 38. [[CrossRef](#)]
1368. J. Ratour, M. Polivka, H. Dahan, L. Hamzi, R. Kania, M. L. Dumuis, R. Cohen, M. Laloi-Michelin, B. Cochand-Priollet. 2013. Diagnosis of Follicular Lesions of Undetermined Significance in Fine-Needle Aspirations of Thyroid Nodules. *Journal of Thyroid Research* **2013**, 1-6. [[CrossRef](#)]
1369. John S. Abele. 2013. Thyroid Ultrasound-Guided Fine-Needle Aspiration. *Pathology Case Reviews* **18**, 28-30. [[CrossRef](#)]
1370. Giuseppina Napolitano, Antonio Romeo, Andrea Bianco, Maurizio Gasperi, Pio Zeppa, Luca Brunese. 2013. B-Flow Twinkling Sign in Preoperative Evaluation of Cervical Lymph Nodes in Patients with Papillary Thyroid Carcinoma. *International Journal of Endocrinology* **2013**, 1-7. [[CrossRef](#)]
1371. Raghunandan Venkat, Marlon A. Guerrero. 2013. Recent Advances in the Surgical Treatment of Differentiated Thyroid Cancer: A Comprehensive Review. *The Scientific World Journal* **2013**, 1-7. [[CrossRef](#)]
1372. Zbigniew Adamczewski, Andrzej Lewiński. 2013. Proposed algorithm for management of patients with thyroid nodules/focal lesions, based on ultrasound (US) and fine-needle aspiration biopsy (FNAB); our own experience. *Thyroid Research* **6**, 6. [[CrossRef](#)]
1373. Dawn M. Elfenbein, Rebecca S. Sippel. 2013. Prophylactic Central Neck Dissection Increases the Cost of Thyroid Cancer Care. *Annals of Surgical Oncology* . [[CrossRef](#)]
1374. Marjory Alana Marcello, Elaine Cristina Morari, Lucas Leite Cunha, Aline Carolina De Nadai Silva, Dirce Maria Carraro, André Lopes Carvalho, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward. 2013. P53 and Expression of Immunological Markers May Identify Early Stage Thyroid Tumors. *Clinical and Developmental Immunology* **2013**, 1-9. [[CrossRef](#)]
1375. Edward D. McAlister, David P. Goldstein, Lorne E. Rotstein. 2013. Redefining classification of central neck dissection in differentiated thyroid cancer. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1376. Yann Godbert, Benedicte Henriques-Figueiredo, Anne-Laure Cazeau, Xavier Carrat, Marc Stegen, Isabelle Soubeyran, Françoise Bonichon. 2013. A Papillary Thyroid Microcarcinoma Revealed by a Single Bone Lesion with No Poor Prognostic Factors. *Case Reports in Endocrinology* **2013**, 1-4. [[CrossRef](#)]
1377. Rossella Elisei, Cristina Romei. 2013. Calcitonin estimation in patients with nodular goiter and its significance for early detection of MTC: european comments to the guidelines of the American Thyroid Association. *Thyroid Research* **6**, S2. [[CrossRef](#)]
1378. Jonathan B. Mitchem, William E. Gillanders. 2013. Endoscopic and Robotic Thyroidectomy for Cancer. *Surgical Oncology Clinics of North America* **22**, 1-13. [[CrossRef](#)]
1379. Christopher K Breuer, Daniel Solomon, Patricia Donovan, Scott A Rivkees, Robert Udelsman. 2013. Effect of patient Age on surgical outcomes for Graves' disease: a case-control study of 100 consecutive patients at a high volume thyroid surgical center. *International Journal of Pediatric Endocrinology* **2013**, 1. [[CrossRef](#)]
1380. Mazin Merdad, Antoine Eskander, Teresa Kroeker, Jeremy L. Freeman. 2013. Metastatic papillary thyroid cancer with lateral neck disease: Pattern of spread by level. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1381. Guglielmo Ardito, Luca Revelli, Erika Giustozzi, Massimo Salvatori, Guido Fadda, Francesco Ardito, Nicola Avenia, Alice Ferretti, Lucia Rampin, Sotirios Chondrogiannis, Patrick M. Colletti, Domenico Rubello. 2013. Aggressive Papillary Thyroid Microcarcinoma. *Clinical Nuclear Medicine* **38**, 25-28. [[CrossRef](#)]
1382. Jin Young Kwak. 2013. Indications for Fine Needle Aspiration in Thyroid Nodules. *Endocrinology and Metabolism* **28**, 81. [[CrossRef](#)]
1383. Robert W. Frank, Laura Middleton, Brendan C. Stack Jr, Horace J. Spencer, Ann T. Riggs, Donald L. Bodenner. 2013. Conservative management of thyroglobulin-positive, nonlocalizable thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1384. Melia Karakose, Oguz Hasdemir, Erman Cakal, Tuncay Delibasi. 2013. A rare coexistence of non-functional adrenocortical carcinoma and multicentric papillary thyroid microcarcinoma: a case report. *Journal of Medical Case Reports* **7**, 200. [[CrossRef](#)]
1385. Edward J. Mathes. 2013. Ultrasound-Guided Biopsies of Superficial Structures (Thyroid and Lymph Nodes). *Ultrasound Clinics* . [[CrossRef](#)]
1386. Hea Min Yu, Jae Min Lee, Kang Seo Park, Tae Sun Park, Heung Young Jin. 2013. Papillary Thyroid Carcinoma: Four Cases Required Caution during Long-Term Follow-Up. *Endocrinology and Metabolism* **28**, 335. [[CrossRef](#)]
1387. Jie Liu, Xiaolei Wang, Shaoyan Liu, Xiangyang Liu, Pingzhang Tang, Zhengang Xu. 2013. Superior Mediastinal Dissection for Papillary Thyroid Carcinoma: Approaches and Outcomes. *ORL* **75**, 228-239. [[CrossRef](#)]
1388. Melanie Goldfarb, Stephen F. Sener. 2013. Comparison of Radioiodine Utilization in Adolescent and Young Adult (AYA) and Older Thyroid Cancers Patients. *Endocrine Practice* **1**, 1-20. [[CrossRef](#)]
1389. Linda Barbour Thyroid disease in pregnancy 318-333. [[CrossRef](#)]

1390. Gina M. Howell, Marina N. Nikiforova, Sally E. Carty, Michael J. Armstrong, Steven P. Hodak, Michael T. Stang, Kelly L. McCoy, Yuri E. Nikiforov, Linwah Yip. 2013. BRAF V600E Mutation Independently Predicts Central Compartment Lymph Node Metastasis in Patients with Papillary Thyroid Cancer. *Annals of Surgical Oncology* **20**, 47-52. [[CrossRef](#)]
1391. Leslie S. Wu, Stacey A. Milan. 2013. Management of microcarcinomas (papillary and medullary) of the thyroid. *Current Opinion in Oncology* **25**, 27-32. [[CrossRef](#)]
1392. Khalid Ahmad Al-Sindi, Mulazim Hussain Bukhari, Kanwal Saba, Wajid Ali, Madiha Arshad, Nasir Raza Zaidi. 2013. Evaluation of non-palpable thyroid nodules by ultra sound guided fine needle aspiration cytology. *Natural Science* **05**, 214-220. [[CrossRef](#)]
1393. Gabriella Pellegriti, Francesco Frasca, Concetto Regalbuto, Sebastiano Squatrito, Riccardo Vigneri. 2013. Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk Factors. *Journal of Cancer Epidemiology* **2013**, 1-10. [[CrossRef](#)]
1394. Kyung Won Kim. 2013. Natural Course of Benign Thyroid Nodules. *Endocrinology and Metabolism* **28**, 94. [[CrossRef](#)]
1395. Fernanda Vaisman, Denise Momesso, Daniel A. Bulzico, Cencita H. C. N. Pessoa, Manuel Domingos Gonçalves da Cruz, Fernando Dias, Rossana Corbo, Mario Vaisman, R. Michael Tuttle. 2013. Thyroid Lobectomy Is Associated with Excellent Clinical Outcomes in Properly Selected Differentiated Thyroid Cancer Patients with Primary Tumors Greater Than 1cm. *Journal of Thyroid Research* **2013**, 1-5. [[CrossRef](#)]
1396. Won Jin Kim, Min Jung Bae, Yang Seon Yi, Yun Kyung Jeon, Sang Soo Kim, Bo Hyun Kim, In Joo Kim. 2013. Clinicopathologic Characteristics of Papillary Microcarcinoma in the Elderly. *Journal of Korean Thyroid Association* **6**, 69. [[CrossRef](#)]
1397. Mina Park, So Park, Eun-Kyung Kim, Jung Yoon, Hee Moon, Hye Lee, Jin Kwak. 2013. Heterogeneous echogenicity of the underlying thyroid parenchyma: how does this affect the analysis of a thyroid nodule?. *BMC Cancer* **13**, 550. [[CrossRef](#)]
1398. Jean Tramalloni, Hervé Monpeyssen Nodules 43-68. [[CrossRef](#)]
1399. Xiang Shen, Zhi-ming Miao, Wei Lu, Da-li Gu, Dan Yang, Hao Shen, Feng Geng. 2013. Clinical experience with modified Miccoli's endoscopic thyroidectomy for treatment of thyroid carcinoma in 86 cases. *European Journal of Medical Research* **18**, 51. [[CrossRef](#)]
1400. Enke Baldini, Salvatore Sorrenti, Cira Di Gioia, Corrado De Vito, Alessandro Antonelli, Lucio Gnassi, Giovanni Carbotta, Eleonora D'Armiento, Paolo Miccoli, Enrico De Antoni, Salvatore Ulisse. 2013. Cervical lymph node metastases from thyroid cancer: does thyroglobulin and calcitonin measurement in fine needle aspirates improve the diagnostic value of cytology?. *BMC Clinical Pathology* **13**, 7. [[CrossRef](#)]
1401. Blair A Williams, Martin J Bullock, Jonathan R Trites, S Mark Taylor, Robert D Hart. 2013. Rates of thyroid malignancy by FNA diagnostic category. *Journal of Otolaryngology - Head & Neck Surgery* **42**, 61. [[CrossRef](#)]
1402. William J. Georgitis Thyroid nodules and goiter 295-300. [[CrossRef](#)]
1403. Kimberly M. Creach, Brian Nussenbaum, Barry A. Siegel, Perry W. Grigsby. 2013. Thyroid carcinoma uptake of 18F-Fluorodeoxyglucose in patients with elevated serum thyroglobulin and negative 131I scintigraphy. *American Journal of Otolaryngology* **34**, 51-56. [[CrossRef](#)]
1404. Shokouh Taghipour Zahir, Fariba Binesh, Mehrdad Mirouliaei, Elias Khajeh, Sina Noshad. 2013. Malignancy Risk Assessment in Patients with Thyroid Nodules Using Classification and Regression Trees. *Journal of Thyroid Research* **2013**, 1-9. [[CrossRef](#)]
1405. Kwang Min Kim, Joon Beom Park, Seong Joon Kang, Keum Seok Bae. 2013. Ultrasonographic guideline for thyroid nodules cytology: single institute experience. *Journal of the Korean Surgical Society* **84**, 73. [[CrossRef](#)]
1406. J. Lemb, M. Hüfner, B. Meller, K. Homayounfar, C. Sahlmann, J. Meller. 2013. How reliable is secondary risk stratification with stimulated thyroglobulin in patients with differentiated thyroid carcinoma?. *Nuklearmedizin* **52**, 88-96. [[CrossRef](#)]
1407. C. M. Hong, B.-C. Ahn, S. Y. Jeong, S.-W. Lee, J. Lee. 2013. Distant metastatic lesions in patients with differentiated thyroid carcinoma. *Nuklearmedizin* **52**, 121-129. [[CrossRef](#)]
1408. Yon Seon Kim, Hye-Jeong Choi, Eun Sook Kim. 2013. Papillary thyroid carcinoma with thyroiditis: lymph node metastasis, complications. *Journal of the Korean Surgical Society* **85**, 20. [[CrossRef](#)]
1409. Eun Sun Lee, Ji-hoon Kim, Dong Gyu Na, Jin Chul Paeng, Hye Sook Min, Seung Hong Choi, Chul Ho Sohn, Ki-Hyun Chang. 2013. Hyperfunction Thyroid Nodules: Their Risk for Becoming or Being Associated with Thyroid Cancers. *Korean Journal of Radiology* **14**, 643. [[CrossRef](#)]
1410. Se Hyun Paek, Young Mi Lee, Sun Young Min, Seok Won Kim, Ki Wook Chung, Yeo Kyu Youn. 2013. Risk Factors of Hypoparathyroidism Following Total Thyroidectomy for Thyroid Cancer. *World Journal of Surgery* **37**, 94-101. [[CrossRef](#)]
1411. Emad Kandil, Barath Krishnan, Salem I. Noureldine, Lu Yao, Ralph P. Tufano. 2013. Hemithyroidectomy: A Meta-Analysis of Postoperative Need for Hormone Replacement and Complications. *ORL* **75**, 6-17. [[CrossRef](#)]

1412. Giorgio Treglia, Salvatore Annunziata, Barbara Muoio, Massimo Salvatori, Luca Ceriani, Luca Giovannella. 2013. The Role of Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography in Aggressive Histological Subtypes of Thyroid Cancer: An Overview. *International Journal of Endocrinology* **2013**, 1-6. [[CrossRef](#)]
1413. Thomas Scherer, Evelyne Wohlschlaeger-Krenn, Michaela Bayerle-Eder, Christian Passler, Angelika Reiner-Concin, Michael Krebs, Alois Gessl. 2013. A Case of simultaneous occurrence of Marine – Lenhart syndrome and a papillary thyroid microcarcinoma. *BMC Endocrine Disorders* **13**, 16. [[CrossRef](#)]
1414. Sasan Mirfakhraee, Dana Mathews, Lan Peng, Stacey Woodruff, Jeffrey M Zigman. 2013. A solitary hyperfunctioning thyroid nodule harboring thyroid carcinoma: review of the literature. *Thyroid Research* **6**, 7. [[CrossRef](#)]
1415. Jeong Hyun Lee, Yoshimi Anzai. 2013. Imaging of Thyroid and Parathyroid Glands. *Seminars in Roentgenology* **48**, 87-104. [[CrossRef](#)]
1416. Steven I. Sherman. 2013. The Role of Recombinant Human Thyrotropin for Diagnostic Monitoring of Patients with Differentiated Thyroid Cancer. *Endocrine Practice* **1**, 1-17. [[CrossRef](#)]
1417. Ji Youn Lee, Stephanie L. Lee Thyroid Disease and Women 883-897. [[CrossRef](#)]
1418. Do Sung Park, Jin Seong Cho, Min Ho Park, Young Jae Ryu, Min Jung Hwang, Sun Hyung Shin, Hee Kyung Kim, Hyo Soon Lim, Ji Shin Lee, Jung Han Yoon. 2013. Malignant thyroid bed mass after total thyroidectomy. *Journal of the Korean Surgical Society* **85**, 97. [[CrossRef](#)]
1419. David Lesnik, Mary Elizabeth Cunnane, David Zurakowski, Gul Ozbilen Acar, Cenk Ecevit, Alasdair Mace, Dipti Kamani, Gregory W. Randolph. 2013. Papillary thyroid carcinoma nodal surgery directed by a preoperative radiographic map utilizing CT scan and ultrasound in all primary and reoperative patients. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1420. Yasuhiro Maruoka, Koichiro Abe, Shingo Baba, Takuro Isoda, Yoshiyuki Kitamura, Noriko Mizoguchi, Go Akamatsu, Masayuki Sasaki, Hiroshi Honda. 2013. Usefulness of partial volume effect-corrected F-18 FDG PET/CT for predicting I-131 accumulation in the metastatic lymph nodes of patients with thyroid carcinoma. *Annals of Nuclear Medicine* **27**:10, 873. [[CrossRef](#)]
1421. Joanna Klubo-Gwiezdzinska, Kenneth Burman, Douglas Van Nostrand, Mihriye Mete, Jacqueline Jonklaas, Leonard Wartofsky. 2013. Potential Use of Recombinant Human Thyrotropin in the Treatment of Distant Metastases in Patients with Differentiated Thyroid Cancer. *Endocrine Practice* **19**, 139-148. [[CrossRef](#)]
1422. Jung Mi Park. 2013. Radioiodine Therapy: Review of the Empiric Fixed Dose Approaches and Their Selective Applications. *Journal of Korean Thyroid Association* **6**, 34. [[CrossRef](#)]
1423. A. Vrachimis, B. Riemann, J. Gerss, T. Maier, O. Schober. 2013. Peace of mind for patients with differentiated thyroid cancer?. *Nuklearmedizin* **52**, 115-120. [[CrossRef](#)]
1424. Eleftherios D. Spartalis, Theodore Karatzas, Petros Charalampoudis, Chrysovalantis Vergadis, Dimitrios Dimitroulis. 2013. Neglected Papillary Thyroid Carcinoma Seven Years after Initial Diagnosis. *Case Reports in Oncological Medicine* **2013**, 1-3. [[CrossRef](#)]
1425. Joshua Klopfer Thyroid cancer 301-308. [[CrossRef](#)]
1426. Matthew D. Byrne. 2013. Little gland, big problems. *OR Nurse* **7**, 22-28. [[CrossRef](#)]
1427. Dong Wook Kim. 2013. How to do it: ultrasound-guided fine-needle aspiration of thyroid nodules that commonly result in inappropriate cytology. *Clinical Imaging* **37**, 1-7. [[CrossRef](#)]
1428. Anna Simon, Margaret Zacharin Thyroid Disorders 69-95. [[CrossRef](#)]
1429. Nathan James Hayward, Simon Grodski, Meei Yeung, William R. Johnson, Jonathan Serpell. 2013. Recurrent laryngeal nerve injury in thyroid surgery: a review. *ANZ Journal of Surgery* **83**:10.1111/ans.2013.83.issue-1-2, 15-21. [[CrossRef](#)]
1430. Giorgio Grani, Anna Calvanese, Giovanni Carbotta, Mimma D'Alessandri, Angela Nesca, Marta Bianchini, Marianna Del Sordo, Angela Fumarola. 2013. Intrinsic factors affecting adequacy of thyroid nodule fine-needle aspiration cytology. *Clinical Endocrinology* **78**:10.1111/cen.2012.78.issue-1, 141-144. [[CrossRef](#)]
1431. SuSheng Miao, XiongHui Mao, Rong Pei, Cheng Xiang, YuanJing Lv, QingTao Shi, Shu Zhao, Ji Sun, ShenShan Jia. 2013. Predictive Factors for Different Subgroups of Central Lymph Node Metastasis in Unilateral Papillary Thyroid Carcinoma. *ORL* **75**, 265-273. [[CrossRef](#)]
1432. Nickolaos Pontikides, Spyridon Karras, Antonios Papagiannis, Athina Kaprara, Panagiotis Anagnostis, George Noussios, Argyrios Doumas, Apostolos Goropoulos, Ioannis Iakovou, Georgios Kotronis, Konstantinos Bantis, Gerasimos Krassas. 2013. Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Tracheal Obstruction by an Invading Well-Differentiated Thyroid Carcinoma. *Case Reports in Otolaryngology* **2013**, 1-4. [[CrossRef](#)]
1433. Christopher D. Raeburn, Jonathan A. Schoen, Robert C. McIntyre Endocrine surgery 466-486. [[CrossRef](#)]

1434. Steven Sherman. 2013. The Role of Recombinant Human Thyrotropin for Diagnostic Monitoring of Patients with Differentiated Thyroid Cancer. *Endocrine Practice* **19**, 157-161. [[CrossRef](#)]
1435. Arnaldo Piccardo, Federico Arecco, Matteo Puntoni, Luca Foppiani, Manlio Cabria, Stefania Corvisieri, Anselmo Arlandini, Vania Altrinetti, Roberto Bandelloni, Fabio Orlandi. 2013. Focus on High-Risk DTC Patients. *Clinical Nuclear Medicine* **38**, 18-24. [[CrossRef](#)]
1436. Dongbin Ahn, Jin Ho Sohn, Ji Young Park. 2013. A Case of Concurrent Papillary and Medullary Thyroid Carcinomas Detected as Recurrent Medullary Carcinoma after Initial Surgery for Papillary Carcinoma. *Journal of Korean Thyroid Association* **6**, 80. [[CrossRef](#)]
1437. John S. Abele. 2012. Putting aspiration back into thyroid fine-needle biopsy—the re-emerging role of vacuum assistance. *Cancer Cytopathology* **120**, 366-372. [[CrossRef](#)]
1438. Emad H. Kandil, Salem I. Noureldine, Ralph P. Tufano Extensive Surgery for Thyroid Cancer 67-77. [[CrossRef](#)]
1439. N. Gopalakrishna Iyer, Ashok R. Shaha Reoperative Thyroid Surgery 105-110. [[CrossRef](#)]
1440. Jeffrey J. Houlton, David L. Steward Surgery for Retrosternal/Upper Mediastinal Thyroid/Parathyroid Disease 93-103. [[CrossRef](#)]
1441. Scott A. Rivkees, Christopher K. Breuer, Robert Udelsman Thyroid Surgery in Paediatric Patients 33-42. [[CrossRef](#)]
1442. Clive S. Grant Lesions Following Lateral Neck Dissection 169-177. [[CrossRef](#)]
1443. Dana M. Hartl, Haïtham Mirghani, Daniel F. Brasnu Extensive Surgery for Thyroid Cancer 79-91. [[CrossRef](#)]
1444. Dana M. Hartl, Martin Schlumberger Extent of Thyroidectomy and Incidence of Morbidity 19-32. [[CrossRef](#)]
1445. R. C. Ferreira, L. L. Cunha, P. S. Matos, R. L. Adam, F. Soares, J. Vassallo, L. S. Ward. 2012. Chromatin changes in papillary thyroid carcinomas may predict patient outcome. *Cellular Oncology* . [[CrossRef](#)]
1446. Vincenzo Triggiani, Marco Moschetta, Vito Angelo Giagulli, Brunella Licchelli, Edoardo Guastamacchia. 2012. Diffuse <sup>131</sup>I Lung Uptake in Bronchiectasis: A Potential Pitfall in the Follow-Up of Differentiated Thyroid Carcinoma. *Thyroid* **22**:12, 1287-1290. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1447. Merica Shrestha, Barbara A. Crothers, Henry B. Burch. 2012. The Impact of Thyroid Nodule Size on the Risk of Malignancy and Accuracy of Fine-Needle Aspiration: A 10-Year Study from a Single Institution. *Thyroid* **22**:12, 1251-1256. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1448. Gaosong Wu, Xiaofei Chang, Yun Xia, Wei Huang, Wayne M. Koch. 2012. Prospective randomized trial of high versus low negative pressure suction in management of chyle fistula after neck dissection for metastatic thyroid carcinoma. *Head & Neck* **34**:10.1002/hed.v34.12, 1711-1715. [[CrossRef](#)]
1449. K. Dennis, J.H. Hay, D.C. Wilson. 2012. Effect of <sup>18</sup>F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography-guided Management of Suspected Recurrent Papillary Thyroid Carcinoma: Long-term Follow-up with Tumour Marker Responses. *Clinical Oncology* **24**, e168-e172. [[CrossRef](#)]
1450. Emily Steinhagen, José G. Guillem, Gerard Chang, Erin E. Salo-Mullen, Jinru Shia, Stephanie Fish, Zsofia K. Stadler, Arnold J. Markowitz. 2012. The Prevalence of Thyroid Cancer and Benign Thyroid Disease in Patients With Familial Adenomatous Polyposis May Be Higher Than Previously Recognized. *Clinical Colorectal Cancer* **11**, 304-308. [[CrossRef](#)]
1451. Tihana Ibrahimasic, Iain J. Nixon, Frank L. Palmer, Monica M. Witcher, Robert M. Tuttle, Ashok Shaha, Snehal G. Patel, Jatin P. Shah, Ian Ganly. 2012. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer— is there a need for radioactive iodine therapy?. *Surgery* **152**, 1096-1105. [[CrossRef](#)]
1452. J.-B. Veyrieres, F. Albarel, J. Vaillant Lombard, J. Berbis, F. Sebag, C. Oliver, P. Petit. 2012. A threshold value in Shear Wave elastography to rule out malignant thyroid nodules: A reality?. *European Journal of Radiology* **81**, 3965-3972. [[CrossRef](#)]
1453. Mira Milas, Jessica Mester, Rosemarie Metzger, Joyce Shin, Jamie Mitchell, Eren Berber, Allan E. Siperstein, Charis Eng. 2012. Should patients with Cowden syndrome undergo prophylactic thyroidectomy?. *Surgery* **152**, 1201-1210. [[CrossRef](#)]
1454. Lucas L. Cunha, Elaine C. Morari, Ana C. T. Guihen, Daniela Razolli, René Gerhard, Suely Nonogaki, Fernando A. Soares, José Vassallo, Laura S. Ward. 2012. Infiltration of a mixture of immune cells may be related to good prognosis in patients with differentiated thyroid carcinoma. *Clinical Endocrinology* **77**:10.1111/cen.2012.77.issue-6, 918-925. [[CrossRef](#)]
1455. Brian Hung-Hin Lang, Patricia Chun-Ling Yih, Tony W.-H. Shek, Koon Yat Wan, Kai Pun Wong, Chung-Yau Lo. 2012. Factors affecting the adequacy of lymph node yield in prophylactic unilateral central neck dissection for papillary thyroid carcinoma. *Journal of Surgical Oncology* **106**:10.1002/jso.v106.8, 966-971. [[CrossRef](#)]
1456. Zhaowei Meng, Shanshan Lou, Jian Tan, Ke Xu, Qiang Jia, Wei Zheng, Shen Wang. 2012. Nuclear factor-kappa B inhibition can enhance therapeutic efficacy of <sup>131</sup>I on the in vivo management of differentiated thyroid cancer. *Life Sciences* **91**, 1236-1241. [[CrossRef](#)]

1457. Jason D. Prescott, Peter M. Sadow, Richard A. Hodin, Long Phi Le, Randall D. Gaz, Gregory W. Randolph, Antonia E. Stephen, Sareh Parangi, Gilbert H. Daniels, Carrie C. Lubitz. 2012. BRAFV600E status adds incremental value to current risk classification systems in predicting papillary thyroid carcinoma recurrence. *Surgery* **152**, 984-990. [[CrossRef](#)]
1458. Tracy S. Wang, Douglas B. Evans, Gilbert G. Fareau, Ty Carroll, Tina W. Yen. 2012. Effect of Prophylactic Central Compartment Neck Dissection on Serum Thyroglobulin and Recommendations for Adjuvant Radioactive Iodine in Patients with Differentiated Thyroid Cancer. *Annals of Surgical Oncology* **19**, 4217-4222. [[CrossRef](#)]
1459. Denise Prado Momesso, Fernanda Vaisman, Cencita Hosanah Cordeiro de Noronha Pessoa, Rossana Corbo, Mario Vaisman. 2012. Small differentiated thyroid cancer: Time to reconsider clinical management and treatment. *Surgical Oncology* **21**, 257-262. [[CrossRef](#)]
1460. Zhong-Ling Qiu, Yan-Li Xue, Hong-Jun Song, Quan-Yong Luo. 2012. Comparison of the diagnostic and prognostic values of <sup>99m</sup>Tc-MDP-planar bone scintigraphy, <sup>131</sup>I-SPECT/CT and <sup>18</sup>F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. *Nuclear Medicine Communications* **33**, 1232-1242. [[CrossRef](#)]
1461. Marco Raffaelli, Carmela De Crea, Luca Sessa, Piero Giustacchini, Luca Revelli, Chiara Bellantone, Celestino Pio Lombardi. 2012. Prospective evaluation of total thyroidectomy versus ipsilateral versus bilateral central neck dissection in patients with clinically node-negative papillary thyroid carcinoma. *Surgery* **152**, 957-964. [[CrossRef](#)]
1462. Yasuhiro Maruoka, Koichiro Abe, Shingo Baba, Takuro Isoda, Hirofumi Sawamoto, Yoshitaka Tanabe, Masayuki Sasaki, Hiroshi Honda. 2012. Incremental Diagnostic Value of SPECT/CT with <sup>131</sup>I Scintigraphy after Radioiodine Therapy in Patients with Well-differentiated Thyroid Carcinoma. *Radiology* **265**, 902-909. [[CrossRef](#)]
1463. Leonard Wartofsky, Douglas Nostrand. 2012. Radioiodine treatment of well-differentiated thyroid cancer. *Endocrine* **42**, 506-513. [[CrossRef](#)]
1464. Po-Hsiang Tsui, Yung-Liang Wan, Chin-Kuo Chen. 2012. Ultrasound imaging of the larynx and vocal folds. *Current Opinion in Otolaryngology & Head and Neck Surgery* **20**, 437-442. [[CrossRef](#)]
1465. Markus Luster, Thomas J. Musholt. 2012. Thyroid gland: Thyroid surgery and radioiodine ablation—the surgeon's role. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1466. Ma Luisa Isidro, Gloria Lugo, Olga Fidalgo, Sara García-Arias. 2012. Adequacy of Pathology Reports of Specimens from Patients with Differentiated Thyroid Cancer. *Endocrine Pathology* . [[CrossRef](#)]
1467. Graziano Ceresini, Luigi Corcione, Maria Michiara, Paolo Sgargi, Giulio Teresi, Annalisa Gilli, Elisa Usberti, Enrico Silini, Gian Paolo Ceda. 2012. Thyroid cancer incidence by histological type and related variants in a mildly iodine-deficient area of Northern Italy, 1998 to 2009. *Cancer* **118**:10.1002/cncr.v118.22, 5473-5480. [[CrossRef](#)]
1468. Pedro Wesley Rosario, Augusto Flávio Campos Mineiro Filho, Brenda Sá Senna Prates, Livia Cristina Oliveira Silva, Maria Regina Calsolari. 2012. Postoperative Stimulated Thyroglobulin of Less Than 1ng/mL as a Criterion to Spare Low-Risk Patients with Papillary Thyroid Cancer from Radioactive Iodine Ablation. *Thyroid* **22**:11, 1140-1143. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1469. Pedro Wesley Rosario, Mariana de Souza Furtado, Augusto Flávio Campos Mineiro Filho, Rafaela Xavier Lacerda, Maria Regina Calsolari. 2012. Value of Diagnostic Radioiodine Whole-Body Scanning After Initial Therapy in Patients with Differentiated Thyroid Cancer at Intermediate and High Risk for Recurrence. *Thyroid* **22**:11, 1165-1169. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1470. Gregory W. Randolph, Quan-Yang Duh, Keith S. Heller, Virginia A. LiVolsi, Susan J. Mandel, David L. Steward, Ralph P. Tufano, R. Michael Tuttle, for the American Thyroid Association Surgical Affairs Committee's Taskforce on Thyroid Cancer Nodal Surgery. 2012. The Prognostic Significance of Nodal Metastases from Papillary Thyroid Carcinoma Can Be Stratified Based on the Size and Number of Metastatic Lymph Nodes, as Well as the Presence of Extranodal Extension. *Thyroid* **22**:11, 1144-1152. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1471. Robert C. Smallridge, Kenneth B. Ain, Sylvia L. Asa, Keith C. Bible, James D. Brierley, Kenneth D. Burman, Electron Kebebew, Nancy Y. Lee, Yuri E. Nikiforov, M. Sara Rosenthal, Manisha H. Shah, Ashok R. Shaha, R. Michael Tuttle for the American Thyroid Association Anaplastic Thyroid Cancer Guidelines Taskforce. 2012. American Thyroid Association Guidelines for Management of Patients with Anaplastic Thyroid Cancer. *Thyroid* **22**:11, 1104-1139. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
1472. Marin Prpic, Nina Dabelic, Josip Stanicic, Tomislav Jukic, Milan Milosevic, Zvonko Kusic. 2012. Adjuvant thyroid remnant ablation in patients with differentiated thyroid carcinoma confined to the thyroid: a comparison of ablation success with different activities of radioiodine (<sup>131</sup>I). *Annals of Nuclear Medicine* **26**, 744-751. [[CrossRef](#)]
1473. J. Tramalloni, J.L. Wémeau. 2012. Consensus français sur la prise en charge du nodule thyroïdien : ce que le radiologue doit connaître. *EMC - Radiologie et imagerie médicale - Cardiovasculaire - Thoracique - Cervicale* **7**, 1-18. [[CrossRef](#)]

1474. Hyun Kyung Lim, Jeong Hyun Lee, Eun Ju Ha, Jin Young Sung, Jae Kyun Kim, Jung Hwan Baek. 2012. Radiofrequency ablation of benign non-functioning thyroid nodules: 4-year follow-up results for 111 patients. *European Radiology* . [[CrossRef](#)]
1475. Giorgio Treglia, Barbara Muoio, Luca Giovanella, Massimo Salvatori. 2012. The role of positron emission tomography and positron emission tomography/computed tomography in thyroid tumours: an overview. *European Archives of Oto-Rhino-Laryngology* . [[CrossRef](#)]
1476. Daniel S. Duick, Joshua P. Klopper, James C. Diggans, Lyssa Friedman, Giulia C. Kennedy, Richard B. Lanman, Bryan McIver. 2012. The Impact of Benign Gene Expression Classifier Test Results on the Endocrinologist–Patient Decision to Operate on Patients with Thyroid Nodules with Indeterminate Fine-Needle Aspiration Cytopathology. *Thyroid* **22**:10, 996-1001. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1477. Jonathan Hugo, Eyal Robenshtok, Ravinder Grewal, Steve Larson, R. Michael Tuttle. 2012. Recombinant Human Thyroid Stimulating Hormone–Assisted Radioactive Iodine Remnant Ablation in Thyroid Cancer Patients at Intermediate to High Risk of Recurrence. *Thyroid* **22**:10, 1007-1015. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1478. Uğur Ünlütürk, Murat Faik Erdoğan, Özgür Demir, Sevim Güllü, Nilgün Başkal. 2012. Ultrasound Elastography Is Not Superior to Grayscale Ultrasound in Predicting Malignancy in Thyroid Nodules. *Thyroid* **22**:10, 1031-1038. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1479. Brian Hung-Hin Lang, Alex H. Tang, Kai Pun Wong, Tony W. Shek, Koon Yat Wan, Chung-Yau Lo. 2012. Significance of Size of Lymph Node Metastasis on Postsurgical Stimulated Thyroglobulin Levels After Prophylactic Unilateral Central Neck Dissection in Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* **19**, 3472-3478. [[CrossRef](#)]
1480. Avital Harari, Rebecca S. Sippel, Ruth Goldstein, Seerat Aziz, Wen Shen, Jessica Gosnell, Quan-Yang Duh, Orlo H. Clark. 2012. Successful Localization of Recurrent Thyroid Cancer in Reoperative Neck Surgery Using Ultrasound-Guided Methylene Blue Dye Injection. *Journal of the American College of Surgeons* **215**, 555-561. [[CrossRef](#)]
1481. Concetto Regalbuto, Francesco Frasca, Gabriella Pellegriti, Pasqualino Malandrino, Ilenia Marturano, Isidoro Di Carlo, Vincenzo Pezzino. 2012. Update on thyroid cancer treatment. *Future Oncology* **8**, 1331-1348. [[CrossRef](#)]
1482. Stephanie L. Lee. 2012. Radioactive iodine therapy. *Current Opinion in Endocrinology & Diabetes and Obesity* **19**, 420-428. [[CrossRef](#)]
1483. Selena Liao, Maisie Shindo. 2012. Management of Well-Differentiated Thyroid Cancer. *Otolaryngologic Clinics of North America* **45**, 1163-1179. [[CrossRef](#)]
1484. F. Pacini, M. G. Castagna, L. Brilli, G. Pentheroudakis. 2012. Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Annals of Oncology* **23**, vii110-vii119. [[CrossRef](#)]
1485. Maria B. Albuja-Cruz, Chad M. Thorson, Bassan J. Allan, John I. Lew, Steven E. Rodgers. 2012. Number of lymph nodes removed during modified radical neck dissection for papillary thyroid cancer does not influence lateral neck recurrence. *Surgery* . [[CrossRef](#)]
1486. Kelly L. McCoy, Sally E. Carty, Michael J. Armstrong, Raja R. Seethala, N. Paul Otori, Adam S. Kabaker, Michael T. Stang, Steven P. Hodak, Yuri E. Nikiforov, Linwah Yip. 2012. Intraoperative Pathologic Examination in the Era of Molecular Testing for Differentiated Thyroid Cancer. *Journal of the American College of Surgeons* **215**, 546-554. [[CrossRef](#)]
1487. Jingdong Zhang, Peng Wang, Mark Dykstra, Pascale Gelebart, David Williams, Robert Ingham, Esther Ekpe Adewuyi, Raymond Lai, Todd McMullen. 2012. Platelet-derived growth factor receptor- $\alpha$  promotes lymphatic metastases in papillary thyroid cancer. *The Journal of Pathology* **228**:10.1002/path.v228.2, 241-250. [[CrossRef](#)]
1488. Chandrasekhar Bal, Prem Chandra, Ajay Kumar, Sadanand Dwivedi. 2012. A randomized equivalence trial to determine the optimum dose of iodine-131 for remnant ablation in differentiated thyroid cancer. *Nuclear Medicine Communications* **33**, 1039-1047. [[CrossRef](#)]
1489. Kathleen C. Lee, Carol Li, Eric B. Schneider, Yongchun Wang, Helina Somervell, Matthew Krafft, Christopher B. Umbricht, Martha A. Zeiger. 2012. Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer?. *Surgery* . [[CrossRef](#)]
1490. Wen-Bin Yu, Song-Yun Tao, Nai-Song Zhang. 2012. Is Level V Dissection Necessary for Low-risk Patients with Papillary Thyroid Cancer Metastasis in Lateral Neck Levels II, III, and IV. *Asian Pacific Journal of Cancer Prevention* **13**, 4619-4622. [[CrossRef](#)]
1491. Valerie A. Smith, Roy B. Sessions, Eric J. Lentsch. 2012. Cervical lymph node metastasis and papillary thyroid carcinoma: Does the compartment involved affect survival? Experience from the SEER database. *Journal of Surgical Oncology* **106**:10.1002/jso.v106.4, 357-362. [[CrossRef](#)]
1492. Davide Giordano, Roberto Valcavi, Geoffrey B. Thompson, Corrado Pedroni, Luigi Renna, Paolo Gradoni, Verter Barbieri. 2012. Complications of Central Neck Dissection in Patients with Papillary Thyroid Carcinoma: Results of a Study on 1087 Patients and Review of the Literature. *Thyroid* **22**:9, 911-917. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

1493. Kerstin Kathrine Soelberg, Steen Joop Bonnema, Thomas Heiberg Brix, Laszlo Hegedüs. 2012. Risk of Malignancy in Thyroid Incidentalomas Detected by 18F-Fluorodeoxyglucose Positron Emission Tomography: A Systematic Review. *Thyroid* **22**:9, 918-925. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1494. Rosália P. Padovani, Teresa S. Kasamatsu, Claudia C.D. Nakabashi, Cleber P. Camacho, Danielle M. Andreoni, Eduardo Z. Malouf, Marília M.S. Marone, Rui M.B. Maciel, Rosa Paula M. Biscolla. 2012. One Month Is Sufficient for Urinary Iodine to Return to Its Baseline Value After the Use of Water-Soluble Iodinated Contrast Agents in Post-Thyroidectomy Patients Requiring Radioiodine Therapy. *Thyroid* **22**:9, 926-930. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1495. Mona M. Sabra, Ravinder K. Grewal, Hernan Tala, Steve M. Larson, R. Michael Tuttle. 2012. Clinical Outcomes Following Empiric Radioiodine Therapy in Patients with Structurally Identifiable Metastatic Follicular Cell-Derived Thyroid Carcinoma with Negative Diagnostic But Positive Post-Therapy 131I Whole-Body Scans. *Thyroid* **22**:9, 877-883. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1496. Iain J. Nixon, Monica M. Whitcher, Frank L. Palmer, R. Michael Tuttle, Ashok R. Shaha, Jatin P. Shah, Snehal G. Patel, Ian Ganly. 2012. The Impact of Distant Metastases at Presentation on Prognosis in Patients with Differentiated Carcinoma of the Thyroid Gland. *Thyroid* **22**:9, 884-889. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1497. Robin P. Peeters, Theo J. Visser. 2012. How to Make a Thyroid Hypothyroid. *Thyroid* **22**:9, 867-869. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1498. Seema Singh, Anutosh Singh, A. K. Khanna. 2012. Thyroid Incidentaloma. *Indian Journal of Surgical Oncology* **3**, 173-181. [[CrossRef](#)]
1499. E. Robenshtok, R. Michael Tuttle. 2012. Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer. *Indian Journal of Surgical Oncology* **3**, 182-189. [[CrossRef](#)]
1500. David T. Hughes, Amanda M. Laird, Barbra S. Miller, Paul G. Gauger, Gerard M. Doherty. 2012. Reoperative Lymph Node Dissection for Recurrent Papillary Thyroid Cancer and Effect on Serum Thyroglobulin. *Annals of Surgical Oncology* **19**, 2951-2957. [[CrossRef](#)]
1501. Yu-rong Hong, Yu-lian Wu, Zhi-yan Luo, Ning-bo Wu, Xue-ming Liu. 2012. Impact of nodular size on the predictive values of gray-scale, color-Doppler ultrasound, and sonoelastography for assessment of thyroid nodules. *Journal of Zhejiang University SCIENCE B* **13**, 707-716. [[CrossRef](#)]
1502. Javier Martínez Trufero, Jaume Capdevila, Juan Jesús Cruz, Dolores Isla. 2012. In answer to: "Comments to SEOM clinical guidelines for the treatment of thyroid cancer" by Garcilaso Riesco-Eizaguirre et al. *Clinical and Translational Oncology* **14**, 711-712. [[CrossRef](#)]
1503. Devendra A. Chaukar, Abhishek D. Vaidya. 2012. Pediatric Thyroid Cancers: An Indian Perspective. *Indian Journal of Surgical Oncology* **3**, 166-172. [[CrossRef](#)]
1504. Lawrence Q. Wong, Zubair W. Baloch. 2012. Analysis of the Bethesda System for Reporting Thyroid Cytopathology and Similar Precursor Thyroid Cytopathology Reporting Schemes. *Advances In Anatomic Pathology* **19**, 313-319. [[CrossRef](#)]
1505. Richard O Wein. 2012. Why is there such a poor prognosis associated with anaplastic thyroid carcinoma?. *Expert Review of Endocrinology & Metabolism* **7**, 483-485. [[CrossRef](#)]
1506. Nidhi Aggarwal, Steven H Swerdlow, Lindsey M Kelly, Jennifer B Ogilvie, Mariana N Nikiforova, Malini Sathanoori, Yuri E Nikiforov. 2012. Thyroid carcinoma-associated genetic mutations also occur in thyroid lymphomas. *Modern Pathology* **25**, 1203-1211. [[CrossRef](#)]
1507. Furio Pacini, Yasuhiro Ito, Markus Luster, Fabian Pitoia, Bruce Robinson, Lori Wirth. 2012. Radioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directions. *Expert Review of Endocrinology & Metabolism* **7**, 541-554. [[CrossRef](#)]
1508. Irene Mancini, Pamela Pinzani, Cinzia Pupilli, Luisa Petrone, Maria Laura De Feo, Lapo Bencini, Mario Pazzagli, Gianni Forti, Claudio Orlando. 2012. A High-Resolution Melting Protocol for Rapid and Accurate Differential Diagnosis of Thyroid Nodules. *The Journal of Molecular Diagnostics* **14**, 501-509. [[CrossRef](#)]
1509. Adrienne L. Melck, Linwah Yip. 2012. Predicting malignancy in thyroid nodules: Molecular advances. *Head & Neck* **34**:10.1002/hed.v34.9, 1355-1361. [[CrossRef](#)]
1510. Ralph P. Tufano, Gilberto V. Teixeira, Justin Bishop, Kathryn A. Carson, Mingzhao Xing. 2012. BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial Treatment. *Medicine* **91**, 274-286. [[CrossRef](#)]
1511. Matthew Kim, Erik Alexander. 2012. Diagnostic Use of Molecular Markers in the Evaluation of Thyroid Nodules. *Endocrine Practice* **18**, 796-802. [[CrossRef](#)]

1512. Marcia S Brose, Johannes Smit, Jaume Capdevila, Rossella Elisei, Christopher Nutting, Fabian Pitoia, Bruce Robinson, Martin Schlumberger, Young Kee Shong, Hiroshi Takami. 2012. Regional approaches to the management of patients with advanced, radioactive iodine-refractory differentiated thyroid carcinoma. *Expert Review of Anticancer Therapy* **12**, 1137-1147. [[CrossRef](#)]
1513. Garcilaso Riesco-Eizaguirre, Juan Carlos Galofré, Carlos Zafón, Cristina Alvarez-Escolá, Emma Anda, Amparo Calleja, Sergio Donnay, Anna Lucas-Martín, Edelmiro Menéndez-Torre, Vicente Pereg, Begoña Pérez-Corral, Javier Santamaría, Jose Manuel Gómez-Sáez. 2012. Comments to SEOM clinical guidelines for the treatment of thyroid cancer. *Clinical and Translational Oncology* **14**, 709-710. [[CrossRef](#)]
1514. Qiu-li Li, Fu-jin Chen, Renchun Lai, Zhu-ming Guo, Rongzhen Luo, An-kui Yang. 2012. ZCCHC12, a potential molecular marker of papillary thyroid carcinoma: a preliminary study. *Medical Oncology* **29**, 1409-1417. [[CrossRef](#)]
1515. L. Licitra, L. D. Locati. 2012. Multikinase inhibitors in thyroid cancer. *Annals of Oncology* **23**, x328-x333. [[CrossRef](#)]
1516. Chanika Sritara, Putthiporn Charoenphun, Mathurose Ponglikitmongkol, Suchawadee Musikarat, Chirawat Utamakul, Payap Chokesuwattanasakul, Ammarin Thakkinstian. 2012. Serum Oncofetal Fibronectin (onfFN) mRNA in Differentiated Thyroid Carcinoma (DTC): Large Overlap between Disease-Free and Metastatic Patients. *Asian Pacific Journal of Cancer Prevention* **13**, 4203-4208. [[CrossRef](#)]
1517. Paul A. VanderLaan, Ellen Marqusee, Jeffrey F. Krane. 2012. Features associated with locoregional spread of papillary carcinoma correlate with diagnostic category in the Bethesda System for reporting thyroid cytopathology. *Cancer Cytopathology* **120**, 245-253. [[CrossRef](#)]
1518. J. Larry Jameson. 2012. Minimizing Unnecessary Surgery for Thyroid Nodules. *New England Journal of Medicine* **367**, 765-767. [[CrossRef](#)]
1519. Erik K. Alexander, Giulia C. Kennedy, Zubair W. Baloch, Edmund S. Cibas, Darya Chudova, James Diggans, Lyssa Friedman, Richard T. Kloos, Virginia A. LiVolsi, Susan J. Mandel, Stephen S. Raab, Juan Rosai, David L. Steward, P. Sean Walsh, Jonathan I. Wilde, Martha A. Zeiger, Richard B. Lanman, Bryan R. Haugen. 2012. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. *New England Journal of Medicine* **367**, 705-715. [[CrossRef](#)]
1520. 2012. Radioiodine Ablation in Low-Risk Thyroid Cancer. *New England Journal of Medicine* **367**, 672-675. [[CrossRef](#)]
1521. Sophie Leboulleux, Intidhar El Bez, Isabelle Borget, Manel Elleuch, Désirée Déandreis, Abir Al Ghuzlan, Cécile Chougnet, François Bidault, Haitham Mirghani, Jean Lumbroso, Dana Hartl, Eric Baudin, Martin Schlumberger. 2012. Postradioiodine Treatment Whole-Body Scan in the Era of 18-Fluorodeoxyglucose Positron Emission Tomography for Differentiated Thyroid Carcinoma with Elevated Serum Thyroglobulin Levels. *Thyroid* **22:8**, 832-838. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1522. Kiminori Sugino, Kaori Kameyama, Koichi Ito, Mitsuji Nagahama, Wataru Kitagawa, Hiroshi Shibuya, Keiko Ohkuwa, Yukiko Yano, Takashi Uruno, Junko Akaishi, Akifumi Suzuki, Chie Masaki, Kunihiko Ito. 2012. Outcomes and Prognostic Factors of 251 Patients with Minimally Invasive Follicular Thyroid Carcinoma. *Thyroid* **22:8**, 798-804. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1523. Rosália P. Padovani, Eyal Robenshtok, Matvey Brokhin, R. Michael Tuttle. 2012. Even Without Additional Therapy, Serum Thyroglobulin Concentrations Often Decline for Years After Total Thyroidectomy and Radioactive Remnant Ablation in Patients with Differentiated Thyroid Cancer. *Thyroid* **22:8**, 778-783. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1524. Pedro Wesley Rosario, Augusto Flávio Campos Mineiro Filho, Brenda Sá Senna Prates, Livia Cristina Oliveira Silva, Rafaela Xavier Lacerda, Maria Regina Calsolari. 2012. Ultrasonographic Screening for Thyroid Cancer in Siblings of Patients with Apparently Sporadic Papillary Carcinoma. *Thyroid* **22:8**, 805-808. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1525. Melanie Goldfarb, Stephan S. Gondek, Yamile Sanchez, John I. Lew. 2012. Clinic-Based Ultrasound Can Predict Malignancy in Pediatric Thyroid Nodules. *Thyroid* **22:8**, 827-831. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1526. Ji Min Han, Won Bae Kim, Ji Hye Yim, Won Gu Kim, Tae Yong Kim, Jin-Sook Ryu, Gyungyub Gong, Tae-Yon Sung, Jong Ho Yoon, Suck Joon Hong, Eui Young Kim, Young Kee Shong. 2012. Long-Term Clinical Outcome of Differentiated Thyroid Cancer Patients with Undetectable Stimulated Thyroglobulin Level One Year After Initial Treatment. *Thyroid* **22:8**, 784-790. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1527. Yan Shen, Maomei Ruan, Quanyong Luo, Yongli Yu, Hankui Lu, Ruisen Zhu, Libo Chen. 2012. Brain Metastasis from Follicular Thyroid Carcinoma: Treatment with Sorafenib. *Thyroid* **22:8**, 856-860. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]



1528. Cintia González Blanco, Eugenia Mato Matute, Alberto de Leiva Hidalgo. 2012. Molecular biomarkers involved in the tumor dedifferentiation process of thyroid carcinoma of epithelial origin: perspectives. *Endocrinología y Nutrición (English Edition)* **59**, 452-458. [[CrossRef](#)]
1529. B. Guerrier, J.-P. Berthet, C. Cartier, D. Dehesdin, A. Edet-Sanson, G. Le Clech, R. Garrel, R. Kania, M. Makeieff, C. Page, S. Poirée, G. Potard, J.-M. Prades, C. Righini, F. Roussel, M.-E. Toubert. 2012. Recommandation de la Société française d'oto-rhino-laryngologie et de chirurgie de la face et du cou pour la prise en charge ganglionnaire dans les cancers différenciés de souche folliculaire du corps thyroïde chez l'adulte. Recommandation pour la pratique clinique. *Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale* **129**, 250-260. [[CrossRef](#)]
1530. Furio Pacini. 2012. Thyroid microcarcinoma. *Best Practice & Research Clinical Endocrinology & Metabolism* **26**, 421-429. [[CrossRef](#)]
1531. B. Guerrier, J.P. Berthet, C. Cartier, D. Dehesdin, A. Edet-Sanson, G. Le Clech, R. Garrel, R. Kania, M. Makeieff, C. Page, S. Poirée, G. Potard, J.M. Prades, C. Righini, F. Roussel, M.E. Toubert. 2012. French ENT Society (SFORL) practice guidelines for lymph-node management in adult differentiated thyroid carcinoma. *European Annals of Otorhinolaryngology, Head and Neck Diseases* **129**, 197-206. [[CrossRef](#)]
1532. Álvaro Larrad Jimenez, Pedro de Quadros Borrajo, Antonio Martin Duce. 2012. Valoración del ganglio centinela en el cáncer papilar de tiroides T1-T2. Estudio preliminar. *Cirugía Española* **90**, 440-445. [[CrossRef](#)]
1533. Harvey K. Chiu, Srinath Sanda, Patricia Y. Fechner, Catherine Pihoker. 2012. Correlation of TSH with the risk of paediatric thyroid carcinoma. *Clinical Endocrinology* **77**:10.1111/cen.2012.77.issue-2, 316-322. [[CrossRef](#)]
1534. Cintia González Blanco, Eugenia Mato Matute, Alberto de Leiva Hidalgo. 2012. Biomarcadores moleculares implicados en el proceso de desdiferenciación tumoral del carcinoma de tiroides de origen epitelial: perspectivas. *Endocrinología y Nutrición* **59**, 452-458. [[CrossRef](#)]
1535. Thera P. Links, Anouk N. A. van der Horst-Schrivers. 2012. Thyroid cancer: Successful remnant ablation—what is success?. *Nature Reviews Endocrinology* **8**, 514-515. [[CrossRef](#)]
1536. Leonardo Haddad, Fernanda L. M. Haddad, Lia Bittencourt, Luis Carlos Gregório, Sergio Tufik, Marcio Abrahão. 2012. Clinical and polysomnographic findings of patients with large goiters. *Sleep and Breathing* . [[CrossRef](#)]
1537. Chisato Tomoda, Akira Miyauchi. 2012. Undetectable Serum Thyroglobulin Levels in Patients with Medullary Thyroid Carcinoma After Total Thyroidectomy Without Radioiodine Ablation. *Thyroid* **22**:7, 680-682. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1538. Justin A. Bishop, Gaosong Wu, Ralph P. Tufano, William H. Westra. 2012. Histological Patterns of Locoregional Recurrence in Hürthle Cell Carcinoma of the Thyroid Gland. *Thyroid* **22**:7, 690-694. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1539. Ralph P. Tufano, Justin Bishop, Gaosong Wu. 2012. Reoperative central compartment dissection for patients with recurrent/persistent papillary thyroid cancer: Efficacy, safety, and the association of the BRAF mutation. *The Laryngoscope* **122**:10.1002/lary.v122.7, 1634-1640. [[CrossRef](#)]
1540. Byung Hyun Byun, Ung-Gill Jeong, Sun-Pyo Hong, Jung-Joon Min, Ari Chong, Ho-Chun Song, Hee-Seung Bom. 2012. Prediction of central lymph node metastasis from papillary thyroid microcarcinoma by 18F-fluorodeoxyglucose PET/CT and ultrasonography. *Annals of Nuclear Medicine* **26**, 471-477. [[CrossRef](#)]
1541. Robert Levine. 2012. Current Guidelines for the Management of Thyroid Nodules. *Endocrine Practice* **18**, 596-599. [[CrossRef](#)]
1542. K. Weber, F. Berger, M. Mustafa, M.F. Reiser, P. Bartenstein, A. Haug. 2012. SPECT/CT zum initialen Staging und Therapiemonitoring in der Onkologie. *Der Radiologe* **52**, 646-652. [[CrossRef](#)]
1543. Bryan Haugen. 2012. Radioiodine Remnant Ablation: Current Indications and Dosing Regimens. *Endocrine Practice* **18**, 604-610. [[CrossRef](#)]
1544. Seong-Su Moon, Young-Sil Lee, In-Kyu Lee, Jung-Guk Kim. 2012. Serum thyrotropin as a risk factor for thyroid malignancy in euthyroid subjects with thyroid micronodule. *Head & Neck* **34**:10.1002/hed.v34.7, 949-952. [[CrossRef](#)]
1545. Hadiza S. Kazaure, Sanziana A. Roman, Julie A. Sosa. 2012. Insular thyroid cancer. *Cancer* **118**:10.1002/cncr.v118.13, 3260-3267. [[CrossRef](#)]
1546. Mitsuhiko Nakahira, Naoko Saito, Shin-ichi Murata, Masashi Sugawara, Yumiko Shimamura, Kei Morita, Fumihiko Takajyo, Go Omura, Satoko Matsumura. 2012. Quantitative diffusion-weighted magnetic resonance imaging as a powerful adjunct to fine needle aspiration cytology for assessment of thyroid nodules. *American Journal of Otolaryngology* **33**, 408-416. [[CrossRef](#)]
1547. Ashok Shaha. 2012. Recurrent Differentiated Thyroid Cancer. *Endocrine Practice* **18**, 600-603. [[CrossRef](#)]

1548. Yoon Seong Choi, Soon Won Hong, Jin Young Kwak, Hee Jung Moon, Eun-Kyung Kim. 2012. Clinical and Ultrasonographic Findings Affecting Nondiagnostic Results upon the Second Fine Needle Aspiration for Thyroid Nodules. *Annals of Surgical Oncology* **19**, 2304-2309. [[CrossRef](#)]
1549. Hee Jung Moon, Eun-Kyung Kim, Jung Hyun Yoon, Jin Young Kwak. 2012. Clinical Implication of Elastography as a Prognostic Factor of Papillary Thyroid Microcarcinoma. *Annals of Surgical Oncology* **19**, 2279-2287. [[CrossRef](#)]
1550. James Brierley, Eric Sherman. 2012. The Role of External Beam Radiation and Targeted Therapy in Thyroid Cancer. *Seminars in Radiation Oncology* **22**, 254-262. [[CrossRef](#)]
1551. Maseeh Uz Zaman, Nosheen Fatima, Zafar Sajjad, Jaweed Akhtar, Najmul Islam, Qamar Masood, Asma Ahmed. 2012. Threshold Primary Tumour Sizes for Nodal and Distant Metastases in Papillary and Follicular Thyroid Cancers. *Asian Pacific Journal of Cancer Prevention* **13**, 2473-2476. [[CrossRef](#)]
1552. Fernando Schmitt, Helena Barroca. 2012. Role of ancillary studies in fine-needle aspiration from selected tumors. *Cancer Cytopathology* **120**, 145-160. [[CrossRef](#)]
1553. F. Magri, V. Capelli, M. Rotondi, P. Leporati, L. La Manna, R. Ruggiero, A. Malovini, R. Bellazzi, L. Villani, L. Chiovato. 2012. Expression of estrogen and androgen receptors in differentiated thyroid cancer: an additional criterion to assess the patient's risk. *Endocrine Related Cancer* **19**, 463-471. [[CrossRef](#)]
1554. Rossella Elisei, Eleonora Molinaro Single Thyroid Nodule 111-132. [[CrossRef](#)]
1555. Furio Pacini, Maria Castagna Differentiated (Papillary and Follicular) and Anaplastic Thyroid Carcinoma 133-150. [[CrossRef](#)]
1556. Rossella Elisei, Laura Agate Thyroid Incidentaloma 161-170. [[CrossRef](#)]
1557. Carrie C. Lubitz, Sushruta S. Nagarkatti, William C. Faquin, Anthony E. Samir, Maria C. Hassan, Giuseppe Barbesino, Douglas S. Ross, Gregory W. Randolph, Randall D. Gaz, Antonia E. Stephen, Richard A. Hodin, Gilbert H. Daniels, Sareh Parangi. 2012. Diagnostic Yield of Nondiagnostic Thyroid Nodules Is Not Altered by Timing of Repeat Biopsy. *Thyroid* **22**:6, 590-594. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1558. Julio Ricarte-Filho, Ian Ganly, Michael Rivera, Nora Katabi, Weimin Fu, Ashok Shaha, R. Michael Tuttle, James A. Fagin, Ronald Ghossein. 2012. Papillary Thyroid Carcinomas with Cervical Lymph Node Metastases Can Be Stratified into Clinically Relevant Prognostic Categories Using Oncogenic BRAF, the Number of Nodal Metastases, and Extra-Nodal Extension. *Thyroid* **22**:6, 575-584. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1559. Adam S. Kabaker, Mitchell E. Tublin, Yuri E. Nikiforov, Michaele J. Armstrong, Steven P. Hodak, Michael T. Stang, Kelly L. McCoy, Sally E. Carty, Linwah Yip. 2012. Suspicious Ultrasound Characteristics Predict BRAFV600E-Positive Papillary Thyroid Carcinoma. *Thyroid* **22**:6, 585-589. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1560. Clare Kahn, Leonardo Simonella, Mark Sywak, Steven Boyages, Owen Ung, Dianne O'Connell. 2012. Postsurgical Pathology Reporting of Thyroid Cancer in New South Wales, Australia. *Thyroid* **22**:6, 604-610. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1561. Hae Won Kim, Byeong-Cheol Ahn, Sang-Woo Lee, Jaetae Lee. 2012. Effect of Parotid Gland Massage on Parotid Gland Tc-99m Pertechnetate Uptake. *Thyroid* **22**:6, 611-616. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1562. Rotem Ben-Shachar, Marisa Eisenberg, Stephen A. Huang, Joseph J. DiStefano III. 2012. Simulation of Post-Thyroidectomy Treatment Alternatives for Triiodothyronine or Thyroxine Replacement in Pediatric Thyroid Cancer Patients. *Thyroid* **22**:6, 595-603. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1563. Hadiza S. Kazaure, Sanziana A. Roman, Julie A. Sosa. 2012. Aggressive Variants of Papillary Thyroid Cancer: Incidence, Characteristics and Predictors of Survival among 43,738 Patients. *Annals of Surgical Oncology* **19**, 1874-1880. [[CrossRef](#)]
1564. E. Mariscal Labrador, A. García Burillo, J. Castell-Conesa, G. Obiols Alfonso, N. Kisiel González, M. Barios Profitós, S. Aguadé-Bruix, J. Mesa Manteca. 2012. La tomografía por emisión de positrones-tomografía computarizada con 18F-fluordesoxiglucosa en los pacientes con cáncer diferenciado de tiroides en recurrencia y rastreo con radioyodo negativo. Rendimiento diagnóstico y relación con los niveles de tiroglobulina. *Revista Española de Medicina Nuclear e Imagen Molecular* . [[CrossRef](#)]
1565. Tara D. Barwick, Ranju T. Dhawan, Valerie Lewington. 2012. Role of SPECT/CT in differentiated thyroid cancer. *Nuclear Medicine Communications* **1**. [[CrossRef](#)]
1566. D. W. Kim, J. S. Park, H. S. In, H. J. Choo, J. H. Ryu, S. J. Jung. 2012. Ultrasound-Based Diagnostic Classification for Solid and Partially Cystic Thyroid Nodules. *American Journal of Neuroradiology* **33**, 1144-1149. [[CrossRef](#)]
1567. C. López-Tinoco, I. Gavilán Villarejo, C. Coserria Sánchez, A. García Curiel. 2012. Protocolo diagnóstico, terapéutico y de seguimiento del cáncer diferenciado de tiroides. *Medicine - Programa de Formación Médica Continuada Acreditado* **11**, 854-858. [[CrossRef](#)]
1568. Furio Pacini. 2012. Thyroid microcarcinoma. *Best Practice & Research Clinical Endocrinology & Metabolism* **26**, 381-389. [[CrossRef](#)]

1569. Xiao-Min Yu, Ricardo Lloyd, Herbert Chen. 2012. Current Treatment of Papillary Thyroid Microcarcinoma. *Advances in Surgery* . [[CrossRef](#)]
1570. Yeon-Hee Han, Seok Tae Lim, Kuk-No Yun, Sung Kyun Yim, Dong Wook Kim, Hwan-Jeong Jeong, Myung-Hee Sohn. 2012. Comparison of the Influence on the Liver Function Between Thyroid Hormone Withdrawal and rh-TSH Before High-Dose Radioiodine Therapy in Patients with Well-Differentiated Thyroid Cancer. *Nuclear Medicine and Molecular Imaging* **46**, 89-94. [[CrossRef](#)]
1571. P. Roldán Caballero, F.J. Vilchez, E. Vallejo, D. Martínez Parra. 2012. Protocolo diagnóstico y terapéutico del nódulo tiroideo. *Medicine - Programa de Formación Médica Continuada Acreditado* **11**, 836-839. [[CrossRef](#)]
1572. Frédérique Albarel, Bernard Conte-Devolx, Charles Oliver. 2012. From nodule to differentiated thyroid carcinoma: Contributions of molecular analysis in 2012. *Annales d'Endocrinologie* **73**, 155-164. [[CrossRef](#)]
1573. Simonetta Piana, Fabrizio Riganti, Elisabetta Froio, Massimiliano Andrioli, Claudio M. Pacella, Roberto Valcavi. 2012. Pathological Findings of Thyroid Nodules After Percutaneous Laser Ablation. *Endocrine Pathology* **23**, 94-100. [[CrossRef](#)]
1574. Brian Hung-Hin Lang, Irene Oi Ling Wong, Kai Pun Wong, Benjamin J. Cowling, Koon-Yat Wan. 2012. Risk of second primary malignancy in differentiated thyroid carcinoma treated with radioactive iodine therapy. *Surgery* **151**, 844-850. [[CrossRef](#)]
1575. Furio Pacini. 2012. Thyroid function: Optimizing molecular testing in thyroid nodule cytology. *Nature Reviews Endocrinology* **8**, 390-391. [[CrossRef](#)]
1576. Erik K. Alexander, P. Reed Larsen. 2012. Radioiodine for Thyroid Cancer — Is Less More?. *New England Journal of Medicine* **366**, 1732-1733. [[CrossRef](#)]
1577. Martin Schlumberger, Bogdan Catargi, Isabelle Borget, Désirée Deandreis, Slimane Zerdoud, Boumédiène Bridji, Stéphane Bardet, Laurence Leenhardt, Delphine Bastie, Claire Schwartz, Pierre Vera, Olivier Morel, Danielle Benisvy, Claire Bournaud, Françoise Bonichon, Catherine Dejax, Marie-Elisabeth Toubert, Sophie Leboulleux, Marcel Ricard, Ellen Benhamou. 2012. Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer. *New England Journal of Medicine* **366**, 1663-1673. [[CrossRef](#)]
1578. Ujjal Mallick, Clive Harmer, Beng Yap, Jonathan Wadsley, Susan Clarke, Laura Moss, Alice Nicol, Penelope M. Clark, Kate Farnell, Ralph McCready, James Smellie, Jayne A. Franklyn, Rhys John, Christopher M. Nutting, Kate Newbold, Catherine Lemon, Georgina Gerrard, Abdel Abdel-Hamid, John Hardman, Elena Macias, Tom Roques, Stephen Whitaker, Rengarajan Vijayan, Pablo Alvarez, Sandy Beare, Sharon Forsyth, Latha Kadalayil, Allan Hackshaw. 2012. Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. *New England Journal of Medicine* **366**, 1674-1685. [[CrossRef](#)]
1579. Brendan C. Stack , Jr. (Chair), Robert L. Ferris, David Goldenberg, Megan Haymart, Ashok Shaha, Sheila Sheth, Julie Ann Sosa, Ralph P. Tufano, for the American Thyroid Association Surgical Affairs Committee. 2012. American Thyroid Association Consensus Review and Statement Regarding the Anatomy, Terminology, and Rationale for Lateral Neck Dissection in Differentiated Thyroid Cancer. *Thyroid* **22:5**, 501-508. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1580. Pedro Wesley Rosario, Mariana Souza Furtado, Augusto Flávio Campos Mineiro Filho, Rafela Xavier Lacerda, Maria Regina Calsolari. 2012. Value of Repeat Stimulated Thyroglobulin Testing in Patients with Differentiated Thyroid Carcinoma Considered to Be Free of Disease in the First Year After Ablation. *Thyroid* **22:5**, 482-486. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1581. Dong Gyu Na, Ji-hoon Kim, Jin Yong Sung, Jung Hwan Baek, Kyeong Cheon Jung, Hunkyung Lee, Hyunju Yoo. 2012. Core-Needle Biopsy Is More Useful Than Repeat Fine-Needle Aspiration in Thyroid Nodules Read as Nondiagnostic or Atypia of Undetermined Significance by the Bethesda System for Reporting Thyroid Cytopathology. *Thyroid* **22:5**, 468-475. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
1582. Nadia Passon, Cinzia Puppini, Elisa Lavarone, Elisa Bregant, Alessandra Franzoni, Jerome M. Hershman, Mike S. Fenton, Maria D'Agostino, Cosimo Durante, Diego Russo, Sebastiano Filetti, Giuseppe Damante. 2012. Cyclic AMP-Response Element Modulator Inhibits the Promoter Activity of the Sodium Iodide Symporter Gene in Thyroid Cancer Cells. *Thyroid* **22:5**, 487-493. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1583. Anthony E. Samir, Abhinav Vij, Melanie K. Seale, Gaurav Desai, Elkan Halpern, William C. Faquin, Sareh Parangi, Peter F. Hahn, Gilbert H. Daniels. 2012. Ultrasound-Guided Percutaneous Thyroid Nodule Core Biopsy: Clinical Utility in Patients with Prior Nondiagnostic Fine-Needle Aspirate. *Thyroid* **22:5**, 461-467. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1584. Cheng-Ping Wang, Tseng-Cheng Chen, Pei-Jen Lou, Tsung-Lin Yang, Ya-Ling Hu, Ming-Jium Shieh, Jenq-Yuh Ko, Tzu-Yu Hsiao. 2012. Neck ultrasonography for the evaluation of the etiology of adult unilateral vocal fold paralysis. *Head & Neck* **34:10.1002/hed.v34.5**, 643-648. [[CrossRef](#)]

1585. Kyung Tae, Yong Bae Ji, Seok Hyun Cho, Seung Hwan Lee, Dong Sun Kim, Tae Wha Kim. 2012. Early surgical outcomes of robotic thyroidectomy by a gasless unilateral axillo-breast or axillary approach for papillary thyroid carcinoma: 2 years' experience. *Head & Neck* **34**, 617-625. [[CrossRef](#)]
1586. Louis Rapkin, Farzana D. Pashankar. 2012. Management of Thyroid Carcinoma in Children and Young Adults. *Journal of Pediatric Hematology/Oncology* **34**, S39-S46. [[CrossRef](#)]
1587. Jennifer Poehls, Herbert Chen, Rebecca Sippel. 2012. Preoperative Ultrasonography Findings Predict the Need for Repeated Surgery in Papillary Thyroid Cancer. *Endocrine Practice* **18**, 403-409. [[CrossRef](#)]
1588. Rashmi Roy, Guennadi Kouniavsky, Raghunandan Venkat, Erin A. Felger, Zita Shiue, Eric Schneider, Martha A. Zeiger. 2012. The role of preoperative neck ultrasounds to assess lymph nodes in patients with suspicious or indeterminate thyroid nodules. *Journal of Surgical Oncology* **105**:10.1002/jso.v105.6, 601-605. [[CrossRef](#)]
1589. Shikha Bose, Ann E. Walts. 2012. Thyroid Fine Needle Aspirate. *Advances In Anatomic Pathology* **19**, 160-169. [[CrossRef](#)]
1590. Luca Giovanella, Luca Ceriani, Diego De Palma, Sergio Suriano, Massimo Castellani, Frederik A. Verburg. 2012. Relationship between serum thyroglobulin and 18FDG-PET/CT in 131I-negative differentiated thyroid carcinomas. *Head & Neck* **34**, 626-631. [[CrossRef](#)]
1591. Sijbrigje G. A. de Meer, Jennifer M. J. Schreinemakers, Pierre M. J. Zelissen, Gerard Stapper, Daisy M. D. S. Sie-Go, Inne H. M. Borel Rinkes, Menno R. Vriens. 2012. Fine-needle aspiration of thyroid tumors: Identifying factors associated with adequacy rate in a large academic center in the Netherlands. *Diagnostic Cytopathology* **40**:10.1002/dc.v40.1s, E21-E26. [[CrossRef](#)]
1592. Marisa Cañadas-Garre, Patricia Becerra-Massare, Martín López de la Torre-Casares, Jesús Villar-del Moral, Susana Céspedes-Mas, Ricardo Vilchez-Joya, Teresa Muros-de Fuentes, Carlos García-Calvente, Gonzalo Piédrola-Maroto, Miguel A. López-Nevot, Rosa Montes-Ramírez, José M. Llamas-Elvira. 2012. Reduction of False-Negative Papillary Thyroid Carcinomas by the Routine Analysis of BRAFT1799A Mutation on Fine-Needle Aspiration Biopsy Specimens. *Annals of Surgery* **255**, 986-992. [[CrossRef](#)]
1593. F.C. Uecker, S. Laban, R. Knecht. 2012. Stellenwert neuer Behandlungsansätze mit Targettherapeutika bei malignen Schilddrüsenerkrankungen. *HNO* **60**, 398-403. [[CrossRef](#)]
1594. Haejin In, Bridget A. Neville, Stuart R. Lipsitz, Katherine A. Corso, Jane C. Weeks, Caprice C. Greenberg. 2012. The Role of National Cancer Institute-Designated Cancer Center Status. *Annals of Surgery* **255**, 890-895. [[CrossRef](#)]
1595. Yi-Li Zhou, Wei Zhang, Er-Li Gao, Xuan-Xuan Dai, Han Yang, Xiao-Hua Zhang, Ou-Chen Wang. 2012. Preoperative BRAF Mutation is Predictive of Occult Contralateral Carcinoma in Patients with Unilateral Papillary Thyroid Microcarcinoma. *Asian Pacific Journal of Cancer Prevention* **13**, 1267-1272. [[CrossRef](#)]
1596. Massimo Bongiovanni, Stefano Crippa, Zubair Baloch, Simonetta Piana, Alessandra Spitale, Fabio Pagni, Luca Mazzucchelli, Camillo Di Bella, William Faquin. 2012. Comparison of 5-tiered and 6-tiered diagnostic systems for the reporting of thyroid cytopathology. *Cancer Cytopathology* **120**, 117-125. [[CrossRef](#)]
1597. Abdul A. Qureshi, V. P. Collins, P. Jani. 2012. Genomic differences in benign and malignant follicular thyroid tumours using 1-Mb array-comparative genomic hybridisation. *European Archives of Oto-Rhino-Laryngology* . [[CrossRef](#)]
1598. Rossella Elisei, Aldo Pinchera. 2012. Advances in the follow-up of differentiated or medullary thyroid cancer. *Nature Reviews Endocrinology* **8**, 466-475. [[CrossRef](#)]
1599. Giuseppe Barbesino, Melanie Goldfarb, Sareh Parangi, Jingyun Yang, Douglas S. Ross, Gilbert H. Daniels. 2012. Thyroid Lobe Ablation with Radioactive Iodine as an Alternative to Completion Thyroidectomy After Hemithyroidectomy in Patients with Follicular Thyroid Carcinoma: Long-Term Follow-Up. *Thyroid* **22**:4, 369-376. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1600. David S. Cooper, Ralph P. Tufano. 2012. Prophylactic Central Neck Dissection in Differentiated Thyroid Cancer: A Procedure in Search of an Indication. *Thyroid* **22**:4, 341-343. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1601. Mauricio A. Moreno, Beth S. Edeiken-Monroe, Eric R. Siegel, Steven I. Sherman, Gary L. Clayman. 2012. In Papillary Thyroid Cancer, Preoperative Central Neck Ultrasound Detects Only Macroscopic Surgical Disease, But Negative Findings Predict Excellent Long-Term Regional Control and Survival. *Thyroid* **22**:4, 347-355. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1602. Young Joo Park, Hwa Young Ahn, Hoon Sung Choi, Kyung Won Kim, Do Joon Park, Bo Youn Cho. 2012. The Long-Term Outcomes of the Second Generation of Familial Nonmedullary Thyroid Carcinoma Are More Aggressive than Sporadic Cases. *Thyroid* **22**:4, 356-362. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1603. Kara Meinke Baehr, Elizabeth Lyden, Kelly Treude, Judi Erickson, Whitney Goldner. 2012. Levothyroxine dose following thyroidectomy is affected by more than just body weight. *The Laryngoscope* **122**, 834-838. [[CrossRef](#)]

1604. Kevin Ka-Wan Chu, Brian Hung-Hin Lang. 2012. Clinicopathologic predictors for early and late biochemical hypothyroidism after hemithyroidectomy. *The American Journal of Surgery* **203**, 461-466. [[CrossRef](#)]
1605. Jill E. Langer, Zubair W. Baloch, Cindy McGrath, Laurie A. Loevner, Susan J. Mandel. 2012. Thyroid Nodule Fine-Needle Aspiration. *Seminars in Ultrasound, CT and MRI* **33**, 158-165. [[CrossRef](#)]
1606. Dana M. Hartl, Sophie Leboulleux, Abir Al Ghuzlan, Eric Baudin, Linda Chami, Martin Schlumberger, Jean-Paul Travagli. 2012. Optimization of Staging of the Neck With Prophylactic Central and Lateral Neck Dissection for Papillary Thyroid Carcinoma. *Annals of Surgery* **255**, 777-783. [[CrossRef](#)]
1607. Pedro Wesley Rosario, Arthur Cezar Malard Xavier. 2012. Recombinant Human Thyroid Stimulating Hormone in Thyroid Remnant Ablation With 1.1 GBq 131Iodine in Low-Risk Patients. *American Journal of Clinical Oncology* **35**, 101-104. [[CrossRef](#)]
1608. Cheng-Xiang Shan, Wei Zhang, Dao-Zhen Jiang, Xiang-Min Zheng, Sheng Liu, Ming Qiu. 2012. Routine central neck dissection in differentiated thyroid carcinoma: A systematic review and meta-analysis. *The Laryngoscope* **122**, 797-804. [[CrossRef](#)]
1609. Jenny K. Hoang, Phillip Raduazo, David M. Yousem, James D. Eastwood. 2012. What to Do With Incidental Thyroid Nodules on Imaging? An Approach for the Radiologist. *Seminars in Ultrasound, CT and MRI* **33**, 150-157. [[CrossRef](#)]
1610. Guennadi Kouniavsky, Martha A. Zeiger. 2012. The quest for diagnostic molecular markers for thyroid nodules with indeterminate or suspicious cytology. *Journal of Surgical Oncology* **105**:10.1002/jso.v105.5, 438-443. [[CrossRef](#)]
1611. Ashley H. Aiken. 2012. Imaging of Thyroid Cancer. *Seminars in Ultrasound, CT and MRI* **33**, 138-149. [[CrossRef](#)]
1612. Gerald T. Kangelaris, Theresa B. Kim, Lisa A. Orloff. 2012. Role of Ultrasound in Thyroid Disorders. *Ultrasound Clinics* **7**, 197-210. [[CrossRef](#)]
1613. Don Yoo, Saad Ajmal, Shilpa Gowda, Jason Machan, Jack Monchik, Peter Mazzaglia. 2012. Level VI Lymph Node Dissection Does Not Decrease Radioiodine Uptake in Patients Undergoing Radioiodine Ablation for Differentiated Thyroid Cancer. *World Journal of Surgery* . [[CrossRef](#)]
1614. Therezia Bokor, Erhard Kiffner, Bibiana Kotrikova, Franck Billmann. 2012. Cosmesis and Body Image after Minimally Invasive or Open Thyroid Surgery. *World Journal of Surgery* . [[CrossRef](#)]
1615. Nijaguna B. Prasad, Jeanne Kowalski, Hua-Ling Tsai, Kristin Talbot, Helina Somervell, Guennadi Kouniavsky, Yongchun Wang, Alan P.B. Dackiw, William H. Westra, Douglas P. Clark, Steven K. Libutti, Christopher B. Umbricht, Martha A. Zeiger. 2012. Three-Gene Molecular Diagnostic Model for Thyroid Cancer. *Thyroid* **22**:3, 275-284. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)] [[Supplemental Material](#)]
1616. Ivo Marchetti, Giorgio Iervasi, Chiara Maria Mazzanti, Francesca Lessi, Sara Tomei, Antonio Giuseppe Naccarato, Paolo Aretini, Baldassare Alberti, Giancarlo Di Coscio, Generoso Bevilacqua. 2012. Detection of the BRAFV600E Mutation in Fine Needle Aspiration Cytology of Thyroid Papillary Microcarcinoma Cells Selected by Manual Macrodissection: An Easy Tool to Improve the Preoperative Diagnosis. *Thyroid* **22**:3, 292-298. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1617. Tobias Carling, Sally E. Carty, Maria M. Ciarleglio, David S. Cooper, Gerard M. Doherty, Lawrence T. Kim, Richard T. Kloos, Ernest L. Mazzaferri Sr., Peter N. Peduzzi, Sanziana A. Roman, Rebecca S. Sippel, Julie A. Sosa, Brendan C. Stack Jr., David L. Steward, Ralph P. Tufano, R. Michael Tuttle, Robert Udelsman, for the American Thyroid Association Surgical Affairs Committee. 2012. American Thyroid Association Design and Feasibility of a Prospective Randomized Controlled Trial of Prophylactic Central Lymph Node Dissection for Papillary Thyroid Carcinoma. *Thyroid* **22**:3, 237-244. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1618. Takeo Kawai, Eijun Nishihara, Takumi Kudo, Hisashi Ota, Shinji Morita, Kaoru Kobayashi, Mitsuru Ito, Sumihisa Kubota, Nobuyuki Amino, Akira Miyachi. 2012. Histopathological Diagnoses of "Accessory" Thyroid Nodules Diagnosed as Benign by Fine-Needle Aspiration Cytology and Ultrasonography. *Thyroid* **22**:3, 299-303. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1619. Joanna Klubo-Gwiedzinska, Kenneth D. Burman, Douglas Van Nostrand, Mihriye Mete, Jacqueline Jonklaas, Leonard Wartofsky. 2012. Radioiodine Treatment of Metastatic Thyroid Cancer: Relative Efficacy and Side Effect Profile of Preparation by Thyroid Hormone Withdrawal Versus Recombinant Human Thyrotropin. *Thyroid* **22**:3, 310-317. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1620. Angela Dardano, Michela Ballardini, Nadia Caraccio, Giuseppe Boni, Claudio Traino, Giuliano Mariani, Marco Ferdeghini, Roberto Barale, Fabio Monzani. 2012. The Effect of Ginkgo biloba Extract on Genotoxic Damage in Patients with Differentiated Thyroid Carcinoma Receiving Thyroid Remnant Ablation with Iodine-131. *Thyroid* **22**:3, 318-324. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1621. Ming-Kai Chen, Mona Yasrebi, Jason Samii, Lawrence H. Staib, Indukala Doddamane, David W. Cheng. 2012. The Utility of I-123 Pretherapy Scan in I-131 Radioiodine Therapy for Thyroid Cancer. *Thyroid* **22**:3, 304-309. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

1622. Won-Jin Moon, Nami Choi, Jin Woo Choi, Suk Kyeong Kim, Tae Sook Hwang. 2012. BRAF Mutation Analysis and Sonography as Adjuncts to Fine-Needle Aspiration Cytology of Papillary Thyroid Carcinoma: Their Relationships and Roles. *American Journal of Roentgenology* **198**, 668-674. [[CrossRef](#)]
1623. I-Chin Huang, Feng-Fu Chou, Rue-Tsuan Liu, Shih-Chen Tung, Jung-Fu Chen, Ming-Chun Kuo, Ching-Jung Hsieh, Pei-Wen Wang. 2012. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma. *Clinical Endocrinology* **76**:10.1111/cen.2012.76.issue-3, 439-447. [[CrossRef](#)]
1624. Eider Pascual Corrales, Rosa Maria Principe, Sara Laguna Muro, Fernando Martínez Regueira, Juan Manuel Alcalde Navarrete, Francisco Guillén Grima, Juan Carlos Galofré. 2012. Incidental differentiated thyroid carcinoma is less prevalent in Graves' disease than in multinodular goiter. *Endocrinología y Nutrición (English Edition)* **59**, 169-173. [[CrossRef](#)]
1625. Geanina Popoveniuc, Jacqueline Jonklaas. 2012. Thyroid Nodules. *Medical Clinics of North America* **96**, 329-349. [[CrossRef](#)]
1626. Stephen Weinrib, Wendy Lane, Jonathan Rappaport. 2012. Successful Management of Differentiated Thyroid Cancer in a Community-Based Endocrine Practice. *Endocrine Practice* **18**, 170-178. [[CrossRef](#)]
1627. Gabriel Glockzin, Matthias Hornung, Klaus Kienle, Katrin Thelen, Marita Boin, Andreas G. Schreyer, Hamid R. Lighvani, Hans J. Schlitt, Ayman Agha. 2012. Completion Thyroidectomy: Effect of Timing on Clinical Complications and Oncologic Outcome in Patients With Differentiated Thyroid Cancer. *World Journal of Surgery* . [[CrossRef](#)]
1628. Ram Moorthy, Adrian Warfield Thyroid and parathyroid gland pathology 328-366. [[CrossRef](#)]
1629. Chae Moon Hong, Byeong-Cheol Ahn, Ji Young Park, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee. 2012. Prognostic implications of microscopic involvement of surgical resection margin in patients with differentiated papillary thyroid cancer after high-dose radioactive iodine ablation. *Annals of Nuclear Medicine* . [[CrossRef](#)]
1630. David S. Cooper, Bryan R. Haugen. 2012. Response to Kuru and Topgul. *Thyroid* **22**:2, 226-227. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1631. Desiree Deandreis, Abir Al Ghuzlan, Anne Auperin, Philippe Vielh, Bernard Caillou, Linda Chami, Jean Lumbroso, Jean Paul Travagli, Dana Hartl, Eric Baudin, Martin Schlumberger, Sophie Leboulleux. 2012. Is 18F-Fluorodeoxyglucose-PET/CT Useful for the Presurgical Characterization of Thyroid Nodules with Indeterminate Fine Needle Aspiration Cytology?. *Thyroid* **22**:2, 165-172. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1632. Nikola Besic, Marija Auersperg, Barbara Gazic, Marta Dremelj, Ivana Zagar. 2012. Neoadjuvant Chemotherapy in 29 Patients with Locally Advanced Follicular or Hürthle Cell Thyroid Carcinoma: A Phase 2 Study. *Thyroid* **22**:2, 131-137. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1633. Bekir Kuru, Koray Topgul. 2012. The 2009 Revised American Thyroid Association Guidelines for Thyroid Cancer: The Extent of Surgery for Thyroid Carcinoma Less Than One and One Half Centimeters or Low-Risk Thyroid Carcinoma. *Thyroid* **22**:2, 225-226. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1634. William B. Inabnet III. 2012. Computed Tomography Scans Before Surgery for Thyroid Cancer. *Thyroid* **22**:2, 112-112. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1635. Concetto Regalbuto, Rosario Le Moli, Vincenzo Muscia, Marco Russo, Riccardo Vigneri, Vincenzo Pezzino. 2012. Severe Graves' Ophthalmopathy After Percutaneous Ethanol Injection in a Nontoxic Thyroid Nodule. *Thyroid* **22**:2, 210-213. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1636. Pedro Wesley Rosario, Augusto Flávio Campos Mineiro Filho, Rafela Xavier Lacerda, Davi Alves dos Santos, Maria Regina Calsolari. 2012. The Value of Diagnostic Whole-Body Scanning and Serum Thyroglobulin in the Presence of Elevated Serum Thyrotropin During Follow-Up of Anti-Thyroglobulin Antibody-Positive Patients with Differentiated Thyroid Carcinoma Who Appeared to Be Free of Disease After Total Thyroidectomy and Radioactive Iodine Ablation. *Thyroid* **22**:2, 113-116. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1637. Min-Hee Kim, Joo Hyun O, Sun Hee Ko, Ja-Seong Bae, Dong-Jun Lim, Sung-Hoon Kim, Ki-Hyun Baek, Jong-Min Lee, Moo-Il Kang, Bong-Yun Cha, Kwang-Woo Lee. 2012. Role of [18F]-Fluorodeoxy-D-Glucose Positron Emission Tomography and Computed Tomography in the Early Detection of Persistent/Recurrent Thyroid Carcinoma in Intermediate-to-High Risk Patients Following Initial Radioactive Iodine Ablation Therapy. *Thyroid* **22**:2, 157-164. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1638. Toni Beninato, David A. Kleiman, Theresa Scognamiglio, Thomas J. Fahey III, Rasa Zarnegar. 2012. Tract Recurrence of a Follicular Thyroid Neoplasm Following Transaxillary Endoscopic Thyroidectomy. *Thyroid* **22**:2, 214-217. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1639. Carles Zafón. 2012. TSH-suppressive treatment in differentiated thyroid cancer. A dogma under review. *Endocrinología y Nutrición (English Edition)* **59**, 125-130. [[CrossRef](#)]

1640. A. Mahajan, X. Lin, R. Nayar. 2012. Thyroid Bethesda reporting category, 'suspicious for papillary thyroid carcinoma', pitfalls and clues to optimize the use of this category. *Cytopathology* no-no. [[CrossRef](#)]
1641. Maria Papaleontiou, Megan R. Haymart. 2012. Approach to and Treatment of Thyroid Disorders in the Elderly. *Medical Clinics of North America* . [[CrossRef](#)]
1642. U. Mallick, C. Harmer, A. Hackshaw, L. Moss. 2012. Iodine or Not (IoN) for Low-risk Differentiated Thyroid Cancer: The Next UK National Cancer Research Network Randomised Trial following HiLo. *Clinical Oncology* . [[CrossRef](#)]
1643. Judy Jin, Christopher R. McHenry. 2012. Thyroid incidentaloma. *Best Practice & Research Clinical Endocrinology & Metabolism* **26**, 83-96. [[CrossRef](#)]
1644. Celestino P. Lombardi, Marco Raffaelli, Carmela Crea, Luca Sessa, Valentina Rampulla, Rocco Bellantone. 2012. Video-Assisted Versus Conventional Total Thyroidectomy and Central Compartment Neck Dissection for Papillary Thyroid Carcinoma. *World Journal of Surgery* . [[CrossRef](#)]
1645. Filipa Neiva, Joana Mesquita, Susana Paco Lima, Maria João Matos, Carla Costa, Cintia Castro-Correia, Manuel Fontoura, Sofia Martins. 2012. Thyroid carcinoma in children and adolescents: A retrospective review. *Endocrinología y Nutrición (English Edition)* **59**, 105-108. [[CrossRef](#)]
1646. Diana L. Diesen, Michael A. Skinner. 2012. Pediatric thyroid cancer. *Seminars in Pediatric Surgery* **21**, 44-50. [[CrossRef](#)]
1647. Emad H. Kandil, Salem I. Noureldine, Lu Yao, Douglas P. Slakey. 2012. Robotic Transaxillary Thyroidectomy: An Examination of the First One Hundred Cases. *Journal of the American College of Surgeons* . [[CrossRef](#)]
1648. Hee Jung Moon, Eun-Kyung Kim, Jung Hyun Yoon, Jin Young Kwak. 2012. Differences in the Diagnostic Performances of Staging US for Thyroid Malignancy According to Experience. *Ultrasound in Medicine & Biology* . [[CrossRef](#)]
1649. Furio Pacini, Maria Grazia Castagna. 2012. Approach to and Treatment of Differentiated Thyroid Carcinoma. *Medical Clinics of North America* . [[CrossRef](#)]
1650. Eider Pascual Corrales, Rosa Maria Príncipe, Sara Laguna Muro, Fernando Martínez Regueira, Juan Manuel Alcalde Navarrete, Francisco Guillén Grima, Juan Carlos Galofré. 2012. El carcinoma diferenciado incidental de tiroides es menos prevalente en la enfermedad de Graves que en el bocio multinodular. *Endocrinología y Nutrición* . [[CrossRef](#)]
1651. Robin M. Cisco, Wen T. Shen, Jessica E. Gosnell. 2012. Extent of Surgery for Papillary Thyroid Cancer: Preoperative Imaging and Role of Prophylactic and Therapeutic Neck Dissection. *Current Treatment Options in Oncology* . [[CrossRef](#)]
1652. Amanda M. Laird, Paul G. Gauger, Barbra S. Miller, Gerard M. Doherty. 2012. Evaluation of Postoperative Radioactive Iodine Scans in Patients who Underwent Prophylactic Central Lymph Node Dissection. *World Journal of Surgery* . [[CrossRef](#)]
1653. S. G. A. Meer, M. Dauwan, B. Keizer, G. D. Valk, I. H. M. Borel Rinkes, M. R. Vriens. 2012. Not the Number but the Location of Lymph Nodes Matters for Recurrence Rate and Disease-Free Survival in Patients with Differentiated Thyroid Cancer. *World Journal of Surgery* . [[CrossRef](#)]
1654. Yasuhiro Ito, Takumi Kudo, Kaoru Kobayashi, Akihiro Miya, Kiyoshi Ichihara, Akira Miyauchi. 2012. Prognostic Factors for Recurrence of Papillary Thyroid Carcinoma in the Lymph Nodes, Lung, and Bone: Analysis of 5,768 Patients with Average 10-year Follow-up. *World Journal of Surgery* . [[CrossRef](#)]
1655. J. Kenneth Byrd, Robert J. Yawn, Christina S. T. Wilhoit, Nicoleta D. Sora, Linda Meyers, Jyotika Fernandes, Terry Day. 2012. Well Differentiated Thyroid Carcinoma: Current Treatment. *Current Treatment Options in Oncology* . [[CrossRef](#)]
1656. Hee Jung Moon, Jin Young Kwak, Yoon Seong Choi, Eun-Kyung Kim. 2012. How to Manage Thyroid Nodules With Two Consecutive Non-Diagnostic Results on Ultrasonography-Guided Fine-Needle Aspiration. *World Journal of Surgery* . [[CrossRef](#)]
1657. Linda Bohacek, Mira Milas, Jamie Mitchell, Allan Siperstein, Eren Berber. 2012. Diagnostic Accuracy of Surgeon-Performed Ultrasound-Guided Fine-Needle Aspiration of Thyroid Nodules. *Annals of Surgical Oncology* **19**, 45-51. [[CrossRef](#)]
1658. Jun Soo Jeong, Hyun Ki Kim, Cho-Rok Lee, Seulkee Park, Jae Hyun Park, Sang-Wook Kang, Jong Ju Jeong, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park. 2012. Coexistence of Chronic Lymphocytic Thyroiditis with Papillary Thyroid Carcinoma: Clinical Manifestation and Prognostic Outcome. *Journal of Korean Medical Science* **27**, 883. [[CrossRef](#)]
1659. Keunyoung Kim, Seong-Jang Kim, In-Joo Kim, Yong-Ki Kim, Bum Soo Kim, Kyoungjune Pak. 2012. Clinical Significance of Diffuse Hepatic Visualization and Thyroid Bed Uptake on Post-Ablative Iodine-131 Whole Body Scan in Differentiated Thyroid Cancer. *Onkologie* **35**, 82-86. [[CrossRef](#)]
1660. Jandee Lee, Kuk Young Nah, Ra Mi Kim, Yeon-Ju Oh, Young-Sil An, Joon-Kee Yoon, Gwang Il An, Tae Hyun Choi, Gi Jeong Cheon, Euy-Young Soh, Woong Youn Chung. 2012. Effectiveness of [ 124 I]-PET/CT and [ 18 F]-FDG-PET/CT for Localizing Recurrence in Patients with Differentiated Thyroid Carcinoma. *Journal of Korean Medical Science* **27**, 1019. [[CrossRef](#)]

1661. Hye Jeong Kim, Hye Won Jang, Seo Young Sohn, Yoon-La Choi, Hee-Jin Kim, Young Lyun Oh, Sun Wook Kim, Jae Hoon Chung. 2012. Frequency of RAS Mutations and PAX8/PPAR $\gamma$  Rearrangement in Follicular Thyroid Tumors in Korea. *Endocrinology and Metabolism* **27**, 45. [[CrossRef](#)]
1662. Bartosz Pula, Pawel Domoslawski, Marzena Podhorska-Okolow, Piotr Dziegiel. 2012. Role of metallothioneins in benign and malignant thyroid lesions. *Thyroid Research* **5**, 26. [[CrossRef](#)]
1663. S. J. Rosenbaum-Krumme, M. Wieduwilt, J. Nagarajah, A. Bockisch, W. Jentzen. 2012. Estimation of tumour mass in patients with differentiated thyroid carcinoma using serum thyroglobulin. *Nuklearmedizin* **51**, 217-222. [[CrossRef](#)]
1664. Dong Gyu Na, Jeong Hyun Lee, So Lyung Jung, Ji-hoon Kim, Jin Yong Sung, Jung Hee Shin, Eun-Kyung Kim, Joon Hyung Lee, Dong Wook Kim, Jeong Seon Park, Kyu Sun Kim, Seon Mi Baek, Younghen Lee, Semin Chong, Jung Suk Sim, Jung Yin Huh, Jae-Ik Bae, Kyung Tae Kim, Song Yee Han, Min Young Bae, Yoon Suk Kim, Jung Hwan Baek. 2012. Radiofrequency Ablation of Benign Thyroid Nodules and Recurrent Thyroid Cancers: Consensus Statement and Recommendations. *Korean Journal of Radiology* **13**, 117. [[CrossRef](#)]
1665. Hala Ahmadih, Sami T. Azar. 2012. Controversies in the Management and Followup of Differentiated Thyroid Cancer: Beyond the Guidelines. *Journal of Thyroid Research* **2012**, 1-8. [[CrossRef](#)]
1666. Brian Hung-Hin Lang. 2012. The Role of 18F-Fluorodeoxyglucose Positron Emission Tomography in the Prognostication, Diagnosis, and Management of Thyroid Carcinoma. *Journal of Thyroid Research* **2012**, 1-8. [[CrossRef](#)]
1667. Xiao-Min Yu, Priyesh N. Patel, Herbert Chen, Rebecca S. Sippel. 2012. False-negative fine-needle aspiration of thyroid nodules cannot be attributed to sampling error alone. *The American Journal of Surgery* . [[CrossRef](#)]
1668. Chan-Hee Jung, Hyeon-Jeong Goong, Bo-Yeon Kim, Jung-Mi Park, Jeong-Ja Kwak, Chul-Hee Kim, Hyun-Sook Hong, Sung-Koo Kang, Ji-Oh Mok. 2012. Lung nodule detected by F-18 fluorodeoxyglucose positron emission tomography-computed tomography in patients with papillary thyroid cancer, negative 131I whole body scan, and undetectable serum-stimulated thyroglobulin levels: two case reports. *Journal of Medical Case Reports* **6**, 374. [[CrossRef](#)]
1669. Alexandra Chrisoulidou, Stylianos Mandanas, Periklis Mitsakis, Paschalia K Iliadou, Kosmas Manafis, Nikolaos Flaris, Maria Boudina, Lemonia Mathiopoulou, Kalliopi Pazaitou-Panayiotou. 2012. Parathyroid involvement in thyroid cancer: an unforeseen event. *World Journal of Surgical Oncology* **10**, 121. [[CrossRef](#)]
1670. Fred A. Mettler, Milton J. Guiberteau Thyroid, Parathyroid, and Salivary Glands 99-130. [[CrossRef](#)]
1671. Zhen-Yu Hong, Hyeon Jung Lee, Dong Yeob Shin, Suk Kyoung Kim, MiRan Seo, Eun Jig Lee. 2012. Inhibition of Akt/FOXO3a signaling by constitutively active FOXO3a suppresses growth of follicular thyroid cancer cell lines. *Cancer Letters* **314**, 34-40. [[CrossRef](#)]
1672. Kimberly M. Creach, Barry A. Siegel, Brian Nussenbaum, Perry W. Grigsby. 2012. Radioactive Iodine Therapy Decreases Recurrence in Thyroid Papillary Microcarcinoma. *ISRN Endocrinology* **2012**, 1-6. [[CrossRef](#)]
1673. A. Vrachimis, O. Schober, B. Riemann. 2012. Radioiodine remnant ablation in differentiated thyroid cancer after combined endogenous and exogenous TSH stimulation. *Nuklearmedizin* **51**. [[CrossRef](#)]
1674. Nami Choi, Won-Jin Moon, Hahn Young Kim, Hong Gee Roh, Jin Woo Choi. 2012. Thyroid Incidentaloma Detected by Time-Resolved Magnetic Resonance Angiography at 3T: Prevalence and Clinical Significance. *Korean Journal of Radiology* **13**, 275. [[CrossRef](#)]
1675. Min Ji Jeon, Ji Min Han, Ji Hye Yim, Tae Yong Kim, Won Bae Kim, Young Kee Shong. 2012. Papillary Thyroid Carcinoma Hidden behind the Hot Nodule. *Journal of Korean Thyroid Association* **5**, 78. [[CrossRef](#)]
1676. Iain J. Nixon, Ian Ganly, Snehal G. Patel, Frank L. Palmer, Monica M. Whitcher, Rony Ghossein, R. Michael Tuttle, Ashok R. Shaha, Jatin P. Shah. 2012. Changing trends in well differentiated thyroid carcinoma over eight decades. *International Journal of Surgery* **10**, 618-623. [[CrossRef](#)]
1677. Sang Mi Kim, Yun Kyung Jeon, Sang Soo Kim, Bo Hyun Kim, In Ju Kim. 2012. A Follicular Thyroid Carcinoma Presenting as Single Bone Metastasis to Distal Femur with Pathologic Fracture: a Case Report. *Journal of Korean Thyroid Association* **5**, 73. [[CrossRef](#)]
1678. S. Rosenbaum-Krumme, J. Nagarajah, M. Ruhlmann, A. Bockisch, W. Jentzen. 2012. 124I-PET/CT images of differentiated thyroid cancer patients. *Nuklearmedizin* **51**, 213-216. [[CrossRef](#)]
1679. Charles M. Intenzo, Hung Q. Dam, Timothy A. Manzone, Sung M. Kim. 2012. Imaging of the Thyroid in Benign and Malignant Disease. *Seminars in Nuclear Medicine* **42**, 49-61. [[CrossRef](#)]
1680. Hemant A. Parmar, Mohannad Ibrahim, Mohammad Arabi, Suresh K. Mukherji Imaging in Thyroid Cancer 621-631. [[CrossRef](#)]
1681. Hayemin Lee, Jina Lee, Ki Sung. 2012. Comparative study comparing endoscopic thyroidectomy using the axillary approach and open thyroidectomy for papillary thyroid microcarcinoma. *World Journal of Surgical Oncology* **10**, 269. [[CrossRef](#)]



1682. Yasuhiro Ito, Takuya Higashiyama, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya, Akira Miyauchi. 2012. Prognosis of Patients with Papillary Thyroid Carcinoma Located in One Lobe Showing Lateral Node Metastasis in the Contralateral but Not Ipsilateral Compartment. *Journal of Thyroid Research* **2012**, 1-4. [[CrossRef](#)]
1683. Jandee Lee, Jong Ho Yun, Un Jong Choi, Sang-Wook Kang, Jong Ju Jeong, Woong Youn Chung. 2012. Robotic versus Endoscopic Thyroidectomy for Thyroid Cancers: A Multi-Institutional Analysis of Early Postoperative Outcomes and Surgical Learning Curves. *Journal of Oncology* **2012**, 1-9. [[CrossRef](#)]
1684. Beatriz Mantinan, Antonia Rego-Iraeta, Alejandra Larrañaga, Enrique Fluiters, Paula Sánchez-Sobrino, Ricardo V. Garcia-Mayor. 2012. Factors Influencing the Outcome of Patients with Incidental Papillary Thyroid Microcarcinoma. *Journal of Thyroid Research* **2012**, 1-5. [[CrossRef](#)]
1685. Takeo KAWAI, Kaoru KOBAYASHI, Mitsuyoshi HIROKAWA, Mitsuhiro FUKUSHIMA, Tomonori YABUTA, Hisashi OTA, Shinji MORITA, Eijyun NISHIHARA, Nobuyuki AMINO, Akira MIYAUCHI. 2012. Ultrasound classification system for the diagnosis of thyroid nodules: diagnostic criteria at Kuma Hospital. *Choonpa Igaku* **39**, 259-269. [[CrossRef](#)]
1686. M. Peli, E. Capalbo, M. Lovisatti, M. Cosentino, E. Berti, R. Mattai Dal Moro, M. Cariati. 2012. Ultrasound guided fine-needle aspiration biopsy of thyroid nodules: Guidelines and recommendations vs clinical practice; a 12-month study of 89 patients. *Journal of Ultrasound* . [[CrossRef](#)]
1687. Emanuele Panza, Charles H. Knowles, Claudio Graziano, Nikhil Thapar, Alan J. Burns, Marco Seri, Vincenzo Stanghellini, Roberto De Giorgio. 2012. Genetics of human enteric neuropathies. *Progress in Neurobiology* . [[CrossRef](#)]
1688. Jae-Joon Han, Ki-Sook Hong. 2012. Review of Molecular Markers for Thyroid Cancer. *The Ewha Medical Journal* **35**, 3. [[CrossRef](#)]
1689. Mi Kyeong Kim, Sung Wook Park, Su Kang Kim, Hae Jeong Park, Young Gyu Eun, Kee Hwan Kwon, Jinju Kim. 2012. Association of Toll-Like Receptor 2 Polymorphisms with Papillary Thyroid Cancer and Clinicopathologic Features in a Korean Population. *Journal of Korean Medical Science* **27**, 1333. [[CrossRef](#)]
1690. Matthew Kim, Paul Ladenson Thyroid e64-e77. [[CrossRef](#)]
1691. Ian D. Hay, Ivy A. Petersen, Robert L. Foote Thyroid Cancer 707-722. [[CrossRef](#)]
1692. Philip W. Smith, Leslie J. Salomone, John B. Hanks Thyroid 886-923. [[CrossRef](#)]
1693. Deepak Khandelwal, Nikhil Tandon. 2012. Overt and Subclinical Hypothyroidism. *Drugs* **72**, 17-33. [[CrossRef](#)]
1694. Eun Kyung Lee, Ki-Wook Chung, Hye Sook Min, Tae Sung Kim, Tae Hyun Kim, Jun Sun Ryu, Yoo Seok Jung, Seok Ki Kim, You Jin Lee. 2012. Preoperative Serum Thyroglobulin as a Useful Predictive Marker to Differentiate Follicular Thyroid Cancer from Benign Nodules in Indeterminate Nodules. *Journal of Korean Medical Science* **27**, 1014. [[CrossRef](#)]
1695. Jesse Gutnick, Oliver Soldes, Manjula Gupta, Mira Milas. 2012. Circulating thyrotropin receptor messenger RNA for evaluation of thyroid nodules and surveillance of thyroid cancer in children. *Journal of Pediatric Surgery* **47**, 171-176. [[CrossRef](#)]
1696. Jong Ju Jeong, Kyu Hyung Kim, Yoon Woo Koh, Kee-Hyun Nam, Woong Youn Chung, Cheong Soo Park. 2012. Surgical completeness of total thyroidectomy using harmonic scalpel: comparison with conventional total thyroidectomy in papillary thyroid carcinoma patients. *Journal of the Korean Surgical Society* **83**, 267. [[CrossRef](#)]
1697. Carles Zafon, Gabriel Obiols, Juan Antonio Baena, Josep Castellví, Belen Dalama, Jordi Mesa. 2012. Preoperative Thyrotropin Serum Concentrations Gradually Increase from Benign Thyroid Nodules to Papillary Thyroid Microcarcinomas Then to Papillary Thyroid Cancers of Larger Size. *Journal of Thyroid Research* **2012**, 1-4. [[CrossRef](#)]
1698. Ji Hyun Kim, Gyeong Jae Na, Ki Won Kim, Hee Ja Ko, Sung Wan Jeon, Yeo Joo Kim, Sang Jin Kim, Hyeun Duk Jo, Chang Jin Kim. 2012. Papillary Thyroid Carcinoma Manifesting as an Autonomously Functioning Thyroid Nodule. *Endocrinology and Metabolism* **27**, 59. [[CrossRef](#)]
1699. Hyo Sub Keum, Yong Bae Ji, Jong Min Kim, Jin Hyeok Jeong, Woong Hwan Choi, You Hern Ahn, Kyung Tae. 2012. Optimal surgical extent of lateral and central neck dissection for papillary thyroid carcinoma located in one lobe with clinical lateral lymph node metastasis. *World Journal of Surgical Oncology* **10**, 221. [[CrossRef](#)]
1700. Kai-Pun Wong, Brian Hung-Hin Lang. 2012. New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature Review. *Journal of Thyroid Research* **2012**, 1-9. [[CrossRef](#)]
1701. Matthew Kim, Paul Ladenson Thyroid 1450-1463. [[CrossRef](#)]
1702. Jin Young Kwak. 2012. Postoperative Surveillance of Thyroid Cancer: in View of US. *Journal of Korean Thyroid Association* **5**, 15. [[CrossRef](#)]
1703. Doina Piciu, Andra Piciu, Alexandru Irimie. 2012. Thyroid carcinoma and primary amenorrhea due to Mayer-Rokitansky-Kuster-Hauser syndrome: a case report. *Journal of Medical Case Reports* **6**, 377. [[CrossRef](#)]

1704. Yoon Jung Choi, Dae Hyoung Kang, Jong Chul Hong, Hyoung Shin Lee, Sung Won Kim, Kang Dae Lee. 2012. The Treatment Outcomes of Medullary Thyroid Carcinoma. *Korean Journal of Otorhinolaryngology-Head and Neck Surgery* **55**, 166. [[CrossRef](#)]
1705. Mujgan Caliskan, Jae Hyun Park, Jun Soo Jeong, Cho-Rok Lee, Seul Kee Park, Sang-Wook Kang, Jong Ju Jeong, Woong Youn Chung, Cheong Soo Park. 2012. Role of prophylactic ipsilateral central compartment lymph node dissection in papillary thyroid microcarcinoma. *Endocrine Journal* **59**, 305-311. [[CrossRef](#)]
1706. Jay Shankar, Sam M Wiseman, Fanrui Meng, Katayoon Kasaian, Scott Strugnell, Alireza Mofid, Allen Gown, Steven JM Jones, Ivan R Nabi. 2012. Coordinated expression of galectin-3 and caveolin-1 in thyroid cancer. *The Journal of Pathology* n/a-n/a. [[CrossRef](#)]
1707. Vijayraj S. Patil, Abhishek Vijayakumar, Neelamma Natikar. 2012. Unusual Presentation of Cystic Papillary Thyroid Carcinoma. *Case Reports in Endocrinology* **2012**, 1-4. [[CrossRef](#)]
1708. Arash Safavi, Aparna Vijayasekaran, Marlon A. Guerrero. 2012. New Insight into the Treatment of Advanced Differentiated Thyroid Cancer. *Journal of Thyroid Research* **2012**, 1-8. [[CrossRef](#)]
1709. Cortney Y. Lee, Samuel K. Snyder, Terry C. Lairmore, Sean C. Dupont, Daniel C. Jupiter. 2012. Utility of Surgeon-Performed Ultrasound Assessment of the Lateral Neck for Metastatic Papillary Thyroid Cancer. *Journal of Oncology* **2012**, 1-4. [[CrossRef](#)]
1710. Sheng-Hwu Hsieh, Szu-Tah Chen, Chuen Hsueh, Tzu-Chieh Chao, Jen-Der Lin. 2012. Gender-Specific Variation in the Prognosis of Papillary Thyroid Cancer TNM Stages II to IV. *International Journal of Endocrinology* **2012**, 1-5. [[CrossRef](#)]
1711. Mubashir G Mulla, Wolfram Trudo Knoefel, Jackie Gilbert, Alan McGregor, Klaus-Martin Schulte. 2012. Lateral cervical lymph node metastases in papillary thyroid cancer: A systematic review of imaging-guided and prophylactic removal of the lateral compartment. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1712. Alan Dardik, David H. Berger, Ronnie A. Rosenthal. Surgery in the Geriatric Patient 328-357. [[CrossRef](#)]
1713. Filipa Neiva, Joana Mesquita, Susana Paco Lima, Maria João Matos, Carla Costa, Cintia Castro-Correia, Manuel Fontoura, Sofia Martins. 2012. Thyroid carcinoma in children and adolescents: A retrospective review. *Endocrinología y Nutrición* . [[CrossRef](#)]
1714. Fabián Pitoia, Robert J. Marlowe, Erika Abelleira, Eduardo N. Faure, Fernanda Bueno, Diego Schwarzstein, Rubén Julio Lutfi, Hugo Niepomnische. 2012. Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer. *Journal of Thyroid Research* **2012**, 1-8. [[CrossRef](#)]
1715. Brian Hung-Hin Lang, Kai Pun Wong, Koon Yat Wan, Chung Yau Lo. 2012. Impact of Routine Unilateral Central Neck Dissection on Preablative and Postablative Stimulated Thyroglobulin Levels after Total Thyroidectomy in Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* **19**, 60-67. [[CrossRef](#)]
1716. Dongbin Ahn, Jin Ho Sohn, Jae Hyug Kim, Ji Young Park, Junesik Park. 2012. Inadvertent Parathyroidectomy during Thyroid Surgery for Papillary Thyroid Carcinoma and Postoperative Hypocalcemia. *Journal of Korean Thyroid Association* **5**, 65. [[CrossRef](#)]
1717. F Vaisman, D Momesso, DA Bulzico, CHCN Pessoa, F Dias, R Corbo, M Vaisman, RM Tuttle. 2012. Spontaneous remission in thyroid cancer patients after biochemical incomplete response to initial therapy. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1718. A. Bazire, S. Lesven, G. Potard, C. Leroyer. 2012. Goitre endothoracique. *EMC - Pneumologie* **9**, 1-8. [[CrossRef](#)]
1719. Marilee Carballo, Roderick M. Quiros. 2012. To Treat or Not to Treat: The Role of Adjuvant Radioiodine Therapy in Thyroid Cancer Patients. *Journal of Oncology* **2012**, 1-11. [[CrossRef](#)]
1720. Hannah G. Piper, Michael A. Skinner. Childhood Diseases of the Thyroid and Parathyroid Glands 745-752. [[CrossRef](#)]
1721. Christian Lerch, Bernd Richter. 2012. Pharmacotherapy Options for Advanced Thyroid Cancer. *Drugs* **72**, 67-85. [[CrossRef](#)]
1722. Sudhi Agarwal, Gyan Chand, Sushila Jaiswal, Anjali Mishra, Gaurav Agarwal, Amit Agarwal, A. K. Verma, S. K. Mishra. 2012. Pattern and Risk Factors of Central Compartment Lymph Node Metastasis in Papillary Thyroid Cancer: A Prospective Study from an Endocrine Surgery Centre. *Journal of Thyroid Research* **2012**, 1-7. [[CrossRef](#)]
1723. Ju-Yeon Kim, Eun-Jung Jung, Soon-Tae Park, Sang-Ho Jeong, Chi-Young Jeong, Young-Tae Ju, Young-Joon Lee, Soon-Chan Hong, Sang-Kyeong Choi, Woo-Song Ha. 2012. Body size and thyroid nodules in healthy Korean population. *Journal of the Korean Surgical Society* **82**, 13. [[CrossRef](#)]
1724. Naifa Lamki Busaidy, Maria E. Cabanillas. 2012. Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive Disease. *Journal of Thyroid Research* **2012**, 1-12. [[CrossRef](#)]
1725. Jin Seong Cho, Jung Han Yoon, Min Ho Park, Sun Hyoung Shin, Young Jong Jegal, Ji Shin Lee, Hee Kyung Kim. 2012. Observational study of central metastases following thyroid lobectomy without a completion thyroidectomy for papillary carcinoma. *Journal of the Korean Surgical Society* **83**, 196. [[CrossRef](#)]

1726. Jeong Won Lee, Sun Hyung Kim, Sang Ah Lee, Gwan Pyo Koh, Sang Mi Lee, Dae Ho Lee. 2012. Serial Measurements of Off-Thyroxine Serum TSH and Thyroglobulin Levels to Predict Local and/or Systemic Metastasis of Papillary Thyroid Cancer after Total Thyroidectomy. *Journal of Korean Thyroid Association* 5, 148. [[CrossRef](#)]
1727. Uma Gunasekaran, Neena Agarwal, Madan H. Jagasia, Shubhada M. Jagasia. 2012. Endocrine Complications in Long-Term Survivors After Allogeneic Stem Cell Transplant. *Seminars in Hematology* 49, 66-72. [[CrossRef](#)]
1728. C. Schneider, C. Kobe, M. Schmidt, D. Kahraman, G. Malchau, M. Faust, H. Schicha, M. Dietlein. 2012. Calcitonin screening in patients with thyroid nodules. *Nuklearmedizin* 51, 228-233. [[CrossRef](#)]
1729. Sze-How Ng, Kai-Pun Wong, Brian Hung-Hin Lang. 2012. Thyroid Surgery for Elderly Patients: Are They at Increased Operative Risks?. *Journal of Thyroid Research* 2012, 1-9. [[CrossRef](#)]
1730. Tae Yong Kim. 2012. Postoperative Follow-Up of Differentiated Thyroid Cancer: Use of Thyroglobulin Assay. *Journal of Korean Thyroid Association* 5, 20. [[CrossRef](#)]
1731. Luca Giovanella. 2012. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. *Expert Review of Endocrinology & Metabolism* 7, 35-43. [[CrossRef](#)]
1732. Jung Eun Huh, Sang Soo Kim, Ji Hyun Kang, Bo Gwang Choi, Byung Joo Lee, Jin Choon Lee, Yun Kyung Jeon, Bo Hyun Kim, Soo Geun Wang, Yong Ki Kim, In Joo Kim. 2012. Predictive Factors for Incidental Contralateral Carcinoma in Patients with Unilateral Micropapillary Thyroid Carcinoma. *Endocrinology and Metabolism* 27, 194. [[CrossRef](#)]
1733. Yasuhiro Ito, Takumi Kudo, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya, Akira Miyauchi. 2011. Lymph Node Recurrence in Patients With N1b Papillary Thyroid Carcinoma Who Underwent Unilateral Therapeutic Modified Radical Neck Dissection. *World Journal of Surgery* . [[CrossRef](#)]
1734. Katsuhiko Tanaka, Hiroshi Sonoo. 2011. Current trends in TSH suppression therapy for patients with papillary thyroid carcinoma in Japan: results of a questionnaire distributed to councilors of the Japanese Society of Thyroid Surgery. *Surgery Today* . [[CrossRef](#)]
1735. M.- S. Ko, K. S. Jeong, Y. K. Shong, G. Y. Gong, J. H. Baek, J. H. Lee. 2011. Collapsing Benign Cystic Nodules of the Thyroid Gland: Sonographic Differentiation from Papillary Thyroid Carcinoma. *American Journal of Neuroradiology* . [[CrossRef](#)]
1736. Fernanda Vaisman, Hernan Tala, Ravinder Grewal, R. Michael Tuttle. 2011. In Differentiated Thyroid Cancer, an Incomplete Structural Response to Therapy Is Associated with Significantly Worse Clinical Outcomes Than Only an Incomplete Thyroglobulin Response. *Thyroid* 21:12, 1317-1322. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1737. Ozlem Soyluk, Harika Boztepe, Ferihan Aral, Faruk Alagol, Nese Colak Özbey. 2011. Papillary Thyroid Carcinoma Patients Assessed to Be at Low or Intermediary Risk After Primary Treatment Are at Greater Risk of Long Term Recurrence If They Are Thyroglobulin Antibody Positive Or Do Not Have Distinctly Low Thyroglobulin at Initial Assessment. *Thyroid* 21:12, 1301-1308. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1738. Jingdong Zhang, Anthony J.M. Gill, Joseph D. Issacs, Bryn Atmore, Amber Johns, Leigh W. Delbridge, Raymond Lai, Todd P.W. McMullen. 2011. The Wnt/ $\beta$ -catenin pathway drives increased cyclin D1 levels in lymph node metastasis in papillary thyroid cancer. *Human Pathology* . [[CrossRef](#)]
1739. Kyu Eun Lee, Do Hoon Koo, Hyung Jun Im, Sue K. Park, June Young Choi, Jin Chul Paeng, June-Key Chung, Seung Keun Oh, Yeo-Kyu Youn. 2011. Surgical completeness of bilateral axillo-breast approach robotic thyroidectomy: Comparison with conventional open thyroidectomy after propensity score matching. *Surgery* 150, 1266-1274. [[CrossRef](#)]
1740. Dorota A. Krajewski, Kenneth D. Burman. 2011. Thyroid Disorders in Pregnancy. *Endocrinology and Metabolism Clinics of North America* 40, 739-763. [[CrossRef](#)]
1741. Hee Kyung Kim, Soo Youn Lee, Ji In Lee, Hye Won Jang, Soo Kyoung Kim, Hye Soo Chung, Alice Hyun Kyung Tan, Kyu Yeon Hur, Jae Hyeon Kim, Jae Hoon Chung, Sun Wook Kim. 2011. Daily urine iodine excretion while consuming a low-iodine diet in preparation for radioactive iodine therapy in a high iodine intake area. *Clinical Endocrinology* 75, 851-856. [[CrossRef](#)]
1742. Iain J. Nixon, Ian Ganly, Snehal Patel, Frank L. Palmer, Monica M. Whitcher, Robert M. Tuttle, Ashok R. Shaha, Jatin P. Shah. 2011. The impact of microscopic extrathyroid extension on outcome in patients with clinical T1 and T2 well-differentiated thyroid cancer. *Surgery* 150, 1242-1249. [[CrossRef](#)]
1743. Aleksandra Popadich, Olga Levin, James C. Lee, Stephanie Smooke-Praw, Kevin Ro, Maisam Fazel, Asit Arora, Neil S. Tolley, Fausto Palazzo, Diana L. Learoyd, Stan Sidhu, Leigh Delbridge, Mark Sywak, Michael W. Yeh. 2011. A multicenter cohort study of total thyroidectomy and routine central lymph node dissection for cN0 papillary thyroid cancer. *Surgery* 150, 1048-1057. [[CrossRef](#)]
1744. A. Georges, J.-B. Corcuff, J. Brossaud, L. Bordenave. 2011. Particularités méthodologiques et interprétation du dosage de thyroglobuline sérique. *Médecine Nucléaire* . [[CrossRef](#)]
1745. Devrim Ersahin, Indukala Doddamane, David Cheng. 2011. Targeted Radionuclide Therapy. *Cancers* 3, 3838-3855. [[CrossRef](#)]

1746. L.-M. Vija, M.-E. Toubert. 2011. Place de l'imagerie dans la thérapeutique des cancers thyroïdiens différenciés. *Médecine Nucléaire* . [[CrossRef](#)]
1747. Gilberto Teixeira, Thiago Teixeira, Fernando Gubert, Horácio Chikota, Ralph Tufano. 2011. The incidence of central neck micrometastatic disease in patients with papillary thyroid cancer staged preoperatively and intraoperatively as N0. *Surgery* **150**, 1161-1167. [[CrossRef](#)]
1748. Iwao Sugitani, Yoshihide Fujimoto. 2011. Effect of postoperative thyrotropin suppressive therapy on bone mineral density in patients with papillary thyroid carcinoma: A prospective controlled study. *Surgery* **150**, 1250-1257. [[CrossRef](#)]
1749. C. Massart. 2011. Suivi au long cours du traitement freinateur des cancers thyroïdiens différenciés. *Médecine Nucléaire* . [[CrossRef](#)]
1750. Carles Zafon. 2011. Tratamiento supresor de la TSH en el cáncer diferenciado de tiroides. Un dogma en revisión. *Endocrinología y Nutrición* . [[CrossRef](#)]
1751. Yung Hsiang Kao, Siew Sing Lim, Seng Chuan Ong, Ajit Kumar Padhy. 2011. Thyroid Incidentalomas on Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography: Incidence, Malignancy Risk, and Comparison of Standardized Uptake Values. *Canadian Association of Radiologists Journal* . [[CrossRef](#)]
1752. Rashmi Roy, Guennadi Kouniavsky, Eric Schneider, John D. Allendorf, John A. Chabot, Paul Logerfo, Alan P.B. Dackiw, Paul Colombani, Martha A. Zeiger, James A. Lee. 2011. Predictive factors of malignancy in pediatric thyroid nodules. *Surgery* **150**, 1228-1233. [[CrossRef](#)]
1753. James T. Broome, Carmen C. Solorzano. 2011. The impact of atypia/follicular lesion of undetermined significance on the rate of malignancy in thyroid fine-needle aspiration: Evaluation of the Bethesda System for Reporting Thyroid Cytopathology. *Surgery* **150**, 1234-1241. [[CrossRef](#)]
1754. Soo Youn Bae, Jung-Hyun Yang, Min-Young Choi, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim. 2011. Right Paraesophageal Lymph Node Dissection in Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]
1755. Tatsuya Higashi, Takashi Kudo, Seigo Kinuya. 2011. Radioactive iodine (131I) therapy for differentiated thyroid cancer in Japan: current issues with historical review and future perspective. *Annals of Nuclear Medicine* . [[CrossRef](#)]
1756. A. M. Sawka, S. Straus, A. Gafni, S. Meiyappan, D. David, G. Rodin, J. D. Brierley, R. W. Tsang, L. Thabane, L. Rotstein, S. Ezzat, D. P. Goldstein. 2011. Thyroid cancer patients' involvement in adjuvant radioactive iodine treatment decision-making and decision regret: an exploratory study. *Supportive Care in Cancer* . [[CrossRef](#)]
1757. Gilberto V. Teixeira, Horacio Chikota, Thiago Teixeira, Gabriel Manfro, Sara I. Pai, Ralph P. Tufano. 2011. Incidence of Malignancy in Thyroid Nodules Determined to be Follicular Lesions of Undetermined Significance on Fine-Needle Aspiration. *World Journal of Surgery* . [[CrossRef](#)]
1758. M. Regina Castro, Rachel P. Espiritu, Rebecca S. Bahn, Michael R. Henry, Hossein Gharib, Pedro J. Caraballo, John C. Morris. 2011. Predictors of Malignancy in Patients with Cytologically Suspicious Thyroid Nodules. *Thyroid* **21**:11, 1191-1198. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1759. Hee Jung Moon, Jin Young Kwak, Eun-Kyung Kim, Min Jung Kim. 2011. A Taller-Than-Wide Shape in Thyroid Nodules in Transverse and Longitudinal Ultrasonographic Planes and the Prediction of Malignancy. *Thyroid* **21**:11, 1249-1253. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1760. Manfred Blum, Serafin Tiu, Michael Chu, Sumina Goel, Kent Friedman. 2011. I-131 SPECT/CT Elucidates Cryptic Findings on Planar Whole-Body Scans and Can Reduce Needless Therapy with I-131 in Post-Thyroidectomy Thyroid Cancer Patients. *Thyroid* **21**:11, 1235-1247. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1761. Gilbert H. Daniels. 2011. Screening for Medullary Thyroid Carcinoma with Serum Calcitonin Measurements in Patients with Thyroid Nodules in the United States and Canada. *Thyroid* **21**:11, 1199-1207. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1762. U. Rajendra Acharya, S. Vinitha Sree, M. Muthu Rama Krishnan, Filippo Molinari, Roberto Garberoglio, Jasjit S. Suri. 2011. Non-invasive automated 3D thyroid lesion classification in ultrasound: A class of ThyroScan™ systems. *Ultrasonics* . [[CrossRef](#)]
1763. Juan Carlos Galofré, José Manuel Gómez-Sáez, Cristina Álvarez Escola, Elías Álvarez García, Emma Anda Apiñaniz, Amparo Calleja, Sergio Donnay, Anna Lucas-Martin, Edelmiro Menéndez Torre, Elena Navarro González, Vicente Pereg, Begoña Pérez Corral, Javier Santamaría Sandi, Garcilaso Riesco Eizaguirre, Carles Zafón Llopis. 2011. Use of new molecules in the treatment of advanced thyroid cancer. *Endocrinología y Nutrición (English Edition)* . [[CrossRef](#)]
1764. Frederik A. Verburg, Boudewijn Brans, Felix M. Mottaghy. 2011. Molecular nuclear therapies for thyroid carcinoma. *Methods* **55**, 230-237. [[CrossRef](#)]

1765. HANNA PELTTARI, CAMILLA SCHALIN-JÄNTTI, JOHANNA AROLA, ELIISA LÖYTTYNIEMI, SAKARI KNUUTILA, MATTI J. VÄLIMÄKI. 2011. BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. *APMIS* no-no. [[CrossRef](#)]
1766. Martin Schlumberger, Cécile Chougnet, Éric Baudin, Sophie Leboulleux. 2011. Cancers réfractaires de la thyroïde. *La Presse Médicale* . [[CrossRef](#)]
1767. Dong Wook Kim, Eun Joo Lee, Jun Hyung Lee. 2011. Role of Ultrasound Diagnosis in Assessing and Managing Thyroid Nodules With Inadequate Cytology. *American Journal of Roentgenology* **197**, 1213-1219. [[CrossRef](#)]
1768. Andrew J Bauer, Gary L Francis. 2011. Update on the molecular signature of differentiated thyroid cancer: clinical implications and potential opportunities. *Expert Review of Endocrinology & Metabolism* **6**, 819-834. [[CrossRef](#)]
1769. Gudrun Leidig-Bruckner, Gerd Cichorowski, Peter Sattler, Thomas Bruckner, Bernd Sattler. 2011. Evaluation of thyroid nodules - combined use of MIBI-scintigraphy and aspiration cytology to assess risk of malignancy and stratify patients for surgical or non-surgical therapy - a retrospective cohort study. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1770. Françoise Borson-Chazot, Claire Bournaud. 2011. Faut-il dépister les cancers de la thyroïde ?. *La Presse Médicale* . [[CrossRef](#)]
1771. Nerea Sebastián-Ochoa, José Carlos Fernández-García, Isabel Mancha Doblas, Arantzazu Sebastián-Ochoa, Diego Fernández García, María Victoria Ortega Jiménez, Elena Gallego Domínguez, Francisco Tinahones Madueño. 2011. Clinical experience in a high-resolution thyroid nodule clinic. *Endocrinología y Nutrición (English Edition)* . [[CrossRef](#)]
1772. Yasuhiro Ito, Yukiko Tsushima, Hiroo Masuoka, Tomonori Yabuta, Mitsuhiro Fukushima, Hiroyuki Inoue, Chisato Tomoda, Minoru Kihara, Takuya Higashiyama, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya, Akira Miyauchi. 2011. Significance of prophylactic modified radical neck dissection for patients with low-risk papillary thyroid carcinoma measuring 1.1–3.0 cm: First report of a trial at Kuma Hospital. *Surgery Today* **41**, 1486-1491. [[CrossRef](#)]
1773. Constantine Theoharis, Sanziana Roman, Julie Ann Sosa. 2011. The molecular diagnosis and management of thyroid neoplasms. *Current Opinion in Oncology* **1**. [[CrossRef](#)]
1774. Michele N. Minuto, Piero Berti, Mario Miccoli, Clara Ugolini, Valeria Matteucci, Manuela Moretti, Fulvio Basolo, Paolo Miccoli. 2011. Minimally invasive video-assisted thyroidectomy: an analysis of results and a revision of indications. *Surgical Endoscopy* . [[CrossRef](#)]
1775. J. A. Smith, J. C. Watkinson, A. Shaha. 2011. Who should perform thyroid surgery? United Kingdom (UK) and United States (US) perspectives with recommendations. *European Archives of Oto-Rhino-Laryngology* . [[CrossRef](#)]
1776. Se Kyung Lee, Sung Hoon Kim, Sung Mo Hur, Jun-Ho Choe, Jung-Han Kim, Jee Soo Kim. 2011. The Efficacy of Lateral Neck Sentinel Lymph Node Biopsy in Papillary Thyroid Carcinoma. *World Journal of Surgery* . [[CrossRef](#)]
1777. Yong Bae Ji, Keon Joong Lee, Yong Soo Park, Sang Mo Hong, Seung Sam Paik, Kyung Tae. 2011. Clinical Efficacy of Sentinel Lymph Node Biopsy Using Methylene Blue Dye in Clinically Node-Negative Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]
1778. Brian Hung-Hin Lang, Kai Pun Wong, Koon Yat Wan, Chung-Yau Lo. 2011. Significance of Metastatic Lymph Node Ratio on Stimulated Thyroglobulin Levels in Papillary Thyroid Carcinoma after Prophylactic Unilateral Central Neck Dissection. *Annals of Surgical Oncology* . [[CrossRef](#)]
1779. Victoriya S. Chernyavsky, Beth-Ann Shanker, Tomer Davidov, Jessica S. Crystal, Oliver Eng, Kareem Ibrahim, Jonathan Kwong, Stanley Z. Trooskin. 2011. Is One Benign Fine Needle Aspiration Enough?. *Annals of Surgical Oncology* . [[CrossRef](#)]
1780. The American Thyroid Association Taskforce on Thyroid Disease During Pregnancy and Postpartum, Alex Stagnaro-Green, Marcos Abalovich, Erik Alexander, Fereidoun Azizi, Jorge Mestman, Roberto Negro, Angelita Nixon, Elizabeth N. Pearce, Offie P. Soldin, Scott Sullivan, Wilmar Wiersinga. 2011. Guidelines of the American Thyroid Association for the Diagnosis and Management of Thyroid Disease During Pregnancy and Postpartum. *Thyroid* **21**:10, 1081-1125. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1781. Beatrix Cochand-Priollet, Henri Dahan, Marie Laloi-Michelin, Marc Polivka, Michele Saada, Philippe Herman, Pierre-Jean Guillausseau, Lounis Hamzi, Nicolas Poté, Emile Sarfati, Michel Wassef, Herve Combe, Danielle Raulic-Raimond, Pierre Chedin, Virginie Medeau, Daniele Casanova, Romain Kania. 2011. Immunocytochemistry with Cytokeratin 19 and Anti-Human Mesothelial Cell Antibody (HBME1) Increases the Diagnostic Accuracy of Thyroid Fine-Needle Aspirations: Preliminary Report of 150 Liquid-Based Fine-Needle Aspirations with Histological Control. *Thyroid* **21**:10, 1067-1073. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1782. Marijn M. Speeckaert, Reinhart Speeckaert, Katrien Wierckx, Joris R. Delanghe, Jean-Marc Kaufman. 2011. Value and pitfalls in iodine fortification and supplementation in the 21st century. *British Journal of Nutrition* **106**, 964-973. [[CrossRef](#)]

1783. Jung Hyun Yoon, Eun-Kyung Kim, Eun Ju Son, Hee Jung Moon, Jin Young Kwak. 2011. Diffuse Microcalcifications Only of the Thyroid Gland Seen on Ultrasound: Clinical Implication and Diagnostic Approach. *Annals of Surgical Oncology* **18**, 2899-2906. [[CrossRef](#)]
1784. Stuart D. Wilson, Kara M. Doffek, Tracy S. Wang, Elizabeth A. Krzywda, Douglas B. Evans, Tina W.F. Yen. 2011. Primary hyperparathyroidism with a history of head and neck irradiation: The consequences of associated thyroid tumors. *Surgery* **150**, 869-877. [[CrossRef](#)]
1785. Jill E Langer, Susan J Mandel. 2011. Thyroid nodule sonography: assessment for risk of malignancy. *Imaging in Medicine* **3**, 513-524. [[CrossRef](#)]
1786. Frederik A. Verburg, Johannes W.A. Smit, Inge Grelle, Theo J. Visser, Robin P. Peeters, Christoph Reiners. 2011. Changes within the thyroid axis after long-term TSH-suppressive levothyroxine therapy. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1787. Cheng-Ping Wang, Tseng-Cheng Chen, Tsung-Lin Yang, Chun-Nan Chen, Chin-Fon Lin, Pei-Jen Lou, Ya-Ling Hu, Ming-Jium Shieh, Fon-Jou Hsieh, Tzu-Yu Hsiao, Jenq-Yuh Ko. 2011. Transcutaneous ultrasound for evaluation of vocal fold movement in patients with thyroid disease. *European Journal of Radiology* . [[CrossRef](#)]
1788. Juan J. Chillarón, Mercè Fernández-Miró, Cristina Colom. 2011. Nódulos tiroideos. *FMC - Formación Médica Continuada en Atención Primaria* **18**, 481-485. [[CrossRef](#)]
1789. Marcin Barczyński, Aleksander Konturek, Małgorzata Stopa, Stanisław Cichoń, Piotr Richter, Wojciech Nowak. 2011. Total Thyroidectomy for Benign Thyroid Disease. *Annals of Surgery* **1**. [[CrossRef](#)]
1790. Iain J. Nixon, Ian Ganly, Snehal G. Patel, Frank L. Palmer, Monica M. Whitcher, Robert M. Tuttle, Ashok Shaha, Jatin P. Shah. 2011. Thyroid lobectomy for treatment of well differentiated intrathyroid malignancy. *Surgery* . [[CrossRef](#)]
1791. Jason D. Prescott, Sareh Parangi. 2011. Bilaterality in Papillary Thyroid Carcinoma: Does It Influence Prognosis?. *Annals of Surgical Oncology* . [[CrossRef](#)]
1792. Patricia Papendieck, Laura Gruñeiro-Papendieck, Marcela Venara, Oscar Acha, Silvana Maglio, Ignacio Bergadá, Ana Chiesa. 2011. Differentiated thyroid carcinoma: presentation and follow-up in children and adolescents. *Journal of Pediatric Endocrinology and Metabolism* ---. [[CrossRef](#)]
1793. D. W. Kim, E. J. Lee, S. J. Jung, J. H. Ryu, Y. M. Kim. 2011. Role of Sonographic Diagnosis in Managing Bethesda Class III Nodules. *American Journal of Neuroradiology* . [[CrossRef](#)]
1794. M. Schlumberger, S. Sherman. 2011. REVIEW TOPIC: ENDOCRINE TUMOURS Approach to the patient with advanced differentiated thyroid cancer. *European Journal of Endocrinology* . [[CrossRef](#)]
1795. Olivier Esnault, Brigitte Franc, Fabrice Ménégau, Agnès Rouxel, Eric De Kerviler, Pierre Bourrier, François Lacoste, Jean-Yves Chapelon, Laurence Leenhardt. 2011. High-Intensity Focused Ultrasound Ablation of Thyroid Nodules: First Human Feasibility Study. *Thyroid* **21**:9, 965-973. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1796. Jill E. Langer, Rajan Agarwal, Hongming Zhuang, Steve Shih-Lin Huang, Susan J. Mandel. 2011. Correlation of Findings from Iodine 123 Scan and Ultrasonography in the Recommendation for Thyroid Fine-Needle Aspiration Biopsy. *Endocrine Practice* **17**, 699-706. [[CrossRef](#)]
1797. A. Mouaden, H. Guerrouj, M. El Amrani, W. Boumaaza, I. Ghfir, N. Ben Rais. 2011. Valeur pronostique du curage ganglionnaire prophylactique dans le cancer différencié de la thyroïde. *Médecine Nucléaire* . [[CrossRef](#)]
1798. M. Sellami, S. Tababi, J. Mamy, R. Zainine, A. Charfi, N. Beltaief, S. Sahtout, G. Besbes. 2011. Interest of fine-needle aspiration cytology in thyroid nodule. *European Annals of Otorhinolaryngology, Head and Neck Diseases* **128**, 159-164. [[CrossRef](#)]
1799. Gabriele Galata, Klaus-Martin Schulte. 2011. Management of the thyroid nodule. *Surgery (Oxford)* **29**, 434-439. [[CrossRef](#)]
1800. Gerardo Amabile, Mario Rotondi, Barbara Pirali, Rosa Dionisio, Lucio Agozzino, Michele Lanza, Luciano Buonanno, Bruno Di Filippo, Rodolfo Fonte, Luca Chiovato. 2011. Interstitial laser photocoagulation for benign thyroid nodules: Time to treat large nodules. *Lasers in Surgery and Medicine* **43**:10.1002/lsm.v43.8, 797-803. [[CrossRef](#)]
1801. Martin Schlumberger. 2011. Targeted therapy in refractory thyroid cancer. *European Journal of Cancer* **47**, S328-S329. [[CrossRef](#)]
1802. Leslie Eisenbud Quint, Kuanwong Watcharotone, James D. Myles, Larry D. Gruppen, Patricia B. Mullan. 2011. Incidental Findings at Chest CT. *Academic Radiology* . [[CrossRef](#)]
1803. M. G. Castagna, F. Maino, C. Cipri, V. Belardini, A. Theodoropoulou, G. Cevenini, F. Pacini. 2011. Delayed risk stratification, to include the response to initial treatment (surgery and radioiodine ablation), has better outcome predictivity in differentiated thyroid cancer patients. *European Journal of Endocrinology* **165**, 441-446. [[CrossRef](#)]
1804. Gilbert Daniels. 2011. What if Many Follicular Variant Papillary Thyroid Carcinomas are Not Malignant? A Review of Follicular Variant Papillary Thyroid Carcinoma and a Proposal for a new Classification. *Endocrine Practice* **17**, 768-787. [[CrossRef](#)]

1805. Nerea Sebastián-Ochoa, José Carlos Fernández-García, Isabel Mancha Doblás, Arantazu Sebastián-Ochoa, Diego Fernández García, María Victoria Ortega Jiménez, Elena Gallego Domínguez, Francisco Tinahones Madueño. 2011. Experiencia clínica en una consulta de alta resolución de nódulo tiroideo. *Endocrinología y Nutrición* . [[CrossRef](#)]
1806. C. Durante, G. Tallini, E. Puxeddu, M. Sponziello, S. Moretti, C. Ligorio, A. Cavaliere, K. J. Rhoden, A. Verrienti, M. Maranghi, L. Giacomelli, D. Russo, S. Filetti. 2011. BRAFV600E mutation and expression of proangiogenic molecular markers in papillary thyroid carcinomas. *European Journal of Endocrinology* **165**, 455-463. [[CrossRef](#)]
1807. Juan Carlos Galofré, José Manuel Gómez-Sáez, Cristina Álvarez Escola, Elías Álvarez García, Emma Anda Apiñaniz, Amparo Calleja, Sergio Donnay, Anna Lucas-Martin, Edelmiro Menéndez Torre, Elena Navarro González, Vicente Pereg, Begoña Pérez Corral, Javier Santamaría Sandi, Garcilaso Riesco Eizaguirre, Carles Zafón Llopis. 2011. Uso de nuevas moléculas en el tratamiento del cáncer avanzado de tiroides. *Endocrinología y Nutrición* . [[CrossRef](#)]
1808. L. Leenhardt, F. Borson-Chazot, M. Calzada, B. Carnaille, A. Charrié, B. Cochand-Priollet, C. Do Cao, S. Leboulleux, G. Le Clech, G. Mansour, F. Menegaux, H. Monpeyssen, J. Orgiazzi, A. Rouxel, J.L. Sadoul, M. Schlumberger, J. Tramalloni, F. Tranquart, J.L. Wemeau. 2011. Guide de bonnes pratiques pour l'usage de l'échographie cervicale et des techniques écho-guidées dans la prise en charge des cancers thyroïdiens différenciés de souche vésiculaire. *Annales d'Endocrinologie* **72**, H1-H26. [[CrossRef](#)]
1809. Jin Young Kwak, Kyung Hwa Han, Jung Hyun Yoon, Hee Jung Moon, Eun Ju Son, So Hee Park, Hyun Kyung Jung, Ji Soo Choi, Bo Mi Kim, Eun-Kyung Kim. 2011. Thyroid Imaging Reporting and Data System for US Features of Nodules: A Step in Establishing Better Stratification of Cancer Risk. *Radiology* **260**, 892-899. [[CrossRef](#)]
1810. Che-Wei Wu, Gianlorenzo Dionigi, Ka-Wo Lee, Pi-Jung Hsiao, Ming-Chen Paul Shin, Kuo-Bow Tsai, Feng-Yu Chiang. 2011. Calcifications in thyroid nodules identified on preoperative computed tomography: Patterns and clinical significance. *Surgery* . [[CrossRef](#)]
1811. J.-L. Wemeau, J.-L. Sadoul, M. d'Herbomez, H. Monpeyssen, J. Tramalloni, E. Leteurtre, F. Borson-Chazot, P. Caron, B. Carnaille, J. Léger, C. Do, M. Klein, I. Raingeard, R. Desailoud, L. Leenhardt. 2011. Guidelines of the French society of endocrinology for the management of thyroid nodules. *Annales d'Endocrinologie* **72**, 251-281. [[CrossRef](#)]
1812. M. Sellami, S. Tababi, J. Mamy, R. Zainine, A. Charfi, N. Beltaief, S. Sahtout, G. Besbes. 2011. Intérêt de la cytoponction à l'aiguille fine des nodules thyroïdiens. *Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale* **128**, 195-201. [[CrossRef](#)]
1813. Yoon Kyoung So, Young-Ik Son, Chung-Hwan Baek, Han-Sin Jeong, Man Ki Chung, Young-Hyeh Ko. 2011. Expression of Sodium-Iodide Symporter and TSH Receptor in Subclinical Metastatic Lymph Nodes of Papillary Thyroid Microcarcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]
1814. Kristien Boelaert, Christopher J. McCabe. 2011. Thyroid cancer: Finding the malignant thyroid nodule in the haystack. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1815. Yuri E. Nikiforov, Marina N. Nikiforova. 2011. Molecular genetics and diagnosis of thyroid cancer. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1816. Haggi Mazeh, Herbert Chen. 2011. Advances in surgical therapy for thyroid cancer. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1817. J. C. Galofre, J. M. Gomez-Saez, C. A. Escola, E. Anda, A. Calleja, S. Donnay, A. Lucas-Martin, E. Menendez-Torre, V. Pereg, B. Perez-Corral, J. Santamaria, G. Riesco-Eizaguirre, C. Zafon. 2011. Treatment of thyroid cancer with the new oral agents. *Annals of Oncology* . [[CrossRef](#)]
1818. Sang Min Hyun, Hyoung Young Song, Sang Yoon Kim, Soon Yuhl Nam, Jong-Lyel Roh, Myung Woul Han, Seung-Ho Choi. 2011. Impact of Combined Prophylactic Unilateral Central Neck Dissection and Hemithyroidectomy in Patients with Papillary Thyroid Microcarcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]
1819. Christoph Reiners, Heribert Hänscheid, Markus Luster, Michael Lassmann, Frederik A. Verburg. 2011. Radioiodine for remnant ablation and therapy of metastatic disease. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1820. Martin Schlumberger, Isabelle Borget, Camila Nascimento, Maryse Brassard, Sophie Leboulleux. 2011. Treatment and follow-up of low-risk patients with thyroid cancer. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1821. Charles H. Emerson. 2011. When Will Thyrotropin Receptor Antagonists and Inverse Thyrotropin Receptor Agonists Become Available for Clinical Use?. *Thyroid* **21**:8, 817-819. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1822. Geneviève Rondeau, Stephanie Fish, Lucy E. Hann, James A. Fagin, R. Michael Tuttle. 2011. Ultrasonographically Detected Small Thyroid Bed Nodules Identified After Total Thyroidectomy for Differentiated Thyroid Cancer Seldom Show Clinically Significant Structural Progression. *Thyroid* **21**:8, 845-853. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1823. Anna M. Sawka, Sharon Straus, Amiram Gafni, Soumia Meiyappan, Mary Ann O'Brien, James D. Brierley, Richard W. Tsang, Lorne Rotstein, Lehana Thabane, Gary Rodin, Susan R. George, David P. Goldstein. 2011. A usability study of a computerized

- decision aid to help patients with, early stage papillary thyroid carcinoma in, decision-making on adjuvant radioactive iodine treatment. *Patient Education and Counseling* **84**, e24-e27. [[CrossRef](#)]
1824. Jong-Ryool Oh, Byung-Hyun Byun, Sun-Pyo Hong, Ari Chong, Jahae Kim, Su-Woong Yoo, Sae-Ryung Kang, Dong-Yeon Kim, Ho-Chun Song, Hee-Seung Bom, Jung-Joon Min. 2011. Comparison of 131I whole-body imaging, 131I SPECT/CT, and 18F-FDG PET/CT in the detection of metastatic thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* **38**, 1459-1468. [[CrossRef](#)]
1825. Megan K. Lessig, Andrew J. Bauer. 2011. Thyroid Cancer: Caring for the Pediatric Patient. *Journal of Pediatric Nursing* **26**, 388-391. [[CrossRef](#)]
1826. H Karga, K Mavroudis, I Giagourta, M Triantaphyllopoulou, V Ktena, G Kassi, H Veloutsou, P Papapetrou. 2011. Changes in TNM stage, reoperation and 131-I ablation rate, during the use of newer methods for the preoperative diagnosis of differentiated thyroid carcinoma. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1827. Alexandre Bozec, Olivier Dassonville, Emmanuel Chamorey, Gilles Poissonnet, Anne Sudaka, Isabelle Peyrottes, Francette Ettore, Juliette Haudebourg, Françoise Bussière, Danielle Benisvy, Pierre-Yves Marcy, Jean Louis Sadoul, Paul Hofman, Sandra Lassale, Jacques Vallicioni, François Demard, José Santini. 2011. Clinical impact of cervical lymph node involvement and central neck dissection in patients with papillary thyroid carcinoma: a retrospective analysis of 368 cases. *European Archives of Oto-Rhino-Laryngology* **268**, 1205-1212. [[CrossRef](#)]
1828. Cristina Aparecida Troques da Silveira Mitteldorf, Juliana Moreira de Sousa-Canavez, Kátia Ramos Moreira Leite, Celso Massumoto, Luis Heraldo Camara-Lopes. 2011. FN1, GALE, MET, and QPCT overexpression in papillary thyroid carcinoma: Molecular analysis using frozen tissue and routine fine-needle aspiration biopsy samples. *Diagnostic Cytopathology* **39**:10.1002/dc.v39.8, 556-561. [[CrossRef](#)]
1829. Hee Jung Moon, Jung Hyun Yoon, Jin Young Kwak, Woong Youn Chung, Kee-Hyun Nam, Jong Ju Jeong, Eun-Kyung Kim. 2011. Positive Predictive Value and Interobserver Variability of Preoperative Staging Sonography for Thyroid Carcinoma. *American Journal of Roentgenology* **197**, W324-W330. [[CrossRef](#)]
1830. Ashok R. Shaha. 2011. Controversies about the central compartment in thyroid cancer. *European Archives of Oto-Rhino-Laryngology* **268**, 1097-1099. [[CrossRef](#)]
1831. Christelle de la Fouchardiere, Jean-Pierre Droz. 2011. Targeted therapies and thyroid cancer. *Anti-Cancer Drugs* **22**, 688-699. [[CrossRef](#)]
1832. Elaine C. Morari, Marjory A. Marcello, Ana Carolina T. Guilhen, Lucas L. Cunha, Paulo Latuff, Fernando A. Soares, José Vassallo, Laura S. Ward. 2011. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. *Clinical Endocrinology* **75**:10.1111/cen.2011.75.issue-2, 247-254. [[CrossRef](#)]
1833. Jong-Lyel Roh, Jin-Man Kim, Chan Il Park. 2011. Central Lymph Node Metastasis of Unilateral Papillary Thyroid Carcinoma: Patterns and Factors Predictive of Nodal Metastasis, Morbidity, and Recurrence. *Annals of Surgical Oncology* **18**, 2245-2250. [[CrossRef](#)]
1834. Ozgur Mete, Sylvia L Asa. 2011. Pathological definition and clinical significance of vascular invasion in thyroid carcinomas of follicular epithelial derivation. *Modern Pathology* . [[CrossRef](#)]
1835. Onyebuchi E Okosieme. 2011. Thyroid hormone replacement: current status and challenges. *Expert Opinion on Pharmacotherapy* 1-14. [[CrossRef](#)]
1836. P. V. Pradeep, Vijayabhaskar Gouru. 2011. Comment on "Surveillance and Intervention after Thyroid Lobectomy". *Annals of Surgical Oncology* . [[CrossRef](#)]
1837. James Nagarajah, Walter Jentzen, Verena Hartung, Sandra Rosenbaum-Krumme, Christian Mikat, Till Alexander Heusner, Gerald Antoch, Andreas Bockisch, Alexander Stahl. 2011. Diagnosis and dosimetry in differentiated thyroid carcinoma using 124I PET: comparison of PET/MRI vs PET/CT of the neck. *European Journal of Nuclear Medicine and Molecular Imaging* . [[CrossRef](#)]
1838. Feriyil Bhajjee, Yuri E. Nikiforov. 2011. Molecular Analysis of Thyroid Tumors. *Endocrine Pathology* . [[CrossRef](#)]
1839. Hiroshi Wakabayashi, Kenichi Nakajima, Makoto Fukuoka, Anri Inaki, Ayane Nakamura, Daiki Kayano, Seigo Kinuya. 2011. Double-phase 131I whole body scan and 131I SPECT-CT images in patients with differentiated thyroid cancer: their effectiveness for accurate identification. *Annals of Nuclear Medicine* . [[CrossRef](#)]
1840. Luca Giovanella, Frederik A. Verburg. 2011. Ruling Out 131I Ablation in Low-Risk Differentiated Thyroid Carcinoma Basing on Thyroglobulin Measurement. *Thyroid* **21**:7, 809-810. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1841. Kiminori Sugino, Koichi Ito, Mitsuji Nagahama, Wataru Kitagawa, Hiroshi Shibuya, Keiko Ohkuwa, Yukiko Yano, Takashi Uruno, Junko Akaishi, Kaori Kameyama, Kunihiro Ito. 2011. Prognosis and Prognostic Factors for Distant Metastases and Tumor Mortality in Follicular Thyroid Carcinoma. *Thyroid* **21**:7, 751-757. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]



1842. Pedro Wesley Rosario. 2011. Response to Giovanella and Verburg. *Thyroid* **21**:7, 811-812. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1843. Adebowale J. Adeniran, Constantine Theoharis, Pei Hui, Manju L. Prasad, Lynwood Hammers, Tobias Carling, Robert Udelsman, David C. Chhieng. 2011. Reflex BRAF Testing in Thyroid Fine-Needle Aspiration Biopsy with Equivocal and Positive Interpretation: A Prospective Study. *Thyroid* **21**:7, 717-723. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1844. Furio Pacini, Mona M. Sabra, R. Michael Tuttle. 2011. Clinical Relevance of Thyroglobulin Doubling Time in the Management of Patients with Differentiated Thyroid Cancer. *Thyroid* **21**:7, 691-692. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1845. Hee Jung Moon, Eun-Kyung Kim, Woong Youn Chung, Jung Hyun Yoon, Jin Young Kwak. 2011. Minimal Extrathyroidal Extension in Patients with Papillary Thyroid Microcarcinoma: Is It a Real Prognostic Factor?. *Annals of Surgical Oncology* **18**, 1916-1923. [[CrossRef](#)]
1846. M. Elola, A. Yoldi, J.I. Emparanza, T. Matteucci, I. Bilbao, M. Goena. 2011. Experiencia con rosiglitazona como tratamiento rediferenciador en un caso de carcinoma papilar de tiroides con metástasis pulmonares y ausencia de captación de radioyodo. *Revista Española de Medicina Nuclear* **30**, 241-243. [[CrossRef](#)]
1847. Jeong Won Lee, Sang Mi Lee, Gwan Pyo Koh, Dae Ho Lee. 2011. The comparison of 131I whole-body scans on the third and tenth day after 131I therapy in patients with well-differentiated thyroid cancer: preliminary report. *Annals of Nuclear Medicine* **25**, 439-446. [[CrossRef](#)]
1848. F. Vaisman, A. Shaha, S. Fish, R. Michael Tuttle. 2011. Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer. *Clinical Endocrinology* **75**:10.1111/cen.2011.75.issue-1, 112-119. [[CrossRef](#)]
1849. Malavika Nathan, Fahim-ul Hassan, Hosahalli K Mohan. 2011. Advances in imaging in differentiated thyroid cancer: focus on SPECT/CT and PET/CT. *Expert Review of Endocrinology & Metabolism* **6**, 599-616. [[CrossRef](#)]
1850. Dana M. Hartl, Jean-Paul Travagli. 2011. Central Compartment Neck Dissection for Thyroid Cancer: A Surgical Technique. *World Journal of Surgery* **35**, 1553-1559. [[CrossRef](#)]
1851. B van Zaane, A Squizzato, J Debeij, O. M. Dekkers, J. C. M. Meijers, A. P. van Zanten, H. R. Büller, V. E. A. Gerdes, S. C Cannegieter, D. P. M. Brandjes. 2011. Alterations in Coagulation and Fibrinolysis after Levothyroxine Exposure in Healthy Volunteers: A Controlled Randomized Crossover Study. *Journal of Thrombosis and Haemostasis* no-no. [[CrossRef](#)]
1852. John I. Lew, Rebecca A. Snyder, Yamile M. Sanchez, Carmen C. Solorzano. 2011. Fine Needle Aspiration of the Thyroid: Correlation with Final Histopathology in a Surgical Series of 797 Patients. *Journal of the American College of Surgeons* **213**, 188-194. [[CrossRef](#)]
1853. Vincenzo Marotta, Maria Rosaria Sapio, Anna Guerra, Mario Vitale. 2011. BRAF mutation in cytology samples as a diagnostic tool for papillary thyroid carcinoma. *Expert Opinion on Medical Diagnostics* **5**, 277-290. [[CrossRef](#)]
1854. Flavia Magri, Spyridon Chytiris, Valentina Capelli, Sarah Alessi, Elisa Nalon, Mario Rotondi, Sara Cassibba, Fabrizio Calliada, Luca Chiovato. 2011. Shear wave elastography in the diagnosis of thyroid nodules: feasibility in the case of coexistent chronic autoimmune Hashimoto's thyroiditis. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1855. Hari A Deshpande, Daniel Morgensztern, Julie Ann Sosa. 2011. Medullary thyroid cancer in the past, present and future: from bench to bedside. *Expert Review of Endocrinology & Metabolism* **6**, 585-597. [[CrossRef](#)]
1856. M. Elola, A. Yoldi, J.I. Emparanza, T. Matteucci, I. Bilbao, M. Goena. 2011. Redifferentiation therapy with rosiglitazone in a case of differentiated thyroid cancer with pulmonary metastases and absence of radioiodine uptake. *Revista Española de Medicina Nuclear (English Edition)* **30**, 241-243. [[CrossRef](#)]
1857. Mubashir Mulla, Klaus-Martin Schulte. 2011. Central cervical lymph node metastases in papillary thyroid cancer: a systematic review of imaging-guided and prophylactic removal of the central compartment. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1858. Dimitra A. Vassiliadi, Stylianos Tsagarakis. 2011. Endocrine incidentalomas—challenges imposed by incidentally discovered lesions. *Nature Reviews Endocrinology* . [[CrossRef](#)]
1859. Hee Jung Moon, Eunju Son, Eun-Kyung Kim, Jung Hyun Yoon, Jin Young Kwak. 2011. The Diagnostic Values of Ultrasound and Ultrasound-Guided Fine Needle Aspiration in Subcentimeter-Sized Thyroid Nodules. *Annals of Surgical Oncology* . [[CrossRef](#)]
1860. The American Thyroid Association and American Association of Clinical Endocrinologists Taskforce on Hyperthyroidism and Other Causes of Thyrotoxicosis, Rebecca S. Bahn, Henry B. Burch, David S. Cooper, Jeffrey R. Garber, M. Carol Greenlee, Irwin Klein, Peter Laurberg, I. Ross McDougall, Victor M. Montori, Scott A. Rivkees, Douglas S. Ross, Julie Ann Sosa, Marius N. Stan. 2011. Hyperthyroidism and Other Causes of Thyrotoxicosis: Management Guidelines of the American Thyroid Association

- and American Association of Clinical Endocrinologists. *Thyroid* **21**:6, 593-646. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1861. George J. Kahaly, Luigi Bartalena, Laszlo Hegedüs. 2011. The American Thyroid Association/American Association of Clinical Endocrinologists Guidelines for Hyperthyroidism and Other Causes of Thyrotoxicosis: A European Perspective. *Thyroid* **21**:6, 585-591. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1862. Dawn M. Holman, Ashwini Soman, Meg Watson, Hannah K. Weir, Katrina F. Trivers, Mary C. White. 2011. Examination of the Increase in Thyroid Cancer Incidence Among Younger Women in the United States by Age, Race, Geography, and Tumor Size, 1999–2007. *Journal of Adolescent and Young Adult Oncology* **1**:2, 95-102. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1863. Haggi Mazeh, Yacov Samet, David Hochstein, Ido Mizrahi, Ilana Ariel, Ahmed Eid, Herbert R. Freund. 2011. Multifocality in well-differentiated thyroid carcinomas calls for total thyroidectomy. *The American Journal of Surgery* **201**, 770-775. [[CrossRef](#)]
1864. Michael Friedman, Kanwar Kelley, Alexander Maley. 2011. Central neck dissection. *Operative Techniques in Otolaryngology-Head and Neck Surgery* **22**, 169-172. [[CrossRef](#)]
1865. Luca Giovannella, Luca Ceriani. 2011. Comparison of thyroglobulin antibody interference in first- and second-generation thyroglobulin immunoassays. *Clinical Chemistry and Laboratory Medicine* **49**, 1025-1027. [[CrossRef](#)]
1866. Sudhi Agarwal, Mayiluaganan Sabaretnam, Agarwal Ritesh, Gyan Chand. 2011. Feasibility and Safety of a New Robotic Thyroidectomy Through a Gasless, Transaxillary Single-Incision Approach. *Journal of the American College of Surgeons* **212**, 1097. [[CrossRef](#)]
1867. Michael Lin, Christine Wong, Peter Lin, Ivan Ho Shon, Ramesh Cuganesan, Seu Som. 2011. The prevalence and clinical significance of 18F-2-fluoro-2-deoxy-D-glucose (FDG) uptake in the thyroid gland on PET or PET-CT in patients with lymphoma. *Hematological Oncology* **29**:10.1002/hon.v29.2, 67-74. [[CrossRef](#)]
1868. Roberto Castello, Anna Frigo. 2011. La funzione e la patologia tiroidea nel corso dell'invecchiamento. *La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine* **7**, 88-93. [[CrossRef](#)]
1869. R. Garrel, C. Tripodi, C. Cartier, M. Makeieff, L. Crampette, B. Guerrier. 2011. Adénopathies cervicales révélatrices de microcarcinomes thyroïdiens. Étude de cas et revue de la littérature. *Annales françaises d'Oto-rhino-laryngologie et de Pathologie Cervico-faciale* **128**, 136-140. [[CrossRef](#)]
1870. Frederico Fernandes Ribeiro Maia, Patrícia S. Matos, Elizabeth J. Pavin, José Vassallo, Denise E. Zantut-Wittmann. 2011. Value of Ultrasound and Cytological Classification System to Predict the Malignancy of Thyroid Nodules with Indeterminate Cytology. *Endocrine Pathology* **22**, 66-73. [[CrossRef](#)]
1871. Thomas J. Musholt, Thomas Clerici, Henning Dralle, Andreja Frilling, Peter E. Goretzki, Michael M. Hermann, Jochen Kußmann, Kerstin Lorenz, Christoph Nies, Jochen Schabram, Peter Schabram, Christian Scheuba, Dietmar Simon, Thomas Steinmüller, Arnold W. Trupka, Robert A. Wahl, Andreas Zielke, Andreas Bockisch, Wolfram Karges, Markus Luster, Kurt W. Schmid. 2011. German Association of Endocrine Surgeons practice guidelines for the surgical treatment of benign thyroid disease. *Langenbeck's Archives of Surgery* **396**, 639-649. [[CrossRef](#)]
1872. Matthew F. Kalady, James M. Church. 2011. Monitoring and Management of Desmoids and Other Extracolonic Manifestations in Familial Adenomatous Polyposis. *Seminars in Colon and Rectal Surgery* **22**, 112-117. [[CrossRef](#)]
1873. Natalya Rukhman, Alan Silverberg. 2011. Thyroid cancer in older men. *The Aging Male* **14**, 91-98. [[CrossRef](#)]
1874. L. Leenhardt, F. Borson-Chazot, M. Calzada, B. Carnaille, A. Charrié, B. Cochand-Priollet, C.D. Cao, S. Leboulleux, G. Le Clech, G. Mansour, F. Menegaux, H. Monpeyssen, J. Orgiazzi, A. Rouxel, J.L. Sadoul, M. Schlumberger, J. Tramalloni, F. Tranquart, J.L. Wemeau. 2011. Good practice guide for cervical ultrasound scan and echo-guided techniques in treating differentiated thyroid cancer of vesicular origin. *Annales d'Endocrinologie* **72**, 173-197. [[CrossRef](#)]
1875. Ralf Paschke, Laszlo Hegedüs, Erik Alexander, Roberto Valcavi, Enrico Papini, Hossein Gharib. 2011. Thyroid nodule guidelines: agreement, disagreement and need for future research. *Nature Reviews Endocrinology* **7**, 354-361. [[CrossRef](#)]
1876. Jung Hyun Yoon, Ji Youn Kim, Hee Jung Moon, Ji Hyun Youk, Eun Joo Son, Eun-Kyung Kim, Kyung Hwa Han, Jin Young Kwak. 2011. Contribution of Computed Tomography to Ultrasound in Predicting Lateral Lymph Node Metastasis in Patients with Papillary Thyroid Carcinoma. *Annals of Surgical Oncology* **18**, 1734-1741. [[CrossRef](#)]
1877. Quan-Yang Duh. 2011. Robot-Assisted Endoscopic Thyroidectomy. *Annals of Surgery* **253**, 1067-1068. [[CrossRef](#)]
1878. Daniela D. Vargens, Ronaldo R.S. Neves, Daniel A. Bulzico, Élide B. Ojopi, Ricardo M.R. Meirelles, Cencita N. Pessoa, Carolina M. Prado, Pedro A. Gonçalves, Vera L.G. Leal, Guilherme Suarez-Kurtz. 2011. Association of the UGT1A1-53(TA)n polymorphism with L-thyroxine doses required for thyrotropin suppression in patients with differentiated thyroid cancer. *Pharmacogenetics and Genomics* **21**, 341-343. [[CrossRef](#)]

1879. Armando Bartolazzi, Carlo Bellotti, Salvatore Sciacchitano. 2011. Methodology and Technical Requirements of the Galectin-3 Test for the Preoperative Characterization of Thyroid Nodules. *Applied Immunohistochemistry and Molecular Morphology* 1. [[CrossRef](#)]
1880. Seon Hyeong Choi, Kyung Hwa Han, Jung Hyun Yoon, Hee Jung Moon, Eun Ju Son, Ji Hyun Youk, Eun-Kyung Kim, Jin Young Kwak. 2011. Factors affecting inadequate sampling of ultrasound-guided fine-needle aspiration biopsy of thyroid nodules. *Clinical Endocrinology* 74:10.1111/cen.2011.74.issue-6, 776-782. [[CrossRef](#)]
1881. R. Garrel, C. Tripodi, C. Cartier, M. Makeieff, L. Crampette, B. Guerrier. 2011. Cervical lymphadenopathies signaling thyroid microcarcinoma. Case study and review of the literature. *European Annals of Otorhinolaryngology, Head and Neck Diseases* 128, 115-119. [[CrossRef](#)]
1882. S. Piana, A. Frasoldati, M. Ferrari, R. Valcavi, E. Froio, V. Barbieri, C. Pedroni, G. Gardini. 2011. Is a five-category reporting scheme for thyroid fine needle aspiration cytology accurate? Experience of over 18 000 FNAs reported at the same institution during 1998-2007. *Cytopathology* 22:10.1111/cyt.2011.22.issue-3, 164-173. [[CrossRef](#)]
1883. Clinical Practice Guidelines for Thyroid Cancer 71-84. [[CrossRef](#)]
1884. Angelo Carpi, Andrea Nicolini The Emerging Role of Percutaneous Needle Biopsy and Molecular Tumor Marker Analysis for the Preoperative Selection of Thyroid Nodules 193-211. [[CrossRef](#)]
1885. Ji Soo Choi, Woong Youn Chung, Jin Young Kwak, Hee Jung Moon, Min Jung Kim, Eun-Kyung Kim. 2011. Staging of Papillary Thyroid Carcinoma with Ultrasonography: Performance in a Large Series. *Annals of Surgical Oncology* . [[CrossRef](#)]
1886. Brian Hung-Hin Lang, Kai Pun Wong. 2011. Risk Factors for Nonsynchronous Second Primary Malignancy and Related Death in Patients with Differentiated Thyroid Carcinoma. *Annals of Surgical Oncology* . [[CrossRef](#)]
1887. Yoon Se Lee, Yun Sung Lim, Jin-Choon Lee, Soo-Geun Wang, In-Ju Kim, Seok-Man Son, Byung-Joo Lee. 2011. Clinical Implications of Bilateral Lateral Cervical Lymph Node Metastasis in Papillary Thyroid Cancer: A Risk Factor for Lung Metastasis. *Annals of Surgical Oncology* . [[CrossRef](#)]
1888. Mio Kitano, Reza Rahbari, Erin E. Patterson, Yin Xiong, Nijaguna B. Prasad, Yongchun Wang, Martha A. Zeiger, Electron Kebebew. 2011. Expression Profiling of Difficult-to-diagnose Thyroid Histologic Subtypes Shows Distinct Expression Profiles and Identify Candidate Diagnostic microRNAs. *Annals of Surgical Oncology* . [[CrossRef](#)]
1889. Byeong-Cheol Ahn, Sang-Woo Lee, Jaetae Lee, Changho Kim. 2011. Pulmonary Aspergilloma Mimicking Metastasis from Papillary Thyroid Cancer. *Thyroid* 21:5, 555-558. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1890. M.A. Muros, J. Arbizu, M.D. Abós, M. Mitjavilla, E. Caballero-Calabuig, J.A. Vallejo. 2011. Los protocolos de tratamiento y seguimiento del carcinoma diferenciado de tiroides: resultados de un cuestionario enviado a las Unidades de Terapia Metabólica españolas. *Revista Española de Medicina Nuclear* 30, 147-155. [[CrossRef](#)]
1891. Lucia Brilli, Furio Pacini. 2011. Targeted therapy in refractory thyroid cancer: current achievements and limitations. *Future Oncology* 7, 657-668. [[CrossRef](#)]
1892. George Sgouros, Robert F. Hobbs, Francis B. Atkins, Douglas Nostrand, Paul W. Ladenson, Richard L. Wahl. 2011. Three-dimensional radiobiological dosimetry (3D-RD) with 124I PET for 131I therapy of thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* 38, 41-47. [[CrossRef](#)]
1893. P. Del Rio, R. Minelli, S. Cataldo, G. Ceresini, G. Robuschi, L. Corcione, A. Guazzi, R. Nizzoli, M. Sianesi. 2011. Can misdiagnosis in pre-operative FNAC of thyroid nodule influence surgical treatment?. *Journal of Endocrinological Investigation* 34, 345-348. [[CrossRef](#)]
1894. Biatta Sholosh, Amir A. Borhani. 2011. Thyroid Ultrasound Part 1: Technique and Diffuse Disease. *Radiologic Clinics of North America* 49, 391-416. [[CrossRef](#)]
1895. N. Gopalakrishna Iyer, Anumeha Kumar, Iain J. Nixon, Snehal G. Patel, Ian Ganly, R. Michael Tuttle, Jatin P. Shah, Ashok R. Shaha. 2011. Incidence and Significance of Delphian Node Metastasis in Papillary Thyroid Cancer. *Annals of Surgery* 253, 988-991. [[CrossRef](#)]
1896. Jung Hyun Yoon, Hee Jung Moon, Eun-Kyung Kim, Jin Young Kwak. 2011. Inadequate Cytology in Thyroid Nodules: Should We Repeat Aspiration or Follow-Up?. *Annals of Surgical Oncology* 18, 1282-1289. [[CrossRef](#)]
1897. Olga Husson, Harm R. Haak, Wilma A. Oranje, Floortje Mols, Peter H.M. Reemst, Lonneke V. van de Poll-Franse. 2011. Health-related quality of life among thyroid cancer survivors: a systematic review. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1898. Jong-Lyel Roh, Jin-Man Kim, Chan Il Park. 2011. Central Compartment Reoperation for Recurrent/Persistent Differentiated Thyroid Cancer: Patterns of Recurrence, Morbidity, and Prediction of Postoperative Hypocalcemia. *Annals of Surgical Oncology* 18, 1312-1318. [[CrossRef](#)]

1899. Markus Dietlein, F. A. Verburg, M. Luster, C. Reiners, F. Pitoia, H. Schicha. 2011. One should not just read what one believes: the nearly irresolvable issue of producing truly objective, evidence-based guidelines for the management of differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* **38**, 793-798. [[CrossRef](#)]
1900. Linwah Yip, Michael T. Stang, Sally E. Carty. 2011. Thyroid Carcinoma: The Surgeon's Perspective. *Radiologic Clinics of North America* **49**, 463-471. [[CrossRef](#)]
1901. Zoltán Lőcsei, Dóra Horváth, Károly Rácz, Erzsébet Toldy. 2011. Szérumtiroglobulin és tiroglobulin-antitest együttes meghatározásának jelentősége a differenciált pajzsmirigy-karcinómás betegek gondozása során. *Orvosi Hetilap* **152**, 743-752. [[CrossRef](#)]
1902. R.M. Tuttle, F. Vaisman, M.D. Tronko. 2011. Clinical Presentation and Clinical Outcomes in Chernobyl-related Paediatric Thyroid Cancers: What Do We Know Now? What Can We Expect in the Future?. *Clinical Oncology* **23**, 268-275. [[CrossRef](#)]
1903. J. Lee, J. H. Lee, K. Y. Nah, E. Y. Soh, W. Y. Chung. 2011. Comparison of Endoscopic and Robotic Thyroidectomy. *Annals of Surgical Oncology* **18**, 1439-1446. [[CrossRef](#)]
1904. Nathan A. Johnson, Shane O. LeBeau, Mitchell E. Tublin. 2011. Imaging Surveillance of Differentiated Thyroid Cancer. *Radiologic Clinics of North America* **49**, 473-487. [[CrossRef](#)]
1905. I Mitra, J R Nichani, B Yap, J J Homer. 2011. Effect of central compartment neck dissection on hypocalcaemia incidence after total thyroidectomy for carcinoma. *The Journal of Laryngology & Otolaryngology* **125**, 497-501. [[CrossRef](#)]
1906. L Pagano, L Samà, F Morani, F Prodam, M Rudoni, R Boldorini, G Valente, P Marzullo, R Baldelli, M Appetecchia, C Isidoro, G Aimaretti. 2011. Thyroid Incidentaloma identified by 18F-fluorodeoxyglucose Positron Emission Tomography with CT (FDG-PET/CT): clinical and pathological relevance. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1907. Judith M. Joyce, Andrew Swihart. 2011. Thyroid: Nuclear Medicine Update. *Radiologic Clinics of North America* **49**, 425-434. [[CrossRef](#)]
1908. Min-Kyung Yeo, Zhe Long Liang, Taejeong Oh, Youngho Moon, Sungwhan An, Min Kyeong Kim, Koon Soon Kim, Minhong Shong, Jin-Man Kim, Young Suk Jo. 2011. Pyrosequencing Cut-off Value Identifying BRAFV600E Mutation in Fine Needle Aspiration Samples of Thyroid Nodules. *Clinical Endocrinology* no-no. [[CrossRef](#)]
1909. Desmond Kwan-Kit Chan, Brian Hung-Hin Lang, Tsz-Ting Law. 2011. Value of fluorodeoxyglucose positron emission tomography in characterizing clinically-significant thyroid carcinomas. *Surgical Practice* **15**:10.1111/ash.2011.15.issue-2, 34-40. [[CrossRef](#)]
1910. Tara L. Henrichsen, Carl C. Reading. 2011. Thyroid Ultrasonography. Part 2: Nodules. *Radiologic Clinics of North America* **49**, 417-424. [[CrossRef](#)]
1911. Amy E. Cox, Shane O. LeBeau. 2011. Diagnosis and Treatment of Differentiated Thyroid Carcinoma. *Radiologic Clinics of North America* **49**, 453-462. [[CrossRef](#)]
1912. Hyunsuk Suh, Ousama A'amar, Eladio Rodriguez-Diaz, Stephanie Lee, Irving Bigio, Jennifer E. Rosen. 2011. Elastic Light-Scattering Spectroscopy for Discrimination of Benign from Malignant Disease in Thyroid Nodules. *Annals of Surgical Oncology* **18**, 1300-1305. [[CrossRef](#)]
1913. Jin Woo Choi, Jeong Hyun Lee. 2011. Response to a Letter Regarding Diagnostic Accuracy of Ultrasound and 18-F-FDG PET or PET/CT for Patients With Suspected Recurrent Papillary Thyroid Carcinoma. *Ultrasound in Medicine & Biology* **37**, 841. [[CrossRef](#)]
1914. D. Taïeb. 2011. [18F]Fluorodeoxyglucose positron emission tomography in advanced thyroid cancer. *Médecine Nucléaire* **35**, 329-331. [[CrossRef](#)]
1915. Jin Woong Choi, Young Hoon Yoon, Yeo Hoon Yoon, Seong Min Kim, Bon Seok Koo. 2011. Characteristics of Primary Papillary Thyroid Carcinoma with False-Negative Findings on Initial 18F-FDG PET/CT. *Annals of Surgical Oncology* **18**, 1306-1311. [[CrossRef](#)]
1916. Frederico F. R. Maia, Patrícia S. Matos, Elizabeth J. Pavin, José Vassallo, Denise E. Zantut-Wittmann. 2011. Value of repeat ultrasound-guided fine-needle aspiration in thyroid nodule with a first benign cytologic result: Impact of ultrasound to predict malignancy. *Endocrine* . [[CrossRef](#)]
1917. Anthony Po Wing Yuen, Ambrose Chung Wai Ho, Birgitta Yee Hang Wong. 2011. Ultrasonographic screening for occult thyroid cancer. *Head & Neck* **33**:10.1002/hed.v33.4, 453-457. [[CrossRef](#)]
1918. Yuri E Nikiforov. 2011. Molecular analysis of thyroid tumors. *Modern Pathology* **24**, S34-S43. [[CrossRef](#)]
1919. Wan Wook Kim, Jee Soo Kim, Sung Mo Hur, Sung Hoon Kim, Se-Kyung Lee, Jae Hyuck Choi, Sangmin Kim, Jeong Eon Lee, Jung-Han Kim, Seok Jin Nam, Jung-Hyun Yang, Jun-Ho Choe. 2011. Is Robotic Surgery Superior to Endoscopic and Open Surgeries in Thyroid Cancer?. *World Journal of Surgery* **35**, 779-784. [[CrossRef](#)]

1920. Hee Jung Moon, Jin Young Kwak, Eun-Kyung Kim, Min Jung Kim. 2011. Ultrasonographic Characteristics Predictive of Nondiagnostic Results for Fine-Needle Aspiration Biopsies of Thyroid Nodules. *Ultrasound in Medicine & Biology* **37**, 549-555. [[CrossRef](#)]
1921. Frederik A. Verburg, Michael Lassmann, Uwe Mäder, Markus Luster, Christoph Reiners, Heribert Hänscheid. 2011. The absorbed dose to the blood is a better predictor of ablation success than the administered <sup>131</sup>I activity in thyroid cancer patients. *European Journal of Nuclear Medicine and Molecular Imaging* **38**, 673-680. [[CrossRef](#)]
1922. Yasuhiro Ito, Takuya Higashiyama, Yuuki Takamura, Kaoru Kobayashi, Akihiro Miya, Akira Miyauchi. 2011. Prognosis of Patients with Papillary Thyroid Carcinoma Showing Postoperative Recurrence to the Central Neck. *World Journal of Surgery* **35**, 767-772. [[CrossRef](#)]
1923. A. M. Sawka, S. Straus, A. Gafni, J. D. Brierley, R. W. Tsang, L. Rotstein, S. Ezzat, L. Thabane, G. Rodin, S. Meiyappan, D. David, D. P. Goldstein. 2011. How can we meet the information needs of patients with early stage papillary thyroid cancer considering radioactive iodine remnant ablation?. *Clinical Endocrinology* **74**:10.1111/cen.2011.74.issue-4, 419-423. [[CrossRef](#)]
1924. G. Guijarro de Armas, R. Elviro Peña, S. Monereo Megías, J.M. Montaña Martínez. 2011. Captación patológica de I-131 en pulmón en paciente con cáncer de tiroides: ¿metástasis o no?. *Revista Clínica Española* **211**, 194-198. [[CrossRef](#)]
1925. Yoon Kyoung So, Min Young Seo, Young-Ik Son. 2011. Prophylactic central lymph node dissection for clinically node-negative papillary thyroid microcarcinoma: Influence on serum thyroglobulin level, recurrence rate, and postoperative complications. *Surgery* . [[CrossRef](#)]
1926. Bálint Tóbiás, Bernadett Balla, János Kósa P, János Horányi, István Takács, Eszter Bölöny, Csaba Halászlaki, Zsolt Nagy, Gábor Speer, Balázs Járay, Eszter Székely, Roland Istók, Péter Lakatos. 2011. Szomatikus onkogén mutációk összehasonlító vizsgálata egészséges és tumoros pajzsmirigy-szövetmintákban. *Orvosi Hetilap* **152**, 672-677. [[CrossRef](#)]
1927. N Gopalakrishna Iyer, Ashok R Shaha. 2011. Central compartment dissection for well differentiated thyroid cancer ... and the band plays on. *Current Opinion in Otolaryngology & Head and Neck Surgery* **19**, 106-112. [[CrossRef](#)]
1928. M. Schlumberger. 2011. Prise en charge des cancers réfractaires de la thyroïde. *Annales d'Endocrinologie* **72**, 149-157. [[CrossRef](#)]
1929. Marcin Barczyński, Aleksander Konturek, Małgorzata Stopa, Alicja Hubalewska-Dydejczyk, Piotr Richter, Wojciech Nowak. 2011. Clinical Value of Intraoperative Neuromonitoring of the Recurrent Laryngeal Nerves in Improving Outcomes of Surgery for Well-Differentiated Thyroid Cancer. *Polish Journal of Surgery* **83**, 196-203. [[CrossRef](#)]
1930. Johannes Biko, Christoph Reiners, Michael C. Kreissl, Frederik A. Verburg, Yuri Demidchik, Valentina Drozd. 2011. Favourable course of disease after incomplete remission on <sup>131</sup>I therapy in children with pulmonary metastases of papillary thyroid carcinoma: 10 years follow-up. *European Journal of Nuclear Medicine and Molecular Imaging* **38**, 651-655. [[CrossRef](#)]
1931. B. N. Savani, M. L. Griffith, S. Jagasia, S. J. Lee. 2011. How I treat late effects in adults after allogeneic stem cell transplantation. *Blood* **117**, 3002-3009. [[CrossRef](#)]
1932. Amanda Johner, Obi L. Griffith, Blair Walker, Leanne Wood, Hannah Piper, Graeme Wilkins, Christopher Baliski, Steven J. M. Jones, Sam M. Wiseman. 2011. Detection and Management of Hypothyroidism Following Thyroid Lobectomy: Evaluation of a Clinical Algorithm. *Annals of Surgical Oncology* . [[CrossRef](#)]
1933. Jandee Lee, Sang Wook Kang, Jeong Ju Jung, Un Jung Choi, Jong Ho Yun, Kee Hyun Nam, Euy-Young Soh, Woong Youn Chung. 2011. Multicenter Study of Robotic Thyroidectomy: Short-Term Postoperative Outcomes and Surgeon Ergonomic Considerations. *Annals of Surgical Oncology* . [[CrossRef](#)]
1934. Charles H. Emerson. 2011. Can Thyroid Ultrasound and Related Procedures Provide Diagnostic Information About Thyroid Nodules: A Look at the Guidelines. *Thyroid* **21**:3, 211-213. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1935. Chung-Che Charles Wang, Lyssa Friedman, Giulia C. Kennedy, Hui Wang, Electron Kebebew, David L. Steward, Martha A. Zeiger, William H. Westra, Yongchun Wang, Elham Khanafshar, Giovanni Fellegara, Juan Rosai, Virginia LiVolsi, Richard B. Lanman. 2011. A Large Multicenter Correlation Study of Thyroid Nodule Cytopathology and Histopathology. *Thyroid* **21**:3, 243-251. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1936. David T. Hughes, Megan R. Haymart, Barbra S. Miller, Paul G. Gauger, Gerard M. Doherty. 2011. The Most Commonly Occurring Papillary Thyroid Cancer in the United States Is Now a Microcarcinoma in a Patient Older than 45 Years. *Thyroid* **21**:3, 231-236. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1937. Frederik A. Verburg, Christoph Reiners. 2011. Cancer: Continuous re-evaluation in differentiated thyroid carcinoma. *Nature Reviews Endocrinology* **7**, 127-128. [[CrossRef](#)]
1938. Tracy-Ann S. Moo, Thomas J. Fahey. 2011. Lymph Node Dissection in Papillary Thyroid Carcinoma. *Seminars in Nuclear Medicine* **41**, 84-88. [[CrossRef](#)]

1939. Stefan Scholz, Jessica R. Smith, Beverly Chaignaud, Robert C. Shamberger, Stephen A. Huang. 2011. Thyroid surgery at Children's Hospital Boston: a 35-year single-institution experience. *Journal of Pediatric Surgery* **46**, 437-442. [[CrossRef](#)]
1940. Iain J. Nixon, Frank L. Palmer, Monica M. Whitcher, Ashok R. Shaha, Jatin P. Shah, Snehal G. Patel, Ian Ganly. 2011. Thyroid Isthmusectomy for Well-Differentiated Thyroid Cancer. *Annals of Surgical Oncology* **18**, 767-770. [[CrossRef](#)]
1941. M. Barczyński. 2011. Systematic review and meta-analysis of sentinel node biopsy in thyroid cancer (Br J Surg 2010; 98: 334-344). *British Journal of Surgery* **98**:10.1002/bjs.v98.3, 344-345. [[CrossRef](#)]
1942. Stanley J. Goldsmith. 2011. To Ablate or Not to Ablate: Issues and Evidence Involved in 131I Ablation of Residual Thyroid Tissue in Patients with Differentiated Thyroid Carcinoma. *Seminars in Nuclear Medicine* **41**, 96-104. [[CrossRef](#)]
1943. F. Vianello, R. Mazzarotto, C. Mian, O. Lora, G. Saladini, O. Servodio, M. Basso, G. Pennelli, M.R. Pelizzo, G. Sotti. 2011. Clinical Outcome of Low-risk Differentiated Thyroid Cancer Patients after Radioiodine Remnant Ablation and Recombinant Human Thyroid-stimulating Hormone Preparation. *Clinical Oncology* . [[CrossRef](#)]
1944. Ghobad Azizi, Carl Malchoff. 2011. Autoimmune Thyroid Disease: A Risk Factor for Thyroid Cancer. *Endocrine Practice* **17**, 201-209. [[CrossRef](#)]
1945. Awad M. Jarrar, Mira Milas, Jamie Mitchell, Lisa Laguardia, Margaret ([a-z])'Malley, Eren Berber, Allan Siperstein, Carol Burke, James M. Church. 2011. Screening for Thyroid Cancer in Patients With Familial Adenomatous Polyposis. *Annals of Surgery* **253**, 515-521. [[CrossRef](#)]
1946. Tony Abraham, Heiko Schöder. 2011. Thyroid Cancer—Indications and Opportunities for Positron Emission Tomography/Computed Tomography Imaging. *Seminars in Nuclear Medicine* **41**, 121-138. [[CrossRef](#)]
1947. Ivan Ho Shon, Barbara Depczynski, Michael Lin, Jonathan R. Clark, Vincent Wong, Peter Lin, Peter Campbell. 2011. Positron emission tomography in non-medullary thyroid cancer. *ANZ Journal of Surgery* **81**:10.1111/ans.2011.81.issue-3, 116-124. [[CrossRef](#)]
1948. Harry S. Hwang, Lisa A. Orloff. 2011. Efficacy of preoperative neck ultrasound in the detection of cervical lymph node metastasis from thyroid cancer. *The Laryngoscope* **121**, 487-491. [[CrossRef](#)]
1949. Edward B. Silberstein. 2011. The Problem of the Patient with Thyroglobulin Elevation but Negative Iodine Scintigraphy: The TENIS Syndrome. *Seminars in Nuclear Medicine* **41**, 113-120. [[CrossRef](#)]
1950. Genevieve Rondeau, R. Michael Tuttle. 2011. Similarities and Differences in Follicular Cell-Derived Thyroid Cancer Management Guidelines Used in Europe and the United States. *Seminars in Nuclear Medicine* **41**, 89-95. [[CrossRef](#)]
1951. Jandee Lee, Jong Ho Yun, Kee Hyun Nam, Un Jong Choi, Woong Youn Chung, Euy-Young Soh. 2011. Perioperative clinical outcomes after robotic thyroidectomy for thyroid carcinoma: a multicenter study. *Surgical Endoscopy* **25**, 906-912. [[CrossRef](#)]
1952. N. Gopalakrishna Iyer, Iain J. Nixon, Frank Palmer, Ian Ganly, Snehal G. Patel, Ashok R. Shaha. 2011. Electronic Synoptic Operative Reporting for Thyroid Surgery using an Electronic Data Management System: Potential for Prospective Multicenter Data Collection. *Annals of Surgical Oncology* **18**, 762-766. [[CrossRef](#)]
1953. Christine Landry, Elizabeth Grubbs, Naifa Busaidy, Brett Monroe, Gregg Staerkel, Nancy Perrier, Beth Edeiken-Monroe. 2011. Cystic Lymph Nodes in the Lateral Neck as Indicators of Metastatic Papillary Thyroid Cancer. *Endocrine Practice* **17**, 240-244. [[CrossRef](#)]
1954. Hee Jung Moon, Eun-Kyung Kim, Woong Youn Chung, Jong Rak Choi, Jung Hyun Yoon, Jin Young Kwak. 2011. Diagnostic Value of BRAFV600E Mutation Analysis of Thyroid Nodules According to Ultrasonographic Features and the Time of Aspiration. *Annals of Surgical Oncology* **18**, 792-799. [[CrossRef](#)]
1955. S. Sanz Viedma, I. Borrego Dorado, J.R. Rodríguez Rodríguez, E. Navarro González, R. Vázquez Albertino, R. Fernández López, A. Agudo Martínez. 2011. Uso de la PET-18F-FDG en pacientes con sospecha de recurrencia de cáncer diferenciado de tiroides por anticuerpos anti-tiroglobulina elevados y rastreo 131I negativo. *Revista Española de Medicina Nuclear* **30**, 77-82. [[CrossRef](#)]
1956. Briseis Aschebrook-Kilfoy, Mary H. Ward, Mona M. Sabra, Susan S. Devesa. 2011. Thyroid Cancer Incidence Patterns in the United States by Histologic Type, 1992-2006. *Thyroid* **21**:2, 125-134. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1957. Hendrieke C Hoftijzer, Ellen Kapiteijn, Tatiana Schneider, Guido C Hovens, Hans Morreau, Hans Gelderblom, Johannes WA Smit. 2011. Tyrosine kinase inhibitors in differentiated thyroid carcinoma: a review of the clinical evidence. *Clinical Investigation* **1**, 241-253. [[CrossRef](#)]
1958. José Miguel Domínguez, René Baudrand, Jaime Cerda, Claudia Campusano, Carlos Fardella, Eugenio Arteaga, Francisco Cruz, Antonieta Solar, Tatiana Arias, Lorena Mosso. 2011. An Ultrasound Model to Discriminate the Risk of Thyroid Carcinoma. *Academic Radiology* **18**, 242-245. [[CrossRef](#)]

1959. Kyung Tae Park, Soon-Hyun Ahn, Ji-Hun Mo, Young Joo Park, Do Joong Park, Sang Il Choi, So-Yeon Park. 2011. Role of core needle biopsy and ultrasonographic finding in management of indeterminate thyroid nodules. *Head & Neck* 33:10.1002/hed.v33.2, 160-165. [[CrossRef](#)]
1960. T. T. Law, Brian Hung-Hin Lang. 2011. Incidental Thyroid Carcinoma by FDG-PET/CT: A Study of Clinicopathological Characteristics. *Annals of Surgical Oncology* 18, 472-478. [[CrossRef](#)]
1961. Soo Yeon Hahn, Jung Hee Shin, Boo-Kyung Han, Eun Young Ko, Seok Seon Kang, Jae Hoon Chung, Jung Han Kim, Young Lyun Oh, Young-Ik Son. 2011. Predictive factors related to the recurrence at US-guided fine needle aspiration in postoperative patients with differentiated thyroid cancer. *Clinical Endocrinology* 74, 270-275. [[CrossRef](#)]
1962. Bianca J. Vazquez, Melanie L. Richards. 2011. Imaging of the Thyroid and Parathyroid Glands. *Surgical Clinics of North America* 91, 15-32. [[CrossRef](#)]
1963. C. Bullmann. 2011. Schilddrüsendiagnostik und -therapie in der täglichen Praxis. *Gynäkologische Endokrinologie* 9, 41-51. [[CrossRef](#)]
1964. Luca Giovanella, Sergio Suriano, Luca Ceriani, Frederik Anton Verburg. 2011. Undetectable Thyroglobulin in Patients With Differentiated Thyroid Carcinoma and Residual Radioiodine Uptake on a Postablation Whole-Body Scan. *Clinical Nuclear Medicine* 36, 109-112. [[CrossRef](#)]
1965. Eveline Predebon Morsch, Roberta Vanacor, Tania Weber Furlanetto, Helena Schmid. 2011. Two Weeks of a Low-Iodine Diet Are Equivalent to 3 Weeks for Lowering Urinary Iodine and Increasing Thyroid Radioactive Iodine Uptake. *Thyroid* 21:1, 61-67. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
1966. Yasuhiro Ito, Akira Miyauchi. 2011. Thyroidectomy and Lymph Node Dissection in Papillary Thyroid Carcinoma. *Journal of Thyroid Research* 2011, 1-6. [[CrossRef](#)]
1967. M. Schott. 2011. Identification and Optimal Postsurgical Follow-Up of Patients with Very Low-Risk Papillary Thyroid Microcarcinomas. *Yearbook of Endocrinology* 2011, 135-137. [[CrossRef](#)]
1968. M. Schott. 2011. The Use of Preoperative Routine Measurement of Basal Serum Thyrocalcitonin in Candidates for Thyroidectomy due to Nodular Thyroid Disorders: Results from 2733 Consecutive Patients. *Yearbook of Endocrinology* 2011, 131-134. [[CrossRef](#)]
1969. Won Gu Kim, Eui Young Kim, Ji Hye Yim, Ji Min Han, Min Ji Jeon, Tae Yong Kim, Jin Sook Ryu, Gyungyub Gong, Suck Joon Hong, Won Bae Kim, Young Kee Shong. 2011. Comparison of Different Staging Systems for Predicting Recurrence of Papillary Thyroid Carcinoma. *Endocrinology and Metabolism* 26, 53. [[CrossRef](#)]
1970. Julia Sastre Marcos, Ofelia Llamazares Iglesias, Almudena Vicente Delgado, Amparo Marco Martínez, Bárbara Cánovas Gaillemín, Juan Luis Orradre Romero, Miguel Ángel Morlan López, José López López. 2011. Differentiated thyroid carcinoma: survival and prognostic factors. *Endocrinología y Nutrición (English Edition)* 58, 157-162. [[CrossRef](#)]
1971. Endokrinologische Erkrankungen 719-825. [[CrossRef](#)]
1972. George Wilson, Arshag Mooradian, Irene Alexandraki, George Samra. *Endocrinology* 756-801. [[CrossRef](#)]
1973. Andrew G. Gianoukakis, Silvana M. Giannelli, Wael A. Salameh, Laron W. McPhaul. 2011. Well differentiated follicular thyroid neoplasia: Impact of molecular and technological advances on detection, monitoring and treatment. *Molecular and Cellular Endocrinology* 332, 9-20. [[CrossRef](#)]
1974. Gaosong Wu, Shannon Fraser, Sara I. Pai, Tarik Y. Farrag, Paul W. Ladenson, Ralph P. Tufano. 2011. Determining the extent of lateral neck dissection necessary to establish regional disease control and avoid reoperation after previous total thyroidectomy and radioactive iodine for papillary thyroid cancer. *Head & Neck* n/a-n/a. [[CrossRef](#)]
1975. Ka Hee Yi. 2011. Updated guidelines for the diagnosis and management of thyroid nodules. *Journal of the Korean Medical Association* 54, 629. [[CrossRef](#)]
1976. Leo A. Niemeier, Haruko Kuffner Akatsu, Chi Song, Sally E. Carty, Steven P. Hodak, Linwah Yip, Robert L. Ferris, George C. Tseng, Raja R. Seethala, Shane O. LeBeau, Michael T. Stang, Christopher Coyne, Jonas T. Johnson, Andrew F. Stewart, Yuri E. Nikiforov. 2011. A combined molecular-pathologic score improves risk stratification of thyroid papillary microcarcinoma. *Cancer* n/a-n/a. [[CrossRef](#)]
1977. S. Sanz Viedma, I. Borrego Dorado, J.R. Rodríguez Rodríguez, E. Navarro González, R. Vázquez Albertino, R. Fernández López, A. Agudo Martínez. 2011. Use of 18FFDG-PET in patients with suspicion of recurrent differentiated thyroid cancer by elevated antithyroglobulin antibodies levels and negative 131I scan. *Revista Española de Medicina Nuclear (English Edition)* 30, 77-82. [[CrossRef](#)]

1978. Carlo Cappelli, Ilenia Pirola, Elvira De Martino, Elena Gandossi, Elena Cimino, Francesca Samoni, Barbara Agosti, Enrico Agabiti Rosei, Claudio Casella, Maurizio Castellano. 2011. Thyroglobulin measurement in fine-needle aspiration biopsy of metastatic lymph nodes after rhTSH stimulation. *Head & Neck* n/a-n/a. [CrossRef]
1979. Marcia S Brose, Christopher M Nutting, Steven I Sherman, Young-Kee Shong, Johannes W.A. Smit, Gerhard Reike, John Chung, Joachim Kalmus, Christian Kappeler, Martin Schlumberger. 2011. Rationale and design of DECISION: a double-blind, randomized, placebo-controlled phase III trial evaluating the efficacy and safety of sorafenib in patients with locally advanced or metastatic radioactive iodine (RAI)-refractory, differentiated thyroid cancer. *BMC Cancer* **11**, 349. [CrossRef]
1980. Martin-Jean Schlumberger, Sebastiano Filetti, Ian D. Hay. Nontoxic Diffuse and Nodular Goiter and Thyroid Neoplasia 440-475. [CrossRef]
1981. Rok Petric, Andraz Perhavec, Barbara Gazic, Nikola Besic. 2011. Preoperative serum thyroglobulin concentration is an independent predictive factor of malignancy in follicular neoplasms of the thyroid gland. *Journal of Surgical Oncology* n/a-n/a. [CrossRef]
1982. Marci J. Neidich, David L. Steward. 2011. Safety and feasibility of elective minimally invasive video-assisted central neck dissection for thyroid carcinoma. *Head & Neck* n/a-n/a. [CrossRef]
1983. Man Ki Chung, Joon Ho Kim, Young-Hyeh Ko, Young-Ik Son. 2011. Correlation of lymphatic vessel density and vascular endothelial growth factor with nodal metastasis in papillary thyroid microcarcinoma. *Head & Neck* n/a-n/a. [CrossRef]
1984. Joanna Klubo-Gwiezdzinska, Kenneth D. Burman, Douglas Van Nostrand, Leonard Wartofsky. 2011. Does an undetectable rhTSH-stimulated Tg level 12 months after initial treatment of thyroid cancer indicate remission?. *Clinical Endocrinology* **74**:10.1111/cen.2010.74.issue-1, 111-117. [CrossRef]
1985. Young Hun Lee, Dong Wook Kim, Hyun Sin In, Ji Sung Park, Sang Hyo Kim, Jae Wook Eom, Bomi Kim, Eun Joo Lee, Myung Ho Rho. 2011. Differentiation between Benign and Malignant Solid Thyroid Nodules Using an US Classification System. *Korean Journal of Radiology* **12**, 559. [CrossRef]
1986. Syed Ali Imran, Murali Rajaraman. 2011. Management of Differentiated Thyroid Cancer in Pregnancy. *Journal of Thyroid Research* **2011**, 1-5. [CrossRef]
1987. Sang Soo Kim, Byung-Joo Lee, Jin-Choon Lee, Seong-Jang Kim, Soo Hyung Lee, Yun Kyung Jeon, Bo Hyun Kim, Yong-Ki Kim, In-Joo Kim. 2011. Preoperative ultrasonographic tumor characteristics as a predictive factor of tumor stage in papillary thyroid carcinoma. *Head & Neck* n/a-n/a. [CrossRef]
1988. Hyun Sook Kim, Seung Joon Lee, Jung Kyu Park, Chang Ho Jo, Ho Sang Shon, Eui Dal Jung. 2011. Association between Serum Thyroid Stimulating Hormone Level and Papillary Thyroid Microcarcinoma in Korean Euthyroid Patients. *Endocrinology and Metabolism* **26**, 297. [CrossRef]
1989. R. Görge, T. Kandrör, S. Kuschnerus, M. Zimny, R. Pink, H. Palmedo, A. Hach, H. Rau, C. Tanner, K. Zaplatnikov, A. Bockisch, L. Freudenberg. 2011. Scintigraphically "hot" thyroid nodules mainly go hand in hand with a normal TSH. *Nuklearmedizin* **50**. [CrossRef]
1990. Marisa Cañadas Garre, Martín López de la Torre Casares, Patricia Becerra Massare, Miguel Ángel López Nevot, Jesús Villar Del Moral, Nuria Muñoz Pérez, Ricardo Vilchez Joya, Rosa Montes Ramírez, José Manuel Llamas Elvira. 2011. BRAFT1799A mutation in the primary tumor as a marker of risk, recurrence, or persistence of papillary thyroid carcinoma. *Endocrinología y Nutrición (English Edition)* **58**, 175-184. [CrossRef]
1991. M.A. Muros, J. Arbizu, M.D. Abós, M. Mitjavilla, E. Caballero-Calabuig, J.A. Vallejo. 2011. Treatment protocols and follow-up of differentiated thyroid carcinoma: results of a questionnaire sent to the Spanish Metabolic Therapy Units. *Revista Española de Medicina Nuclear (English Edition)* **30**, 147-155. [CrossRef]
1992. Chun-Ping Ning, Shuang-Quan Jiang, Tao Zhang, Li-tao Sun, Yu-Jie Liu, Jia-Wei Tian. 2011. The value of strain ratio in differential diagnosis of thyroid solid nodules. *European Journal of Radiology*. [CrossRef]
1993. Tracy S Wang, Sanziana A Roman, Julie A Sosa. 2011. Differentiated thyroid cancer: an update. *Current Opinion in Oncology* **23**, 7-12. [CrossRef]
1994. Duck Jin Hong, Seung Jun Choi, Sinyoung Kim. 2011. Usefulness of Thyroglobulin Measurement in Fine-needle Aspirates of Lymph Nodes for the Diagnosis of Lymph Node Metastasis of Papillary Thyroid Cancer. *Laboratory Medicine Online* **1**, 132. [CrossRef]
1995. Leslie S Wu, Sanziana A Roman, Julie A Sosa. 2011. Medullary thyroid cancer: an update of new guidelines and recent developments. *Current Opinion in Oncology* **23**, 22-27. [CrossRef]
1996. Won-Jin Moon, Jung Hwan Baek, So Lyung Jung, Dong Wook Kim, Eun Kyung Kim, Ji Young Kim, Jin Young Kwak, Jeong Hyun Lee, Joon Hyung Lee, Young Hen Lee, Dong Gyu Na, Jeong Seon Park, Sun Won Park. 2011. Ultrasonography and the Ultrasound-Based Management of Thyroid Nodules: Consensus Statement and Recommendations. *Korean Journal of Radiology* **12**, 1. [CrossRef]



1997. Efsio Puxeddu, Serena Romagnoli, Massimo Eugenio Dottorini. 2011. Targeted therapies for advanced thyroid cancer. *Current Opinion in Oncology* **23**, 13-21. [[CrossRef](#)]
1998. Kai-Pun Wong, Brian Hung-Hin Lang. 2011. The Role of Prophylactic Central Neck Dissection in Differentiated Thyroid Carcinoma: Issues and Controversies. *Journal of Oncology* **2011**, 1-12. [[CrossRef](#)]
1999. Young Hun Lee, Dong Wook Kim, Hyun Sin In, Ji Sung Park, Sang Hyo Kim, Jae Wook Eom, Bomi Kim, Eun Joo Lee, Myung Ho Rho. 2011. Differentiation between Benign and Malignant Solid Thyroid Nodules Using an US Classification System. *Korean Journal of Radiology* **12**, 416. [[CrossRef](#)]
2000. Neda Ahmadi, Ameet Grewal, Bruce J. Davidson. 2011. Patterns of Cervical Lymph Node Metastases in Primary and Recurrent Papillary Thyroid Cancer. *Journal of Oncology* **2011**, 1-5. [[CrossRef](#)]
2001. Gary Francis, Steven G Waguespack. 2011. An individualized approach to the child with thyroid cancer. *Expert Review of Endocrinology & Metabolism* **6**, 85-92. [[CrossRef](#)]
2002. Keigo Honda, Ryo Asato, Jun Tsuji, Tomoko Kanda, Koji Ushiro, Yoshiki Watanabe, Yusuke Mori. 2011. Analysis of Papillary Thyroid Carcinoma with Multicentric Intraglandular Microscopic Lesions. *Practica Oto-Rhino-Laryngologica* **104**, 727-732. [[CrossRef](#)]
2003. Hiroshi Takami, Yasuhiro Ito, Takahiro Okamoto, Akira Yoshida. 2011. Therapeutic Strategy for Differentiated Thyroid Carcinoma in Japan Based on a Newly Established Guideline Managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. *World Journal of Surgery* **35**, 111-121. [[CrossRef](#)]
2004. Daniel Bulzico, Fernanda Vaisman, Cencita H. Cordeiro de Noronha Pessoa, Rossana Corbo. 2011. Cavernous Angioma Mimicking a Differentiated Thyroid Carcinoma Brain Metastasis. *Clinical Nuclear Medicine* **36**, 62-63. [[CrossRef](#)]
2005. M. Luster, D. Simon. 2011. Von der fehlenden Übertragbarkeit internationaler Leitlinien zur Schilddrüsendiagnostik. *Nuklearmedizin* **50**, 175-177. [[CrossRef](#)]
2006. Fernando Lizcano, Javier Salvador Rodríguez. 2011. Thyroid hormone therapy modulates hypothalamo-pituitary-adrenal axis. *Endocrine Journal* **58**, 137-142. [[CrossRef](#)]
2007. Nephtali R. Gomez, Guennadi Kouniavsky, Hua-Ling Tsai, Helina Somervell, Sara I. Pai, Ralph P. Tufano, Christopher Umbricht, Jeanne Kowalski, Alan P.B. Dackiw, Martha A. Zeiger. 2011. Tumor size and presence of calcifications on ultrasonography are pre-operative predictors of lymph node metastases in patients with papillary thyroid cancer. *Journal of Surgical Oncology* n/a-n/a. [[CrossRef](#)]
2008. Jandee Lee, Jong Ho Yun, Kee Hyun Nam, Euy-Young Soh, Woong Youn Chung. 2011. The Learning Curve for Robotic Thyroidectomy: A Multicenter Study. *Annals of Surgical Oncology* **18**, 226-232. [[CrossRef](#)]
2009. M. Schott. 2011. Thyroid Cancer Recurrence in Patients Clinically Free of Disease with Undetectable or Very Low Serum Thyroglobulin Values. *Yearbook of Endocrinology* **2011**, 145-147. [[CrossRef](#)]
2010. David Taïeb, Karine Baumstarck-Barrau, Frédéric Sebag, Cécile Fortanier, Catherine De Micco, Anderson Loundou, Pascal Auquier, Fausto F Palazzo, Jean-françois Henry, Olivier Mundler. 2011. Heath-related quality of life in thyroid cancer patients following radioiodine ablation. *Health and Quality of Life Outcomes* **9**, 33. [[CrossRef](#)]
2011. Dongbin Ahn, Sun Jae Lee, Sun-Kyun Park, Jin Ho Sohn, June Sik Park. 2011. Is Comprehensive Neck Dissection a Sole Choice for the Treatment of Recurrent Papillary Thyroid Carcinoma in the Lateral Neck?. *Korean Journal of Otorhinolaryngology-Head and Neck Surgery* **54**, 62. [[CrossRef](#)]
2012. Fernanda Vaisman, Rossana Corbo, Mario Vaisman. 2011. Thyroid Carcinoma in Children and Adolescents—Systematic Review of the Literature. *Journal of Thyroid Research* **2011**, 1-7. [[CrossRef](#)]
2013. Rare Tumors 1772-1773. [[CrossRef](#)]
2014. Barbra S Miller, Gerard M Doherty. 2011. An examination of recently revised differentiated thyroid cancer guidelines. *Current Opinion in Oncology* **23**, 1-6. [[CrossRef](#)]
2015. N. Gopalakrishna Iyer, Luc G. T. Morris, R. Michael Tuttle, Ashok R. Shaha, Ian Ganly. 2011. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. *Cancer* n/a-n/a. [[CrossRef](#)]
2016. Jesús Herránz González-Botas, Carlos Vázquez Barro, José Martínez Vidal. 2011. Risk groups in differentiated thyroid carcinomas. *Acta Otorrinolaringologica (English Edition)* **62**, 14-19. [[CrossRef](#)]
2017. Mariela Varsavsky, María Cortés Berdonces, Guillermo Alonso, Antonia García Martín, Manuel Muñoz Torres. 2011. Metastatic adenopathy from a thyroid microcarcinoma: final diagnosis of a presumed paraganglioma. *Endocrinología y Nutrición (English Edition)* **58**, 143-144. [[CrossRef](#)]

2018. Frederico FR Maia, Patrícia S Matos, Bradley P Silva, Ana T Pallone, Elizabeth J Pavin, José Vassallo, Denise E Zantut-Wittmann. 2011. Role of ultrasound, clinical and scintigraphic parameters to predict malignancy in thyroid nodule. *Head & Neck Oncology* **3**, 17. [[CrossRef](#)]
2019. Ka Hee Yi, Young Joo Park, Sung-Soo Koong, Jung-Han Kim, Dong Gyu Na, Jin-Sook Ryu, So Yeon Park, In Ae Park, Chung-Hwan Baek, Young Kee Shong, Young Don Lee, Jaetae Lee, Jeong Hyun Lee, Jae Hoon Chung, Chan Kwon Jung, Seung-Ho Choi, Bo Youn Cho. 2011. Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. *Korean Journal of Otorhinolaryngology-Head and Neck Surgery* **54**, 8. [[CrossRef](#)]
2020. Angela M Leung, Shalini Dave, Stephanie L Lee, Francis X Champion, Jeffrey R Garber, Elizabeth N Pearce. 2011. Factors determining the persistence or recurrence of well-differentiated thyroid cancer treated by thyroidectomy and/or radioiodine in the Boston, Massachusetts area: A retrospective chart review. *Thyroid Research* **4**, 9. [[CrossRef](#)]
2021. Meei J. Yeung, Janice L. Pasiaka. 2011. Well-Differentiated Thyroid Carcinomas: Management of the Central Lymph Node Compartment and Emerging Biochemical Markers. *Journal of Oncology* **2011**, 1-6. [[CrossRef](#)]
2022. Yoo Seung Chung, Changyoung Yoo, Ji Han Jung, Hyun Joo Choi, Young-Jin Suh. 2011. Review of atypical cytology of thyroid nodule according to the Bethesda system and its beneficial effect in the surgical treatment of papillary carcinoma. *Journal of the Korean Surgical Society* **81**, 75. [[CrossRef](#)]
2023. Gary L. Clayman, Maisie Shindo, Gregory W. Randolph, Gianlorenzo DionigiSubtotal and Total Thyroidectomy 465-474. [[CrossRef](#)]
2024. Jesús Herránz González-Botas, Carlos Vázquez Barro, José Martínez Vidal. 2011. Grupos de riesgo en carcinomas diferenciados de tiroides. *Acta Otorrinolaringológica Española* **62**, 14-19. [[CrossRef](#)]
2025. Artür Salmashoğlu, Yeşim Erbil, Gamze Çıtlak, Feyzullah Ersöz, Serkan Sarı, Aydemir Olmez, Mehtap Tunacı, Dilek Yılmazbayhan, Neşe Çolak, Selçuk Özarmağan. 2011. Diagnostic value of thyroglobulin measurement in fine-needle aspiration biopsy for detecting metastatic lymph nodes in patients with papillary thyroid carcinoma. *Langenbeck's Archives of Surgery* **396**, 77-81. [[CrossRef](#)]
2026. U. S. Tetikkurt, F. Oz Puyan, F. Oz, N. Erdogan, S. Ceylan, A. Yakupoglu. 2011. Diagnostic value of liquid-based (Liqui-PREP) preparations and interobserver reproducibility in fine needle aspiration cytology of the nodular thyroid lesions. *Diagnostic Cytopathology* n/a-n/a. [[CrossRef](#)]
2027. Marlon A. Guerrero, Orlo H. Clark. 2011. Controversies in the Management of Papillary Thyroid Cancer Revisited. *ISRN Oncology* **2011**, 1-5. [[CrossRef](#)]
2028. Emad Kandil, Paul Friedlander, Salem Noureldine, Tareq Islam, Ralph P. Tufano. 2011. Impact of Extensive Neck Dissection on Survival from Papillary Thyroid Cancer. *ORL* **73**, 330-335. [[CrossRef](#)]
2029. Luca Giovanella, Emanuela Toffalori, Renato Tozzoli, Marco Caputo, Luca Ceriani, Frederik A. Verburg. 2011. Multiplexed immunoassay of thyroglobulin autoantibodies in patients with differentiated thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
2030. Dennis Vriens, Johannes H. W. de Wilt, Gert J. van der Wilt, Romana T. Netea-Maier, Wim J. G. Oyen, Lioe Fee de Geus-Oei. 2011. The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy. *Cancer* n/a-n/a. [[CrossRef](#)]
2031. David I. Kutler, Audrey D. Crummey, William I. Kuhel. 2011. Routine central compartment lymph node dissection for patients with papillary thyroid carcinoma. *Head & Neck* n/a-n/a. [[CrossRef](#)]
2032. D. van Dijk, J. T. M. Plukker, A. N. A. van der Horst-Schrivers, L. Jansen, A. H. Brouwers, A. Muller-Kobold, W. J. Sluiter, T. P. Links. 2011. The value of detectable thyroglobulin in patients with differentiated thyroid cancer after initial 131I therapy. *Clinical Endocrinology* **74**:10.1111/cen.2010.74.issue-1, 104-110. [[CrossRef](#)]
2033. Jordi L. Reverter, Eulàlia Colomé. 2011. Potential risks of the adverse effects of thyrotropin suppression in differentiated thyroid carcinoma. *Endocrinología y Nutrición (English Edition)* **58**, 75-83. [[CrossRef](#)]
2034. John S. Abele, Robert A. Levine. 2010. Diagnostic criteria and risk-adapted approach to indeterminate thyroid cytodiagnosis. *Cancer Cytopathology* **118**:10.1002/cncy.v118.6, 415-422. [[CrossRef](#)]
2035. Richard C. Cabot, Nancy Lee Harris, Jo-Anne O. Shepard, Eric S. Rosenberg, Alice M. Cort, Sally H. Ebeling, Christine C. Peters, Madhusmita Misra, Sareh Parangi, Douglas S. Ross, Randheer Shailam, Peter M. Sadow. 2010. Case 38-2010. *New England Journal of Medicine* **363**, 2445-2454. [[CrossRef](#)]
2036. R. Michael Tuttle, Hernan Tala, Jatin Shah, Rebecca Leboeuf, Ronald Ghossein, Mithat Gonen, Matvey Brokhhin, Gal Omry, James A. Fagin, Ashok Shaha. 2010. Estimating Risk of Recurrence in Differentiated Thyroid Cancer After Total Thyroidectomy and Radioactive Iodine Remnant Ablation: Using Response to Therapy Variables to Modify the Initial Risk Estimates Predicted by the New American Thyroid Association Staging System. *Thyroid* **20**:12, 1341-1349. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

2037. Tomer Davidov, Stanley Z. Trooskin, Beth-Ann Shanker, Dana Yip, Oliver Eng, Jessica Crystal, Jun Hu, Victoriya S. Chernyavsky, Malik F. Deen, Michael May. 2010. Routine second-opinion cytopathology review of thyroid fine needle aspiration biopsies reduces diagnostic thyroidectomy. *Surgery* **148**, 1294-1301. [[CrossRef](#)]
2038. Tracy S. Wang, Douglas B. Evans. 2010. The importance of a multidisciplinary approach to endocrine tumors. *Surgery* **148**, 1311-1312. [[CrossRef](#)]
2039. Linwah Yip, Electron Kebebew, Mira Milas, Sally E. Carty, Thomas J. Fahey III, Sareh Parangi, Martha A. Zeiger, Yuri E. Nikiforov. 2010. Summary statement: Utility of molecular marker testing in thyroid cancer. *Surgery* **148**, 1313-1315. [[CrossRef](#)]
2040. William R. Burns, Martha A. Zeiger. 2010. Differentiated Thyroid Cancer. *Seminars in Oncology* **37**, 557-566. [[CrossRef](#)]
2041. Jandee Lee, Kuk Young Nah, Ra Mi Kim, Yeun Hee Ahn, Euy-Young Soh, Woong Youn Chung. 2010. Differences in postoperative outcomes, function, and cosmesis: open versus robotic thyroidectomy. *Surgical Endoscopy* **24**, 3186-3194. [[CrossRef](#)]
2042. Gerald T. Kangelaris, Theresa B. Kim, Lisa A. Orloff. 2010. Role of Ultrasound in Thyroid Disorders. *Otolaryngologic Clinics of North America* **43**, 1209-1227. [[CrossRef](#)]
2043. Gregory W. Randolph. 2010. Papillary cancer nodal surgery and the advisability of prophylactic central neck dissection: Primum, non nocere. *Surgery* **148**, 1108-1112. [[CrossRef](#)]
2044. Jennifer B. Ogilvie, Kepal N. Patel, Keith S. Heller. 2010. Impact of the 2009 American Thyroid Association guidelines on the choice of operation for well-differentiated thyroid microcarcinomas. *Surgery* **148**, 1222-1227. [[CrossRef](#)]
2045. Kimberly M. Creach, William E. Gillanders, Barry A. Siegel, Bruce H. Haughey, Jeffrey F. Moley, Perry W. Grigsby. 2010. Management of cervical nodal metastasis detected on I-131 scintigraphy after initial surgery of well-differentiated thyroid carcinoma. *Surgery* **148**, 1198-1206. [[CrossRef](#)]
2046. Trimble L. Bailey Spitzer. 2010. What the Obstetrician/Gynecologist Should Know About Thyroid Disorders. *Obstetrical & Gynecological Survey* **65**, 779-785. [[CrossRef](#)]
2047. Ari Chong, Ho-Chun Song, Jung-Joon Min, Shin Young Jeong, Jung-Min Ha, Jahae Kim, Su-Ung Yoo, Jong-Ryool Oh, Hee-Seung Bom. 2010. Improved Detection of Lung or Bone Metastases with an I-131 Whole Body Scan on the 7th Day After High-Dose I-131 Therapy in Patients with Thyroid Cancer. *Nuclear Medicine and Molecular Imaging* **44**, 273-281. [[CrossRef](#)]
2048. John D. Cramer, Pingfu Fu, Karem C. Harth, Seunghye Margevicius, Scott M. Wilhelm. 2010. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. *Surgery* **148**, 1147-1153. [[CrossRef](#)]
2049. Iain J. Nixon, Ian Ganly, Lucy E. Hann, Oscar Lin, Changhong Yu, Suzanne Brandt, Jatin P. Shah, Ashok Shaha, Michael W. Kattan, Snehal G. Patel. 2010. Nomogram for predicting malignancy in thyroid nodules using clinical, biochemical, ultrasonographic, and cytologic features. *Surgery* **148**, 1120-1128. [[CrossRef](#)]
2050. David T. Hughes, Matthew L. White, Barbra S. Miller, Paul G. Gauger, Richard E. Burney, Gerard M. Doherty. 2010. Influence of prophylactic central lymph node dissection on postoperative thyroglobulin levels and radioiodine treatment in papillary thyroid cancer. *Surgery* **148**, 1100-1107. [[CrossRef](#)]
2051. Geeta Lal, Tricia Fairchild, James R. Howe, Ronald J. Weigel, Sonia L. Sugg, Yusuf Menda. 2010. PET-CT scans in recurrent or persistent differentiated thyroid cancer: Is there added utility beyond conventional imaging?. *Surgery* **148**, 1082-1090. [[CrossRef](#)]
2052. Walter Jentzen, Dorothee Balschuweit, Jochen Schmitz, Lutz Freudenberg, Ernst Eising, Thomas Hilbel, Andreas Bockisch, Alexander Stahl. 2010. The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET/(CT) imaging. *European Journal of Nuclear Medicine and Molecular Imaging* **37**, 2298-2306. [[CrossRef](#)]
2053. Paolo Zanotti-Fregonara, Elif Hindié. 2010. On the effectiveness of recombinant human TSH as a stimulating agent for 131I treatment of metastatic differentiated thyroid cancer. *European Journal of Nuclear Medicine and Molecular Imaging* **37**, 2264-2266. [[CrossRef](#)]
2054. Elaine Cristina Morari, Joyce Rosário Silva, Ana Carolina Trindade Guilhen, Lucas Leite Cunha, Marjory Alana Marcello, Fernando Augusto Soares, José Vassallo, Laura Sterian Ward. 2010. Muc-1 Expression May Help Characterize Thyroid Nodules but Does Not Predict Patients' Outcome. *Endocrine Pathology* **21**, 242-249. [[CrossRef](#)]
2055. Chao Ma, Jiawei Xie, Wanxia Liu, Guoming Wang, Shuyao Zuo, Xufu Wang, Fengyu Wu. Recombinant human thyrotropin (rhTSH) aided radioiodine treatment for residual or metastatic differentiated thyroid cancer. [[CrossRef](#)]
2056. Wendy Sacks, Constance H. Fung, John T. Chang, Alan Waxman, Glenn D. Braunstein. 2010. The Effectiveness of Radioactive Iodine for Treatment of Low-Risk Thyroid Cancer: A Systematic Analysis of the Peer-Reviewed Literature from 1966 to April 2008. *Thyroid* **20**:11, 1235-1245. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

2057. Roberto Valcavi, Fabrizio Riganti, Angelo Bertani, Debora Formisano, Claudio M. Pacella. 2010. Percutaneous Laser Ablation of Cold Benign Thyroid Nodules: A 3-Year Follow-Up Study in 122 Patients. *Thyroid* **20**:11, 1253-1261. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2058. Alptekin GURSOY, Cuneyd Anil, Betül Erismis, Semra Ayturk. 2010. Fine-Needle Aspiration Biopsy of Thyroid Nodules: Comparison of Diagnostic Performance of Experienced and Inexperienced Physicians. *Endocrine Practice* **16**, 986-991. [[CrossRef](#)]
2059. Charles T. Tuggle, Lesley S. Park, Sanziana Roman, Robert Udelsman, Julie Ann Sosa. 2010. Rehospitalization among Elderly Patients with Thyroid Cancer after Thyroidectomy are Prevalent and Costly. *Annals of Surgical Oncology* **17**, 2816-2823. [[CrossRef](#)]
2060. H. Pelttari, M. J. Valimäki, E. Loyttyniemi, C. Schalin-Jantti. 2010. Post-ablative serum thyroglobulin is an independent predictor of recurrence in low-risk differentiated thyroid carcinoma: a 16-year follow-up study. *European Journal of Endocrinology* **163**, 757-763. [[CrossRef](#)]
2061. Deborah K. Cunningham, Katherine A. Yao, Roderick R. Turner, Frederick R. Singer, Andre R. Herle, Armando E. Giuliano. 2010. Sentinel Lymph Node Biopsy for Papillary Thyroid Cancer: 12 Years of Experience at a Single Institution. *Annals of Surgical Oncology* **17**, 2970-2975. [[CrossRef](#)]
2062. Yeşim Erbil, Serkan Sarı, Orhan Ağcaoğlu, Feyzullah Ersöz, Adem Bayraktar, Artür Salmaslıoğlu, Osman Gozkun, Işık Adalet, Selçuk Özarmağan. 2010. Radio-Guided Excision of Metastatic Lymph Nodes in Thyroid Carcinoma: A Safe Technique for Previously Operated Neck Compartments. *World Journal of Surgery* **34**, 2581-2588. [[CrossRef](#)]
2063. Jonathan Serpell. 2010. Management guidelines for patients with thyroid nodules. *ANZ Journal of Surgery* **80**:10.1111/ans.2010.80.issue-11, 765-766. [[CrossRef](#)]
2064. Marcel P. M. Stokkel, Daria Handkiewicz Junak, Michael Lassmann, Markus Dietlein, Markus Luster. 2010. EANM procedure guidelines for therapy of benign thyroid disease. *European Journal of Nuclear Medicine and Molecular Imaging* **37**, 2218-2228. [[CrossRef](#)]
2065. Michael Rivera, Julio Ricarte-Filho, Robert Michael Tuttle, Ian Ganly, Ashok Shaha, Jeffrey Knauf, James Fagin, Ronald Ghossein. 2010. Molecular, Morphologic, and Outcome Analysis of Thyroid Carcinomas According to Degree of Extrathyroid Extension. *Thyroid* **20**:10, 1085-1093. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2066. Anna M. Sawka, Irada Ibrahim-Zada, Philip Galacgac, Richard W. Tsang, James D. Brierley, Shereen Ezzat, David P. Goldstein. 2010. Dietary Iodine Restriction in Preparation for Radioactive Iodine Treatment or Scanning in Well-Differentiated Thyroid Cancer: A Systematic Review. *Thyroid* **20**:10, 1129-1138. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2067. Miloš Žarković. 2010. Diagnosis of Thyroid Disease: Principles and Problems. *Journal of Medical Biochemistry* **29**, 231-236. [[CrossRef](#)]
2068. Paolo Zanotti-Fregonara, Isabelle Keller, Marie Calzada-Nocaudie, Adil Al-Nahhas, Jean-Yves Devaux, Gaia Grassetto, Maria Cristina Marzola, Domenico Rubello, Elif Hindié. 2010. Increased serum thyroglobulin levels and negative imaging in thyroid cancer patients. *Nuclear Medicine Communications* **1**. [[CrossRef](#)]
2069. S.-Y. Sheu, K.W. Schmid. 2010. Multiple endokrine Neoplasien Typ 2. *Der Pathologe* **31**, 449-454. [[CrossRef](#)]
2070. Theresa Tran, Andrew G Gianoukakis. 2010. Familial thyroid neoplasia: impact of technological advances on detection and monitoring. *Current Opinion in Endocrinology, Diabetes and Obesity* **17**, 425-431. [[CrossRef](#)]
2071. Ashok R. Shaha. 2010. Completion thyroidectomy: fact or fiction?. *American Journal of Otolaryngology* . [[CrossRef](#)]
2072. Konstantinos D. Markou, John K. Goudakos, Stefanos Triaridis, Despoina Televantou, Prodromos Hytioglou, Angelos Nikolaou. 2010. Simultaneous Metastatic Papillary Thyroid Carcinoma and Carcinoid of the Small Intestine in the Cervical Lymph Node Group. *Thyroid* **20**:9, 1025-1028. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2073. Antonella Camera, Flavia Magri, Rodolfo Fonte, Laura Villani, Matteo G. Della Porta, Vittorio Fregoni, Luigi La Manna, Luca Chiovato. 2010. Burkitt-Like Lymphoma Infiltrating a Hyperfunctioning Thyroid Adenoma and Presenting as a Hot Nodule. *Thyroid* **20**:9, 1033-1036. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2074. F. Pacini, S. Cantara, M. Capezzone. 2010. Search for genetic mutations in cytological samples from thyroid nodules as a diagnostic tool: Reality, hope or myth?. *Journal of Endocrinological Investigation* **33**, 576-578. [[CrossRef](#)]
2075. Stergios A Polyzos, Athanasios D Anastasilakis. 2010. Infectious thyroiditis as a complication of fine-needle biopsy: a systematic review. *Expert Review of Endocrinology & Metabolism* **5**, 673-679. [[CrossRef](#)]
2076. Gregory Randolph, Elizabeth Pearce. 2010. Surgery of Well-Differentiated Thyroid Carcinoma: The Pendulum Swings Back in the Central Neck. *Endocrine Practice* **16**, 913-917. [[CrossRef](#)]
2077. Gui-Zhou Xiao. 2010. Central Lymph Node Metastasis as a Predictor of Lateral Node Involvement in Papillary Thyroid Carcinoma: Reply to Letter. *World Journal of Surgery* **34**, 2252-2253. [[CrossRef](#)]

2078. Matthew C. Miller. 2010. The Patient with a Thyroid Nodule. *Medical Clinics of North America* **94**, 1003-1015. [[CrossRef](#)]
2079. Mark Urken. 2010. Management of Well-Differentiated Thyroid Cancer in 2010: Perspectives of a Head and Neck Surgical Oncologist. *Endocrine Practice* **16**, 903-912. [[CrossRef](#)]
2080. Andreas Hillenbrand, Jan-Erik Varhaug, Michael Brauckhoff, Rumen Pandev, Sabine Haufe, Cornelia Dotzenrath, Roswitha Köberle, Rainer Hoffmann, Günther Klein, Martina Kadmon, Thomas Negele, Tatjana Hagieva, Doris Henne-Bruns, Markus Luster, Theresia Weber. 2010. Familial nonmedullary thyroid carcinoma—clinical relevance and prognosis. A European multicenter study. *Langenbeck's Archives of Surgery* **395**, 851-858. [[CrossRef](#)]
2081. Jong-Lyel Roh, Wayne M Koch. 2010. Role of sentinel lymph node biopsy in thyroid cancer. *Expert Review of Anticancer Therapy* **10**, 1429-1437. [[CrossRef](#)]
2082. E. Papini, R. Negro, A. Pinchera, R. Guglielmi, A. Baroli, P. Beck-Peccoz, P. Garofalo, M. P. Pisoni, M. Zini, R. Elisei, L. Chiovato. 2010. Thyroid nodule and differentiated thyroid cancer management in pregnancy. An Italian Association of Clinical Endocrinologists (AME) and Italian Thyroid Association (AIT) Joint Statement for Clinical Practice. *Journal of Endocrinological Investigation* **33**, 579-586. [[CrossRef](#)]
2083. Angelo Carpi, Jeffrey I. Mechanick, Sven Saussez, Andrea Nicolini. 2010. Thyroid tumor marker genomics and proteomics: Diagnostic and clinical implications. *Journal of Cellular Physiology* **224**, 612-619. [[CrossRef](#)]
2084. Christian P. Hasney, Ronald G. Amedee. 2010. What is the appropriate extent of lateral neck dissection in the treatment of metastatic well-differentiated thyroid carcinoma?. *The Laryngoscope* **120**, 1716-1717. [[CrossRef](#)]
2085. P. V. Pradeep, S. Kuldeep. 2010. Central Lymph Node Metastasis: Is It a Reliable Indicator of Node Involvement in Papillary Thyroid Carcinoma? Letter to the Editor. *World Journal of Surgery* **34**, 2251-2251. [[CrossRef](#)]
2086. Sherman S. H. Kueh, Paul J. Roach, Geoffrey P. Schembri. 2010. Role of Tc-99m Pertechnetate for Remnant Scintigraphy Post-Thyroidectomy. *Clinical Nuclear Medicine* **35**, 671-674. [[CrossRef](#)]
2087. Kathleen E. Hands, Antonio Cervera, Larry J. Fowler. 2010. Enlarged Benign-Appearing Cervical Lymph Nodes by Ultrasonography Are Associated with Increased Likelihood of Cancer Somewhere Within the Thyroid in Patients Undergoing Thyroid Nodule Evaluation. *Thyroid* **20**:8, 857-862. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2088. Keith S. Heller. 2010. Is Screening Appropriate for Occult Cervical Lymph Node Metastases in Patients with Well-Differentiated Thyroid Cancer?. *Thyroid* **20**:8, 933-934. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2089. Pedro Wesley Rosario, Daniela Santos Salles, Saulo Purisch. 2010. Fine-Needle Biopsy Should Be Performed in Solid Hypoechoic Thyroid Nodules Greater Than One Centimeter Even in the Absence of Suspicious Ultrasonographic Characteristics. *Thyroid* **20**:8, 939-940. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2090. David S. Cooper. 2010. Response to Heller. *Thyroid* **20**:8, 934-935. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2091. 2010. Correction. *Thyroid* **20**:8, 942-942. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2092. N. Sharma, K. Boelaert, J.C. Watkinson. 2010. Who Should Treat Thyroid Cancer? A UK Surgical Perspective. *Clinical Oncology* **22**, 413-418. [[CrossRef](#)]
2093. U.K. Mallick. 2010. The Revised American Thyroid Association Management Guidelines 2009 for Patients with Differentiated Thyroid Cancer: an Evidence-Based Risk-Adapted Approach. *Clinical Oncology* **22**, 472-474. [[CrossRef](#)]
2094. Barbra S. Miller. 2010. Fine Needle Aspiration—Is There a Difference in Indication for Use Based on Gender?. *Journal of Surgical Research* **162**, 165-167. [[CrossRef](#)]
2095. H. Tala, R.M. Tuttle. 2010. Contemporary Post Surgical Management of Differentiated Thyroid Carcinoma. *Clinical Oncology* **22**, 419-429. [[CrossRef](#)]
2096. Wen T. Shen, Lauren Ogawa, Daniel Ruan, Insoo Suh, Quan-Yang Duh, Orlo H. Clark. 2010. Central neck lymph node dissection for papillary thyroid cancer: The reliability of surgeon judgment in predicting which patients will benefit. *Surgery* **148**, 398-403. [[CrossRef](#)]
2097. Nicole V. Tilluckdharry, Rajan Krishnamani, David DeNofrio, Kenneth D. Burman, Caroline S. Kim. 2010. Thyroid nodule and thyroid cancer management pre- and post-cardiac transplantation. *The Journal of Heart and Lung Transplantation* **29**, 831-837. [[CrossRef](#)]
2098. S. Vergez, J. Sarini, J. Percodani, E. Serrano, Ph. Caron. 2010. Lymph node management in clinically node-negative patients with papillary thyroid carcinoma. *European Journal of Surgical Oncology (EJSO)* **36**, 777-782. [[CrossRef](#)]
2099. S.E.M. Clarke. 2010. Radioiodine Therapy in Differentiated Thyroid Cancer: a Nuclear Medicine Perspective. *Clinical Oncology* **22**, 430-437. [[CrossRef](#)]

2100. N.G. Iyer, A.R. Shaha. 2010. Management of Thyroid Nodules and Surgery for Differentiated Thyroid Cancer. *Clinical Oncology* **22**, 405-412. [[CrossRef](#)]
2101. L. Moss. 2010. Thyroid Cancer Forum-UK (TCF-UK): a Free, Independent, Multidisciplinary Education Resource and Peer Support Organisation for Consultants. *Clinical Oncology* **22**, 508-511. [[CrossRef](#)]
2102. M. Chao. 2010. Management of Differentiated Thyroid Cancer with Rising Thyroglobulin and Negative Diagnostic Radioiodine Whole Body Scan. *Clinical Oncology* **22**, 438-447. [[CrossRef](#)]
2103. C. Chougnet, M. Brassard, S. Leboulleux, E. Baudin, M. Schlumberger. 2010. Molecular Targeted Therapies for Patients with Refractory Thyroid Cancer. *Clinical Oncology* **22**, 448-455. [[CrossRef](#)]
2104. J.A. Sipos, E.L. Mazzaferri. 2010. Thyroid Cancer Epidemiology and Prognostic Variables. *Clinical Oncology* **22**, 395-404. [[CrossRef](#)]
2105. U.K. Mallick. 2010. Thyroid Cancer: Evidence-based Optimal Management and the Search for a Cure. *Clinical Oncology* **22**, 394. [[CrossRef](#)]
2106. P. Perros. 2010. 2009 American Thyroid Association Guidelines on Thyroid Nodules. *Clinical Oncology* **22**, 469-471. [[CrossRef](#)]
2107. Flavia Prodam, Loredana Pagano, Sara Belcastro, Giuliana Golisano, Arianna Busti, Mariateresa Samà, Marina Caputo, Simonetta Bellone, Andrea Voci, Guido Valente, Gianluca Aimaretti. 2010. Pituitary Metastases from Follicular Thyroid Carcinoma. *Thyroid* **20**:7, 823-830. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2108. Ralph P. Tufano, Emad Kandil. 2010. Considerations for Personalized Surgery in Patients with Papillary Thyroid Cancer. *Thyroid* **20**:7, 771-776. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2109. N. G. Iyer, Ashok R. Shaha, Carl E. Silver, Kenneth O. Devaney, Alessandra Rinaldo, Phillip K. Pellitteri, Alfio Ferlito. 2010. Thyroid incidentalomas: to treat or not to treat. *European Archives of Oto-Rhino-Laryngology* **267**, 1019-1026. [[CrossRef](#)]
2110. A. Machens, H. Dralle. 2010. Decreasing tumor size of thyroid cancer in Germany: institutional experience 1995-2009. *European Journal of Endocrinology* **163**, 111-119. [[CrossRef](#)]
2111. D. Vordermark, T. Pelz, F. Sieker. 2010. Die Rolle der externen Strahlentherapie bei der Behandlung des Schilddrüsenkarzinoms. *Der Onkologe* **16**, 695-700. [[CrossRef](#)]
2112. W. Karges, G. Brabant. 2010. Schilddrüsenkarzinom – Klinik und Diagnostik. *Der Onkologe* **16**, 657-665. [[CrossRef](#)]
2113. M. Hermann, K. Tonninger, F. Kober, E.-M. Furtlehner, A. Schultheis, N. Neuhold. 2010. Minimal-invasives follikuläres Schilddrüsenkarzinom. *Der Chirurg* **81**, 627-635. [[CrossRef](#)]
2114. M. Dietlein, M. Luster, C. Reiners. 2010. Nuklearmedizinische Therapie und Nachsorge des differenzierten Schilddrüsenkarzinoms: Status quo. *Der Onkologe* **16**, 678-689. [[CrossRef](#)]
2115. H. Dralle, K. Lorenz, A. Machens, M. Brauckhoff, P. Nguyen Thanh. 2010. Tumortyp- und tumorstadienorientiertes chirurgisches Konzept bei Karzinomen der Schilddrüse. *Der Onkologe* **16**, 666-677. [[CrossRef](#)]
2116. W. Karges. 2010. Kalzitininbestimmung zur Frühdiagnose des medullären Schilddrüsenkarzinoms. *Der Chirurg* **81**, 620-626. [[CrossRef](#)]
2117. Dong Li, Zhaowei Meng, Guizhi Zhang, Tielian Yu, Jian Tan, Feng Dong. 2010. Visualization of Thyroglossal Duct Cyst in Differentiated Thyroid Cancer Patient. *Clinical Nuclear Medicine* **35**, 499-504. [[CrossRef](#)]
2118. Michael Wehmeier, Thorsten Petrich, Korbinian Brand, Ralf Lichtinghagen, Eric Hesse. 2010. Oncofetal Fibronectin mRNA Is Highly Abundant in the Blood of Patients with Papillary Thyroid Carcinoma and Correlates with High-Serum Thyroid-Stimulating Hormone Levels. *Thyroid* **20**:6, 607-613. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2119. Joanna Klubo-Gwiedzinska, Douglas Van Nostrand, Kenneth D. Burman, Vasyl Vasko, Stanley Chia, Tom Deng, Kanchan Kulkarni, Leonard Wartofsky. 2010. Salivary Gland Malignancy and Radioiodine Therapy for Thyroid Cancer. *Thyroid* **20**:6, 647-651. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2120. Carole Spencer, Shireen Fatemi, Peter Singer, John Nicoloff, Jonathan LoPresti. 2010. Serum Basal Thyroglobulin Measured by a Second-Generation Assay Correlates with the Recombinant Human Thyrotropin-Stimulated Thyroglobulin Response in Patients Treated for Differentiated Thyroid Cancer. *Thyroid* **20**:6, 587-595. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2121. Elizabete R. Miranda, Eduardo L. Padrão, Barbara C. Silva, Luiz De Marco, Marta S. Sarquis. 2010. Papillary Thyroid Carcinoma with Brain Metastases: An Unusual 10-Year-Survival Case. *Thyroid* **20**:6, 657-661. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]

2122. Anastasios Gkountouvas, Ifigeneia Kostoglou-Athanassiou, Eirini Veniou, Panagiotis Repousis, Nikolaos Ziras, Philippos Kaldrimidis. 2010. Hematologic Toxicity in Patients Treated with Sunitinib for Advanced Thyroid Cancer. *Thyroid* **20**:6, 597-600. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2123. 2010. Correction. *Thyroid* **20**:6, 674-675. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2124. Cüneyd Anil, Sibel Goksel, Alptekin Gursoy. 2010. Hashimoto's Thyroiditis Is Not Associated with Increased Risk of Thyroid Cancer in Patients with Thyroid Nodules: A Single-Center Prospective Study. *Thyroid* **20**:6, 601-606. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2125. Babita Panigrahi, Sanziana A. Roman, Julie Ann Sosa. 2010. Medullary Thyroid Cancer: Are Practice Patterns in the United States Discordant From American Thyroid Association Guidelines?. *Annals of Surgical Oncology* **17**, 1490-1498. [[CrossRef](#)]
2126. Marcin Barczyński, Aleksander Konturek, Alicja Hubalewska-Dydejczyk, Filip Gołkowski, Stanisław Cichoń, Wojciech Nowak. 2010. Five-year Follow-up of a Randomized Clinical Trial of Total Thyroidectomy versus Dunhill Operation versus Bilateral Subtotal Thyroidectomy for Multinodular Nontoxic Goiter. *World Journal of Surgery* **34**, 1203-1213. [[CrossRef](#)]
2127. Ian D. Hay. 2010. Managing Patients with a Preoperative Diagnosis of AJCC/UICC Stage I (T1N0M0) Papillary Thyroid Carcinoma: East Versus West, Whose Policy is Best?. *World Journal of Surgery* **34**, 1291-1293. [[CrossRef](#)]
2128. Diana L. Fitzpatrick, Michelle A. Russell. 2010. Diagnosis and Management of Thyroid Disease in Pregnancy. *Obstetrics and Gynecology Clinics of North America* **37**, 173-193. [[CrossRef](#)]
2129. Jordi L. Reverter, Eulàlia Colomé, Susana Holgado, Eva Aguilera, Berta Soldevila, Lourdes Mateo, Anna Sanmartí. 2010. Bone mineral density and bone fracture in male patients receiving long-term suppressive levothyroxine treatment for differentiated thyroid carcinoma. *Endocrine* **37**, 467-472. [[CrossRef](#)]
2130. Gregory W. Randolph. 2010. The Importance of Pre- and Postoperative Laryngeal Examination for Thyroid Surgery. *Thyroid* **20**:5, 453-458. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2131. Omer Turker, Ismail Dogan, Kamil Kumanlioglu. 2010. Radioiodine Accumulation in a Large Adnexal Cystadenofibroma. *Thyroid* **20**:5, 561-562. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2132. Mingzhao Xing. 2010. Prognostic utility of BRAF mutation in papillary thyroid cancer. *Molecular and Cellular Endocrinology* **321**, 86-93. [[CrossRef](#)]
2133. Clodagh S. O'Gorman, Jill Hamilton, Marianna Rachmiel, Abha Gupta, Bo Ye Ngan, Denis Daneman. 2010. Thyroid Cancer in Childhood: A Retrospective Review of Childhood Course. *Thyroid* **20**:4, 375-380. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2134. John H. Yim, Sally E. Carty. 2010. Thyroid Surgery and Surgeons: The Common Interest. *Thyroid* **20**:4, 357-358. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2135. David S. Cooper. 2010. Response to Pitoia and Ward. *Thyroid* **20**:4, 362-362. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2136. Fabian Pitoia, Laura S. Ward. 2010. Differences Between Latin American and American Associations' Thyroid Cancer Guidelines. *Thyroid* **20**:4, 361-362. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2137. Sara I. Pai, Ralph P. Tufano. 2010. Reoperation for Recurrent/Persistent Well-Differentiated Thyroid Cancer. *Otolaryngologic Clinics of North America* **43**, 353-363. [[CrossRef](#)]
2138. Torsten Kuwert, Daniela Schmidt. 2010. SPECT/CT in differentiated thyroid carcinoma. *Imaging in Medicine* **2**, 235-243. [[CrossRef](#)]
2139. Danielle Fritze, Gerard M. Doherty. 2010. Surgical Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer. *Otolaryngologic Clinics of North America* **43**, 285-300. [[CrossRef](#)]
2140. Devendra A. Chaukar, Anuja D. Deshmukh, Mitali R. Dandekar. 2010. Management of thyroid cancers. *Indian Journal of Surgical Oncology* **1**, 151-162. [[CrossRef](#)]
2141. Amin Sabet, Matthew Kim. 2010. Postoperative Management of Differentiated Thyroid Cancer. *Otolaryngologic Clinics of North America* **43**, 329-351. [[CrossRef](#)]
2142. Lisa Licitra, Laura D. Locati, Angela Greco, Roberta Granata, P. Bossi. 2010. Multikinase inhibitors in thyroid cancer. *European Journal of Cancer* **46**, 1012-1018. [[CrossRef](#)]
2143. L. J. Layfield, E. S. Cibas, Z. Baloch. 2010. Thyroid fine needle aspiration cytology: a review of the National Cancer Institute state of the science symposium. *Cytopathology* **21**:10.1111/cyt.2010.21.issue-2, 75-85. [[CrossRef](#)]
2144. Kristien Boelaert. 2010. Thyroid gland: Revised guidelines for the management of thyroid cancer. *Nature Reviews Endocrinology* **6**, 185-186. [[CrossRef](#)]

2145. R. Michael Tuttle, Norma Lopez, Rebecca Leboeuf, Shaye M. Minkowitz, Ravinder Grewal, Matvey Brokhin, Gal Omry, Steve Larson. 2010. Radioactive Iodine Administered for Thyroid Remnant Ablation Following Recombinant Human Thyroid Stimulating Hormone Preparation Also Has an Important Adjuvant Therapy Function. *Thyroid* **20**:3, 257-263. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
2146. Elizabeth N. Pearce, Alex Stagnaro-Green. 2010. Hypothyroidism in Pregnancy: Do Guidelines Alter Practice?. *Thyroid* **20**:3, 241-242. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
2147. G.E. Gerrard, L. O'Toole, F. Roberts. 2010. Should We Routinely Offer a Second Admission for Radioiodine to Patients with High-risk Differentiated Thyroid Cancer?. *Clinical Oncology* **22**, 136-139. [CrossRef]
2148. Bernadette Biondi, David S. Cooper. 2010. Benefits of Thyrotropin Suppression Versus the Risks of Adverse Effects in Differentiated Thyroid Cancer. *Thyroid* **20**:2, 135-146. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
2149. John C. Morris. 2010. Resveratrol, Thyroid Cancer, and Iodide: Drink Up?. *Thyroid* **20**:2, 125-126. [Citation] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
2150. Ralf Paschke, Kurt Werner Schmid, Roland Gärtner, Klaus Mann, Henning Dralle, Christian Reiners. 2010. Epidemiologie, Pathophysiologie, leitliniengerechte Diagnostik und Therapie des Schilddrüsenknotens. *Medizinische Klinik* **105**, 80-87. [CrossRef]
2151. Carrie C. Lubitz, William C. Faquin, Jingyun Yang, Michal Mekel, Randall D. Gaz, Sareh Parangi, Gregory W. Randolph, Richard A. Hodin, Antonia E. Stephen. 2010. Clinical and Cytological Features Predictive of Malignancy in Thyroid Follicular Neoplasms. *Thyroid* **20**:1, 25-31. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links] [Supplemental Material]
2152. Victoria Hoperia, Alexander Larin, Kirk Jensen, Andrew Bauer, Vasily Vasko. 2010. Thyroid Fine Needle Aspiration Biopsies in Children: Study of Cytological-Histological Correlation and Immunostaining with Thyroid Peroxidase Monoclonal Antibodies. *International Journal of Pediatric Endocrinology* **2010**, 690108. [CrossRef]
2153. Jung Jin Cho. 2010. Screening of Thyroid Cancer and Management of Thyroid Incidentaloma. *Korean Journal of Family Medicine* **31**, 87. [CrossRef]
2154. Victoria Hoperia, Alexander Larin, Kirk Jensen, Andrew Bauer, Vasily Vasko. 2010. Thyroid Fine Needle Aspiration Biopsies in Children: Study of Cytological-Histological Correlation and Immunostaining with Thyroid Peroxidase Monoclonal Antibodies. *International Journal of Pediatric Endocrinology* **2010**, 1-5. [CrossRef]
2155. Kyungji Lee, Chan-Kwon Jung, Kyo-Young Lee, Ja-Seong Bae, Dong-Jun Lim, So-Lyung Jung. 2010. Application of Bethesda System for Reporting Thyroid Aspiration Cytology. *The Korean Journal of Pathology* **44**, 521. [CrossRef]
2156. Nam Seop Lee, Ja Seong Bae, So-Ryeong Jeong, Chan Kwon Jung, Dong Jun Lim, Woo Chan Park, Jeong Soo Kim, Seung Nam Kim. 2010. Risk Factors of Lymph Node Metastasis in Papillary Thyroid Microcarcinoma. *Journal of the Korean Surgical Society* **78**, 82. [CrossRef]
2157. Yoo Seung Chung, Young-Jin Suh. 2010. Is Central Lymph Node Dissection Mandatory in 2 cm or Less Sized Papillary Thyroid Cancer?. *Journal of the Korean Surgical Society* **79**, 332. [CrossRef]
2158. Mira Milas, Joyce Shin, Manjula Gupta, Tomislav Novosel, Christian Nasr, Jennifer Brainard, Jamie Mitchell, Eren Berber, Allan Siperstein. 2010. Circulating Thyrotropin Receptor mRNA as a Novel Marker of Thyroid Cancer. *Transactions of the ... Meeting of the American Surgical Association* **128**, 253-263. [CrossRef]
2159. Dong-Jun Lim, Joo Hyun O, Min-Hee Kim, Ji-Hyun Kim, Hyuk-Sang Kwon, Sung-Hoon Kim, Moo-Il Kang, Bong-Yun Cha, Kwang-Woo Lee, Ho-Young Son. 2010. Clinical Significance of Observation without Repeated Radioiodine Therapy in Differentiated Thyroid Carcinoma Patients with Positive Surveillance Whole-Body Scans and Negative Thyroglobulin. *The Korean Journal of Internal Medicine* **25**, 408. [CrossRef]
2160. Ka Hee Yi, Young Joo Park, Sung-Soo Koong, Jung-Han Kim, Dong Gyu Na, Jin-Sook Ryu, So Yeon Park, In Ae Park, Chung-Hwan Baek, Young Kee Shong, Young Don Lee, Jaetae Lee, Jeong Hyun Lee, Jae Hoon Chung, Chan Kwon Jung, Seung-Ho Choi, Bo Youn Cho. 2010. Revised Korean Thyroid Association Management Guidelines for Patients with Thyroid Nodules and Thyroid Cancer. *Endocrinology and Metabolism* **25**, 270. [CrossRef]
2161. Jung Min Kim, Yun Yong Lee, Chang Woon Choi, Sang Moo Lim, Seung-Sook Lee, Soo Youn Cho, Guk Haeng Lee, Byeong-Cheol Lee, Ka Hee Yi. 2010. The Clinical Importance of Minimal Extrathyroid Extension on Tumor Recurrence in Patients with Papillary Thyroid Carcinoma. *Endocrinology and Metabolism* **25**, 340. [CrossRef]
2162. Rebecca S. Sippel, Herbert Chen. 2009. Controversies in the Surgical Management of Newly Diagnosed and Recurrent/Residual Thyroid Cancer. *Thyroid* **19**:12, 1373-1380. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]
2163. Jennifer A. Sipos. 2009. Advances in Ultrasound for the Diagnosis and Management of Thyroid Cancer. *Thyroid* **19**:12, 1363-1372. [Abstract] [Full Text HTML] [Full Text PDF] [Full Text PDF with Links]



2164. Caroline S. Kim, Xuguang Zhu. 2009. Lessons from Mouse Models of Thyroid Cancer. *Thyroid* 19:12, 1317-1331. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2165. Douglas Van Nostrand. 2009. The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer. *Thyroid* 19:12, 1381-1391. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2166. Martin Schlumberger, Steven I. Sherman. 2009. Clinical Trials for Progressive Differentiated Thyroid Cancer: Patient Selection, Study Design, and Recent Advances. *Thyroid* 19:12, 1393-1400. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2167. Marina N. Nikiforova, Yuri E. Nikiforov. 2009. Molecular Diagnostics and Predictors in Thyroid Cancer. *Thyroid* 19:12, 1351-1361. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2168. Charles H. Emerson. 2009. Guidelines for Guidelines: Content, Accountability, Peer Review, and Intellectual Ownership. *Thyroid* 19:11, 1137-1138. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2169. Efisio Puxeddu, Sebastiano Filetti. 2009. The 2009 American Thyroid Association Guidelines for Management of Thyroid Nodules and Differentiated Thyroid Cancer: Progress on the Road from Consensus- to Evidence-Based Practice. *Thyroid* 19:11, 1145-1147. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2170. Leonard Wartofsky. 2009. Highlights of the American Thyroid Association Guidelines for Patients with Thyroid Nodules or Differentiated Thyroid Carcinoma: The 2009 Revision. *Thyroid* 19:11, 1139-1143. [[Citation](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2171. Sally E. Carty, David S. Cooper, Gerard M. Doherty, Quan-Yang Duh, Richard T. Kloos, Susan J. Mandel, Gregory W. Randolph, Brendan C. Stack, Jr., David L. Steward, David J. Terris, Geoffrey B. Thompson, Ralph P. Tufano, R. Michael Tuttle, Robert Udelsman. 2009. Consensus Statement on the Terminology and Classification of Central Neck Dissection for Thyroid Cancer. *Thyroid* 19:11, 1153-1158. [[Abstract](#)] [[Full Text HTML](#)] [[Full Text PDF](#)] [[Full Text PDF with Links](#)]
2172. Martha A. Zeiger. 2009. Evolution in the surgical management of well-differentiated thyroid cancer or not: To dissect or not dissect the central lymph node compartment. *Journal of Surgical Oncology* n/a-n/a. [[CrossRef](#)]